Page 1

m a r g o r P 7 e 1 0 c 2 n e i c S g n i t e e M l a u nn A AAN

on ng i t tra eeti s i eg al M R } } nu dule n A }} Sche

Early R egistra tion De adline : Marc h 30, 2 017

y. g o ol r u e N g in c n a v d A

u. o Y g n i c an v d A


Discover the All-inclusive Registration Rate Everyone’s Talking About The one registration fee with freedom to move about was an AMAZING improvement to the meeting. ~ 2016 Annual Meeting Attendee z No pre-registration is required for most individual courses z Customize your schedule any way you want— come and go from sessions at your convenience

z Includes expanded experiential learning areas, not-to-be missed social events, and much more

AAN.com/view/AM17


Contents Introduction

Poster Sessions ������������������������������������������������������� 76 Poster Session I����������������������������������������������������� 78 Poster Session II ��������������������������������������������������� 88 Poster Session III �������������������������������������������������� 98 Poster Session IV ������������������������������������������������ 108 Poster Session V ��������������������������������������������������118 Poster Session VI ������������������������������������������������ 128

Welcome����������������������������������������������������������������������� 2 See What’s New in 2017! �������������������������������������������� 4 Plan Your Meeting Experience������������������������������������� 6 Experiential Learning Areas������������������������������������� 8

Meeting Overviews Meeting-at-a-Glance Tear Out������������������������������� 17 2017 Plenary Speakers�������������������������������������������17 2017 Meeting Schedule Summary ����������������������� 18

Highlights Connect at Social Events ����������������������������������������� 138 Annual Meeting On Demand ����������������������������������� 140

Program Glossary��������������������������������������������������������21

2017 Award Recipients �������������������������������������������� 142

Annual Meeting Schedule Saturday, April 22 �������������������������������������������������� 23 Sunday, April 23����������������������������������������������������� 24 Monday, April 24 ��������������������������������������������������� 25 Tuesday, April 25 ��������������������������������������������������� 26 Wednesday, April 26 ��������������������������������������������� 27 Thursday, April 27�������������������������������������������������� 28 Friday, April 28������������������������������������������������������� 29

2017 Research Program Recipients������������������������� 146

Annual Meeting Information

Annual Meeting Program List by Topic����������������� 31

Session Information Plenary Sessions ����������������������������������������������������� 39 Hot Topics Plenary Session ���������������������������������� 40 Presidential Plenary Session����������������������������������41 Contemporary Clinical Issues Plenary Session����� 42 Clinical Trials Plenary Session ������������������������������� 43 Frontiers in Neuroscience Plenary Session ���������� 44 Controversies in Neurology Plenary Session��������� 45 Neurology Year in Review Plenary Session���������� 46 “Best of” Scientific Platform Sessions ����������������� 47 “Best of” Scientific Platform Sessions������������������ 48 Neuroscience in the Clinic Sessions����������������������51 Sunday, April 23����������������������������������������������������� 52 Monday, April 24 ��������������������������������������������������� 53 Tuesday, April 25 ��������������������������������������������������� 54 Wednesday, April 26 ��������������������������������������������� 55 Thursday, April 27�������������������������������������������������� 56 Friday, April 28������������������������������������������������������� 57 Scientific Platform Sessions���������������������������������� 59 Sunday, April 23����������������������������������������������������� 60 Monday, April 24 ��������������������������������������������������� 62 Tuesday, April 25 ��������������������������������������������������� 64 Wednesday, April 26 ��������������������������������������������� 66 Thursday, April 27�������������������������������������������������� 69 Friday, April 28������������������������������������������������������� 72

Program current as of 2/17/17. Program subject to change.

General Information��������������������������������������������������� 148 Hotels and Amenities����������������������������������������������� 152 Hotel and Reservations �������������������������������������������� 154 Travel Information ����������������������������������������������������� 155 69th Annual Meeting Exhibitors���������������������������������157 69th Annual Meeting Committee Members ������������ 158 Meeting Information and Contacts��������������������������� 162

The 69th AAN Annual Meeting Deadlines-at-a-Glance March 8, 2017 Annual Meeting Hotel Reservation Deadline March 30, 2017 Annual Meeting Early Registration Deadline

Location Boston Convention and Exhibition Center

Headquarter Hotels Renaissance Boston Waterfront Hotel Westin Boston Waterfront

AAN.com/view/AM17

Fast and easy registration · AAN.com/view/AM17

1


S

cience is always evolving. And the AAN Annual Meeting Science Program continually

innovates to meet both the reality and the demands. 2017 is no exception. We’ve enhanced and expanded the Annual Meeting experience to offer more ways to discover the very latest research across the widest variety of neurology topics of any meeting out there. Our new Neuroscience in the Clinic and Clinical Discussions sessions will offer an entirely new way of engaging scientists and clinicians in important discussions about scientific application to the clinic setting. Best of Science Sessions will highlight the year’s most important research. And we’ve made the popular poster sessions easier than ever to navigate and spur discussions by grouping topicrelated posters together in what we are calling ‘neighborhoods.’

Lisa M. DeAngelis, MD, FAAN Chair, AAN Science Committee

With an anticipated 2,700+ abstracts covering the most cutting-edge science out there, I’m certain you will be impressed by this year’s innovative new Scientific Program—and am anxious to hear what you have to say about it when I see you in beautiful Boston this April!


1. Neurobowl®:  Because you’re too smart for Jeopardy 2. Opening Party:  Just a little get together with thousands of your closest friends 3. Networking:  Rub shoulders with your favorite neurologist 4. Customization:  Yes, you can have it your way! 5. Leadership University:  Feel like taking over the world 6. Passing of the Presidential Gavel:  Neurology’s Olympic Torch 7. Boston:  Not just a band, and “more than a feeling” 8. Plenaries:  Prepare to be star struck 9. Experiential Learning Areas:  Sometimes the best learning comes in small packages 10. CME:  Enough said!


See What’s New in 2017! Neuroscience in the Clinic Sessions These new sessions will feature a mix of scientists and clinicians actively engaged in lively case discussions to integrate scientific research with clinical application. A moderator will introduce and provide background on a case and invited speakers will frame the case in scientific and clinical context. Thematic abstract presentations will provide additional framework. Session will conclude with panel discussion.

Poster Session Neighborhoods We’ve made the posters easier to navigate by clustering topic-related posters into “neighborhoods” designed to enhance your discussions with colleagues. See page 76 » for the floorplan.

See page 51 » for more details.

“Best of” Science Sessions

New Scientific Platform Session Format

These daily platform sessions will precede the plenary sessions and feature the top four scoring abstracts in a particular topic, as rated by topic reviewers, as well as an opportunity to meet and discuss findings with the investigators.

Shorter platform presentations allow for the distillation of essential data. The session will conclude with a discussant bringing one or more of the abstracts into context focusing on concepts, ideas, issues, and controversies. See page 59 » for more details.

See page 47 » for more details.


Expanded Experiential Learning Areas Get ready to experience interactive—and totally flexible—new ways of exploring, engaging, and learning throughout each day of the Annual Meeting. Experiential Learning Areas will offer a variety of real-world experiences designed to engage you intellectually, emotionally, and socially while serving up fresh ideas to help you personally and professionally. See page 8 » for more details.

Office of the Future Located inside the Exhibit Hall, this exciting new area will let you experience how an office of the future will look and operate. Reimagine your exam room with the latest ergonomic equipment and cutting-edge technology that engages your patients and encourages shared decision-making—from touch-screen learning to lighting, and everything in-between!

Now Easier to Find the Sessions You Seek! We’ve made changes to this year’s book to make it quicker and easier for you to find the sessions of most interest to you. }} You can find the Experiential Learning Areas starting on page 8 » }} You can find all the Plenary Sessions starting on page 39 » }} You can find all the Scientific Platform Sessions starting on page 59 » }} You can find all the Neuroscience in the Clinic Sessions starting on page 51 » }} You can find all of the “Best of” Scientific Platform Sessions starting on page 47 » }} You can find all the Poster Sessions starting on page 76 »


Plan Your Meeting Experience Registration The 69th AAN Annual Meeting registration site makes planning your week as easy as 1-2-3:

1 2

 3

Register and book your hotel quickly and easily online—enjoy the convenience and value of the single registration rate! Use the convenient pages starting on page 17 » of this book to plan your week, incorporating your favorite education programs, scientific sessions, and other Annual Meeting social and informational events. Show up and experience the excellence of the world’s largest gathering of neurologists.

Ways to Register

Registration Options

Online

Annual Meeting Registration

AAN.com/view/register

The single meeting registration fee is mandatory for all registrants and is determined by AAN member type.

Telephone International: (415) 979-2283

To qualify for the member registration rate, your 2017 membership dues must be paid by April 22, 2017. Failure to do so will result in a balance due.

Registration Deadline: March 30, 2017

Gold Registration

US/Canada: (800) 676-4226

Registrations received after March 30, 2017, will be processed at a higher rate.

Upgrade your meeting registration to include a copy of Annual Meeting On Demand.

For questions go to aanam.cmrushelp.com To obtain a registration form to pay by check, please contact CMR. Registration forms will only be accepted for check payments.

Ways to Save }} Renew your AAN membership or join the AAN for maximum registration savings. Visit AAN.com/view/membership. }} Register by the March 30, 2017, early registration deadline to avoid increased rates after this date.

2017 AAN Annual Meeting Fees Membership Type

Early Registration (Before March 30, 2017)

Late Registration (After March 30, 2017)

Early Gold Registration (Before March 30, 2017)

Late Gold Registration (After March 30, 2017)

Students

$0

$0

$199

$199

Senior/Honorary

$0

$0

$399

$399

Junior1

$245

$335

$444

$534

$420

$570

$619

$769

$720

$980

$1,119

$1,379

Nonmember

$1,220

$1,660

$1,819

$2,259

1  Junior, Intern 2 Researcher, Advanced Practice Provider, Business Administrator

3 Neurologist, Physician Affiliate

Non-neurologist Member Neurologist Member

6

2

3

2017 AAN Annual Meeting Science Program


What Is Not Included with Annual Meeting Registration? While the single registration rate provides an exceptional value, the following few programs are not included, may require a separate registration fee, and are subject to closure due to reaching maximum capacity. For information on pricing please visit AAN.com/view/register.

C6 Early Career Research Training Symposium: A Roadmap to Academic Success for Residents and Fellows

C7 Neurology MOC Prep Course C8 Clerkship and Program Directors Leadership Academy C9 Women in Leadership C15 Practical Training in Injection Techniques in the

Treatment of Headache Disorders Skills Workshop C49 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop C50 Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop C76 Mentoring…Growing the Next Generation of Neurologist C88 Improving Your Leadership Skills: A Practical Approach C89 Neurophysiologic Intraoperative Monitoring Skills Workshop C133 The Most Important Tool in Your Black Bag: Gallup StrengthFinder™ Assessment C135 Neuromuscular Ultrasound Skills Workshop C170 Sports Concussion Skills Workshop I: Event Coverage Skills C171 The Most Important Tool in Your Black Bag: Gallup StrengthFinder™ Assessment: Advanced Workshop C172 EMG Skills Workshop: Basic C185 Sports Concussion Skills Workshop II: Office-based Skills C209 Clinical Usefulness of Botulinum Toxin for Spasticity Workshop C238 Epilepsy Skills Workshop

Additional Information Cancelled or Closed Programs Education programs may be closed due to reaching maximum capacity or cancelled due to insufficient enrollment. In the event of cancellation, registration for the cancelled course will be fully refunded for courses that have a separate registration fee. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration closure or cancellation.

Cancellations/Refunds of Registration Until March 30, 2017—Refund less $100 administrative fee March 31–April 15, 2017—Refund less $200 administrative fee After April 15, 2017—No refund •• All cancellations must be submitted in writing to aanam. cmrushelp.com or faxed to (415) 293-4071. •• No-shows will not receive a refund. •• Name substitutions are not permitted. •• No refunds will be processed for amounts of $20 or less.

Special Accommodations Deadline: March 30, 2017 The Boston Convention and Event Center and the AAN strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, submit your request while registering online or contact Laurie Dixon no later than March 30, 2017, at ldixon@aan.com or (612) 928-6154. Kosher meals may be provided at any lunch and must be arranged on or before March 30, 2017, through the registration website or by contacting AAN Registration/CMR at aanam.cmrushelp.com, (800) 676-4226, or (415) 979-2283. There is a $50 surcharge per kosher meal. On-site requests cannot be accommodated. There are no refunds for kosher meals.

Group Registration Deadline: March 30, 2017 Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. Special registration instructions are available online at AAN.com/view/register or by contacting CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 979-2283 (International) or aanam.cmrushelp.com. See page 154 » for housing information.

“These changes enabled me to tailor my learning and get the most out of the conference to benefit my patients!” ~ 2016 Annual Meeting Attendee

Fast and easy registration · AAN.com/view/AM17

7


Experiential Learning Areas

Experiential Learning Areas We’re taking learning outside the traditional classroom with these interactive areas. Happening each day during the meeting, these areas offer new ways of learning that will engage you intellectually, emotionally, and socially, and offer you fresh ideas to help you personally and professionally.

 1 Education and Publication Station: Knowledge Is Power

 3 Research Corner: Moving Neurology Forward

 2 HeadTalks Engage in creative and provocative presentations on some of the timeliest topics in neurology. See page 14 ».

Explore the AAN’s host of top-quality e-learning and publications. See page 11 ».

Discover new and valuable resources to help you move your research forward. See page 13 ».

EAST REGISTRATION

SOUTH WEST LOBBY

 4 Advocacy to Action: Empowering Patients and Physicians

NORTH WEST LOBBY

 1

 2

Learn how you can get involved and make your voice heard for you and your patients. See page 15 ». MAIN ENTRANCE LOBBY

BCEC Meeting Level 1

SOUTH EAST LOBBY

NORTH EAST LOBBY

 6

SOUTH WEST LOBBY

NORTH WEST LOBBY

 3

 4 5

 5 Maximize Your Value: Improve Your Neurology Practice Discover the best business practices for neurology to help you grow and sustain your practice. See page 12 ».

 6 Navigating Your Career: Choose a Track, Stay on Track, Change Tracks Find useful advice for every stage of your career development. See page 10 ».

BCEC Meeting Level 2

SOUTH EAST LOBBY

 7

NORTH EAST LOBBY

 7 Live Well: Taking Care of Your Patients Starts with Taking Care of You Get inspired about the importance of taking care of your mental and physical health. See page 9 ».

Visit AAN.com/view/ela for the most up-to-date topics and speakers Schedule current as of February 8, 2017


Live Well: Taking Care of Your Patients Starts with Taking Care of You Feeling burned out? Get inspired about the importance of taking care of your mental and physical health. From yoga and meditation to important information on managing personal, professional, and practice burdens, and one-on-one mentoring, this area will motivate you to take charge of your well-being. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations: Saturday, April 22

Sunday, April 23

Monday, April 24

Tuesday, April 25

Wednesday, April 26

Thursday, April 27

10:00 a.m.–10:45 a.m. Integrating Management of Activity and Exercise in Routine Clinical Practice Lisa M. Shulman, MD, FAAN

8:00 a.m.–8:45 a.m. Back from the Abyss: My Experience with the Patient Experience Laurence J. Kinsella, MD, FAAN

8:00 a.m.–8:45 a.m. Enhanced Well-being through Mentoring Joanne Smikle, PhD

8:00 a.m.–8:45 a.m. Complementary Therapies in Parkinson's Disease Veronica E. Santini, MD

8:00 a.m.–8:45 a.m. The Mindful Practice Curriculum at the University of Rochester Frederick J. Marshall, MD

12:00 p.m.–4:00 p.m. Massage Chairs

12:00 p.m.–4:00 p.m. Massage Chairs

1:00 p.m.–1:45 p.m. Mastering the Art of Practice: Recapturing the Joy of Neurology: Personal and Professional Balance Heidi B. Schwarz, MD, FAAN; Jennifer Rose Molano, MD, FAAN; Neil A. Busis, MD, FAAN

1:00 p.m.–1:45 p.m. Enhanced Well-being Through Mentoring— Session 1 Joanne Smikle, PhD

1:00 p.m.–1:45 p.m. Physical Exercise and Cognitive Training in Neurology— Application in Aging and Neurodegenerative Disease Ergun Y. Uc, MD

8:00 a.m.–8:45 a.m. The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist Charlene Gamaldo, MD, FAAN 12:00 p.m.–4:00 p.m. Massage Chairs

1:00 p.m.–1:45 p.m. Integrative Approach to the Management of Chronic Pain Syndromes Jessica Robinson-Papp, MD, FAAN

2:00 p.m.–2:45 p.m. Mastering the Art of Practice: Recapturing the Joy of Neurology–Your Organization and Health Care Policy Neil A. Busis, MD, FAAN

3:00 p.m.–3:45 p.m. Mind over Matter: Meditation for the Practicing Neurologist Sarah Mulukutla, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Sarah Bird Nelson, JD, RYT, 200

3:00 p.m.–3:45 p.m. Tips for Managing Patients with Functional Disorders Laurence J. Kinsella, MD, FAAN 4:45 p.m.–5:15 p.m. Guided Meditation Divya Singhal, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Sarah Bird Nelson, JD, RYT, 200

2:00 p.m.–2:45 p.m. How Social Relationships Contribute to Healthy Cognitive Aging Joel A. Salinas, MD

4:45 p.m. Guided Meditation Divya Singhal, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Sarah Bird Nelson, JD, RYT, 200

12:00 p.m.–4:00 p.m. Massage Chairs

2:00 p.m.–2:45 p.m. Acupuncture Demonstration Jennifer Bickel, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Jessica Robinson-Papp, MD, FAAN

12:00 p.m.–4:00 p.m. Massage Chairs 1:00 p.m.–1:45 p.m. Guts & Glory: The Importance of Diet and Exercise in Managing Persons with Multiple Sclerosis Barbara S. Giesser, MD, FAAN 2:00 p.m.–2:45 p.m. Nutritional Neuroscience: General Principles for Physicians and Translation to Patient Counseling Vanessa Baute, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Jessica Robinson-Papp, MD, FAAN

2:00 p.m.–2:45 p.m. Physical Exercise and Cognitive Training After Stroke A.M. Barrett, MD, FAAN, FASNR

3:00 p.m.–3:45 p.m. Introduction to Acupuncture II— Evidence-based 3:00 p.m.–3:45 p.m. Applications for Introduction to Acupuncture in the Acupuncture I— Treatment of Neurologic Conceptual Framework 3:00 p.m.–3:45 p.m. and Mechanism of Action Nutritional Neurosicence: Conditions Alexandra Dimitrova, MD Alexandra Dimitrova, MD General Principles and Translation to Patient 4:45 p.m.–5:15 p.m. 4:00 p.m.–4:45 p.m. Counseling—Talk 2 Guided Meditation StrengthsFinder Vanessa Baute, MD Divya Singhal, MD Social Hour 4:00 p.m –4:45 p.m. Keri Bischoff and Julie Striking the Balance–A Anderson Neurologist's Personal 5:00 p.m.–5:30 p.m. Wellness Story Guided Meditation Neil A. Busis, MD, FAAN Divya Singhal, MD 4:45 p.m.–5:15 p.m. Guided Meditation Divya Singhal, MD

7:00 a.m.–7:45 a.m. Yoga (All-levels Vinyasa) Jessica Robinson-Papp, MD, FAAN

12:00 p.m.–4:00 p.m. Massage Chairs

2:00 p.m.–2:45 p.m. Diets and Supplements in MS—What’s the Evidence Thus Far? Vijayshree Yadav, MD 3:00 p.m.–3:45 p.m. Cultivating Resilience in the Practice of Neurology Frederick J Marshall, MD 4:45 p.m.–5:15 p.m. Guided Meditation Divya Singhal, MD

Don't m • Free iss... ch

• Mor air massag ni es • Atte ng yoga n • Free tion meditat io w • Run ater bottle n / Walk t-shirt

AAN.com/view/AM17

9


Experiential Learning Areas

Navigating Your Career: Choose a Track, Stay on Track, Change Tracks Looking for useful advice for every stage of your career development? One-on-one mentoring and small-group sessions and a lively presentation stage will offer something for everyone: medical students, residents, fellows, junior faculty, senior faculty, and advanced practice providers. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations:

Presentations are focused on one of three tracks Choose a Track: Decide on the Best Career Option AAN Resident & Fellow Members: Meet and Greet Academic Career Panel: Find out How to Get Your Career Started Being a Great Chief Resident Career as a MuDPhuD: Choosing NOT to Choose Career Development for Medical Educators Choosing a Career in Neurocritical Care Choosing a Neurohospitalist Career Choosing Teleneurology as a Career Foreign Medical Graduates Adjustment Skills How Educating Can Improve Productivity During Clinical Activities How to Become and Get Promoted as a Clinician Educator How to Evaluate a Practice How to Start a Career in Neurology Education International Resident & Fellow Round Table Interviewing Skills Involving Students through a SIGN Chapter Patient Centered Teaching Private and Group Practice Panel: Find out How to Start a Career in Private Practice

Stay on Track: Get Tips on How to Succeed in Your Current Career An Interview with Stanley B. Prusiner, MD, FAAN, for the Oral History Archive Project

Change Tracks: Learn How to Make a Smooth Transition in Your Career Child Neurology—Staying on Track

Audience-specific Teaching Career Stories: Challenges for the Physician Scientist

Exploring Teleneurology Models in Private and Academic Practice

Career Stories: Nuts and Bolts of Academic Leadership— Strategies I Have Learned in My Career

Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator

Effective Neurology Residency Program

The Teaching Environment

How to Give Effective Feedback

Transitioning from Private Practice to Academics

Choosing a Career in Clinical Practice

Interviewing Skills: Negotiation Measuring Success: Quality Improvement 101 Mentorship Is Only as Good as the Mentee Research in Residency: How to Choose the Right Project Social Media for Clinicians Staying on an Academic Clinical Track The Encompassing Value of the PatientPhysican Relationship Up Your Game as a Medical Educator in Neurology Using the R&F Section of Neurology® for Your Residents and Residency

Teleneurology Panel

Navigating Your Career focuses on career development at every stage. Sessions will occur throughout the course of the meeting aimed at medical students, residents, fellows, junior faculty, senior faculty, and advanced practice providers. The formats will vary, from forums, to one-on-one mentoring, to group discussions. Come and hear career stories about how neurologists at all stages chose their subspecialties and practice types. Listen to successful pairs of neurologists and advanced practice providers discuss the keys to effective partnership. Engage in dialogue with neurologists who chose careers outside of academia. Sign up for on-site mentoring to help you navigate your career track. Join us for these innovative, informative sessions.

What I Learned About Research—An Early Career Perspective

—Maisha Robinson, MD

Subspecialty Sessions: IOM and cEEG Subspecialty Sessions: Neuroimmunology and Neurological Infections Teaching During a Busy Clinic Teaching History and Exam with Teleneurology

What to Expect: A General Overview of How to Pick the Right Career Path


Education and Publication Station: Knowledge Is Power Are you up-to-date on the latest news, information, and education opportunities in the world of neurology? Explore the AAN’s host of top-quality eLearning and other publications offering the very latest science, education, and news in neurology—and valuable CME—like Neurology ® journal, Continuum ®, Neurology Today ®, Neurology Now ®, and so much more. The Education and Publication Station is an opportunity to be hands-on with the AAN’s educational offerings and take part in small group discussion on a variety of topics. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations: Gamification of Neurology Zachary N. London, MD, FAAN

Prepping for the RITE and Certification Gauri V. Pawar, MD, FAAN

How to Get the Most of Your Annual Meeting Experience Joseph I. Sirven, MD, FAAN

How to Meet Part IV of MOC Kerry H. Levin, MD, FAAN

How to Use Continuum for Resident Education Steven L. Lewis, MD, FAAN MOC Information Sessions J. Clay Goodman, MD, FAAN A. Gordon Smith, MD, FAAN How to Use an RSS Feed for Your Own Learning Barry M. Czeisler, MD, MS Tips for Successful Submission to Neurology Robert A. Gross, MD, PhD, FAAN Tips for Successful Submission to Neurology ® Clinical Practice John Corboy, MD, FAAN You’ve Purchased Annual Meeting On Demand: Now What? Joseph E. Safdieh, MD, FAAN

These are a sampling of some of the talks and coaching sessions that will be held in the Education and Publication Station. For the most up-to-date list of offerings, access the AAN Annual Meeting app.

Get the Most of the Annual Meeting App Nate Kosher, AAN Staff NeuroTracker Sessions Multiple Physicians/Staff Throughout the Week Neuro Product Small Group Sessions Multiple Physicians/Staff Throughout the Week How to Onboard Your Advance Practice Providers Charles Zollinger, MD, FAAN Writing Better Papers by Sharpening Your Reviewing Skills Bradford B. Worrall, MD, MSc, FAAN Sharing Your Best Practices and Seeing Real-time Results Luca Bartolini, MD

The new Education and Publication Station at the Annual Meeting in your one-stop for educational offerings including eLearning, publications, presentations, demonstrations, and coaching sessions. Come learn about innovative products and services, educational strategies, and how to meet your CME and MOC needs. Be sure to plan to work the Education and Publication Station into your Annual Meeting schedule several times throughout the week because the offerings change daily. —Zachary London, MD, FAAN, Chair, Education and Publication Station Work Group

Small Group Talks with Key Plenary Speakers Plenary Speakers

Innovative Teaching Methods Shaheen E. Lakhan, MD, PhD, MEd Residents & Fellows Section: Tips for Successful Submission John J. Millichap, MD

... of 20% s t s n i u o m c Don't uum on-site dis stop

r tin ns: You • Con o i t a c i l Pub ls gs • AAN AAN journa offerin l l g a n i r n o r f ea lity eL ession a s u n q o i h t ma • Hig C infor f O M N t out o s o m • ABP the to get eeting w o H M • nnual your A

AAN.com/view/AM17 11


Experiential Learning Areas

Maximize Your Value: Improve Your Neurology Practice Are you employing the best strategies for ensuring the success of your practice? Discover the best business practices for neurology and leave with readily implementable strategies on how to grow and sustain your practice. Get your most pressing questions answered at the daily “Ask the Expert” booth and learn about a variety of topics from quality improvement to demonstrating your value as a neurologist at the presentation stage. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations: Saturday, April 22

1:00 p.m. Using Forms and Clinical Decision Support to Integrate Your Guidelines into Your EHR David A. Evans, MBA 1:30 p.m. Ask the Expert Booth: Using Forms and Clinical Decision Support to Integrate Your Guidelines into Your EHR David A. Evans, MBA 2:00 p.m.-2:30 p.m. The AAN’s Effort to Enhance Your EHR Experience Allison L. Weathers, MD, FAAN 2:30 p.m.-3:00 p.m. Ask the Expert: Optimizing Your EHR Allison L. Weathers, MD, FAAN 3:30 p.m. Top 10 Technologies for Your Neurology Practice William S. Henderson, FACMPE 4:00 p.m. Telemedicine Beyond Tele-stroke Eric R. Anderson, MD, PhD 4:30 p.m. Ask the Expert Booth: Telemedicine Beyond Tele-stroke Eric R. Anderson, MD, PhD

Sunday, April 23

3:00 p.m. Data You Need to Improve Care Anup D. Patel, MD 3:30 p.m. Ask the Expert Booth: Data You Need to Improve Your Care Anup D. Patel, MD

Monday, April 24

1:00 p.m. Ethics Course: Physician Burnout Jennifer Rose Molano, MD, FAAN Julie Anna Kurek, MD Robin A. Conwit, MD, FAAN 1:30 p.m. Ethics Course: Ethics of Drug Pricing Lynne P. Taylor, MD, FAAN 2:00 p.m. Ethics Course: The Electronic Health Record Justin A. Sattin, MD 2:30 p.m. Ethics Course: Telemedicine Zachary Simmons, MD, FAAN 3:00 p.m. Coding and Reimbursement for APPs Korwyn Williams, MD, PhD 3:30 p.m. Patient Reported Outcomes Scales for Parkinson’s Disease Justin P. Martello, MD

8:30 a.m.-9:00 a.m. Patient Reported Outcomes Scales for Neuropsych Brenden Kelley, MD, MS

4:00 p.m. New Codes for 2017—Are You Leaving Money on the Table? Bruce A. Cohen, MD, FAAN

8:30 a.m.-9:00 a.m. Top 3 Patient Reported Outcome Tools Cindy J. Nowinski, MD, PhD

4:30 p.m. Ask the Expert Booth: New Codes for 2017—Are You Leaving Money on the Table? Bruce A. Cohen, MD, FAAN

Tuesday, April 25

Thursday, April 27

1:00 p.m. Improving Patient and Family Satisfaction David Y. Hwang, MD Sarah Benish, MD, FAAN

4:00 p.m. Using Forms and Clinical Decision Support to Integrate Your Guidelines into Your EHR Allison L. Weathers, MD, FAAN

2:00 p.m. MACRA Overview Lyell K. Jones, MD, FAAN

Friday, April 28

8:30 a.m. Axon Registry Lyell K. Jones, MD, FAAN

3:30 p.m. Rising Drug Costs Brian Callaghan, MD

1:00 p.m. Ask the Expert Booth: Neurology Compensation and Productivity Survey

3:00 p.m. MIPS: What Is MIPS and How Do I Participate Anup D. Patel, MD

1:30 p.m. Ask the Expert Booth: Neurology Compensation and Productivity Survey

3:30 p.m. Ask the Expert Booth: MIPS Anup D. Patel, MD

2:00 p.m. Ask the Expert Booth: Axon Registry

5:00 p.m. Axon Registry Bruce Sigsbee, MD, FAAN

2:30 p.m. Ask the Expert Booth: Axon Registry

5:30 p.m. Ask the Expert Booth: Axon Registry Bruce Sigsbee, MD, FAAN

Wednesday, April 26

4:00 p.m. Ask the Expert Booth: MACRA

1:00 p.m. Hot Topics in Guideline Development Sonja Potrebic, MD, PhD, FAAN

4:30 p.m. Ask the Expert Booth: MACRA

1:30 p.m. Ask the Expert Booth: Hot Topics in Guideline Development Sonja Potrebic, MD, PhD, FAAN 2:30 p.m. Patient Reported Outcome Scales for Sleep Rachel Marie E. Salas, MD 4:30 p.m. Hospital Patient Coding Mark J. Bailey, DO, PhD

iss... m t ' n Do CRA

• MA Registry n • Axo Guidelines n nsatio N e A p A m o • C urvey rology • Neu roductivity S and P

12 2017 AAN Annual Meeting Science Program


Research Corner: Moving Neurology Forward Do you know how important research is the future of neurology? See how it’s making a significant impact on patient care and everyday neurology, and discover new and valuable resources to help you move your research forward. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations:

Don't Miss! Themed days including the AAN Research Program, Awards Day, and NINDS Day. Saturday, April 22

11:30 a.m.–12:00 p.m. Grantwriting 101: Getting Started Stephen Greenberg, MD, PhD 1:00 p.m.–1:30 p.m Your Grant Proposal Was Rejected: Now What? Turning a Feedback into a Successful Project Amy Brooks-Kayal MD, FAAN

Sunday, April 23— AAN Research Program Day

8:00 a.m.–8:30 a.m. "I Don't Feel Like a Researcher"—How to Make the Career Work Even if You Aren't the "Typical" Fit David Hwang, MD 1:00 p.m.–1:30 p.m. Selecting an AAN Research Program Mentor Michael Wilson, MD 1:30 p.m.–2:00 p.m. AAN Research Program Alumni Panel Discussion Michael Wilson, MD 2:00 p.m.–2:30 p.m. Clinical Trials Methodology Course— Information Session William Meurer, MD, MS, CTMC Principal Investigator 2:30 p.m.–3:00 p.m. Nuts and Bolts of AAN Research Program: Explanations of How Much Funding Is Available and What Kind of Research Is Accepted Aleksandar Videnovic, MD, MS, FAAN 3:00 p.m.–4:00 p.m. Transitioning from an AAN Research Program Grant to NIH Funding Daniel Claassen, MD

4:00 p.m.–4:30 p.m. Writing a Great AAN Research Program Proposal Jeffrey Gelfand, MD, MAS, FAAN

2:00 p.m.–2:30 p.m. Q&A with an NIH BRAIN Initiative Grantee Harrison Walker, MD

4:30 p.m.–5:00 p.m. Congratulations! Your Research Training Application Was Accepted! Now Make the Most of it! Aleksandar Videnovic, MD, MS, FAAN

2:30 p.m.–3:30 p.m. Panel of NIH Grant Review Committees Adam Hartman, MD, Program Director, Office of Clinical Research, NINDS

5:00 p.m.–5:30 p.m. Current Research Program Recipients Panel Discussion

Monday, April 24—Awards Day 1:00 p.m.–2:00 p.m. Scientific Platform Session S11 Autonomic Disorders: Synucleinopathies Presentation of Irwin Schatz Award for Autonomic Disorders

Thursday, April 27

1:00 p.m.–2:00 p.m. Scientific Platform Session S38 Pain and Palliative Care Presentation of the Mitchell B. Max Award for Neuropathic Pain 3:30 p.m.–4:30 p.m. Scientific Platform Session S43 Exciting New Results in Neuro-rehabilitation

3:30 p.m.–4:00 p.m. NIH Clinical Trials Recruitment Clinton Wright, MD, Director, Office of Clinical Research, NINDS

Wednesday, April 26

8:00 a.m.–8:30 a.m. Women in Basic Science Amy Brooks–Kayal, MD, FAAN; Phyllis Zee, MD, PhD

8:00 a.m.–8:30 a.m. Learn About Opportunities to Work with the NIH Intramural Program Avindra Nath, MD, Chief Section of Infections of the Nervous System, Clinical Director, NINDS, NIH 8:30 a.m.–9:00 a.m. NIH Funding and Professional Development Opportunities for Diverse Researchers Michelle Jones-London, PhD, Chief, Office of Programs to Enhance Neuroscience Workforce Diversity, NINDS 1:00 p.m.–1:30 p.m. Introduction and Overview of NIH Funding Walter Koroshetz, MD, FAAN, Director, NINDS 1:30 p.m.–2:00 p.m. Panel of K Awardees Brian Wainger, MD, PhD

12:00 p.m.-12:30 p.m. FDA Introductory Seminar on Navigating the Regulatory Landscape for Neurological Devices and Moving Neurotechnologies to Patients and Caregivers William Heetderks, MD, PhD and Katrina Gwinn, MD 12:30 p.m.-1:00 p.m. Small Group Mentoring Session: FDA Introduction Continued William Heetderks, MD, PhD and Katrina Gwinn, MD 1:00 p.m.–2:00 p.m. Scientific Platform Session S28 History of Neurology 3:30 p.m.–4:15 p.m. Scientific Platform Session S32 Global Health

Time Management/Work-life Balance When to Say Yes—and No! (Committees, Paper Presentations, Teaching, and Reviewing Abstracts) Careers in Industry Panel Air Pollution and Stroke How to Give a Talk at AAN

Are You My Mentor? Finding One and Growing Your Career Deborah Hall MD, PhD, FAAN

Are You My Basic Research Mentor?

How to Find Training: The Best Clinical Research and Methodology Training Options

Small Group Mentoring Sessions

Publication Strategies

Careers in Industry Brandy Matthews, MD, FAAN

Epidemiology—What It Is and How to Get Started

8:30 a.m.–9:00 a.m. Presentations and Discussions Income Disparity in Research Current and Former Award Careers Recipients Phyllis Zee, MD, PhD

Tuesday, April 25—NINDS Day

Additionally, Don’t Miss:

PCORI – What's All the Fuss?

History of Parkinson's Disease IRB Reviews Deborah Hall, MD, PhD, FAAN

Health Outcomes Research

Finding/Working with Epidemiologists on Your Grant

Publication Strategies When Manuscripts Are Rejected

Finding/Working with Statisticians on Your Grant

"Grit" and Work-life Balance in Grantwriting

Statistics—Sample Size

American Brain Foundation Crowdfunding

Building Contracts and Budgets Creating "Bridge" Funding— How to Use Non-NIH Funding

Don't M Corne iss These R r Opp ortun esearch Them ities! ed Da ys: Re

searc Spotl and th h Program, A ight on the A e A A Disord National Ins N Award R N e t ers an d Stro itute of Neu cipients, NEW k r e ologica (NIND !S l S) platfor cientific S ms ses e sions i ssions: Att Resea n end a new r learnin small- ch Careers g expe gr :R rience add yo oup mentori esearcher p ng ses ur pho r o files, si to resear ch is im to the Face ons, and a ch sW a portan Awar t to yo all to tell u nce to d Rec u s ! why ipi the rec ipients ent Recog ni of the 2017 A tion: Celebr at AN Aw ards e


Experiential Learning Areas

HeadTalks Interested in out-of-the-box learning? Engage in creative and provocative presentations on some of the timeliest topics in neurology. These unique talks will follow a wide variety of formats and include everything from the history of neurologic medicine in Boston to live neuro exams, panel discussions with past AAN presidents, and “ask-the-expert” and interactive-style sessions that challenge your creativity. Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations*: Saturday, April 22

2:00 p.m.–3:00 p.m. The Role of Medical Illustration in Neurology Andrew Swift, MS, CMI 4:00 p.m.–5:00 p.m. Ask Me Anything—Neurology® Robert A. Gross, MD, PhD, FAAN

Sunday, April 23

8:00 a.m.–9:00 a.m. Annual Meeting Orientation Carlayne E. Jackson, MD, FAAN 1:00 p.m.–2:00 p.m. Patient Engagement: The Good, The Bad, Is There Any Ugly? Allison L. Weathers, MD, FAAN Jeffrey R. Buchhalter, MD, FAAN Daniel B. Hoch, MD, PhD, FAAN Melissa Yu, MD Allan Ding Wu, MD

Monday, April 24

12:00 p.m.–2:00 p.m. Neurological Exam Tips and Tricks Thomas R. Swift, MD, FAAN Christopher H. Hawkes, MD, Bsc, FRCP

Wednesday, April 26

7:00 a.m.–9:00 a.m. Annual Meeting Orientation Maisha T. Robinson, MD, MS 12:00 p.m.–1:00 p.m. The Purpose Checkup: Find Meaning, Live Longer, Better Richard Leider 3:30 p.m.–5:30 p.m. Paint and Wine Hour Note participation is limited

Thursday, April 27

1:00 p.m.–2:00 p.m. Telemovement: Using Telemedicine in an Outpatient Neurology Setting Jaime Hatcher-Martin, MD

Friday, April 28

2:00 p.m.–3:00 p.m. Improvisation and the Brain...at the Piano Phillip L. Pearl, MD, FAAN

Additionally, don’t miss:

Work Life Balance in Neurology Kim P. Gannon, MD, PhD Lyell K. Jones, MD, FAAN Maisha T. Robinson, MD, MS Jennifer Molano, MD, FAAN

Globalization and Neurology Jerome H. Chin, MD, PhD, MPH, FAAN Ask Us Anything—Expert Panel on Multiple Sclerosis Brenda Banwell, MD, FAAN Janis Miyasaki, MD, FAAN Ask Us Anything—Expert Panel on Stroke Bart M. Demaerschalk, MD, MSc, FRCPC Larry B. Goldstein, MD, FAAN, FAHA

Being a Neurologist in the Digital Age: Managing Your Professional Personal Digital Profile Jeff Kraakevik, MD

Ask Us Anything—Expert Panel on Headache and Pain Kathleen B. Digre, MD, FAAN Peter Goadsby, MD, PhD

How to Engage with the AAN Terrence L. Cascino, MD, FAAN Jeffrey C. McClean II, MD, FAAN Christine Phelps, Deputy Executive Director, AANI

Hot Topics en Español Edgar A. Samaniego, MD Jose I. Suarez, MD Alejandro Tobon, MD

Stories of Boston Neurology Thomas D. Sabin, MD, FAAN

Healthcare Disparities Amongst Groups Jeffrey C. McClean II, MD, FAAN Holly E. Hinson, MD, MCR Charles C. Flippen II, MD, FAAN Hope O'Brien, MD Temitayo Oyegbile, MD

Publication Editors Tell All: Hits, Misses, and Tips Robert A. Gross, MD, PhD, FAAN Steven P. Ringel, MD, FAAN Lisa M. Shulman, MD, FAAN Orly Avitzur, MD, MBA, FAAN Caring for Your Neurologic Patient for $500 or Less Donn Dexter, MD, FAAN Cynthia L. Comella, MD, FAAN

Is There a Neurologist on This Flight? Joseph I. Sirven, MD, FAAN Neurology Pictionary Challenge Bert B. Vargas, MD, FAAN

Ask Us Anything—Expert Panel on Parkinson Disease and Dementia David S. Knopman, MD, FAAN Ronald C. Petersen, PhD, MD Lisa M. Shulman, MD, FAAN

Mastering EMG Waveform Recognition Skills in One Hour! Devon I. Rubin, MD, FAAN

Hall of Presidents: Neurology Through the Years Terrence L. Cascino, MD, FAAN Robert C. Griggs, MD, FAAN Stephen M. Sergay, MB BCh, FAAN Thomas R. Swift, MD, FAAN Sandra F. Olson, MD, FAAN Francis I. Kittredge Jr., MD, FAAN Steven P. Ringel, MD, FAAN Roger N. Rosenberg, MD, FAAN

Stuff No One Tells You Regarding the Mentormentee Relationship Neil Masangkay, MD

Rural Neurology Michael Stitzer, MD

Bullying and Cyberbullying Prevention Peter Raffalli, MD, FAAP

Neurology and Art David E. Thaler, MD, PhD

Talks s: Neurology d e r u Feat l of President s

• Hal gh the Year ol Throu cs en Españ s and Tricks Tip Topi • Hot logical Exam ro t • Neu logy and Ar r ro ou • Neu and Wine H t • Pain


Advocacy to Action: Empowering Patients and Physicians Learn how you can get involved and make your voice heard for you, your patients, and the future of neurology. Get inspired to make a difference when you hear directly from AAN member advocates and AAN advocacy staff on initiatives such as BrainPAC, Neurology on the Hill, and the Palatucci Advocacy Leadership Forum. Get inspired to make a difference! Visit AAN.com/view/ela for the most up-to-date topics and speakers. Schedule current as of February 8, 2017.

Scheduled Presentations: Saturday, April 22

Antidote to Burnout: Advocacy Donn Dexter, MD, FAAN Neurology and the 115th Congress Mike Amery, Esq.

Sunday, April 23

How to: Obtain a Grant Jennifer Bickel, MD Practice Makes Perfect: Mock Legislative Visits Joe Gagen, Legislative Grassroots Consultant

Monday, April 24

Practice Makes Perfect: Mock Legislative Visits Joe Gagen, Legislative Grassroots Consultant How to: Make the Media Your Friend Anthony G. Alessi, MD, FAAN Neurology and the 115th Congress Derek Brandt

Tuesday, April 25

Follow the Dollar: BrainPAC Donation to Candidate Contribution Lily Jung Henson, MD, MMM, FAAN Painting in Twilight: An Artist’s Escape from Alzheimer’s Daniel C. Potts, MD, FAAN How to: Raise Research Funding David B. Watson, MD, FAAN

Wednesday, April 26

How to: Be a Lobbyist for a Day Janice F. Wiesman, MD, FAAN How to: Fight for Neurology Nicholas E. Johnson, MD

Thursday, April 27

Follow the Dollar: BrainPAC Donation to Candidate Contribution Glen R. Finney, MD

I chose to get involved with AAN advocacy because the AAN actively engages with policymakers to improve our practices. I saw that the AAN was working to increase the research funding for neurosciences, advocating for better access for patients with neurological disease, and working to reduce the regulatory burdens on practicing neurologists. I became involved because these efforts need every one of us to work together to affect change for unique burdens faced by patients with neurological disease. In this period of change, get involved in advocacy to ensure neurology is valued in the future. I encourage you to visit Advocacy to Action to learn how you can fight for neurology. — Nicholas E. Johnson, MD, Chair, AAN Government Relations Committee

Don't miss: Brai

nPA politic C: Donate al to solely action comm the only to neu rology ittee dedica Advoc ted acy A to con c tact yo tion Cente u r: positiv r e chan legislator to Learn how g neurol i ogy pa es for you a nfluence nd you tients Photo r Booth #AAN : Advoc Capture a p acy ph h oto wa oto for the ll

Fast and easy registration · AAN.com/view/AM17 15


OPENING PARTY Sunday, April 23 • 6:00 p.m.–10:00 p.m.

Kick Off the Annual Meeting Everyone’s Talking About with the Party Everyone Will Be Talking About Neurobowl® 6:00 p.m.–8:00 p.m. This popular event, hosted by AAN former president Thomas R. Swift, MD, FAAN, is one of the Annual Meeting’s premier happenings. Neurobowl showcases the best and brightest in neurology competing for the coveted Neurobowl trophy in an entertaining game-show format.

Trinity Irish Dance Company 8:30 p.m.–9:15 p.m. Billed as “everything you expect but nothing you imagine,” Trinity Irish Dance Company quickly dispels whatever notions you may have about Irish dance. The company dazzles audiences with hard-driving percussive power, lightning-fast agility, aerial grace, and the awe-inspiring precision of its dancers that led them to win an unprecedented 17 World Championships for the US and appearances in feature films by Disney, DreamWorks, Touchstone, and Universal and on the Tonight Show.

Live DJ and Dancing 9:15 p.m.–10:00 p.m. Get down with friends and colleagues to some of the most memorable dance tunes spanning the past six decades.

AAN.com/view/AM17


Sat April 22,  5:00 p.m.–6:30 p.m.

10:00 a.m. 11:00 a.m. 12:00 p.m. 1:00 p.m. 2:00 p.m.

10:30 a.m.– 12:30 p.m.

5:00 p.m. 6:00 p.m. 7:00 p.m. 8:00 p.m.

Education and Science

Education Education & Science & Science 1:00 p.m.– 3:00 p.m.

1:00 p.m.– 5:00 p.m.

Education & Science 2:00 p.m.– 4:00 p.m.

3:00 p.m. 4:00 p.m.

Presidential Plenary Session

AAN Business Meeting 4:00 p.m.–4:30 p.m.

1:00 p.m.– 3:00 p.m.

Education and Science

9:15 a.m.–11:30 a.m.

3:30 p.m.–5:30 p.m.

Education and Science

1:00 p.m.–3:00 p.m.

Education and Science

3:30 p.m.–5:30 p.m.

Clinical Trials Plenary Session

1:00 p.m.–3:00 p.m.

Education and Science

3:30 p.m.–5:30 p.m.

9:15 a.m.–11:30 a.m.

Education and Science 1:00 p.m.– 3:00 p.m.

6:00 p.m.–10:00 p.m.

Industry Therapeutic Updates 7:00 p. m.–10:00 p.m.

6:00 p.m.–8:00 p.m.

Neurobowl

®

8:30 p.m.–9:15 p.m.

Trinity Irish Dance Company DJ, Music, and Dancing

Faculty and Trainee Reception

Education and Science

3:30 p.m.–5:30 p.m.

6:00 p.m.– 9:00 p.m.

Education and Science 1:00 p.m.– 3:00 p.m.

Education and Science

3:30 p.m.– 5:30 p.m.

9:15 a.m.–11:30 a.m.

Education and Science 1:00 p.m.– 3:00 p.m.

Education and Science

3:30 p.m.– 5:30 p.m.

5:30 p.m.–7:00 p.m.

Industry Therapeutic Updates

7:00 p.m.–10:00 p.m.

Moderators: Joseph Jankovic, MD, FAAN

Deborah Hall, MD, PhD, FAAN Member, Science Committee

Aleksandar Videnovic, MD, MSc, FAAN

Jonathan Kipnis, PhD

Member, Science Committee

Paul S. Fishman, MD, PhD

O. Carter Snead, III, MD, FAAN

University of Minnesota, Minneapolis, MN

University of Florida, Gainesville, FL

Sunday, April 23,  9:15 a.m.–12:00 p.m.

The Research Institute at Nationwide Children’s Hospital, Columbus, OH

Scott Powers, PhD

University of Colorado School of Medicine, Aurora, CO

Dimitri Krainc, MD, PhD

Commitment Industry to Cures Therapeutic 7:00 p.m.– Updates

9:30 p.m.

7:00 p.m.– 10:00 p.m.

Hospital for Sick Children, Toronto, ON, Canada

Neurology Year in Review Plenary Session

Closing Party Happy Hour

Education and Science 6:00 p.m.– 9:00 p.m.

Controversies in Neurology Plenary Session 9:15 a.m.–11:30 a.m.

5:00 p.m.–6:30 p.m.

Opening Party

Moderators: Natalia Sana Rost, MD, FAAN

Member, Science Committee

University of Virginia, Charlottesville, VA

7:00 a.m.–9:00 a.m.

Thursay, April 27,  9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session

Columbia University, New York, NY

Education and Science

7:00 a.m.–9:00 a.m.

Frontiers in Neuroscience Plenary Session

9:15 a.m.–11:30 a.m.

Education and Science

7:00 a.m.–9:00 a.m.

Hot Topics Plenary Session

9:15 p.m.–10:00 p.m.

9:00 p.m.

Contemporary Clinical Issues Plenary Session

9:15 a.m.–12:00 p.m.

Education & Science

7:00 a.m.–9:00 a.m.

7:00 a.m.–9:00 a.m.

Education and Science

Poster Session VI 8:30 a.m.–5:30 p.m.

8:00 a.m.– 5:00 p.m.

7:00 a.m.–9:00 a.m.

Education and Science

Poster Session V 8:30 a.m.–7:00 p.m.

8:00 a.m.– 12:00 p.m.

Education and Science

Tuesday, April 25,  9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session

Moderator: Eric Klawiter, MD

Claudia A. Chiriboga, MD

Poster Session IV 8:30 a.m.–7:00 p.m.

8:00 a.m.– 10:00 a.m.

Run/Walk for Brain Research Education 6:30 a.m.–8:30 a.m. and Science

Thur April 27 Fri April 28

Hot Topics Plenary Session

Northwestern University, Chicago, IL

Exhibit Hall 11:30 a.m.–3:00 p.m.

9:00 a.m.

Education Education Education & Science & Science & Science

Wed April 26

Poster Session III 8:30 a.m.–7:00 p.m.

8:00 a.m.

Education and Science

Tue April 25

Poster Session II 8:30 a.m.–7:00 p.m.

7:00 a.m.

Mon April 24

Exhibit Hall 11:30 a.m.–4:00 p.m.

Sun April 23

Exhibit Hall 11:30 a.m.–6:00 p.m.

Sat April 22

Poster Session I 8:30 a.m.–5:30 p.m.

6:00 a.m.

2017 Plenary Speakers

Exhibit Hall 11:30 a.m.–4:00 p.m.

Tear out along perforation

Meeting-at-a-Glance

Presidential Plenary Session

Vice Chair, AAN Science Committee

Petra Kaufmann, MD, FAAN

Member, Science Committee

Member, Science Committee

Adnan I. Qureshi, MD

University of Maryland School of Medicine, Baltimore, MD

Jerry R. Mendell, MD, FAAN

Michael S. Okun, MD, FAAN John Corboy, MD, FAAN

Moderator: Natalia Sana Rost, MD, FAAN

Cincinnati Children’s Hospital, Cincinnati, OH

Ludwig Kappos, MD

Robert T. Naismith, MD

Terrence L. Cascino, MD, FAAN

J. Helen Cross, PhD

Reisa A. Sperling, MD

Vice Chair, AAN Science Committee Mayo Clinic, Rochester, MN

Nancy J. Newman, MD, FAAN

Emory University School of Medicine, Atlanta, GA

J. Helen Cross, PhD

UCL-Institute of Child Health, London, United Kingdom

Ronald C. Petersen, PhD, MD, FAAN Mayo Clinic, Rochester, MN

Monday, April 24,  9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session Moderator:  Natalia Sana Rost, MD, FAAN Vice Chair, AAN Science Committee

Nancy L. Kuntz, MD,

Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

Charlotte J. Sumner, MD,

Johns Hopkins Medicine, Baltimore, MD

Alessandro Biffi, MD

Massachusetts General Hospital, Boston, MA

Daniel F. Hanley, MD, FAAN

Johns Hopkins Medicine, Baltimore, MD

Michelle Monje, MD, PhD

Stanford University, Stanford, CA

University Hospital Basel, Basel, Switzerland

Washington University, St. Louis, MO

UCL-Institute of Child Health, London, United Kingdom

Brigham and Women’s Hospital, Boston, MA

Gil I. Wolfe, MD, FAAN

The University of Texas at San Antonio, San Antonio, TX

Wednesday, April 26,  9:15 a.m.–11:30 a.m.

Neurology Year in Review Plenary Session

University at Buffalo, Buffalo, NY

Frontiers in Neuroscience Plenary Session

George Perry, PhD

Friday, April 28,  9:15 a.m.–11:30 a.m.

Randolph S. Marshall, MD, FAAN

Moderator: Shafali Jeste, MD

Charles Gersbach, PhD

Susan Fox, MD

Mary Reilly, MD, FRCP, FRCPI

Erika Fullwood Augustine, MD, FAAN

Amy R. Brooks-Kayal, MD, FAAN

Brett M. Kissela, MD, MS, FAAN

Xandra O. Breakefield, PhD

Peter A. Calabresi, MD, FAAN

Moderator:

Member, Science Committee

Duke Center for Genomic and Computational Biology, Durham, NC National Hospital for Neurology and Neurosurgery, London, United Kingdom Children’s Hospital Colorado, Aurora, CO

Member, Science Committee Toronto Western Hospital, Toronto, ON, Canada

University of Rochester Medical Center, Rochester, NY

University of Cincinnati Hospital, Cincinnati, OH

Massachusetts General Hospital, Charlestown, MA

Johns Hopkins University, Baltimore, MD

M. Elizabeth Ross, MD, PhD

University of California Los Angeles, Los Angeles, CA

Cornell University, New York, NY

Paul Vespa, MD

Eliezer Masliah, MD

National Institute on Aging, Bethesda, MD

Tracy T. Batchelor, MD, MPH

Massachusetts General Hospital, Boston, MA

Louise D. McCullough, MD, PhD

The University of Texas Health Science Center at Houston, Houston, TX

Amaal J. Starling, MD Mayo Clinic, Phoenix, AZ

10:00 p.m.

Dennis N. Bourdette, MD, FAAN

Oregon Health & Science University, Portland, OR

See page 39 » for full Tittles and descriptions


Saturday, April 22

Sunday, April 23

8:00 a.m.–10:00 a.m.

7:00 a.m.–9:00 a.m.

1:00 p.m.–5:00 p.m.

7:00 a.m.–9:00 a.m.

C1 C2 C3 C4

C23 Using Sleep Medicine to Help Solve

C46 Resident Basic Science III:

C62 Mild Cognitive Impairment: Implications

The Neurology of Social Behavior Parkinson’s Disease Update Status Epilepticus Multiple Sclerosis Essentials

Difficult Neurologic Cases

C26

C5 Resident Basic Science I:

C27

8:00 a.m.–5:00 p.m.

C28 C29 C30 C31 C32

C6 Early Career Research Training C7 C8 C9

Symposium: A Roadmap to Academic Success for Residents and Fellows (registration required) Neurology MOC Prep Course $ (registration required) L Clerkship and Program Directors Leadership Academy (registration required) L Women in Leadership$ (registration required)

10:30 a.m.–12:30 p.m. C10 Making Sure You Get Paid Under the New C11 C12 C13 C14

Health Care Laws Neuromyelitis Optica Spectrum Disorders Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular and MuSK Myasthenia Neurologic Complications of Medical Disease Concussion: From Mechanisms to Management

1:00 p.m.–3:00 p.m. C15 Practical Training in Injection Techniques

in the Treatment of Headache Disorders Skills Workshop $ (registration required)

1:00 p.m.–5:00 p.m. C16 Resident Basic Science II: Neuropathology

2:00 p.m.–4:00 p.m.

S1 “Best of” Session: Parkinson’s Disease

8:30 a.m.–5:30 p.m. P1 Poster Session I—Presenters Stand by

9:15 a.m.–12:00 p.m.

Presidential Plenary Session 11:30 a.m.–4:00 p.m.

Exhibit Hall

11:30 a.m.–1:30 p.m. NEW Exhibit Hall Opening Lunch

N1 Neuroscience in the Clinic: Neurobiology S2 S3 S4 S5

C34

C21 C22

4:00 p.m.–4:30 p.m.

C35 C36 C37 C38 C39

AAN Business Meeting

5:00 p.m.–6:30 p.m.

C40

Hot Topics Plenary Session

C41

7:00 p.m.–10:00 p.m.

Industry Therapeutic Updates

C49 Clinical Uses of Botulinum Toxin

for Dystonia Skills Workshop $ (registration required) C50 Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop $ (registration required)

3:30 p.m.–5:30 p.m.

C42 C43 C44 C45

and Treatment of Disorders of Language and Action Neuroimaging in MS ALS: Disease Mechanism and Therapeutics Movement Disorders: Beyond Oral Levodopa in Parkinson’s Disease General Neurology: Pathogenesis, Modulation, and Biomarkers of Complex Neurological Disorders Non-Alzheimer’s Dementia I: Frontotemporal Dementias and Chronic Traumatic Encephalopathy Introduction to Primary Headache Disorders I: Migraine and Other Primary Headaches Including Tension-type, Hypnic, Primary Stabbing, and Nummular Headache Syndromes Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Multiple Sclerosis Therapy: Diseasemodifying Treatment I Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Case Studies: Neurologic Consultations in Cancer Patients I So You’ve Diagnosed Your Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases Neurology Update I: Epilepsy, Headache, and Neurologic Infections Clinical Epilepsy II: Considerations Across the Age Span—Pediatrics, Pregnancy, and Elderly Cerebrovascular Disease II: Hemorrhagic Stroke Introduction to Clinical Research and Methods Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies I Navigating the World of Mobile Health

for Clinicians

C68 C69

S6

C71 C72

S7 S8 S9 C51 C52

C53 C54 C55 C56 C57 C58 C59 C60 C61

6:00 p.m.–8:00 p.m. Neurobowl 8:30 p.m.–9:15 p.m. Trinity Irish Dance Company 9:15 p.m.–10:00 p.m. DJ, Music, and Dancing

Diagnostic Testing of Neurological Infections Approach to the Shaky Patient Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Sports Neurology: Enhancing Athletic Performance Hot Topics in Sleep Neurology Gender-specific Care for Neurological Disorders Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Annual A.B. Baker Program: Focus on Professionalism

1:00 p.m.–3:00 p.m. N3 Neuroscience in the Clinic: Cutting Edge S12 S13 S14 C76 C77 C78 C79 C80 C81 C82 C83 C84

18 2017 AAN Annual Meeting Early Look

American Neurology Part I

Practices, Academic Centers, and the Future

1:00 p.m.–5:00 p.m. C88 L Improving Your Leadership Skills: A

Practical Approach (registration required)

1:00 p.m.–5:30 p.m. C89 Neurophysiologic Intraoperative Monitoring Skills Workshop $ (registration required)

3:30 p.m.–5:30 p.m.

Invited Science: Headache S15 Neuroepidemiology S16 MS Characterizations and Tools for C74 Measurement S17 Movement Disorders: Ataxia and the Cerebellum 8:00 a.m.–9:00 a.m. S18 Behavioral and Cognitive Neurology S10 “Best of” Session: MS and CNS C90 Behavioral Neurology II: Memory and Inflammatory Disease Praxis C91 Neuro-rheumatology: Neurological 8:30 a.m.–7:00 p.m. Manifestations of Systemic Inflammatory P2 Poster Session II—Presenters Stand by and Autoimmune Disease II Posters 5:30 p.m.–7:00 p.m. C92 Neuroimaging for the General Neurologist II: Brain and Spine 9:15 a.m.–11:30 a.m. C93 Boston City Hospital: The Cradle of American Neurology Part II Contemporary Clinical Issues C94 Child Neurology III: Headache, TBI/Postconcussion Plenary Session C95 Common Spine Disorders II: Treatment 11:30 a.m.–6:00 p.m. C96 Infections of the Nervous System III: Advanced Topics in Infectious Neurology Exhibit Hall C97 The Dystonias: Diagnosis, Treatment, and 4:30 p.m.–6:00 p.m. Update on Causes NEW Exhibit Hall Networking Reception C98 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle 12:00 p.m.–5:30 p.m. Pathology C99 Therapeutic Temperature Modulation in C75 Clerkship and Program Directors the ICU Conference: Wellness and Burnout During C100 Neuro-otology II: Diagnosis and Treatment Training of Nuanced Causes of Dizziness C101 Drug-induced Neurologic Emergencies 1:00 p.m.–2:00 p.m. Business Strategies for Payer Negotiations S11 Autonomic Disorders: Synucleinopathies C102 and/or How to Go off the Grid

C73

6:00 p.m.–10:00 p.m.

Opening Party

C85 Boston City Hospital: The Cradle of

Autoimmune

C66 Neuro-oncologic Emergencies C67 Infections of the Nervous System I:

C70

Neurology: Neurologic Disorder Through a Lifespan—A Focus on MS Research Methodology and Education: Education Research Aging and Dementia: Clinical and Translational Studies in Neurodegenerative Diseases Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment Neuro Trauma and Sports Neurology Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias Introduction to Primary Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Primary Thunderclap Headaches Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Multiple Sclerosis Therapy: Diseasemodifying Treatment II Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Case Studies: Neurologic Consultations in Cancer Patients II Neurology Update II: Movement, Spine, and Autonomic Neurology Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Cerebrovascular Disease III: Acute Ischemic Stroke Precision Neurology: The Promise and Perils of Personalized Medicine in the Genomic Era Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies II

Tuesday, April 25

C63 CNS Toxicities C86 Neuro-otology I: The Common Peripheral Vestibular Disorders C64 ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement C87 How to Run a Practice: Business Strategies for Neurology Private C65 Child Neurology I: Pediatric Stroke, MS/

N2 Neuroscience in the Clinic: Child

1:00 p.m.–3:00 p.m.

C18

C20

1:00 p.m.–5:30 p.m.

Posters 4:00 p.m.–5:30 p.m.

C33

C19

Diagnosis and Management Clinical EMG I: Principles and Practice of NCS and Needle EMG Differential Diagnosis of Neurologic Infections Advances in Neurogenetics Clinical Epilepsy I: Basics Cerebrovascular Disease I: Prevention Advanced Neurologic Coding Emergency Room Neuro-ophthalmology

8:00 a.m.–9:00 a.m.

C17 How Is Your Patient Really Doing? Patient

Reported Scales, Tools and Shared Decision Making Vascular Cognitive Impairment and Dementia: Current Status and Future Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission Neurologic Complications of Medical and Surgical Therapies Concussion: Evaluation and Management in the Acute and Chronic Phases It’s a Bird, It’s a Plane, It’s… The Doctor Who Cured My Benign Paroxysmal Positional Vertigo

Neuropharmacology

C24 Child Neurology: A Case-based Approach C47 L Gender Issues in Leadership C25 Cerebellar and Afferent Ataxias: C48 L Leadership Challenges in Practice

8:00 a.m.–12:00 p.m. Neuroanatomy—All the Lesions

Monday, April 24

Concussion Data from the NCAA-DoD Grand Alliance MS Therapeutics and MRI Outcomes Motor Neuron Diseases: Biomarkers, Outcome Measures, and Therapeutics Highlights in Sleep Science L Mentoring… Growing the Next Generation of Neurologist $ (registration required) Behavioral Neurology I: Network Anatomy of Behavior and Language Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Neuroimaging for the General Neurologist I: Brain and Spine Child Neurology II: Epilepsy and Neuromuscular Common Spine Disorders I: Evaluation Infections of the Nervous System II: Neuro-ID Emergencies Hot Topics and Controversies in Parkinson’s Disease Clinical Approach to Muscle Disease I: Muscle Disorders and Rhabdomyolysis

6:00 p.m.–9:00 p.m.

Faculty and Trainee Reception 6:00 p.m.–9:00 p.m. C103 Case Studies: Dementia C104 Case Studies: Multiple Sclerosis C105 Test Your Knowledge: A Case-based Approach to Neuroimaging

C106 Case Studies: Unusual Movement Disorders

C107 Case Studies: Unusual Diagnostic and

Management of Cases in Neuromuscular Disease C108 Case Studies in the ICU C109 Case Studies: How to Analyze Spells by Video-EEG C110 Case Studies: Challenging Headache Cases

Wednesday, April 26

Thursday, April 27

Friday, April 28

6:30 a.m.–8:30 a.m.

1:00 p.m.–5:00 p.m.

7:00 a.m.–9:00 a.m.

7:00 a.m.–9:00 a.m.

1:00 p.m.–5:00 p.m.

7:00 a.m.–9:00 a.m.

2017 AAN Run/Walk for Brain Research

C133 L The Most Important Tool in Your Black

C149 Low and High Pressure Headache: Clinical C168 Neuroimaging for the General Neurologist I:

C186 Chronic Traumatic Encephalopathy:

C210 L Being a Resilient Leader: How Do You

C187 Mitochondrial Disorders in Neurology C188 Clinical EEG I: Normal EEG, Normal

C222 The Global Burden of Neurologic Diseases C238 Epilepsy Skills Workshop $ (registration required) C223 Movement Disorders for the General

3:30 p.m.–4:30 p.m.

$ (registration required)

7:00 a.m.–9:00 a.m. C111 Principles of Genomic Medicine: Clinical

Exome Sequencing in Neurologic Disease C112 Stroke in Young Adults and Women C113 Neuroimaging Biomarkers Across the Dementia Spectrum C114 Therapy of Movement Disorders: A Casebased Approach C115 The Burden of Epilepsy: Managing Comorbidities and Quality of Life C116 Multiple Sclerosis Therapy: Symptom Management C117 The Palliative Care Guide in Neurology: Best Practice Guidelines in Communication, Symptom Management, and End of Life Care of Patients with Brain Tumors and Other Life Limiting Neurological Disorders C118 Nystagmus and Saccadic Intrusions Made Simple C119 Management of Migraine and Psychiatric Comorbidities C120 Mastering EMG Waveform Recognition Skills in Just Two Hours!

Bag: Gallup StrengthsFinder™ Education Workshop $ (registration required) C134 L Advanced Leadership Training: Lifeafter-the-Limelights

1:00 p.m.–5:30 p.m. C135 Neuromuscular Ultrasound Skills Workshop

3:30 p.m.–5:00 p.m.

Section Topic Controversies: Stem Cells for the Treatment of Neurological Diseases: The Ecstasy and the Agony

3:30 p.m.–5:30 p.m. S23 Neurocritical Care: Neurological Intensive Care

S24 MS Therapeutics and Clinical Research I S25 Cerebrovascular Disease and

Interventional Neurology: Prehospital and Emergency Department Ischemic Stroke Care S26 Neuro-opthalmology/Neuro-otology C136 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System C137 Neurology Update IV: Multiple Sclerosis, Dizziness, and Autoimmune 8:00 a.m.–9:00 a.m. Encephalopathies C138 Myelopathies II: Symptom Management S19 “Best of” Session: Cerebrovascular and Rehabilitation Disease and Interventional Neurology C139 Behavioral Neurology: A Case-based Approach 8:30 a.m.–7:00 p.m. C140 Nonmotor Manifestations of Parkinson’s P3 Poster Session III—Presenters Stand by Disease II Posters 5:30 p.m.–7:00 p.m. C141 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases 9:15 a.m.–11:30 a.m. C142 Pediatric MS: Diagnosis and Treatment C143 Non-Neuro-oncology: Case-based Clinical Trials Plenary Session Palliative Care Throughout the Continuum of Disease 11:30 a.m.–4:00 p.m. C144 Approaching the Management of Common Sleep Disorders: Case-based Exhibit Hall Review for the Non-sleep Specialist C145 Hot Topics in Neurologic Practice: 1:00 p.m.–3:00 p.m. Managing the Patient Experience in 2017 and Beyond Invited Science: Neuro-oncology N4 Neuroscience in the Clinic: Zika Virus: The C146 Eponymous Women in Neurology II Global Outbreak of a Neurotropic Virus C147 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, S20 Neuromyelitis Optica and Other Childhood Headaches, and Head Trauma Autoimmune Disorders C148 Developing the Treatments of Tomorrow S21 Epilepsy and Clinical Neurophysiology II: Clinical Trials in Neurology (EEG) I S22 Parkinson’s Disease: Observational 5:45 p.m.–7:15 p.m. Studies C121 Small Fiber Neuropathies: Sensory, Emerging Science Session Autonomic, and Both I: Focus on Autonomic Nervous System 7:00 p.m.–10:00 p.m. C122 Neurology Update III: Neuromuscular, Dementia, and Stroke Industry Therapeutic Updates C123 Myelopathies I: Inflammatory and Vascular Etiologies C124 Unilateral Neglect and Anosognosia: Chalk Talk C125 Nonmotor Manifestations of Parkinson’s Disease I C126 Critical Care EEG Monitoring C127 Neuroendocrine Update: Nuts and Bolts of What You Need to Know C128 Sleep Apnea and Related Disorders Over the Lifecycle: What Neurologists Need to Know C129 Pediatric Neuro-ophthalmology Update C130 Eponymous Women in Neurology I C131 Hot Topics in Headaches and Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances C132 Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man

Presentation and Approach to Evaluation Spine and Peripheral Nerve and Management C169 Core Concepts in Pain Management I: Refractory Neuropathic Pain— C150 Neurological Intensive Care: The Essentials Practical Pharmacologics, Advances in C151 Neuro-ophthalmology I: Visual Loss, Optic Neuromodulation, and a Balanced Look at Neuropathies, and Papilledema Cannabinoids C152 Clinical Pearls: Learning from Complex C170 Sports Concussion Skills Cases—Simple Lessons that Apply to Workshop I: Event Coverage Skills Everyday Problems $ (registration required) C153 Alzheimer’s Dementia: Diagnosis and Treatment 1:00 p.m.–5:00 p.m. C154 Autism Spectrum Disorders—What We Know and Where We Are Going C171 L The Most Important Tool in Your Black Bag: Gallup StrengthFinders™ C155 Controversies in Stroke Therapy Assessment: Advanced Workshop C156 Rehabilitation in Neurology $ (registration required) C157 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back 1:00 p.m.–5:30 p.m. Syndrome C172 EMG Skills Workshop: Basic 8:00 a.m.–9:00 a.m. $ (registration required) S27 “Best of” Session: Neuromuscular 3:30 p.m.–4:15 p.m. Disease Therapeutics S32 Global Health

8:30 a.m.–7:00 p.m. P4

Poster Session IV—Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session

3:30 p.m.–5:30 p.m. N6 Neuroscience in the Clinic: Functional

Recovery in Neurology and Neuroscience

S33 Progressive MS Therapeutics S34 Epilepsy and Clinical Neurophysiology

(EEG) II S35 Aging and Dementia: Neuroimaging in Neurodegenerative Diseases 11:30 a.m.–3:00 p.m. S36 Cerebrovascular Disease and Interventional Neurology: Epidemiology Exhibit Hall C173 Comprehensive Migraine Education Program II: Behavioral and Psychological Aspects, 1:00 p.m.–2:00 p.m. Preventative Pharmacology, and Treatment Advances S28 History of Neurology C174 Neurological Intensive Care III: Vascular Diseases 1:00 p.m.–2:30 p.m. C175 Neuro-ophthalmology III: Diplopia, Ocular Section Topic Controversies: Neurologists Motility Disorders, and Nystagmus Should Take a Position Regarding the Cost C176 Bedside Evidence-based Medicine: How of Neurological Treatments to Find and Deconstruct Articles in Order to Take Care of Patients II 1:00 p.m.–3:00 p.m. C177 Continuum ® Test Your Knowledge: A Multiple-choice Question Review II N5 Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and C178 Biomarkers in Dementia What Is the Provider to Do? C179 Treatments for Drug-resistant Epilepsy: S29 Cerebrovascular Disease and An Update Interventional Neurology: Critical Care C180 Evaluation and Management of Autonomic and Hemorrhage Disorders II: Diagnostic Approach and S30 Infectious Disease: HIV, Syphilis, Borrelia, Treatments for Dysautonomia TB, Cysticercosis, and Other Infections C181 Clinical Neurology for Advanced Practice S31 MS Therapeutics and Clinical Research II Providers II C158 Comprehensive Migraine Education C182 Autoimmune Neurology II Advanced: Program I: Diagnosis, Risk Factors, and Autoimmune Encephalitis—At the Neurobiology Frontiers of Neuroscience C159 Neurological Intensive Care II: From the C183 Neuroimaging for the General Neurologist II: Brain to the Muscles Spine and Peripheral Nerve C160 Neuro-ophthalmology II: Optic Neuritis, C184 Core Concepts in Pain Management Visual Fields, and Anisocoria II: Safe Opioid Prescribing—Practical Considerations, Unintended C161 Bedside Evidence-based Medicine: How Consequences, and Legal Issues to Find and Deconstruct Articles in Order to Take Care of Patients I C185 Sports Concussion Skills ® Workshop II: Office-based Skills C162 Continuum Test Your Knowledge: A $ (registration required) Multiple-choice Question Review I C163 An Introduction to Research in Medical 7:00 p.m.–9:30 p.m. Education C164 Evaluation and Management of Autonomic Commitment to Cures Disorders I: Autonomic Testing, Failure, and $ (registration re quired) Peripheral Neuropathies

C165 Clinical Neurology for Advanced Practice

7:00 p.m.–10:00 p.m.

C166 Circadian Rhythm Disorders: Implications

Industry Therapeutic Updates

Providers I

for Neurology

C167 Autoimmune Neurology I Basics and

Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS

Update

Variants, and How to Avoid Over-reading EEGs C189 Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors? C190 Multiple Sclerosis Overview: Basic and Translational Science C191 A Case-based Approach to Neuroophthalmology: What Went Wrong? C192 Paroxysmal Movement Disorders C193 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies C194 Basic Principles of Brain Tumors: For Practice and for Certification C195 Stroke Team Action Therapy (STAT): Current State of the Art and New Frontiers C196 Emergency and Inpatient Management of Migraine and Other Headache Disorders C197 Interpreting Sleep Study Procedure(s), Data, and Reports: What the Non-sleep Specialist Needs to Know

8:00 a.m.–9:00 a.m. S37 “Best of” Session: Epilepsy

8:30 a.m.–7:00 p.m. P5 Poster Session V—Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session 1:00 p.m.–2:00 p.m. S38 Pain and Palliative Care

1:00 p.m.–3:00 p.m. N7 Neuroscience in the Clinic: Dopamine Transporter (DaT) Imaging

S39 Movement Disorders: Functional and

Structural Imaging in Parkinson’s Disease

S40 Infectious Disease: The Neurology of Zika, Chikungunya, and Acute Flaccid Myelitis

S41 Neuro-oncology S42 Update in Muscular Dystrophy

Section Topic Controversies: Chemo Brain: Neuro-cognitive Impact of Anticancer Therapies C198 Functional Neurologic Disorders I: Movement, Non-epileptic Seizures, and MS-like Disorders C199 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults C200 Therapy in Neurology I: Multiple Sclerosis and Headache C201 Multiple Sclerosis Overview I: Clinical Pearls C202 Higher Cortical Visual Disorders: Casebased Review C203 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment C204 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies C205 Neurologic Complications in Adults with Down Syndrome C206 Neurologic Case Studies in Pregnancy I: Stroke and Headache C207 Severe TBI: From ICU to Rehabilitation C208 A Case-based Approach to Acute CNS Infections C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop $ (registration required)

Lead the Change?

S43 Exciting New Results in Neurorehabilitation

3:30 p.m.–5:30 p.m. N8 Neuroscience in the Clinic: Novel

Therapeutic Targets in Critical Care Neurology: Intracerebral and Intraventricular Hemorrhage S44 MS Risk Factors and Modifications S45 Peripheral Nerve Disorders S46 Child Neurology: Molecular Biology to Clinical Trials S47 Headache: Basic and Clinical Science S48 Practice, Policy, and Ethics C211 Functional Neurologic Disorders II: Management, CBT, and Inpatient Therapeutic Strategies C212 Clinical EEG III: Pediatric and Neonatal C213 Therapy in Neurology II: Epilepsy and Neuro-oncology C214 Multiple Sclerosis Overview II: Clinical Advances C215 Canalith Repositioning for Benign Paroxysmal Positional Vertigo C216 Balance and Gait Disorders C217 Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing C218 Cutting Edge Neuro-oncology— Understanding Current Trends C219 Neurologic Case Studies in Pregnancy II: Epilepsy and Neuro-ophthalmology C220 Memory Disorders: A Case-based Approach C221 Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease

Neurologist I: Diagnosis and Management of Parkinsonian Disorders C224 Controversies in Multiple Sclerosis Therapy C225 Update on Medical Management of Stroke C226 How to Integrate Sleep Medicine into Your Child Neurology Practice C227 Borderlands of Neurology and Internal Medicine: Chalk Talk C228 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C229 Emerging Therapies in Epilepsy C230 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia

1:00 p.m.–5:30 p.m. 3:30 p.m.–5:30 p.m.

Tear out along perforation

2017 Meeting Schedule Summary

S54 Motor Neuron Disease and Myopathies S55 Epilepsy and Clinical Neurophysiology (EEG) III

S56 Movement Disorders: Huntington’s

Disease and Drug-induced Dyskinesias

C239 Therapy in Neurology IV: Movement

Disorders and Cerebrovascular Disease

C240 Movement Disorders for the General

Neurology Year in Review Plenary Session

Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypes, and Tics C241 Update on Endovascular Treatment of Acute Stroke and Cerebrovascular Diseases C242 Sleep for the Practicing Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment C243 Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia C244 Emergency Neurology II: Consultations in the General ICU C245 Now You See It, Now You Know It— Pathognomonic Neuro-ophthalmology Findings

1:00 p.m.–3:00 p.m.

5:30 p.m.–7:00 p.m.

8:00 a.m.–9:00 a.m. S49 “Best of” Session: Aging and Dementia

8:30 a.m.–5:30 p.m. P6 Poster Session VI—Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

9:15 a.m.–11:30 a.m.

N9 Neuroscience in the Clinic: Afferent and

Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment S50 MS Novel Therapeutics and Animal Models S51 Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation S52 Headache: Clinical Trials and Disease Burden S53 General Neurology: Mechanisms and Diagnosis in Overlapping Medical and Neurological Diseases C231 Therapy in Neurology III: Neuromuscular Disease and Neuro-infectious Disease C232 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia C233 Multiple Sclerosis: A Case-based Approach C234 Sleep for the Practicing Neurologist I: Is It Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence C235 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy C236 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Neurodegenerative Rapidly Progressive Dementia C237 Emergency Neurology I: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

Closing Party Happy Hour


Annual Meeting Mobile App Now Available Tap into the meeting from anywhere and start planning your 2017 experience: • View and customize your program schedule • Access program syllabi and slide materials • Access program evaluations • Find room locations • Get hotel information • Access information about Boston Available for iPhone®, iPad®, or Android® Sponsored by:

AAN.com/view/app


WE ARE BREAKING BARRIERS AveXis is relentlessly focused on bringing gene therapy out of the lab and into the clinical setting. We are a clinical-stage gene therapy company dedicated to developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial proprietary gene therapy candidate, AVXS-101, currently is the most advanced gene therapy in development for spinal muscular atrophy (SMA).

Join us at Booth 493. For more information about AveXis, please visit avexis.com.

Š 2017 AveXis, Inc. All Rights Reserved.


Program Glossary “BEST OF” SCIENCE SESSION: A platform session that brings together the top four scoring abstracts in a particular topic, as rated by the topic reviewers. Offers an opportunity to interact with the author in a smaller setting at the conclusion of the session. COURSE: (C) An education program using one or more teaching methods, including didactic, interactive, and case-based. CURBSIDE CONSULTS: A casual walk-up opportunity to discuss your most challenging cases with experts in a variety of disease states. Even if you don’t have a case to discuss, come to listen and learn from other cases. EMERGING SCIENCE SESSION: A special session emphasizing ongoing neuroscience research of an extraordinary nature, which warrants expedited presentation. Key aspects of the research must have taken place after October 24, 2016. E-POSTER SESSION: A group of abstracts presented on an on-site, interactive touch screen allowing attendees to explore the research more deeply. EXPERIENTIAL LEARNING AREAS: Interactive new ways of learning that will engage you intellectually, emotionally, and socially and offer you fresh ideas to help you personally and professionally. INVITED SCIENCE SESSION: An AAN platform session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting. LEADERSHIP UNIVERSITY: Live courses focused on building select skills to enhance leadership abilities. NEUROSCIENCE IN THE CLINIC (N): A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion. PLENARY SESSION: A premier general session highlighting the latest advances in neuroscience.

POSTER SESSION (P): A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. POSTER DISCUSSION SESSION (P): A group of abstracts presented as both a data blitz and a poster. A moderator leads attendees in discussion and stimulates conversation based on the content of the selected posters. SCIENTIFIC PLATFORM SESSION (S): A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts. SECTION TOPIC CONTROVERSIES: A lively format with AAN Sections debating controversies related to specific section topics and featuring two speakers arguing a side of the topic, followed by a rebuttal and question and answer period. VIRTUAL POSTERS: Electronic versions of posters in the physical poster hall, featuring an online, interactive, fully searchable database.


Annual Meeting Edition Planning for the 2017 AAN Annual Meeting—and earning 10 FREE self-assessment CME credits—has never been easier: Pre-test

Annual Meeting

Post-test

Take pre-test by

Attend Annual Meeting

Take post-test by

April 22, 2017

April 22–28, 2017

An AAN Member Exclusive—FREE to Members! AAN.com/view/NeuroSAEAM

July 29, 2017


Saturday, April 22 8:00 a.m.–10:00 a.m. C1 C2 C3 C4

1:00 p.m.–5:00 p.m.

The Neurology of Social Behavior Parkinson’s Disease Update Status Epilepticus Multiple Sclerosis Essentials

C16

2:00 p.m.–4:00 p.m. C17 C18

8:00 a.m.–12:00 p.m. C5

Resident Basic Science I: Neuroanatomy—All the Lesions

8:00 a.m.–5:00 p.m. C6

Early Career Research Training Symposium: A Roadmap to Academic Success for Residents and Fellows (registration required) Neurology MOC Prep Course $ (registration required) L Clerkship and Program Directors Leadership Academy (registration required) L Women in Leadership$ (registration required)

C7 C8 C9

10:30 a.m.–12:30 p.m. C10 C11 C12 C13 C14

Making Sure You Get Paid Under the New Health Care Laws Neuromyelitis Optica Spectrum Disorders Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular and MuSK Myasthenia Neurologic Complications of Medical Disease Concussion: From Mechanisms to Management

1:00 p.m.–3:00 p.m. C15

Resident Basic Science II: Neuropathology

C19 C20 C21 C22

How Is Your Patient Really Doing? Patient Reported Scales, Tools and Shared Decision Making Vascular Cognitive Impairment and Dementia: Current Status and Future Neuromuscular Junction Disorders II: Toxins, LambertEaton Syndrome and Less Common Disorders of Neuromuscular Transmission Neurologic Complications of Medical and Surgical Therapies Concussion: Evaluation and Management in the Acute and Chronic Phases It’s a Bird, It’s a Plane, It’s… The Doctor Who Cured My Benign Paroxysmal Positional Vertigo

4:00 p.m.–4:30 p.m.

AAN Business Meeting 5:00 p.m.–6:30 p.m.

Hot Topics Plenary Session �������������������������������������������40 7:00 p.m.–10:00 p.m.

Industry Therapeutic Updates

Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop $ (registration required)

Curbside Consults

Bring Your Cases!

Be sure to attend—and bring your colleagues—to this unique opportunity to discuss your most challenging cases with experts in select topics. There’s no sign-up required—just show up! Even if don’t have a challenging case to discuss, come and listen and learn from other cases.

Clinical topics include: }} Neuro-oncology }} Headache }} Stroke }} Neuromuscular }} Alzheimer's Disease }} Movement Disorders }} Multiple Sclerosis

$ = Additional Fee Required  L = Leadership University

Academic topics include: }} Feedback and Evaluation }} Dealing with Problem Students/Residents }} Mentoring Residents/Students }} Including Research in the Program }} Organizing a Clerkship/Didactic Curriculum }} Dealing with the Administration

Fast and easy registration · AAN.com/view/AM17 23


Sunday, April 23 7:00 a.m.–9:00 a.m. C23 C24 C25 C26 C27 C28 C29 C30 C31 C32

Using Sleep Medicine to Help Solve Difficult Neurologic Cases Child Neurology: A Case-based Approach Cerebellar and Afferent Ataxias: Diagnosis and Management Clinical EMG I: Principles and Practice of NCS and Needle EMG Differential Diagnosis of Neurologic Infections Advances in Neurogenetics Clinical Epilepsy I: Basics Cerebrovascular Disease I: Prevention Advanced Neurologic Coding Emergency Room Neuro-ophthalmology

8:00 a.m.–9:00 a.m. S1

Poster Session I�����������������������������������������������������������������������������78 Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

11:30 a.m.–4:00 p.m.

C35 C36 C37 C38 C39 C40 C41 C42

Neuroscience in the Clinic: Neurobiology and Treatment of Disorders of Language and Action�����������������������������������������������52 Neuroimaging in MS���������������������������������������������������������������������60 ALS: Disease Mechanism and Therapeutics�������������������������������60 Movement Disorders: Beyond Oral Levodopa in Parkinson’s Disease�������������������������������������������������������������������������������������������60 General Neurology: Pathogenesis, Modulation, and Biomarkers of Complex Neurological Disorders������������������������� 61 Non-Alzheimer’s Dementia I: Frontotemporal Dementias and Chronic Traumatic Encephalopathy Introduction to Primary Headache Disorders I: Migraine and Other Primary Headaches Including Tension-type, Hypnic, Primary Stabbing, and Nummular Headache Syndromes Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Multiple Sclerosis Therapy: Disease-modifying Treatment I Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Case Studies: Neurologic Consultations in Cancer Patients I So You’ve Diagnosed Your Patient with a Neuroinfectious Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases Neurology Update I: Epilepsy, Headache, and Neurologic Infections Clinical Epilepsy II: Considerations Across the Age Span— Pediatrics, Pregnancy, and Elderly Cerebrovascular Disease II: Hemorrhagic Stroke

24 2017 AAN Annual Meeting Science Program

N2 S6 S7

C51

1:00 p.m.–3:00 p.m.

C34

C49

S9

11:30 a.m.–1:30 p.m. NEW Exhibit Hall Opening Lunch

C33

Resident Basic Science III: Neuropharmacology L Gender Issues in Leadership L Leadership Challenges in Practice

1:00 p.m.–5:30 p.m.

S8

Exhibit Hall

S5

C46 C47 C48

Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop $ (registration required) Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop $ (registration required)

3:30 p.m.–5:30 p.m.

Presidential Plenary Session��������������������������������������� 41

S2 S3 S4

Introduction to Clinical Research and Methods Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies I Navigating the World of Mobile Health

1:00 p.m.–5:00 p.m.

C50

9:15 a.m.–12:00 p.m.

N1

C45

“Best of” Session: Parkinson’s Disease���������������������������������������48

8:30 a.m.–5:30 p.m. P1

C43 C44

C52

C53 C54 C55 C56 C57 C58 C59 C60 C61

Neuroscience in the Clinic: Child Neurology: Neurologic Disorder Through a Lifespan— A Focus on MS�������������������������������������������������������������������������������52 Research Methodology and Education: Education Research����������������������������������������������������������������������� 61 Aging and Dementia: Clinical and Translational Studies in Neurodegenerative Diseases ������������������������������������ 61 Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment ��������������������������������������������������������������� 61 Neuro Trauma and Sports Neurology�������������������������������������������62 Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias Introduction to Primary Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Primary Thunderclap Headaches Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Multiple Sclerosis Therapy: Disease-modifying Treatment II Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Case Studies: Neurologic Consultations in Cancer Patients II Neurology Update II: Movement, Spine, and Autonomic Neurology Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Cerebrovascular Disease III: Acute Ischemic Stroke Precision Neurology: The Promise and Perils of Personalized Medicine in the Genomic Era Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies II

6:00 p.m.–10:00 p.m.

Opening Party������������������������������������������������������������������������� 138 6:00 p.m.–8:00 p.m. Neurobowl® 8:30 p.m.–9:15 p.m. Trinity Irish Dance Company 9:15 p.m.–10:00 p.m. DJ, Music, and Dancing

Scientific programs are denoted with an “N”, “S” or “P”, and are also displayed in bold text.


Monday, April 24 7:00 a.m.–9:00 a.m. C62 C63 C64 C65 C66 C67 C68 C69 C70 C71 C72 C73 C74

Mild Cognitive Impairment: Implications for Clinicians CNS Toxicities ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement Child Neurology I: Pediatric Stroke, MS/Autoimmune Neuro-oncologic Emergencies Infections of the Nervous System I: Diagnostic Testing of Neurological Infections Approach to the Shaky Patient Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Sports Neurology: Enhancing Athletic Performance Hot Topics in Sleep Neurology Gender-specific Care for Neurological Disorders Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Annual A.B. Baker Program: Focus on Professionalism

8:00 a.m.–9:00 a.m.

S10 “Best of” Session: MS and CNS Inflammatory Disease�����������48

8:30 a.m.–7:00 p.m. P2

Poster Session II����������������������������������������������������������������������������88 Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Contemporary Clinical Issues Plenary Session����������������������������������������������������������������������� 42 11:30 a.m.–6:00 p.m.

Exhibit Hall

4:30 p.m.–6:00 p.m. NEW Exhibit Hall Networking Reception

12:00 p.m.–5:30 p.m. C75

Clerkship and Program Directors Conference: Wellness and Burnout During Training

1:00 p.m.–2:00 p.m.

S11 Autonomic Disorders: Synucleinopathies.�����������������������������������62

1:00 p.m.–3:00 p.m. N3

Neuroscience in the Clinic: Cutting Edge Concussion Data from the NCAA-DoD Grand Alliance�������������������������������������������53 S12 MS Therapeutics and MRI Outcomes�����������������������������������������62 S13 Motor Neuron Diseases: Biomarkers, Outcome Measures, and Therapeutics���������������������������������������������������������������������������63 S14 Highlights in Sleep Science�����������������������������������������������������������63 C76 L Mentoring… Growing the Next Generation of Neurologist $ (registration required) C77 Behavioral Neurology I: Network Anatomy of Behavior and Language C78 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I C79 Neuroimaging for the General Neurologist I: Brain and Spine C80 Child Neurology II: Epilepsy and Neuromuscular $ = Additional Fee Required  L = Leadership University

C81 C82 C83 C84 C85 C86 C87

Common Spine Disorders I: Evaluation Infections of the Nervous System II: Neuro-ID Emergencies Hot Topics and Controversies in Parkinson’s Disease Clinical Approach to Muscle Disease I: Muscle Disorders and Rhabdomyolysis Boston City Hospital: The Cradle of American Neurology Part I Neuro-otology I: The Common Peripheral Vestibular Disorders How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future

1:00 p.m.–5:00 p.m. C88

L Improving Your Leadership Skills: A Practical Approach (registration required)

1:00 p.m.–5:30 p.m. C89

Neurophysiologic Intraoperative Monitoring Skills Workshop $ (registration required)

3:30 p.m.–5:30 p.m.

Invited Science: Headache�����������������������������������������������������������53

S15 Neuroepidemiology�����������������������������������������������������������������������63 S16 MS Characterizations and Tools for Measurement�������������������63 S17 Movement Disorders: Ataxia and the Cerebellum���������������������64 S18 Behavioral and Cognitive Neurology�������������������������������������������64 C90 C91

Behavioral Neurology II: Memory and Praxis Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II C92 Neuroimaging for the General Neurologist II: Brain and Spine C93 Boston City Hospital: The Cradle of American Neurology Part II C94 Child Neurology III: Headache, TBI/Post-concussion C95 Common Spine Disorders II: Treatment C96 Infections of the Nervous System III: Advanced Topics in Infectious Neurology C97 The Dystonias: Diagnosis, Treatment, and Update on Causes C98 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology C99 Therapeutic Temperature Modulation in the ICU C100 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness C101 Drug-induced Neurologic Emergencies C102 Business Strategies for Payer Negotiations and/or How to Go off the Grid

6:00 p.m.–9:00 p.m.

Faculty and Trainee Reception 6:00 p.m.–9:00 p.m. C103 C104 C105 C106 C107

Case Studies: Dementia Case Studies: Multiple Sclerosis Test Your Knowledge: A Case-based Approach to Neuroimaging Case Studies: Unusual Movement Disorders Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease C108 Case Studies in the ICU C109 Case Studies: How to Analyze Spells by Video-EEG C110 Case Studies: Challenging Headache Cases Fast and easy registration · AAN.com/view/AM17 25


Tuesday, April 25 6:30 a.m.–8:30 a.m.

2017 AAN Run/Walk for Brain Research

$ (registration required)��������������������������������������������������������������������������138

7:00 a.m.–9:00 a.m. C111 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease C112 Stroke in Young Adults and Women C113 Neuroimaging Biomarkers Across the Dementia Spectrum C114 Therapy of Movement Disorders: A Case-based Approach C115 The Burden of Epilepsy: Managing Comorbidities and Quality of Life C116 Multiple Sclerosis Therapy: Symptom Management C117 The Palliative Care Guide in Neurology: Best Practice Guidelines in Communication, Symptom Management, and End of Life Care of Patients with Brain Tumors and Other Life Limiting Neurological Disorders C118 Nystagmus and Saccadic Intrusions Made Simple C119 Management of Migraine and Psychiatric Comorbidities C120 Mastering EMG Waveform Recognition Skills in Just Two Hours!

8:00 a.m.–9:00 a.m.

S19 “Best of” Session: Cerebrovascular Disease and

Interventional Neurology���������������������������������������������������������������48

8:30 a.m.–7:00 p.m. P3

Poster Session III���������������������������������������������������������������������������98 Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Clinical Trials Plenary Session �����������������������������������43 11:30 a.m.–3:30 p.m.

Exhibit Hall

1:00 p.m.–3:00 p.m. N4 S20 S21 S22 C121 C122 C123 C124 C125 C126 C127 C128 C129

Invited Science: Neuro-oncology�����������������������������������������87 Neuroscience in the Clinic: Zika Virus: The Global Outbreak of a Neurotropic Virus�������������������������������54 Neuromyelitis Optica and Other Autoimmune Disorders�����������64 Epilepsy and Clinical Neurophysiology (EEG) I����������������������������65 Parkinson’s Disease: Observational Studies�������������������������������65 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Neurology Update III: Neuromuscular, Dementia, and Stroke Myelopathies I: Inflammatory and Vascular Etiologies Unilateral Neglect and Anosognosia: Chalk Talk Nonmotor Manifestations of Parkinson’s Disease I Critical Care EEG Monitoring Neuroendocrine Update: Nuts and Bolts of What You Need to Know Sleep Apnea and Related Disorders Over the Lifecycle: What Neurologists Need to Know Pediatric Neuro-ophthalmology Update

26 2017 AAN Annual Meeting Science Program

C130 Eponymous Women in Neurology I C131 Hot Topics in Headaches and Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances C132 Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man

1:00 p.m.–5:00 p.m. C133 L The Most Important Tool in Your Black Bag: Gallup StrengthsFinder™ Education Workshop $ (registration required) C134 L Advanced Leadership Training: Life-after-the-Limelights

1:00 p.m.–5:30 p.m. C135 Neuromuscular Ultrasound Skills Workshop $ (registration required)

3:30 p.m.–5:00 p.m. Section Topic Controversies: Stem Cells for Treatment of Neurological Diseases: The Ecstasy and the Agony������� 74

3:30 p.m.–5:30 p.m.

S23 Neurocritical Care: Neurological Intensive Care������������������������65 S24 MS Therapeutics and Clinical Research I�����������������������������������65 S25 Cerebrovascular Disease and Interventional Neurology: Prehospital and Emergency Department Ischemic Stroke Care ������������������������������������������������������������������������������������������������66 S26 Neuro-opthalmology/Neuro-otology�������������������������������������������66 C136 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System C137 Neurology Update IV: Multiple Sclerosis, Dizziness, and Autoimmune Encephalopathies C138 Myelopathies II: Symptom Management and Rehabilitation C139 Behavioral Neurology: A Case-based Approach C140 Nonmotor Manifestations of Parkinson’s Disease II C141 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases C142 Pediatric MS: Diagnosis and Treatment C143 Non-Neuro-oncology: Case-based Palliative Care Throughout the Continuum of Disease C144 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C145 Hot Topics in Neurologic Practice: Managing the Patient Experience in 2017 and Beyond C146 Eponymous Women in Neurology II C147 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Head Trauma C148 Developing the Treatments of Tomorrow II: Clinical Trials in Neurology

5:45 p.m.–7:15 p.m. Emerging Science Session

7:00 p.m.–10:00 p.m.

Industry Therapeutic Updates

Scientific programs are denoted with an “N”, “S” or “P”, and are also displayed in bold text.


Wednesday, April 26 7:00 a.m.–9:00 a.m. C149 Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management C150 Neurological Intensive Care: The Essentials C151 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema C152 Clinical Pearls: Learning from Complex Cases—Simple Lessons that Apply to Everyday Problems C153 Alzheimer’s Dementia: Diagnosis and Treatment C154 Autism Spectrum Disorders—What We Know and Where We Are Going C155 Controversies in Stroke Therapy C156 Rehabilitation in Neurology C157 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome

8:00 a.m.–9:00 a.m.

S27 “Best of” Session: Neuromuscular

Disease Therapeutics �������������������������������������������������������������������48

8:30 a.m.–7:00 p.m. P4

Poster Session IV�������������������������������������������������������������������������108 Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Frontiers in Neuroscience Plenary Session������44 11:30 a.m.–3:00 p.m.

Exhibit Hall

C167 Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS C168 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve C169 Core Concepts in Pain Management I: Refractory Neuropathic Pain—Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids C170 Sports Concussion Skills Workshop I: Event Coverage Skills $ (registration required)

1:00 p.m.–5:00 p.m. C171 L The Most Important Tool in Your Black Bag: Gallup StrengthFinders™ Assessment: Advanced Workshop $ (registration required)

1:00 p.m.–5:30 p.m. C172 EMG Skills Workshop: Basic $ (registration required)

3:30 p.m.–4:15 p.m.

S32 Global Health���������������������������������������������������������������������������������67

3:30 p.m.–5:30 p.m. N6

S33 S34 S35 S36

1:00 p.m.–2:00 p.m.

C173

1:00 p.m.–2:30 p.m.

C174 C175

S28 History of Neurology���������������������������������������������������������������������66 Section Topic Controversies: Neurologists Should Take a Position Regarding the Cost of Neurological Treatments �������74

1:00 p.m.–3:00 p.m. N5

S29 S30 S31 C158 C159 C160 C161 C162 C163 C164 C165 C166

Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do?��������������55 Cerebrovascular Disease and Interventional Neurology: Critical Care and Hemorrhage�������������������������������������������������������67 Infectious Disease: HIV, Syphilis, Borrelia, TB, Cysticercosis, and Other Infections���������������������������������������������67 MS Therapeutics and Clinical Research II�����������������������������������67 Comprehensive Migraine Education Program I: Diagnosis, Risk Factors, and Neurobiology Neurological Intensive Care II: From the Brain to the Muscles Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients I Continuum ® Test Your Knowledge: A Multiple-choice Question Review I An Introduction to Research in Medical Education Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Clinical Neurology for Advanced Practice Providers I Circadian Rhythm Disorders: Implications for Neurology

C176 C177 C178 C179 C180 C181 C182 C183 C184 C185

Neuroscience in the Clinic: Functional Recovery in Neurology and Neuroscience���������������������������������������������������55 Progressive MS Therapeutics�������������������������������������������������������68 Epilepsy and Clinical Neurophysiology (EEG) II���������������������������68 Aging and Dementia: Neuroimaging in Neurodegenerative Diseases�������������������������������������������������������68 Cerebrovascular Disease and Interventional Neurology: Epidemiology���������������������������������������������������������������68 Comprehensive Migraine Education Program II: Behavioral and Psychological Aspects, Preventative Pharmacology, and Treatment Advances Neurological Intensive Care III: Vascular Diseases Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients II Continuum ® Test Your Knowledge: A Multiple-choice Question Review II Biomarkers in Dementia Treatments for Drug-resistant Epilepsy: An Update Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Clinical Neurology for Advanced Practice Providers II Autoimmune Neurology II Advanced: Autoimmune Encephalitis—At the Frontiers of Neuroscience Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve Core Concepts in Pain Management II: Safe Opioid Prescribing—Practical Considerations, Unintended Consequences, and Legal Issues Sports Concussion Skills Workshop II: Office-based Skills $ (registration required)

7:00 p.m.–9:30 p.m.

Commitment to Cures $ (registration required)

7:00 p.m.–10:00 p.m.

Industry Therapeutic Updates $ = Additional Fee Required  L = Leadership University

Fast and easy registration · AAN.com/view/AM17 27


Thursday, April 27 7:00 a.m.–9:00 a.m. C186 Chronic Traumatic Encephalopathy: Update C187 Mitochondrial Disorders in Neurology C188 Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid Over-reading EEGs C189 Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors? C190 Multiple Sclerosis Overview: Basic and Translational Science C191 A Case-based Approach to Neuro-ophthalmology: What Went Wrong? C192 Paroxysmal Movement Disorders C193 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies C194 Basic Principles of Brain Tumors: For Practice and for Certification C195 Stroke Team Action Therapy (STAT): Current State of the Art and New Frontiers C196 Emergency and Inpatient Management of Migraine and Other Headache Disorders C197 Interpreting Sleep Study Procedure(s), Data, and Reports: What the Non-sleep Specialist Needs to Know

C199 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults C200 Therapy in Neurology I: Multiple Sclerosis and Headache C201 Multiple Sclerosis Overview I: Clinical Pearls C202 Higher Cortical Visual Disorders: Case-based Review C203 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment C204 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies C205 Neurologic Complications in Adults with Down Syndrome C206 Neurologic Case Studies in Pregnancy I: Stroke and Headache C207 Severe TBI: From ICU to Rehabilitation C208 A Case-based Approach to Acute CNS Infections C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop $ (registration required)

1:00 p.m.–5:00 p.m. C210 L Being a Resilient Leader: How Do You Lead the Change?

3:30 p.m.–4:30 p.m.

S43 Exciting New Results in Neuro-rehabilitation���������������������������� 70

3:30 p.m.–5:30 p.m. N8

8:00 a.m.–9:00 a.m.

S37 “Best of” Session: Epilepsy�����������������������������������������������������������49

8:30 a.m.–7:00 p.m. P5

Poster Session V���������������������������������������������������������������������������118 Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

9:15 a.m.–11:30 a.m.

Controversies in Neurology Plenary Session ����45 1:00 p.m.–2:00 p.m.

S38 Pain and Palliative Care ����������������������������������������������������������������69

1:00 p.m.–3:00 p.m. N7

Neuroscience in the Clinic: Dopamine Transporter (DaT) Imaging�������������������������������������������56 S39 Movement Disorders: Functional and Structural Imaging in Parkinson’s Disease �������69 S40 Infectious Disease: The Neurology of Zika, Chikungunya, and Acute Flaccid Myelitis �����������������������������������������������������������69 S41 Neuro-oncology�����������������������������������������������������������������������������70 S42 Update in Muscular Dystrophy ����������������������������������������������������70 Section Topic Controversies: Chemo Brain: Neuro-cognitive Impact of Anti-cancer Therapies��������� 74 C198 Functional Neurologic Disorders I: Movement, Nonepileptic Seizures, and MS-like Disorders

28 2017 AAN Annual Meeting Science Program

S44 S45 S46 S47 S48 C211 C212 C213 C214 C215 C216 C217 C218 C219 C220 C221

Neuroscience in the Clinic: Novel Therapeutic Targets in Critical Care Neurology: Intracerebral and Intraventricular Hemorrhage��������������������������������������������������������56 MS Risk Factors and Modifications���������������������������������������������70 Peripheral Nerve Disorders����������������������������������������������������������� 71 Child Neurology: Molecular Biology to Clinical Trials ���������������� 71 Headache: Basic and Clinical Science����������������������������������������� 71 Practice, Policy, and Ethics ����������������������������������������������������������� 71 Functional Neurologic Disorders II: Management, CBT, and Inpatient Therapeutic Strategies Clinical EEG III: Pediatric and Neonatal Therapy in Neurology II: Epilepsy and Neuro-oncology Multiple Sclerosis Overview II: Clinical Advances Canalith Repositioning for Benign Paroxysmal Positional Vertigo Balance and Gait Disorders Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing Cutting Edge Neuro-oncology—Understanding Current Trends Neurologic Case Studies in Pregnancy II: Epilepsy and Neuro-ophthalmology Memory Disorders: A Case-based Approach Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease

Scientific programs are denoted with an “N”, “S” or “P”, and are also displayed in bold text.


Friday, April 28 7:00 a.m.–9:00 a.m. C222 The Global Burden of Neurologic Diseases C223 Movement Disorders for the General Neurologist I: Diagnosis and Management of Parkinsonian Disorders C224 Controversies in Multiple Sclerosis Therapy C225 Update on Medical Management of Stroke C226 How to Integrate Sleep Medicine into Your Child Neurology Practice C227 Borderlands of Neurology and Internal Medicine: Chalk Talk C228 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders C229 Emerging Therapies in Epilepsy C230 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia

8:00 a.m.–9:00 a.m.

S49 “Best of” Session: Aging and Dementia�������������������������������������49

8:30 a.m.–5:30 p.m. P6

Poster Session VI�������������������������������������������������������������������������128 Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

9:15 a.m.–11:30 a.m.

Neurology Year in Review Plenary Session�������46 1:00 p.m.–3:00 p.m. N9

S50 S51 S52 S53 C231 C232

Neuroscience in the Clinic: Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment�����������������������������������57 MS Novel Therapeutics and Animal Models �����������������������������72 Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation�����������������������������������������������72 Headache: Clinical Trials and Disease Burden ���������������������������72 General Neurology: Mechanisms and Diagnosis in Overlapping Medical and Neurological Diseases�����������������������73 Therapy in Neurology III: Neuromuscular Disease and Neuro-infectious Disease Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia

$ = Additional Fee Required  L = Leadership University

C233 Multiple Sclerosis: A Case-based Approach C234 Sleep for the Practicing Neurologist I: Is It Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence C235 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy C236 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Neurodegenerative Rapidly Progressive Dementia C237 Emergency Neurology I: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

1:00 p.m.–5:30 p.m. C238 Epilepsy Skills Workshop $ (registration required)

3:30 p.m.–5:30 p.m.

S54 Motor Neuron Disease and Myopathies ������������������������������������73 S55 Epilepsy and Clinical Neurophysiology (EEG) III���������������������������73 S56 Movement Disorders: Huntington’s Disease and Drug-induced Dyskinesias�����������������������������������������������������73 C239 Therapy in Neurology IV: Movement Disorders and Cerebrovascular Disease C240 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypes, and Tics C241 Update on Endovascular Treatment of Acute Stroke and Cerebrovascular Diseases C242 Sleep for the Practicing Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment C243 Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia C244 Emergency Neurology II: Consultations in the General ICU C245 Now You See It, Now You Know It—Pathognomonic Neuro-ophthalmology Findings

5:30 p.m.–7:00 p.m.

Closing Party Happy Hour��������������������������������������������� 138

Fast and easy registration · AAN.com/view/AM17 29


Run/Walk for Brain Research On your mark, get set… help cure BRAIN DISEASE! Join your colleagues on Tuesday, April 25, 2017, at 6:30 a.m., for a friendly run/walk. All proceeds will help support brain research. Sign up for the Run/Walk at AAN.com/view/RunWalk

Sponsored by:


Annual Meeting Program List by Topic AGING, DEMENTIA, COGNITIVE, AND BEHAVIORAL NEUROLOGY

CEREBROVASCULAR DISEASE AND INTERVENTIONAL NEUROLOGY

C1 The Neurology of Social Behavior C18 Vascular Cognitive Impairment and Dementia: Current

C30 P1 C42 C59 S8

Status and Future

P1 Poster Session I���������������������������������������������������������������������������78 C33 Non-Alzheimer’s Dementia I: Frontotemporal Dementias

and Chronic Traumatic Encephalopathy N1 Neuroscience in the Clinic: Neurobiology and Treatment of Disorders of Language and Action���������������������������������������52 C51 Non-Alzheimer’s Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias S7 Aging and Dementia: Clinical and Translational Studies in Neurodegenerative Diseases���������������������������������������������������61 C62 Mild Cognitive Impairment: Implications for Clinicians P2 Poster Session II�������������������������������������������������������������������������88 C77 Behavioral Neurology I: Network Anatomy of Behavior and Language Curbside Consult: Alzheimer's Disease �����������������������������������23 C90 Behavioral Neurology II: Memory and Praxis S18 Behavioral and Cognitive Neurology����������������������������������������64 C103 Case Studies: Dementia C113 Neuroimaging Biomarkers Across the Dementia Spectrum P3 Poster Session III������������������������������������������������������������������������98 C124 Unilateral Neglect and Anosognosia: Chalk Talk C139 Behavioral Neurology: A Case-based Approach C153 Alzheimer’s Dementia: Diagnosis and Treatment P4 Poster Session IV���������������������������������������������������������������������108 N5 Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do?�����������55 C178 Biomarkers in Dementia S35 Aging and Dementia: Neuroimaging in Neurodegenerative Diseases���������������������������������������������������68 C186 Chronic Traumatic Encephalopathy: Update P5 Poster Session V ���������������������������������������������������������������������� 118 C202 Higher Cortical Visual Disorders: Case-based Review C205 Neurologic Complications in Adults with Down Syndrome C207 Severe TBI: From ICU to Rehabilitation C220 Memory Disorders: A Case-based Approach C228 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders S49 “Best of” Session: Aging and Dementia����������������������������������49 P6 Poster Session VI���������������������������������������������������������������������128 C236 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Neurodegenerative Rapidly Progressive Dementia C243 Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia $ = Additional Fee Required

C73 P2 C99 C112 S19 P3 S25 C155 P4 S29 S36 C195 P5

C225 P6 S51 C241

Cerebrovascular Disease I: Prevention Poster Session I���������������������������������������������������������������������������78 Cerebrovascular Disease II: Hemorrhagic Stroke Cerebrovascular Disease III: Acute Ischemic Stroke Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment������������������������������������������������������������61 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Poster Session II�������������������������������������������������������������������������88 Therapeutic Temperature Modulation in the ICU Stroke in Young Adults and Women “Best of” Session: Cerebrovascular Disease and Interventional Neurology�����������������������������������������������������������48 Poster Session III������������������������������������������������������������������������98 Cerebrovascular Disease and Interventional Neurology: Prehospital and Emergency Department Ischemic Stroke Care���������������������������������������������������������������������������������66 Controversies in Stroke Therapy Poster Session IV���������������������������������������������������������������������108 Cerebrovascular Disease and Interventional Neurology: Critical Care and Hemorrhage���������������������������������������������������67 Cerebrovascular Disease and Interventional Neurology: Epidemiology�������������������������������������������������������������������������������68 Stroke Team Action Therapy (STAT): Current State of the Art and New Frontiers Poster Session V ���������������������������������������������������������������������� 118 Curbside Consult: Stroke�����������������������������������������������������������23 Update on Medical Management of Stroke Poster Session VI���������������������������������������������������������������������128 Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation �������������������������������������������72 Update on Endovascular Treatment of Acute Stroke and Cerebrovascular Diseases

CHILD NEUROLOGY AND DEVELOPMENTAL NEUROLOGY C24 Child Neurology: A Case-based Approach N2 Neuroscience in the Clinic: Child Neurology: Neurologic C65 C80 C94 C112 P3 C129

Disorder Through a Lifespan—A Focus on MS�����������������������52 Child Neurology I: Pediatric Stroke, MS/Autoimmune Child Neurology II: Epilepsy and Neuromuscular Child Neurology III: Headache, TBI/Post-concussion Stroke in Young Adults and Women Poster Session III������������������������������������������������������������������������98 Pediatric Neuro-ophthalmology Update Fast and easy registration · AAN.com/view/AM17 31


Annual Meeting Program List by Topic C142 Pediatric MS: Diagnosis and Treatment C154 Autism Spectrum Disorders—What We Know and P4 C205 S46 C226 C244

Where We Are Going Poster Session IV���������������������������������������������������������������������108 Neurologic Complications in Adults with Down Syndrome Child Neurology: Molecular Biology to Clinical Trials�������������71 How to Integrate Sleep Medicine into Your Child Neurology Practice Emergency Neurology II: Consultations in the General ICU

EPILEPSY/CLINICAL NEUROPHYSIOLOGY (EEG) C3 C29 P1 C41

Status Epilepticus Clinical Epilepsy I: Basics Poster Session I���������������������������������������������������������������������������78 Clinical Epilepsy II: Considerations Across the Age Span—Pediatrics, Pregnancy, and Elderly C58 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) P2 Poster Session II�������������������������������������������������������������������������88 C89 Neurophysiologic Intraoperative Monitoring Skills Workshop $ (registration required) C109 Case Studies: How to Analyze Spells by Video-EEG C115 The Burden of Epilepsy: Managing Comorbidities and Quality of Life P3 Poster Session III������������������������������������������������������������������������98 C126 Critical Care EEG Monitoring S21 Epilepsy and Clinical Neurophysiology (EEG) I ������������������������65 C141 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases P4 Poster Session IV���������������������������������������������������������������������108 C179 Treatments for Drug-resistant Epilepsy: An Update S34 Epilepsy and Clinical Neurophysiology (EEG) II �����������������������68 C188 Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid Over-reading EEGs P5 Poster Session V ���������������������������������������������������������������������� 118 C199 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults C212 Clinical EEG III: Pediatric and Neonatal C229 Emerging Therapies in Epilepsy P6 Poster Session VI���������������������������������������������������������������������128 C238 Epilepsy Skills Workshop $ (registration required) S55 Epilepsy and Clinical Neurophysiology (EEG) III�����������������������73

32 2017 AAN Annual Meeting Science Program

GENERAL NEUROLOGY C7

Neurology MOC Prep Course $ (registration required) C13 Neurologic Complications of Medical Disease C20 Neurologic Complications of Medical and Surgical Therapies C23 Using Sleep Medicine to Help Solve Difficult Neurologic Cases C28 Advances in Neurogenetics C31 Advanced Neurologic Coding P1 Poster Session I���������������������������������������������������������������������������78 C40 Neurology Update I: Epilepsy, Headache, and Neurologic Infections C44 Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies I S5 General Neurology: Pathogenesis, Modulation, and Biomarkers of Complex Neurological Disorders ���������������������61 C57 Neurology Update II: Movement, Spine, and Autonomic Neurology C60 Precision Neurology: The Promise and Perils of Personalized Medicine in the Genomic Era C61 Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies II C63 CNS Toxicities C72 Gender-specific Care for Neurological Disorders P2 Poster Session II�������������������������������������������������������������������������88 C78 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I C79 Neuroimaging for the General Neurologist I: Brain and Spine C85 Boston City Hospital: The Cradle of American Neurology Part I C92 Neuroimaging for the General Neurologist II: Brain and Spine C93 Boston City Hospital: The Cradle of American Neurology Part II C101 Drug-induced Neurologic Emergencies S15 Neuroepidemiology �������������������������������������������������������������������63 C105 Test Your Knowledge: A Case-based Approach to Neuroimaging C111 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease C122 Neurology Update III: Neuromuscular, Dementia, and Stroke C127 Neuroendocrine Update: Nuts and Bolts of What You Need to Know C137 Neurology Update IV: Multiple Sclerosis, Dizziness, and Autoimmune Encephalopathies C145 Hot Topics in Neurologic Practice: Managing the Patient Experience in 2017 and Beyond Section Topic Controversies: Stem Cells for Treatment of Neurological Diseases: The Ecstasy and the Agony���������������74 C152 Clinical Pearls: Learning from Complex Cases—Simple Lessons that Apply to Everyday Problems P4 Poster Session IV���������������������������������������������������������������������108 C162 Continuum ® Test Your Knowledge: A Multiple-choice Question Review I


C167 Autoimmune Neurology I Basics and Beyond:

Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS C168 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve N5 Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do?�����������55 Section Topic Controversies: Neurologists Should Take a Position Regarding the Cost of Neurological Treatments�������74 C177 Continuum ® Test Your Knowledge: A Multiple-choice Question Review II C182 Autoimmune Neurology II Advanced: Autoimmune Encephalitis—At the Frontiers of Neuroscience C183 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve N6 Neuroscience in the Clinic: Functional Recovery in Neurology and Neuroscience �����������������������������������������������55 C187 Mitochondrial Disorders in Neurology C189 Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors? C190 Multiple Sclerosis Overview: Basic and Translational Science C198 Functional Neurologic Disorders I: Movement, Nonepileptic Seizures, and MS-like Disorders C200 Therapy in Neurology I: Multiple Sclerosis and Headache C206 Neurologic Case Studies in Pregnancy I: Stroke and Headache C211 Functional Neurologic Disorders II: Management, CBT, and Inpatient Therapeutic Strategies C213 Therapy in Neurology II: Epilepsy and Neuro-oncology C219 Neurologic Case Studies in Pregnancy II: Epilepsy and Neuro-ophthalmology C221 Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease C222 The Global Burden of Neurologic Diseases C227 Borderlands of Neurology and Internal Medicine: Chalk Talk P6 Poster Session VI���������������������������������������������������������������������128 C231 Therapy in Neurology III: Neuromuscular Disease and Neuro-infectious Disease C237 Emergency Neurology I: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room S53 General Neurology: Mechanisms and Diagnosis in Overlapping Medical and Neurological Diseases�������������������73 C239 Therapy in Neurology IV: Movement Disorders and Cerebrovascular Disease C244 Emergency Neurology II: Consultations in the General ICU

GLOBAL HEALTH P3 Poster Session III������������������������������������������������������������������������98 S32 Global Health�������������������������������������������������������������������������������67 C222 The Global Burden of Neurologic Diseases

$ = Additional Fee Required

HEADACHE C15 Practical Training in Injection Techniques in the P1 C34

C52

P2

C110 C119 C131

C147 C149 C158 C173 C196 S47 S52

Treatment of Headache Disorders Skills Workshop $ (registration required) Poster Session I���������������������������������������������������������������������������78 Introduction to Primary Headache Disorders I: Migraine and Other Primary Headaches Including Tension-type, Hypnic, Primary Stabbing, and Nummular Headache Syndromes Introduction to Primary Headache Disorders II: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Primary Thunderclap Headaches Poster Session II�������������������������������������������������������������������������88 Invited Science: Headache��������������������������������������������������������53 Case Studies: Challenging Headache Cases Management of Migraine and Psychiatric Comorbidities Hot Topics in Headaches and Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances Curbside Consult: Headache�����������������������������������������������������23 Hot Topics in Headaches and Related Disorders II: Unusual Headaches, Childhood Headaches, and Head Trauma Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management Comprehensive Migraine Education Program I: Diagnosis, Risk Factors, and Neurobiology Comprehensive Migraine Education Program II: Behavioral and Psychological Aspects, Preventative Pharmacology, and Treatment Advances Emergency and Inpatient Management of Migraine and Other Headache Disorders Headache: Basic and Clinical Science �������������������������������������71 Headache: Clinical Trials and Disease Burden ������������������������72

INFECTIOUS DISEASE C27 Differential Diagnosis of Neurologic Infections P1 Poster Session I���������������������������������������������������������������������������78 C39 So You’ve Diagnosed Your Patient with a Neuroinfectious

Disease, Now What? Practical Pearls in the Treatment and Management of Neuroinfectious Diseases C67 Infections of the Nervous System I: Diagnostic Testing of Neurological Infections P2 Poster Session II�������������������������������������������������������������������������88 C82 Infections of the Nervous System II: Neuro-ID Emergencies C96 Infections of the Nervous System III: Advanced Topics in Infectious Neurology P3 Poster Session III������������������������������������������������������������������������98 N4 Neuroscience in the Clinic: Zika Virus: The Global Outbreak of a Neurotropic Virus ���������������������������54 Fast and easy registration · AAN.com/view/AM17 33


Annual Meeting Program List by Topic S30 Infectious Disease: HIV, Syphilis, Borrelia, TB,

Cysticercosis, and Other Infections�������������������������������������������67 C208 A Case-based Approach to Acute CNS Infections S40 Infectious Disease: The Neurology of Zika, Chikungunya, and Acute Flaccid Myelitis��������������������������������������������������������69

C8 C9 C47 C48 C76 C88 C133 C134 C171 C210

Clerkship and Program Directors Leadership Academy (registration required) Women in Leadership $ (registration required) Gender Issues in Leadership Leadership Challenges in Practice Mentoring… Growing the Next Generation of Neurologist $ (registration required) Improving Your Leadership Skills: A Practical Approach (registration required) The Most Important Tool in Your Black Bag: Gallup StrengthsFinder™ Education Workshop $ (registration required) Advanced Leadership Training: Life-after-the-Limelights The Most Important Tool in Your Black Bag: Gallup StrengthFinders™ Assessment: Advanced Workshop $ (registration required) Being a Resilient Leader: How Do You Lead the Change?

MOVEMENT DISORDERS C2

C24 C25 S1 P1 C35 S4 C49 C53 C68 P2 C83 C97 S17

Parkinson’s Disease Update Curbside Consult: Movement Disorders�����������������������������������23 Child Neurology: A Case-based Approach Cerebellar and Afferent Ataxias: Diagnosis and Management “Best of” Session: Parkinson’s Disease�����������������������������������48 Poster Session I���������������������������������������������������������������������������78 Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Movement Disorders: Beyond Oral Levodopa in Parkinson’s Disease�������������������������������������������������������������������60 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop $ (registration required) Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Approach to the Shaky Patient Poster Session II�������������������������������������������������������������������������88 Hot Topics and Controversies in Parkinson’s Disease The Dystonias: Diagnosis, Treatment, and Update on Causes Movement Disorders: Ataxia and the Cerebellum �����������������64

34 2017 AAN Annual Meeting Science Program

C106 C114 P3 C125 S22 C140 P4 N5

Case Studies: Unusual Movement Disorders Therapy of Movement Disorders: A Case-based Approach Poster Session III������������������������������������������������������������������������98 Nonmotor Manifestations of Parkinson’s Disease I Parkinson’s Disease: Observational Studies���������������������������65 Nonmotor Manifestations of Parkinson’s Disease II Poster Session IV���������������������������������������������������������������������108 Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do?����������������������������55 C192 Paroxysmal Movement Disorders P5 Poster Session V ���������������������������������������������������������������������� 118 C203 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment C209 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop $ (registration required) N7 Neuroscience in the Clinic: Dopamine Transporter (DaT) Imaging���������������������������������������56 S39 Movement Disorders: Functional and Structural Imaging in Parkinson’s Disease ����69 C216 Balance and Gait Disorders C223 Movement Disorders for the General Neurologist I: Diagnosis and Management of Parkinsonian Disorders P6 Poster Session VI���������������������������������������������������������������������128 C232 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia N9 Neuroscience in the Clinic: Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment �������������57 C240 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypes, and Tics S56 Movement Disorders: Huntington’s Disease and Druginduced Dyskinesias�������������������������������������������������������������������73

MS AND CNS INFLAMMATORY DISEASE C4 C11 P1 C36 S2 C54 S10 P2 C78

Multiple Sclerosis Essentials Neuromyelitis Optica Spectrum Disorders Poster Session I���������������������������������������������������������������������������78 Multiple Sclerosis Therapy: Disease-modifying Treatment I Neuroimaging in MS�������������������������������������������������������������������60 Multiple Sclerosis Therapy: Disease-modifying Treatment II “Best of” Session: MS and CNS Inflammatory Disease��������48 Poster Session II�������������������������������������������������������������������������88 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I S12 MS Therapeutics and MRI Outcomes �������������������������������������62 C91 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II S16 MS Characterizations and Tools for Measurement����������������63


C104 C116 P3 S20 C142

Case Studies: Multiple Sclerosis Multiple Sclerosis Therapy: Symptom Management Poster Session III������������������������������������������������������������������������98 Neuromyelitis Optica and Other Autoimmune Disorders�������64 Pediatric MS: Diagnosis and Treatment Curbside Consult: Multiple Sclerosis ���������������������������������������23 S24 MS Therapeutics and Clinical Research I��������������������������������65 P4 Poster Session IV���������������������������������������������������������������������108 S31 MS Therapeutics and Clinical Research II�������������������������������67 S33 Progressive MS Therapeutics���������������������������������������������������68 C190 Multiple Sclerosis Overview: Basic and Translational Science P5 Poster Session V ���������������������������������������������������������������������� 118 C201 Multiple Sclerosis Overview I: Clinical Pearls C214 Multiple Sclerosis Overview II: Clinical Advances S44 MS Risk Factors and Modifications �����������������������������������������70 C224 Controversies in Multiple Sclerosis Therapy P6 Poster Session VI���������������������������������������������������������������������128 C233 Multiple Sclerosis: A Case-based Approach S50 MS Novel Therapeutics and Animal Models���������������������������72

NEURO TRAUMA, CRITICAL CARE, AND SPORTS NEUROLOGY C14 Concussion: From Mechanisms to Management C21 Concussion: Evaluation and Management in the Acute C32 S9 C70 N3 C108 P3 C126 S23 C150 C159 C170 C174 C185 P5 C207 N8 P6

and Chronic Phases Emergency Room Neuro-ophthalmology Neuro Trauma and Sports Neurology���������������������������������������62 Sports Neurology: Enhancing Athletic Performance Neuroscience in the Clinic: Cutting Edge Concussion Data from the NCAA-DoD Grand Alliance�������������������������������53 Case Studies in the ICU Poster Session III������������������������������������������������������������������������98 Critical Care EEG Monitoring Neurocritical Care: Neurological Intensive Care���������������������65 Neurological Intensive Care: The Essentials Neurological Intensive Care II: From the Brain to the Muscles Sports Concussion Skills Workshop I: Event Coverage Skills $ (registration required) Neurological Intensive Care III: Vascular Diseases Sports Concussion Skills Workshop II: Office-based Skills $ (registration required) Poster Session V ���������������������������������������������������������������������� 118 Severe TBI: From ICU to Rehabilitation Neuroscience in the Clinic: Novel Therapeutic Targets in Critical Care Neurology: Intracerebral and Intraventricular Hemorrhage ����������������������������������������������������56 Poster Session VI���������������������������������������������������������������������128

$ = Additional Fee Required

C237 Emergency Neurology I: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room

C244 Emergency Neurology II: Consultations in the General ICU

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG) C12 Neuromuscular Junction Disorders I: Myasthenia Gravis, C19 C26 P1 C37 S3 C55 C69 P2 S11 C84 S13 C98 C107 C120 P3 C121 C135 C136 S27 P4 C164 C172 C180 C193

Ocular and MuSK Myasthenia Neuromuscular Junction Disorders II: Toxins, LambertEaton Syndrome and Less Common Disorders of Neuromuscular Transmission Clinical EMG I: Principles and Practice of NCS and Needle EMG Poster Session I���������������������������������������������������������������������������78 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG ALS: Disease Mechanism and Therapeutics���������������������������60 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Poster Session II�������������������������������������������������������������������������88 Autonomic Disorders: Synucleinopathies��������������������������������62 Clinical Approach to Muscle Disease I: Muscle Disorders and Rhabdomyolysis Motor Neuron Diseases: Biomarkers, Outcome Measures, and Therapeutics����������������������������������������������������63 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease Mastering EMG Waveform Recognition Skills in Just Two Hours! Poster Session III������������������������������������������������������������������������98 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Neuromuscular Ultrasound Skills Workshop $ (registration required) Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System “Best of” Session: Neuromuscular Disease Therapeutics ����48 Poster Session IV���������������������������������������������������������������������108 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies EMG Skills Workshop: Basic $ (registration required) Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies

Fast and easy registration · AAN.com/view/AM17 35


Annual Meeting Program List by Topic P5 Poster Session V ���������������������������������������������������������������������� 118 C204 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies S42 Update in Muscular Dystrophy�������������������������������������������������70 C217 Peripheral Neuropathy III: Genetic Testing and Next

Generation Sequencing S45 Peripheral Nerve Disorders�������������������������������������������������������71 P6 Poster Session VI���������������������������������������������������������������������128 Curbside Consult: Neuromuscular��������������������������������������������23 S54 Motor Neuron Disease and Myopathies���������������������������������73

NEURO-ONCOLOGY P1 Poster Session I���������������������������������������������������������������������������78 C38 Case Studies: Neurologic Consultations in Cancer Patients I

Curbside Consult: Neuro-oncology�������������������������������������������23

C56 Case Studies: Neurologic Consultations in Cancer Patients II C66 Neuro-oncologic Emergencies C117 The Palliative Care Guide in Neurology: Best Practice

Guidelines in Communication, Symptom Management, and End of Life Care of Patients with Brain Tumors and Other Life Limiting Neurological Disorders P2 Poster Session II�������������������������������������������������������������������������88 Invited Science: Neuro-oncology ���������������������������������������������87 C194 Basic Principles of Brain Tumors: For Practice and for Certification P5 Poster Session V ���������������������������������������������������������������������� 118 S41 Neuro-oncology �������������������������������������������������������������������������70 Section Topic Controversies: Chemo Brain: Neuro-cognitive Impact of Anti-cancer Therapies�����������������74 C218 Cutting Edge Neuro-oncology—Understanding Current Trends P6 Poster Session VI���������������������������������������������������������������������128

NEURO-OPHTHALMOLOGY/NEURO-OTOLOGY C22 It’s a Bird, It’s a Plane, It’s… The Doctor Who Cured My Benign Paroxysmal Positional Vertigo

C32 Emergency Room Neuro-ophthalmology C50 Neuro-ophthalmology and Neurovestibular Exam Lab

Skills Workshop $ (registration required) C86 Neuro-otology I: The Common Peripheral Vestibular Disorders C100 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness C118 Nystagmus and Saccadic Intrusions Made Simple C129 Pediatric Neuro-ophthalmology Update S26 Neuro-opthalmology/Neuro-otology���������������������������������������66 C151 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema

36 2017 AAN Annual Meeting Science Program

C160 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria

C175 Neuro-ophthalmology III: Diplopia, Ocular Motility

Disorders, and Nystagmus C191 A Case-based Approach to Neuro-ophthalmology: What Went Wrong? P5 Poster Session V ���������������������������������������������������������������������� 118 C202 Higher Cortical Visual Disorders: Case-based Review C215 Canalith Repositioning for Benign Paroxysmal Positional Vertigo C230 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia P6 Poster Session VI���������������������������������������������������������������������128 N9 Neuroscience in the Clinic: Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment �������������57 C245 Now You See It, Now You Know It—Pathognomonic Neuro-ophthalmology Findings

NEURO-REHABILITATION C81 C95 C123 C138 C156 C157

Common Spine Disorders I: Evaluation Common Spine Disorders II: Treatment Myelopathies I: Inflammatory and Vascular Etiologies Myelopathies II: Symptom Management and Rehabilitation Rehabilitation in Neurology Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome P4 Poster Session IV���������������������������������������������������������������������108 N6 Neuroscience in the Clinic: Functional Recovery in Neurology and Neuroscience �����������������������������������������������55 P5 Poster Session V ���������������������������������������������������������������������� 118 C207 Severe TBI: From ICU to Rehabilitation S43 Exciting New Results in Neuro-rehabilitation�������������������������70 C235 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

PAIN AND PALLIATIVE CARE C15 Practical Training in Injection Techniques in the

Treatment of Headache Disorders Skills Workshop $ (registration required) P1 Poster Session I���������������������������������������������������������������������������78 C81 Common Spine Disorders I: Evaluation C95 Common Spine Disorders II: Treatment C117 The Palliative Care Guide in Neurology: Best Practice Guidelines in Communication, Symptom Management, and End of Life Care of Patients with Brain Tumors and Other Life Limiting Neurological Disorders


C143 Non-Neuro-oncology: Case-based Palliative Care C157 C169 C184 S38 C235

Throughout the Continuum of Disease Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome Core Concepts in Pain Management I: Refractory Neuropathic Pain—Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids Core Concepts in Pain Management II: Safe Opioid Prescribing—Practical Considerations, Unintended Consequences, and Legal Issues Pain and Palliative Care.������������������������������������������������������������69 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy

PRACTICE, POLICY, AND ETHICS C10 Making Sure You Get Paid Under the New Health Care Laws C17 How Is Your Patient Really Doing? Patient Reported C31 P1 C45 C48 C64 P2 C87 C102 P3 C143 C145 C161 C165 C176 C181 S48

Scales, Tools and Shared Decision Making Advanced Neurologic Coding Poster Session I���������������������������������������������������������������������������78 Navigating the World of Mobile Health L Leadership Challenges in Practice ICD-10-CM: How to Optimize for Accurate Diagnosis and Reimbursement Poster Session II�������������������������������������������������������������������������88 How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future Business Strategies for Payer Negotiations and/or How to Go off the Grid Poster Session III������������������������������������������������������������������������98 Non-Neuro-oncology: Case-based Palliative Care Throughout the Continuum of Disease Hot Topics in Neurologic Practice: Managing the Patient Experience in 2017 and Beyond Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients I Clinical Neurology for Advanced Practice Providers I Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients II Clinical Neurology for Advanced Practice Providers II Practice, Policy, and Ethics��������������������������������������������������������71

RESEARCH METHODOLOGY, EDUCATION, AND HISTORY C5 C6

Resident Basic Science I: Neuroanatomy—All the Lesions Early Career Research Training Symposium: A Roadmap to Academic Success for Residents and Fellows (registration required)

$ = Additional Fee Required  L = Leadership University

C16 P1 C43 C46 C60 S6 C74 P2 C75 C85 C93 C130 C132

C145 C146 C148 S28 C163 C189

Resident Basic Science II: Neuropathology Poster Session I���������������������������������������������������������������������������78 Introduction to Clinical Research and Methods Resident Basic Science III: Neuropharmacology Precision Neurology: The Promise and Perils of Personalized Medicine in the Genomic Era Research Methodology and Education: Education Research�������������������������������������������������������������������61 Annual A.B. Baker Program: Focus on Professionalism Poster Session II�������������������������������������������������������������������������88 Clerkship and Program Directors Conference: Wellness and Burnout During Training Boston City Hospital: The Cradle of American Neurology Part I Boston City Hospital: The Cradle of American Neurology Part II Eponymous Women in Neurology I Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man Curbside Consult: Academic . . . . . . . . . . . . . 23 Hot Topics in Neurologic Practice: Managing the Patient Experience in 2017 and Beyond Eponymous Women in Neurology II Developing the Treatments of Tomorrow II: Clinical Trials in Neurology History of Neurology�������������������������������������������������������������������66 An Introduction to Research in Medical Education Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors?

SLEEP C23 C71 S14 P3 C128

Using Sleep Medicine to Help Solve Difficult Neurologic Cases Hot Topics in Sleep Neurology Highlights in Sleep Science�������������������������������������������������������63 Poster Session III������������������������������������������������������������������������98 Sleep Apnea and Related Disorders Over the Lifecycle: What Neurologists Need to Know C144 Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist C166 Circadian Rhythm Disorders: Implications for Neurology C197 Interpreting Sleep Study Procedure(s), Data, and Reports: What the Non-sleep Specialist Needs to Know C226 How to Integrate Sleep Medicine into Your Child Neurology Practice C234 Sleep for the Practicing Neurologist I: Is It Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence C242 Sleep for the Practicing Neurologist II: Night Fighting: Sleep Related Hypermotor Epilepsy, Sleepwalking, and Dream Enactment

Fast and easy registration · AAN.com/view/AM17 37


Please join us at Commitment to Cures, a fundraiser for the American Brain Foundation, featuring this year’s Public Leadership in Neurology recipients Dan Gasby and B. Smith. Formal invitation to follow.

WHEN Wednesday, April 26, 2017

Cocktail hour 7pm – 8pm Dinner 8pm – 8:30pm Program 8:30pm – 9:30pm WHERE

The Westin Boston Waterfront, Marina Ballroom 425 Summer St, Boston, MA 02210 (adjacent to the Boston Convention and Exhibition Center)

SPEAKERS Dan Gasby and B. Smith

E N T E R TA I N M E N T

Delfeayo Marsalis Jazz Quartet

R E G I S T E R AT

AmericanBrainFoundation.org/commitment2cures

201 Chicago Ave Minneapolis, MN 55415 For questions contact events@americanbrainfoundation.org

le Ce

b

t in a r

gO

u

5 r2

th

An

v ni

er

r sa

y


These daily not-to-be-missed premier sessions offer a unique opportunity to hear from some of the most inspiring and innovative thought leaders in the field of neurology.

Hot Topics Plenary Session

Saturday, April 22  5:00 p.m.–6:30 p.m. . . . . . . . . . . . . . . . . .40

Presidential Plenary Session

Sunday, April 23  9:15 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . 41

Contemporary Clinical Issues Plenary Session

Monday, April 24  9:15 a.m.–11:30 a.m. . . . . . . . . . . . . . . . . . 42

Clinical Trials Plenary Session

Tuesday, April 25  9:15 a.m.–11:30 a.m. . . . . . . . . . . . . . . . . . 43

Frontiers in Neuroscience Plenary Session

Wednesday, April 26  9:15 a.m.–11:30 a.m. . . . . . . . . . . . . . . .44

Controversies in Neurology Plenary Session

Thursday, April 27  9:15 a.m.–11:30 a.m. . . . . . . . . . . . . . . . . 45

Neurology Year in Review Plenary Session

Friday, April 28  9:15 a.m.–11:30 a.m. . . . . . . . . . . . . . . . . . . .46

Plenary Sessions

Plenary Sessions


Plenary Sessions

Hot Topics Plenary Session Saturday, April 22

5:00 p.m.–6:30 p.m.

This session features translational research related to clinical issues of importance. Four outstanding physicianscientists provide summaries of their recent research findings and describe the clinical implications of the results.

Moderator Eric Klawiter, MD

Member, Science Committee

SATURDAY

Lysosomal Proteins as a Therapeutic Target in Neurodegeneration Dimitri Krainc, MD, PhD

The Role of CNS-draining Lymphatics in Neurological Diseases

Northwestern University, Chicago, IL

Jonathan Kipnis, PhD

Antisense Oligonucleotide Treatment (ASO) and SMA: Results of Clinical Trials

Population-based Comprehensive Epilepsy Care in Ontario, Canada: A Model Network

Claudia A. Chiriboga, MD

O. Carter Snead, III, MD, FAAN

Columbia University, New York, NY

40 2017 AAN Annual Meeting Science Program

University of Virginia, Charlottesville, VA

 ospital for Sick Children, H Toronto, ON, Canada


Sunday, April 23

9:15 a.m.–12:00 p.m.

This session features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2017. Don’t miss the final presentation from AAN President Terrence L. Cascino, MD, FAAN, before he passes the gavel to President Elect Ralph L. Sacco, MD, MS, FAHA, FAAN.

Plenary Sessions

Presidential Plenary Session

Moderator Natalia Sana Rost, MD, FAAN Vice Chair, AAN Science Committee

Presidential Lecture Terrence L. Cascino, MD, FAAN Mayo Clinic, Rochester, MN

Sidney Carter Award in Child Neurology

J. Helen Cross, PhD

 UCL-Institute of Child Health, London, United Kingdom

H. Houston Merritt Lecture

Robert Wartenberg Lecture

Ophthalmoscopy in the 21st Century

How Early Can We Diagnose Alzheimer’s Disease?

Nancy J. Newman, MD, FAAN E mory University School of Medicine, Atlanta, GA

Ronald C. Petersen, PhD, MD, FAAN Mayo Clinic, Rochester, MN

Fast and easy registration · AAN.com/view/AM17 41

SUNDAY

Improving Outcomes in Childhood Epilepsy in Dravet Syndrome: Results of a Multi-center, Randomized, Controlled Trial (GWPCARE1)


Plenary Sessions

Contemporary Clinical Issues Plenary Session Monday, April 24 

9:15 a.m.–11:30 a.m.

This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.

Moderator Natalia Sana Rost, MD, FAAN Vice Chair, AAN Science Committee

Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA): Study Design and Initial Interim Efficacy and Safety Findings from the Phase 3 International ENDEAR Study

Presenter: Nancy L. Kuntz, MD

A Woman “Found Down” Louise D. McCullough, MD, PhD

T he University of Texas Health Science Center at Houston, Houston, TX

 nn & Robert H. Lurie Children’s A Hospital of Chicago, Chicago, IL

Discussant: Charlotte J. Sumner, MD J ohns Hopkins Medicine, Baltimore, MD

MONDAY

Resumption of Oral Anticoagulation After Intracerebral Hemorrhage Is Associated with Decreased Mortality and Favorable Functional Outcome

The Era of Targeted Preventive Treatment for Migraine: CGRP Monoclonal Antibodies Amaal J. Starling, MD Mayo Clinic, Phoenix, AZ

Presenter: Alessandro Biffi, MD

 assachusetts General Hospital, M Boston, MA

Discussant: Daniel F. Hanley, MD, FAAN J ohns Hopkins Medicine, Baltimore, MD

Targeting Neuronal Activity-regulated Neuroligin-3 Secretion for Glioma Therapy

Presenter: Michelle Monje, MD, PhD Stanford University, Stanford, CA

Discussant: Tracy T. Batchelor, MD, MPH  assachusetts General Hospital, M Boston, MA

42 2017 AAN Annual Meeting Science Program

High Drug Prices: The Elephant in the Clinic Dennis N. Bourdette, MD, FAAN

Oregon Health & Science University, Portland, OR


Tuesday, April 25

9:15 a.m.–11:30 a.m.

This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented.

Moderators Natalia Sana Rost, MD, FAAN Vice Chair, AAN Science Committee

Deborah Hall, MD, PhD, FAAN Member, Science Committee

Plenary Sessions

Clinical Trials Plenary Session

Petra Kaufmann, MD, FAAN Member, Science Committee

Effect of Intensive Systolic Blood Pressure Lowering on Hematoma Expansion in Patients with Intracerebral Hemorrhage: Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II Trial

A 2-year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring Versus Control to Prevent Cognitive Decline in At-risk Elderly People (FINGER): A Randomized Controlled Trial

Adnan I. Qureshi, MD

TBD

Longitudinal Effect of Eteplirsen Versus Historical Control on Ambulation in Duchenne Muscular Dystrophy

AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Event Free Survival and Achievement of Developmental Milestones

University of Minnesota, Minneapolis, MN

Jerry R. Mendell, MD, FAAN

T he Research Institute at Nationwide Children’s Hospital, Columbus, OH

Jerry R. Mendell, MD, FAAN

Kids Are Not Just Little Adults: The Childhood and Adolescent Migraine Prevention Trial (CHAMP)

Cannabidiol (CBD) Reduces Convulsive Seizure Frequency in Dravet Syndrome: Results of a Multi-center, Randomized, Controlled Trial (GWPCARE1)

Cincinnati Children’s Hospital, Cincinnati, OH

J. Helen Cross, PhD

Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study

MGTX: Results of the Multinational Thymectomy Trial in Non-thymomatous Myasthenia Gravis

Ludwig Kappos, MD

Gil I. Wolfe, MD, FAAN

University Hospital Basel, Basel, Switzerland

 CL-Institute of Child Health, U London, United Kingdom

University at Buffalo, Buffalo, NY

Fast and easy registration · AAN.com/view/AM17 43

TUESDAY

Scott Powers, PhD

T he Research Institute at Nationwide Children’s Hospital, Columbus, OH


Plenary Sessions

Frontiers in Neuroscience Plenary Session Wednesday, April 26

9:15 a.m.–11:30 a.m.

This plenary session features basic and translational research related to clinical issues of importance. Six outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.

Moderator Randolph S. Marshall, MD, FAAN Member, Science Committee

Genome and Epigenome Editing for Gene Therapy and Cell Programming

Vesicle Communication in the Tumor-bearing Brain

Charles Gersbach, PhD

 assachusetts General Hospital, M Charlestown, MA

 uke Center for Genomic and D Computational Biology, Durham, NC

Axonopathies: What Next? Mary Reilly, MD, FRCP, FRCPI  ational Hospital for Neurology and N Neurosurgery, London, United Kingdom

Xandra O. Breakefield, PhD

The Lives of a Gene: Diverse Roles in Diseases of Developing and Mature Brain M. Elizabeth Ross, MD, PhD Cornell University, New York, NY

WEDNESDAY

Epilepsy at the Cutting Edge: Using Novel Models for Therapeutic Advances

The Promise of Immunotherapy for Neurodegenerative Disorders: Progress and Challenges

Amy R. Brooks-Kayal, MD, FAAN

Eliezer Masliah, MD

Children’s Hospital Colorado, Aurora, CO

44 2017 AAN Annual Meeting Science Program

National Institute on Aging, Bethesda, MD


Thursday, April 27

9:15 a.m.–11:30 a.m.

This session features experts discussing the most current and controversial issues in neuroscience. It is set up as a debate format in which two speakers argue one side of a single topic, followed by a rebuttal.

Moderators Joseph Jankovic, MD, FAAN

Plenary Sessions

Controversies in Neurology Plenary Session

Member, Science Committee

Aleksandar Videnovic, MD, MSc, FAAN Member, Science Committee

Is Focused Ultrasound Better Than Deep Brain Stimulation?

Yes: Paul S. Fishman, MD, PhD

University of Maryland School of Medicine, Baltimore, MD

No: Michael S. Okun, MD, FAAN University of Florida, Gainesville, FL

Should Disease-modifying Therapies Be Stopped in Progressive MS?

Yes: John Corboy, MD, FAAN

University of Colorado School of Medicine, Aurora, CO

No: Robert T. Naismith, MD

Washington University, St. Louis, MO

Does Removal of Amyloid Improve Cognition in Alzheimer’s Disease?

Yes: Brigham and Women’s Hospital, Boston, MA

No: George Perry, PhD

The University of Texas at San Antonio, San Antonio, TX

Fast and easy registration · AAN.com/view/AM17 45

THURSDAY

Reisa A. Sperling, MD


Plenary Sessions

Neurology Year in Review Plenary Session Friday, April 28

9:15 a.m.–11:30 a.m.

This session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic.

Moderator Shafali Jeste, MD

Member, Science Committee

Movement Disorders

Multiple Sclerosis

Susan Fox, MD

Peter A. Calabresi, MD, FAAN

Pediatric Neurology

Neurocritical Care

Erika Fullwood Augustine, MD, FAAN

Paul Vespa, MD

T oronto Western Hospital, Toronto, ON, Canada

 niversity of Rochester Medical Center, U Rochester, NY

Stroke Brett M. Kissela, MD, MS, FAAN  niversity of Cincinnati Hospital, U Cincinnati, OH

FRIDAY 46 2017 AAN Annual Meeting Science Program

Johns Hopkins University, Baltimore, MD

 niversity of California Los Angeles, U Los Angeles, CA

Epilepsy TBD


NEW! A platform session that brings together the top four scoring abstracts in a particular topic, as rated by the topic reviewers. Offers an opportunity to interact with the author in a smaller, more intimate setting at the conclusion of the session. These “Best of” sessions are the perfect lead-in to the plenary sessions that immediately follow.

S1 “Best of” Session: Parkinson’s Disease

Sunday, April 23  8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . . 48

S10 “Best of” Session: MS and CNS Inflammatory Disease

Monday, April 24  8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . 48

S19 “Best of” Session: Cerebrovascular Disease and Interventional Neurology

Tuesday, April 25  8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . 48

S27 “Best of” Session: Neuromuscular Disease Therapeutics

Wednesday, April 26  8:00 a.m.–9:00 a.m. . . . . . . . . . . . 48

S37 “Best of” Session: Epilepsy

Thursday, April 27  8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . 49

S49 “Best of” Session: Aging and Dementia

Friday, April 28  8:00 a.m.–9:00 a.m. . . . . . . . . . . . . . . 49

“Best of” Scientific Platform Sessions

“Best of” Scientific Platform Sessions


“Best of” Scientific Platform Sessions

“Best of” Scientific Platform Sessions Sunday  8:00 a.m.–9:00 a.m.

Monday  8:00 a.m.–9:00 a.m.

Tuesday  8:00 a.m.–9:00 a.m.

Wednesday  8:00 a.m.–9:00 a.m.

S1 “Best of” Session:

S10 “Best of” Session: MS and

S19 “Best of” Session:

S27 “Best of” Session:

8:00 a.m.

8:00 a.m.

8:00 a.m.

8:00 a.m.

S27.001

8:08 a.m.

S27.002

Parkinson’s Disease S1.001

Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease  —Laurie Robak, Iris Jansen, Jeroen van Rooij, Andre Uitterlinden, Robert Kraaj, Peter Heutink, Joshua Shulman

8:08 a.m.

S1.002

Neuropathic Gaucher’s Mutations: Shifting Parkinson’s Into High Gear  —Ganqiang Liu, Brendon Boot, Joseph Locascio, Zhixiang Liao, Daly Franco, Karen Duong, Kara Page, Iris Jansen, Tom Yi, Ana Trisini-Lipsanopoulos, Xianjun Dong, Samantha J. Hutten, Sophie Winder-Rhodes, Sami Amr, Caroline Tanner, Anthony Lang, Michael Nalls, Shirley Eberly, Clemens Scherzer, Lewis Sudarsky, Alexis Elbaz, Alexis Brice, Bernard Ravina, Ira Shoulson, J.J. Van Hilten, Florence Cormier, Jean Christophe Corvol, Roger Barker, Peter Heutink, Johan Marinus, Caroline WilliamsGray

8:16 a.m.

S1.003

Discovery and systematic functional validation of Parkinson’s disease genes from exome sequencing  —Joshua Shulman, Iris Jansen, Hui Ye, Sasja Heetveld, J. Raphael Gibbs, Amit Chouhan, Andrew Singleton, Shushant Jain, Peter Heutink

8:24 a.m.

S1.004

The role of habenula and amygdala in Parkinson’s disease patients with punding  —Elisa Canu, Federica Agosta, Vladana pica, Alberto Inuggi, Milica Jecmenica, Francesca Imperiale, Alexandra Tomic, Vladimir Kostic, Massimo Filippi

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

CNS Inflammatory Disease S10.001

Longitudinal characterization of cortical lesion evolution in multiple sclerosis by ultra high field MRI  —Constantina A Treaba, Tobias Granberg, Elena Herranz, Russell Ouellette, Celine Louapre, Revere Kinkel, Jacob Sloane, Caterina Mainero

8:08 a.m.

S10.002

Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study  — Douglas Arnold, Michael Barnett, Giancarlo Comi, Gavin Giovannoni, Daniel Pelletier, Alex Rovira, Sven Schippling, Bart Van Wijmeersch, David Margolin, Kathinathan Thangavelu, Anthony Traboulsee, on Behalf of the CAR Investigators

8:16 a.m.

S10.003

Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited.  — Shayandokht Taleb, Bardia Nourbakhsh, Jennifer Graves, Theron Casper, Amy Waldman, Sabeen Lulu, Anita Belman, Bianca Guttman, Benjamin Greenberg, Gregory Aaen, Janace Hart, Jayne Ness, Jennifer Rubin, JanMendelt Tillema, Lauren Krupp, Mark Gorman, Leslie Benson, Moses Rodriguez, Tanuja Chitnis, John Rose, Lisa Barcellos, Emmanuelle Waubant

8:24 a.m.

S10.004

Self-reported fatigue and lower limb problems predictive of conversion to secondary progressive multiple sclerosis in an aging sample of patients  —Caila Vaughn, Katelyn Kavak, Aisha Bushra, Ekaterina Noyes, Keith Edwards, Andrew Goodman, Patricia Coyle, Lauren Krupp, Burk Jubelt, Malcolm Gottesman, Ralph Benedict, Bianca Weinstock-Guttman

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

Cerebrovascular Disease and Interventional Neurology S19.001

Fully automated pipeline for white matter hyperintensity segmentation using clinical scans in patients with acute ischemic stroke  —Markus D Schirmer, Adrian V Dalca, Ramesh Sridharan, Anne-Katrin Giese, Joseph Broderick, Jordi Jimenez-Conde, Lukas Holmegaard, Brett Kissela, Dawn Kleindorfer, Robin Lemmens, Arne Lindgren, James Meschia, Tatjana Rundek, Ralph Sacco, Reinhold Schmidt, Pankaj Sharma, Agnieszka Slowik, Vincent Thijs, Daniel Woo, Bradford Worrall, Steven Kittner, Jonathan Rosand, Ona Wu, Polina Golland, Natalia Rost

Neuromuscular Disease Therapeutics

Rasagiline for the Treatment of ALS: a randomized controlled study  —Richard Barohn, Jeffrey Statland, Dan Moore, Maureen Walsh, Tahseen Mozaffar, Lauren Elman, Sharon Nations, Hiroshi Mitsumoto, J. Americo Fernandes, David Saperstein, Ghazala Hayat, Laura Herbelin, Chafic Karam, William Martens, Nuran Dilek, Lindsey Atchity, Jonathan Katz Oral Fingolimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (FORCIDP): Results from a Phase III Randomized Placebo-controlled Trial  —Hans-Peter Hartung, Marinos Dalakas, Ingemar Merkies, Norman Latov, Jean-Marc Leger, Eduardo Nobile-Orazio, Gen Sobue, Angela Genge, Martin Bernhard Merschhemke, Ervin Carolyn Marie, Catherine Agoropoulou, Richard Hughes

8:08 a.m.

S19.002

8:16 a.m.

S19.003

8:16 a.m.

S27.003

8:24 a.m.

S19.004

8:24 a.m.

S27.004

Recanalization Therapy is Associated with Lower Odds of 30-Day Readmission: An Analysis of the Nationwide Readmission Database  —Farhaan Vahidy, John Donnelly, Louise McCullough, Jon Tyson, Charles Miller, Sean Savitz, Karen Albright Disparities in Delivery of Endovascular Therapy: The Florida Puerto Rico Collaboration to Reduce Stroke Disparities Study (CReSD)  —Negar Asdaghi, Lais Granzoti Cintra, Kefeng Wang, Chuanhui Dong, Maria A. Ciliberti-Vargas, Carolina Gutierrez, Sebastian Koch, Hannah Gardener, Erika Marulanda-Londono, Nils Mueller, Dileep Yavagal, Brijesh Mehta, Ricardo Hanel, David Rose, Salina Waddy, Mary Robichaux, Dianne Foster, Juan Carlos Zevallos, Ulises Nobo, Tatjana Rundek, Ralph Sacco, Jose Romano Time-course of functional recovery after acute ischaemic stroke and its relationship to cause-specific mortality: Implications for follow-up of stroke trials  —Aravind Ganesh, Ramon Luengo-Fernandez, Rose M Wharton, Sergei A Gutnikov, Louise E Silver, Ziyah Mehta, Peter Rothwell, on behalf of the Oxford Vascular Study

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Event Free Survival and Achievement of developmental milestones  —Jerry Mendell, Samiah AlZaidy, Richard Shell, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, Katherine Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Douglas Sproule, Minna Du, Jessica A. Cardenas, Arthur Burghes, Kevin Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy  —David Adams, Teresa Coelho, Isabel Conceicao, Marcia Waddington Cruz, Hartmut Schmidt, Buades Juan, Josep Campistol, Jean Pouget, John Berk, Michael Polydefkis, Nour Ziyadeh, Angela Partisano, Jihong Chen, Jared Gollob, Ole Suhr

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

48 2017 AAN Annual Meeting Science Program


Friday  8:00 a.m.–9:00 a.m.

S37 “Best of” Session: Epilepsy

S49 “Best of” Session: Aging

8:00 a.m.

S37.001

In vivo two-photon calcium imaging of excitatory pyramidal neurons and inhibitory fast-spiking parvalbumin-positive interneurons during temperature-induced seizures in a mouse model of Dravet syndrome  —Conny Tran, Ethan Goldberg

8:08 a.m.

S37.002

Seizure triggers in epilepsy patients: a national perspective  —Anjie Ge, Erie Gonzalez, Seung Wook Lee, Yaretson Carmenate, Maxwell Collard, Tracy DixonSalazar, Nathan Crone, Gregory Krauss

8:16 a.m.

S37.003

8:24 a.m.

S37.004

The Importance of Family Planning as a Determinant of Spontaneous Fetal Loss in Women with Epilepsy: Findings of the Epilepsy Birth Control Registry  —Andrew Herzog, Hannah Mandle, Devon MacEachern, W. Hauser, Anne Davis Extrapolation of efficacy data from adults with primary generalized tonic-clonic seizures (PGTC) to pediatric patients: a meta-analysis of published clinical trials  —Douglas Nordli, Emilia Bagiella, Alexis Arzimanoglou, Jinping Wang, Dinesh Kumar, Antonio Laurenza, Jacqueline French

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

and Dementia

8:00 a.m.

S49.001

8:08 a.m.

S49.002

8:16 a.m.

S49.003

8:24 a.m.

S49.004

Ante mortem CSF tau levels correlate with post mortem tau pathology in FTLD  —David Irwin, Alberto Lleo, Corey McMillan, David Wolk, Vivianna Van Deerlin, Leslie Shaw, John Trojanowski, Murray Grossman The Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL) North American Rare Disease Clinical Research Consortium: Progress and Characterization of Initial Participants  — Adam Boxer, Howard Rosen, Bradley Boeve, Hilary Heuer, Giovanni Coppola, Bradford Dickerson, Yvette Bordelon, Robin Conwit, Christina Dheel, Kelley Faber, Howard Feldman, Julie Fields, Jamie Fong, Tatiana Foroud, Nupur Ghoshal, Neill Graff-Radford, Murray Grossman, Ging-Yuek Hsiung, Edward Huey, David Irwin, Kejal Kantarci, Daniel Kaufer, Anna Karydas, David Knopman, John Kornak, Joel Kramer, Walter Kukull, Irene Litvan, Ian R.A. Mackenzie, Mario Mendez, Bruce Miller, Matt Miller, Matthew Miller, Matthew Miller, Chiadi Onyike, Alexander Pantelyat, Madeline Potter, Rosa Rademakers, Erik Roberson, Margaret Sutherland, Carmela Tartaglia, Arthur Toga, Ashley Vetor, Sandra Weintraub, Zbigniew Wszolek Blood Pressure Trajectories from Mid to Late Life and Risk of Dementia: The Framingham Study  —Emer McGrath, Alexa Beiser, Charles DeCarli, Kendra Plourde, Vasan Ramachandran, Steven Greenberg, Sudha Seshadri Sleep apnea during NREM but not REM inversely correlates with CSF amyloid beta 42 but not Tau levels  —John Werner, Kylie Abeson, Aruna Rao, David Solomon, Olivia Petrusky, Mark Wu, Adam Spira, Abhay Moghekar

“Best of” Scientific Platform Sessions

Thursday  8:00 a.m.–9:00 a.m.

8:32 a.m.

Panel Discussion

8:45 a.m.

Meet the Investigators

Fast and easy registration · AAN.com/view/AM17 49


NEW! Exhibit Hall New dates, Sunday, April 23–Wednesday, April 26

The Exhibit Hall is your destination for enjoying good food, socializing, networking, and learning in a fun and relaxed environment. Plan your Exhibit Hall visit today!

Exhibit Hall Opening Luncheon

Sunday, April 23, 11:30 a.m.–1:30 p.m. Sponsored by Attend the opening lunch to mingle with fellow attendees and preview the latest products and services available in the neurologic industry.

Office of the Future

Sunday, April 23–Wednesday, April 26, in the Exhibit Hall Sponsored by Outcome Health and Sunovion Pharmaceuticals Showcasing recent technological advancements that help physicians streamline their processes, which allows for better patient care. Come explore!

Exhibit Hall Networking Reception

Monday, April 24, 4:30 p.m.–6:00 p.m. Sponsored by Network and socialize with fellow attendees in a fun and relaxed environment.

rt to o p s l Pas l a H ibit h x E the n i e t ipa Partic

win

zes! i r p y dail


NEW! A two-hour session featuring a mix of scientists and clinicians actively engaged in lively case discussion to integrate scientific research with clinical application. Scientists will introduce and provide background on a case and clinicians will apply the case to a patient. Sessions will feature abstract presentations related to the topic. Sessions end with a panel discussion.

N1 Neurobiology and Treatment of Disorders of

Language and Action . . . . . . . . . . . . . . . . . . . . . . . . .52 N2 Child Neurology: Neurologic Disorder Through a Lifespan—A Focus on MS . . . . . . . . . . . . . . 52 N3 Cutting Edge Concussion Data from the NCAA-DoD Grand Alliance . . . . . . . . . . . . . . . . . . . . . 53 N4 Zika Virus: The Global Outbreak of a Neurotropic Virus . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 N5 Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do? . . . . . . . . . . . . . . . . . . . . . . 55 N6 Functional Recovery in Neurology and Neuroscience . . . . 55 N7 Dopamine Transporter (DaT) Imaging . . . . . . . . . . . . . . . 56 N8 Novel Therapeutic Targets in Critical Care Neurology: Intracerebral and Intraventricular Hemorrhage . . . . . . . . 56 N9 Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . .57

Fast and easy registration ¡ AAN.com/view/AM17 51

Neuroscience in the Clinic Sessions

Neuroscience in the Clinic Sessions


Neuroscience in the Clinic Sessions

Neuroscience in the Clinic N1

Sunday, April 23

Neuroscience in the Clinic: Neurobiology and Treatment of Disorders of Language and Action Coordinator: H. Branch Coslett, MD, FAAN

Program Description Recent advances in behavioral neurology, neuroimaging and neurophysiology have substantially updated the understanding of aphasia and disorders of action such as hemiparesis and apraxia. This evolving conceptualization, however, has not been incorporated into the prevailing notions of these disorders and their treatment. The lack of familiarity with current concepts of the neurobiology of language and action is important as it prevents clinicians from evaluating and exploiting current and emerging treatments for these disorders. To address this issue, this course will focus on recent behavioral, non-invasive brain stimulation (e.g., TMS, tDCS) and neuroimaging investigations of the neurobiology of language and action. In separate talks followed by ample time for discussion, recent advances in the neurobiology of language and action will be presented. These presentations will be followed by talks discussing the potential clinical implications of the evolving understanding of language and action.

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:10 p.m. Introduction and Presentation of a Case H. Branch Coslett, MD, FAAN 1:10 p.m.–1:40 p.m. Neurobiology of Language and Implications for Therapy Peter Turkeltaub, MD, PhD 1:40 p.m.–2:00 p.m. Neurobiology of Higher Level Action and Implications for Therapy H. Branch Coslett, MD, FAAN 2:00 p.m.–2:15 p.m. N1.001: Anatomical Network Degeneration in Primary Progressive Aphasia John Medaglia, PhD 2:15 p.m.–2:30 p.m. N1.002: Characterization of Primary Progressive Aphasia and Prediction of Naming Decline by Multi-Modality MRI Andreia Faria 2:30 p.m.–3:00 p.m. Panel Discussion

SUNDAY

Upon Completion Participants are expected to gain a richer understanding of the brain processes underlying language and action. Importantly, participants will also learn how an updated understanding of disorders of language and action may translate into therapies.

N2

Neuroscience in the Clinic: Child Neurology: Neurologic Disorder Through a Lifespan—A Focus on MS Coordinators: Shafali Jeste, MD; Rebecca K. Lehman, MD

Program Description The onset of multiple sclerosis (MS) most commonly occurs in young adults, but onset may also occur in children and in the elderly. Pathological features include both focal demyelination, inflammation, neuronal and axonal loss, as well as a more global loss of central nervous system tissue integrity. Cognitive impairment is a major source of morbidity for patients with MS, but cognitive sequelae vary by age. In this course, we will take a “lifespan” approach to the clinical, neurobiologic, and radiographic aspects of cognitive impairment in MS. This course will provide up-todate information for all clinicians caring for patients with MS and will foster discourse between pediatric and adult neurologists. Upon Completion The foremost goal of this course is to bring the neurology community together to consider the impact of MS on cognitive function—a key patient-centered outcome. Attendees will gain insight into the biological underpinings of cognitive performance in MS with a focus on MS in the maturing, mature, and senescent CNS.

52 2017 AAN Annual Meeting Scientific Program

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:35 p.m. Case Report: Pediatric MS Patient Story Outlining Cognitive Changes Maria Pia Amato, PhD 3:35 p.m.–3:40 p.m. Case Report: Elderly Adult MS Patient Story Outlining Changes Over Time in Cognition Lauren B. Krupp, MD, FAAN 3:40 p.m.–3:50 p.m. Neuropsychological and MRI Features of Cognitive Impairment in Youth with MS Christine Till, PhD 3:50 p.m.–4:00 p.m. Neuropsychological and MRI Features of Cognitive Impairment in Elderly with MS Lauren B. Krupp, MD, FAAN 4:00 p.m.–4:10 p.m. Management of Cognitive Impairment in Pediatric MS Patients Brenda Banwell, MD, FAAN 4:10 p.m.–4:20 p.m. Management of Cognitive Impairment in Elderly MS Patients Lauren B. Krupp, MD, FAAN 4:20 p.m.–4:35 p.m. N2.001: Risks of Psychiatric Disorders in Children and Young Adults with Demyelinating Diseases of the Central Nervous System: A National Record-linkage Study Julia Pakpoor, MBBS 4:35 p.m.–4:50 p.m. N2.002: Structural Connectivity Abnormalities Underlying Cognitive Impairment in Pediatric Multiple Sclerosis Ermelinda De Meo 4:50 p.m.–5:30 p.m. Panel Discussion: Emerging Studies, Role of Current Therapies, Consideration of NEDA (No Evidence of Disease Activity, and the Concept of Cognitive Rehabilitation)


Monday, April 24

N3

Neuroscience in the Clinic: Cutting Edge Concussion Data from the NCAA-DoD Grand Alliance Coordinators: Christopher Giza, MD; Brian W. Hainline, MD, FAAN

Program Description To date, there is a paucity of data to define the natural history of concussion, and even less to define neurobiological recovery in concussion. The NCAA-DoD CARE Consortium is the largest, prospective, longitudinal study of concussion ever conducted. Athletes from all NCAA sports, including non-contact sports, are part of the study. In 1.5 years, approximately 20,000 studentathletes have been evaluated and over 1,000 concussions have been evaluated. In this session, cutting-edge, newly released data will be presented, including advanced research data of neuroimaging, blood biomarkers, genomics and helmet/head sensors. Clinical and policy implications of the emerging data will be discussed. Upon Completion Participants should be able to understand the study design and methodology of the study. They will further understand emerging concussion data, which will update current concussion knowledge. This emerging knowledge will provide a framework for managing concussion, developing concussion policy, and developing future research paradigms.

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:05 p.m. Introduction Brian W. Hainline, MD, FAAN 1:05 p.m.–1:15 p.m. Concussion as a Public Health Matter: Setting the Stage Brian W. Hainline, MD, FAAN 1:15 p.m.–1:35 p.m. Concussion Pathophysiology: What We Know and What We Need to Know Christopher Giza, MD 1:35 p.m.–2:00 p.m. CARE Consortium: Emerging Results and Implications for Concussion Management and Policy Michael McCrea, PhD 2:00 p.m.–2:15 p.m. N3.001: Migraine History and Associated Comorbidities in High School Athletes Katherine Breedlove 2:15 p.m.–2:30 p.m. N3.002: Between Trial Reliability of the King Devick Test Magdalena Wojtowicz, PhD 2:30 p.m.–3:00 p.m. Panel Discussion

MONDAY

Invited Science: Headache Monday, April 24, 3:30 p.m.–5:30 p.m.

Top abstracts previously presented at the American Headache Society Annual Meeting will be presented by their authors in 20-minute platform presentations. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of headache with the overall goal of developing more effective prevention and treatment. 1:00 p.m. to 1:20 p.m.  Early Life Stress Increases Susceptibility to Cortical Spreading Depression and Anxiety in Rodents

Stuart Collins, PhD Toledo, OH

1:20 p.m. to 1:40 p.m.  TBD 1:40 p.m. to 2:00 p.m.  Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Ann Scher, PhD

2:00 p.m. to 2:20 p.m.  TBD 2:20 p.m. to 2:40 p.m.  CRP and Migraine in Young Adults— Results from the Add Health Study

Gretchen E. Tietjen, MD Toledo, OH

2:40 p.m. to 3:00 p.m.  TBD

Current as of February 15, 2017

Bethesda, MD

Neuroscience in the Clinic Sessions



Fast and easy registration · AAN.com/view/AM17 53


Neuroscience in the Clinic Sessions

Neuroscience in the Clinic N4

Neuroscience in the Clinic: Zika Virus: The Global Outbreak of a Neurotropic Virus Coordinators: Allen J. Aksamit, Jr., MD, FAAN; Kiran Thakur, MD

Program Description This program will update the audience on recent outbreaks of Zika and other neurologic infections, and the overlap between neurological infections and autoimmune manifestations. The last decade has seen the emergence and re-emergence of several neurotropic infections, including Zika virus, Chikungunya virus, and drug resistant tuberculous meningitis. Infections which were once thought to be limited to tropical and subtropical regions are now having global impact, the most recent and expansive being Zika virus. The clinical manifestations and socioeconomic impact of Zika virus and other neurological infections is often devastating, particularly in resource-limited settings. Upon Completion Participants should be more familiar with the risk factors, clinical and laboratory diagnosis of Zika virus and other emerging infections, and understand the advances in pathogenesis, therapies with their limitations, and prognosis. Participants will also learn of public health strategies and challenges to prevent the spread of future neurological outbreaks.

TUESDAY 54 2017 AAN Annual Meeting Scientific Program

Tuesday, April 25 1:00 p.m.–3:00 p.m.

1:00 p.m.–1:05 p.m. Introduction Omar Siddiqi, MD 1:00 p.m.–1:15 p.m. Zika Case Presentation-Adult Manifestation Kiran Thakur, MD 1:15 p.m.–1:45 p.m. Epidemiological Update James J. Sejvar, MD 1:45 p.m.–2:15 p.m. Neurovirology and Neuropathogenesis Carlos A. Pardo-Villamizar, MD 2:15 p.m.–2:20 p.m. Introduction of Science Presentations Allen J. Aksamit, Jr., MD, FAAN; Arun Venkatesan, MD, PhD 2:20 p.m.–2:30 p.m. N4.001: Expanding Spectrum of Neurologic manifestations with Zika Virus Infection Laura S. Surillo Dahdah, MD 2:30 p.m.–2:40 p.m. N4.002: Neuroviruses Emerging in the Americas Study (NEAS): The Colombian experience during the 2016 outbreak of Zika virus infection Laura S. Munoz 2:40 p.m.–3:00 p.m. Panel Discussion


Wednesday, April 26

N5

Neuroscience in the Clinic: Stress and Neurologic Diseases: What Is It, and What Is the Provider to Do? Coordinators: Riley Bove, MD; Thomas Neylan, MD

Program Description Stress is everywhere in modern life. Stressors—acute and chronic, emotional, physical or social—influence our brain from birth to ageing. Whereas much is known about the effects of stress on brain programming during development, and about the adverse effects of chronic stress on neurological health and disease, there are major gaps in our understanding of what exactly stresses do to brain functions and how stress influences our brain. This knowledge is a prerequisite to devising interventions and therapies. This session will present clinical cases, demonstrating stress-related exacerbation of a range of neurologic diseases (e.g. migraine, seizures, multiple sclerosis). It will continue with a state-of the art discussion of the mechanisms by which diverse stresses that patients and care-providers encounter affect cognitive and emotional brain functions throughout life. We will then focus on clinically relevant advances in handling and mitigating the profound effects of stress on our brain. Upon Completion Recognize clinical manifestations of stress in patients with or without neurologic diseases. Recognize types of stressors (including modern life stress), and how to define and measure them. Understand how stress influences brain functions. Understand the multiple modalities and approaches available to reduce stress.

N6

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:10 p.m. Clinical Examples of Stress Across the Lifespan—Case Presentation Marie E. Pasinski, MD 1:10 p.m.–1:40 p.m. How Stress Influences the Brain throughout the Lifespan Tallie Z. Baram, MD, PhD 1:40 p.m.–1:50 p.m. Clinician Follow Up Marie E. Pasinski, MD 1:50 p.m.–2:00 p.m. Scientific Wrap Up Tallie Z. Baram, MD, PhD 2:00 p.m.–2:15 p.m. N5.001: Cingulo-Insular Structural Alterations Associated with Psychogenic Symptoms, Childhood Abuse and PTSD in Functional Neurological Disorders David L. Perez, MD 2:15 p.m.–2:30 p.m. N5.002: Does Psychological Stress Affect the Progression of Parkinson’s Disease Amie L. Hiller, MD 2:30 p.m.–3:00 p.m. D   iscussion Session: Mitigating the Impact of Stress in the Neurology Clinic: What Works?

Neuroscience in the Clinic: Functional Recovery in Neurology and Neuroscience

Coordinators: Deborah Hall, MD, PhD, FAAN; Massimo Pandolfo, MD, FAAN

Upon Completion Participants should become familiar with the scientific background of functional recovery after neurological damage and its potential clinical implications, including the most recent developments and future perspectives.

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:40 p.m. Case Presentations Brian Edlow, MD 3:40 p.m.–4:00 p.m. Neural Regeneration and Repair: Scientific Background, Historic Prospective, Challenges/Successes, Interim Clinical Applications Mark H. Tuszynski, MD, PhD, FAAN 4:00 p.m.–4:10 p.m. Neural Regeneration and Repair: Clinical Perspective Brian Edlow, MD 4:10 p.m.–4:30 p.m. Where is the Research Heading: Latest Developments/Future Directions Faculty 4:30 p.m.–4:45 p.m. N6.001: Specific human antisense oligonucleotide (ASO) targeting TGF-flRII rescues proliferation of TGF-fl arrested human neuronal progenitor cells (ReNcell CX) Sabrina Kuespert, PhD 4:45 p.m.–5:00 p.m. N6.002: Promoting network recovery after traumatic brain injury: exploring the targeted application of transcranial direct current stimulation Lucia M Li 5:00 p.m.–5:30 p.m. Panel Discussion

Fast and easy registration · AAN.com/view/AM17 55

WEDNESDAY

Program Description Two-hour highly integrated program that combines scientific research on functional recovery in neurology and neuroscience with clinical application and brings them together in context. The program will start with the presentation of a clinical case, then the scientific and clinical perspectives will be provided by two invited speakers. Two relevant abstracts will then be presented and discussed. The program will end with a roundtable discussion involving the invited speakers, the abstract presenters, the cochairs and the audience.

Neuroscience in the Clinic Sessions




Neuroscience in the Clinic Sessions

Neuroscience in the Clinic N7

Neuroscience in the Clinic: Dopamine Transporter (DaT) Imaging Coordinator: Ryan R. Walsh, MD, PhD, FAAN

Program Description Dopamine transporter (DaT) imaging has recently been developed as an adjunctive diagnostic tool in Parkinson’s disease. There remain questions, however, regarding how DaT imaging is optimally utilized in the clinical setting. This program will endeavor to improve understanding of DaT imaging through case presentation, discussion of the scientific development of DaT imaging, review of the impact of DaT imaging on the case presented, and review of the current understanding of DaT imaging and other emerging imaging modalities in Parkinson’s disease. An interactive panel discussion immediately following the didactic session will provide further opportunity for participants to consider DaT imaging and other emerging imaging modalities in Parkinson’s disease. Upon Completion Participants should have an improved understanding of the clinical utility of DaT imaging as well as its limitations, including as applied in a real-world clinical setting. Participants should also have improved understanding of the science behind both DaT imaging and other emerging imaging modalities, as well as what is on the horizon for neuroimaging in Parkinson’s disease.

N8

Thursday, April 27 1:00 p.m.–3:00 p.m.

1:00 p.m.–1:05 p.m. Introduction Ryan R. Walsh, MD, PhD, FAAN 1:05 p.m.–1:15 p.m. Case Presentation Deborah Hall, MD, PhD, FAAN 1:15 p.m.–1:45 p.m. The Science Behind Dompamine Transporter (DaT) Imaging Joel S. Perlmutter, MD, FAAN 1:45 p.m.–2:00 p.m. Case Presentation Conclusion: Impact of DaT Imaging Deborah Hall, MD, PhD, FAAN 2:00 p.m.–2:30 p.m. The Future of DaT Imaging and Emerging Imaging Modalities in Parkinson’s Disease Joel S. Perlmutter, MD, FAAN 2:30 p.m.–3:00 p.m. Panel Discussion

Neuroscience in the Clinic: Novel Therapeutic Targets in Critical Care Neurology: Intracerebral and Intraventricular Hemorrhage Coordinators: David Y. Hwang, MD; Sherry Chou, MD

Program Description Recent clinical trials have provided new insights in how best to manage primary intracerebral and intraventricular hemorrhage, both from medical and surgical perspectives. The first half of this program will center on an intraventricular hemorrhage case presentation, with discussion regarding the scientific evidence for intraventricular tPA administration and its clinical indications. Faculty will facilitate discussion with course participants regarding updates in intracerebral hemorrhage management during the second half of this program.

THURSDAY

Upon Completion Participants should become familiar with the most recent clinical trials related to intracerebral and intraventricular hemorrhage management, including when intraventricular tPA may be indicated for patients with intraventricular hemorrhage.

56 2017 AAN Annual Meeting Scientific Program

3:30 p.m.–5:30 p.m.

3:30 p.m.–3:40 p.m. Welcome and Case Presentation David Y. Hwang, MD; Sherry Chou, MD 3:40 p.m.–4:00 p.m. Intraventricular Hemorrhage: the History of Intraventricular tPA Use and the CLEAR III Trial Results Daniel F. Hanley, MD, FAAN 4:00 p.m.–4:15 p.m. After CLEAR III: When Might One Consider Using Intraventricular tPA? Alejandro A. Rabinstein, MD, FAAN 4:15 p.m.–4:30 p.m. The Future of Clinical Research in Intraventricular Hemorrhage Management Wendy C. Ziai, MD 4:30 p.m.–4:45 p.m. N8.001: Association between Leucocyte Count and Perihematomal Edema Growth After Primary Intracerebral Hemorrhage Aaron M. Gusdon, MD 4:45 p.m.–5:00 p.m. N8.002: Role Of Sulfonylureas In Perihematomal Edema In Spontaneous Intracerebral Hemorrhage Shailesh Male, MD 5:00 p.m.–5:30 p.m. Panel Discussion


Friday, April 28

N9

Neuroscience in the Clinic: Afferent and Efferent Visual Pathway Manifestations of Neurodegenerative Diseases: Implications for Diagnosis and Treatment Coordinators: Heather Moss, MD, PhD, FAAN; Gregory P. Van Stavern, MD, FAAN

Program Description Neurodegenerative diseases, particularly dementing disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are increasing in prevalence, related in part to the aging of the population. Visual dysfunction is an under-recognized and important cause of overall neurologic disability and reduced quality of life in neurodegenerative diseases. This program will review visual dysfunction (including the afferent and efferent systems as well as the cognitive visual manifestations of disease) in several neurodegenerative disorders, with special focus on clinical neuro-ophthalmic testing and vision disability in AD and PD and other neurodegenerative conditions. This will be achieved with faculty presentations on clinical aspects, scientific aspects and abstract presentations. The aim is to increase recognition of the types of visual dysfunction that occur in association with neurodegenerative diseases, as well as the causes, impact on quality of life, and the steps in evaluation and treatment in patients who experience these symptoms. Upon Completion Participants should be familiar with patterns of afferent and efferent visual dysfunction in patients with neuro-degenerative disease, understand an approach to diagnosis and treatment of resulting visual symptoms and get an update on new breakthroughs in the field.

1:00 p.m.–3:00 p.m.

1:00 p.m.–1:05 p.m. Introduction Heather Moss, MD, PhD, FAAN 1:05 p.m.–1:10 p.m. Case: Afferent Visual Dysfunction Faculty 1:10 p.m.–1:20 p.m. Clinical Aspects of Afferent Visual Dysfunction in Neurodegenerative Diseases Victoria S. Pelak, MD 1:20 p.m.–1:35 p.m. Scientific Aspects of Afferent Visual Dysfunction in Neurodegenerative Disease Geoffrey Karl Aguirre, MD, PhD 1:35 p.m.–1:45 p.m. N9.001: Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults Michael Ward, MD, PhD 1:45 p.m.–1:50 p.m. Case: Efferent Visual Dysfunction Faculty 1:50 p.m.–2:00 p.m. Clinical Aspects of Efferent Visual Dysfunction in Neurodegenerative Diseases Matthew J. Thurtell, MD 2:00 p.m.–2:15 p.m. Eye Movement and Reading Abnormalities in Parkinsonism Y. Joyce Liao, MD, PhD 2:15 p.m.–2:25 p.m. N9.002: What are the phenotypes of Brazilian patients with autossomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)?: Neurological, ophthalmological and neuroimaging features of seven genetically confirmed cases Flavio Rezende Filho 2:25 p.m.–2:35 p.m. The Visual System as a Biomarker for Neurodegenerative Diseases Gregory P. Van Stavern, MD, FAAN 2:35 p.m.–3:00 p.m. Panel Discussion

Neuroscience in the Clinic Sessions



FRIDAY

Fast and easy registration · AAN.com/view/AM17 57


Child Neurolo Frontiers in Child Neurology: Cultivating Careers, Exploring a Neurologic Disorder Through a Lifespan, and Networking Sunday, April 23  12:30 p.m.-6:00 p.m. Plan to attend this exciting half day of programming dedicated to child neurology. The afternoon starts with a luncheon for future child neurologists, followed by a Neuroscience in the Clinic focused on the latest science and therapies in pediatric to adult multiple sclerosis. The day ends with a networking reception. This is a unique event for attendees to engage with experts about pursuing a career in child neurology, sharing knowledge, and networking with new and familiar colleagues.

Highlights Careers in Child Neurology Luncheon—Ask the Experts Co-chairs: Ann Tilton, MD, FAAN, and Rujuta Bhatt, MD To provide an opportunity for medical students and residents who are considering, or recently decided on, a career as a child neurologist to have their questions answered by experts in the field, and to learn why and how to get involved in professional neurology organizations. By invitation only. 12:30 p.m.-1:00 p.m. Arrivals and assigned seating 1:00 p.m.-2:00 p.m. Lunch and table discussions 2:00 p.m.-3:00 p.m. The World of Child Neurology: Why and How to Get Involved  Panel Discussion with representatives from AAN, AAN Child Neurology Section, Child Neurology Society, and Child Neurology Foundation

Neuroscience in the Clinic: Neurologic Disorder Through a Lifespan—Focus on MS Coordinators: Shafali Jeste, MD, and Rebecca K. Lehman, MD This session will combine scientific research with clinical application and bring them together in context regarding pediatric and adult MS and the new exciting therapies on the horizon. See page 52 » for full schedule.

Networking Reception The program will conclude with a wine and cheese reception allowing attendees an opportunity to talk with presenters and network with colleagues.


These popular sessions will feature a group of abstracts covering a similar topic presented in an oral format. This year’s new format will feature shorter, eight-minute presentation followed by four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.

Sunday, April 23

1:00 p.m.–3:00 p.m. . . . . S2–S5 3:30 p.m.–5:30 p.m. . . . . S6–S9

Monday, April 24

1:00 p.m.–3:00 p.m. . . . S12–S14 3:30 p.m.–5:30 p.m. . . . S15–S18

Wednesday, April 26

1:00 p.m.–3:00 p.m. . . . S29–S31 3:30 p.m.–5:30 p.m. . . . S33–S36

Friday, April 28 1:00 p.m.–3:00 p.m. . . . S50–S53 3:30 p.m.–5:30 p.m. . . . S54–S56

Thursday, April 27

1:00 p.m.–3:00 p.m. . . . S39–S42 3:30 p.m.–5:30 p.m. . . . S44–S48

Tuesday, April 25

1:00 p.m.–3:00 p.m. . . . S20–S22 3:30 p.m.–5:30 p.m. . . . S23–S26

Fast and easy registration · AAN.com/view/AM17 59

Scientific Platform Sessions

Scientific Platform Sessions


Scientific Platform Sessions

Scientific Platform Sessions

Sunday, April 23

Sunday  8:00 a.m.–9:00 a.m.

Sunday  1:00 p.m.–3:00 p.m.

Sunday  1:00 p.m.–3:00 p.m.

Sunday  1:00 p.m.–3:00 p.m.

S1 “Best of” Session:

S2 Neuroimaging in MS

S3 ALS: Disease Mechanism

S4 Movement Disorders:

Parkinson’s Disease

Titles and authors of these abstracts

are listed in “Best of” Scientific Platform Sessions on page 48 »

1:00 p.m.

S2.001

Comparison of MRI Dissemination in Space Criteria for Predicting a First Clinical Event in Children with the Radiologically Isolated Syndrome  —Naila Makhani, Christine Lebrun Frenay, Aksel Siva, Sona Narula, Evangeline Wassmer, James Brenton, Clarisse CarraDalliere, Jerome De Seze, Francoise Durand Dubief, Megan Langille, Rinze F Neuteboom, Jean Pelletier, Daniela Pohl, Juan Ignacio Rojas, Eugene Shapiro, Robert ThompsonStone, Silvia Tenembaum, Mar Tintoré, Ugur Uygunoglu, Wendy Vargas, Orhun Kantarci, Darin Okuda, Daniel Pelletier

1:12 p.m.

S2.002

Longitudinal Assessment of Cervical Cord Atrophy Across MS Clinical Phenotypes: A Multicenter Study  —Maria Rocca, Mohammad Aboulwafa, Paola Valsasina, Paolo Preziosa, Frederik Barkhof, Hugo Vrenken, Claudio Gobbi, Chiara Zecca, Alex Rovira, Xavier Montalban, Hugh Kearney, Olga Ciccarelli, Lucy Matthews, Jacqueline Palace, Antonio Gallo, Alvino Bisecco, Achim Gass, Philipp Eisele, Carsten Lukas, Barbara Bellenberg, Giancarlo Comi, Massimo Filippi

SUNDAY

1:24 p.m.

S2.003

1:36 p.m.

S2.004

1:48 p.m.

S2.005

2:00 p.m.

S2.006

2:12 p.m.

S2.007

2:24 p.m.

S2.008

Atrophy of spinal cord gray matter is detectable at an early stage of multiple sclerosis  —Regina Schlaeger, Nico Papinutto, Alyssa Zhu, Esha Datta, Carolyn Bevan, Eduardo Caverzasi, Kesshi Jordan, Iryna Lobach, Anisha Keshavan, Gina Kirkish, William Stern, Michael Devereux, Nicholas Baker, Riley Bove, Jeffrey Gelfand, Jennifer Graves, Ari Green, Emmanuelle Waubant, Michael Wilson, Douglas Goodin, Bruce Cree, Stephen Hauser, Roland Henry Thalamic MRI and histopathologic correlations in advanced multiple sclerosis  —Kedar Mahajan, Kunio Nakamura, Harsha Battapady, Jacqueline Chen, Bruce Trapp, Daniel Ontaneda In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis  —Tobias Granberg, Qiuyun Fan, Constantina Andrada Treaba, Russell Ouellette, Elena Herranz, Gabriel Mangeat, Celine Louapre, Julien Cohen-Adad, Eric Klawiter, Jacob Sloane, Caterina Mainero Structural Connectivity Shapes Patterns of Cortical Atrophy in Multiple Sclerosis  — Kevin Patel, Sean Tobyne, Boratyn Daria, John Bireley, Victoria Smith, Brian Healy, Constantina A Treaba, Caterina Mainero, Eric Klawiter Prevalence of Leptomeningeal Contract Enhancement in Multiple Sclerosis Versus Other Chronic Neuroinflammatory Diseases  —Martina Absinta, Irene Cortese, Luisa Vuolo, Govind Nair, Joan Ohayon, Alessandro Meani, Vittorio Martinelli, Roberta Scotti, Andrea Falini, Bryan Smith, Avindra Nath, Steven Jacobson, Massimo Filippi, Daniel Reich Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Post-Contrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis  —Deepa Ramasamy, David Hojnacki, Channa Kolb, Jesper Hagemeier, Niels Bergsland, Ferdinand Schweser, Michael Dwyer, Bianca Weinstock-Guttman, Robert Zivadinov

2:36 p.m.

60 2017 AAN Annual Meeting Science Program

Discussion

and Therapeutics

1:00 p.m. Sheila Essey Award: An

Award for ALS Research Presented by the AAN and the ALS Association and supported through the philanthropy of the Essey family and the ALS Association.

Recipient:

John M. Ravits, MD, FAAN La Jolla, CA

1:24 p.m.

S3.003

Postnatal CRISPR-mediated genome editing prolongs survival in a mouse model of amyotrophic lateral sclerosis  —Zachary Kennedy, Wen Xue, Robert Brown

1:36 p.m.

S3.004

Beyond Oral Levodopa in Parkinson’s Disease

1:00 p.m.

S4.001

1:12 p.m.

S4.002

Global long-term registry on efficacy and safety of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients (GLORIA)—final results in a subgroup of patients with dyskinesia at baseline  — Werner Poewe, Kallol Chaudhuri, Lars Bergmann, Ashley Yegin, Stephanie Dubow, Angelo Antonini ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson’s disease achieves stable levodopa plasma levels when administered in low and high doses  — Nir Giladi, Yossi Caraco, Ruth Djaldetti, Liat Adar, Yael Cohen, Tamar Rahmilevich, Sheila Oren

Plasma Neurofilament Heavy Chain Levels correlate with disease severity and progression on multiple clinical outcomes in Amyotrophic Lateral Sclerosis (ALS)  —Steve Han, Dawei Liu, Shawn Ciotti, Toby Ferguson, 1:24 p.m. S4.003 Soma Ray, Donald Johns Continuous Administration of Subcutaneous 1:48 p.m. S3.005 Levodopa/Carbidopa (ND0612) Distinct patterns of disease progression in Demonstrated Comparable Levodopa SOD1-associated familial ALS: A study of 25 Pharmacokinetics to Levodopa/Carbidopa mutations. Pooled analysis of two trials of Intestinal Gel (LCIG)  —Liat Adar, Tamar pyrimethamine in familial ALS.  —Pantelis Rahmilevich, Yael Cohen, Sheila Oren Pavlakis, Mona Shahbazi, Amy Thoman, F Bin S4.004 Bin, Albert Ludolph, Stefan Marklund, Vincenzo 1:36 p.m. Preliminary Results of the Phase I Clinical Silani, Senda Arjous-Driss, Stanley Appel, Study Evaluating Neural Stem Cell Based Peter Andersen, Dale Lange Therapy for Parkinson’s Disease  —Russell 2:00 p.m. S3.006 Kern, Ibon Garitaonandia, Rodolfo Gonzalez, Immuno-modulation in Amyotrophic Lateral Glenn Sherman, Andrey Semechkin, Evan Sclerosis- A Phase II Study of Safety Snyder, Azmin Shahrul, Girish Nair, Andrew and Activity of Low Dose Interleukin-2 Evans (IMODALS study)  —Gilbert Bensimon, 1:48 p.m. S4.005 William Camu, Christine Payan, Timothy Tree, Quality of Life in Homebound People with Jean-Luc Veyrune, Andrea Malaspina, Cecilia Advanced Parkinson’s Disease: Feasibility Garlanda, Massimo Locati, Safaa Saker, Raul and Outcomes of an Interdisciplinary Home Juntas-Morales, Nicolas Pageot, John De Vos, Visit Program  —Jori Fleisher, Meghan Janine Kirby, Ammar Al-Chalabi, Peter Leigh Sweeney, Sarah Oyler, Amy Lemen, Talia 2:12 p.m. S3.007 Meisel, Arash Fazl, Geraldine Dacpano, The NEALS Randomized, Placebo Controlled Rebecca Wolf Gilbert, Alessandro Di Rocco, Trial of Diaphragm Pacing in Patients with Joshua Chodosh ALS  —Jonathan Katz, Jeremy Shefner, David 2:00 p.m. S4.006 Schoenfeld Effects of a Parkinson-Specific, 2:24 p.m. S3.008 Interdisciplinary Approach, To Inpatient The polymorphisms of CX3CR1 gene Rehabilitation  —Christian Benedict, Kelly influence ALS survival in an Italian Lyons, David Fredericks, Clare Manganiello, population-based study  —Cristina Moglia, Hannah Herrstrom, Dan Schmitt Andrea Calvo, Antonio Canosa, Maura 2:12 p.m. S4.007 Brunetti, Bryan Traynor, Marco Barberis, Motor retraining (MoRe) for functional Gabriele Mora, Adriano Chio movement disorders: Outcomes from a 2:36 p.m. Discussion one-week multidisciplinary rehabilitation program  —Alexandra Jacob, Darryl Kaelin, Courtney Smith, Megan Jablonski, Abbey Roach, Kathrin LaFaver

2:24 p.m.

S4.008

2:36 p.m.

Discussion

Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation for Parkinson’s Disease  —Guenther Deuschl, Roshini Jain, Alex Wang, Heleen Scholtes, Karsten Witt, Hubertus Mehdorn, Lars Timmermann, Veerle Visser-Vandewalle, Andrea Kuhn, Gerd-Helge Schneider, Alfons Schnitzler, Esther Suarez San Martin, Fernando Seijo, Paul Eldridge, Farah Jibril, Monica Pötter-Nerger, Wolfgang Hamel, Michele Cavallo, Mariachiara Sensi, Ignacio Regidor, Del Alamo Marta Del Alamo, Jens Volkmann, Cordula Matthies, Alan Whone, Nagaraja Sarangmat, Nicola Pavese, Sharon Hassin, Roberto Spiegelmann, James Fitzgerald, Alex Green, Jan Vesper


Sunday  3:30 p.m.–5:30 p.m.

Sunday  3:30 p.m.–5:30 p.m.

Sunday  3:30 p.m.–5:30 p.m.

S5 General Neurology:

S6 Research Methodology and

S7 Aging and Dementia: Clinical

S8 Cerebrovascular Disease and

3:30 p.m. Potamkin Prize for Research

3:30 p.m.

S8.001

3:42 p.m.

S8.002

3:54 p.m.

S8.003

4:06 p.m.

S8.004

4:18 p.m.

S8.005

4:30 p.m.

S8.006

4:42 p.m.

S8.007

4:54 p.m.

S8.008

5:06 p.m.

Discussion

Pathogenesis, Modulation, and Biomarkers of Complex Neurological Disorders

1:00 p.m.

S5.001

Impact of NEOD001 on Neuropathy in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From the Expansion Phase of a Phase 1/2 Study  —Michaela Liedtke, Raymond L. Comenzo, Heather Landau, Vaishali Sanchorawala, Brendan M. Weiss, Jeffrey Zonder, Jackie Walling, Gene Kinney, Martin Koller, Dale Schenk, Spencer Guthrie, Enchi Liu, Morie A. Gertz

1:12 p.m.

S5.002

Corticokinematic coherence is decreased in patients with Friedreich Ataxia and correlates with GAA1 expansion  —Gilles Naeije, Brice Marty, vincent wens, Massimo Pandolfo, Xavier De Tiege

1:24 p.m.

S5.003

1:36 p.m.

S5.004

Long-Term Risk of Seizures in Survivors of Sepsis  —Michael Reznik, Alexander Merkler, Ali Mahta, Santosh Murthy, Jan Claassen, Hooman Kamel Impact of Neurological Magnetic Resonance Imaging in Non-Approved Cardiac Devices  —Lina Ya’qoub, Sanjaya Gupta, Ibrahim Saeed, Stanley Fisher

1:48 p.m.

S5.005

2:00 p.m.

S5.006

3:30 p.m.

S6.001

A Randomized Education Research Trial of Fundoscopy Training Methods in Neurology Residency.  —Deepak Gupta, Namir Khandker, Kristin Stacy, Curtis Tatsuoka, David Preston

3:42 p.m.

S6.002

The Effect of a Clerkship Didactic Curriculum on Medical Student Career Choice in Neurology  —Aaron Farrow, David Gordon, Calin Prodan

3:54 p.m.

S6.003

Effectiveness of AlzU.org on recruitment for an Alzheimer’s disease prevention clinical trial  —Emily Caesar, Cara Berkowitz, Chiashin Shih, Jessica Shum, Katherine Hackett, Mark McInnis, Octavio Rodriguez, Richard Isaacson

4:06 p.m.

S6.004

Developing a Mobile Application for Stroke Caregivers  —Jonathan Singer, Sarah Weingast, Dimitre Stefanov, Nadege Gilles, Shirley Girouard, Mohammad Faysel, Alyssa Conigliaro, Marilyn Fraser-White, Amy Jensen, Dee Burton, Steven Levine

4:18 p.m.

S6.005

Timing of curriculum affects medical student career choice.  —Vicki Ramsey-Williams, Imran Ali

4:30 p.m.

S6.006

4:42 p.m.

S6.007

Engaging Neurology Residents in LearnerCentered Medical Student Education: A Novel Resident-Led, Video-Based Pilot Curriculum  —Jeffrey Dewey, Jeremy Moeller Improving Stroke Clinical Trial Enrollment via the Use of Telemedicine  —Jared Noroozi, Navdeep Sangha

Clinical features of post-vaccination GuillainBarré Syndrome (GBS) in the Republic of 4:54 p.m. S6.008 Korea  —Bum Chun Suh, Yong-shik Park The State of Diversity and Cultural Diversity Training in Neurology Residency 2:12 p.m. S5.007 Programs  —Nicole Rosendale, John Specific human antisense oligonucleotide Engstrom, S. Josephson (ASO) targeting TGF-flRII rescues proliferation of TGF-fl arrested human 5:06 p.m. Discussion neuronal progenitor cells (ReNcell CX)  — Sabrina Kuespert, Tim-Henrik Bruun, Eva Zitzelsperger, Rosmarie Heydn, Sebastian Peters, Siw Johannesen, Ludwig Aigner, Ulrich Bogdahn

2:24 p.m.

S5.008

Glia maturation factor inhibits mitochondrial biogenesis, increase oxidative stress and apoptotic cell death in dopaminergic neurons  —Govindhasamy Pushpav Selvakumar, Duraisamy Kempuraj, Ramasamy Thangavel, Mohammad Ejaz Ahmed, Prashant Natteru, Thamilarasan Manivasagam, Smita Zaheer, Shankar Iyer, Asgar Zaheer

2:36 p.m.

Discussion

and Translational Studies in Neurodegenerative Diseases

in Pick’s, Alzheimer’s, and Related Diseases Sponsored by the AAN and the American Brain Foundation and funded through the philanthropy of the Potamkin family.

Recipients:

Claudia Kawas, MD Irvine, CA Kristine Yaffe, MD San Francisco, CA

3:54 p.m.

S7.003

Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebocontrolled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer’s Disease  —Vissia Viglietta, John OGorman, Leslie Williams, Tianle Chen, Ahmed Enayetallah, Ping Chiao, Christoph Hock, Roger Nitsch, Samantha Budd Haeberlein, Alfred Sandrock

4:06 p.m.

S7.004

An Investigation on Repetitive Head Impact Exposure and Plasma Total Tau Concentrations in Former National Football League Players  —Michael Alosco, Yorghos Tripodis, Johnny Jarnagin, Christine Baugh, Brett Martin, Christine Chaisson, Nate Estochen, Linan Song, Robert Cantu, Andreas Jeromin, Robert Stern

4:18 p.m.

S7.005

Crenezumab’s Preferential Binding Of Oligomeric Amyloid-Beta Species Underlies Its Unique Mechanism Of Action  — Jasvinder Atwal, William Meilandt, Monica Wetzel-Smith, Bing Li, Travis Bainbridge, Mike Reichelt, Mark Ultsch, James Ernst, Weiru Wang, Susan Crowell, Angelica Quartino, Reina Fuji, Greg Ferl

4:30 p.m.

S7.006

Comparison of detergent-insoluble proteome changes in autosomal dominant Alzheimer’s disease brain to late onset AD and transgenic rodents  —Chad Hales, Eric Dammer, Duc Duong, Marla Gearing, Robert Cohen, Thomas Wingo, James Lah, Allan Levey, Nicholas Seyfried

4:42 p.m.

S7.007

Sporadic FTLD TDP type C is a distinct clinicopathological entity from FTLD types A/B  —G Michael Baer, Mathew Byrne, Felicia Cooper, Eunran Suh, Leo McCluskey, Lauren Elman, David Wolk, Vivianna Van Deerlin, Virginia Lee, Edward Lee, Murray Grossman, John Trojanowski, David Irwin

4:54 p.m.

S7.008

Mortality and risk of dementia in normal pressure hydrocephalus: 25-year follow-up of a population-based cohort  —Daniel Jaraj, Carsten Wikkelso, Katrin Rabiei, Tom Marlow, Christer Jensen, Svante Östling, Ingmar Skoog

5:06 p.m.

Interventional Neurology: Acute Stroke Treatment

Impact of hyperglycemia according to collateral status on reperfusion and outcomes in acute ischemic stroke after mechanical thrombectomy  —Joontae Kim, David Liebeskind, Reza Jahan, Bijoy Menon, Raul Nogueira, Jeffrey Saver Ultra-short door-to-needle times of 10 minutes or less in stroke thrombolysis— experience from 63 cases  —Raffi Topakian, Birgit Hörmanseder, Stefan Einsiedler, Ursula Straka, Dierk Oel, Bettina Metschitzer, Barbara Pischinger, Sabine Groicher, Petra Mueller, Peter Vollmann, Violetta Kure, David Farmer, Miriam Mezger, Florian Wimmer, Wolfgang Sperl, Andreas Karrer, Siegfried Funk, Ronald Lampl, Herbert Lugmayr, Günther Schustereder Impact of Neurologist In-Hospital 24/7 on stroke patients arriving to the Emergency Department activated as a Code Stroke  — Alexander Schneider, Robin Jones, Jackie Gosnell, Sean Snyder, Reid Taylor An analysis of fixed dose IV recombinant tissue plasminogen activator (rtPA) and clinical outcomes in acute ischemic stroke patients with body weight >100 kilograms: pooled data from three randomized clinical trials  —Shahram Majidi, Christopher Leon Guerrero, Kathleen Burger, Adnan Qureshi The effect of baseline blood pressure on the benefit and safety of intra-arterial treatment in MR CLEAN.  —Maxim Mulder, Saliha Ergezen, Hester Lingsma, Olvert Berkhemer, Puck Fransen, Debbie Beumer, Lucie Van den Berg, Geert Lycklama a Nijeholt, Bart Emmer, H. Bart Van Der Worp, Paul Nederkoorn, Yvo Roos, Robert Van Oostenbrugge, Wim Van Zwam, Charles Majoie, Aad Van Der Lugt, Diederik Dippel

Reliability of automated software to assign e-ASPECTS to CT scans for acute ischemic changes  —Lisa Hoyte, Abdulaziz Al Sultan, Sara Finkelstein, Matthew Boyko, Daniel Fok, Pooneh Pordeli, Mackenzi Horn, Annaliese Neweduk, Amy Yu, Ramana Appireddy, Carol Tham, Bijoy Menon Thrombectomy and thrombolysis in pediatric acute ischemic stroke  —Kathryn Ess, Rima Dafer, James Conners, Laurel Cherian, Bichum Ouyang, Sarah Song Disruption of the Blood-Ocular Barriers in Stroke Patients  —Emi Hitomi, Lawrence Latour, Richard Leigh

Discussion

Fast and easy registration · AAN.com/view/AM17 61

SUNDAY

Resting cerebral perfusion impairment in Type 2 Diabetes  —Weiying Dai, Freddy Alfaro-Martinez, Wenna Duan, Anna Gavrieli, Peter Novak, Vera Novak

Education: Education Research

Scientific Platform Sessions

Sunday  1:00 p.m.–3:00 p.m.


Scientific Platform Sessions

Scientific Platform Sessions

Monday, April 24

Sunday  3:30 p.m.–5:30 p.m.

Monday  8:00 a.m.–9:00 a.m.

Monday  1:00 p.m.–2:00 p.m.

Monday  1:00 p.m.–3:00 p.m.

S9 Neuro Trauma and Sports

S10 “Best of” Session:

S11 Autonomic Disorders:

S12 MS Therapeutics and MRI

Neurology

3:30 p.m.

S9.001

APOE 4 is a risk factor for chronic traumatic encephalopathy severity  —Courtney Verscaj, Bobak Abdolmohamadi, Patrick Kiernan, Jaeyoon Chung, John Crary, Thor Stein, Lindsay Farrer, Ann McKee, Jesse Mez

3:42 p.m.

MS and CNS Inflammatory Disease

Titles and authors of these abstracts

are listed in “Best of” Scientific Platform Sessions on page 48 »

S9.002

Hyperphosphorylation of tau contributes to anxiety-like behavior and LTP-decline after mild traumatic brain injury  —Jianhua Qiu, Xixia Liu, Zhengrong Mei, Sasha Alcon, Jumana Hashim, William Meehan III, Rebekah Mannix

3:54 p.m.

S9.003

Oculomotor function and white matter integrity in patients with post-concussion syndrome  —Foad Taghdiri, Jonathan Chung, Samantha Irwin, Namita Multani, Apameh Tarazi, Ahmed Ebraheem, Mozghan Khodadadi, Ruma Goswami, Richard Wennberg, Karen Davis, David Mikulis, Robin Green, Charles Tator, Moshe Eizenman, Carmela Tartaglia

4:06 p.m.

S9.004

4:18 p.m.

S9.005

4:30 p.m.

S9.006

4:42 p.m.

S9.007

Motor Findings in former National Football League Players  —Samuel Frank, Michael Alosco, Johnny Jarnagin, Jesse Mez, Christine Chaisson, Brett Martin, Robert Cantu, Yorghos Tripodis, Robert Stern

Environmental Enrichment Mitigates Deficits after Repetitive Mild TBI  —Jianhua Qiu, Xixia Liu, Sasha Alcon, Jumana Hashim, William Meehan III, Rebekah Mannix

SUNDAY

Near point convergence and other measures of vestibulo-ocular dysfunction are associated with protracted neurological recovery after sports concussion  —Andrew Russman, Susan Linder, Bob Gray, Richard Figler, Tanujit Dey, Jason Cruickshank, Maureen Lally, Jay Alberts [18F]AV-1451 positron emission tomography reveals tau pathology in long-term survivors of traumatic brain injury  —Nikos Gorgoraptis, Lucia Li, Alex Whittington, Linda Mclean, Claire McLeod, Ewan Ross, Karl A. Zimmerman, Jan Passchier, Paul Matthews, Roger Gunn, Tom M. McMillan, David Sharp

4:54 p.m.

S9.008

5:06 p.m.

Discussion

Disruption to the dopaminergic system following traumatic brain injury  —Peter Jenkins, Sara De Simoni, Niall Bourke, James Cole, David Sharp

Synucleinopathies

T his session will be presented at the Research Corner area located in the North Lobby of the Boston Convention and Exhibition Center. See page 13 » for more information on the Research Corner.

1:00 p.m. Irwin Schatz Award for

Autonomic Disorders Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Recipient:

Phillip A. Low, MD, FAAN Rochester, MN

1:12 p.m.

S11.002

Outcomes

1:00 p.m.

S12.001

1:12 p.m.

S12.002

Daclizumab Reduced Brain Tissue Loss Compared With Intramuscular Interferon Beta-1a in the 2-3 Year DECIDE Study  — John Rose, Douglas Arnold, David Hojnacki, Steven J. Greenberg, Ping Wang, Wei Ma, Sami Fam MRI Outcomes at Seven Years in RelapsingRemitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE  —Douglas Arnold, Robert Fox, Ralf Gold, Eva Havrdova, Ludwig Kappos, Tarek Yousry, David MacManus, Lili Yang, Katherine Riester, Catherine Miller, Monica Fay

Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System 1:24 p.m. S12.003 Atrophy—A Phase I/II Dose-Escalation Alemtuzumab Reduces the Rate of Brain Trial  —Wolfgang Singer, Allan Dietz, Anita Volume Loss in RRMS Patients Over 4 Zeller, Tonette Gehrking, James Schmelzer, Years Following Switch From SC IFNβ-1a: David Sletten, Jade Gehrking, Elizabeth Coon, CARE-MS Extension Study  —Daniel Paola Sandroni, Eduardo Benarroch, Robert Pelletier, Anthony Traboulsee, Giancarlo Comi, Fealey, Joseph Matsumoto, James Bower, Alex Rovira, Sven Schippling, David Margolin, J. Ahlskog, Anhar Hassan, Andrew McKeon, Karthinathan Thangavelu, Kunio Nakamura, Bryan Klassen, Phillip Low Douglas Arnold, on Behalf of the CAR and 1:24 p.m. S11.003 CAMMS03409 Investigators Impact of Neurogenic Orthostatic S12.004 Hypotension on Healthcare Costs in Patients 1:36 p.m. Feasibility of brain atrophy measurement in with Parkinson Disease  —Amy Duhig, clinical routine: Results from MS-MRIUS, a Italo Biaggioni, Cyndya Shibao, Augustina longitudinal observational, multicenter realOgbonnaya, Huai-Che Shih, Eileen Farrelly, world outcome study in RRMS patients  — Adam Ziemann, Clement Francois Michael Dwyer, Niels Bergsland, Diego Silva, 1:36 p.m. S11.004 Jonathan Korn, Nasreen Khan, Jennie Medin, Differences in Symptom Manifestation and Jennifer Price, Bianca Weinstock-Guttman, Survival Patterns in Males and Females with Robert Zivadinov Multiple System Atrophy  —Renee Nelson, 1:48 p.m. S12.005 Elizabeth Coon, David Sletten, Jayawant Brain Volume Loss Correlates With LongMandrekar, Phillip Low, Wolfgang Singer term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI Data  — Till Sprenger, Laura Gaetano, Nicole MuellerLenke, Jens Wuerfel, Kathinathan Thangavelu, Steven Cavalier, Ernst-Wilhelm Radue, Jerry Wolinsky, Maria Pia Sormani

2:00 p.m.

S12.006

2:12 p.m.

S12.007

2:24 p.m.

S12.008

2:36 p.m.

Discussion

Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study  —Alex Rovira, Aaron Boster, Giancarlo Comi, Regina Berkovich, Daniel Pelletier, Sven Schippling, Anthony Traboulsee, Christopher LaGanke, David Margolin, Sourav Santra, Douglas Arnold, on Behalf of the CAR Investigators Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNβ-1a: CARE-MS II Extension Study 4-Year Follow-up  —Daniel Pelletier, Michael Barnett, Aaron Boster, Giancarlo Comi, Hans-Peter Hartung, Alex Rovira, Sven Schippling, Barry Singer, Anthony Traboulsee, David Margolin, Sourav Santra, Douglas Arnold, on Behalf of the CAR Investigators Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis  —Frederik Barkhof, Ludwig Kappos, Amit Bar-Or, David Li, Shibeshih Belachew, Laura Julian, Annette Sauter, Daniela Stokmaier, Stephen Hauser

62 2017 AAN Annual Meeting Science Program


Monday  1:00 p.m.–3:00 p.m.

Monday  3:30 p.m.–5:30 p.m.

Monday  3:30 p.m.–5:30 p.m.

S13 Motor Neuron Diseases:

S14 Highlights in Sleep Science

S15 Neuroepidemiology

S16 MS Characterizations and

1:00 p.m. Sleep Science Award

3:30 p.m. Bruce S. Schoenberg

Biomarkers, Outcome Measures, and Therapeutics

1:00 p.m.

S13.001

AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Experience with pre-existing anti-AAV9 antibody in the SMA1 population  — Douglas Sproule, Samiah Al-Zaidy, Richard Shell, William Arnold, Louise Rodino-Klapac, Thomas Prior, Linda Lowes, Lindsay Alfano, K Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L’Italien, Minna Du, Jessica A. Cardenas, Arthur Burghes, Kevin Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, Jerry Mendell

1:12 p.m.

S13.002

AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Correlation between CHOPINTEND and Motor Milestone achievements  — Linda Lowes, Samiah Al-Zaidy, Richard Shell, William Arnold, Louise Rodino-Klapac, Thomas Prior, Lindsay Alfano, K Berry, Kathleen Church, John Kissel, Sukumar Nagendran, James L?Italien, Douglas Sproule, Minna Du, Jessica A. Cardenas, Arthur Burghes, Kevin Foust, Kathrin Meyer, Shibi Likhite, Brian Kaspar, JR Mendell

1:24 p.m.

S13.003

A placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy  —Christopher Grunseich, Ram Miller, Therese Swan, David Glass, Mohamed ElMouelhi, Mara Fornaro, Olivier Petricoul, Igor Vostiar, Ronenn Roubenoff, Matthew Meriggioli, John Vissing, Gianni Soraru, Tahseen Mozaffar, Albert Ludolph, John Kissel, Kenneth Fischbeck

1:36 p.m.

S13.004

1:48 p.m.

S13.005

Tracking longitudinal evolution of amyotrophic lateral sclerosis using multimodal MRI  —Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Nilo Riva, Yuri Falzone, Alberto Doretti, Barbara Poletti, Vincenzo Silani, Andrea Falini, Giancarlo Comi, Massimo Filippi

2:00 p.m.

S13.006

Recipients:

Carlos H. Schenck, MD Minneapolis, MN Mark W. Mahowald, MD Minneapolis, MN

1:24 p.m. Wayne A. Hening Sleep

Medicine Investigator Award Sponsored by the AAN and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening.

Recipient:

Tiffany Braley, MD Ann Arbor, MI

1:36 p.m.

Excessive daytime sleepiness predicts increased ß-amyloid accumulation in nondemented elderly: a longitudinal PiB-PET study  —Diego Carvalho, Erik St. Louis, David Knopman, Bradley Boeve, Val Lowe, Rosebud Roberts, Michelle Mielke, Scott Przybelski, Ronald Petersen, Clifford Jack, Prashanthi Vemuri

1:48 p.m.

S13.007

2:24 p.m.

S13.008

2:36 p.m.

Discussion

Patient Activity of Daily Living for Amyotrophic Lateral Sclerosis  —Laura Herbelin, Jeffrey Statland, Kim Kimminau, Tamara McMahon, Bhargav Adagarla, Paul Barkhaus, Carlayne Jackson, David Walk, J. Americo Fernandes, Jaya Trivedi, Steve Goebel, Andrew Waclawik, Jaime Boero, Andrea Swenson, Russ Waitman, Richard Barohn, GPC ALS Investigators

S14.005

Mortality and comorbidities in narcolepsy— an Olmsted County, Minnesota communitybased study  —Alexander Cohen, Jayawant Mandrekar, Erik St. Louis, Michael Silber, Suresh Kotagal

2:00 p.m.

S14.006

Associated of insufficient sleep with symptoms of anxiety and depression in the general population  —Kelly Sullivan

2:12 p.m.

S14.007

Time course for Phenoconversion to a Defined Neurodegenerative Disease in Women with Idiopathic REM Sleep Behavior Disorder with and without Antidepressant Use  —Grace Tabatabai, Angel Boeve, Nadia Commers, Stuart McCarter, Siri McCord, David Sandness, Paul Timm, Mithri Junna, Melissa Lipford, Maja Tippmann-Peikert, Bradley Boeve, Michael Silber, Erik St. Louis

2:24 p.m.

S14.008

A Pilot Study of Cognition in Veterans with Traumatic Brain Injury and Obstructive Sleep Apnea  —Lynn Kataria, Sophia Sundararajan, Lauren Skalina, Medha Shah, Marshall Balish, Julie Chapman

Multimodal structural MRI in the diagnosis of motor neuron diseases  —Federica Agosta, 2:36 p.m. Pilar Maria Ferraro, Nilo Riva, Massimiliano Copetti, Edoardo Spinelli, Yuri Falzone, Adriano Chio, Gianni Soraru, Andrea Falini, Giancarlo Comi, Massimo Filippi

2:12 p.m.

S14.004

Discussion

Tools for Measurement

International Award in Neuroepidemiology Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

3:30 p.m.

S16.001

Recipient:

3:42 p.m.

S16.002

3:54 p.m.

S16.003

4:06 p.m.

S16.004

4:18 p.m.

S16.005

4:30 p.m.

S16.006

4:42 p.m.

S16.007

4:54 p.m.

S16.008

5:06 p.m.

Discussion

Yogeshwar V. Kalkonde, MD Gadchiroli, Maharashtra, India

3:54 p.m.

S15.003

Diet Clusters in Relation to Cognitive Performance and Decline in the Northern Manhattan Study  —Hannah Gardener, Chuanhui Dong, Tatjana Rundek, Consuelo McLaughlin, Ken Cheung, Mitchell Elkind, Ralph Sacco, Clinton Wright

4:06 p.m.

S15.004

Neurologic care access and utilization patterns in the United States  —Altaf Saadi, David Himmelstein, Steffie Woolhandler, Nicte Mejia

4:18 p.m.

S15.005

Secular trends of ALS incidence in an Italian population-based register, 1995-2014: evidence for a cohort effect in women  — Adriano Chio, Cristina Moglia, Antonio Canosa, Davide Bertuzzo, Enrica Bersano, Stefania Cammarosano, Umberto Manera, Fabrizio Pisano, Letizia Mazzini, Gabriele Mora, Andrea Calvo

4:30 p.m.

S15.006

4:42 p.m.

S15.007

4:54 p.m.

S15.008

Migraine and the Risk of Incident Hypertension among Women  —Pamela Rist, Anke Winter, Julie Buring, Howard Sesso, Tobias Kurth Risk Factors for Pregnancy-Associated Stroke in Women with Preeclampsia: a Case-Control Study  —Eliza Miller, Hajere Gatollari, Gloria Too, Amelia Boehme, Lisa Leffert, Mitchell Elkind, Joshua Willey Fish consumption, mercury levels, and amyotrophic lateral sclerosis (ALS)  —Elijah Stommel, Celia Chen, Tracie Caller, Patricia Henegan, Brian Jackson, Brenda Hall, Rup Tandan, Walter Bradley, Angeline Andrew

5:06 p.m.

Discussion

Genetic descriptors of a multiple sclerosis cohort  —Noriko Isobe, for The University of MS EPIC team A Global Epidemiological Forecast of Multiple Sclerosis and Disease Subtypes  — Sunali Goonesekera Progressive degeneration of RNFL and GCL is seen in pediatric MS in comparison to monophasic demyelination and controls  — Giulia Longoni, Ade Oyefiade, Austin Noguera, Stephanie Grover, Colin Wilbur, Michael Wan, Jean Mah, Fiona Costello, Brenda Banwell, Donald Mabbott, Arun Y. Reginald, Ann Yeh Sample sizes and clinical relevance of MSspecific atrophy markers: A comprehensive, unbiased, simulation-based method accounting for normal aging  —Christina Azevedo, Ling Zheng, Steven Cen, Amirhossein Jaberzadeh, Yonggang Shi, Daniel Pelletier Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II)  —Stephen Hauser, Amit Bar-Or, Jeffrey Cohen, Giancarlo Comi, Jorge Correale, Patricia Coyle, Anne Cross, Jerome De Seze, Xavier Montalban, Krzysztof Selmaj, Wiendl Heinz, Algirdas Kakarieka, Goeril Karlsson, Dieter Haering, Katy Demery, Ludwig Kappos Microstructural Deterioration in Multiple Sclerosis Patients Meeting Criteria for “no evidence of disease activity”: Correlations with Clinical Variables  —Dylan Sperling, Asaff Harel, Maria Petracca, Colleen Farrell, Ilana Katz Sand, Matilde Inglese Upper Cervical Cord Area Atrophy for Clinical Trials in Multiple Sclerosis  —Esha Datta, Nico Papinutto, Carolyn Bevan, Gina Kirkish, William Stern, Alyssa Zhu, Elizabeth Crabtree-Hartman, Jeffrey Gelfand, Douglas Goodin, Jennifer Graves, Ari Green, Emmanuelle Waubant, Scott Zamvil, Bruce Cree, Stephen Hauser, Roland Henry Circulating microRNAs are associated with acute inflammation in patients with multiple sclerosis.  —Maria Antonietta Mazzola, Brian Healy, Keren Regev, Radhika Raheja, anu paul, Camilo Diaz-Cruz, Shahamat Tauhid, Christopher Hemond, Sheena Dupuy, Pia Kivisakk, Tanuja Chitnis, Howard Weiner, Rohit Bakshi, Roopali Gandhi

Phenotypic heterogeneity in Italian patients with motor neuron disease  —Nicola Ticozzi, Federico Verde, Claudia Morelli, Stefano Messina, Alberto Doretti, Barbara Poletti, Cinzia Tiloca, Antonia Ratti, Luca Maderna, Vincenzo Silani

Fast and easy registration · AAN.com/view/AM17 63

MONDAY

Reliability of functional outcome measures in spinal muscular atrophy: Results from multi-centered, global, phase 3 clinical trials  —Allan Glanzman, Elena Mazzone, Sally Dunaway, Richard Gee, Kristy Cokayne Rose, Anna Mayhew, Chris Yun, Katie Alexander, Gihan Tennekoon, John Day, Richard Finkel, Eugenio Mercuri, Darryl De Vivo, Frank Bennett, Kathie Bishop, Jacqueline Montes

Sponsored by the American Academy of Neurology and the Sleep Section and endowed by Cephalon, Inc.

Scientific Platform Sessions

Monday  1:00 p.m.–3:00 p.m.


Scientific Platform Sessions

Scientific Platform Sessions

Tuesday, April 25

Monday  3:30 p.m.–5:30 p.m.

Monday  3:30 p.m.–5:30 p.m.

Tuesday  8:00 a.m.–9:00 a.m.

Tuesday  1:00 p.m.–3:00 p.m.

S17 Movement Disorders: Ataxia

S18 Behavioral and Cognitive

S19 “Best of” Session:

S20 Neuromyelitis Optica

3:30 p.m.

3:30 p.m. Norman Geschwind Prize in

Titles and authors of these abstracts

1:00 p.m.

S20.001

1:12 p.m.

S20.002

1:24 p.m.

S20.003

1:36 p.m.

S20.004

1:48 p.m.

S20.005

2:00 p.m.

S20.006

2:12 p.m.

S20.007

2:24 p.m.

S20.008

2:36 p.m.

Discussion

and the Cerebellum S17.001

ATXN2 antisense therapy improves SCA2 mouse motor and Purkinje cell electrophysiological phenotypes.  —Daniel Scoles, Matthew Schneider, Pratap Meera, Karla Figueroa, Frank Rigo, Frank Bennett, Thomas Otis, Stefan Pulst

3:42 p.m.

S17.002

Fragile X Gray Zone Alleles are associated with Better Global Motor Function in an Elderly Community Population  —Deborah Hall, Aisha Ali, David Bennett, Bichum Ouyang, Aron Buchman, Lili Zhou, Elizabeth Berry-Kravis

3:54 p.m.

S17.003

RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia  —Theresa Zesiewicz, Frederic Heerinckx, Marcus Kilpatrick, Omid Omidvar, Gregory Bonomo, Mary Freeman, Jessica Shaw, Jessica Streit, Robert DeJager

4:06 p.m.

S17.004

4:18 p.m.

S17.005

Exome Sequencing Offers a Comprehensive Genetic Evaluation and High Diagnostic Rate for Ataxia-related Disorders  —Francisca Millan, Dianalee McKnight, Julie Scuffins, Jane Juusola, Gabriele Richard, Amanda Lindy EPI-743 (Alpha-tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich’s Ataxia  —Theresa Zesiewicz, Susan Perlman, Kelly Sullivan, Yangxin Huang, Jason Salemi, Matthew Klein, Charles Isaacs, Clifton Gooch, Jessica Shaw, David Lynch

MONDAY

4:30 p.m.

S17.006

4:42 p.m.

S17.007

Cerebellar Pathology in Early Onset and Late Onset Essential Tremor  —Sheng-Han Kuo, Jie Wang, William Tate, Ming-Kai Pan, Geoffrey Kelly, Jesus Gutierrez, Etty Cortes, Jean Paul Vonsattel, Elan Louis, Phyllis Faust Structure-Phenotype relationships in ATP1A3 (Na,K-ATPase) diseases  —Kathleen Sweadner, Elena Arystarkhova, John Penniston, Jared Cook, Kathryn Swoboda, Allison Brashear, Laurie Ozelius

4:54 p.m.

S17.008

5:06 p.m.

Discussion

In vivo drug discovery for progressive supranuclear palsy using a novel zebrafish model  —Qing Bai, Edward Burton

Neurology

Behavioral Neurology Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology.

Recipient:

Peter Turkeltaub, MD, PhD Washington, DC

3:42 p.m. Alliance Awards:

S. Weir Mitchell Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient:

Richard Ryan Darby, MD Boston, MA

3:54 p.m.

S18.003

Do We Practice What We Preach Regarding Clinical Cognitive Testing: Results From an AAN Behavioral Neurology Section Survey  —James Bateman, Kirk Daffner, Seth Gale, A. Barrett, Bradley Boeve, Glen Finney, Darren Gitelman, John Hart, Alan Lerner, Kimford Meador, Mary Quiceno, Kytja Voeller, Valerie Whitney, Daniel Kaufer

4:06 p.m.

S18.004

Hippocampal and white matter hyperintensity volumes are associated with domain-specific cognitive decline: the Northern Manhattan Study  —Michelle Caunca, Chuanhui Dong, Chensy Marquez, Ken Cheung, Tatjana Rundek, Noam Alperin, Ahmet Bagci, Mitchell Elkind, Charles DeCarli, Sang Lee, Ralph Sacco, Yaakov Stern, Clinton Wright

4:18 p.m.

S18.005

4:30 p.m.

S18.006

Systems-level network integration predicts TMS effects on time perception  —Rachel Wurzman, Martin Wiener, Roy Hamilton, H. Coslett, John Medaglia Relative preservation of affect recognition in posterior cortical atrophy  —Peter Pressman, Kelly Gola, Suzie Shdo, Bruce Miller, Katherine Rankin

4:42 p.m.

S18.007

Dysmetria of Thought and the Universal Cerebellar Transform: empirical evidence, future approaches, and relevance for embodied cognition.  —Xavier Guell, Mark Halko, Faranak Farzan, Catherine Stoodley, Alvaro Pascual-Leone, John Gabrieli, Jeremy Schmahmann

4:54 p.m.

S18.008

Cingulo-Insular Structural Alterations Associated with Psychogenic Symptoms, Childhood Abuse and PTSD in Functional Neurological Disorders  —David Perez, Nassim Matin, Arthur Barsky, Victor Costumero-Ramos, Sara Makaretz, Sigrid Young, Jorge Sepulcre, W. LaFrance, Matcheri Keshavan, Bradford Dickerson

5:06 p.m.

64 2017 AAN Annual Meeting Science Program

Discussion

Cerebrovascular Disease and Interventional Neurology

are listed in “Best of” Scientific Platform Sessions on page 48 »

and Other Autoimmune Disorders

Justification for New Diagnostic Criteria for Susac Syndrome: Evolving Beyond the Triad  —Robert Carruthers, Gillian Paton, Claire Sheldon, Anthony Traboulsee, Mollie Carruthers, Robert Rennebohm Specificity of glial fibrillary acidic protein IgG autoantibody (GFAP-IgG) for Autoimmune Meningoencephalomyelitis Diagnosis  — Eoin Flanagan, Divyanshu Dubey, Shannon Hinson, Vanda Lennon, Boyan Fang, Allen Aksamit, Brian Weinshenker, Sean Pittock, Andrew McKeon Pathophysiological impact of anti-AMPA receptor antibodies in autoimmune encephalitis  —Holger Haselmann, Christian Werner, Benedikt Grünewald, Christian Geis IgLON5 Autoimmunity: Serological Findings, Neurological Disorders & Outcomes in 16 patients  —Josephe Archie Honorat, Lars Komorowski, Erik St. Louis, Kai Fechner, Shannon Hinson, Sabine Lederer, Neeraj Kumar, Vanda Lennon, Sean Pittock, Andrew McKeon Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders  —Maureen Mealy, Su-Hyun Kim, Felix Schmidt, Reydmar Lopez, Jorge Jimenez Arango, Friedemann Paul, Dean Wingerchuk, Benjamin Greenberg, Ho Jin Kim, Michael Levy Placental transmission of AQP4-IgG to neonate from mothers with neuromyelitis optica spectrum disorder (NMOSD)  — Jessica Sagen, Masoud Majed, Vanda Lennon, Claudia Lucchinetti, James Fryer, Sean Pittock Aquaporin-4 antibody titration in NMO patients treated with Rituximab: a retrospective study.  —Antonio Bertolotto, Marco Alfonso Narduc Capobianco, Letizia Granieri, Fabiana Marnetto, Paola Valentino Central Dysregulation of Heart Rate and Blood Pressure in Autoimmune AQP4 Channelopathy: Expanding the neuromyelitis optica spectrum disorder (NMOSD).  — Masoud Majed, Eduardo Benarroch, Claudia Lucchinetti, Karl Krecke, Jessica Sagen, Yong Guo, Chiara Costanzi, Sean Pittock


Tuesday  1:00 p.m.–3:00 p.m.

Tuesday  3:30 p.m.–5:30 p.m.

Tuesday  3:30 p.m.–5:30 p.m.

S21 Epilepsy and Clinical

S22 Parkinson’s Disease:

S23 Neurocritical Care:

S24 MS Therapeutics and

1:00 p.m. Movement Disorders

3:30 p.m.

S23.001

3:30 p.m.

S24.001

3:42 p.m.

S23.002

3:42 p.m.

S24.002

3:54 p.m.

S24.003

4:06 p.m.

S24.004

4:18 p.m.

S24.005

4:30 p.m.

S24.006

4:42 p.m.

S24.007

4:54 p.m.

S24.008

5:06 p.m.

Discussion

Neurophysiology (EEG) I

1:00 p.m.

S21.001

Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox–Gastaut syndrome (LGS): results of a multi-center, randomized, double–blind, placebo controlled trial (GWPCARE4)  —Jacqueline French, Elizabeth Thiele, Maria Bronislawa Mazurkiewicz-Beldzin, Selim Benbadis, Eric Marsh, Charuta Joshi, Claire Roberts, Adam Taylor, Kenneth Sommerville

1:12 p.m.

S21.002

Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology—APE Study  —Divyanshu Dubey, Abdulradha Alqallaf, Ryan Hays, Matthew Freeman, Kevin Chen, Kan Ding, Mark Agostini, Steven Vernino

1:24 p.m.

S21.003

Relationship between Cognitive Performance and Subjective Symptoms in Patients with Newly Diagnosed Focal Epilepsy  —Kimford Meador, Andres Kanner, Chris Morrision, Adrian Schembri, Dale Hesdorffer, Terence O’Brien, Patricia Penovich, Michael Sperling, David Darby, Kevin McKenna, Melodie Winawer, Sabrina Cristofaro

1:36 p.m.

S21.004

Long-term safety and efficacy of responsive brain stimulation in adults with medically intractable partial onset seizures  —Dileep Nair, Martha Morrell

1:48 p.m.

S21.005

Post-Diagnosis Neurological Care for Patients with Psychogenic Nonepileptic Spells (PNES)  —Chloe Hill, Hannah Schwartz, Kathryn Davis, Brian Litt

2:00 p.m.

S21.006

2:12 p.m.

S21.007

To Reveal or Conceal? Adult Patient Perspectives on SUDEP Disclosure.  — Lucretia Long, Sheri Hart, Jesse Mindel

2:24 p.m.

S21.008

Chronic Cortical Electrode Stimulation is Effective for Focal Epilepsy  —Brian Lundstrom, Jamie Van Gompel, Jeffrey Britton, Katherine Nickels, Nicholas Wetjen, Gregory Worrell, Squire Stead

2:36 p.m.

Discussion

Research Award Sponsored by the AAN, the Parkinson’s Disease Foundation, and the AAN Movement Disorders Section and endowed by the Parkinson’s Disease Foundation.

Recipient:

Andrew Singleton, PhD Bethesda, MD

1:24 p.m. Jon Stolk Award in Movement Disorders for Young Investigators Sponsored by the AAN and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma.

Recipient:

Marios Politis, MD, MSC, DIC, PhD, FAAN London, United Kingdom

1:36 p.m.

S22.004

A large observational study using mobile phone sensors reveals a personalized drug response in patients with Parkinson’s Disease  —Larsson Omberg, Elias Chaibub Neto, Thanneer Perumal, Brian M. Bot, Abhishek Pratap, Lara Mangravite

1:48 p.m.

S22.005

Racial differences in the diagnosis of atypical parkinsonism  —Sneha Mantri, Jayne Wilkinson, John Duda, James Morley

2:00 p.m.

S22.006

Understanding of Palliative Care Among Parkinson Disease Patients at the University of Florida  —Addie Patterson, Leonardo Brito De Almeida, Nikolaus McFarland, Michael Okun, Irene Malaty

2:12 p.m.

S22.007

2:24 p.m.

S22.008

Worse cognitive functioning is associated with an increased risk of incident parkinsonism: the Rotterdam Study  — Sirwan Darweesh, Frank Wolters, Kamran Ikram, Bruno Stricker, Peter Koudstaal, Mohammad Ikram Clinical-pathological discrepancies in a population based incidence cohort study on parkinsonism in Olmsted County, MN: 19912005  —Pierpaolo Turcano, Michelle Mielke, Keith Josephs, Jonathan Graff-Radford, J. Ahlskog, James Bower, Joseph Parisi, Rodolfo Savica

2:36 p.m.

Discussion

Neurological Intensive Care

Argon treatment provides short and longterm neuroprotection in a mouse model of traumatic brain injury  —Jennifer Creed, Daniel Laskowitz, Ulrike Hoffmann Safety of Thrombolysis for Acute Ischemic Stroke in Patients with Recent Stroke  — Setareh Salehi Omran, Alexander Merkler, Gino Gialdini, Michael Lerario, Shadi Yaghi, Mitchell Elkind, Babak Navi

3:54 p.m.

S23.003

Analysis of adjudicated edema endpoints in the Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial  —W. Kimberly, Rudiger Von Kummer, Andrew Demchuk, Javier Romero, Jordan Elm, Holly Hinson, Bradley Molyneaux, Kevin Sheth

4:06 p.m.

S23.004

Machine Learning Approach to Automate Detection of Cerebral Vasospasm Using Transcranial Doppler Monitoring  — Gyanendra Kumar, Khaled Elzaafrani, Arie Nakhmani

4:18 p.m.

S23.005

Predictors of family satisfaction with support during shared decision making in neuroscience intensive care units  —Derek Ou, James Garritano, Urs Weber, Jennifer Johnson, Nathanial Anderson, Andrea Knies, Belinda Nhundu, Cynthia Bautista, Kevin Sheth, Jonathan Rosand, David Hwang

4:30 p.m.

S23.006

4:42 p.m.

S23.007

4:54 p.m.

S23.008

5:06 p.m.

Discussion

Caring for the Whole Person: Resilience, Spirituality and Religious Coping in the Neurocritical Care Environment  —Barbara Gordon, Neha Dangayach, Stephen Griffiths, Alana Kornspun, Zach Davidson, Maggie Keough, Danielle Wheelwright, Stanislaw Sobotka, Vansh Sharma, Deborah Marin, Errol Gordon, Joshua Bederson, J Mocco, Stephan Mayer Ominous EEG patterns do not preclude recovery in post-arrest patients treated with neurostimulants  —Alexis Steinberg, Jonathan Elmer, Maria Baldwin, Jon Rittenberger Neurologic Consultation and Use of Therapeutic Hypothermia for Cardiac Arrest  —Elan Guterman, Anthony Kim, S. Josephson

Clinical Research I

Dimethyl fumarate treatment produces alterations in lipid metabolism that are linked to occurrence of lymphopenia  — Pavan Bhargava, Kathryn Fitzgerald, Matthew Smith, Michael Kornberg, Ellen Mowry, Peter Calabresi Depletion of CD8+ cells in patients with multiple sclerosis on dimethyl fumarate and its association with shingles  —Ursela Siddiqui, Jacob Sloane, Emily Egnor, Pamela Johnson, Chamariela Mojica Ofatumumab Differs from Rituximab by Effectively Targeting Lymph Node B cells and Achieving Faster Post-treatment Repletion  —Paul Smith, Catherine Huck, Cindy Schmid, Reto Baumgartner, Nathalie Stuber, Diethilde Theil, Francisco Cordoba, Erik Wallstroem, David Leppert Ambulation Assistive Device Training Prevents Falls, Increases Device Satisfaction and May Decrease Sitting and Increase Walking in MS: A Randomized-Controlled Pilot Study  —Andrea Hildebrand, Doug Martini, Brett Fling, Michelle Cameron Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CAREMS I)  —Barry Singer, Alasdair Coles, Alexey Boyko, Jeffrey Cohen, Jerome De Seze, Edward Fox, Eva Havrdova, Hans-Peter Hartung, Jihad Inshasi, Pamela McCombe, Krzysztof Selmaj, Patrick Vermersch, Bart Van Wijmeersch, David Margolin, Karthinathan Thangavelu, Claudio Rodriguez, Xavier Montalban, on Behalf of the CAR Investigators Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II)  —Edward Fox, David Brassat, Raed Alroughani, Simon Broadley, Jeffrey Cohen, Hans-Peter Hartung, Eva Havrdova, Celia Oreja Guevara, Krzysztof Selmaj, Barry Singer, Patrick Vermersch, Sibyl Wray, David Margolin, Karthinathan Thangavelu, Madalina Chirieac, Alasdair Coles, on Behalf of the CAR Investigators Fitness to drive in persons with MS and cognitive impairment: a pilot study  —Sarah Morrow, Miriam Monahan, Tim Danter, Robert Taylor, Sarah Krasniuk, Heather Rosehart, Wenqing He, Sherrilene Classen Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis  —Jeffrey Cohen, Krzysztof Selmaj, Douglas Arnold, Giancarlo Comi, Amit Bar-Or, Allan Olson, Jeff Kopicko, Paul Frohna

Fast and easy registration · AAN.com/view/AM17 65

TUESDAY

Antibodies to neuronal surface antigens in possible autoimmune encephalitis and new-onset refractory status epilepticus (NORSE)  —Takahiro Iizuka, Juntaro Kaneko, Naomi Tominaga, Naomi Kanazawa, Yutaka Nonoda, Atsuko Hara, Yuya Onozawa, Hiroki Asari, Takashi Hata, Junya Kaneko, Kenji Yoshida, Yoshihiro Sugiura, Yoshikazu Ugawa, Masashi Watanabe, Hitomi Tomita, Arifumi Kosakai, Atsushi Kaneko, Daisuke Ishima, Eiji Kitamura, Josep Dalmau, Kazutoshi Nishiyama

Observational Studies

Scientific Platform Sessions

Tuesday  1:00 p.m.–3:00 p.m.


Scientific Platform Sessions

Scientific Platform Sessions

Wednesday, April 26

Tuesday  3:30 p.m.–5:30 p.m.

Tuesday  3:30 p.m.–5:30 p.m.

Wednesday  8:00 a.m.–9:00 a.m. Wednesday  1:00 p.m.–2:00 p.m.

S25 Cerebrovascular Disease

S26 Neuro-opthalmology/

S27 “Best of” Session:

and Interventional Neurology: Prehospital and Emergency Department Ischemic Stroke Care

3:30 p.m. Michael S. Pessin Stroke

Leadership Prize Sponsored by the AAN and endowed by Dr. Pessin’s family, friends, and colleagues.

Recipient:

James F. Burke, MD, MS Ann Arbor, MI

3:42 p.m.

S25.002

Emergency Medical Services Survey Of A Low-cost, Ambulance-based System For Mobile Neurological Assessment: The iTREAT Study  —William Clark, Nicole ChiotaMcCollum, Jack Cote, Brett Schneider, Haydon Pitchford, Brian Gunnell, Timothy McMurry, George Lindbeck, Debra Perina, Robert O’Connor, Sherita Chapman, Nina Solenski, Bradford Worrall, Andrew Southerland

3:54 p.m.

S25.003

Results of Successful Tiered Stroke Triage Process  —Angela Hawkins, Karin Olds, Coleman Martin, Harold Morris

4:06 p.m.

S25.004

4:18 p.m.

S25.005

External Validation of the TeleStroke Mimic (TM) Score for Predicting Stroke Mimics Evaluated during Telestroke  —Syed Ali, Gordian Hubert, Jeffrey Switzer, Jennifer Majersik, Kishore Vedala, Lee Schwamm Modeling the Impact of Interhospital Transfer Protocol Design on Mechanical Thrombectomy Eligibility and Outcomes in a Large Metropolitan Area  —Neal Parikh, Abhinaba Chatterjee, Alexander Merkler, Gino Gialdini, Benjamin Kummer, Saad Mir, Michael Lerario, Babak Navi, Hooman Kamel

4:30 p.m.

S25.006

TUESDAY

Developing a Family of Visual Decision Aids for Intravenous and Endovascular Reperfusion Therapies for Acute Ischemic Stroke  —Ivie Tokunboh, Marta Vales Montero, Matheus Zopelaro, Latisha Sharma, Nestor Gonzalez, Sidney Starkman, Viktor Szeder, Reza Jahan, David Liebeskind, Jeffrey Saver

4:42 p.m.

S25.007

Characteristics and Outcomes among Patients Transferred to Regional Stroke Centers across the United States for Specialized Stroke Care  —Syed Ali, Gregg Fonarow, Eric Smith, Li Liang, Ying Xian, Deepak Bhatt, Lee Schwamm

4:54 p.m.

S25.008

5:06 p.m.

Discussion

Neuro-otology

3:30 p.m.

S26.001

Overdiagnosis of optic neuritis.  —Leanne Stunkel, Nathan Kung, Collin McClelland, Gregory Van Stavern

3:42 p.m.

S26.002

Sensory prosthetics - clinical and scientific utility of a vestibular implant  —Csilla Haburcakova, Daniel Merfeld, Wangsong Gong, Nils Guinand, Angelica Perez Fornos, Lara Thompson, Jean-Philippe Guyot

3:54 p.m.

S26.003

Ischemic Optic Neuropathy in Cardiac Surgery: Incidence and Risk Factors in the United States from the Nationwide Inpatient Sample 1998-2013  —Heather Moss, Daniel Rubin, Charlotte Joslin, Avery Tung, Steven Roth

4:06 p.m.

S26.004

4:18 p.m.

S26.005

4:30 p.m.

S26.006

4:42 p.m.

S26.007

4:54 p.m.

S26.008

5:06 p.m.

Discussion

Gene Therapy for LHON : Low and Medium Dose Results  —John Guy, William Feuer, Janet Davis, Vittorio Porciatti, Phillip Gonzalez, Rajeshwari Koilkonda, Huijuan Yuan, Byron Lam Intravitreal rAAV2/2-ND4 (GS010): A gene therapy for vision loss in Leber’s Hereditary Optic Neuropathy (LHON) caused by the G11778A ND4 mitochondrial mutation  — Scott Uretsky, Catherine Vignal-Clermont, Nitza Thomasson, Celine Bouquet, Anne Galy, Jean Philipppe Combal, Serge Fitoussi, Jose-Alain Sahel Jun and Ddit3 (CHOP) deficiency provides additive protection for retinal ganglion cell death after optic nerve injury  —Stephanie Syc, Kimberly Fernandes, Richard Libby Does the Combination of Acute Hearing Loss and Vertigo Increase Stroke Risk?  —Tzu-Pu Chang, Zheyu Wang, Ariel Winnick, Hsun-Yang Chuang, Victor Urrutia, John Carey, David Newman-Toker Visual Fixation Instability for Evaluating Multiple Sclerosis Using OCT-Based Quantification of Retinal Movements  — Robert Mallery, Pieter Poolman, Matthew Thurtell, Jan Full, Teresa Frohman, Elliot Frohman, Randy Kardon

Effect of Prestroke Aspirin on Infarct Volume in Ischemic Stroke  —Soo-Hyun Park, Wi-Sun Ryu

66 2017 AAN Annual Meeting Science Program

Neuromuscular Disease Therapeutics

Titles and authors of these abstracts

are listed in “Best of” Scientific Platform Sessions on page 48 »

S28 History of Neurology

T his session will be presented at the Research Corner area located in the North Lobby of the Boston Convention and Exhibition Center. See page 13 » for more information on the Research Corner.

1:00 p.m. Lawrence C. McHenry Award: An Award for the History of Neurology Sponsored by the American Academy of Neurology.

Recipient:

Christopher J. Boes, MD, FAAN Rochester, MN

1:24 p.m.

S28.003

1:36 p.m.

S28.004

1:48 p.m.

S28.005

Historical perspectives on the association of trigeminal neuralgia and multiple sclerosis  —David Burkholder, Peter Koehler, Christopher Boes Brainwaves in Concert: the 20th Century Sonification of the Electroencephalogram  —Bart TH Lutters, Peter Koehler

Ebbinghaus’s contributions to our understanding of human memory  —Bernard Patten


S29 Cerebrovascular Disease and

S30 Infectious Disease: HIV, Syphilis, S31 MS Therapeutics and

1:00 p.m.

1:00 p.m.

Interventional Neurology: Critical Care and Hemorrhage S29.001

Oral anticoagulation is a significant risk factor for spontaneous primary intraventricular hemorrhage  —Bhaskar Roy, Jussie Lima, Ilene Staff, Gil Fortunato, Nora Lee

1:12 p.m.

S29.002

Ten-year temporal trends in medical complications following acute intracerebral hemorrhage in the United States  —Fadar Otite, Priyank Khandelwal, Amer Malik, Seemant Chaturvedi, Ralph Sacco, Jose Romano

1:24 p.m.

S29.003

The therapeutic benefit of systolic blood pressure lowering may be obscured in intent to treat analysis due to lack of achieving therapeutic systolic blood pressure targets in a proportion of randomized subjects  —Antihypertensive Tre Hemorrhage II Investigators

1:36 p.m.

S29.004

Temporal trends in medical complications and mortality following subarachnoid hemorrhage in the United States from 2004-2013  —Ashutosh Mahapatra, Fadar Otite, Nirav Bhatt, Priyank Khandelwal, Amer Malik, Seemant Chaturvedi, Ralph Sacco, Jose Romano

1:48 p.m.

S29.005

National Estimates of Recurrent Intracranial Hemorrhage among Patients with Ruptured Intracranial Aneurysms: Effect of Treatment Modality  —Saqib Chaudhry, MohammadRauf Afzal, Burhan Chaudhry, Haseeb Rahman, Ahmed Riaz, Ali Saeed, Adnan Safdar, Mounzer Kassab, Adnan Qureshi

2:00 p.m.

S29.006

Radiographic Predictors of Prognosis In Intracerebral Hemorrhage: “If It Ain’t Broke, Don’t Fix It”  —Amanda Pennington, Amelia Boehme, Karen Albright, Mini Singh, Michael Lyerly, Toby Gropen, Angela Hays Shapshak

2:12 p.m.

S29.007

2:24 p.m.

S29.008

Early Surgery for Infective Endocarditis with Stroke Does Not Increase Post-operative Neurological Complications: What are We Waiting For?  —Lucy Zhang, Sung Cho, Robert Marquardt, Muhammad Hussain, Ken Uchino, Dolora Wisco

2:36 p.m.

Discussion

S30.001

Apolipoprotein E4 May Suppress Neuronal Gene expression in Differentiating Human Neuronal Progenitor Cells Exposed to HIV  —Micheline McCarthy, Biju Issac, Alicia De Las Pozas, Rebeca Geffin

1:12 p.m.

S30.002

Cognitive function among antiretroviral treatment-naïve individuals infected with HIV-1 Subtype G versus CRF02_AG in Nigeria  —Jibreel Jumare, Nicaise Ndembi, Samer El-Kamary, Larry Magder, Laura Hungerford, Tricia Burdo, Lindsay Eyzaguirre, Mariana Cherner, Anya Umlauf, Alash[apos] le Abimiku, Man Charurat, William Blattner, Walter Royal

1:24 p.m.

S30.003

Guillian-Barre Syndrome (GBS) in Children after Influenza Vaccination , An analysis of the Vaccine Adverse Event Reporting System (VAERS) Database, 1991-2015  — Jesyree Veitia, Jeffrey Kornitzer, Francisco Gomez, Kambiz Nasir, Nizar Souayah

1:36 p.m.

S30.004

1:48 p.m.

S30.005

Brain autoimmunity following herpes simplex encephalitis (HSE): 100 cases  — Thais Armangue, Eugenia Martinez-Hernandez, Francesc Graus, Josep Dalmau How well do neurologic symptoms identify individuals with neurosyphilis?  —Arielle Davis, Joshua Stern, Shelia Dunaway, Lauren Tantalo, Sharon Sahi, Sarah Holte, Christina Marra

2:00 p.m.

S30.006

Improving Cost and Laboratory Utilization in the Diagnosis of Neuroborreliosis  —Dana Vanino, Kelly Baldwin

2:12 p.m.

Clinical Research II

1:00 p.m.

S31.001

Dalfampiridine improves cognitive impairment in multiple sclerosis (MS): results from a randomised, double-blind, placebo-controlled trial  —Laura De Giglio, Francesca De Luca, Flavia Gurreri, Ilaria Ferrante, Luca Prosperini, Maria Esmeralda Quartuccio, Giovanna Borriello, Claudio Gasperini, Carlo Pozzilli

1:12 p.m.

S31.002

Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis  — Stephen Hauser, Ludwig Kappos, Amit Bar-Or, Hans-Peter Hartung, Shibeshih Belachew, Jian Han, Laura Julian, Julie Napieralski, Jerry Wolinsky

1:24 p.m.

S31.003

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up  —Carrie Hersh, Anasua Bandyopadhyay, Samuel Cohn, Claire Hara-Cleaver, Robert Fox, Robert Bermel, Jeffrey Cohen, Daniel Ontaneda

1:36 p.m.

S31.004

1:48 p.m.

S31.005

2:00 p.m.

S31.006

2:24 p.m.

S31.008

2:36 p.m.

Discussion

Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study  — Robert Naismith, Mark Cascione, Luigi Maria Grimaldi, Stephen Hauser, Ludwig Kappos, Xavier Montalban, Jerry Wolinsky, Peter Chin, Hideki Garren, Laura Julian, Fabian Model, William Honeycutt

S32 Global Health

T his session will be presented at the Research Corner area located in the North Lobby of the Boston Convention and Exhibition Center. See page 13 » for more information on the Research Corner.

3:30 p.m.

S32.001

3:42 p.m.

S32.002

3:54 p.m.

S32.003

Exploring knowledge and attitudes regarding autosomal dominant Alzheimer disease among an at-risk population in Mexico  —Mellissa Withers, Angélica Zuno Reyes, Maria Casado, Chizoba Mosieri, Lucy Montoya, Yaneth Rodriguez, Esmeralda Matute, John Ringman Stroke Mortality Outcomes in Uganda  — Sam Olum, Anthony Muyingo, Tony Wilson, Joseph Hoxworth, Nan Zhang, Bart Demaerschalk, Joseph Hentz, Maria Aguilar, Amir Abdallah, Adrian Kayanja, Cumara O’Carroll Use of a tablet-based epilepsy diagnosis app by computer-naïve health workers: Our experience in a tribal Indian community  — Mamta Singh, Shruti Samant, Victor Patterson, Vaibhav Agavane, Yogesh Jain

Benign multiple sclerosis in the era of disease modifying therapies  —Camilo Diaz-Cruz, Cindy Gonzalez, Alicia Chua, Brian Healy, Neda Sattarnezhad, James Stankiewicz, Christopher Severson, Shamik Bhattacharyya, Dorlan Kimbrough, Bonnie Glanz, Howard Weiner, Tanuja Chitnis

S30.007 Comparison of Natalizumab vs Fingolimod Trends and Characteristics of Tuberculous and Dimethyl Fumarate in the Treatment of Meningitis in the United States, 1993Multiple Sclerosis: Two Year Experience  — 2013  —Alexander Merkler, Abhinaba Brandi Vollmer, Kavita Nair, Stefan Sillau, John Chatterjee, Gino Gialdini, Alexandra Reynolds, Corboy, Timothy Vollmer, Enrique Alvarez Nicholas Morris, Santosh Murthy, Kiran Thakur, 2:12 p.m. S31.007 Hooman Kamel Alternate dosing of fingolimod for Multiple 2:24 p.m. S30.008 Sclerosis  —Ilya Kister, Daniel Kantor, Samia Reliability and Validity of New Diagnostic Khoury, Marcus Rice, Ellen Lathi, Ana Belen Criteria for Neurocysticercosis  —Arturo Caminero Rodriguez, Siddharama Pawate, Carpio, Agnes Fleury, Matthew Romo, Ronaldo Keith Edwards, Anne Cross, Becky Parks, Abraham, Jaime FandiÒo, Juan Duran Quiroz Jennifer Lynch, Robert Archer, William 2:36 p.m. Discussion Meador, Regina Berkovich, Bassem Yamout, Maya Zeineddine, Danita VanderKodde, Gloria Von Geldern, Lilly Ge, Shira Russell, Erin Longbrake A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: Oral-CORTEM trial.  —Ferran Torres, Jose Vicente Hervas, Silvia Presas, Jaume Capellades, Gema Domenech, Sandra Serrano, Cristina Ramo

Fast and easy registration · AAN.com/view/AM17 67

WEDNESDAY

Long Term Outcomes of IV Glyburide In Patients 70 Years of Age or Under: Subgroup Analysis from the Phase II GAMES-RP Study of Patients with Large Hemispheric Infarction  —Kevin Sheth, Ken Cheung, Jordan Elm, Holly Hinson, Bradley Molyneaux, Lauren Beslow, Gordon Sze, Ann-Christin Ostwaldt, W. Kimberly

Borrelia, TB, Cysticercosis, and Other Infections

Scientific Platform Sessions

Wednesday  1:00 p.m.–3:00 p.m. Wednesday  1:00 p.m.–3:00 p.m. Wednesday  1:00 p.m.–3:00 p.m. Wednesday  3:30 p.m.–4:15 p.m.


Scientific Platform Sessions

Scientific Platform Sessions

Wednesday, April 26

Wednesday  3:30 p.m.–5:30 p.m. Wednesday  3:30 p.m.–5:30 p.m. Wednesday  3:30 p.m.–5:30 p.m. Wednesday  3:30 p.m.–5:30 p.m.

S33 Progressive MS

S34 Epilepsy and Clinical

3:30 p.m. John Dystel Prize for Multiple

3:30 p.m. Dreifuss-Penry Epilepsy

Therapeutics

Sclerosis Research Sponsored by the AAN and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

Recipient:

Alan J. Thompson, MD, FRCP, FAAN London, United Kingdom

3:54 p.m.

S33.003

Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression  —Pablo Villoslada, Ari Green, John Keltner, Rolf Meinert, Diego Silva, Marlies Van Hoef, Peter Calabresi

4:06 p.m.

S33.004

Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab  — Michelle Mellion, Keith Edwards, Raymond Hupperts, Jelena Drulovic, Xavier Montalban, Hans-Peter Hartung, Bruno Brochet, Peter Calabresi, Richard Rudick, Adama Ibrahim, Yiwei Zhang, Lei Xu, Diego Cadavid, on behalf of the SYNERGY investigators

4:18 p.m.

S33.005

Development of a sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis  —Peter Kosa, Danish Ghazali, Makoto Tanigawa, Irene Cortese, William Kelly, Blake Snyder, Joan Ohayon, Kaylan Fenton, Tanya Lehky, Tianxia Wu, Christopher Barbour, Mark Greenwood, Govind Nair, Bibiana Bielekova

4:30 p.m.

S33.006

The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study  —Deborah Miller, Stephen Hauser, Ludwig Kappos, Fred Lublin, Xavier Montalban, Fiona McDougall, Gurpreet Deol-Bhullar, Jian Han, Laura Julian, Bruno Musch, Jerry Wolinsky

4:42 p.m.

S33.007

Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis:  —Robert Fox, Ludwig Kappos, Amit Bar-Or, Bruce Cree, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Harold Pohlmann, Christian Wolf, Frank Dahlke, Katy Demery, Tatiana Sidorenko

4:54 p.m.

S33.008

WEDNESDAY

Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data  — Flavia Nelson, Christine Lebrun Frenay, Camu William, Alexey Boyko, Kathinathan Thangavelu, Pascal Rufi, Steven Cavalier, Philippe Truffinet, Jinjun Liang, Fred Lublin

5:06 p.m.

Discussion

Neurophysiology (EEG) II

Award Sponsored by the AAN and endowed by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Neuroscience; OrthoMcNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.

Recipient:

William Stacey, MD, PhD Ann Arbor, MI

3:42 p.m.

S34.002

Comparing the healthcare utilization and direct medical costs in newly diagnosed epilepsy patients and a comparator non-epilepsy population: a US database analysis  —R Faught, Sandra Helmers, David Thurman, Hyunmi Kim, Tracy Durgin, Linda Kalilani

3:54 p.m.

S34.003

Laser Interstitial Thermal Therapy (LITT) outcomes for intractable epilepsy  — Scheherazade Le, Allen Ho, Kai J. Miller, Gerald Grant, Casey Halpern

4:06 p.m.

S34.004

Use of sEMG to inform GTC seizure semiology  —Jose Cavazos, Jonathan Halford, Michael Sperling, Dileep Nair, Dennis Dlugos, William Tatum, J. Harvey, Jacqueline French, John Pollard, R Faught, Katherine Noe, Thomas Henry, Gina Jetter, Octavian Lie, Lola Morgan, Michael Girouard, Damon Cardenas, Luke Whitmire

4:18 p.m.

S34.005

High-resolution intracranial recordings provide direct electrophysiological evidence for music and speech-selective neural populations in human auditory cortex  —Samuel Norman-Haignere, Jenelle Feather, Peter Brunner, Anthony Ritaccio, Josh McDermott, Nancy Kanwisher, Gerwin Schalk

4:30 p.m.

S34.006

Passive Functional Mapping of Language Areas Using Electrocorticographic Signals in Humans  —James Swift, William Coon, Christoph Guger, Peter Brunner, Marjorie Bunch, Timothy Lynch, Bridget Frawley, Anthony Ritaccio, Gerwin Schalk

4:42 p.m.

S34.007

Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy  —Baibing Chen, Kamil Detyniecki

4:54 p.m.

S34.008

Association of Hippocampal CA3 Transcriptional Modules with Language Impairment in Mesial Temporal Lobe Epilepsy  —Joao Mansano-Oliveira, Silvia Bando, Fernanda Bertonha, Bettina Castro, Cristiane Messas, Hung Wen, Carlos MoreiraFilho, Luiz Castro

5:06 p.m.

68 2017 AAN Annual Meeting Science Program

Discussion

S35 Aging and Dementia:

S36 Cerebrovascular Disease

3:30 p.m. Alliance Awards: Founders

3:30 p.m.

S36.001

Neuroimaging in Neurodegenerative Diseases

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance.

Recipient:

Emer McGrath, MBChB Boston, MA

and Interventional Neurology: Epidemiology

National Patterns of Carotid Revascularization in the Pre- and PostCarotid Revascularization Endarterectomy vs. Stenting Trial (CREST) Era  —Fadar Otite, Priyank Khandelwal, Amer Malik, Seemant Chaturvedi

3:42 p.m.

S35.002

3:42 p.m.

S36.002

3:54 p.m.

S35.003

3:54 p.m.

S36.003

4:06 p.m.

S36.004

4:18 p.m.

S36.005

4:30 p.m.

S36.006

4:42 p.m.

S36.007

4:54 p.m.

S36.008

5:06 p.m.

Discussion

PET Staging of Brain Amyloidosis Using Striatum  —Bernard Hanseeuw, Rebecca Betensky, Elizabeth Mormino, Aaron Schultz, Kathryn Papp, Rachel Buckley, Jasmeer Chhatwal, Gad Marshall, Dorene Rentz, Reisa Sperling, Keith Johnson 18F-AV-1451 in frontotemporal dementia spectrum disorders  —Richard Tsai, Alexandre Bejanin, Daniel Schonhaut, Rik Ossenkoppele, James O’Neil, Mustafa Janabi, Suzanne Baker, Andreas Lazaris, Nagehan Ayakta, Gautam Tammewar, Maria Gorno Tempini, Bruce Miller, Adam Boxer, William Jagust, Gil Rabinovici

4:06 p.m.

S35.004

Brain tissue metabolites on baseline MRS are associated with greater-amyloid accumulation rate from serial PET in clinically normal older adults  —Zuzana Nedelska, Scott Przybelski, Timothy Lesnick, Christopher Schwarz, Val Lowe, Mary Machulda, David Knopman, Walter Kremers, Ronald Petersen, Clifford Jack, Kejal Kantarci

4:18 p.m.

S35.005

Reduced emotional sensitivity and responsiveness measured by the Revised Self-Monitoring Scale is a behavioral marker of early salience network dysfunction in neurodegenerative disease  —Gianina Toller, Jesse Brown, Kelly A. Gola, Suzie Shdo, Clinton Mielke, Paul Sukhanov, Bruce Miller, Katherine Rankin

4:30 p.m.

S35.006

Alzheimer’s Disease: 3-Dimensional MRItexture for Prediction of Conversion from Mild Cognitive Impairment  —Collin Luk, Abdullah Ishaque, Muhammad Khan, Daniel Ta, Dennell Mah, Yee Hong Yang, Sanjay Kalra

4:42 p.m.

S35.007

Dementia Incidence and Predictors in Cerebral Amyloid Angiopathy Patients without Intracerebral Hemorrhage  —Li Xiong, Gregoire Boulouis, Andreas Charidimou, Duangnapa Roongpiboonsopit, Michael Jessel, Marco Pasi, Yael Reijmer, Panagiotis Fotiadis, Alison Ayers, M. Emily Merrill, Kristin Schwab, Edip Gurol, Steven Greenberg, Anand Viswanathan

4:54 p.m.

S35.008

5:06 p.m.

Discussion

Intracranial arterial blood flow in individuals with Mild Cognitive Impairment (MCI) is associated with cognitive performance and amyloid positivity  —Sara Berman, Leonardo Rivera, Annie Racine, Derek Norton, Lindsay Clark, Richard Chappell, Howard Rowley, Barbara Bendlin, Kaj Blennow, Henrik Zetterberg, Cynthia Carlsson, Sanjay Asthana, Patrick Turski, Oliver Wieben, Sterling Johnson

Association between Imaging Markers of Cerebral Small Vessel Disease and Motor Performance in Community-dwelling Populations  —Ning Su, Fei-Fei Zhai, Jun Ni, Li-Xin Zhou, Ming Yao, Ming-Li Li, Zheng-Yu Jin, Gao-Lang Gong, Shu-Yang Zhang, Liying Cui, Feng Tian, Yi-Cheng Zhu Stroke Risk Factors, Post Stroke Anxiety and Neurocognitive Function  —Mayowa Owolabi, Rufus Akinyemi, Joshua Akinyemi, Mulugeta Gebregziabher, EZINNE UVERE, Bruce Ovbiagele Prevalence and risk factors of intracranial arterial stenosis in asymptomatic population in a Chinese cohort  —Fei Han, Shuang Yan, Feifei Zhai, Lixin Zhou, Jun Ni, Ming Yao, Liying Cui, Shuyang Zhang, Mingli Li, Zhengyu Jin, Yi-Cheng Zhu Whole-genome Sequencing in Familial Cases of Intracranial Atherosclerotic Disease  —Thomas Leung, Elvis Dong, Bonaventure Ip, Ka Wong, Ricard KW Choy Hospital Tax Status and Carotid Artery Stent Utilization in US Hospitals  —Justin Chandler, Benjamin George, Adam Kelly, Robert Holloway Risk of Ischemic Stroke in Patients with Atrial Flutter  —Mais Alkawaz, Setareh Salehi Omran, Neal Parikh, Mitchell Elkind, Elsayed Soliman, Hooman Kamel An exploratory study to investigate the association between short-term exposure to air pollution on the occurrence of ischemic or hemorrhagic stroke in a case crossover study design.  —Awadh Pandit, Kameshwar Prasad, Amit Kumar, Pradeep Kumar


Thursday  8:00 a.m.–9:00 a.m.

Thursday  1:00 p.m.–2:00 p.m.

Thursday  1:00 p.m.–3:00 p.m.

Thursday  1:00 p.m.–3:00 p.m.

S37 “Best of” Session:

S38 Pain and Palliative Care

S39 Movement Disorders:

S40 Infectious Disease: The

1:00 p.m.

S39.001

1:00 p.m.

S40.001

1:12 p.m.

S39.002

1:12 p.m.

S40.002

1:24 p.m.

S40.003

1:36 p.m.

S40.004

1:48 p.m.

S40.005

2:00 p.m.

S40.006

2:12 p.m.

S40.007

2:24 p.m.

S40.008

2:36 p.m.

Discussion

Epilepsy

Titles and authors of these abstracts

are listed in “Best of” Scientific Platform Sessions on page 49 »

T his session will be presented at the Research Corner area located in the North Lobby of the Boston Convention and Exhibition Center. See page 13 » for more information on the Research Corner.

1:00 p.m. Mitchell B. Max Award for

Neuropathic Pain Sponsored by the AAN and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max

Recipient:

C Peter N Watson, MD Toronto, ON, Canada

1:12 p.m.

S38.002

1:24 p.m.

S38.003

Excitatory CXCR4/SDF-1 signaling and calcium overload in Nav1.8 nociceptors are responsible for small fiber degeneration in Painful Diabetic Neuropathy  —Nirupa Jayaraj, Bula Bhattacharyya, Richard Miller, Daniela Menichella Hippocampal atrophy in older adults with chronic pain is associated with higher levels of depressive symptoms  —Ali Ezzati, Mindy Katz, Michael Lipton, Richard Lipton

1:36 p.m.

S38.004

Mexiletine for the treatment of muscle cramps in ALS: a randomized double-blind crossover trial  —Bjorn Oskarsson, Dan Moore, Tahseen Mozaffar, John Ravits, Martina Wiedau-Pazos, Nicholas Parziale, Nanette Joyce, Ross Mandeville, Namita Goyal, Merit Cudkowicz, Michael Weiss, Robert Miller, Craig McDonald

Functional and Structural Imaging in Parkinson’s Disease

Volumetric analysis of limbic structures in patients with functional movement disorders  —Carine Maurer, Kathrin LaFaver, Gaurang Limachia, Geanna Capitan, Silvina Horovitz, Mark Hallett Inferior parietal cortex as a hub of loss of inhibition and maladaptive plasticity  — Kristina Simonyan

1:24 p.m.

S39.003

1:36 p.m.

S39.004

1:48 p.m.

S39.005

2:00 p.m.

S39.006

2:12 p.m.

S39.007

2:24 p.m.

S39.008

Distinct Mesocorticolimbic blood flow response to dopamine therapy in patients with Parkinson’s disease and compulsive reward-driven behaviors  —Daniel Claassen, Adam Stark, Robert Kessler, David Zald, Manus Donahue Hippocampal and entorhinal cortex atrophy across the Parkinson’s disease cognitive impairment spectrum  —Roshni Patel, Glenn Stebbins, Bryan Bernard, Jennifer Goldman The effects of different modalities of gait training on brain activation in patients with Parkinson’s disease: an fMRI study  —Anat Mirelman, Keren Rosenberg, Michal Klein, Yael Jacob, Nir Giladi, Jeffrey Hausdorff Effects of Subthalamic Stimulation in Elderly patients with Parkinson’s Disease  — Vibhash Sharma, Bhavana Patel, Kelly Lyons, Jules Nazzaro, Rajesh Pahwa Identification of Usp8 as a toxicity modifying Deubiquitinase for -synuclein  —Zoi Alexopoulou, Johannes Lang, Rebecca Perrett, Alfred Goldberg, Olaf Ansorge, Tudor Fulga, George Tofaris Glucose-regulated protein 78 (GRP78) in plasma and CSF is associated with Parkinson’s disease.  —Deepak Gupta, Charles Hoppel, Jennifer Goldman, Paul Minkler, Ruifu Liu, Janos Kerner, Curtis Tatsuoka, Tivadar Orban, Hui Jin, Zhaoyang Feng

2:36 p.m.

Discussion

Neurology of Zika, Chikungunya, and Acute Flaccid Myelitis

A Human MiniBrain as a model to study Zika virus associated neurological disease.  — Paula Barreras, David Pamies, Laura S. Munoz, Anupama Kumar, Beatriz Parra, Celina Abreu, Lucio Gamma, Helena Hogberg, Thomas Hartung, Carlos Pardo-Villamizar Neuroviruses Emerging in the Americas Study (NEAS): The Colombian experience during the 2016 outbreak of Zika virus infection  —Laura S. Munoz, Paula Barreras, Jairo Lizarazo, Jorge Andres Jimenez-Arango, Guillermo Gonzalez-Manrique, Andres Felipe Zea-Vera, Jorge Angarita Diaz, Jose Vargas, Gonzalo Zuniga, Cindy L. Beltran, Reydmar López-Gonz·lez, Lina MuÒoz, Angela Gomez, Gustavo Ramos, Maria Reyes-Mantilla, Gustavo Pradilla-Ardila, Anupama Kumar, David Cornblath, Lyda Osorio, Beatriz Parra, Carlos Pardo-Villamizar Mortality in Newborns with Microcephaly Due to Maternal Zika Virus Infection in Rio Grande Do Norte State- Northeast Brazil: A Cross-Sectional Study  —Nilson Nogueira Mendes Neto, Jessika Thais da Silva Maia, Marcelo Rodrigues Zacarkim, Daniel Duarte Rolim, Maria Goretti Linz, Thiago Gomes Trindade, Kleber Luz, Giovanna Fulco, Tatyana Vidal Mendes, Sebastiana Jayne Alves Vidal, Iracema Augusta Cortez Muniz, Servulo Marciano Pinheiro de Souza, Igor Queiroz, Angelle Desiree LaBeaud

Scientific Platform Sessions

Thursday, April 27

Indirect Immunoflourescence assay for the screening of Zika antibodies in serum and cerebrospinal fluid  —Anupama Kumar, Francisco Ocazionez, Celina Abreu, Beatriz Parra, Laura Munoz, Gregory Samuel, Kiran Thakur, Lucio Gama, Carlos Pardo-Villamizar Zika-associated Atypical Guillain–Barre Variants in rural Haiti  —Roosevelt Francois, Aaron Berkowitz Zik-V outbreak and Guillain–Barre syndrome in Jamaica  —Amza Ali, Marie Williams Neurological involvement in Chikangunya Virus infection  —Rajiv Anand, Gaurav Kasundra, Atul Prasad, Rahul Handa Acute Flaccid Myelitis: Characteristics and Outcomes in 2014 and 2016 Clusters  — Sarah Hopkins, Jennifer McGuire, Sanjeev Swami, E.R. Ulloa, Brenda Banwell

THURSDAY

Fast and easy registration · AAN.com/view/AM17 69


Scientific Platform Sessions

Scientific Platform Sessions

Thursday, April 27

Thursday  1:00 p.m.–3:00 p.m.

Thursday  1:00 p.m.–3:00 p.m.

Thursday  3:30 p.m.–4:30 p.m.

Thursday  3:30 p.m.–5:30 p.m.

S41 Neuro-oncology

S42 Update in Muscular

S43 Exciting New Results in

S44 MS Risk Factors and

1:00 p.m. Neuro-oncology Investigator Award Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner.

Recipient:

Michelle Monje, MD, PhD Stanford, CA

1:12 p.m. Neuro-oncology Scientific

Award Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung.

Recipient:

Mario Suva, MD, PhD Boston, MA

1:24 p.m.

S41.003

Clinical and molecular characteristics of glioneuronal tumors  —Julie Miller, Christopher Alvarez-Breckenridge, Naema Nayyar, Corey Gill, Megan D’Andrea, Long Le, Jesse Lee, Ju Cheng, Zongli Zheng, Pratik Multani, Edna Chow, Brian Toyota, Dora DiasSantagata, Sandro Santagata, Stephen Yip, Anna Farago, Tracy Batchelor, Daniel Cahill, A. John Iafrate, Priscilla Brastianos

1:36 p.m.

S41.004

Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial  —Anastasie Dunn-Pirio, Katherine Peters, Annick DesJardins, Dina Randazzo, Henry Friedman, Patrick Healy, James Herndon II, Elizabeth Reap, Gerald Archer, Qi-Jing Li, John Sampson, Gordana Vlahovic

1:48 p.m.

S41.005

2:00 p.m.

S41.006

Targeting carcinoma–astrocyte gap junctions in brain metastasis  —Adrienne Boire, Qing Chen, Mariza Daras, Thomas Kaley, Krishnaben Patel, Lisa DeAngelis, Joan Massagué Identification of clinically actionable PI3K pathway mutations in brain metastases from breast cancer  —Ugonma Chukwueke, Naema Nayyar, Megan D’Andrea, Sandro Santagata, Tracy Batchelor, Daniel Cahill, Scott Carter, Priscilla Brastianos

2:12 p.m.

S41.007

Microtubule Associated Protein (MAP) 1B: Antigen of PCA-2 IgG, Biomarker of SmallCell Lung Carcinoma-related Paraneoplastic Neurological Autoimmunity  —Avi Gadot, Thomas Kryzer, James Fryer, Andrew McKeon, Vanda Lennon, Sean Pittock

2:24 p.m.

S41.008

Germline genetic mutations contribute to the development of primary brain tumors: a review of a multigene panel testing cohort  —Amanda Bergner, Michelle Jackson

2:36 p.m.

Discussion

Dystrophy

1:00 p.m.

S42.001

Eteplirsen for the Treatment of Duchenne Muscular Dystrophy (DMD)  —JS Charleston, F Schnell, J Dworzak, C Donoghue, J Lynch, Sarah Lewis, L Chen, Louise Rodino-Klapac, Zarife Sahenk, J Voss, U DeAlwis, DE Frank, H Eliopoulos, JR Mendell

1:12 p.m.

S42.002

Genetic landscape of Limb-Girdle Muscular Dystrophies from a Large Cohort of Neuromuscular Disease Patients  —Samya Chakravorty, Babi Nallamilli Redd Ramesh, Yinwei Cheng, Matthew Wicklund, Matthew Harms, Tahseen Mozaffar, Madhuri Hegde

1:24 p.m.

S42.003

1:36 p.m.

S42.004

Therapeutic Effect of KPT-350 in a Preclinical Model of Duchenne Muscular Dystrophy  —Devin Gibbs, Rylie Hightower, Christopher Lee, Janelle Spinazzola, Lillian Mead, Jeffrey Widrick, Sharon Tamir, Shelton Cochran, Yosef Landesman, Louis Kunkel, Matthew Alexander Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) and Loss of Ambulation (LOA)  —JR Mendell, Nathalie Goemans, Louise Rodino-Klapac, Linda Lowes, Lindsay Alfano, K Berry, S Moody, Emily Naughton, Eugenio Mercuri, DMD Italian Network

1:48 p.m.

S42.005

2:00 p.m.

S42.006

Genetic markers of myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) in human urine  —Layal Antoury, Ningyan Hu, Leonora Balaj, Xandra Breakefield, Thurman Wheeler Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 distal and proximal muscles  —Giovanni Meola, Valentina Renna, Francesca BosË, Barbara Fossati, Elisa Brigonzi, Michele Cavalli, Rosanna Cardani

2:12 p.m.

S42.007

Cardiac function in the dystroglycanopathies  —Julia Collison, Katie Lutz, Benton Ng, Shelley Mockler, Katie Laubscher, Carrie Stephan, Bridget Zimmerman, Erik Edens, Benjamin Reinking, Katherine Mathews

2:24 p.m.

S42.008

Development of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Treatment of Duchenne Muscular Dystrophy (DMD)  —P Duda, Genevieve Laforet, Celeste Di Johnson, H Eliopoulos, Arvind Narayana, DE Frank, S Ruff, JR Mendell

THURSDAY

2:36 p.m.

70 2017 AAN Annual Meeting Science Program

Discussion

Neuro-rehabilitation

T his session will be presented at the Research Corner area located in the North Lobby of the Boston Convention and Exhibition Center. See page 13 » for more information on the Research Corner.

3:30 p.m.

S43.001

Age at the time of injury as key determinant of inflammatory response to, oligodendrocyte apoptosis, and axonal survival after acute traumatic spinal cord injury  —Julio Furlan, Yang Liu, W. Dalton Dietrich, Michael Norenberg, Michael Fehlings

3:42 p.m.

S43.002

3:54 p.m.

S43.003

Action Observation Training Modifies the Function and Structure of the Mirror Neuron System in Multiple Sclerosis Patients with Right Upper Limb Motor Deficits  —Maria Rocca, Silvia Fumagalli, Annachiara Ravetto, Angelo M. Dirito, Paolo Preziosa, Roberto Gatti, Filippo Martinelli Boneschi, Mauro Comola, Giancarlo Comi, Massimo Filippi Constraint-Induced Movement Therapy for Chronic Hemiparesis: Neuroscience Evidence from Basic Laboratory Research and Quantitative Structural Brain MRI in Patients with Diverse Disabling Neurological Disorders  —Victor Mark, Edward Taub

4:06 p.m.

S43.004

Respiratory muscle unloading (RMU) to treat dyspnea on exertion (DOE) in ambulatory patients with Amyotrophic Lateral Sclerosis (ambALS).  —Mohammed Sanjak, Dillon Malloy, Scott Holsten, Velma Langford, Lisa Ranzinger, Allison Newell-Sturdivant, Cynthia Lary, Nicol Brandon, Elena Bravver, Benjamin Bringardner, Scott C Lindblom, William Bockenek, Benjamin Brooks

Modifications

3:30 p.m.

S44.001

3:42 p.m.

S44.002

3:54 p.m.

S44.003

4:06 p.m.

S44.004

4:18 p.m.

S44.005

4:30 p.m.

S44.006

4:42 p.m.

S44.007

4:54 p.m.

S44.008

5:06 p.m.

Discussion

The effect of hospitalization on subsequent disability in multiple sclerosis  —Ruth-Ann Marrie, Luanne Metz, Allan Garland A survey of current dietary habits within a large population of people with multiple sclerosis  —Kathryn Fitzgerald, Tuula Tyry, Stacey Cofield, Amber Salter, Robert Fox, Gary Cutter, Ruth-Ann Marrie Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited.  — Shayandokht Taleb, Bardia Nourbakhsh, Jennifer Graves, Theron Casper, Amy Waldman, Sabeen Lulu, Anita Belman, Bianca Guttman, Benjamin Greenberg, Gregory Aaen, Janace Hart, Jayne Ness, Jennifer Rubin, JanMendelt Tillema, Lauren Krupp, Mark Gorman, Leslie Benson, Moses Rodriguez, Tanuja Chitnis, John Rose, Lisa Barcellos, Emmanuelle Waubant Cholecalciferol supplementation in Relapsing Multiple Sclerosis patients treated with subcutaneous interferon beta1a: a Randomized Controlled Trial.  —William Camu, Charles Pierrot-Deseilligny, Patrick Hautecoeur, Anne Besserve, Anne-Sophie Jean Deleglise, Philippe Lehert, Jean-Claude Souberbielle High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis (RRMS) receiving subcutaneous interferon 1a (scIFNβ-1a)  —Raymond Hupperts, Joost Smolders, Reinhard Vieth, Trygve Holm¯y, Kurt Marhardt, Myriam Schluep, Joep Killestein, Frederik Barkhof, Luigi Maria Grimaldi, Manolo Beelke Maternal levels of Epstein-Barr virus IgG antibodies and risk of multiple sclerosis in offspring in the Finnish Maternity Cohort  — Kassandra Munger, Zhongli Zhang, Julia Aivo, Kira Hongell, Merja Soilu-Hanninen, HeljaMarja Surcel, Alberto Ascherio Epstein-Barr virus, Cytomegalovirus, the Hygeine Hypothesis and Multiple Sclerosis Susceptibility: A Multi-Ethnic Study  — Annette Langer-Gould, Jun Wu, Robyn Lucas, Jessica Smith, Edlin Gonzales, Lilyana Amezcua, Samantha Haraszti, Hong Quach, Judith James, Lisa Barcellos, Anny Xiang Familial Transverse Myelitis Associated with Mutation in VPS37A Gene  —Santiago Pardo, Tai Seung Nam, Kathleen Burns, Michael Levy


Thursday  3:30 p.m.–5:30 p.m.

Thursday  3:30 p.m.–5:30 p.m.

Thursday  3:30 p.m.–5:30 p.m.

S45 Peripheral Nerve Disorders

S46 Child Neurology: Molecular

S47 Headache: Basic and

S48 Practice, Policy, and Ethics

3:30 p.m.

3:30 p.m.

3:30 p.m.

S45.001

A Randomized, Double-blind, Placebocontrolled, Delayed-start Trial to Evaluate the Safety and Efficacy of L-Serine in Subjects with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)  — Vera Fridman, Peter Novak, William David, Eric Macklin, Diane McKenna-Yasek, Kailey Walsh, Anne Louise Oaklander, Robert Brown, Thorsten Hornemann, Florian Eichler

3:42 p.m.

S45.002

Axonal Degeneration in CMT2P and Alterations of Stoichiometry of Transcription Protein Complex  —Jun Li, Bo Hu, Stephan Zuchner, Sezgi Arpag

3:54 p.m.

S45.003

Subcutaneous immunoglobulin as first-line therapy in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy RCT study  —Lars Markvardsen, Soren Sindrup, Ingelise Christiansen, Niels Olsen, Johannes Jakobsen, Henning Andersen

4:06 p.m.

S45.004

The Missing Piece: Ultrasound as an Ancillary Study in the Diagnosis of Peroneal Mononeuropathy  —Julia Bucklan, John Morren, Steven Shook

4:18 p.m.

S45.005

Biology to Clinical Trials S46.001

Microcephaly proteins Wdr62 and Aspm define a mother centriole complex regulating centriole biogenesis, apical complex and cell fate  —Divya Jayaraman, Andrew Kodani, Dilenny Gonzalez, Joseph Mancias, Ganeshwaran Mochida, Cristiana Vagnoni, J. Wade Harper, Jeremy Reiter, Timothy Yu, Byoung-il Bae, Christopher Walsh

3:42 p.m.

S46.002

Outcome following hemicraniectomy in children with acute stroke in the International Pediatric Stroke Study  —Laura Lehman, Michael Dowling, Ryan Felling, Melissa Chung, Paola Pergami, Kristin Guilliams, Gabrielle DeVeber, Michael Rivkin

3:54 p.m.

S46.003

Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy  —Darryl De Vivo, Wuh-Liang Hwu, Sandra Reyna, Wildon Farwell, Sarah Gheuens, Peng Sun, John Zhong, John Su, Eugene Schneider, Enrico Bertini, on behalf of the NURTURE Study Investigators

4:06 p.m.

S46.004

Motor mapping by transcranial magnetic stimulation reveals a pathologically preserved immature motor lateralization in patients with intractable focal epilepsy  — Harper Kaye, Roman Gersner, Aaron Boes, Alvaro Pascual-Leone, Alexander Rotenberg

Neurolymphomatosis: Clinical, Radiographic, and Pathologic Characteristics  —Jennifer Martinez-Thompson, Narupat Suanprasert, Rebecca King, William Macon, Michelle Mauermann, Kimberly Amrami, Robert Spinner, Peter Dyck, P. James B. Dyck 4:18 p.m. S46.005 A Randomized Double-blind, Placebo4:30 p.m. S45.006 controlled, Cross-over Trial of Ganaxolone Molecular Mechanisms of Conduction Block in Children and Adolescents with Fragile X in HNPP  —Bo Hu, Sezgi Arpag, Xuebao Syndrome  —Julia Tsai, Andrew Ligsay, Anke Zhang, Audra Hamilton, Jonathan Chernoff, Van Dijck, Frank Kooy, David Hessl, Erika Bickel, Jun Li Randi Hagerman, Albena Patroneva 4:42 p.m. S45.007 S46.006 A Prospective Study of Benign Fasciculation 4:30 p.m. Long Term Outcomes and Risk Factors Syndrome  —Alexandra Filippakis, Jordan for Chemotherapy Induced Peripheral Jara, Nick Ventura, Robin Ruthazer, James Neuropathy in Childhood Cancer Russell, Doreen Ho Survivors  —Tejaswi Kandula, Michelle Farrar, 4:54 p.m. S45.008 Matthew Kiernan, David Mizrahi, Kate Carey, Identification of a novel TRPA1 mutation Arun Krishnan, Richard Cohn, Susanna Park associated with carbamazepine-responsive cramp-fasciculation syndrome  —Tara Biller, Coro Paisan-Ruiz, Rebecca Gilbert, Rita Chaouni, Melissa Nirenberg

5:06 p.m.

Discussion

4:42 p.m.

S46.007

Physician- and Patient-Reported Outcomes in X-linked Adrenoleukodystrophy: Accelerated Roadmap from Patients’ Insights to Clinical Trials  —Alexander Sherman, Erin Connors, Kailey Walsh, Florian Eichler

4:54 p.m.

S46.008

5:06 p.m.

S47.001

Cortical spreading depression closes the paravascular space and impairs glymphatic flow: Implications for migraine headache.  — Aaron Schain, Andrew Strassman, Agustin Melo-Carrillo, Rami Burstein

3:42 p.m.

S47.002

Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: implications to extracranial origin of headache  —Rami Burstein, Pamela Blake, Carlton Perry

3:54 p.m.

S47.003

4:06 p.m.

S47.004

4:18 p.m.

S47.005

4:30 p.m.

S47.006

4:42 p.m.

S47.007

In vivo imaging of CSD-induced activation of resident meningeal immune cells: implications for activation of meningeal nociceptors  —Aaron Schain, Agustin MeloCarrillo, Andrew Strassman, Rami Burstein Increased cortical network activity in a migraine mutant mouse following traumatic brain injury  —Chad Service, PM SawantPokam, Jorge Mendez, K.C. Brennan Green light alleviates migraine photophobia  —Rodrigo Noseda, Rony Reuven-Nir, Carolyn Bernstein, David Borsook, Catherine Buettner, Rami Burstein Migraine is comorbid with Attention Deficit Hyperactivity Disorder in childhood: a nationwide populational study  —Marco Arruda, Renato Arruda, Vincenzo Guidetti, Marcelo Bigal Epidemiology of Migraine in Men: Disease Presentation and Comorbidities from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study  —Ann Scher, Shuu-Jiun Wang, Zaza Katsarava, Dawn Buse, Kristina Fanning, Aubrey Manack Adams, Richard Lipton

4:54 p.m.

S47.008

5:06 p.m.

Discussion

Exploring the Role of the Hippocampus in Migraine  —Catherine Chong, Gina Dumkrieger, Todd Schwedt

3:30 p.m.

S48.001

3:42 p.m.

S48.002

3:54 p.m.

S48.003

4:06 p.m.

S48.004

4:18 p.m.

S48.005

4:30 p.m.

S48.006

4:42 p.m.

S48.007

4:54 p.m.

S48.008

5:06 p.m.

Discussion

Implementation of an on-line communication interface (“Ask-a-doc”) in a neurology department  —Muhammad Taimur Malik, Kristina Barron, Neil Holland MyChart Enrollment and other Factors that Affect No Show Rates in the Neurology Resident Clinic  —Kavit Shah, Abdullah Alshammaa, Muhammad Affan, Lonni Schultz, Iram Zaman Factors affecting post-discharge outcomes in hospital patients with non-surgical neurological diseases  —Krishna Mourya Galla, Moayd Alkhalifah, Swetha Pedavally, Dharani Mudugal, Vamshi Balasetti, Kalyan Sajja, Lakshman Arcot Jaygaopal, Faisal Ahmed, Sandeep Devarapalli, Lucas Stenzel, Aashrayata Aryal Pandit, Sanath Kasi Reddy, Erin Smith, Hae Young Baang, Fuad-al Ali, Hannah Maher, Kaeli Samson, Matthew Rizzo, T. Scott Diesing, Marco Gonzalez Castellon, Sachin Kedar Reducing delays to imaging and thombolysis in acute stroke care  —Tracie Caller, Carol Rieser, Jonathan Savelle, Jackie Norviel, Jessica Kisicki A multimodal quality improvement program for delirium in stroke  —Sophia Ryan, Vanessa Gormley, Claire Jacobs, Adam Cohen, Eyal Kimchi Enhancing Efficiency of the Epilepsy Center King Faisal-Specialist Hospital and Research Center-Jeddah (KFSH&RC–Jeddah)  — Youssef Al Said, Edward Cupler, Saleh Baeesa, Ibrahim Zabani, Donald Lighter Factors in Unplanned Readmission or ED Visit within 30 Days of Discharge from an Inpatient Neurology Service  —Faisal Ahmed, Vamshi Balasetti, Kalyan Sajja, Lakshman Arcot Jaygaopal, Lucas Stenzel, Sandeep Devarapalli, Aashrayata Aryal Pandit, Sanath Kasi Reddy, Erin Smith, Fuad-al Ali, Krishna Mourya Galla, Hae Young Baang, Hannah Maher, Kaeli Samson, Sachin Kedar, Matthew Rizzo, T. Scott Diesing, Marco Gonzalez Castellon Validation of i1 Biometrics Vector MouthGuard: Measuring Head Impact Frequency in Sport  —Geoffrey McKendry, Harrison Brown, Jean-Sebastien Blouin

THURSDAY

PREPL deficiency: delineation of the phenotype and development of a functional blood assay  —Luc Regal, Emma Martensson, Isabelle Maystadt, N.C. Voermans, Damien Lederer, Alberto Burlina, Maria Jesus Juan Fita, A Jeannette M Hoogeboom, Mia Olsson Engman, Tess Hollemans, Meyke Schouten, Sandra Meulemans, Tord Jonson, Inge Francois, David Gil Ortega, Erik-Jan Kamsteeg, John Creemers

Clinical Science

Scientific Platform Sessions

Thursday  3:30 p.m.–5:30 p.m.

Discussion

Fast and easy registration · AAN.com/view/AM17 71


Scientific Platform Sessions

Scientific Platform Sessions

Friday, April 28

Friday  8:00 a.m.–9:00 a.m.

Friday  1:00 p.m.–3:00 p.m.

Friday  1:00 p.m.–3:00 p.m.

Friday  1:00 p.m.–3:00 p.m.

S49 “Best of” Session:

S50 MS Novel Therapeutics and

S51 Cerebrovascular Disease and

S52 Headache: Clinical Trials

Titles and authors of these abstracts

1:00 p.m.

Aging and Dementia

are listed in “Best of” Scientific Platform Sessions on page 49 »

Animal Models

S50.001

Astrocytic Junctional Adhesion Molecule-A (JAM-A) Promotes CNS Inflammatory Lesion Pathogenesis  —Candice Chapouly, Alexandra Gordon, Anthony Therattil, Gareth John, Sam Horng

1:12 p.m.

S50.002

CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study  —David Weinstein, Alexey Boyko, Lisa Pugliese, Hong Tang, Dennis Lanfear, Robert Zivadinov, Barbara Finck

Interventional Neurology: Stroke Prevention and Translation

1:00 p.m.

S51.001

Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients  —Craig Coleman, Thomas Bunz

1:12 p.m.

S51.002

and Disease Burden

1:00 p.m. Harold Wolff-John Graham

Award: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.

Recipient:

Simple Futarmal Kothari, PhD Aarhus, Denmark

“Worth the Walk:” A Randomized 1:12 p.m. S52.002 Controlled Trial of a Walking Intervention Evaluating the Efficacy and Safety of to Decrease Stroke Risk Among Minority Erenumab (AMG 334) In Chronic Migraine Seniors  —Sarah Song, Daniel Araiza, Carmen Prevention in a Phase 2 Randomized, Reyes, Phyllis Willis, Sarah Choi, John Kotick, Double-Blind, Placebo-Controlled Study  — Elizabeth Jimenez, Sin Ma, Laura Trejo, Carmen Stewart Tepper, Katherine Widnell, David Carrillo, Catherine Sarkisian 1:24 p.m. S50.003 Dolezil, Messoud Ashina, Uwe Reuter, Jan A high-throughput screen identifies Brandes, Stephen Silberstein, Paul Winner, 1:24 p.m. S51.003 a candidate molecule that promotes Dean Leonardi, Daniel Mikol Long-term Risk of Complications after remyelination with significant translational Percutaneous Transcatheter Closure 1:24 p.m. S52.003 potential  —Kelsey Rankin, Yun-An Shen, Feng of Patent Foramen Ovale  —Alexander Randomized, Double-blind, PlaceboMei, Caroline Desponts, Daniel Lorrain, Ari Merkler, Gino Gialdini, Shadi Yaghi, Peter Okin, controlled Trial of ALD403, an anti-CGRP Green, Jonah Chan, Riley Bove Costantino Iadecola, Babak Navi, Hooman peptide antibody in the prevention of chronic 1:36 p.m. S50.004 Kamel migraine.  —David Dodick, Peter Goadsby, Accelerated cellular senescence in a Stephen Silberstein, Richard Lipton, Joe 1:36 p.m. S51.004 model of multiple sclerosis  —Dimitrios Hirman, Jeff Smith Histopathological differences between the Papadopoulos, Maria Karamita, Dimos anterior and posterior cerebral circulation 1:36 p.m. S52.004 Dimitrios Mitsikostas, Vassilis Gorgoulis, as a function of aging  —William Roth, Susan A Multicenter, Prospective, Single Arm, Lesley Probert, Richard Nicholas Morgello, James Goldman, J. Mohr, Mitchell Open Label, Post-Market, Observational Elkind, Randolph Marshall, Jose Gutierrez 1:48 p.m. S50.005 Study to evaluate the use of sTMS in Serum and CSF Neurofilament Light Levels reduction of Migraine Headache (ESPOUSE 1:48 p.m. S51.005 Predict Long-Term Outcomes in Multiple Study)  —Amaal Starling, Stewart Tepper, Leukocyte response in ischemic stroke is Sclerosis Patients  —Jens Kuhle, Tatiana Michael Marmura, Ejaz Shamim, Matthew regulated by let7i microRNA  —Glen Jickling, Plavina, Christian Barro, Dipen Sangurdekar, Robbins, Nada Hindiyeh, Andrew Charles, Bradley Ander, Natasha Shroff, Boryana Carol Singh, Carl DeMoor, Bob Engle, Elizabeth Peter Goadsby, Richard Lipton, Stephen Stamova, DaZhi Liu, Frank Sharp Fisher, Ludwig Kappos, Richard Rudick, Jaya Silberstein, David Dodick 2:00 p.m. S51.006 Joyal 1:48 p.m. S52.005 Associations between Parkinson Disease 2:00 p.m. S50.006 Efficacy of Zolmitriptan Nasal Spray for the and Stroke  —Benjamin Kummer, Ashley The characterisation of an inducible Treatment of Acute Migraine in Adolescents: Aaroe, Hooman Kamel, Costantino Iadecola, demyelination zebrafish model to aid the Subgroup analysis by Age  —Paul Winner, Babak Navi investigation and development of novel Robert Rubens, Nathan Rustay, Sarita Khanna, 2:12 p.m. S51.007 therapeutics in multiple sclerosis  — Heather Wray Recurrent Stroke after Silent Brain Infarction Alexander McGown, Basil Sharrack, Tennore 2:00 p.m. S52.006 in Patients with Primary Brain Tumors  — Ramesh Statin and Vitamin D for Prevention of Neal Parikh, Jaclyn Burch, Hooman Kamel, Lisa 2:12 p.m. S50.007 Migraine  —Catherine Buettner, Rony-Reuven DeAngelis, Babak Navi Fc RI (CD64) Receptors Are Widely Nir, Rami Burstein 2:24 p.m. S51.008 Expressed on CNS Neurons and Are 2:12 p.m. S52.007 Incidence of Stroke in the US Centers Required for Neuronal IgG Binding and The Effect of Psychiatric Symptoms on for AIDS Research (CFAR) Network of Uptake: Implications for Antibody-Mediated Headache-Related Disability in Migraine: Integrated Clinical Systems (CNICS) Neuronal Injury  —Suzanne Liu, Kenneth Hill, Results From the Chronic Migraine Cohort  —David Tirschwell, Felicia Chow, Kyra Blair Wood, Susan Clawson, Stacey Clardy, Epidemiology and Outcomes (CaMEO) Becker, Christina Marra, Joseph Zunt, Emily Ho, Noel Carlson, John Greenlee Study  —Richard Lipton, Min Kyung Chu, Rizwan Kalani, Andrew Huffer, Robin Nance, 2:24 p.m. S50.008 Elizabeth Seng, Michael Reed, Kristina Jessica Williams-Nguyen, Greer Burkholder, Investigating the Role of Fibrinogen and Fanning, Aubrey Manack Adams, Dawn Buse Richard Moore, William Mathews, Joseph Iron in Inflammatory Demyelination Using Eron, Daniel Drozd, Mari Kitahata, Michael 2:24 p.m. S52.008 Combined High-Resolution MRI and Saag, Heidi Crane Headache Outcomes in the Idiopathic Histopathology in marmoset Experimental Intracranial Hypertension Treatment 2:36 p.m. Discussion Autoimmune Encephalomyelitis  — Trial  —Deborah Friedman, Luis Mejico, Nathanael Lee, Seung-Kwon Ha, Nicholas Prem Subramanian, Peter Quiros, Michael Luciano, Emily Leibovitch, Jennifer Lefeuvre, McDermott Pascal Sati, Matthew Schindler, Katerina 2:36 p.m. Discussion Akassoglou, Afonso Silva, Steven Jacobson, Daniel Reich

2:36 p.m.

FRIDAY 72 2017 AAN Annual Meeting Science Program

Discussion


Friday  3:30 p.m.–5:30 p.m.

Friday  3:30 p.m.–5:30 p.m.

Friday  3:30 p.m.–5:30 p.m.

S53 General Neurology:

S54 Motor Neuron Disease and

S55 Epilepsy and Clinical

S56 Movement Disorders:

3:30 p.m.

3:30 p.m.

Mechanisms and Diagnosis in Overlapping Medical and Neurological Diseases

1:00 p.m.

S53.001

1:12 p.m.

S53.002

Decreased Ceramide in Charcot Marie Tooth 2F Mediates Mitochondrial Dysfunction  — Nicholas Schwartz, Ryan Linzer, Lina Obeid Using Artificial Intelligence to Reduce Risk of Non-Adherence in Patients on Anticoagulation Therapy  —Daniel Labovitz, Laura Shafner, Deepti Virmani, Adam Hanina

1:24 p.m.

S53.003

Approach towards an ALS-specific structural marker of motor tract integrity for the description of different ALS progression types using diffusion-weighted imaging  — Anna Maria Wirth, Andrei Khomenko, Dobri Baldaranov, Siw Johannesen, Ines Kobor, TimHenrik Bruun, Mark William Greenlee, Michael Deppe, Ulrich Bogdahn

1:36 p.m.

S53.004

1:48 p.m.

S53.005

Synthetic Cannabinoids / K2 :Recognizing the neurotoxicity of a legal but potentially lethal substance of abuse  —Ali Sheharyar, Dilip Kumar Jayaraman, Aparna Prabhu, David Roby A Proposed Mechanism of Neuronal Injury in Pilots and Aircrew Personnel with Hypobaric Exposure  —Michael Hossack, John Sladky, Stephen McGuire

2:00 p.m.

S53.006

Visual Disturbances in a Case of Tentorium Hypoplasia Associated with Migrational Abnormality  —Christeena Kurian, Adil Iqbal, Charlotte Zisman, Yankai Sun, Michael Tenner, Hasit Mehta, Shalabh Bobra, Brij AhluwaliaSingh, Anila Thomas

2:12 p.m.

S53.007

Examining the Spectrum of Reversibles: RCVS and PRES at Mayo Clinic Arizona  — Kristen Steenerson, Ashley Pena, Amaal Starling, Brent Goodman, M’hamed Temkit, Cumara O’Carroll

2:24 p.m.

S53.008

Neurite Orientation Dispersion and Density Imaging (NODDI) highlights axonal degeneration of the motor tracts as the core feature underlying Amyotrophic Lateral Sclerosis.  —Rebecca Broad, Matthew Gabel, Nicholas Dowell, Hui Zhang, Daniel C. Alexander, Mara Cercignani, Peter Leigh

2:36 p.m.

Discussion

Myopathies

S54.001

Quantitative ultrasound reveals the impact of corticosteroids on skeletal muscle  — Maria Martucci, Courtney McIlduff, Joo Yeon Nam, Carmen Shin, Kester Phillips, Penny Greenstein, Erik Uhlmann, Eric Wong, Seward Rutkove

3:42 p.m.

S54.002

RNA-seq for the diagnosis of inherited myopathies: a pilot study  —Stefan Nicolau, Martine Tetreault, Karine Choquet, Yi-Hong Shao, Erin O’Ferrall, Eric Bareke, Jacek Majewski, Bernard Brais, Jason Karamchandani

3:54 p.m.

S54.003

4:06 p.m.

S54.004

Spread of pathogenic and non-pathogenic cytosolic proteins between motor neurons in chimeric mice  —Eleanor Thomas, Wayne Fenton, James McGrath, Arthur Horwich Structural organization of the brain connectome in patients with primary lateral sclerosis  —Silvia Basaia, Federica Agosta, Pilar Maria Ferraro, Nilo Riva, Sebastiano Galantucci, Yuri Falzone, Adriano Chio, Andrea Falini, Giancarlo Comi, Massimo Filippi

4:18 p.m.

S54.005

Connexin 43 affects disease progression and motor neuron toxicity in Amyotrophic Lateral Sclerosis  —Akshata Almad, Connor Welsh, Aneesh Patankar, Jean-Yves Richard, Yuqing Huo, Sarah Gross, Nicholas Maragakis

4:30 p.m.

S54.006

4:42 p.m.

S54.007

Amyloid Myopathy With and Without Systemic Amyloidosis  —Teerin Liewluck, Margherita Milone Myopalladin recessive mutations cause congenital cap myopathy  —Edoardo Malfatti, XaviËre Lornage*, Chrystel Cheraud, Raphael Schneider, Valerie Biancalana, Jaime Stretz, Matteo Garibaldi, Bruno Eymard, Michel Fardeau, Anne Boland, Jean-FranÁois Deleuze, Julie Thompson, Johann Bohm, Norma Romero, Jocelyn Laporte

4:54 p.m.

S54.008

Development of the UK Hereditary Spastic Paraplegia registry: analysis of SPAST patients reveals high rate of psychiatric comorbidities  —Viorica Chelban, Arianna Tucci, Henry Houlden, Nicholas Wood

5:06 p.m.

Discussion

Neurophysiology (EEG) III S55.001

Interictal network synchrony and local heterogeneity predict seizure relief following pediatric epilepsy surgery  — Samuel Tomlinson, Eric Marsh, Brenda Porter

3:42 p.m.

S55.002

3:54 p.m.

S55.003

Chronic Ambulatory Human ECoG as a Tool to Assess Response to Antiepileptic Medications  —Tara Crowder Skarpaas, Sharanya Desai, Thomas Tcheng, Martha Morrell Improving Quality of Life in Epilepsy: Replication and Generalizability of an Epilepsy Self-Management and Cognitive Training Program (HOBSCOTCH)  —Nicholas Streltzov, Samantha Schimdt, Wenyan Zhao, Robert Roth, Karen Secore, Lindsay Schommer, Kimberly Birney, Paul Jarvis, Heidi Henninger, Felicia Chu, Keith Nagle, Barbara Jobst

4:06 p.m.

S55.004

4:18 p.m.

S55.005

The Sabril Registry After 7 Years: Patient Characteristics and Vision Loss  —Robert Sergott, Rod Foroozan, R Faught, W Shields, Adam Ziemann, Feisal Othman, Salma Sayeed, Yekaterina Dribinsky Pharmacokinetics of Midazolam Nasal Spray in Pediatric Subjects with Epilepsy  —Al Berg, Lindy Bancke, Barbara Kapelan, TzeChiang Meng, Cindy Moe, Peter Van Ess

4:30 p.m.

S55.006

4:42 p.m.

S55.007

7T MRS in findings in focal epilepsy related to common malformations of cortical development  —Robert Knowlton, Yee-Leng Tan, Hosung Kim, Christopher Hess, Yan Li Neuroinflammation in epilepsy: an analysis of patients’ sera and its effect on microglialike cells  —Rani Sarkis, Marta Olah, Nichelle Llewellyn, Thomas Buttrick, Katie Ryan, Philip De Jager, Page Pennell, Elizabeth Bradshaw, Wassim Elyaman

4:54 p.m.

S55.008

Thirty-day readmission rate, cost, causes and predictors for Convulsive Status Epilepticus  —Smit Patel, Rupak Desai, Uvesh Mansuri, Chankrit Sethi, Tapan Mehta

5:06 p.m.

Discussion

Huntington’s Disease and Drug-induced Dyskinesias

3:30 p.m.

S56.001

3:42 p.m.

S56.002

3:54 p.m.

S56.003

4:06 p.m.

S56.004

4:18 p.m.

S56.005

4:30 p.m.

S56.006

4:42 p.m.

S56.007

4:54 p.m.

S56.008

5:06 p.m.

Discussion

Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntington’s Disease  —Meena M, Lori Zboray, Nenad Svrzikapa, Alex Mas Monteys, Susovan Mohapatra, Pallavi Lonkar, Anna Sokolovsk, Hailin Yang, Naoki Iwamoto, David Butler, Keith Bowman, Stephany Standley, Mamoru Shimizu, Maria Frank-Kamenetsky, Chris Francis, Beverly Davidson, Chandra Vargeese Huntingtin As a Scaffold for Selective Macroautophagy  —Erin Furr-Stimming, YanNing Rui, Zehn Xu, Bindi Patel, Zhihua Chen, Dongsheng Chen, Hugo Bellen, Antonio Tito, Gabriela David, Yamin Sun, Ana Maria Cuervo, Sheng Zhang Pooled Analysis of Phase 3 studies of ADS5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results  —Rajesh Pahwa, Caroline Tanner, Robert Hauser, Stuart Isaacson, Reed Johnson, Larissa Felt, Mary Jean Stempien Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD)  —Hubert Fernandez, Robert Hauser, Mat Davis, Stewart Factor, Jouko Isojarvi, Joohi Jimenez-Shahed, William Ondo, David Stamler, Karen E. Anderson Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)  — Stewart Factor, Cynthia Comella, Christoph Correll, Grace Liang, Joshua Burke, Christopher O’Brien Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities  —Karen E. Anderson, Stewart Factor, Mat Davis, Robert Hauser, Jouko Isojarvi, Joohi Jimenez-Shahed, David Stamler, William Ondo, Hubert Fernandez Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD)  —Karen E. Anderson, David Stamler, Mat Davis, Stewart Factor, Robert Hauser, Jouko Isojarvi, Joohi Jimenez-Shahed, William Ondo, Hubert Fernandez

Fast and easy registration · AAN.com/view/AM17 73

FRIDAY

Safety of OnabotulinumtoxinA Treatment With Concomitant Antithrombotic Therapy in Patients With Post-stroke Spasticity: A Pooled Analysis of Randomized, DoubleBlind Studies  —Rozalina Dimitrova, Lynn James, Chengcheng Liu, Amelia Orejudos, Irina Yushmanova, Mitchell Brin

Scientific Platform Sessions

Friday  1:00 p.m.–3:00 p.m.


Section Topic Controversies A lively format with AAN Sections debating controversies related to specific section topics and featuring two speakers arguing a side of the topic, followed by a rebuttal and question-and-answer period.

Section Topic Controversies: Stem Cells for Treatment of Neurological Diseases: The Ecstasy and the Agony Tuesday, April 25  3:30 p.m.– 5:00 p.m. 3:30 p.m.–4:00 p.m. Evidence Supporting Stem Cell Treatment Michael K. Racke, MD

4:30 p.m.–5:00 p.m. Questions and Answers Faculty

4:00 p.m.–4:30 p.m. The Devilish Details, Challenges, and Uncertainties Jeffrey Cohen, MD

Section Topic Controversies: Neurologists Should Take a Position Regarding the Cost of Neurological Treatments 

Wednesday, April 26 1:00 p.m.–2:30 p.m. 1:00 p.m. – 1:30 p.m. Neurologists Should More Vocally Protest Some of the Marked Price Increases Involving Neurological Treatments Dennis N. Bourdette, MD, FAAN

2:00 p.m.–2:30 p.m. Panel Discussion: The Most Productive Ways for AAN Members to Work for the Benefit of our Patients Faculty

1:30 p.m.–2:00 p.m. Neurologists Should Influence Policies that Allow Companies to Commit MORE Resources to R&D for Neurological Diseases While Not Allowing for Rapacious Pricing Practices Dennis W. Choi, MD, PhD

Section Topic Controversies: Chemo Brain: Neuro-cognitive Impact of Anti-cancer Therapies Thursday, April 27 1:00 p.m.–3:00 p.m. 1:00 p.m.–1:30 p.m. Current Mechanisms and Basic Science of "Chemobrain"—Facts or Fiction? Jorg Dietrich, MD, PhD

2:00 p.m.–2:30 p.m. Neurocognitive Evaluation of Cancer Patients: Current Concepts, Challenges, and Pitfalls Mike Parsons, PhD

1:30 p.m.–2:00 p.m. Neurotoxicity from Cancer Therapy: Lessons Learned from Neuroimaging Josh Klein, MD, PhD

2:30 p.m.–3:00 p.m. Questions and Answers, and Round Table Discussions Faculty

74 2017 AAN Annual Meeting Scientific Program


Industry Therapeutic Updates Saturday, April 22, Tuesday, April 25, and Wednesday, April 26 Starting at 7:00 p.m. Registration is free and open to registered Annual Meeting attendees. Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you the opportunity to learn about current therapies and projects in the industry pipeline.

Saturday, April 22, 2017 Amgen Unmet Needs in Migraine: Can New Insights Help to Bridge the Gap? Location: Renaissance Boston Waterfront Pacific Grand Ballrooms ABCD

Biogen Location: Westin Boston Waterfront Grand Ballroom

Tuesday, April 25, 2017 AbbVie, Inc. Addressing Motor Fluctuations in Advanced Parkinson’s Disease: A Patient and HCP Perspective

Location: Westin Boston Waterfront Ballroom A

ACADIA Pharmaceuticals Inc.

Location: Westin Boston Waterfront Ballroom CDE

Arbor Pharmaceuticals

Location: Westin Boston Waterfront Ballroom B

Biogen

Location: Renaissance Boston Waterfront Pacific Grand Ballroom

Neurocrine Biosciences Tardive Dyskinesia Presentation and Management: A Case-based Approach

Genentech

Location: ALOFT Boston Seaport Mann Ballroom 1 & 2

Lilly USA, LLC

Novartis Pharma AG Industry Therapeutic Update in Multiple Sclerosis from Novartis Pharma AG

Location: Westin Boston Waterfront Marina Ballroom Location: Westin Boston Waterfront Commonwealth Ballroom

MT Pharma America

Location: Westin Boston Waterfront Harborfront Ballroom 1

Location: Seaport Hotel Plaza Ballroom

Sunovion Pharmaceuticals Inc. An Interactive Live Panel Event Location: Westin Boston Waterfront Harborfront Ballroom 2 & 3

Wednesday, April 26, 2017 Lilly USA, LLC Location: Seaport Hotel Plaza Ballroom

Sanofi Genzyme Understanding Functional Improvement in the RMS Patient: Is There Evidence of Neuropreservation and Repair? Location: Westin Boston Waterfront Grand Ballroom

RSVP is recommended for these events. Please visit AAN.com/view/ITU for more information. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.


Poster Discussion Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The following boards will be presented in the order listed below.

104 12:00 p.m.–12:05 p.m. 105 12:05 p.m.–12:10 p.m. 106 12:10 p.m.–12:15 p.m.

Tuesday, April 25 8:30 a.m.–7:00 p.m.

Poster Session III See page 98 » Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

Wednesday, April 26 8:30 a.m.–7:00 p.m.

Poster Session IV See page 108 » Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

Thursday, April 27 8:30 a.m.–7:00 p.m. Poster Session V See page 118 » Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

Friday, April 28

8:30 a.m.–5:30 p.m. Poster Session VI See page 128 » Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

76 2017 AAN Annual Meeting Science Program

E

C D

96 95

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

G F

98 97 93 94 88 87

Poster Session II See page 88 »

111 112 113 114

8:30 a.m.–7:00 p.m.

118 117 116 115

Monday, April 24

119 120 121 122 123 124

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

130 129 128 127 126 125

Poster Session I See page 78 »

131 132 133 134 135 136 137

8:30 a.m.–5:30 p.m.

109 12:25 p.m.–12:30 p.m. 110 12:30 p.m.–12:35 p.m.

161 148 223 240 160 162 149 241 250 147 159 163 224 239 146 150 158 164 242 249 225 238 178 145 151 157 165 243 248 152 179 226 237 156 166 176177180 244 247 155 167 175 181 227 236 246 235 245 154 168 174 182 193 228 153 169 173 183 192 194 229 234 170 195 191 172 184 230 233 190 196 171 185 206 232 197 189 186 205 207 231 198 107 188 208 108 106 204 187 199 203 209 217 109 200 202 210 216 218 110 201 211 215 219 212 214 220 251 213 221 256 252 222 253 257 255 105 254 258 104 266 267 265 259260 103 102 282 268 264263 261 269 101 283 281 270 262 280 284 302 279 271 76 63 301 285 278 272 43 77 75 303 62 64 300 286 42 277 273 44 78 74 304 328 65 61 299 287 41 276 274 45 79 73 305 327 60 66 298 288 40 275 46 80 72 306 326 59 297 289 71 47 39 307 325 290 329 48 38 324 308 296295 291 358 330 67 37 323 309 357 331 292 68 58 359 322 310 294293 356 57 332 69 386 360 321 311 70 56 50 49 36 385 361 355354 333 320 312 55 387 334 384 362 319 313 51 35 353 412 388 335 383 363 318 314 52 34 352 411 389 382 364 317 315 53 33 410 390 381 365 316 54 32 409 336 391 336 380 31 408 392 351 337 337 16 15 407 393 350 338 338 366 406 349 339 339 17 14 379 367 348 340 340 378 368 18 13 347 341 341 394 405 395 377376 369 346 342 342 54 27 26 19 12 370 404 396 345 343 343 375 63 28 25 20 11 371 403 397 344 374 372 72 29 24 402 398 21 10 401 399 373 81 30 23 22 9 400

4 14 3 14 142 141 0 14 139 138

Sunday, April 23

107 12:15 p.m.–12:20 p.m. 108 12:20 p.m.–12:25 p.m.

99 92 89 86 83 82

101 11:45 a.m.–11:50 a.m. 102 11:50 a.m.–11:55 a.m. 103 11:55 a.m.–12:00 p.m.

100 91 90 85 84 81

Poster Sessions

Poster Sessions Floorplan and Schedule

B

A

H

I


Visit the neighborhood! No more long aisles or rows—we are clustering topic-related posters together into “neighborhoods” to enhance your discussions and make the posters easier to navigate. Please see floor plan on page 76 ». Check out the interactive, touchscreen e-posters at the virtual hall kiosk for another great opportunity to view scientific posters. And if you can’t get enough cutting-edge science, join the quick lunchtime Poster Discussion Session! A group of 10 abstracts will be presented as both a data blitz and a poster with a moderator leading stimulating discussion on the content of the selected posters.

Fast and easy registration · AAN.com/view/AM17 77

Poster Sessions

Posters


Poster Sessions

Poster Session I



PARKINSON’S DISEASE: BIOMARKERS AND GENETICS

Patients —Mahsa Dolatshahi, Seyyed

P1.001 Genome-wide Association for

P1.012 Lewy Body and Tau pathology

the Park10 Locus in Iopathic, Autopsyproven, Lewy Body Parkinson Disease and Autopsy-Proven Controls —Jeffery

Vance, Karen Nuytemans, Lissette Gomez, William Scott, Gary Beecham, Djordje Gveric, Eden Martin, APDGC Consortium

P1.002 Genetic analysis of the

Glucocerebrosidase gene in Indian patients with Parkinson’s disease —Ravi YADAV, Saketh Kapoor, Mayank Madhukar, Rajini Manja, Pramod Pal, Arun Kumar

P1.003 Interplay Between LRRK2 Action in Neurons and Macrophages in Mediating α-Synuclein linked Neurodegeneration —Hisham

Abdelmotilib, Andrew West, Laura VolpicelliDaly, Ashley Harms

Shayan PourMirbabaei, Mehdi Yaseri, Aida Kamalian, Mohammad Hadi Aarabi

in a patient with parkinsonism, cognitive decline, rapid progression and the GBA1 T369M variant —Hannah Walters, Rachel Saunders-Pullman, John Crary, Deborah Raymond, Susan Bressman

Thomas Beach, Tatiana Foroud, Charles Adler, Holly Riss, Dixie Ecklund, Chelsea CaspellGarcia, Kuldip Dave, Sampada Deshpande, Shirley Lasch, Vanessa Arnedo, Lindsey Riley, Danna Jennings, Brit Mollenhauer, Lama Chahine

Houghton

P1.005 Baseline Cerebrospinal Fluid

P1.015 Neurons with oscillatory

Biomarkers Associated with Longitudinal Cognitive and Functional Decline in Early Parkinson’s Disease —Olga Kofman, David

activity in the basal ganglia and the ventral thalamus in patients with Parkinson’s disease —Ping Zhuang, Mark

Wolk, Corey McMillan

Hallett, Gang Du, Yuqing Zhang, Yongjie Li

P1.006 Elevated GM3 Plasma

P1.016 Objective gait parameters as

Chan, Adler Perotte, Bowen Zhou, Christopher Liong, Evan Shorr, Karen Marder, Un Kang, Cheryl Waters, Oren Levy, Yimeng Xu, Hong Bin Shim, Itsik Pe’er, Gilbert Di Paolo

Tuhin Virmani

SUNDAY

and Plasma-Based miRNA Levels in Parkinson’s disease Patients —Dominic

Facciponte, Jackson Storm, Haley Grigel, Jacob Rauh, Patricia Henegan, Angeline Andrew, Mary Feldman, Stephen Lee, Elijah Stommel

P1.008 Functional MAOB gene

intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson’s disease —Matthias Lohle, Graziella Mangone, Martin Wolz, Bettina Beuthien-Baumann, Liane Oehme, Jorg Van Den Hoff, Jorg Kotzerke, Heinz Reichmann, Jean Christophe Corvol, Alexander Storch

P1.009 Serum Oxidant and

Antioxidant Status of Patients with Parkinson’s Disease —Mustafa Yurtdas,

Tahir Kurtulus Yoldas, Burcu Gokce Cokal, Nalan Gunes, Zahide Esra Durak, Selda Keskin Guler, Bilal Aytac, Ilker Durak, Mehmet Ilker Yon, Aysegul Akyuz, Ufuk Atak Donger

P1.010 Enteric neurons reveal

substantial ex vivo mitochondrial changes in Parkinson’s disease —

Paul Antony, Aidos Baumuratov, Marek Ostaszewski, Feng He, Luis Salamanca, Laurent Antunes, Jos Weber, Laura Longhino, Pascal Derkinderen, Rudi Balling, Werner Koopman, Nico Diederich

P1.011 An Exploratory Study of

Associations Between longitudinal Changes of different CSF Biomarkers in Early, Drug-naïve Parkinson’s Disease

P1.145–222

G

P1.223–250

D

P1.101–110

Poster Discussion

C

P1.081–100

P1.014 Comparison of quantitative

Theresa Bartels, Susan Lindquist

P1.007 Environmental Risk Factors

F

E

P1.111–144

Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) —Carly Linder, Christopher Coffey,

measures of Pupil Light Reflex measured using Automated Pupillometer in patients with Parkinson’s disease and controls —Robin Ulep, Fawad Khan, David

Concentration in Parkinson’s Disease: a Lipidomics Analysis —Roy Alcalay, Robin

Poster Session I Neighborhoods

P1.013 Feasibility and Safety of

Networks Mechanistically Link Alphasynuclein to Diverse Genetic Risk Factors for Parkinsonism —Vikram Khurana,

P1.004 Proteome-scale Molecular

Sunday, April 23  8:30 a.m.—5:30 p.m.

H

B

P1.251–328

P1.031–070 ePosters

P1.071–080

I

P1.329–412

a noninvasive biomarker for freezing of gait in Parkinson disease —Jesal Shah,

PARKINSON’S DISEASE: THERAPEUTICS AND TELEHEALTH I

P1.017 Efficacy of sublingual

apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase —Robert Hauser, Stuart Isaacson,

Alberto Espay, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Hubert Fernandez

P1.018 Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease —

Christopher Goetz, Glenn Stebbins, Kathryn Chung, Anthony Nicholas, Robert Hauser, Mark Stacy, Kathleen Shannon

A

P1.001–030 A: Movement Disorders B: Research Methodology and Education; Practice, Policy, and Ethics; Movement Disorders ePosters C: Aging and Dementia D: Movement Disorders Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: General Neurology; Neuro-oncology; Headache; Pain and Palliative Care G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease I: MS and CNS Inflammatory Disease

P1.019 Identification of the Carbidopa Concentration in Subcutaneously Administered ND0612 (Levodopa/ Carbidopa) that Provides Optimal Levodopa Bioavailability —Liat Adar, Tami Rachmilewitz, Sheila Oren

P1.020 Duration of “on” periods after treatment with extended-release vs. immediate-release carbidopa-levodopa in patients with advanced Parkinson’s disease —William Ondo, Margery Mark, Nishit Modi, Sarita Khanna, Suneel Gupta

P1.021 Pooled Analysis of Phase

3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of PD Home Diary Results —Caroline Tanner,

78 2017 AAN Annual Meeting Scientific Program

Rajesh Pahwa, Robert Hauser, Stuart Isaacson, Reed Johnson, Larissa Felt, Mary Jean Stempien

Isaacson, Alberto Espay, Rajesh Pahwa, Daniel Truong, Eric Pappert, Peter Gardzinski, Bruce Dzyngel, Albert Agro, Robert Hauser

P1.022 Rotigotine transdermal

P1.024 Effect of levodopa-carbidopa

Kawabe, Takanori Takazawa, Takehisa Hirayama, Masaru Yanagihashi, Ken Miura, Yuichi Ishikawa, Junya Ebina, Maya Kyuzen, Tetsuro Nagaoka, Masahiro Sawada, Sayori Hanashiro, Harumi Morioka, Yasuo Iwasaki

Poewe, David Standaert, Cindy Zadikoff, Stephanie Dubow, Lars Bergmann, Ashley Yegin, Coleen Hall, Vanessa Felipe, Weining Robieson, Luigi Barbato

patch attenuates freezing of gait during wearing off in patients with Parkinson’s disease —Ken Ikeda, Osamu Kano, Kiyokazu

P1.023 Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL130277) in patient with Parkinson’s disease —Hubert Fernandez, Stuart

intestinal gel on dyskinesia: design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients —Angelo Antonini, Werner

P1.025 ND0612—a Newly

Developed Liquid Levodopa/Carbidopa Formulation Administered Continuously Subcutaneously by a Mini-pump—


Patient Use Perspective —Sophie Nash,

P1.037 Physician Retention in the

P1.026 Safety and efficacy

J Koehler, Jaclyn Goodfellow, Alan T Davis, John VanSchagen, Lori Schuh

Moran Gera, Eran Shor, Tamar Rahmilevich, Sheila Oren

of pardoprunox for patients with Parkinson’s disease: A meta-analysis —

Ahmed Abdou Negida, Doaa Attia, Nada Elsagheer, Hussien Ahmed, Attia Attia, Kamal Awad, Eslam Ezzat, Mohamed Abd Elalem Aziz

P1.027 Dosing and efficacy of

extended-release carbidopa-levodopa in advanced Parkinson’s disease patients with or without concomitant medication use —Suneel Gupta, Sarita Khanna, Sherron Kell, Robert Rubens

P1.028 Effects of age and disease

duration on quality of life outcomes in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusions: a post-hoc analysis from the GLORIA registry — Angelo Antonini, Weining Robieson, Lars Bergmann, Ashley Yegin, Werner Poewe

P1.029 Clinical Experience with

Outpatient Initiation of Carbidopa/ Levodopa Enteral Suspension in Parkinson’s Disease Patients in the Medication ON State —Phaedra Dowell, Kelly Lyons, John Alley, Rajesh Pahwa

P1.030 Effect of “Off” Time on

the Recommended Starting Dose for Rytary —Nishit Modi, Sarita Khanna, Suneel Gupta

P1.038 The Status of Multiple

P1.049 The Child Neurology and

Neurodevelopmental Disabilities Trainee-as-Teacher: Tailoring a Clinical Teaching Curriculum to Specialty Trainees’ Needs and Developmental Roles —Miya Bernson-Leung, David Urion

Welch, Rolando Brual, Christina Gallo, Andrew Grzybowski

Goldschmidt, Jorge Ortiz-Garcia, Michael Doerrler, Lauren Ottenhoff, Michael Schneck, Matthew McCoyd

P1.051 Fatigue and sleep deprivation

P1.061 Outcome of a model for

Fiorella Adrianzen Alvarez, Kevin R. Duque, Darwin Vizcarra, German Malaga Rodriguez, Etbert Pizarro Salas, Daniel Cordova Ccasa

Campbell, Steven Moore

for Remote Resident Supervision and Evaluation —Joseph Carrera, Nicole Chiota-

McCollum, Sneha Mantri, William Clark, Connor Wang, Valerie Odell, Jimmy Berthaud, Brian Gunnell, Timothy McMurry, Bradford Worrall, Andrew Southerland

P1.040 Early Career Neurologists’

Feedback About the Primary Care and Psychiatry Components of Residency Training —Laurie Gutmann, Harold Adams, Sarah O’Shea, Dorthea Juul, Larry Faulkner

P1.041 Neurology Training for

Psychiatric Residents: A Narrative Review —Daniel Shalev, Nuri Jacoby

P1.042 Intensive Training can lead to significant improvement in resident EEG skills —Anand Venkatraman, Nilay Kumar

P1.043 Impact of Live Patient Didactic Conference on Neurology Resident Outpatient Education —Christopher Doughty, Tracey Milligan, Tracey Cho

P1.044 Impact of epilepsy curriculum

redesign and milestone self-assessment in neurology residency —Heidi Munger

in interns of medicine and its burden in vehicle driving —Brian Villafuerte Trisolini,

UNDERGRADUATE MEDICAL EDUCATION RESEARCH

P1.052 Numerical vs Narrative:

a comparison between methods to measure student clerkship performance —Josef Bartels, Christopher Mooney, Robert Thompson-Stone

P1.053 An integrated emergency

department based neurology curriculum for medical students: design, implementation, and results —David Lin, Stacy Tyman, Rebecca Lueders, Tracey Cho

P1.054 Neurology Clerkship Students’ Perceptions of Assessment for Learning Using Frequent Mini-CEXs —Justin

P1.045 Non-Neurologist Self

P1.032 Inter-Provider Communication

Assessment of Emergency Neurology Proficiency and Interest in a Novel Intensive Stroke and Neurocritical Care Training Program: The X-CHANGE Program —Alan Yee, Michael Ke, Christine

P1.055 Precision Education in

Wong, Nobl Barazangi, David Tong, Charlene Chen

P1.046 Published Coma Simulation

Neurology: The impact of student learning preference on predicting knowledge, skills, and satisfaction by type of learning environment in neurology —Irene Vargas, Deanna Saylor,

Tiana Cruz, Veronique Gugliucciello, Jaqueline Nunn, Rachel Marie Salas, Charlene Gamaldo, Roy Strowd

had Face Validity in allowing trainees to demonstrate Neurology Residency Milestones and AAMC Entrustable Professional Activities —Diana Barratt,

P1.056 Compassionate Neurological

Sheryl Strasser

Anukrati Shukla, Penny McQueen, Syeda Alqadri, Raghav Govindarajan

P1.034 The Accreditation and

P1.047 Creation of a diversity

P1.057 Brain death determination:

Gutmann, Larry Faulkner

Saadi, Kathleen McKee, Grace Crotty, Sophia Ryan, Luis Gonzalez Castro, Tracey Cho, Sashank Prasad, Nicte Mejia, Jennifer Lyons

P1.033 A Teleneurology Curriculum: Applications, Evidence, and Practice for Neurology Residents —Nicole

Chiota-McCollum, Andrew Southerland, Nina Solenski

Certification of the Movement Disorders Subspecialty —Sarah O’Shea, Laurie

P1.035 A Four Part Communication

Skills Training Curriculum for Neurology Residents —Michael Lyerly, Lucas McElwain, Michael Barnett

P1.036 Peer observation and

feedback of resident teaching during neurology rounds —David Lin, Stacy Tyman,

P1.060 Simulation-based training in

P1.039 Feasibility of Google Glass

Jassam, Rachelle Ramirez, June Halper

Collaborating to Address Local Caregiver and Patient Needs in National CME Programming —Matthew Frese, Lauren

Clary

Kasner, Raymond Price

Gabriel Moreno, Katherine Park, Derek Holder, Benjamin Koo, Roy Poblete

P1.050 The Power of Partnerships:

P1.031 Recognizing the Deficits in

Using a Scheduled Provider AlertResponse Communication System (SPARCS) in 3 Inpatient Neurology Units —James Siegler, Daniel Finegan, Scott

Education in Acute Neurologic Emergencies —Mustfa Ansari, Dionne Swor,

Sclerosis and Neuroimmunology Fellowship Training in the United States: A Pilot Study —Ahmed Obeidat, Yasir

Mowchun, Mary Feldman, Glenda Hostetter Shoop

Neurology Residents’ Neurophysiology Knowledge: Results from a National Survey —Kate Daniello, Daniel Weber

P1.059 Simulation-Based Medical

and inclusion certificate program for neurology residents —Anna Bank, Altaf

P1.048 Bad News or Life Altering

Diagnoses? Neurology Residents’ Attitudes towards Disclosing Diagnoses —Janis Miyasaki, Catherine Bell,

Care OSCE-A Primer for Teaching Patient Centered Care in Neurology Clerkship —

Addressing the Concept at the Medical Student Level to Ensure Competency and Consistency in Practice —Sheryl Strasser, Diana Barratt

P1.058 Redesigning the Student

Interest Group in Neurology (SIGN) Chapters —Amal Al-Lozi, Angie Richmond, Penny McQueen, Syeda Alqadri, Raghav Govindarajan

brain death determination incorporating family discussion: An update on an ongoing project —Preston Douglas, Carolyn

medical student engagement in child neurology —Katherine Mathews, Kevin

P1.062 Impact of Review Sessions

on NBME Subject Examination Performance —Suma Das, Karissa Gable, Vern Juel

P1.063 Moving the Neurology

Clerkship to the Third Year: A Survey of Medical Students —Michelle Caunca, Damianie Montero, Yolanda Reyes-Iglesias

P1.064 Utility of an Emergency

Neurologic Life Support- based simulation course for First Year Neurology resident independent call readiness: A Quality Improvement Project —Ferhad Bashir, Anna Lerant,

Michael Holder, Jeffrey Orledge, Christa San Luis

PRACTICE, POLICY, AND ETHICS I

P1.065 Resident-driven protocol for improving admissions to the Epilepsy Monitoring Unit —Kate Essad, Barbara Jobst, Krzysztof Bujarski

P1.066 Length of stay for stroke

patients to a primary stroke center is dependent on the day of admission — Davida Goltz, Claire Carrazco, Saeyoan Thirunavukkarasu, Jeffrey Katz, Richard Libman, Paul Wright

P1.067 Derivation and Validation of a Proposed Long Length of Stay (≥ 7 days) Score in Patients Hospitalized for Acute Ischemic Stroke —Sadiqa Mahmood, Syed Ali, Muhammad Ahmed Chauhan, Nicolas Bianchi, Aneesh Singhal, Lee Schwamm

P1.068 Using Root Cause Analysis to

Improve Patient Safety in the Outpatient Neurology Setting —Ramesh Cherukuri, Vishal Shah, Shahram Izadyar, Deborah Bradshaw, Amy Sanders

P1.069 NA P1.070 NA

Carol Hodgson

Rebecca Lueders, Tracey Cho

Fast and easy registration · AAN.com/view/AM17 79

SUNDAY

GRADUATE MEDICAL EDUCATION RESEARCH

Same State as Residency Training: Data From 1 Michigan GME Institution —Tracy

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session I



Sunday, April 23  8:30 a.m.—5:30 p.m.

Movement Disorders ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P1.071 Evaluation of dynamic gait

stability after a single-session of waistpull perturbation training in Parkinson’s disease using an Active Tethered Pelvic Assist Device (A-TPAD). —Lan Luo, Dario

Martelli, Un Kang, Stanley Fahn, Sunil Agrawal

P1.072 Altered small world brain

connectivity in patients with Primary Writing Tremor: A graph theory approach —Abhishek Lenka, Ketan

Jhunjhunwala, Rajanikant Panda, Jitender Saini, Ravi YADAV, Rose Dawn Bharath, Pramod Pal

AGING AND DEMENTIA: GENETIC STUDIES

P1.081 Clinical Application of Next

P1.073 Whole Genome Sequencing and Rare Variant Analysis in Essential Tremor Families —Lorraine Clark, Zagaa

Odgerel, Nora Hernandez, Ruth Ottman, Elan Louis

P1.074 Steroid-responsive

encephalopathy with associated thyroiditis (SREAT) presenting with pure cerebellar ataxia —Pichet Termsarasab,

P1.075 Sensory trick phenomenon

P1.077 Severe Dystonia as

Stefano Amadio, Butera Calogera, Francesca

Daniel Savitt, Mered Parnes

in cervical dystonia: a functional MRI study —Elisabetta Sarasso, Federica Agosta,

Roeland Crols, Peter De Deyn, Julie Van Der Zee, Marc Cruts, Sebastiaan Engelborghs, Christine Van Broeckhoven

P1.082 Gertsmann syndrome and

Enayetallah, Carlos Cruchaga, Aaron DayWilliams, The Alzheimer’s Dise (ADNI)

SUNDAY

Beldarrain, Esther Sarasola, Alberto Rabano, Juan Carlos Garcia-Monco Carra

P1.083 Metagenomic Analysis

of Neural Tissue in patients with Alzheimer’s Disease and Amyotrophic Lateral Sclerosis —Kristin Keith, Terence Mitchell

P1.084 APOE E4 is a lesser

risk factor for frontotemporal than amnestic dementia with Alzheimer’s neuropathology —Letizia Borges, Alfred

Rademaker, Eileen Bigio, M. Mesulam, Sandra Weintraub

P1.085 Comprehensive phenotypic description of the Belgian GRN founder family and genetic onset age modifiers —Sara Van Mossevelde, Eline

Wauters, Anne Sieben, Kristel Sleegers, Ilse Gijselinck, Stephanie Philtjens, Tim Van Langenhove, Mathieu Vandenbulcke, Patrick Cras, Patrick Santens, Jan De Bleecker, Rik Vandenberghe, Adrian Ivanoiu, Jan Versijpt,

Sensitive MRI Measures Detect Parkinson’s Disease Effects in Catecholamine Nuclei: Discovery and Validation in Separate Cohorts —Daniel Huddleston, Jason Langley, Rebecca McMurray, Fabiola De Louis, Stewart Factor, Xiaoping Hu

P1.086 Characterization of

ideomotor apraxia as the first symptoms of a corticobasal syndrome due to a new progranulin mutation —Marian Gomez-

P1.076 Advanced Neuromelanin

Yuvadee Pitakpatapee, Steven Frucht, Prachaya Srivanitchapoom

Generation Sequencing to Unexpected Young Onset Dementia: A Pilot Study —

Richard Caselli, Bryan Woodruff, Eric Wieben, Noralane Lindor

Bianchi, Paola Valsasina, Roberta Guerriero, Andrea Falini, Giancarlo Comi, Ubaldo Del Carro, Massimo Filippi

the underlying mechanism behind Alzheimer’s disease loci using human genetics —Karol Estrada, Ahmed

a Manifestation of West Nile Neuroinvasive Disease —Rachelle Herring,

P1.089 Whole Transcriptome

Sequencing Reveals Gene Expression Difference and Novel Non-coding RNAs in Alzheimer’s disease —Lin Tan, Jin-Tai Yu, Lan Tan

P1.090 GWAS-Linked Loci and

Neuroimaging Measures in Alzheimer’s Disease —JieQiong Li

80 2017 AAN Annual Meeting Scientific Program

Disease with Novel GFAP p.Ser385Cys Mutation —Scott Le, Michael Soileau

P1.080 Long Term Follow up of

Weight Changes in STN and GPi Deep Brain Stimulation —Syed Shah, Leonardo Almeida, Michael Okun, Aparna WagleShukla, Justin Hilliard, Kelly Foote

Enriquez Macias, Ildefonso Rodriguez-Leyva, Mariana Salgado-Bustamante, Erika Chi, Juan Carrizales-Rodriguez, Ernesto Martinez-Leija, Luis Arredondo, Maria Jimenez-Capdeville

P1.092 The extended Belgian

presenilin 1 Alzheimer family AD/A revisited. —Tobi Van Den Bossche, Peter

P1.093 Elevated cerebrospinal fluid

Kotaro Ogaki, Makoto Eriguchi, Hiroki Yamazaki, Kenichi Komatsu, Natsuki Ono, Sumihiro Kawajiri, Hiroaki Nozaki, Kensaku Kasuga, Yasuyuki Okuma, Hideo Hara, Osamu Onodera, Takeshi Ikeuchi

P1.079 Adult Onset Alexander

Der Zee, Charlotte Steger, Lotte Verwilligen, Patrick Cras, Sebastiaan Engelborghs, Christine Van Broeckhoven

Kim, Seongbeom Park, Jin San Lee, Hyemin Jang, Yeshin Kim, Ko Woon Kim, Young Kyoung Jang, Sung Tae Kim, Seonwoo Kim, Duk L. Na, Sang Won Seo, Hee Jin Kim

dominant leukodystrophy: genetic and clinical studies of three Japanese families —Naomi Mezaki, Takeshi Miura,

Mittal, Anhar Hassan, Joyce Sanchez, Carrie Robertson

P1.096 Expression of Tau and BIN1

mutation is a founder mutation in Belgium —Sara Van Mossevelde, Julie Van

De Deyn, Jean-Jacques Martin, Patrick Cras, Christine Van Broeckhoven

P1.088 LMNB1-related autosomal

Post-encephalitic Parkinsonism —Shivam

P1.091 The MAPT p.Arg406Trp

P1.087 Age modulates impact of

APOE e4 in Alzheimer’s disease —Jaeho

P1.078 Powassan virus causing

AGING AND DEMENTIA: BIOMARKERS total Tau levels reflects predominant cortical involvement in Alzheimer’s disease —Jagan Pillai, Maria Khrestian, Lynn Bekris, Jiri Safar, James Leverenz

P1.094 Diagnostic Accuracy of ELISA

and Luminex Technology (xMAP) for the Quantitation of CSF Amyloid Beta 40 and 42 Peptides to differentiate Patients with Probable Alzheimer Disease (AD) from Elderly Non-demented Controls —Pankaj Mehta, Mony DeLeon, Kaj Blenow, Warren Zigman, Henrik Zetterberg

P1.095 The BIOCARD Index: A

Summary Measure to Predict Onset of Mild Cognitive Impairment —Ned Sacktor, Anja Soldan, Maura Grega, Leonie Farrington, Qing Cai, Mei-Cheng Wang, Rebecca Gottesman, R Turner, Marilyn Albert

in the Skin of Healthy Subjects and Alzheimer’s Disease Patients —Maria

P1.097 Expression profile of Tau

protein in oral mucosa of Alzheimer’s disease patients. —Luis Arredondo,

Ildefonso Rodriguez-Leyva, Erika Chi, MarÌa Saray Aranda-Romo, Mariana SalgadoBustamante, Diana Portales-Perez, Maria Enriquez Macias, Robert Norman, Maria Jimenez-Capdeville

P1.098 EEG-based geometric

modeling and analysis of cognitive deterioration in patients with possible and probable Alzheimer’s disease —Tal

Shnitzer, Natalya Yarovinsky, Ronen Talmon, Judith Aharon-Peretz

P1.099 Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer’s disease —Kok Pin Ng,

Tharick Pascoal, Sulantha Mathotaarachchi, Chang-Oh Chung, Andrea Benedetti, Monica Shin, Min Su Kang, Xiaofeng Li, Maowen Ba, Nagaendran Kandiah, Pedro Rosa Neto, Serge Gauthier

P1.100 Factors affecting plasma Aβ levels in IHP Project and second year follow —Takumi Nakamura, Mikio Shoji


Movement Disorders Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 a.m. P1.101 Parkinson’s disease, Suicidal ideation and associated risk factors —

Data Blitz:  12:00 p.m.–12:05 p.m. P1.104 A New Composite Outcome Measure for Parkinson’s Disease —Ergun

Data Blitz:  11:50 a.m.–11:55 a.m. P1.102 Longitudinal Changes in CSF Biomarkers of Parkinson’s Disease (PD) Patients —Seyyed Shayan PourMirbabaei,

Data Blitz:  12:05 p.m.–12:10 p.m. P1.105 Oculomotor abnormalities are ubiquitous in the spinocerebellar ataxias —Christopher Stephen, Jeremy

Data Blitz:  11:55 a.m.–12:00 p.m. P1.103 Probabilistic conversion of neurosurgical DBS electrode coordinates into MNI space —Andreas Horn, Andrea

Data Blitz:  12:10 p.m.–12:15 p.m. P1.106 Genome-wide Methylation Changes in the Dorsal Motor Nucleus of the Vagus Contribute to the Risk of Parkinson Disease —Jeffery Vance,

Data Blitz:  12:20 p.m.–12:25 p.m. P1.108 DCTN1-related Neurodegeneration: Perry Syndrome and Beyond —Takuya Konno, Owen Ross,

MYOPATHIES AND MYASTHENIA GRAVIS I

P1.117 The Facioscapulohumeral

Keith Morneau, Brian Sansoucy, Amy Goldberger, Urszula Trela, Nigel Clarke, Joseph Higgins

Zahra Rezvani, Erik Barr, Ann Gruber-Baldini, Joseph Savitt, F. Rainer Von Coelln, David Glovinsky, Lisa Shulman

Mahsa Dolatshahi, Mehdi Yaseri, Aida Kamalian, Mohammad Hadi Arabi

Kuehn, Angela Merkl, Ludy Shih, Ronald Alterman, Michael Fox

P1.111 RESILIENT: A Randomized,

Amato, Umesh Badrising, Olivier Benveniste, Merrilee Needham, Hector Chinoy, Min Wu, Barbara Koumaras, Ana De Vera, Dimritris Papanicolaou, Michael Hanna

P1.112 Prolonged Compound Muscle

Action Potential Duration and Its Pathological Correlation in Critical Illness Myopathy —Bing Liao, Teerin Liewluck

P1.113 Evaluation of Therapeutic

Response Between Idiopathic Inflammatory Myopathies and Autoimmune Necrotizing Myopathies at a Tertiary Neuromuscular Center — Robert Murphy, Mazen Dimachkie, Omar Jawdat, Jeffrey Statland, Melanie Glenn, Richard Barohn, Laura Herbelin, Mamatha Pasnoor

P1.114 A case of LGMD2A caused

by a novel splice site mutation identified by RNA-seq —Stefan Nicolau, Martine Tetreault, Karine Choquet, Yi-Hong Shao, Bernard Brais, Jason Karamchandani, Erin O’Ferrall

P1.115 Challenges and Feasibility of an Investigator-Initiated Multi-site Pompe Disease Screening Study — Tahseen Mozaffar, Marie Wencel, Namita Goyal

P1.116 Childhood activity on

progression in limb girdle muscular dystrophy 2I —Brianna Brun, Shelley

Mockler, Katie Laubscher, Carrie Stephan, Julia Collison, Bridget Zimmerman, Katherine Mathews

Schmahmann

Sathesh Sivasankaran, Lily Wang, Arpit

Dystrophy Composite Outcome Measure: 1 Year Findings —Katy Eichinger, Chad Heatwole, Susanne Heininger, Alrabi Tawil, Jeffrey Statland

P1.118 Relative prevalence of limb-

girdle muscular dystrophy subtypes at the UC Irvine MDA Clinic —Tim Lai, Namita Goyal, Tahseen Mozaffar

P1.119 Development and

Implementation of Bone Health Protocol (BHP) in Duchenne Muscular Dystrophy (DMD) —Alexandra Otto, Karen Loechner, Sumit Verma

P1.120 Long-Term Efficacy of

Alglucosidase Alfa in Late-Onset Pompe Disease —Paula Clemens, Pascal Laforet, Katherine Kacena, Bernd-Jan Sanson, Robert Hopkin, Ans Van Der Ploeg

P1.121 Perioperative Management of Autoimmune Myasthenia Gravis in Patients Undergoing Thymectomy — Francis Huttinger, Lyell Jones

P1.122 A Pilot Trial of Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation: An Update on Efficacy —Grayson Beecher,

Dustin Anderson, Derrick Blackmore, Ashley Mallon, Zaeem Siddiqi

P1.123 Clinical Testing for Titin and Ryanodine Receptor Autoantibodies in Myasthenia Gravis Patients —Amy

Goldberger, Keith Mourneau, Brian Sansoucy, Nigel Clarke, Joseph Higgins

P1.124 Clinical and histopathological

findings in myotonic muscular dystrophy type 2 (DM2): retrospective review of 49 DNA-confirmed cases —Bhaskar Roy, Qian Wu, Charles Whitaker, Kevin Felice

P1.125 LRP4 Autoimmune Reactivity

in a Diverse Double-Seronegative Myasthenia Gravis Patient Population —

Data Blitz:  12:15 p.m.–12:20 p.m. P1.107 Phosphorylated alpha synuclein within cutaneous autonomic nerves of patients with Parkinson’s disease (PD)—the implications of sample thickness on results —Ningshan

Wang, Christopher Gibbons, Jenniffer Garcia, Roy Freeman

Data Blitz:  12:25 p.m.–12:30 p.m. P1.109 A novel paradigm of variable frequency deep brain stimulation to improve freezing of gait in Parkinson’s disease —Fumin Jia, Aparna Wagle Shukla, Leonardo Almeida, Wei Hu, Michael Okun, Lumin Li

Data Blitz:  12:30 p.m.–12:35 p.m. P1.110 Heart rate variability as a screening tool for Parkinson’s disease has age-dependent performance —

Michael Christiansen, Shyamal Mehta, Joseph Hentz, Thomas Beach, Geidy Serrano, Holly Shill, Erika Driver-Dunckley, Marwan Sabbagh, Kathryn Davis, J Langston, Charles Adler

Helio Afonso Teive, Mercedes Olaya, Dennis Dickson, Zbigniew Wszolek

P1.126 Analysis of infections and

the relationship to immunosuppressive treatment in autoimmune neuromuscular disorders: a series of 631 patients —

Devin Prior, Emily Nurre, Stephanie Roller, David Kline, Ramit Panara, John Davis, Miriam Freimer, William Arnold

P1.127 Congenital Myesthenic

Syndrome with Autophagic Vacuoles Caused by Homozygous c.686-2A>G Mutations in GFPT1 —Hacer Durmus, Serdar Ceylaner, Memduh Dursun, Yesim Parman, Feza Deymeer, Piraye Serdaroglu

P1.128 Retrospective Analysis of the

Nephrotoxic and Hemolytic Side Effects of Chronic High Dose IVIG Therapy in Neurologic Disorders —Aidan Levine, Todd Levine, Kathie Clarke, David Saperstein

P1.129 Utility of Sleep Related

questionnaires in Patients with Myasthenia Gravis. —Annabel Wang, Dat

Le, Namita Goyal, Tahseen Mozaffar, Luis Chui, Marcel Hungs

P1.130 Upper arm, pulmonary and

cardiac magnetic resonance imaging for relative disease status in Duchenne muscular dystrophy —Ami Mankodi, W.Patricia Bandettini, William Kovacs, Alexander Hanna, Hirity Shimellis, Chioma Nnamdi-Emetarom, Lasya Gaur, Kenneth Fischbeck, Jianhua Yao, Andrew Arai

P1.131 Feasibility and validation of

modified oculobulbar facial respiratory score (mOBFRS) in amyotrophic lateral sclerosis (ALS) and sporadic inclusion body myositis (sIBM) —Namita Goyal, Nadia Araujo, Marie Wencel, Tahseen Mozaffar

P1.132 A Pilot Trial of Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation: An

Update on Safety, Feasibility, and Pharmacokinetics —Grayson Beecher,

Dustin Anderson, Derrick Blackmore, Ashley Mallon, Zaeem Siddiqi

P1.133 Congenital Fiber Type

Disproportion Myopathy in Children — Fouad Al-Ghamdi, Partha Ghosh

P1.134 A Prospective Natural

History Study of Sporadic Inclusion Body Myositis: 1-Year Results —Namita

Goyal, Parul Houston, Pedro Machado, Angela Genge, Lisa Jean-Louis, Linda Lowes, Didier Laurent, Dimritris Papanicolaou, Michael Hanna

P1.135 Evaluation of clinical and

electrophysiological myasthenic features in patients with alphadystroglycanopathies. —Paloma GonzalezPerez, Cheryl Smith, Wendy Sebetka, Seth Perlman, Katherine Mathews

P1.136 Five-year experience with dystrophinopathy muscle biopsies —

Courtney Carlson, Steven Moore, Katherine Mathews

P1.137 A Retrospective Analysis

of Cellcept in Generalized Myasthenia Gravis —Anjali Sharma, Ariel Jablonow,

Nasheed Jamal, Robert Freundlich, Patricia Pittman, Nastaran Rafiei, Shrikant Mishra

P1.138 A novel SYNE1 variant

segregates with a wrist-drop phenotype in a large multigeneration pedigree —

Jennifer Roggenbuck, Radha Patel, Michael Hehir, Stanley Iyadurai

P1.139 Patients derived cellular

models to investigate the pathogenesis and to develop therapies for human disorders caused by acid ceramidase deficiency. —Dario Ronchi, Federico Ribaudo, Massimo Aureli, Domitilla Schiumarini, Sabrina Salani, Silvia Tartari, Manuela Garbellini, Andreina Bordoni, F. Danilo Tiziano, Enrico Bertini, Massimiliano

Fast and easy registration · AAN.com/view/AM17 81

SUNDAY

Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients With Sporadic Inclusion Body Myositis —Anthony

Uc, Warren Darling, Teri Thomsen, Kevin Doerschug, Matthew Rizzo, Steven Anderson, Joel Kline, Jeffrey Dawson

Mehta, David Davis, Kinsley Belle, Derek Dykxhoorn, Gary Beecham, Eden Martin, Deborah Mash, William Scott, Juan Young

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session I



Filosto, Mirella Filocamo, Sandro Sonnino, Raffaele De Francesco, Stefania Corti, Nereo Bresolin, Giacomo Comi

P1.140 Molecular Mechanisms of

Autoantibodies to Contactin-associated protein-like 2 (Caspr2). —Kristina Patterson, Eric Lancaster

P1.141 McArdle Disease: clinical

features, muscle biopsy and genetics —

Paulo Lorenzoni, Raquel Arndt, Claudia Kay, Carlos Silvado, Lineu Werneck, Rosana Scola

P1.142 A Randomized Placebo-

Controlled Clinical Trial Evaluating Efficacy and Safety of IGIV-C in Symptomatic Subjects with Generalized Myasthenia Gravis —Rhonda Griffin, Junliang Chen, Kim Hanna, Elsa Mondou

P1.143 NA P1.144 NA GENERAL NEUROLOGY: THE EYES HAVE IT AND WHITE MATTER MATTERS

P1.145 Visual Dysfunction and

P1.155 A Case of Delayed

Post-Hypoxic Leukoencephalopathy Masquerading as a Primary Psychiatric Disorder —Dinesh Jillella, Lisa Herrera, Amanda Deligtisch

P1.156 Assessment of radiation-

induced white matter changes using myelin water imaging —Emmanuelle

Lapointe, Ludmila Litvin, Shannon Kolind, Irene Vavasour, Vanessa Wiggermann, David Li, Anthony Traboulsee

P1.157 Exome sequencing uncovers a rare and treatable condition: Cerebrotendinous Xanthomatosis — Ahmet Arac, Nicholas Olney, Brent Fogel

P1.158 Nerve Injury Following

Sclerotherapy: A Case Report and Review of the Literature —Christa Seligman, Karin Woodman

P1.159 Neuropsychological clinical picture of veterans of Afghan war — Cholpon Shambetova

NEURO-ONCOLOGY: GLIOMAS I

P1.160 IDH mutations define a subset

P1.146 Seeing Eye to Eye: A Case

Derek Oakley, Matthew Frosch, Sy Han Chiou, Rebecca Betensky, Fred Hochberg, Tracy Batchelor, Daniel Cahill, Jorg Dietrich

of Missed Incidental Optic Nerve Meningioma in the Setting of a Symptomatic Chiari I Malformation — Andrea Harriott, Paul Mathew

SUNDAY

P1.147 Persistent Upward Gaze in

of gliomatosis cerebri patients with improved outcome —Ina Ly, Alexander Pine,

P1.161 A Fifteen-Year Retrospective

Series of Patients with Leptomeningeal Spread of Glioma at Memorial Sloan Kettering Cancer Center (MSKCC) —Brian

Usha Pasupuleti, Devakinanda Pasupuleti

Andersen, Alexandra Miller, Caroline Miranda, Vaios Hatzoglou, Lisa DeAngelis

P1.148 Real Eyes Realize Real Lies —

P1.162 Prognostic Importance of

Coma and Its Prognostic Implications — Mohammad El-Ghanem, Muhammad Niazi, David Ermak

P1.149 Three cases of juvenile and adult-onset Niemann-Pick disease type C: Variability in neurological and psychiatrical phenotypes —Tomoya

Kawazoe, Toshiyuki Yamamoto, Aya Narita, Kousaku Ohno, Eiji Nanba, Atsuko Noguchi, Tsutomu Takahashi, Masafumi Ogawa, Miho Murata, Yuji Takahashi

P1.150 Cerebrotendinous

Xanthomatosis Without Neurological Involvement —Bianca ML Stelten, Aad

Verrips, Frederick J Raal, Tuula Rinne, Leo AJ Kluijtmans, Ron Wevers

P1.151 Mechanism of autophagy-

lysosomal pathway dysfunction in Gaucher disease iPSC neurons —Antanina Voit, Ola Awad, Ricardo Feldman

P1.152 An unusual case of Toxic

Leukoencephalopathy. —Bader Alenzi,

Navin Kesari, Tiffany Fleet, J. Clay Goodman

P1.153 Tacrolimus Neurotoxicity

Mimicking Progressive Multifocal Leukoencephalopathy 16 Years After Renal Transplant —Fareed Khan, Alicia Parker, Nadir Haider, Laszlo Mechtler

P1.154 Neuropathic pain as the

presenting symptom of adult-onset Alexander’s Disease —Jason Massa, Brandon Beaber, Yuri Bronstein

Bevacizumab: A Population-Based Study —Ping Zhu, Xianglin Du, GuangRong

P1.183 Migraine with Aura (MA)

P1.169 Comparative Effectiveness of

Couch, Kenneth Stewart

Lu, Jay-Jiguang Zhu

Electronic and Written Patient-Reported Data Entry in Patients with NeuroOncologic Disease —Mariya Mohammed, Roy Strowd, Fang-Chi Hsu, Michael Chan, Christina Cramer, Adrian Laxton, Stephen Tatter, Glenn Lesser

P1.170 PIK3CB Inhibitors Selectively Block the Survival of Glioblastoma Cells —Lamvy Le, Zhi Sheng

P1.171 Inpatient Use of Bevacizumab in Neuro-Oncology Patients— Challenges and Practice —Akanksha

Sharma, Justin Low, Jennifer Wax, Maciej Mrugala

P1.172 Inflammasome Activation in Glioblastoma Multiforme —Erin Balcom,

William Branton, Ken Petruk, Matt Wheatley, Frank Van Landeghem, Christopher Power

P1.173 1H-MRS for the differentiation

Retinal Pathology occurs in Stiff-Person Syndrome —Alissa Rothman, Thomas Shoemaker, Jerry Prince, Shiv Saidha, Peter Calabresi, Scott Newsome

Sunday, April 23  8:30 a.m.—5:30 p.m.

Brain Tumor Specific Health-Related Quality of Life Impairments and Fatigue in Newly Diagnosed Glioblastoma —

Katherine Peters, Mary Affronti, Eric Lipp, Janet Minchew, Frances McSherry, James Herndon II, Elizabeth Miller, Dina Randazzo, Annick DesJardins, Gordana Vlahovic, Hentry Friedman

P1.163 Defining Molecular

Mechanisms of Resistance to Glioblastoma (GBM) Immunity —Martha Neagu, Robert Manguso, Hans Pope, John Doench, Arlene H. Sharpe, Nicholas W. Haining

P1.164 Intractable seizures and IDH

mutation in low grade gliomas —Edward Avila, Anne Reiner, Yoshie Umemura

P1.165 Early Palliative Care

Consultation in Glioblastoma —Lauryn Hemminger, Christine Pittman, Jennifer Serventi, David Korones, Robert Holloway, Nimish Mohile

P1.166 Compliance of Tumor Treating Fields Therapy and Overall Survival in Glioblastoma —Eric Wong, Johnson Fong, Edwin Lok, Shiva Gautam

P1.167 Effect of Temozolomide

Chemotherapy on Seizure Frequency in Patients with WHO grade II oligodendrogliomas. —Aya Haggiagi, Edward Avila

P1.168 Survival Benefit of

Glioblastoma Patients after FDA Approval of Temozolomide and

82 2017 AAN Annual Meeting Scientific Program

of glioma recurrence from radiation necrosis —Ian Crain, Petra Elias, Kristina

is the most common phenotype for Post-Traumatic Headache (PTH) —James

P1.184 Childhood sexual abuse

and migraine among female university students —Juliana Gomez

P1.185 Natural Course of Cluster

Headache: a retrospective cohort study with long-term follow-up —Mi-Ji Lee,

Hyun Ah Choi, Jong Hwa Shin, Hea Ree Park, Chin-Sang Chung

P1.186 What kind of treatment do patients really want for headache? — Natalia Murinova, Melissa Schorn, Daniel Krashin, Sau Mui Chan-Goh

P1.187 A Surveillance of Quality of Care Utilizing the 2014 American Academy of Neurology Quality Measurement Set for Patients with Migraine —Jason Lin, Huma Sheikh

P1.188 Incidence and impact of

headaches in the post-traumatic stress disorder —Laurent Guilloton, Julie Defrance,

Chapple, Adrienne Scheck, John Karis, Mark Preul

Pierre Antoine Blanc, Marion Trousselard, Jean Pierre Simson

P1.174 Stroke-like migraine attacks

P1.189 Pseudotumorcerebri in

in long term survivors of high grade glioma. —Pamela New, Hira Mirza

P1.175 Age as a prognostic factor for treatment outcomes in glioblastoma. — Kelly Braun, Suryanarayan Mohapatra, April Choi, Manmeet Ahluwalia, Xuefei Jia

P1.176 The phenomenon of long-term

survivorship of patients with glioblastoma. The Burdenko Neurosurgery Institute experience. —Maria Goldberg, Sergey Goraynov, Evgenia Alexandrova

P1.177 Tumor Treating Fields (TTF)

with Triple Chemotherapy for Recurrent Glioblastoma —Jay-Jiguang Zhu, GuangRong Lu, Mayank Rao, Ping Zhu

P1.178 Analysis of Glioblastoma

Physical Characteristics in Patients Benefiting from Tumor Treating Fields Therapy —Pyay San, Joshua Timmon, Edwin Lok, Kenneth Swanson, Eric Wong

P1.179 Ventriculomegaly in patients with glioblastoma multiforme (GBM) — Caroline Miranda, Alexandra Miller, Brian Andersen, Vaios Hatzoglou, Lisa DeAngelis

HEADACHE: EPIDEMIOLOGY AND DISEASE CHARACTERISTICS

P1.180 Direct Costs Associated with Migraine in the US —Machaon Bonafede,

Katherine Cappell, Sandhya Sapra, Neel Shah, Pooja Desai, Stewart Tepper

P1.181 Clinical Characteristics and

Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in U.S. Healthcare Claims Data —Casey K.

Choong, Janet H. Ford, Allen W. Nyhuis, Rebecca L. Robinson, Sheena Aurora, James Martinez

P1.182 Variation in Prescription

Drug Coverage for Triptans: Analysis of Insurance Formularies in New York State —Mia Minen, Kate Lindberg, Aisha Langford, Elizabeth Loder

systemic lupus erythematous activity —

Helena Yacoub, Eduardo Estephan, Ida Fortini, Ricardo Nitrini

P1.190 Pain characteristics in Chiari Type-1 —Fredric Cantor, Josie Skala, Ryan Toledo, John Heiss

P1.191 An atypical presentation

of Tolosa-Hunt syndrome —Paula Pires, Marta Villa, Juan Pareja, Laura Lillo

P1.192 Visual Field Deficits in

Patients with Headache Disorders: A 2-year Prospective Cohort Study —Fred Odagp, Jonathan Smith, Sachin Kedar, Padmaja Sudhakar

P1.193 Thunderclap headache

with no neurological deficit: Clinical differences between Primary and Secondary Causes —Patricio Millar

Vernetti, Lucas Alessandro, Mariano Marrodan, Abril Marone, Alejandro Kohler, Veronica Bruno, Maria Goicochea, Lucas Bonamico

P1.194 Headache Update 1917 — Noah Rosen, Robert Duarte

P1.195 Predictors of healthcare

costs among patients with migraine in a commercial claims database —Machaon

Bonafede, Qian Cai, Katherine Cappell, Gilwan Kim, Sandhya Sapra, Neel Shah, Pooja Desai, Paul Winner

P1.196 Ergotamine use and overuse in Taiwan : a retrospective cohort study —Chuling Chen, Yi-Chun Yeh, Yen-Yu Chen

P1.197 The Anxious Brain in Pain:

Increased Levels of Anxiety, Depression and Stress Associated with Chronic Daily Headache Patients Presenting to Universitybased Headache Clinic —Natalia Murinova, Daniel Krashin, Melissa Schorn

P1.198 Challenges in managing

migraine after bariatric surgery —Yulia

Orlova, Andrea Harriott, Paul Mathew, Paul Rizzoli


P1.199 Alphaherpesviruses and

headache disorders: retrospective study —

Laura J Weinkle, Stefan Sillau, Laur Marius Birlea

P1.200 Complex Dural Arteriovenous Fistula Masquerading as Pseudotumor Cerebri —Lesley Kaye, Swetha Renati, Brian

Corliss, William Stetler, Adam Polifka, Michael Waters

P1.201 Association between Patient

and Provider Characteristics and Diagnosis of Migraine: An Observational Electronic Health Record Study —Maya Marzouk, Elizabeth Seng, Robert Nicholson

P1.202 An Unheard of Diagnosis:

Hereditary Syndrome with Migraine and Hearing Loss —Andrea Harriott, Paul Mathew

P1.203 A Brief Survey on Academic

Headache Centers Knowledge of and Interest in ACGME recognition of Headache Medicine Fellowships —Noah Rosen, Deborah Friedman, David Dodick

P1.204 Inhaled oxygen in cluster

headache: Results of the Clusterbusters Medication Use Survey —Emmanuelle Schindler, Marsha Weil, Douglas Wright, Christopher Gottschalk

P1.205 Patients Preferences for

Headache Treatment —Dimos Dimitrios

Mitsikostas, Ioanna Belesioti, Efi Mitropoulou, Christina Deligianni, Elina Kasioti, Theodoros Constantinidis, Emmanouil Dermitzakis, Michael Vikelis

P1.206 A Rare Case of Seasonal Subhendu Rath, Amre Nouh

P1.207 Are headaches more

common among epilepsy patients with neurocysticercosis compared to other structural brain lesions? —Bhavesh Trikamji, Erin Saito, Bijal Mehta, Frances Wang, Beau Nakamoto, Aaron McMurtray

P1.208 Uncommon Presentation of

an Uncommon Disease: Ophthalmoplegic Migraine with Alternating Contralateral Extraocular Movement Paresis —Diego

P1.226 Immune Cell Infiltration

Carla Zapata Del Mar, Juan Luis Cam, Claire Creutzfeldt

Ebru Nur Vanli-Yavuz, Ece Erdag, Betul Baykan

Peru: Barriers to Transparency in Communication —Anastasia Vishnevetsky,

in CASPR2-Antibody Associated Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis —Erdem Tuzun,

P1.215 Neurological Complication

P1.227 Type IIA procollagen

Lee, Byung-Joo Park

Richard Shek-kwan, Danny Chan, Patrick Tam, Kathryn Song Eng Cheah, Shu Leong Ho

Rates Associated with Epidural Injections —Byungkwan Hwang, Joongyub

P1.216 Dysfunction of the

descending pain modulatory system in neuropathic limb pain related to MS. A case: control clinical and neuroimaging study. —Peter Foley, Yazhuo Kong, Maria

Valdes-Hernandez, Ramune Dirvanskiene, Neil Roberts, Jonathan Murnane, Robin Sellar, Lesley Colvin, Christopher Weir, Thomas Bak, Siddharthan Chandran, Irene Tracey, Marie Fallon

P1.217 Analysis of risk for side

effects due to drug-drug and drug-gene interactions in a cohort of patients with Complex Regional Pain Syndrome —

Sameer Jain, Arash Danesh, Ricardo Cruciani, Christina Maxwell, Saba Bakhtiari, Marcus Laroche

P1.218 Primary Care and Palliative Care Needs of ALS Patients in the last 6 months of life —Ezgi Tiryaki, Samuel Maiser, Katherine Esse, Jeffrey Rubins, Nathan Pankratz

P1.219 Motor cortex tRNS

ameliorates pain, anxiety, depression, quality of life and cognitive impairment in patients with fibromyalgia: preliminary results of a randomized sham-controlled trial. —Giuseppe La Bianca, Massimiliano

regulates TGF-β superfamily signaling in epileptogenesis —YUAN GAO, Chang

P1.228 The Effect of Cannabidiol on

Human CNS-Expressed Voltage-Gated Sodium Channels —Royston A. Gray, Colin Stott, Nicholas Jones, Stephen Wright

P1.229 Late treatment with choline

alfoscerate increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment —Jinhyuk Yoo, Dong Jin Shin, Byung-In Lee, Hongki Song

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: GENETICS

P1.230 Novel Clinical Presentations and Characteristics in Patients with KCNA2 Mutations —Monisha Sachdev, Marina GaÌnza Lein, Dmitry Tchapyjnikov, Tobias Loddenkemper, Mohamad Mikati

P1.231 Phenotype is not Always a

Positive Predictor of Detection Rate in Epilepsy Panels —Heather Newman, Zoe Powis, Amal Yussuf, Jing Wang

P1.232 Genetic generalized epilepsy

Changes Following Participation in Online and Live ER/LA Opioid CME/CE Programs from the CO*RE Collaborative —Piyali

P1.234 Many testing roads can lead

P1.210 Single-nucleotide polymorphism

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: BASIC SCIENCE

Steven Tversky, Jeffrey Katz, Paul Wright

P1.212 Depression among

Inpatients with Low Back Pain: Patient Characteristics and Outcomes —Emily Lane Schlitz Fortenberry, Sahil Gupta, Zina Trost

P1.213 The Role of Pain-related Fear and Pain Catastrophizing during Acute Spinal Cord Injury —Emily Lane Schlitz

Fortenberry, Sahil Gupta, Kimberly Monden, Zina Trost

P1.241 Incidence of acute

symptomatic seizures due to NCC in children accessing government primary schools in south India: Is there a need to sub-categorize acute symptomatic seizures due to CNS infections into those with enduring predisposition for seizure recurrence and those without? — Jagarlapudi Murthy, Shyam Jaiswal, Padmanabh Reddy M, Sri Krishna S

P1.242 Prevalence of epilepsy and

non-epileptic seizures in adults with developmental delay —Stephan Schuele, Aparna Sarma

P1.243 The value of observing

paroxysmal events: Comparing the diagnostic accuracy and confidence for clinical history compared to observation. —Brian Hanrahan, Anto Bagic,

Rick Hendrickson, Cheryl Plummer, Gena Ghearing, Alexandra Popescu, Jullie Pan, Arun Antony

Borlot, Anne Bassett, Brigid Regan, James Stavropoulos, Danielle Andrade

P1.209 Increase in Rate of Utilization

Consultation Decreases Length of Stay in Severe Stroke Patients —Evan Schloss,

Dilip Kumar Jayaraman, Anusha Edara, George Newman

P1.221 Interim Analysis of Practice

Manganas

P1.211 Early Palliative Care

Gaustaut Syndrome with Response to Vagal Nerve Stimulator —Jalyoung Joe,

Varun Chauhan, Aashit Shah

variation in adults with epilepsy and intellectual disability —Felippe

Stefano Magon, Laura Gaetano, Yanika Jaeger, Ludwig Kappos, Till Sprenger

Wei David Ho, Margaret Wallace, Roger Fillingim

P1.240 Quantitative EEG in Lennox-

P1.233 Prevalence of copy number

facial sensations —Fredric Cantor

P1.235 A Novel KCNQ2 Mutation in

in COL11A2 associated with thermal hyperalgesia in knee osteoarthritis —Kwo

Vannucci, Daniel Goldenholz, Robert Moss, John Stern

P1.220 Human central pathways for

P1.222 Do patients with thalamic

of Withdrawal of Care in Acute Ischemic Stroke in USA —Malik Adil, Richard Zweifler

history of epilepsy and epilepsy subgroups —Sharon Chiang, Marina

P1.244 Unique Place of Ambulatory

Rezazadeh, Danielle Andrade

to KCNQ2 diagnosis. —Amal Yussuf, Zoe

PAIN AND PALLIATIVE CARE

P1.239 Variations in the natural

and intellectual disability is associated with 8q21-q22 duplication —Arezoo

Curatolo, Marcello Romano, Brigida Fierro, Filippo Brighina

Chatterjee, Thomas Finnegan, Cynthia Grimes, Cynthia Kear, Tom McKeithen

Condes, Danielle Spengler, Hong Jiang

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CLINICAL EPILEPSY I

pain have a specific somatosensory phenotype? —Athina Papadopoulou,

P1.223 Uniform direct current

stimulation induces region-specific longterm modulation of cortical excitability in mouse and human cortex in vitro —Yan Sun, Sameer Dhamne, Joseph Madsen, Alexander Rotenberg

P1.224 Cannabidiol does not convert

to Δ9- tetrahydrocannabinol in an in vivo animal model —Louise Wray, Colin Stott, Nicholas Jones, Stephen Wright

P1.225 Positive Allosteric Modulation

of Metabotropic Glutamate Receptor 5 (mGluR5) Delays Seizure Onset in a Mouse Model of Viral-induced Seizures —Tyler Hanak, Ana Beatriz DePaula-

Powis, Kirsten Blanco, Jing Wang

a Child with Benign Familial Neonatal Seizures —Leena Youssefian, Louis

P1.236 Increased Epilepsy

Prevalence in Adults with 22q11 Deletion Syndrome —Robert Wither, Alex MacDonald, Felippe Borlot, Nancy Butcher, Eva Chow, Anne Bassett, Danielle Andrade

P1.237 Epilepsy phenotype in

patients with autism, developmental delay and congenital abnormalities associated to 15q11.2, 15q13.3 and 16p13.11 microdeletions —Fabio

Nascimento, Richard Wennberg, Danah Aljaafari, Abdullah Tahiri, Edwin Young, James Stavropoulos, Danielle Andrade

P1.238 Single center analysis of the yield of genetic testing in suspected genetic etiologies of epilepsy —Sarah

Barnard, Dennis Matthews, Jessica DePreto, Daniel Friedman, Sanjeev Kothare

EEG (aEEG) in Management of Epilepsy —Hardik Doshi, Richa Tripathi,

P1.245 The predictability of

smartphone video in distinguishing epileptic and nonepileptic seizures —

Sikawat Thanaviratananich, Paul Van Ness, Zulfi Haneef, David Chen

P1.246 Ontogeny of Seizure

Semiology: a longitudinal study —Ahmed Abdelkader, Andreas Alexopoulos, Prakash Kotagal

P1.247 Catching and counting

seizures for patients with epilepsy using an automated telemedicine platform - EpxEpilepsy —Stephanie Zhang, Robert Chen, Kavon Javaherian, Jacob Groenendyk, Michael Pan, Luigi Maccotta

P1.248 Correlation of Seizure

Frequency and Medication Downtitration Rate During Video-EEG Monitoring —Sami Alkasab, Rachael A

Dawson, Jorge L Jaramillo, Jonathan Halford

P1.249 Use of the DISCOVER form

(a structured diagnostic interview) to ensure correct classification in a study of disease impact —Jay Louik, Betsy Williams, Daniel Friedman, Manu Hegde, Kwee Thio, Rachel Hennessy, Jacqueline French

P1.250 NA

Silva, Jordan Sim, Daniel Doty, Jane Libbey, Robert Fujinami

Fast and easy registration · AAN.com/view/AM17 83

SUNDAY

Episodic Paroxysmal Hemicrania —

P1.214 Neuropalliative Care in

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session I



CEREBROVASCULAR DISEASE: GENETIC STROKE SYNDROMES, BIOMARKERS, AND TRANSLATIONAL/BASIC RESEARCH

P1.263 Purinoreceptors and VZV

P1.251 Misdiagnosis of CADASIL:

P1.264 Preconditioned M2 microglia

A single Medical Center experience — Jorge Ortiz-Garcia, Karen Orjuela, Rochelle Sweis, Jose Biller

P1.252 Is Fabry’s Disease a Risk

Factor for Stroke in Young Patients? — Carolina Ikuta, Valeria Scavasine, Mariana Canever, Laura Zamproni, Marcos Lange, Francisco Germiniani, Viviane Zetola, Lineu Werneck, Edison Novak

Vasculopathy —Ann Wyborny, Alex Choe, Rocco Totaro, Evgenia Gerasimovskaya, Donald Gilden, Maria Nagel

by oxygen-glucose deprivation promote functional recovery in ischemic rats —Masato Kanazawa, Minami Miura,

Masafumi Toriyabe, Misaki Koyama, Masahiro Hatakeyama, Masanori Ishikawa, Takeshi Nakajima, Osamu Onodera, Masatoyo Nishizawa, Takayoshi Shimohata

Corticospinal Tract Recovery after Intraarterial Mesenchymal Stem Cell Infusion in a Canine Stroke Model —Luis Guada,

Noll, Elizabeth Kessler, Sean Gratton

Pradip Pattany, Kevin Ramdas, Kunakorn Atchaneeyasakul, Guarav Saigal, Dileep Yavagal

P1.255 MELAS Syndrome: How

P1.267 Development and Feasibility

Nicholas Liaw, Richard Lewis, Vasu Saini, Sakir Gultekin, Sebastian Koch, Negar Asdaghi

P1.256 The Single Nucleotide

Polymorphisms (SNPs) in Cytochrome P450 2C19 amd Clopidogrel Resistance in Indian Population —Arun Shivaraman

M M, Anto Nazarene, Lakshmi Ranganathan, Christianne Sandhya Ravi Chandar, Pratheep Kumar S, S Gobinathan

SUNDAY

P1.257 Circulating Microparticles

are Associated with Visuospatial Ability in the Framingham Heart Study —Hugo

Javier Aparicio, Jayandra Himali, Matthew Pase, Claudia Satizabal, Kendra PlourdeDavis, Chantal Boulanger, Nicolas Amabile, Susan Cheng, Martin Larson, Charles DeCarli, Ramachandran Vasan, Thomas Wang, Alexa Beiser, Sudha Seshadri

P1.258 D-Lactate and Intestinal

Fatty-Acid Binding Protein are elevated in serum in patients with acute ischemic stroke —Carlos Camara-Lemarroy, Nicolás Escobedo-Z˙Òiga, Francisco Guzman-De La Garza, Jorge Castro-Garza, Javier VargasVillarreal, Fernando Góngora-Rivera

P1.259 Relationship Between

Admission Serum Bilirubin and Severity of Acute Ischaemic Stroke in a Nigerian Tertiary Hospital —Babatunde Ademiluyi, Emmanuel Sanya, Kolawole Wahab

P1.260 Interleukin-37 is Elevated in Acute Ischemic Stroke. —Saif Bushnaq, Atif Zafar, Kempuraj Duraisamy, Nudrat Tasneem, Mohammad Khan, Enrique Leira, Asgar Zaheer

P1.261 Increased Cysteinylated

Albumin is Associated with More Favorable Outcomes in Ischemic Stroke Patients, A Reflection of Collateral Circulation? —Russell Bartt, Jan Leonard, Raphael Bar-Or, Leonard Rael, David Bar-Or

P1.262 The relationship between

chemerin levels and carotid intima-media thickness in patients with ischemic stroke —Caner Demir, Iklimya Atas, Emrah AytaÁ, Murat Gonen, Zeynep Erten

P1.275 Lytic therapy and mechanical

thrombecomty over tele-stroke, a comprehensive stroke center experience — Sami Alkasab, Ellen Debenham, David J Jones, Christine Holmstedt

Steinberg, Cynthia Kenmuir, Tudor Jovin, Lawrence Wechsler, Ashutosh Jadhav

P1.266 Diffusion Tensor Imaging of

Stroke-like are the Stroke episodes? —

El-Ghanem, Muhammad Niazi, Raymond Reichwein, David Ermak

Levy, Meaghan Roy-O’Reilly, Louise McCullough

Fitzgerald, Shivika Chandra, Mark Dannenbaum, Anjail Sharrief

Deaminase 2: A Recently Described Autoinflammatory Disease with Neurological Manifestations —Aaron

Prehospital Acute Stroke Scale to Predict Large Vessel Occlusion in Patients with Proven Large Vessel Occlusion? Single Center study in US —Mohammad

P1.276 Safety and Efficacy of

Dynamics Following Ischemic Stroke in Humans and Mice —Hetal Mistry, Madeline

P1.254 Deficiency of Adenosine

P1.274 Evaluation and Validation of

P1.265 Orosomucoid-1 Protein

P1.253 A rare cause of stroke

in young: PHACE syndrome —Keely

Sunday, April 23  8:30 a.m.—5:30 p.m.

of a Canine Endovascular Reversible Middle Cerebral Artery Occlusion Stroke Model: a Novel anterior circulation approach —Luis Guada, Kevin Ramdas, Kunakorn Atchaneeyasakul, Mitsuyoshi Watanabe, Charif Sidani, Dileep Yavagal

CEREBROVASCULAR DISEASE: PREHOSPITAL STROKE, TELE-STROKE, AND MHEALTH

P1.268 Analysis of Run Sheets of EMS Serving a Metropolitan Comprehensive Stroke Center —Haitham Hussein, Bhavani

Kashyap, Lauren Erickson, Anna Forsberg, Aaron Burnett, Stephen Stanfield, Sandi Wewerka, Alexia Terwilliger, Leah Hanson

P1.269 Early Experience on

Intravenous Tissue Plasminogen Activator Delivery in Mobile Stroke Unit Patients with Stroke Mimics —Lila Sheikhi, Stacey Winners, Pravin George, Andrew Russman, Zeshaun Khawaja, Ken Uchino, Muhammad Hussain

P1.270 Patient characteristics

affecting stroke recognition by emergency medical service providers in Kings County Hospital Center —Fernando Cuascut Lassus, Susan Law

P1.271 Walk-in Versus EMS-

prenotified Stroke Codes—Time Targets in a Comprehensive Stroke Center — Gurmeen Kaur, Aashrai Gudlavalleti, Jennifer Schleier, Michelle Vallelunga, Joshua Onyan, Julius Latorre

P1.272 Evaluation of NIHSS-Onset to

Groin Time (OGT) and Prehospital Acute Stroke Severity Scale (PASS)-OGT scores in prediction of outcomes after Endovascular Treatment in Acute Ischemic Stroke patients: A Retrospective Single-Center Study —Muhammad Niazi, Mohammad

Thrombolysis in Telestroke for the Extended Time Window —Alexis

P1.277 Door to Page Time to Initiate a Telemedicine Consult Varies Among Spoke Hospitals for Acute Stroke —

Jaskaren Randhawa, Amanda Jagolino, Christy Ankrom, Shima Bozorgui, Arvind Bambhoroliya, Farhaan Vahidy, Tiffany Cossey, Sean Savitz, Tzu-Ching Wu

P1.278 The Experience of Spoke

Hospitals in an Academic Telestroke Network —Rajan Gadhia, Lee Schwamm,

Anand Viswanathan, Cynthia Whitney, Arianna Moreno, Kori Sauser Zachrison

P1.279 Implementing a Publically

Funded Regional Telestroke Network — Annemarei Ranta, Jeremy Lanford, Suzanne Busch, Carolyn Providence, Ivan Iniesta, Victoria Richmond

P1.280 Quality Improvement in

Telestroke Interactions —Deena Nasr,

Sherri Braksick, Robert Brown, Sara Hocker

CEREBROVASCULAR DISEASE CASE REPORTS I

P1.281 Apixaban for the treatment of

Cerebral Venous Thrombosis: A Report of Two Cases —Shishir Rao, Kushak Suchdev, Claudia Hanni, Mohammad Ibrahim, Dennis Parker Jr., Kumar Rajamani, Wazim Mohamed

P1.282 Hyperacute Carotid Stenting

for Acute Ischemic Stroke After Systemic Thrombolysis with IV rt-PA —Erika Marulanda-Londono, Andres De LeonBenedetti, Gustavo Ortiz

P1.283 Paradoxical Embolism in

the Setting of Inferior Vena Cava Filter Removal —Micah Yost, James Klaas

P1.284 Successful endovascular

stroke therapy in a 103-year-old woman —Sohyun Boo, Uzoma Duru, Ansaar Rai, Matthew Smith

P1.285 4-year-old boy with acute

ischemic stroke treated with intravenous tissue plasminogen activase. —Talal Derani, Mounzer Kassab

P1.286 Aortic Valvular Papillary

Fibroelastoma Leading to Acute Ischemic Stroke in a Pediatric Patient —Imran Farooqui,

El-Ghanem, Raymond Reichwein, Kevin Cockroft, David Ermak

Robert Mannel, Scott Silliman

P1.273 Differences in the last

Questioning Validity of Aphasia as a Cortical Infarct Sign —Gurmeen Kaur,

known well time between neurology, ED providers and EMS providers. —Alexander Doyle, Lindsay Horton, Alejandro MagadanDuggan

84 2017 AAN Annual Meeting Scientific Program

P1.287 Subcortical AphasiasAntonio Culebras

P1.288 Convexal Subarachnoid

Hemorrhage and Superficial Siderosis: Under-Recognized Presentations of Cerebral Amyloid Angiopathy — Christopher Whiting, Shivakrishna Kovi, Christopher Cummings

P1.289 Convexity SAH and multiple

punctate infarcts secondary to Cerebral Amyloid Angiopathy —Yogesh Gujrati, Dennis Chuang, Michael De Georgia

P1.290 Cerebral Amyloid AngitpathyRelated Inflammation and the changing role of micro bleeds in diagnosis: A Case Report —Danielle Lux, Harikrishnan Sreedharan, Neil Munro

P1.291 “What Are the Odds?”: A Rare Clinical Syndrome from a Rare Vascular Condition Caused By a Commonly Used Medication —Tarun Girotra, Abdullah Alshammaa, Reema Butt, Shaneela Malik

P1.292 Bilateral hypertrophic

olivary degeneration: case report of an exceedingly rare condition developed after pontine infarct —Katherine Kudyba Morone, Shilpi Mittal

P1.293 Superior Vena Cava

Syndrome Causing Recurrent Intracranial Hemorrhage by Venous Congestion — Hatim Attar, Vishakhadatta Mathur Kumaraswamy, Benjamin Miller, Michael De Georgia

P1.294 Basal ganglia and caudate

infarction following episodic hemiballism and dystonia secondary to radiotherapyinduced atherosclerosis in a patient with a right parasellar chondrosarcoma — Michael Ruff, Stephen English, James Klaas

P1.295 Rare Cases of

Thrombotic and Embolic Stroke with Hypereosinophilia —Deana Finelli, Ashkan Shoamanesh, Kanjana Perera

P1.296 Recurrent ischemic strokes

as the initial presentation of thrombotic thrombocytopenic purpura with normal platelets: a case report. —Lindsay Horton, Alexander Doyle, Craig Powell, Mehari Gebreyohanns

P1.297 Eagle’s Syndrome: Viewing a

Rare Disorder from a New Perspective — Kavit Shah, Daniel Miller

P1.298 Bilateral persistent primitive

hypoglossal arteries associated with unilateral symptomatic carotid occlusion —Riddhi Patira, Christopher Kyper, Kadir Erkmen

P1.299 Rapidly Progressive Occlusive Intracranial Vasculopathy in Graftversus-Host-Disease —Theodore Bowen, Shawn Silver, Cathy Sila

P1.300 Unique Cerebrospinal Fluid,

Diffusion-weighted Spinal Imaging and Spinal Angiography Findings in a Patient with Heroin Myelopathy —Kyle Mahoney,

Meghan Romba, Izlem Izbudak, Deanna Saylor

P1.301 Cerebrospinal Fluid Drainage

for Acute Spinal Cord Infarction —Tamara Strohm, Seby John, Muhammad Hussain

P1.302 Multiplanar CT

Reconstruction to Aid in Recognition of the MCA “Dot” Sign: The Sagittal String Sign —Robert Mannel, Scott Silliman


AUTOIMMUNITY WITH INFECTION, SYPHILIS, LYME, TUBERCULOSIS, AND OTHER BACTERIA

P1.303 40-year old Pilot with

Fevers, Diplopia, Hypertropia, Skew Deviation, and Visual Field Loss due to H. parainfluenza endocarditis —Brian Stephens, Anthony Frattalone

P1.304 Brainstem skew deviation

as the presenting symptom of mycoplasma pneumoniae meningoencephalomyelitis —David Lin,

Seth Levin, Anoopum Gupta, Sebastian Urday, Catherine Albin, Nagagopal Venna

P1.305 Mixed Curvularia and

Klebsiella brain microabscesses in an immunocompromised patient —Rituparna Das, Michael Pohlen, Joseph Kass

P1.306 Ring Enhancing Brain

Lesions in a Patient With Sarcoidosis: A Diagnostic Challenge. —Carson Van Sanford, Ahmed Obeidat, Aram Zabeti

P1.307 Limbic Encephalitis

associated with neurosyphilis —Omar

Al-Louzi, Xenos Mason, Matthew W. Rondeau, Daniel Rubin, Jennifer Lyons, Shamik Bhattacharyya

P1.308 Neurosyphilis with unique neuroimaging findings —Harmanpreet Tiwana, Aiesha Ahmed

P1.309 The Resurgence of

P1.316 Demyelination as

presentation in leprosy neuropathy —

Izabela Pitta, Raquel Silveira, Ligia Andrade, Louise Giesel, Marcia Rodrigues, Robson Vital, Sergio Antunes, Euzenir Sarno, Marcia Jardim

P1.317 Acute onset and rapid

progression of tubercular meningitis and ischemic infarcts in an immune competent patient. —Erica Utigard,

Vladimir Katyshev, Carlos Isada, Dhimant Dani

P1.318 Idiopathic Spinal Cord

Compression in a Patient with Newly Diagnosed Tuberculosis —Shruthi Agashe, Xiang Fang

P1.319 Disseminated Tuberculosis

with Initial Presentation of Focal Myositis Diagnosed by Muscle Biopsy — Laura Stein, Susan Shin, Lan Zhou

P1.320 A Rare Case of Central

Nervous System Tuberculosis Presenting as Transient Splenial Lesion: Case Report and Literature Review —Jr-Wei Wu,

Gudin

P1.312 A case of CNS Lyme disease

presenting with multiple cranial neuropathies and mimicking a B cell lymphoma —Christopher Perrone, Denise Xu, Taneeta Ganguly, Donna Kurowski, Michael Mullen, Amy Pruitt

P1.313 Chronic inflammatory

demyelinating polyneuropathy in a leprosy patient with type 1 reaction —

Ligia Andrade, Robson Vital, Izabela Pitta, Raquel Silveira, Louise Giesel, Roberta Olmo, Euzenir Sarno, Marcia Rodrigues

P1.314 IL-6 is a marker of neuropathic pain in patients with leprosy —Marcia

Rodrigues, Raquel Silveira, Izabela Pitta, Louise Giesel, Ligia Andrade, Robson Vital, Euzenir Sarno, Roberta Olmo

P1.315 Neural pain in leprosy

neuropathy —Louise Giesel, Izabela Pitta,

Raquel Silveira, Ligia Andrade, Robson Vital, Euzenir Sarno, Marcia Jardim

neuroinflammation associated with cytotoxic T-lymphocyte antigen-4 (CTLA4) haploinsufficiency —Matthew

Disease and its association in the clinical characteristics, Incidence and outcomes in the hospitalized patients with Community-Acquired Pneumonia in Louisville, KY —Pooja SirDeshpande, Murali Kolikonda, Paula Peyrani, Julio Ramirez, Forest Arnold, Timothy Wiemken

meningitis and intracranial vasculopathy: Clinical correlation with improving transcranial Doppler hemodynamics —

P1.323 NNICU acquired VAP:

Spectrum, risk factors and antibiotic sensitivity profile —Man Mohan Mehndiratta, Rajeev Nayak, Sana Ali

Following Post-herpes Encephalitis —

Marco Zoccarato, Michele Gennuso, Sarah Ottaviani, Stefano Sartori, Irene Toldo, Luigi Zuliani, Bruno Giometto

P1.332 Disease course and treatment of neurosarcoidosis in a single center cohort study of 113 cases —Muhammad

Sabater, Eugenia Martinez-Hernandez, Myrna Rosenfeld, Francesc Graus, Josep Dalmau

P1.334 Clinical profile and long term

P1.335 Infliximab for the treatment

Masami Tanaka, Ko Tsutsui, Kenji Sakimura

P1.325 Convulsive spasms,

of neurosarcoidosis: a multi-institutional case series —Michael Bradshaw, Jeffrey

Darakhshan Naheed, Manoj Goyal, Manish Modi, Vivek Lal

P1.327 External Ventricular Drain

Related Infection Characteristics and Outcomes: A Case Series —Rui Feng,

Alexander Chartrain, Juhyun Kim, Stanislaw Sobotka, Margaret Pain, Neha Dangayach, Stephan Mayer, Errol Gordon

P1.328 NA

Receptor Encephalitis have Better Long-Term Functional Outcomes Than Those With Other Autoimmune Encephalitides. —Eliza Gordon-Lipkin,

Anusha Yeshokumar, Ana Arenivas, Deanna Saylor, John Probasco

P1.340 Predictive Variables of

Cognitive Dysfunction in Patients with Lupus —Helena Alessi, Livia Dutra Antonio, LÌlia Maria, Plácido Xavier, Paula Couce, Cristiane Kayser, Orlando Barsottini

P1.341 Immunosuppressive-

responsive, chronic, isolated pinealitis — Matthew Techy, Roumen Balabanov

PEDIATRIC MULTIPLE SCLEROSIS

P1.342 Evidence Supporting the

Use of MRI as a Surrogate for Clinical Endpoints in Randomized Controlled Trials for Pediatric Multiple Sclerosis —

P1.343 Regional Grey Matter Atrophy

encephalitis with antibodies against the metabotropic glutamate receptor 5 (mGluR5) —Marianna Spatola, Lidia

Doherty, Deanna Saylor

dementia: An eight year retrospective study —Anuja Patil, Venugopalan Vishnu,

P1.339 Patients With Anti-NMDA

P1.333 Novel findings in autoimmune

following lumbar puncture —Leana

P1.326 Infections masquerading as

Venna

Affan, Mohammed Kananeh, Lonni Schultz, Stanton Elias, Mirela Cerghet

outcome of the Japanese patients with NMDAR-encephalitis —Keiko Tanaka,

Doddamani, Jamal Khattak, Adriana Palade, Priyanga Jayakumar

man with multifocal encephalitis in the context of remote treatment with azathioprine and infliximab for ulcerative colitis—clinical, MRI, neuropathology findings, and exquisite steroidresponsive course —David Lin, Nagagopal

Robert Brown, Julia O’Mahony, E. Ann Yeh, Ruth-Ann Marrie, Amit Bar-Or, Brenda Banwell, Douglas Arnold, On Behalf Of The Canadian Pediatric Demyelinati

P1.324 Corynebacterium discitis

autonomic instability and electroencephalographic changes in an Amish female with clinically diagnosed tetanus —Murali Kolikonda, Rajiv

P1.338 Unusual case of a young

Gelfand, Barney Stern, David Clifford, Yunxia Wang, Tracey Cho, NgocHanh Vu, Subramaniam Sriram, Harold Moses, Francesca Bagnato, Laura Koth, Stephen Hauser, Jason Dierkhising, Jeffrey Kaufmann, Deidre Ammah, Tsion H. Yohannes, Mark J. Hamblin, Nagagopal Venna, Ari Green, Siddharama Pawate

P1.336 A case of SLIPPERS

(Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids) presenting with isolated cognitive dysfunction. —Sam Horng, John Crary, Michelle Fabian

P1.337 Patients with Autoimmune

Encephalitis Have Persistent Impairment in Neurocognitive and Adaptive Function —Anusha Yeshokumar, Eliza Gordon-Lipkin, Ana Arenivas, Deanna Saylor, John Probasco

in Pediatric Patients with Multiple Sclerosis: A Longitudinal MRI Study —

Ermelinda De Meo, Maria Rocca, Elisabetta Pagani, Angelo Ghezzi, Lucia Moiola, Pierangelo Veggiotti, Ruggero Capra, Maria Amato, Agnese Fiorino, Lorena Pippolo, Maria Carmela Pera, Giancarlo Comi, Andrea Falini, Massimo Filippi

P1.344 Predictors of Long term

disability in Pediatric patients with relapse-onset Multiple Sclerosis (MS) on immunomodulatory therapy —Areeba Basit, Jenny Wang, Tiffany Lin, Alyssa Lui, Emily Egbert, Marvin Petty, Olga Novak, Amber Salter, Soe Mar

P1.345 Diagnostic algorithm for

relapsing acquired demyelinating syndromes of the central nervous system in children —Yael Hacohen, Kshitij Mankad, W Kling Chong, Frederik Barkhof, Angela Vincent, Ming Lim, Evangeline Wassmer, Olga Ciccarelli, Cheryl Hemingway

P1.346 Final results from the

BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS —Jutta Gaertner, Wolfgang Brueck, Andreas Weddige, Hannah Hummel, Christiane Norenberg, Joerg-Peter Bugge

P1.347 Baseline Characteristics

of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-ß1a —Tanuja Chitnis, Douglas Arnold, Brenda

Fast and easy registration · AAN.com/view/AM17 85

SUNDAY

as the Initial Presentation for Lyme neuroborreliosis —Anas Hannoun, Jeffrey

P1.330 Severe recurrent

P1.321 Burden of Cerebrovascular

P1.310 Lyme Neuroborreliosis—A

P1.311 Cervical Radiculopathy

Taieb, Thibaut Allou, Elsa Kaphan, Bertrand Audoin, Jean Pelletier, Jean Ouallet, Patrice Desbordes, David Brassat, Giovanni Castelnovo, Eric Thouvenot, Valerie Rigao, Caroline Arquizan, Xavier Ayrignac, Nadege Limousin, Delphine Loussouarn, Laurent Magy, Cecilia Rousselot, Romain Lefaucheur, Jerome De Seze, Christine Tranchant, Christine Lebrun-Freney, Yannick Bejot, Vincent Guiraud, Jean-Phillippe Camdessanche, Fernando Pico, Bob Van Oosten, Philippe Kerschen, Vera Fominykh, Patricia Mulero, Maria TintoreSubirana, Joerg Seebach, Dimitri Psimaras, Khe Hoang-Xuan, Pierre Labauge

P1.331 NMDAR Encephalitis

Mohamed Idris, Sharon Mei Ling Tai, ChongTin Tan, Kay-Sin Tan

Almendra, Michel Mendes, Andreia Veiga, Alexandre Costa, Ana Graca Velon, Pedro Guimaraes

the diagnosis of CLIPPERS —Guillaume

ShuTing Chen

P1.322 Streptococcus pneumoniae

Portuguese Northern Hospital Experience —Vera Espirito Santo, Ricardo

P1.329 Proposed revised criteria for

Schindler, Stefania Pittaluga, Gulbu Uzel, Daniel Reich, Irene Cortese

Neurosyphilis—A South Brazilian case series. —Conrado Borges, Francisco Germiniani, Jessyca Koslyk, Helio Afonso Teive

CNS INFLAMMATORY DISEASES AND DIFFERENTIAL DIAGNOSIS I

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session I



Sunday, April 23  8:30 a.m.—5:30 p.m.

Banwell, Wolfgang Brueck, Angelo Ghezzi, Gavin Giovannoni, Benjamin Greenberg, Lauren Krupp, Kevin Rostasy, Marc Tardieu, Emmanuelle Waubant, Jerry Wolinsky, Amit Bar-Or, Tracy Stites, Nicola Jessop, Martin Bernhard Merschhemke, Jutta Gaertner

P1.359 Pregnancy Outcome and

P1.370 The Expanded Timed

Jean Mah, Lauren Mednick, Jayne Ness, Teri Schreiner, Amy Waldman, Emmanuelle Waubant, Carolyn Schwartz

Karageorgiou, Asimina Athanasouli, Themistokles Kalamatas

P1.348 Early childhood development

P1.360 Pregnancy outcomes with

Katelyn Kavak, Muhammad Nadeem, Sirin Ghandi, Dejan Jakimovski, Susan Bennett, Murali Ramanathan, Ralph Benedict, Robert Zivadinov, Bianca Weinstock-Guttman

BIOMARKERS AND EXPERIMENTAL STUDIES FOR MULTIPLE SCLEROSIS I

up to kindergarten age after glatiramer acetate exposure during early pregnancy in women with multiple sclerosis —Evelyn Adamus, Sandra Thiel, Annette QueiflerWahrendorf, Melanie In Het Panhuis, DorinaJohanna Neumann, Kerstin Hellwig

P1.349 Risk factors for non-

adherence to disease-modifying therapy in pediatric multiple sclerosis —Carolyn

Teriflunomide Treatment Exposure for Relapsing Remitting Multiple Sclerosis A 4 year follow up —Clementine

interferons or glatiramer acetate exposure in Multiple Sclerosis —Nigar Dargah-Zada, Cynthia Harden

P1.361 Multiple Sclerosis Relapse

Rates, Before, During, and After Pregnancy: a US Retrospective Claims Database Analysis —Amy Phillips, Maria Houtchens, Natalie Edwards

Schwarz, Stephanie Grover, Victoria Powell, Austin Noguera, Jean Mah, Soe Mar, Lauren Mednick, Brenda Banwell, Gulay Alper, Jennifer Graves, Timothy Lotze, Jan-Mendelt Tillema, Mary Rensel, Mark Gorman, Jayne Ness, Amy Waldman, Teri Schreiner, Emmanuelle Waubant, E. Ann Yeh

P1.362 Outcomes following

P1.350 Gender effects on

occurring during clinical trials for multiple sclerosis therapeutics —Afsaneh Shirani,

disease progression in pediatric MS population —Anat Achiron, Shay Menascu,

David Magalashvili, Yulia Khavkin, Mark Dolev Dolgopiat, Michael Gurevich

P1.351 Childhood Adversity Predicts Clinical Disease Features in Patients with Multiple Sclerosis —Natalie Pawlak, Michael Shaw, Ariana Frontario, Kathleen Sherman, Leigh Charvet

P1.352 Natalizumab treatment

SUNDAY

for highly active pediatric multiple sclerosis —Anat Achiron, David

Magalashvili, Mark Dolev Dolgopiat, Shay Menascu

P1.353 Utility of Physical Disability

Outcome Measures in Pediatric-Onset Multiple Sclerosis —James Brenton, Hitoshi Koshiya, Casey Engel, Sarah Herod, Matthew Engelhard, Myla Goldman

P1.354 Early ganglion cell layer loss

is seen in pediatric optic neuritis —Colin

Wilbur, Giulia Longoni, Arun Reginald, Michael Wan, Stephanie Grover, Austin Noguera, Donald Mabbott, Jean Mah, Brenda Banwell, Fiona Costello, E. Ann Yeh

P1.355 Factors associated with

Pediatric Onset Multiple Sclerosis slowed gait, does mood matter? — Carolyn Bauer, Hong Li, Mary Rensel

P1.356 Symbol Digit Modalities Test

and Academic Outcomes in Pediatric MS: Preliminary Findings —Wendy Vargas, Hannah Street, Gabriella Tosto, Victoria Leavitt, James Sumowski

P1.357 Fine motor speed predicts

cognitive functioning in pediatric onset multiple sclerosis (POMS) —David Liu, Michael Shaw, Colleen Schwarz, Lauren Krupp, Leigh Charvet

PREGNANCY AND MULTIPLE SCLEROSIS

P1.358 Multiple Sclerosis and

Pregnancy: Moving Towards a Better Understanding of Treatment Practices by Neurologists for Women with Multiple Sclerosis of Childbearing Age —Lori Travis, Lynette McKinney, Todd Levine

natalizumab exposure throughout pregnancy in patients with relapsing multiple sclerosis (RMS) or Crohn’s disease —Susan Friend, Bill Haddock, Denise Campagnolo, Lily Lee

P1.363 Unintended pregnancies Helen Tremlett, Gary Cutter, Olaf Stuve

P1.364 Quantitative MRI analysis

of cerebral lesions and atrophy in postpartum multiple sclerosis patients — Fariha Khalid, Brian Healy, Sheena Dupuy, Renxin Chu, Rohit Bakshi, Maria Houtchens

P1.365 Pregnancy Outcomes in

Patients with MS Exposed to Branded Glatiramer Acetate —Peleg Baruch, Sigal

Melamed-Gal, Scott Kolodny, Orit Neudorfer

P1.366 Rate of relapse occurrence

in pregnancy and post-partum period —

Raed Alroughani, Maryam Alowayesh, Samar Ahmed, Raed Behbehani, Jasem Al-Hashel

P1.367 Disease activity during

pregnancy and pregnancy outcomes in patients with multiple sclerosis treated with Alemtuzumab—A case series from the German MS and Pregnancy Registry —Kerstin Hellwig, Tjalf Ziemssen,

Thorsten Rosenkranz, Sandra Thiel, Volker Limmroth, Juergen Faiss, Ina Van Loh, Ralf Loos, Chrstoph Lassek, Claudia Klemm, Rainer Goetze, Peter Emrich, Carina Wessels, Magdalena Pernauer, Bert Wagner, Ralf Gold, Kathrin Gerbershagen

TOOLS AND MEASURES FOR CLINICAL EVALUATION IN MULTIPLE SCLEROSIS

P1.368 Multiple Sclerosis Care

Optimization Tool (MS-COT): A Clinical application prototype to predict future disease activity —Diego Silva, Daniela Piani Meier, Shannon Ritter, Davorka Tomic, Jennie Medin, Markus Lange, David Ohlssen

P1.369 Multicenter MRI

standardization to allow quantitative metrics in routine care of multiple sclerosis patients: the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) initiative —Robert Bermel, Stephen Jones, Izlem Izbudak, Yvonne Lui, Dominique Jennings, Lauren Krupp, Ellen Mowry, Nancy Richert, Richard Rudick, James Williams, Elizabeth Fisher

86 2017 AAN Annual Meeting Scientific Program

Up-and-Go (ETUG) is significantly and strongly correlated with EDSS in multiple sclerosis patients —Caila Vaughn,

P1.371 Brain Age: A novel approach

to quantify the impact of multiple sclerosis on the brain —Joel Raffel, James Cole, Chris Record, Sujata Sridharan, David Sharp, Richard Nicholas

P1.372 Multiple Sclerosis Partners

Advancing Technology and Health Solutions (MS PATHS): Initial Launch Experience —Robert Bermel, Ellen Mowry,

Lauren Krupp, Stephen Jones, Robert Naismith, Aaron Boster, Megan Hyland, Izlem Izbudak, Yvonne Lui, Tammie Benzinger, Carrie Hersh, James Williams, Elizabeth Fisher, Jaya Goyal, Jane Relton, Carl De Moor, Glenn Phillips, Bernd Kieseier, Wendy Gabel, Kendra Buzzell, Shoibal Datta, Richard Rudick

P1.373 New multiple sclerosis

severity model predicts future accumulation of disability —Bibiana

Bielekova, Christopher Barbour, Marco Tapia Maltos, Ann Weideman, Peter Kosa, Mika Komori, Kory Johnson, Mark Greenwood

P1.374 Development of a Gait

Module to Complement the 12-item Patient-Reported Multiple Sclerosis Walking Scale —Sharon Chen, Farrah

P1.380 Death of oligodendrocytes

induced by secretory products of B cells of patients with relapsing multiple sclerosis is mediated by extracellular vesicles —Robert Lisak, Liljana Nedelkoska, Hanane Touil, Riu Li, Paul Stemmer, Amit BarOr, Joyce Benjamins

P1.381 MCAM in Multiple Sclerosis:

a biomarker of disease activity? — Alexandra Muccilli, Marc Charabati, Laure Michel, Lyne BourbonniËre, Catherine Larochelle, Alexandre Prat

P1.382 Baseline characteristics and cytokine profiles across demographic subsets in the Intermountain Multiple Sclerosis Project —Laura Baldassari,

Hanieh Seraj, Dee Husebye, M. Paz Soldan, Thomas Martins, Noel Carlson, John Rose

P1.383 Clonal B cell persistence in

multiple sclerosis: A longitudinal immune repertoire study —Ariele Greenfield, Erica Eggers, Hao Wu, Sarah Laurent, Brady Michel, William Harkin, Natalie Pierson, Bruce Cree, Michael Wilson, Stephen Hauser, H. Von Budingen

P1.384 Basic Immunological Profile

Pompilus, Sara Strzok, Sophie Cleanthous, Stefan Cano, Patrick Marquis, Stanley Cohan, Myla Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, Michelle Mellion

Changes of SPMS Patients Treated with BAF312 —Yang Mao-Draayer, Qi Wu, Qin

P1.375 Effectiveness of a

and CXCL 13,-relationship with other CSF parameters and disease variables in MS —Bjorn Evertsson, Viveka Lofstrom,

Medical Education Activity on Improving Knowledge of Prognostic Factors in Multiple Sclerosis among Neurologists —Thomas Finnegan, Gena Dolson, Thomas Scott

P1.376 Continuous Daily Assessment Of Multiple Sclerosis Disability Using Remote Step Count Monitoring —Valerie Block, Antoine Lizee, Elizabeth CrabtreeHartman, Carolyn Bevan, Jennifer Graves, Riley Bove, Ari Green, Bardia Nourbakhsh, Matthew Tremblay, Pierre-Antoine Gourraud, Madelana Ng, Mark Pletcher, Jeffrey Olgin, Gregory Marcus, Diane Allen, Bruce Cree, Jeffrey Gelfand

P1.377 Wearable electromyogram

device associated with disability outcomes in adults with multiple sclerosis —Jennifer Graves, Jennifer Arjona, Pierre-Antoine Gourraud

P1.378 The state of the art of

technologies for the assessment of gait in multiple sclerosis: Filling the gap — Stephen Czarnuch, Andrew Hynes, Hayley Crichton

P1.379 Impact of an electronic

monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: Results of a randomized trial —E. Ann Yeh, Stephanie Grover, Victoria Powell, Austin Noguera, Kim Edwards, Ruth Slater, Brenda Banwell, Mark Gorman, Jennifer Graves, Timothy Lotze,

Wang, Catherine Dowling, Steven Lundy, Katy Demery, David Fox

P1.385 Novel CSF biomarkers NFL

Ali Manouchehrinia, Jan Hillert, Virginija Karrenbauer

P1.386 Construction of a new in vitro blood-brain barrier (BBB) model that incorporates triple-culturing system of BBB components. —Yukio Takeshita, Yuki

Tomoe, Susumu Fujikawa, Yasuteru Sano, Hideaki Nishihara, Toshihiko Maeda, Fumitaka Shimizu, Takashi Kanda

P1.387 Sera of relapsing-

remitting multiple sclerosis (RRMS) patients express high levels of bone morphogenetic protein-2 that correlate with BMP-4 and BMP-5 levels, and induce low neuronal phenotype in vitro. —Moran Penn, Karin MausnerFainberg, Maya Golan, Arnon Karni

P1.388 Longitudinal monitoring of

metabolic alterations in TMEV mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy — Michelle Sudyn, Ferdinand Schweser, Claire Modica, Suyog Pol, Michael Dwyer, Danielle Siebert, Jesper Hagemeier, Marilena Preda, Nicola Bertolino, Robert Zivadinov

P1.389 Serial MRI of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis —Suyog

Pol, Ferdinand Schweser, Nicola Bertolino, Marilena Preda, Michele Svienson, Michelle Sudyn, Natan Babek, Danielle Siebert, Robert Zivadinov


P1.390 Combinatorial CNS Cell-

Specific CSF Biomarkers for Multiple Sclerosis —Ruturaj Masvekar, Bibiana Bielekova, Peter Kosa, Valentina Fossatti

P1.391 Expression and regulation

of GMCSF in immune cell subsets in MS —Cris Constantinescu, Jehan Aram, Radu Tanasescu, Elena Morandi, Nanci Frakich, Ian Spendlove, Bruno Gran

P1.392 Comprehensive analysis

of the intrathecal B-cell response in patients with multiple sclerosis [MS] —

Antara Finney-Stable, Allison Liang, Jerry Lin, Saud Sadiq

P1.393 Identification of the

flotillin-1/2 heterocomplex as a target of autoantibodies in multiple sclerosis —

Stefanie Hahn, George Trendelenburg, Madeleine Scharf, Yvonne Denno, Stefanie Brakopp, Bianca Teegen, Christian Probst, Klaus-Peter Wandinger, Mathias Buttmann, Florian Szabados, Matthias Vom Dahl, Tania Kuempfel, Peter Eichhorn, Hans- Juergen Gold, Friedemann Paul, Sven Jarius, Nico Melzer, Winfried Stoecker, Lars Komorowski

P1.394 Interferon-β mediates

oligodendrocyte-associated CYP17A1 repression in multiple sclerosis: dehydroepiandrosterone-sulphate regulates inflammatory demyelination — Roobina Boghozian, Brienne McKenzie, Leina Saito, Ninad Mehta, William Branton, Jian Lu, Glen B. Baker, Farshid Noorbakhsh, Christopher Power

P1.395 Fatty acid-binding protein

4 (FABP4) enhances TLR2, TNFa and IL23 expression in CD14+ monocytes in vitro. —Kiandokht Keyhanian, Vahid Davoudi, Shrishti Saxena, Pia Kivisakk, Moogeh Baharnoori, Tanuja Chitnis

P1.401 Aberrant profile of serum

exosomal miRNA and peripheral blood cells secretion of exosomes in RR MS —Marcin Mycko, Igor Selmaj, Magdalena Namiecinska, Maria Cichalewska, Krzysztof Selmaj

P1.396 Microglial modulation for gray

P1.402 Oligodendroglial FGFR 1 gene

Matthew Bellizzi, Harris Gelbard

Rajendran, Mario Giraldo Velasquez, Christine Stadelmann-Nessler, Martin Berghoff

matter neuroprotection: mixed-lineage kinase 3 inhibitor URMC-099 protects hippocamapal synapses in EAE —

P1.397 Increased methionine

sulfoxide levels in the CSF of multiple sclerosis patients. —Zerina Balic, Fozia Mir, Saud Sadiq

P1.398 Tumefactive demyelinating

lesions (TDLs): Does MOG IgG play a role? —Ayse Altintas, Toshiyuki Takahashi,

Aksel Siva, Sabahattin Saip, Ugur Uygunoglu, Cengiz Yalcinkaya, Kazuo Fujihara

P1.399 Novel strategies for

remyelination: Modifying the way oligodendrocytes translate lysine acetylation to promote myelin repair — Achillefs Ntranos, Patrizia Casaccia

P1.400 Peripheral CD19+ cell counts

and therapy intervals as a surrogate marker for B-cell depleting therapy in multiple sclerosis and neuromyelitis optica —Jan Bolz, Maren Peschke, De-Hyung Lee, Gisa Ellrichmann, Ralf Linker, Aiden Haghikia, Ralf Gold

targeting protects against inflammation and demyelination in EAE through ERK/ AKT phosphorylation —Ranjithkumar

P1.403 Longitudinal Diffusion Tensor Imaging and Quantitative Susceptibility Mapping of encephalomyelitis driven demyelinating rodent brain —Suyog Pol,

Claire Modica, Ferdinand Schweser, Michelle Sudyn, Nicola Bertolino, Marilena Preda, Michael Dwyer, Jesper Hagemeier, Danielle Siebert, Robert Zivadinov

P1.404 Early hematopoiesis in

multiple sclerosis patients. —Daniel Jons, Maria Kneider, Linda Fogelstrand, Anders Jeppsson, Stefan Jacobsson, Oluf Andersen

P1.405 SINE Compounds

Demonstrate Efficacy in a Preclinical Model of Multiple Sclerosis and an In Vitro Screening of Viral Agents of Coinfection —Sharon Tamir, Jeffery Haines,

P1.406 MSDx Complex-1: A potential marker of drug response? —Vanessa White, Ramesh Nayak

P1.407 Anti-GAD65 Antibody

Testing at a Tertiary Care Center —Ivana Vodopivec, Alexandra Loomis, Jason Baron, Tracey Cho, Shamik Bhattacharyya

NEUROSCIENCE RESEARCH PRIZE RECIPIENTS

P1.408 ALZCan: Predicting Future

Onset of Alzheimer’s Using Polygenic Risk Scores, Cognitive Tests, CSF Biomarkers, and Multiple Neuroimaging Modalities Recipient:

Pravin Ravishanker

P1.409 Inhibiting the Proliferation of

Patient-Derived Glioblastoma Multiforme (GBM) Cells and U-87 MG Cell Line Using Leaf Extract of Bacopa monnieri Recipient:

Tejas Athni

P1.410 Triggering the brain to heal

itself after traumatic brain injury: where glia, anesthesia and nanomedicine meet Recipient:

Gokul Kannan

Olivier Herbin, Konstantina Alexandropoulos, Yosef Landesman, Dilara McCauley, Sharon Shacham, Patrizia Casaccia

Tuesday, April 25, 1:00 p.m. to 3:00 p.m.

Top abstracts previously presented at the Society for Neuro-oncology Annual Meeting will be presented by their authors in 20-minute platform presentations. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of neurooncology with overall goal of developing more effective prevention and treatment. 2:00 p.m.–2:20 p.m.  Transformation of Tumor Endothelial Cells to Mesenchymal Stem Cell-like Cells Induces Therapy Resistance in Glioblastoma

Michael Weller, MD

Menggui Huang, PhD

1:20 p.m.–1:40 p.m.  Targeting Carcinoma-astrocyte Gap Junctions in Brain Metastasis

Adrienne Boire, MD

2:20 p.m.–2:40 p.m.  Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 (Durvalumab [DUR]) in Patients with Glioblastoma (GBM): Results For Cohort B (DUR Monotherapy), Bevacizumab (BEV) Naïve Patients with Recurrent GBM

1:40 p.m.–2:00 p.m.  Single-cell Profiling of Glioblastoma Biopsies Identifies a Family of Activating PDGF-receptor Deletions

Boston, MA

Zurich, Switzerland

New York, NY

Soeren Mueller, PhD San Francisco, CA

Philadelphia, PA

David A. Reardon, MD

2:40 p.m.–3:00 p.m.  Redefining the Cellular Architecture of Adult and Pediatric Glioblastomas Through Large-scale Singlecell Analyses

Mariella Filbin, MD, PhD

Boston, MA

Current as of February 15, 2017

Fast and easy registration · AAN.com/view/AM17 87

SUNDAY

Invited Science: Neuro-oncology

1:00 p.m.–1:20 p.m.  ACT IV: An International, Double-blind, Phase 3 Trial of Rindopepimut in Newly Diagnosed, EGFRvIIIexpressing Glioblastoma

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session II



MOVEMENT DISORDERS: HUNTINGTON’S DISEASE, CHOREA, AND TARDIVE DYSKINESIA

P2.001 Targeting sphingosine-1-

HART Subjects with Historical Placebo Controls —Andrew McGarry, Victor Abler,

Peggy Auinger, Igor Grachev, Sanjay Gandhi, Spyros Papapetropoulos

phosphate lyase is neuroprotective in a neuron model of Huntington’s disease —

P2.012 Central cognitive processing

P2.002 Behavioral Changes on the

Sungmee Park, Laya Dasari, Paul Gilbert, Jody Corey-Bloom

Erin Furr-Stimming, Andrey Tsvetkov

UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD) —Jody Corey-

Bloom, Seon Nam, Ayesha Haque, Ameera Haque, Sungmee Park, Ajay Nathan, Aeri Kim, Evelyn Corona, Paul Gilbert

P2.003 The Balance Tracking

System (BTrackS™) Measures Disease Progression and Fall Risk in Huntington’s Disease —Sungmee Park, Jody Corey-Bloom, Seon Nam, Ameera Haque, Ajay Nathan, Stephen Howell, Chase Snell, Laura Zima, Larry Phung, Paul Gilbert, Daniel Goble

P2.004 Assessment of capacity to

consent in a Huntington disease clinical trial: implications for future clinical trial design in neurodegenerative disease populations —Claudia Testa, Mary

Edmondson, Pinky Agarwal, Karen Blindauer, Carolyn Gray, Joseph Jankovic, Rajeev Kumar, David Shprecher, Philip Siragusa, Jacquelyn Whaley, Samuel Frank

P2.005 Efficacy, Safety, and

Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD —Karl

Kieburtz, Bernhard Landwehrmeyer, Ralf Reilmann, Juha Savola, Eli Eyal, Igor Grachev, Beth Borowsky, Andrew McGarry, Spyros Papapetropoulos, Michael Hayden

P2.006 Multicenter, Randomized,

MONDAY

Double-blind, Placebo-controlled Phase 1b/2a Studies of WVE-120101 and WVE120102 in Patients with Huntington’s Disease —Steven Hersch, Daniel Claassen, Mary Edmondson, Edward Wild, Roberto Guerciolini, Michael Panzara

P2.007 When DBS can be of benefit in Huntington’s disease —Jessica Karl,

Konstantin Slavin, Kathleen Shannon, Leonard Verhagen Metman

P2.008 Tetrabenazine and olanzapine in management of Huntington disease: comparative retrospective analysis of data from the worldwide observational study Enroll-HD —Yury Seliverstov, Artyom

Borzov, Ravil Niyazov, Mikhail Belyaev, Sergei Illarioshkin

P2.009 Tetrabenazine Use in

Patients With Huntington’s Disease (HD) Chorea —Victor Sung, Ravi Iyer, Traci Schilling, Paul N. Buzinec

P2.010 Late-Onset Huntington

Disease: Clinical Cases with Intermediate CAG Repeat Expansions — Dana McDermott, Jee Bang, Alayna Liptak, Divya Krishnakumar, Alexandra Nelson, Michael Geschwind

P2.011 Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): A Comparison of Open-

speed is an early marker of Huntington’s disease (HD) onset —Ajay Nathan,

Monday, April 24  8:30 a.m.—7:00 p.m. Poster Session II Neighborhoods

F

E

P2.145–222

P2.111–144

P2.013 Implementation and

D

Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington’s Disease in a Phase II Clinical Trial —Spyros Papapetropoulos, Shai Fine, Shayna Taylor, Kathleen Blatt, Elie Cohen, Chen Admati, Yonatan Dolan, Josh Lemieux, Igor Grachev, Iris Grossman, Michael Hayden

P2.014 Epidemiology of Juvenile

Huntington’s Disease in the United States —Anh-Thu Vu, Allison Wright Willis,

P2.101–110

Poster Discussion

C

P2.081–100

H

Pedro Gonzalez-Alegre, Dylan Thibault

P2.015 Huntington Disease-like 2: a case series of six patients —Victor Calil

Da Silveira, Luiz Felipe Vasconcellos, Mariana Spitz, Vitor Tumas

P2.016 Deutetrabenazine Treatment Response by Concomitant DopamineReceptor Antagonists in the Phase III, Randomized, Double-Blind, PlaceboControlled AIM-TD Trial in Tardive Dyskinesia (TD) —Joohi Jimenez-Shahed,

B

ePosters

P2.071–080

P2.018 Estimation of Epidemiology of Tardive Dyskinesia in the United States —Amit Dhir, Traci Schilling, Victor Abler, Ravi Potluri, Benjamin Carroll

P2.019 Hyperglycemic chorea/

hemiballism ascertained at a large medical center over 15 years: Frequency & characteristics —Conor Ryan, J. Ahlskog, Rodolfo Savica

P2.020 Deutetrabenazine is

Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIMTD Study —Joohi Jimenez-Shahed, Hubert Fernandez, David Stamler, Mat Davis, Stewart Factor, Robert Hauser, Jouko Isojarvi, William Ondo, Karen E. Anderson

P2.021 Reducing Variability in the

Measurement of Chorea —Samuel Frank, Shirley Eberly, David Oakes, David Stamler, Francis Walker, Claudia Testa, Huntington Study Group

P2.022 Mesial Temporal Lobe

Epilepsy with Hippocampal Sclerosis in Chorea-Acanthocytosis —Karin Mente,

Sun A Kim, Christopher Grunseich, Marco Hefti, John Crary, Barbara Karp, Ruth Walker

88 2017 AAN Annual Meeting Scientific Program

I

P2.329–412

A

P2.017 Safety and Tolerability of

Cynthia Comella, Grace Liang, Joshua Burke, Christopher O’Brien

P2.251–328

P2.031–070

Hubert Fernandez, David Stamler, Mat Davis, Stewart Factor, Robert Hauser, Jouko Isojarvi, William Ondo, Karen E. Anderson

Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of Long-Term Exposure Data from Three Studies —Gary Remington, Stewart Factor,

G

P2.223–250

P2.001–030 A: Movement Disorders B: History of Neurology; Research Methodology and Education; Practice, Policy, and Ethics; MS and CNS Inflammatory Disease ePosters C: Aging and Dementia D: MS and CNS Inflammatory Disease Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Headache; General Neurology G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease I: MS and CNS Inflammatory Disease

P2.023 A Rare Case of Paraneoplastic

MOVEMENT DISORDERS: OTHER I

Robert Pierce

P2.026 Efficacy and Safety of a Novel

Chorea —Andrea Stoner, William Boudouris,

P2.024 An unusual case of

hemichorea in a woman with newly discovered renal cell carcinoma and inconclusive LGI-1 antibody —Kalea Colletta, Ninith Kartha, Sean Ruland

P2.025 Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites —Dimitri Grigoriadis, Evan

Smith, Ajay Madan, Dimitri Grigoriadis, Clinton Wright, Haig Bozigian

Copper Modulating Agent (WTX-101) for Wilson Disease: Results of a Phase 2, Multi-Center, Open Label Study —Danny Bega, Aftab Ala, Fred Askari, Jeff Bronstein, Anna Czlonkowska, Peter Ferenci, David Nicholl, Karl-Heinz Weiss, Michael Schilsky

P2.027 Correspondence between

MRI borders of the subthalamic nucleus and its electrophysiological borders: a comparison study using intraoperative


CT. —Sander Bus, Pepijn Van Den Munckhof, Maarten Bot, Gian Pal, Bichum Ouyang, Sepehr Sani, Leonard Verhagen Metman

P2.028 Basal Ganglia and Limbic

Striatal Regions are Differentially Affected by Pramipexole: D3 receptor— Mediated Changes in Markers of Synaptic Strength —Meagan Bailey, Amanda Persons, Celeste Napier

P2.029 Imaging Biomarkers of

Delayed Sequelae in Mild Traumatic Brain Injury —Nicole Reams, Julie Anderson,

P2.041 The Influence of Social

sclerosis —Michal Greenberg-Abrahami,

P2.062 The 10-Point Disability

Matthew Schelke

Neomi Bitterman, David Magalashvili, Shay Menascu, Anat Achiron

P2.042 Alice In Wonderland

P2.054 Computer algorithm as a

Ahmed Obeidat, Elizabeth Dragan, Aram Zabeti

Vinny, Venugopalan Vishnu, Neeraj Balaini, Manish Modi, Bishan Radotra, Vivek Lal

PRACTICE, POLICY, AND ETHICS II

Science on the Nosology of Dementia —

Syndrome: A History —Edward Fine, Osman Farooq, Naimeen Mahfooz

P2.043 The Evolutionary Saga of

Corticosteriod in Myasthenia Gravis and What We Have Learnt From This… — Sankar Bandyopadhyay

P2.044 On the History of Multiple

Reid Perlman, Wei Li, Shaun Walters, Chi Wang, Roberta Frigerio, Demetrius Maraganore

Sclerosis and War —Ahmed Obeidat,

P2.030 2 Cases of Thiamine

in Paris – A Neurological Guide to Pinpointing the Houses of Famous Neurologists in the Late XIX Century; Charcot and his Triumvirate of Favourite Pupils. —Carlos Camargo, Francisco

Pyrophosphokinase Mutation Identified in United States —Serena Liu, Christos Sidiropoulos

Bakkiam Subbiah, Aram Zabeti

P2.045 “Flaneur Neurologique”

HISTORY OF NEUROLOGY

Germiniani, Olivier Walusinski, Andrew Lees, Helio Afonso Teive

P2.031 Da Costa’s Syndrome and

P2.046 Remembering James

Postural Tachycardia Syndrome: A rose by any other name? —Kelsey Klaas, David Burkholder

Parkinson (1755-1824): His historic essay on the shaking palsy and his prodigious eclectic career as a “physician for all seasons” —Alison Roby, David Roby

supporting tool for clinical decision making on a mobile platform —Wilson

P2.055 Probable Rates vs. Self-

Reported: Variances in Concussion Reporting and Extent of Education for High School Athletes —Constance

Johnson, Philip Rosenbaum, Christopher Giza

P2.056 Development and Validation

of a Patient Centered Young Stroke Outcome Measure Tool —Ravish Kothari, Souvik Sen, Amy Edmunds, Julian Duda, Viktoriya Duda

P2.057 Psychometric evaluation of

quality of life measures in a three-arm, randomized, double-blind, placebocontrolled phase III study of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who have refractory partial-onset seizures (EXIST-3) —Petrus De Vries, David Franz,

outcomes: prehistoric Peru (c. 400 BC) to Modern Neurosurgery (early 20th century) —David Kushner, John W. Verano

P2.047 The Reflex Hammer: A Brief

Paolo Curatolo, Rima Nabbout, Noah Berkowitz, Maureen Neary, Fabian Herbst, Kate Sully, Elaine Brohan, John Lawson

Daniella Sisniega

P2.058 Chiari I Malformation

P2.033 Dr. Paula Coutinho’s Seminal

P2.048 Soul-searching in the Brain:

P2.032 Trepanation procedures and

Contributions to the Understanding of Machado-Joseph’s Disease. —Bruno Carniatto Marques Garcia, Francisco Germiniani, Helio Afonso Teive

P2.034 The Illustrated Mind —Harry Sutherland-Foggio

P2.035 The forgotten semiology: the evolution of neurological diagnosis —

P2.036 Serendipity & Neurology — Yuan-Kai Lee, Hardev Pall

P2.037 William Hammond’s

perspective on the assassination of President Garfield —Eric Prince, George Paulson, E. Massey

P2.038 History of neuroimaging in

Multiple Sclerosis: 1838-2016 —Nicoletta Caputi, Domenico Passafiume, Francois Boller

P2.039 Religious and political

conflicts could cause the incidence of conversion disorders in 17th century— the analysis of “The Anatomy of Melancholy” by Robert Burton. —Joanna

Classical Antiquity to 17 Century —Suraj th

Rajan

P2.049 Hitler’s Neuro-psychiatric

Medley, an Un-ignorable War History for Neurologists. —Sankar Bandyopadhyay

P2.050 Marc Chagall’s L’homme A

La Tete Renversee (Man With His Head Thrown Back) – An Artistic Depiction of Severe Retrocollis in Neurodegeneration with Brain Iron Accumulation —Marlon Caeira, Francisco Germiniani, Helio Afonso Teive

P2.051 Historical Perspective of

Cambodian Medicine with a focus on Neurology —Sandeep Singh, Soma Sahai-

Srivastava, Shaweta Khosa, Shrikant Mishra

RESEARCH METHODOLOGIES

P2.052 Development of an Algorithm to Identify Multiple Sclerosis (MS) Disease Severity Based on Healthcare Costs in a US Administrative Claims Database —Jacqueline Nicholas, Daniel

Bielewicz, Adam Górniak, Konrad Rejdak

Ontaneda, Matthew Carraro, Ning Wu, Mehul Jhaveri, Kun Yang, Daniel Jones, Terrie Livingston

P2.040 Argyll Robertson and Spinal

P2.053 Interactive sensory digital

Myosis —Jennifer Creed, M. Tariq Bhatti, E. Massey

platform for upper limb sensory assessment in patients with multiple

Common Data Element Project: The National Institute of Neurological Disorders and Stroke (NINDS) Chiari I Malformation Common Data Elements (CDE) Recommendations Version 1.0 Website Release —Robin Feldman, Sherita Alai, Joanne Odenkirchen, Kristen Joseph, Kaitlyn Esposito, Dorothy Poppe

P2.059 Primary and secondary

progressive MS subjects in clinical trials: Are they similar? —Robert Fox, Akshata

Ashokkumar, Christopher Coffey, Robin Conwit, Merit Cudkowicz, Dixie Ecklund, Trevis Gleason, Andrew Goodman, Eric Klawiter, Maxine Koepp, Kazuko Matsuda, Michelle McGovern, Robert Naismith, Sneha Natarajan, Brenda Thornell, Jon Yankey

P2.060 A Common Data Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) Cerebral Palsy Common Data Elements Version 1.0 Recommendations —Robin Feldman,

P2.063 Pilot for the Implementation

of a Telemedicine Program (Home Video Visits) at an ALS Center of Excellence —

Samuel Maiser, Lisa Molnar, Elizabeth Rossini, JoLynn Spaeth, Mary Meeks, Yeng Moua, Katherine Esse, Ezgi Tiryaki

P2.064 To Assess the Efficacy of Dr.

Stroke Activation System in Optimization Door to Needle Time at Primary Stroke Center-A Quality Improvement Project — Syed Abbas, Oleg Chernyshev, Alireza Minagar, Hugo Cuellar-Saenz, Jeanie McGee, Leatrice Williams, Eduardo Gonzalez-Toledo

P2.065 Addressing direct admission workflow through process mapping —

Kyle Rossi, Bridget Mueller, Elizabeth Pedowitz, Laura Stein, James Young, Ji-Yeoun Yoo, Stanley Tuhrim

P2.066 Misinformation on

the internet means public health organizations need to reassess their Zika policies —Anand Venkatraman, Dhruvika Mukhika, Nilay Kumar, Sajanjiv Singh Nagpal

P2.067 A multi-faceted approach to reduce no show rates in an outpatient specialty clinic —Tracie Caller, Ashley Godwin, Jodi Willoughby, Payden Bunning, Marti Paquette, Matthew LaHiff

P2.068 Quality of Stroke Care Among Ischemic Stroke Patients Discharged from Non-Neurology Services —Elena Gibson, Karen Albright, Jessica Ellison, Michael Lyerly

P2.069 Which patients are

deemed not appropriate for neurologic consultation, and what happens to them? —Roland Brilla, Stephanie Gardon, Anne Weiss, Audrey Jantzen

P2.070 Ethics of Medical Marijuana

Use in Pediatric Epilepsy —Alison Christy, Sara Taub

Joanne Odenkirchen, Sherita Alai, Joy Esterlitz, Tracy Burr

P2.061 First Global Multifocal Motor

Neuropathy (MMN) Quality of Life (QOL) Patient Survey Identifies Needs in Education and Treatment —Jonathan Katz, Richard Lewis, Dominick Spatafora

Fast and easy registration · AAN.com/view/AM17 89

MONDAY

Victor Calil Da Silveira, Pedro Sudbrack Oliveira, Renan Vallier, Pericles Maranhao Filho, Abelardo Araujo

History of the Tool We Know and Love —

Scale in Multiple Sclerosis: Phase I Development and Planning study —

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session II



Monday, April 24  8:30 a.m.—7:00 p.m.

MS and CNS Inflammatory Disease ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P2.071 Relevance of functional

connectivity abnormalities to cognitive impairment in neuromyelitis optica spectrum disoder —Filippo Savoldi, Maria

Rocca, Paola Valsasina, Gianna Carla Riccitelli, Marta Radaelli, Paolo Preziosa, Giancarlo Comi, Andrea Falini, Massimo Filippi

P2.072 The clinical profile of NMOSD

Multiple Sclerosis: A Two-Year Comparative Study —Paolo Preziosa, Maria Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Lucia Moiola, Andrea Falini, Giancarlo Comi, Massimo Filippi

P2.074 Elsberg syndrome: A rarely

recognized cause of cauda equina syndrome and lower thoracic myelitis —

Clarke, Simon Broadley

Filippo Savoldi, Timothy Kaufmann, Eoin Flanagan, Brian Weinshenker

P2.073 The Effects of Natalizumab

P2.075 Upper gastrointestinal

in Australia and New Zealand —Laura

and Fingolimod on Clinical and MRI Measures in Relapsing Remitting

FRONTOTEMPORAL DEMENTIA

P2.081 Instrumental activities

of daily living in clinical subtypes of frontotemporal dementia —Negar Moheb, Mario Mendez, Sarah Kremen, Edmond Teng

P2.082 Rescue of Tau Phenotypes in

Human iPSC-Derived Neuronal Models of Frontotemporal Degeneration with Experimental Therapeutics —M. Catarina

Silva, L. Ashley Watson, Steven D. Sheridan, Diane Lucente, Nicholas J. Brandon, Li-Huei Tsai, Bradford Dickerson, Stephen J. Haggarty

P2.083 Evaluation of quantitative EEG as a disease and treatment response biomarker in frontotemporal dementia —

MONDAY

Elena Ratti, Sebastian Von Rosenstiel, Shani Waninger, Chris Berka, Mario Mendez, Ajay Verma

P2.084 Structural and functional

brain connectome architecture in early onset Alzheimer’s disease and the behavioral variant of frontotemporal dementia —Massimo Filippi, Silvia Basaia,

Elisa Canu, Sebastiano Galantucci, Alessandro Meani, Francesca Caso, Giuseppe Magnani, Roberto Santangelo, Monica Falautano, Andrea Falini, Giancarlo Comi, Federica Agosta

P2.085 Cognitive reserve and

TMEM106B genotype modulate brain damage in pre-symptomatic monogenic FTD: results from the GENFI study — Enrico Premi, Mario Grassi, John Van Swieten, Daniela Galimberti, Caroline Graff, Mario Masellis, Carmela Tartaglia, Fabrizio Tagliavini, James Rowe, Robert Laforce, Elizabeth Finger, Giovanni Frisoni, Alexandre Mendonca, Sandro Sorbi, Stefano Gazzina, Maura Cosseddu, Silvana Archetti, Roberto

lymphoma: an emerging late complication of natalizumab therapy? —

P2.076 Lumbosacral

Radiculomyelopathy- a rare presentation in an established case of Neuromyelitis Optica Spectrum Disorders —Shweta Sapnar, Aparna Prabhu

P2.077 Tissue–specific MRI features in the brainstem and corpus callosum of MS and NMOSD cohorts, compared to healthy control subjects —Lisa Eunyoung

P2.086 Bilingualism delays the age

of onset in Frontotemporal Dementia but not Alzheimer’s disease —Ratnavalli Ellajosyula, Jwala Narayanan

P2.087 Perfusion alterations reveal distinct patterns of early vulnerability to damage across the ALS-FTLD continuum —Pilar Maria Ferraro, Charles A. Jester, Katerina Placek, Christopher Olm, Federica Agosta, Lauren Elman, Leo McCluskey, David Irwin, Massimo Filippi, Murray Grossman, Corey McMillan

P2.088 Characteristics and Progress on the Initial 209 Subjects in the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol —Bradley Boeve,

Howard Rosen, Adam Boxer, Giovanni Coppola, Christina Dheel, Bradford Dickerson, Kelley Faber, Julie Fields, Tatiana Foroud, Ralitza Gavrilova, Nupur Ghoshal, Jill Goldman, Neill Graff-Radford, Murray Grossman, Hilary Heuer, John Hsiao, GingYuek Hsiung, Edward Huey, David Irwin, Kejal Kantarci, Anna Karydas, David Knopman, John Kornak, Walter Kukull, Ian R.A. Mackenzie, Bruce Miller, Matt Miller, Creighton Phelps, Rosa Rademakers, Katherine Rankin, Leslie Shaw, Margaret Sutherland, Jeremy Syrjanen, Arthur Toga, John Trojanowski, Ashley Vetor, Sandra Weintraub, Zbigniew Wszolek

90 2017 AAN Annual Meeting Scientific Program

IGG4 Related Disease: A Case Report — Alison Walsh, Anthony Allen

P2.079 A challenging case of

a AQP-4-seronegative, anti-MOG positive, NMOSD patient. —Clementine Karageorgiou, Ermioni Giannouli

P2.080 Differential brainstem

Lee, Anna Combes, Robert Carruthers, Jacqueline Palace, Lucy Matthews, Anthony Traboulsee, Shannon Kolind

atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders among Hong Kong Chinese —Chi Yan Lee,

AGING AND DEMENTIA: NEUROPATHOLOGY

Early Untreated Parkinson’s Disease —

Emily Watson, Renee Squires, Mike Boggild

Gasparotti, Marta Manes, Antonella Alberici, M. George Cardoso, Martina Bocchetta, David Cash, Sebastien Ourselin, Alessandro Padovani, Jonathan Rohrer, Barbara Borroni

P2.078 Neurologic Complications of

P2.089 Neuropathological Basis of

Apolipoprotein E Genotype on Psychosis in Alzheimer’s Disease —Julia Kim,

Corinne Fischer, Tom Schweizer, David Munoz

P2.090 Globular Glial Tauopathy

(GGT): clinical-pathological study of two autopsied cases and review of the literature —Takeshi Miura, Naomi Mezaki,

Sanpei Kazuhiro, Kenju Aoki, Ryoko Takeuchi, Hidetomo Tanaka, Yasuko Toyoshima, Akiyoshi Kakita, Hitoshi Takahashi, Osamu Onodera, Takeshi Ikeuchi

P2.091 Clinical challenges in rapidly progressive dementia:lessons learned from an autopsy series —Andrew

Natonson, Ho-Yann Jong, Madeline Nguyen, Frank Bittner, Marian Dale, Dennis Bourdette, Randall Woltjer, Deniz Erten-Lyons

P2.092 Neuropathological correlates

of apathy in Alzheimer’s disease —Wendy Chen

VASCULAR DISEASE AND DEMENTIA

P2.093 Modeling the Relationships

Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer’s Disease Neuropathology in 1,421 Participants from the National Alzheimer’s Coordinating Center Neuropathology Data Set —Jonathan

Duskin, Michael Alosco, Lilah Besser, Brett Martin, Christine Chaisson, Neil Kowall, Ann McKee, Robert Stern, Yorghos Tripodis

P2.094 High Pulse Pressure and

Hypertension are Independently Associated with Cognitive Impairment in

Henry Mak, Pui Wai Chiu, Frederik Barkhof, Koon Ho Chan

Maxime Doiron, Melanie Langlois, Nicolas Dupre, Martine Simard

P2.095 Early Diagnosis of Vascular

Cognitive Impairment Leads to Improved Treatment of Vascular Risk Factors — Angelia Kirkpatrick, Andrea Vincent, Elliott Ross, Calin Prodan

P2.096 Neurofilament light chain as

a serum marker for cerebral small vessel disease —Marco Duering, Steffen Tiedt, Ebru Baykara, Philippe Lyrer, Stefan Engelter, Benno Gesierich, Melanie Achmueller, Christian Barro, Ruth Adam, Michael Ewers, Martin Dichgans, Jens Kuhle, Nils Peters

P2.097 White matter microstructure in the DMN mediates the effects of aging, Alzheimer’s, and cerebrovascular pathology on executive function —

Christopher Brown, Frederick Schmitt, Charles Smith, Brian Gold

P2.098 Predicting long term cognitive outcomes after stroke using pre and post-stroke cognitive trajectories. —Neil

Thomas, Nora Mattek, Katherine Wild, Hiroko Dodge, Lisa Silbert, Jeffrey Kaye, Deniz ErtenLyons

P2.099 Impact of co-morbid amyloid pathology on clinical phenotype of patients with vascular cognitive impairment —David Bergeron, Niels Prins, Colin Groot, Anita Van Loenhoud, Robert Laforce, Bart Van Berckel, Frederik Barkhof, Wiesje Van Der Flier, Philip Scheltens, Rik Ossenkoppele

P2.100 NA


MS and CNS Inflammatory Disease Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 p.m. P2.101 Long-term exposure to natalizumab during pregnancy—a prospective case series from the German Multiple Sclerosis and Pregnancy Registry —Kerstin Hellwig, Sandra Thiel, Ingrid Meinl, Ralf Gold, Tania Kuempfel

Data Blitz:  11:50 a.m.–11:55 a.m. P2.102 EVOLVE-MS-1: Phase 3 OpenLabel Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis —Robert Naismith, Richard Leigh-

Pemberton, Amy Claxton, Yangchun Du, Marjie Hard, Lisa Von Moltke, Jerry Wolinsky

Data Blitz:  11:55 a.m.–12:00 p.m. P2.103 Outcomes of the TOPIC Extension Study of Teriflunomide in Patients With Early Multiple Sclerosis: Up to 7 Years of Clinical Results —Aaron

MYOPATHIES AND MYASTHENIA GRAVIS II

P2.111 Frequency and duration of

electrical myotonia as biomarkers of myotonia congenita —Samantha LoRusso, John Kissel, William Arnold

P2.112 Camptocormia with Anti Ku

antibodies in Inclusion Body Myositis —

P2.113 TRPV1 as a biomarker for regenerating muscle fibers —Kenya Murata, Megumi Mori, Hidefumi Ito

P2.114 Congenital myasthenic

syndrome presenting in the sixth decade. —Bernadette Monaghan, Albi

Chalissery, Francesca Brett, Yvonne Langan, Janice Redmond

P2.115 Vitamin Deficiencies in

Patients with Myopathies and Other Neuromuscular Conditions —Dubravka Dodig, Mark Tarnopolsky, Sarah Currie

P2.116 A case of concurrent

AL-amyloidosis with transthyretin c.371G>A/p.R124H polymorphism treated with autologous stem cell transplantation for 3 years. —Sleiman El

Jamal, Lindsey Coleman, Yanhua Li, He Wang, Lleras Armando Samuels, Mary Kraemer, Jin Luo

P2.117 Dermatomyositis plus

seronegative Lambert-Eaton myasthenic syndrome —William Kean, Shauna O’Sullivan, Glen Cook

P2.118 Health Utilities in Myasthenia Gravis —Carolina Barnett Tapia, Vera Bril, Ahmed Bayoumi

Demyelination —Matthew Tremblay, Javier

Data Blitz:  12:00 p.m.–12:05 p.m. P2.104 Alemtuzumab Durably Slows Brain Volume Loss Over 6 Years in the Absence of Continuous Treatment in Patients With Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II) —Anthony Traboulsee,

Data Blitz:  12:10 p.m.–12:15 p.m. P2.106 DPPX-antibody associated encephalitis: main syndrome and antibody effects —Makoto Hara, Helena

Michael Barnett, Giancarlo Comi, Christopher LaGanke, Daniel Pelletier, Alex Rovira, Sven Schippling, David Margolin, Karthinathan Thangavelu, Kunio Nakamura, Douglas Arnold, On Behalf Of The CAR And CAMMS03409 Investigators

Data Blitz:  12:05 p.m.–12:10 p.m. P2.105 Clinical and Radiographic Correlations in Patients with Brain Biopsy-Confirmed Tumefactive

VIllanueva-Meyer, Soonme Cha, Tarik Tihan, Jeffrey Gelfand

Arino, Mar Petit-Pedrol, Lidia Sabater, Maarten Titulaer, Eugenia MartinezHernandez, Marco Schreurs, Francesc Graus, Josep Dalmau

Data Blitz:  12:15 p.m.–12:20 p.m. P2.107 Exploratory MRI Biomarkers of Opicinumab (Anti-LINGO-1) Show Stabilization of Pre-existing T2 Lesions in Relapsing Multiple Sclerosis: Results from the Phase 2b SYNERGY Trial —

Karleyton Evans, Robert Naismith, Douglas Arnold, Alexey Boyko, Nikolaos Evangelou, Martin Valis, Elizabeth Fisher, Nancy Richert, Jie Li, Lei Xu, Diego Cadavid, Michelle Mellion

Data Blitz:  12:20 p.m.–12:25 p.m. P2.108 Comparison of blood lymphocyte counts and reported rates of infection in patients treated with fingolimod and iDMTs in PREFERMS —

Edward Fox, Florian Thomas, Mark Cascione, Xiangyi Meng, Lesley Schofield, Fernanda Boulos, Nadia Tenenbaum

Data Blitz:  12:25 p.m.–12:30 p.m. P2.109 Neuroanatomical Correlates of Memory and Speed are Dissociable in Multiple Sclerosis —James Sumowski,

Victoria Leavitt, Maria Rocca, Matilde Inglese, Korhan Buyukturkoglu, Gianna Carla Riccitelli, Alessandro Meani, Massimo Filippi

Data Blitz:  12:30 p.m.–12:35 p.m. P2.110 Pregnancy Complications of Women With and Without Multiple Sclerosis in a Large US Claims Database —Maria Houtchens, Natalie Edwards, Kevin Stern, Amy Phillips

P2.119 Amyloid Myopathy Presenting

P2.127 Amyloid Myopathy as an

P2.135 VCP Gene Mutation in a

Gary Gallagher, Eva Feldman

Hamasaki, Mazen Dimachkie, Mamatha Pasnoor, Jeffrey Statland, Omar Jawdat, Richard Barohn, Melanie Glenn, Laura Herbelin

Dimachkie, Mamatha Pasnoor, Richard Barohn

with Dysphagia and an Inclusion Body Myositis Phenotype —Ryan Jacobson,

P2.120 Beyond the Antibodies: Sera

Metabolomic Biomarker Signatures Discriminate Myasthenic and Healthy Cohorts —Derrick Blackmore, Zaeem Siddiqi, Liang Li, Nan Wang

P2.121 Late-onset Pompe disease

due to known and novel variants in GAA gene with possible contribution of a dystrophinopathy carrier state in a female patient. —Eric Veloso, Jaya Ganesh, David Lacomis, Joseph Campellone

Inclusion Body Myositis Mimic —Anai

P2.128 Tongue abnormalities on Brain MRI in patients with neuromuscular disorders —Chafic Karam, Diana Dimitrova,

Veteran Presenting with Proximal Weakness —Daniel Kimple, Mazen

P2.136 Managing Myasthenia Gravis

with Immunosuppressive Drugs: Lessons from the Patient Perspective —Riaz

Elizabeth Yutan, Nizar Chahin

Mahmood, Adeeba Khan, Donald Sanders, Pushpa Narayanaswami, Nancy Law, Jeff Guptill

P2.129 A Rare Case of Asymptomatic

P2.137 Necrotizing myopathy in two

Khan, Usama Tariq, S Subramony, Alicia Parker, Bilal Ansari

Simona Treidler, Kapil Arya, Roberta Seidman, Mahendra Somasundaram, Yaacov Anziska, Adrian Marchidann, Paul Maccabee

Becker Muscular Dystrophy —Fareed

P2.130 Molecular dysregulation of

patients after the use of Moringa —

lipolysis and lipophagy in Lipid Storage Myopathies —Corrado Angelini, Daniela

P2.138 Duration of Botox effects in

Tavian, Sara Missaglia

Neuromuscular junction using single fiber EMG —Elham Bayat, Mary Russo

P2.131 Concentric exercise effects

P2.139 Clinicodemographic

a post-synaptic congenital myasthenic syndrome —Stanley Iyadurai, Samantha

Azzabou, Thomas Bulea, Harmen Reyngoudt, Hirity Shimellis, Yupeng Ren, Eunhee Kim, Kenneth Fischbeck, Pierre Carlier

Gummi, Raghav Govindarajan

P2.124 Intervention Effect on Fellow

P2.132 Performance test evaluation

P2.122 A Case of new onset

antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. —Iyad Alnahhas, Scott Vota, Jason Wong

P2.123 Post-exercise facilitation in LoRusso

Muscle Biopsy Reading Accuracy in Inflammatory Myositis —Anai Hamasaki, Omar Jawdat, Daniel Kimple, Mazen Dimachkie, Mamatha Pasnoor, Jeffrey Statland, Richard Barohn, Melanie Glenn, Laura Herbelin

P2.125 Clinical Dermatomyositis

Associated with Anti-HMG-CoA Reductase Antibody Positive Immune Mediated Necrotizing Myopathy: A Case Report —Monica Lavian, Tahseen Mozaffar, Namita Goyal

P2.126 Atypical Presentation of

CLCN1 Mutations: A Case Series —

on skeletal muscle water T2 in Duchenne muscular dystrophy —Ami Mankodi, Noura

of intra-rater and inter-rater reliability among examiners of histopathological findings in myositis subtypes —Daniel Kimple, Richard Barohn, Mazen Dimachkie, Mamatha Pasnoor, Melanie Glenn, Laura Herbelin, Jeffrey Statland, Omar Jawdat

P2.133 Evaluation of Postural Control and Falls in Individuals with Myotonic Dystrophy Type 1 —Katy Eichinger, Jill R. Quinn, Shree Pandya

P2.134 Hereditary Myopathy with

Early Respiratory Failure (HMERF) in an Afghan Woman: A Case Report —Tim Lai, Namita Goyal, Tahseen Mozaffar

Predictors of the Impact of Infections on Myasthenia Gravis —Natalie Kukulka, Rohit

P2.140 Identification of dysregulated musclin expression and elevated atrial natriuretic peptide levels in adult and congenital myotonic dystrophy. —Donald McCorquodale, Katie Mayne, Brith Otterud, Diane Dunn, Nicholas Johnson

P2.141 Anti-PD1 Antibody

Pembrolizumab treatment of Metastatic Thymic Cancer as Antigenic Trigger for Myasthenia Gravis —Ahmareen Baten, Nadia Yusuf, Carlo Tornatore

P2.142 Review of muscle biopsy

technical safety and quality using a self-contained, vacuum-assisted biopsy technique —Antonio Gallo, Hans Katzberg, Vera Bril, Ari Breiner

Anisha Bhangav, Georgios Manousakis

Fast and easy registration · AAN.com/view/AM17 91

MONDAY

William Jens, Mary Elizabeth Kovacik Eicher, Divpreet Kaur

Miller, Mark Freedman, Jiwon Oh, Jerome De Seze, Philippe Truffinet, Myriam Benamor, Annie Purvis, Giancarlo Comi

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session II



P2.143 Myofibrillar myopathy

associated with DNAJB6 mutations —

Karthika Veerapaneni, Mamatha Pasnoor, Laura Herbelin, Melanie Glenn, Omar Jawdat, Mazen Dimachkie, Richard Barohn, Jeffrey Statland

P2.144 NA HEADACHE: BASIC AND CLINICAL SCIENCE

P2.145 Prolonged activation and

sensitization of central trigeminovascular neurons by a single wave of CSD in male and female rats —Agustin Melo-Carrillo, Andrew Strassman, Rony Reuven-Nir, Aaron Schain, Rami Burstein

P2.146 Glutamate and Glutamine

Distributions in Chronic Migraine: a Whole Brain MR Spectroscopy Study — Teshamae Monteith, Andrew Maudsley, Mohammed Goryawala, Peter Goadsby, Richard Lipton, Ralph Sacco, Tatjana Rundek

P2.147 Pharmacokinetic Modeling

Study to Evaluate Two Intranasal Formulations of Sumatriptan for Nasal vs Gastrointestinal Tract Absorption —Mary Lor, Laura Pope, Jean R. Lavigne, Kenneth Shulman, Per Djupesland, Joao Siffert

P2.148 Trigeminal Hyperexcitability

in Idiopathic Intracranial Hypertension: A Blink Reflex Study —Bedia Marangozoglu Samanci, Gunes Altiokka Uzun, Elif Kocasoy Orhan, Esme Ekizoglu, Ali Oge, Betul Baykan

P2.149 Headache Version

2.0 Common Data Element (CDE) Recommendations: Update of the National Institute of Neurological Disorders and Stroke (NINDS) Headache CDEs —Joy Esterlitz, Sarah Tanveer, Joanne Odenkirchen, Sherita Alai, Michael Oshinsky

MONDAY

P2.150 Pain Induced Neurogenic

Inflammation of the Meninges —Zdravko Lackovic, Ivica Matak, Boris Filipovic

P2.151 Metabolic signatures

for migraine using NMR-based metabolomics —Dong Jin Shin, Dong Hoon Shin, Hyun-Hwi Kim

P2.152 Mechanisms underlying

motion sickness and dizziness in migraine disorders —Susan King, Joanne

Wang, Daniel Merfeld, Adrian Priesol, Richard Lewis

P2.153 Ocular and Cervical

Vestibular Evoked Myogenic Potentials In Migraine —Hesna Bektas, Gonul Vural, Sadiye Gumusyala, Kazim Bozdemir, CENGIZ CANDAN

P2.154 Magnetic resonance imaging in pediatric recurrent ophthalmoplegic cranial neuropathy —Abdulla Alawadhi, Christine Saint-Martin, Maryam Oskoui

P2.155 Rational Design of a

Monoclonal Antibody (mAb) Inhibiting Calcitonin Gene-Related Peptide (CGRP), ALD403, Intended for the Prevention of Migraine —Brian Baker, Barbara Schaeffler, Roger Cady, John Latham, Tim Whitaker, Jeff Smith

P2.156 Evaluating the Measurement

Properties of a New Instrument- the Migraine Physical Function Impact Diary (MPFID) —Ariane Kawata, Ray Hsieh, Asha

Hareendran, Randall Bender, Shannon Shaffer,

Sandhya Sapra, Pooja Desai, Katherine Widnell, Martha Bayliss, Dawn Buse, Dennis Revicki

P2.157 Challenges to Stakeholder

Engagement in Population Headache Care in an Academic Health System —

Susan Baggaley, K.C. Brennan, Kathleen Digre, Lynne Kerr, Lisa Gren, Gregory Keough, Rachel Jaggi, Scott Junkins, Karly Pippitt

P2.158 Primary Headache Induced

by the Valsalva Maneuver Is Associated with Cerebral Hyperemia due to Autoregulatory Failure. —Peter Novak

P2.159 What does the humanized

monoclonal anti-CGRP antibody (TEV48125) teach us about the perception of migraine headache? —Agustin MeloCarrillo, Andrew Strassman, Aaron Schain, Rony Reuven-Nir, Rami Burstein

HEADACHE: CLINICAL TRIALS AND THERAPEUTICS

P2.160 Simultaneously Evaluating

Treatment Differences in Mean Level and Consistency in Migraine Pain Intensity Using Location Scale Mixed Effects Modeling: Results from the COMPASS Study —Richard Lipton, James McGinley, RJ Wirth, Dawn Buse, Kenneth Shulman

P2.161 Phase 1, Randomized,

Parallel-Group, Double-Blind, PlaceboControlled Trial to Evaluate the Effects of Erenumab (AMG 334) and Concomitant Sumatriptan on Blood Pressure in Healthy Subjects —J. De Hoon, Anne Van Hecken, Corinne Vandermeulen, Marissa Herbots, Yumi Kubo, Ed Lee, Osa Eisele, Gabriel Vargas, Kristin Gabriel

Monday, April 24  8:30 a.m.—7:00 p.m. Study —Stewart Tepper, Richard Lipton, Uwe Reuter, Stephen Silberstein, Walter Stewart, Dean Leonardi, Pooja Desai, Sunfa Cheng, Daniel Mikol, Robert Lenz

P2.168 Introduction to Progressive

Muscle Relaxation Therapy for Migraine in the Emergency Department: A Pilot Feasibility Study —Mia Minen, Alexandra Boubour, Scott Powers, Corita Grudzen, Richard Lipton

Claims Analysis Comparing Outcomes with Extended-Release Topiramate (Trokendi XR®) and Immediate-Release Topiramate —Welton O’Neal, Elizabeth Hur, Tesfaye Liranso, Haechung Chung, Tao Gu, Ralph M. Turner

P2.170 Reduction in Chronic

Migraine following Occipital Nerve Decompression Surgery: Further Implications for Extracranial Origin of Headache —Pamela Blake, Carlton Perry, Rami Burstein

P2.171 Characterizing the Most

Common AEs Following Treatment with AVP-825: Exploring Abnormal Taste and Nasal Discomfort Across Multiple Attacks in COMPASS Study —James McGinley, Kenneth Shulman, Dawn Buse, RJ Wirth, Joao Siffert, Richard Lipton

P2.164 Hepatic safety of

galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials —Arie Regev, Angelo Camporeale, Vladimir Skljarevski, Shufang Wang, Jeff Carter

P2.165 75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. —Richard Lipton, David Dodick, Peter Goadsby, Stephen Silberstein, Joe Hirman, Jeff Smith, Roger Cady

P2.166 Comparing Average Level and

Within-person Consistency in Clinical Disability Using AVP-825 vs. Sumatriptan Tablets: Applying Location Scale Mixedeffects Models —Kenneth Shulman, James McGinley, RJ Wirth, Dawn Buse, Richard Lipton

P2.167 Patient-Reported Outcomes in

Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind

92 2017 AAN Annual Meeting Scientific Program

in Cluster Headache Trials: A Patient Survey —Melissa Rayhill, Brian McGeeney, Peter Goadsby, Elizabeth Loder

GENERAL NEUROLOGY: PRACTICE IMPROVEMENT AND NOVEL APPROACHES TO CARE

P2.181 Post hospitalization

follow-up clinic visits in neurological diseases —Vamshi Balasetti, Kaeli Samson,

Hannah Maher, Kalyan Sajja, Lakshman Arcot Jaygaopal, Faisal Ahmed, Sandeep Devarapalli, Sanath Kasi Reddy, Lucas Stenzel, Aashrayata Aryal Pandit, Krishna Mourya Galla, Erin Smith, Fuad-al Ali, Hae Young Baang, Swetha Pedavally, Moayd Alkhalifah, Dharani Mudugal, Marco Gonzalez Castellon, T. Scott Diesing, Matthew Rizzo, Sachin Kedar

P2.182 Utilization and Cost Savings

of Neuroscience Telemedicine Clinic for State Prison Inmates —Jennifer Majersik,

P2.173 Posterior Hypothalamic

in the presence of cerebral mass effect —Krishna Kandregula, Stephanie

Visvanathan, K Subramanian, Rahul Nimmakayala

Stimulation in Chronic Cluster Headache —Nilson Nogueira Mendes

P2.174 Non-invasive vagus

Gelfand, William Qubty, Irene Patniyot, Mark Pletcher, Peter Goadsby, Steve Cummings

P2.180 Acceptability of Placebo

of Vestibular Migraine —Natarajan

P2.172 Flunarizine for the Prophylaxis

Wei, Matthew Robbins

Migraine Prevention: A Pilot Internetbased Randomized Controlled Trial —Amy

Ayer, Allen Nyhuis, Sheena Aurora, Jeff Carter

Daniel Fults MD, Eric DiFrancesco RN, Ka-Ho Wong, Stephen Chatwin MPP, Peter Hannon, Aleksander Tkach, Hanford Shuman III RN, Bruce Bernam MD, Richard Garden MD

P2.162 Greater occipital injection

P2.163 Melatonin for Adolescent

using MSQ v2.1 in patients with a history of episodic migraine and treated with galcanezumab or placebo injections in a Phase 2 clinical trial —Janet Ford, David

P2.169 Medical and Pharmacy

Neto, Jessika Thais Da Silva Maia, Daniel Duarte Rolim, Marcelo Rodrigues Zacarkim, Juliano Jose Da Silva, Levi Higino Jales Junior, Servulo Marciano Pinheiro De Souza, Sebastiana Jayne Alves Vidal, Tatyana Vidal Mendes, Sergio Adrian Fernandes Dantas, Erich Talamoni Fonoff

versus oral steroids for short term prophylaxis of cluster headache: a retrospective comparative study —Jerry

P2.179 Measures of functioning

nerve stimulation for treatment of indomethacin-sensitive headaches — Amy Tso, Juana Marin, Peter Goadsby

P2.175 Peripheral nerve blocks for the treatment of headache in older adults: a retrospective study —Jacob Hascalovici, Matthew Robbins

P2.176 Effect on Verbal (Phonemic) Fluency and Patient Satisfaction in Chronic Migraine Patients Converted from Immediate-Release Topiramate (TPM-IR) to Extended-Release Topiramate (Trokendi XR®) —John

Rothrock, Amanda Michael, Diane AndressRothrock

P2.177 Factors Associated with

Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab — Sheena Aurora, Tina Oakes, Qi Zhang, Jonna Ahl, James Martinez

P2.178 Efficacy and Safety of

OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL —Andrew Blumenfeld, Richard Stark, Aubrey Manack Adams, Amelia Orejudos, Sheena Aurora

P2.183 Feasibility of lumbar puncture Chen, Jonathan Pace, Alireza Bozorgi, Gagandeep Singh, Sunil Manjila, Sankalp Gokhale, Elisabeth Dorn, Ciro RamosEstebanez

P2.184 Ask a Neurologist: What

Primary Care Providers want to know, and the potential for reducing referrals through eConsults —Ana Bradi, Lucian

Sitwell, Clare Liddy, Amir Afkham, Erin Keely

P2.185 Randomized Trial to Evaluate Optimal Recumbent Time after Lumbar Puncture —Babar Khokhar, Rosamaria Didiano, Brian Mac Grory

P2.186 The path to specialist

multidisciplinary care: A population based study of consultations, interventions and costs —Miriam Galvin,

Padhraig Ryan, Sinead Maguire, Mark Heverin, Caoifa Madden, Alice Vajda, Charles Normand, Orla Hardiman

P2.187 Patterns of utilization of

extracranial neurovascular ultrasound in patients with syncope in the context of the American Academy of Neurology (AAN) Choosing Wisely initiative. —

Jorge Ortiz-Garcia, Maria Bruzzone, Diana Andino, Rochelle Sweis, Camilo Gomez, Jose Biller

P2.188 Diagnosis of Mitochondrial

Diseases: Utility of a Clinical-molecular Approach Incorporating High Performance Sequencing —Julieta

Rosales, Nancy Medina, Nerina Martinez, Sergio Rodriguez Quirofa, Marta Cordoba, Cecilia Vazquez Dustafante, Patricia Vega, Ana Lia Taratuto, Marcelo Kauffman, Dolores Moron


P2.189 Analysis of Psychopharmacs and Potentially Inappropiated Medications Use in an Elderly Population —Maria Bullrich, Virginia Laura Parisi, Gabriel Persi, Galeno Rojas, Gustavo Da Prat De Magahlaes, Dario Lisei, Victoria Aldinio, Pilar Sanchez De Paz, Emilia Gatto

P2.190 The role of neurology in a

medicine-based undiagnosed patient clinic: The Emory Special Diagnostic Clinic experience —Joash Lazarus, William Clyde Partin Jr., Debra Cohen, Jorge Juncos

P2.191 Followup on Discrepant

Clinical Signs among Patients with Organic Neurological Diseases —Orwa

Aboud, Ayman Al-Salaimeh, Kinshuk Sahaya, Archana Hinduja

P2.192 Neurology At Your

P2.205 An interesting differential for

acute truncal ataxia —Edouard Kamel, Oleg Yerokhin, Carolina Ionete

Ruaa Nughays, Omar Ayoub, Areej Abdulrahman Mohamed Bushnag, Ahmed Gaweesh, Wail Tashkandi

P2.206 Pattern reversal visual

P2.219 Concurrent Duloxetine

evoked potentials (prVEPs) in autosomal recessive hereditary spastic paraplegia with thin corpus callosum (ARHSPTCC) patients with SPG 11 mutations in Saudi Arabia —Nouf Al-Faidi, Qurban Ali, Youssef Al Said, Gulzar Karim, Haji Khan, Saeed Bohlega, Edward Cupler

Withdrawal and Neuroleptic Malignant Syndrome Mimicking Creutzfeldt-Jakob Disease: A Case Report —Emily Zucker,

Robin P Miller, Daniel Rubin, Paul Wright, Evan Schloss

P2.220 New onset epilepsy in the

Modern Mad Hatter —HIMMAT GREWAL,

setting of middle fossa encephalocele and suspected idiopathic intracranial hypertension: a case report. —Benjamin

Shashidhara Nanjundaswamy

Savage, Aimee Szewka, Miral Jhaveri

P2.208 A Case of Sensory Ataxia and

P2.221 The number of Enteral

P2.207 An Unusual Tale of Falls: a

Cardiac Hypertrophy Associated with Anti- Voltage Gated Potassium Channel (VGKC) Autoantibodies. —Catherine

Antiepileptic Drugs in Refractory Status Epilepticus: Their effect on patient mortality and clinical outcome —Ruaa

Solomon

Alessi, Gurcharanjeet Kaur, Louis Manganas, Tejwant Bindra

P2.193 The neurology of noise:

P2.209 A case of secondary

Nughays, Bashair Ibrahim, Sohaib Shafei, Omar Ayoub, Ahmed Gaweesh, Wail Tashkandi, Areej Abdulrahman Mohamed Bushnag

Erika Horta, Parth Dhruv, James Ashe

P2.222 NA

Fingertips —Paola Mendez Gomez, Diane

Musical therapy both path and present —Nathan Carberry, Kenneth Guber, Mill Etienne

P2.194 Clinical Drug Development for Rare Disease in Neurology —Bilal

Abuasal, Salwa Albusaysi, Venkatesh Atul Bhattaram, Ramana Uppoor, Mehul Mehta

parkinsonism responsive to Ibrutinib —

P2.210 Clinical characteristics of

a novel ALS/SCA crossroad mutation Asidan (SCA36) —Koji Abe

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: EEG AND IMAGING

P2.211 Subacute Cerebellar

P2.223 The responsive

P2.195 Neurologic Complications

Degeneration due to Thiamine Deficiency after a Gastric Sleeve —Rejo Cherian,

Shehab-Eldin, Paloma R. Sánchez, Mirla Avila

P2.212 Dysphagia in a Patient with

P2.196 A case of discrepancy

Rodrigues

Following Bariatric Surgery: A Case Report and Literature Review —Mohamed

between clinical and radiological findings in determination of brain death —Vidita Khatri, Tim Lachman, Ivan Cuesta Isabel

P2.197 Impulse Control Disorders

associated with Aripiprazole —Farwa Ali, Charlene Gaw, J. Bostwick, Anhar Hassan

Neurological Disorders: a Case Series — Tamara Strohm, Michelle Lee, Yuebing Li

P2.199 Sexuality and disability,

a poorly studied relationship in neurology —Alejando Nasimbera, Julieta

Rosales, Cecilia Quarracino, Gabriel Rodriquez

P2.200 Levofloxacin Induced

Dyschronometria —Alexandra Weller

P2.201 Differential Diagnosis of MRI

Corticospinal Tract Abnormalities —Asya Wallach, Danielle Stember, David Valentine, Jonathan Howard

P2.202 Development of an Algorithm for Treatment of Altered Mental Status in the Emergency Department —Gabriel Moreno, David Bissig, Tyrell Simpkins, Alexandra Duffy, Jeffrey Kennedy

GENERAL NEUROLOGY: ATAXIA, SPASTICITY, AND GAIT DISORDERS

P2.203 Cortical processing of tactile

novelty detection in Friedreich ataxia —

Gilles Naeije, Brice Marty, Vincent Wens, Serge Goldman, Massimo Pandolfo, Xavier De Tiege

P2.204 Adult Onset Opsoclonus

Myoclonus Ataxia Syndrome —Alejandro Kohler, Veronica Bruno, Mariano Marrodan, Lucas Alessandro, Alfredo Laffue

Issa, James Tao, Sandra Rose, Peter Warnke, Shasha Wu

Fahr’s Disease —Jussie Lima, Bernardo

P2.224 Application of sEMG Feature

GENERAL NEUROLOGY: STATUS EPILEPTICUS AND CRITICAL CARE

Damon Cardenas, Luke Whitmire, Jose Cavazos, Michael Girouard

P2.213 Mortality and clinical

outcome of post cardiac arrest patients with refractory status epilepticus, —

Bashair Ibrahim, Sohaib Shafei, Ruaa Nughays, Omar Ayoub, Ahmed Gaweesh, Wail Tashkandi

P2.214 Riluzole-induced interstitial

pneumonia: a rare and potentially lifethreatening adverse event successfully treated with high-dose steroids. —Yuji

Saitoh, Yohei Aoshima, Taiji Mukai, Masayuki Miyazaki, Yuko Morimoto, Asami Tasaki, Hajime Ariga, Madoka Mori-Yoshimura, Toshiyuki Yamamoto, Tomoko Okamoto, Miho Murata, Yuji Takahashi

P2.215 Status Epilepticus and

Blindness in a Patient with Carfilzomib Associated Posterior Reversible Encephalopathy Syndrome —Scott Cooper, Rawaa Ebrahem, Salam Kadhem, Emily Manlove, Lorna Nguutu, Ricky Lee

P2.216 Postictal changes in

brain magnetic resonance imaging: non convulsive status epilepticus in transplanted patients —Alejandro

Thomson, Blas Couto, Jos Molina Melendres, Diego Nadile, Guido Vazquez, Carlos Santiago Claverie, Diego Minarro, Matias Mazzucco, Guillermo Di Lorenzo, Alfredo Thomson

P2.217 A rare case of CNS

involvement with Chronic Lymphocytic Leukemia CLL —Leslie Witton, Suresh Menon, Sashi Perera

P2.218 Refractory status epilepticus, report from a single center in Saudi Arabia —Sohaib Shafei, Bashair Ibrahim,

characteristics in cooled and re-warmed periods in post-cardiac arrest therapeutic hypothermia patients —Kyung-Wha Kim, Kimberly Pargeon, Padmaja Kandula, Douglas Labar

P2.233 Common etiologies of

acute symptomatic seizures evolving from lateralized periodic discharges in patients monitored with continuous EEG —Subin Mathew, Pirouz Piran, Stephen Hantus, Chetan Malpe

P2.234 The effects of perampanel,

lacosamide, and lamotrigine on secondary generalized (SG) seizures in a rat amygdala kindling model —Wu Ting, Takahisa Hanada, Katsutoshi Ido

P2.235 Use of functional cortical

networks model for the assessment of transcranial direct current stimulation effects —Camila Cosmo, C‚ndida Ferreira,

Jose Garcia Vivas Miranda, Raphael Do Rosario, Abrahao Baptista, Joan Camprodon, Pedro Montoya, Eduardo Ponde De Sena

P2.236 The evolution of EEG in the

disease course of NMDA-receptor encephalitis: 2 illustrative case studies and a review of the literature —Claude Steriade, Stephen Hantus, Ahsan Moosa, Alexander Rae-Grant

P2.237 Larger amygdala volumes

in patients with “Sudden Unexpected Death in Epilepsy” —Varun Chauhan,

Extraction from EEG Recordings for Evaluation of Generalized Tonic-Clonic Seizure Semiology —Jonathan Halford,

Kalyan Yarraguntla, Navid Seraji-Bozorgzad, Fen Bao, Monica Dhakar, Maysaa Basha, Aashit Shah

P2.225 Are automated topographic

of ictal EEG source localization in presurgical workup of neocortical epilepsy —Deanne Kennedy, Liana Rusu,

analyses of visual-evoked potentials reliable and feasible in clinical routine? —Henrik Hörster, Martin Hardmeier, Florian Hatz, Peter Fuhr

P2.226 Generalized Paroxysmal

Fast Activity in EEG: not an uncommon finding in genetic generalized epilepsy — Vishwanath Sagi, Amar Bhatt, Bassel AbouKhalil, Hasan Sonmezturk, Amir Arain

P2.227 Adjunctive Monitoring

with Quantitative EEG During Carotid Endarterectomy —Brad Kamitaki, Bin Tu, Anil Mendiratta, Hyunmi Choi

P2.228 Utility of SSEP and EEG as

prognostic indicators in patients with postanoxic injury with and without hypothermia. —Advait Mahulikar, Maysaa

Basha, Souad Saleh, Wazim Mohamed, Aashit Shah

P2.229 Multistate Survival Analysis for Seizure Prediction on Continuous EEG —Aaron Struck, Gamaleldin Osman,

Nishi Rampal, Siddhartha Biswal, Benjamin Legros, Lawrence Hirsch, M. Westover, Nicolas Gaspard

P2.230 Abnormalities in Routine

Clinical EEG Reports are Correlated with Delirium Severity —Anudeepthi Neelagiri, Eyal Kimchi, Avinash Sagi, M. Westover

P2.231 Oscillation alterations by

hippocampal interictal discharges as a mechanism of transient cognitive impairment —Jonathan Kleen, Gregory Holmes

P2.238 Clinical utility and validity

June Yoshii-Contreras, Beatriz Chavarria, Robert Knowlton

P2.239 Semantic fluency impairment in unilateral mesial temporal sclerosis related epilepsy is associated with extensive white matter involvement: a diffusion tensor imaging study. —

Matheus Peres, Bettina Castro, Cristiane Messas, Caio Martucci, Khallil Chaim, Bruno Pastorello, Rosa Valerio, Carmen Jorge, Katarina Lyra, Maria Otaduy, Claudia Leite, Luiz Castro

P2.240 Cortical Thickness Correlates

of Social Cognition Abilities in Temporal Lobe Epilepsy —Jeffrey Binder, Lisa Conant,

Christopher Anderson, Rasmus Birn, Chad Carlson, Edgar DeYoe, Leonardo Fernandino, William Gross, Bruce Hermann, Colin Humphries, Gyujoon Hwang, Kevin Koch, Peter Kraegel, Rama Maganti, Jedidiah Mathis, Taylor McMillan, Mary Meyerand, Veena Nair, Andrew Nencka, Vivek Prabhakaran, Manoj Raghavan, Megan Rozman, Candida Ustine, Gengyan Zhao

P2.241 White matter tracts

integrity in children with focal cortical dysplasia —Sabrina Gouvea, Enrico Ghizoni, Brunno De Campos, Simone Appenzeller, Fernando Cendes, Ana Coan

P2.242 Periictal MRI findings

of hypervascularity with restricted diffusion contralateral to gaze deviation —Rita Marshall, Sharon Kim, Mary Zupanc

Fast and easy registration · AAN.com/view/AM17 93

MONDAY

P2.198 Catatonia Associated with

Anwar Ahmed

neurostimulation (RNS) artifact on scalp EEG recording. —Maria Bruzzone, Naoum

P2.232 Electroencephalogram

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session II



EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CLINICAL EPILEPSY II

P2.243 Electrophysiological and

radiological characteristics in posterior reversible encephalopathy syndrome (PRES) —Riddhi Patira, Vidita Khatri, Jeffrey Ruta, Camilo Gutierrez

P2.244 EEG correlates of outcome in patients with posterior reversible encephalopathy syndrome —Archana Hinduja, Sunil Kumar, Kinshuk Sahaya

P2.245 Rates and Predictors of 1 year of Readmission with Seizures in Patients with Stroke and Stroke Subtypes: Analysis of a National Cohort of 557,033 Stroke Patients —Burhan Chaudhry, Saqib Chaudhry, Mohammad-Rauf Afzal, Tariq Gheith, Shitong Gu, Ali Saeed, Adnan Safdar, Mounzer Kassab, Adnan Qureshi

P2.246 Adult-Onset Rasmussen’s

Encephalitis: Diagnostic and Therapeutic Challenges —James Castellano, Jenny Meyer, Fred Lado

P2.247 Incidence of unprovoked

seizures, epilepsies, and epilepsy syndromes in a cohort of children accessing government primary schools and organization of seizures and epilepsies using ILAE 2010 system: A study in south India —Shyam Jaiswal,

Jagarlapudi Murthy, Sri Krishna S, Padmanabh Reddy M

P2.248 Epilepsy Awareness in

a South Florida community—an observational study —Subin Mathew, Chantal Goudreau, Amanda Lonergan, Dominique Cordero, Adriana Rodriguez, Camilo Garcia-Gracia, Chetan Malpe

P2.249 Recurrent Seizure-related

MONDAY

Takotsubo Syndrome —Yuri Bronstein, Daniel Daneshvar, Jane Hwang, Nazely Ashikian, Bruce Enos

P2.250 NA INTRACEREBRAL HEMORRHAGE

P2.251 Intraventricular hemorrhage score and outcome after spontaneous intracerebral hemorrhage —Gabriela Trifan, Maureen Hillmann, Fernando Testai

P2.252 The Influence Of Cerebral

Microbleeds On Blood Pressure Control In Acute Intracerebral Haemorrhage — Dheeraj Khurana, Ramalingam Rajendran, Paramjeet Singh, Chirag Ahuja

P2.253 What are the barriers for

use of pharmacological prophylaxis (PP) to prevent deep vein thrombosis (DVT) in spontaneous intracranial bleeding (sICH)? —Dilip Kumar Jayaraman, Shweta

Sapnar, Jalyoung Joe, Anusha Edara, Sridhara Yaddanapudi

P2.254 Clinical outcomes of

methamphetamine use in patients presenting with intracerebral hemorrhage —Dionne Swor, Kwan Ng

P2.255 Effect Of Insufficient Blood

Pressure Control On Intracerebral Hemorrhage Volume In Patients Transferred To A Comprehensive Stroke Center —Steven Tversky

Monday, April 24  8:30 a.m.—7:00 p.m.

P2.256 Intraventricular Hemorrhage

P2.267 Clinical presentation and

P2.279 Could Cocaine Exposure

Albright, Michael Lyerly, Mini Singh, Toby Gropen, Angela Hays Shapshak

Miyares, Audrey Leasure, Steven Kittner, Carl Langefeld, Achala Vagal, Kevin Sheth, Daniel Woo

Amanda Pennington, Toby Gropen, Angela Hays Shapshak

(Graeb) Score Predicts Prognosis in Lobar and Thalamic Intracerebral Hemorrhage —Amanda Pennington, Karen

P2.257 Hyperosmolar therapy is not

associated with improved outcomes in patients with large Intracerebral Hemorrhage. —Shaista Alam, Hope Moser, Nicole Gonzales

P2.258 Long Term Functional

Outcome and Mortality in Elderly Patients After Intracerebral Hemorrhage —Audrey Leasure, Anirudh Sreekrishnan, Sonya Zhou, David Hwang, Lauren Sansing, David Greer, Kevin Sheth

P2.259 To study the impact of chronic vasodilator therapy on perihematomal edema in primary intracerebral hemorrhage(ICH) —Mini Singh, Karen Albright, Amanda Pennington, Sahil Gupta, Angela Hays Shapshak

P2.260 Transcranial Doppler

Utilization in Non-Traumatic Intracerebral Hemorrhage: A Nationwide CrossSectional Analysis of Predictors and Outcomes. —Abhishek Lunagariya, Yumei Liu, Urvish Patel, Achint Patel, Wayne Feng, Bruce Ovbiagele

P2.261 A Comparison of Age, Gender, and Initial Blood Pressure between Hispanic and Non-Hispanic Intracerebral Hemorrhage Patients —Lauren Fanty,

Alejandro Santillan, Andrew Slusher, Tijil Agarwal, Aachi Raghav, Christopher Topel, Lee Birnbaum, Vivek Misra, Santiago Palacio, Reza Behrouz

P2.262 Perihematomal Edema

is Associated with Poor Outcome in Patients with Cerebellar Intracerebral Hemorrhage —Audrey Leasure, Anirudh

Sreekrishnan, Sonya Zhou, Lauren Sansing, David Greer, Kevin Sheth

P2.263 Exploring the worth of CTA for

outcomes of young adults enrolled in the Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study —Laura

P2.268 Diagnostic yield of brain MRI

in patients presenting with spontaneous intracerebral hemorrhage —Andrew Slusher, Tijil Agarwal, Alejandro Santillan, Venkat Raghav Aachi, Lauren Fanty, Reza Behrouz, Christopher Topel, Vivek Misra, Lee Birnbaum, Santiago Palacio

P2.269 Foley Catheter Use and

Infection in Non-Intubated Intracerebral Hemorrhage Patients —Elena Gibson, Karen Albright, Sahil Gupta, Amelia Boehme, Angela Hays Shapshak, Michael Lyerly

Feeding Tube Placement In Intracerebral Hemorrhage? —Aurangzeb Memon, William

Jackson, Anjail Sharrief, Kristen Brown, Umair Saeed, Hari Indupuru, Maria DeGuzman, Paige Shoemake, Alana Clayton, Stephanie Cooper, Andreea Xavier, Chunyan Cai, Kim Yen Thi Vu, Andrew Barreto

P2.266 Utilization of Modified SPAN100 index in Patients with Intracerebral Hemorrhage: Predictor of Outcomes and Functionality —Cyrus Escabillas, Kathreen Jane Lara, Jose Navarro

94 2017 AAN Annual Meeting Scientific Program

Shenoy, Lucas Fleuren, Siddharth Biswal, Emily Boyle, Sahar Zafar, Aman Patel, M. Westover, Eric Rosenthal

Kurowski, James Siegler, Taneeta Ganguly, Brett Cucchiara

Gupta, Jenna Leclerc, Terrie Vasilopoulos, Sylvain Dore

of Microcirculatory Dysfunction in the Prediction of Ischemia or Infarction in Patients with Aneurysmal Subarachnoid Hemorrhages —Arelys Zamora, Avigeet

P2.271 Infection is Not Associated

P2.282 Re-bleed in Nontraumatic

with Poor Outcome in Young Adults with Hemorrhagic Stroke —Kathryn Sundheim, Eliza Miller, Joshua Willey, Randolph Marshall, Yuefan Shao, Amelia Boehme

P2.272 Trends and Outcomes of

Intracranial Hemorrhage in HIV Positive Population(2002-2012) —Achint Patel, Kaustubh Limaye, Mihir Dave, Harshil Shah, Vishal Jani, Sanjeeva Onteddu

P2.273 Resumption of Antithrombotic Therapy in LVAD-associated Intracranial Hemorrhages —Sung Cho, Jennifer Frontera

P2.274 Neuroimaging Characteristics of Intracranial Hemorrhages and Microhemorrhages in Infective Endocarditis —Lucy Zhang, Sung Cho,

Robert Marquardt, Prateek Thatikunta, Ken Uchino, Dolora Wisco

P2.264 The role of a history of

P2.265 Does Race Predict Surgical

Neuronal Activity to Mean Arterial Pressure and Neurocritical Interventions Measured by Intracranial EEG following Subarachnoid Hemorrhage —Apeksha

P2.281 The Temporospatial Role

Gupta, Karen Albright, Toby Gropen, Michael Lyerly

Khawaja, Amelia Boehme, Alexander George, Angela Hays Shapshak, Gyanendra Kumar, Muhammad Alvi, Anand Venkatraman, David Miller, Sheryl Martin-Schild, Maira Mirza, Mark Harrigan

P2.280 Dynamic Response of

hypodensity detected by computed tomography and risk of hemorrhage expansion in spontaneous intracerebral hemorrhage —Joshua VanDerWerf, Donna

P2.275 Off-Hours Emergency

coronary artery disease, the need for transfusion and outcomes in patients with intracerebral hemorrhage —Ayaz

SUBARACHNOID HEMORRHAGE, INTRACRANIAL ANEURYSM, AND OTHER CEREBROVASCULAR MALFORMATIONS

P2.270 Intra-hematomal

ICHUsefulness of CT Angiography in the Diagnosis and Treatment of Intracranial Hemorrhage —Abdul Rahman Alchaki, Francisco Gomez, Mohammad El-Ghanem, Helen Han, Machteld Hillen

Mitigate Edema Formation in Spontaneous Intracerebral Hemorrhage? —Mini Singh, Karen Albright,

Department Arrival Does Not Result in Poor Outcomes Among Intracerebral Hemorrhage Patients Admitted to a Comprehensive Stroke Center —Sahil

P2.276 Systematic Review and MetaAnalysis of Cohort Studies Examining Effect of Anticoagulation and Risk of Cerebral Hemorrhage in patients with Cerebral Microbleeds —Nida Faheem, Yunxia Wang, Gary Gronseth

P2.277 Diagnostic yield of

computed tomography angiography and cerebral angiography in patients with acute spontaneous intracerebral hemorrhage —Alejandro Santillan, Andrew

Slusher, Tijil Agarwal, Lauren Fanty, Venkat Raghav Aachi, Christopher Topel, Lee Birnbaum, Santiago Palacio, Vivek Misra, Reza Behrouz

P2.278 Headache as an Independent Predictor of Favorable Outcome in Older Intracerebral Hemorrhage Patients — Sahil Gupta, Angela Hays Shapshak, Toby Gropen, Michael Lyerly

Convexity Subarachnoid Hemorrhage — Jennifer Harris, Rachel Forman, James Conners, Rajeev Garg, Sayona John, Vivien Lee

P2.283 MR Perfusion predicts

angiographic vasospasm after aneurysmal subarachnoid hemorrhage — Kassi Kronfeld, Kasra Khatibi, Karen Hirsch, Jeremy Heit

P2.284 Quantitative EEG spectral

categories related to corticothalamic integrity and short-term clinical outcomes after aneurysmal subarachnoid hemorrhage—an exploratory analysis —Peter Forgacs,

Halinder Mangat, Baxter Allen, Malik Fakhar, Philip Stieg, Nicholas Schiff

P2.285 Safety of Eptifibatide in

Subarachnoid Hemorrhage Patients Requiring Antiplatelet Agents. —Siddhart

Mehta, Yong-Bum Song, Briana DeCarvalho, Audrey Arango, Ashish Kulhari, Jawad Kirmani

P2.286 Reversible Cerebral

Vasoconstriction Syndrome presenting as Convexity Subarachnoid Hemorrhage —Rachel Forman, Jennifer

Harris, Vivien Lee, Rajeev Garg, Sayona John, James Conners

P2.287 Torsades de Pointes as a

Late Complication of Subarachnoid Hemorrhage —Kyle Carpenter, Iftekhar Ahmed, Torrey Birch

P2.288 Comparison of Pipeline

Embolization Device With Conventional Endovascular Procedures For The Treatment Of Carotid Cavernous Aneurysms —Norman Ajiboye

P2.289 Delayed Onset Transient

Pupillary Involving Third Cranial Nerve Palsy in Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage —Lesley Kaye, Swetha Renati, Bernadette Nazario-Lopez


P2.290 The Evaluation of the

Treatment of Ruptured Intracranial Aneurysms with Pipeline Embolization Device. —Norman Ajiboye

P2.291 Success of Intravenous

Infusion of Verapamil for Refractory Vasospasm in aneurysmal Subarachnoid Hemorrhage —Siddhart Mehta, Ashish Kulhari, Audrey Arango, Laura Suhan, Briana DeCarvalho, Aashish Patel, Jawad Kirmani

P2.292 Trends and Predictors of

Utilization of Endovascular Coiling vs Microsurgical Clipping of Ruptured Intracranial Aneurysms —Vamshi

Balasetti, Urvish Patel, Vishal Jani, Chiu Yuen To, Richard Fessler

P2.293 Does the unruptured

intracranial aneurysm treated score (UIATS) have a high risk of rupture threshold? —Mohtashim Qureshi, Hunter

P2.302 Cognitive function in newly

diagnosed patients with HIV infection in a Nigerian Tertiary Health Centre: assessment using Community Screening Interview for Dementia —Taofiki Sunmonu, Frank Imarhiagbe, Olubunmi Ogunrin, Lukman Owolabi, Morenikeji Komolafe, Olayinka Ilesanmi

P2.303 Sensitivity and Specificity of

Three Screening Questions for Cognitive Disorders —Melanie Metral, Isabella

Brandon Bond, Kamila Bond, Chike Ilorah, Jorge Kattah

P2.296 The Characteristics of

Infectious Intracranial Aneurysm and Indication of Cerebral Angiogram in Infective Endocarditis —Sung Cho, Robert

patients with HIV infection —Paulo

Lorenzoni, Renata Ducci, Giuliano Dalladone, Claudia Kay, Lineu Werneck, Rosana Scola

P2.306 NMDAR-Encephalitis

Masquerading as Recurrent HIVEncephalitis with CSF escape in an HIV+ Patient —C. Frances Fan, Robert McInnis,

Khella, Joseph Berger

P2.309 Longitudinally Extensive

Transverse Myelitis (LETM) related to Human T-Cell Lymphotropic Virus 1 and 2 (HTLV-1/2): surprising clinical picture and neuroimaging findings —Bianca Aleixo,

HTLV-1 Associated Myelopathy with Chronic Immunosuppression —Alessandro Iliceto, Bridget Bagert

P2.311 Herpes simplex virus 2: a rare

cause of ascending encephalomyelitis — Tigran Kesayan, Rebecca Hurst

Mohtashim Qureshi, Mohammad-Rauf Afzal, Ihtesham Qureshi, Paisith Piriyawat, Rakesh Khatri, Gustavo Rodriguez, Salvador CruzFlores

P2.312 Fatal VZV Myelitis In

HIV, HTLV-I, PML, OTHER VIRAL INFECTIONS, AND CJD

P2.313 Isolated seizures complicating

P2.301 Prevalence of Neurocognitive

Ruisanchez Nieva, Amaia Martinez Arroyo, Jone Bocos Portillo, Angeles Gomez Beldarrain

Disorders in a Well-treated and Aging Swiss HIV-cohort —Melanie Metral, Isabella Locatelli, Peter Brugger, Klemens Gutbrod, Ursula Kunze, Isaure Nadin, Marc Schwind, Riccardo Pignatti, Matthias Cavassini, Renaud Du Pasquier

and the importance of age in risk stratification of progressive multifocal leukoencephalopathy —Elena Grebenciucova, Joseph Berger

P2.319 PML in the absence of HIV

or immunosuppressive therapy —Stacy

Chu, Kent Owusu, Bryan Brown, Emily Hyun, Ashish Ranpura, Joachim Baehring, Dhanashri Miskin, Igor Koralnik, Ana-Claire Meyer

Michael Levy

P2.330 Phase 1b clinical trial with

antigen-specific tolerogenic dendritic in Multiple Sclerosis and Neuromyelitis optica: safety and immunological effects —Irati Zubizarreta, Georgina Florez, Gemma Vila, Raquel Cabezon, Carolina Espana, Daniel Benitez, Sara Varea, Joan Albert Arnaiz, Albert Saiz, Pablo Villoslada

P2.331 Different patterns of

structural damage in neuromyelitis optica spectrum disorders, recurrent optic neuritis and recurrent myelitis —

Association With Chronic Corticosteroid and Mycophenolate Mofetil Therapy — Christopher Spears, Deepak Soneji, Franca Cambi

influenza A and B infection in healthy adults —Juan Garcia Monco, Aintzine

effectively blocks Ebola virus infection — Omid Motabar

P2.322 A Case of Post-EBV

Cerebellitis Treated with IVIG —Ugur Sener, Benjamin Eidelman

P2.323 A Stormy Case of

Rhinocerebral Mucormycosis, and A Recovery Against All Odds. —Saman Zafar, Aparna Prabhu, George Newman, Sridhara Yaddanapudi

ZIKA, CHIKUNGUNYA, WEST NILE VIRUS, AND OTHER VIRAL INFECTIONS I

P2.324 Expanding Spectrum of

Neurologic manifestations with Zika Virus Infection —Laura Surillo Dahdah,

Marie Hidalgo, Jose Avila-Ornelas, Tania Zayas Torres, Sonia Caraballo-Cartagena, Luis Serrano Torres, Marisel Vazquez, Jose Carlo, Carlos Luciano

P2.325 Movement Disorder

Development Later After Acute Disseminated Encephalomyelitis Associated with Zika Virus: Case Report —Pamela Santos, Fernanda Nogueira, Leonardo Modenezi, Ana Carolina Andorinho, Camila Pupe, Ivan Da Silva, Celso Hygino, Osvaldo Nascimento

P2.326 Probable Zika virus-

associated Guillain-Barre syndrome: Challenges with clinico-laboratory diagnosis —Zoe Becker, Eliza Miller, Daniel Shalev, Comana Cioroiu, Kiran Thakur

Neuromyelitis Optica Spectrum Disorder (NMOSD) diagnostic criteria in older, non-Asian subjects —Karly Stratos, Liesly Lee, Ashley Cohen, Katerina Pavenski, Dalia Rotstein

P2.333 Microstructural changes

in the afferent visual system of asymptomatic patients with AQP4antibody positive neuromyelitis optica spectrum disorders. —Frederike Oertel,

Joseph Kuchling, Hanna Zimmermann, Claudia Chien, Felix Schmidt, Judith Bellmann-Strobl, Michael Scheel, Alexander Klistorner, Klemens Ruprecht, Friedemann Paul, Alexander Brandt

P2.334 An open-label, add-on trial of

cetirizine for neuromyelitis optica —Ilana Katz Sand, Russell Telford, Michelle Fabian, Thomas Kraus, Colleen Farrell, Shelly Phelps, Mirna Chehade, Madhan Masilamani, Mary Ellen Riffle, Thomas Moran, Lawrence Cook, Fred Lublin

P2.335 Superficial Siderosis

Masquerading as Neuromyelitis Optica —Scott Belliston, Judson Bertsch, Sharon Lynch

P2.336 Steroid responsive anti-

MOG antibody mediated meningoencephalomyelitis and optic neuritis —

Melanie Truong, Brian Hitt, Divyanshu Dubey, Jeffrey Ortstadt

P2.337 Quality of healthcare in

patients with myelitis: A pilot study — Valentina Galvis, Paula Barreras, Laura S. Munoz, Gabriel Pinilla Monsalve, Anupama Kumar, Carlos Pardo-Villamizar

Fast and easy registration · AAN.com/view/AM17 95

MONDAY

Demyelinating Lesion in HIV: A case report —Natalie Manalo, Jacqueline Chu,

P2.310 Successful Treatment of

stay and inhospital mortality in patients with subarachnoid hemorrhage among different racial groups —Alberto Maud,

P2.318 Immunosenescence

in Neuromyelitis Optica Spectrum Disorders —Remi Kessler, Maureen Mealy,

P2.332 Increased sensitivity of 2015

P2.299 Two-Year Observational

P2.300 Hospital utilization, length

Franco Campanella, John Andreoni, Melvin Wichter

P2.329 Clinical Predictors of Death

P2.321 Synergistic drug combination

neuron disease with unique radiographic findings —Johannes Pulst-Korenberg, Sami

Cajigas, Amer Malik, Sebastian Koch

Schwartz, Xu Li, Maureen Mealy, Michael Levy

Multifocal Leukoencephalopathy (PML) in an African American Female with Sarcoidosis Associated Lymphopenia (SAL). A Rare Case Report and Literature Review. —Jaivir Rathore, Nadera Sweiss,

NEUROMYELITIS OPTICA SPECTRUM DISORDER, TRANSVERSE MYELITIS, AND OPTIC NEURITIS I

day Epidemic —Nikil Swamy, Harley Morgan

Anna Assis, Tayla Romao, Henrique Prado, Marcos Freitas, Camila Pupe, Osvaldo José Moreira Do Nascimento, Andre Matta

Study of Deferiprone in Superficial Siderosis —Remi Kessler, Kateryna

Yoo, Minwoo Lee, Dong Jin Shin, Byungin Lee, Hongki Song

Kerr, Kottil Rammohan

P2.307 AIDS-associated upper motor

Howard Heller, Nagagopal Venna

Strokes due to Cerebral AVM Vascular Steal Phenomenon —Nirav Bhatt, Iahn

P2.316 Painful neuralgia of C2-3

P2.320 Resurgence of Polio? Modern

P2.297 A Rare Association of

P2.298 Multiple Acute Ischemic

Michal Lubomski, Romesh Markus, Lauren Brown

fatal disseminated Strongyloidiasis with central nervous system involvement in a White South Floridian HIV positive man —Ima Ebong, Elvia Goez-Gutierrez, Darcy

Benjamin Linas, Ioana Bica, Anna Marisa Cervantes-Arslanian

P2.308 Solitary Cerebral Tumefactive

Malik, Neha Prakash, Eliahu Feen, Aaron Bress

P2.328 Case Report: A rare case of

of Varicella Zoster Virus with Acute Cerebellitis and SIADH without a rash. —

syndrome in the United States —Gabriella

Alessandro D’Ambrosio, Maria Rocca, Elisabetta Pagani, Filippo Savoldi, Marta Radaelli, Giancarlo Comi, Andrea Falini, Massimo Filippi

Marquardt, Lucy Zhang, Prateek Thatikunta, Ken Uchino, Dolora Wisco

Vertebrobasilar Territory Arterial Fenestration with Aneurysm And Arteriovenous Malformation —Asma

P2.315 An Unusual Presentation

P2.317 Fatal Atypical Progressive

abnormalities in Thai men and women with presumed subtype CRF01_AE HIV-1 infection improve with antiretroviral therapy —Andrew Silverman, Phillip

P2.305 Motor neuron disease in

pediatric intracranial aneurysms: A systematic review and meta-analysis —

Tantillo, Gary Sclar, Chirag Vasa, Susan Shin, Mark Sivak

P2.304 Prominent motor

P2.294 Intra-Operative

P2.295 Endovascular treatment of

Yasaman Kianirad, Cindy Zadikoff, Danny Bega

Locatelli, Helen Kovari, Alexandra Calmy, Klemens Gutbrod, Peter Brugger, Andreas Monsch, Katharine Darling, Renaud Du Pasquier, Matthias Cavassini

Chan, Robert Paul, Joanna Hellmuth, Pasiri Sithinamsuwan, Jintanat Ananworanich, Nittaya Phanuphak, James Fletcher, Thep Chalermchai, Somporn Tipsuk, Duanghathai Suttichom, Victor Valcour, Serena Spudich

Leila Darki, Nerses Sanossian, Andres Gonzalez, Steven Cen, Ling Zheng

P2.327 Zika associated Guillain-Barre

myoclonus Ataxia Syndrome due to West Nile Virus: Two case reports —Kenny Tan,

followed by herpes zoster in the trigeminal nerve distribution —Jinhyuk

Collins, Ihtesham Qureshi, Mohammad-Rauf Afzal, Rakesh Khatri, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez, Paisith Piriyawat

Neurophysiologic Monitoring for Brain Aneurysm Surgeries in the United States: national use and outcomes —

P2.314 Adult Onset Opsoclonus-

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session II



P2.338 Brain and spinal cord MRI

findings in a South Florida cohort of Neuromyelitis Optica Spectrum Disorder patients —Melissa Alberts, Alexandra Cocores, Luis Tornes, Leticia Tornes

P2.339 Is there a link between

Neuro-Behcet’s Syndrome longitudinally extensive transverse myelitis and antibodies against MOG/AQP4 IgG? — Aksel Siva, Toshiyuki Takahashi, Ugur Uygunoglu, Burcu Zeydan, Sabahattin Saip, Ayse Altintas, Kazuo Fujihara

P2.340 Retinal Optical Coherence

Tomography in Chronic Relapsing Inflammatory Optic Neuropathy: a retrospective analysis of distinctive features. —Maziar Eslami, Sara Razmjou,

Sheridan Reed, Samuel Lichtman-Mikol, Alexandros Tselis, Christina Caon, Navid Seraji-Bozorgzad, Evanthia Bernitsas, Omar Khan

P2.341 What is the relationship of

anti-MOG Antibodies with Optic Neuritis of Multiple Schlerosis and Neuromyelitis Optica? —Fethi Idiman, Egemen Idiman, Fethi Idiman, Omercan Hasankoyoglu, Betul Tercan, Pinar Ozcelik, Zekiye Altun

P2.342 A case of neuromyelitis optica spectrum disorder with a non-traumatic syringomyelia —Shirley Nah, Farzan Ghodsianzadeh, Subhashie Wijemanne

P2.343 Drug-abuse Related

Myelopathies: A Rising Neurological Problem —Gabriel Pinilla Monsalve, Francisco Ocazionez, Paula Barreras, Shiv Saidha, Carlos Pardo-Villamizar

P2.344 A Rare Presentation of

Neuromyelitis Optica Spectrum Disorder (NMOSD) with Headache and Abnormal Imaging —Sahyli Perez Parra, Nancy Song, Hena Waseem, Andrew Pachner

MONDAY

BIOMARKERS AND EXPERIMENTAL STUDIES FOR MULTIPLE SCLEROSIS II

P2.345 Extending lipid biomarkers

of disease progression in people with multiple sclerosis —Charlie Mckechnie, Arie Gafson, Constantinos Savva, Paul Matthews

P2.346 EBV Serological Status in

Southeastern Spain. Possible Relation Between Clinical Activity and the Reactivation of the EBV —Ester Carreon

Guarnizo, Maria Cerdan, Rocio Hernandez Clares, Jose Diaz Perez, Estefania Garcia Molina, Jose Javier Martin Fernandez, Jose Meca Lallana

P2.347 Olfactory threshold predicts

short term relapse activity in relapsingremitting multiple sclerosis —Gabriel

induced by treatment with MIS416 — Pamela McCombe, Jun Yan, Gill Webster, Judith Greer

P2.350 Multimodal evoked potentials in primary progressive MS: A potential biomarker for prognosis and course —

Martin Hardmeier, Regina Schlaeger, Florian Hatz, Leticia Grize, Christian Schindler, David Leppert, Ludwig Kappos, Peter Fuhr

P2.351 Intrathecal delivery of primary

Monday, April 24  8:30 a.m.—7:00 p.m. P2.361 RAM-589.555 a new

P2.372 Hemophagocytic

Mashiach, Michael Gurevich

Gokaldas, Gary Gualberto

Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis —Anat Achiron, Rina Falb, Roi

P2.362 Novel Mechanism of

Disease: Altered RNA metabolism due a dysfunctional RNA binding protein contributes to neurodegeneration in MS —Michael Levin, Sangmin Lee, Yoojin

progressive MS cerebrospinal fluid induces behavioral deficits and spinal cord pathology in mice —Jamie Wong,

Shin, Hannah Salapa, Peter Ketch

P2.352 CSF Biomarkers of Disease

Song-Yi Yao, Subramaniam Sriram

Nathan Kung, Marwan Alahiri, Saud Sadiq

Progression in Patients with Multiple Sclerosis —Shayna Zanker, Violaine Harris, Saud Sadiq

P2.353 Laquinimod modulates central nervous system inflammation via the aryl hydrocarbon receptor and is effective in the chronic NOD progressive EAE model —Joel Kaye, Ralph Laufer, Jessica

Kenison, Veit Rothhammer, Francisco Quintana

P2.354 Disability Progression and

Cerebrospinal Fluid Status in PPMS: Re-Analysis of the ProMiSe Clinical Trial Data Set —Joshua Steinerman, Mat Davis, Volker Knappertz, Gavin Giovannoni, Jerry Wolinsky

P2.355 Laquinimod is a potent

arylhydrocarbon receptor dependent activator of natural killer cells —Erika

Avendano-Guzman, Martina Ott, Christiane Wegner, Liat Hayardeny, Evelyn Ullrich, Michael Schoen, Wolfgang Brueck, Stefan Nessler

P2.356 Kynurenine pathway profiling

in phase 2a trial secondary progressive multiple Sclerosis patients treated with a myeloid directed innate immune modulator MIS416 —Chai Lim, Gill Webster, Erin Lynch, Hongyan An, Gilles Guillemin

P2.357 Immunomodulatory effects

of oral dimethyl fumarate on intestinal immune regulation during experimental autoimmune neuritis in Lewis rats —

Jeremias Motte, Kalliopi Pitarokoili, Hussein Bachir, Melissa Sgodzai, Bjorn Ambrosius, Ralf Linker, Ralf Gold

P2.358 Cerebrospinal Fluid

Biomarkers Associated with the Reparative Effects of Intrathecal MSC-NP Treatment in Patients with Progressive Multiple Sclerosis —John

Tuddenham, Violaine Harris, Tamara Vyshkina, Saud Sadiq

P2.359 Low-dose Subcutaneous

P2.363 Absences of HDAC3 and IL-33 in Neurons in Spinal Cord of Patients with Progressive Multiple Sclerosis —

P2.364 Localized over expression of

FGF9 in the rat motor cortex reproduces the pathological features of grey matter lesions in progressive multiple sclerosis. —Claudia Wrzos, Daniel McElroy, Katja Thuemmler, Sebastian Sebastian, Andreas Junker, Christine StadelmannNessler, Christopher Linington

P2.365 Laquinimod targets the aryl

hydrocarbon receptor (AhR) pathway in periphery and brains of naive and EAE mice —Tal Birnberg, Joel Kaye, Kevin Fowler,

Brian Weiner, Ignacio Caballero, Steve Barash, Emanuel Raymond, Inbal Ben-Eliezer, Ianai Fishbein, Aric Orbach, Daphna Laifenfeld, Ralph Laufer, Iris Grossman

P2.366 Direct neuroprotective effect

of laquinimod on glutamate excitotoxicity in experimental multiple sclerosis — Francesca De Vito, Alessandra Musella, Antonietta Gentile, Silvia Bullitta, Diego Fresegna, Georgia Mandolesi, Diego Centonze

P2.367 Inhibition of myelination

by FGF2 in the central nervous system is Wnt-dependent: implications for endogenous repair in multiple sclerosis. —Katja Thuemmler, Thomas Zeis, Daniel McElroy, Nicole Schaeren-Wiemers, Christopher Linington

P2.368 Immunization against CCL20,

aTh17 cell related chemokine, may confer protection against multiple sclerosis (MS). —Arnon Karni, Michal Abraham, Karin Mausner-Fainberg, Ido Weiss, Amnon Peled

P2.369 Xenogeneic assessment of

mitochondrial bioenergetic impairment induced by CSF from MS patients —

Maureen Erwin, Ilana Katz Sand, Carlos Lopez Gomez, Tomasz Rusielewicz, Elise Digga, Sarah Rothstein, Valentina Fossati, Catarina Quinzii Hirano, Patrizia Casaccia

CNS INFLAMMATORY DISEASES AND DIFFERENTIAL DIAGNOSIS II

Anti-CD20 Therapy Effectively Depletes B Cells and Ameliorates Central Nervous System Autoimmunity —Paul Smith,

P2.370 Intrathecal NMDA receptor

P2.348 Teriflunomide Impacts Primary

P2.360 Odor identification is

Bashir, Joseph Kass

Agrawal, Amy Mahan, Tracy Garron, Nellwyn Hagan, William Siders

Gabriel Bsteh, Lisa Nothegger, Klaus Berek, Felix Ladstatter, Stefan Raschbacher, Barbara Teuchner, Michael Auer, Harald Hegen, Franziska Di Pauli, Florian Deisenhammer, Markus Reindl, Andreas Lutterotti, Thomas Berger

Bsteh, Lisa Nothegger, Klaus Berek, Felix Ladstatter, Stefan Raschbacher, Sebastian Wurth, Michael Auer, Harald Hegen, Franziska Di Pauli, Florian Deisenhammer, Markus Reindl, Andreas Lutterotti, Thomas Berger

Microglia and Astrocyte Functions In Vitro —Andrea Edling, Lisa Woodworth, Rajiv

P2.349 Progressive multiple sclerosis patients with NFKBIA mutations are less responsive to the immune changes

Catherine Huck, Vanessa Wegert, Cindy Schmid, Robert Dunn, David Leppert, Erik Wallstroem

associated with neurodegeneration in relapsing-remitting multiple sclerosis —

96 2017 AAN Annual Meeting Scientific Program

antibody reactivation due new ovarian teratoma in patient with previously resected ovarian teratoma for antiNMDA receptor encephalitis —Hassaan

P2.371 CNS manifestations

of voltage-gated calcium channel antibodies —John Adair

Lymphohistiocytosis (HLH) / Macrophage Activated Syndrome (MAS) with CNS Aspergillus —Jay Rosenberg, Reshma

P2.373 Tdap Vaccination and Acute Demyelinating Events —Nicholas Gregg,

Neil Nadkarni, Stephen VanHaerents, Jessica Templer, Sabra Abbott, Elizabeth Gerard

P2.374 Hemorrhagic Acute

Disseminated Encephalomyelitis (ADEM) as first Neuropsychiatric presentation of Systemic Lupus Erythematosus — Gustavo Ribas, Bruna Chu, Felipe Dos Santos, Marcel Morsch, Eduardo Paiva, Francisco Germiniani

P2.375 Fecal GABA levels are

reduced in multiple sclerosis but not in neuro-Behcet disease —Recai Turkoglu, Cem Kucukali, Erdem Tuzun

P2.376 Prodromal Stiffperson

Syndrome: Two cases of antibody detection over a decade after symptom onset —Amanda Piquet, Steve O’Donnell,

John Greenlee, Judith Warner, Stacey Clardy

P2.377 Tumefactive demyelinating

lesions: Clinical and radiological features of 12 patients. —Pedro Sanchez Lopez, Virginia Meca Lallana, Antonio Barbosa, Itziar PalmÌ, Julio Dotor, Jose Vivancos Mora

P2.378 Giant-Cell Arteritis Presenting as Isolated Bilateral CN-VI Palsies: A Rare Case Report of a 65 Year Male. — Abhishek Lunagariya, Urvish Patel, Fenil Kotadiya, Christina Wilson

P2.379 Thalamic germinoma

masquerading as CNS inflammatory disease: a case report —Laura Baldassari, Amanda Piquet, M. Paz Soldan

P2.380 Acute disseminated

encephalomyelitis in China, Singapore, and Japan: a comparison with the U.S.A. —Diederik Koelman, David Benkeser,

Yan Xu, Xiumin Shermyn Neo, Kevin Tan, Masahisa Katsuno, Gen Sobue, Jun Natsume, Salim Chahin, Soe Mar, Arun Venkatesan, Tanuja Chitnis, George Hoganson, Anusha Yeshokumar, Paula Barreras, Bittu Majmudar, Marco Carone, Farrah Mateen

P2.381 Histopathological

neurosarcoidosis in response to disseminated seminoma with absence of central nervous system metastases — Jennifer Massey

P2.382 WITHDRAWN P2.383 Adult Onset Hereditary

Diffuse Leucoencephalopathy with Axonal Spheroids (HDLS): First Case Report in South America —Veronica

Tkachuk, Gisele Pacio, Ariel Bustos, Marianela Crespo Arizmendi, Vanesa Toneguzzo, Juan Pablo Paviolo, Cristian Calandra, Juan Manuel Toranzo, Maria Saccoliti, Ana Lia Taratuto, Marcelo Kauffman

P2.384 Central nervous system

demyelination in a patient with Cryopirin-Associated Periodic Syndrome treated with canakinumab —Barbara Willekens, Vito Sabato


P2.385 Overlap of idiopathic

and IgG4-related hypertrophic pachymeningitis: Case Series —Uzma Usman, Suraj Muley, Mark Agius

P2.386 Glutamic Acid Decarboxylase Antibodies in Neurological Diseases: Validation of Enzyme-linked Immunosorbent Assay and Proposal of a Cut Off for Clinical Relevance —Marco

Zoccarato, Stefania Bellio, Piera De Gaspari, Irene Rosellini, Anna Grisold, Livio Caberlotto, Luigi Zuliani, Giuseppina Barberio, Bruno Giometto

P2.387 CLIPPERS Syndrome in

Association P/Q type Voltage Calcium Channel Antibody —Michelle Devine, Divyanshu Dubey, Kyle Blackburn, Worthy Warnack

P2.388 MRI, Psychiatric and

Neuropsychological Sequelae in Children with anti-NMDAR Encephalitis —Lauren

Sham, Giulia Longoni, Michelle Peralta, Arlette Lefebvre, Katia Sinopoli, Tricia Williams, E. Ann Yeh

P2.389 Neurosarcoidosis in a public safety net hospital: a study of 82 cases —James Dorman, Lakshmi Warrior,

Vishal Pandya, Ying Sun, Jacob Ninan, William Trick, Helen Zhang

P2.390 Neurologic and cranial

manifestations of Erdheim-Chester disease —Natalie Parks, Gaurav Goyal, Ronald Go, W. Tobin

P2.391 VGKC antibody testing in a tertiary referral center —Grace Crotty,

Ivana Vodopivec, Alexandra Loomis, Jason Baron, Tracey Cho, Shamik Bhattacharyya

P2.392 A rare case of immune

Diana Londono, Manas Upadhyaya, Sarah Parker, Gregory Blume

DISCONTINUATION AND SWITCHING DISEASE MODIFYING THERAPIES IN MULTIPLE SCLEROSIS

Crystal Watson

P2.397 Persistence with multiple

sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis —Jonathan Korn, Jennie Medin, Juanzhi Fang, Norman Putzki

P2.398 Effect of switching from daily injections of 20mg glatiramer acetate to 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis over 33 months —Jesper Hagemeier, Bianca

Weinstock-Guttman, Niels Bergsland, Deepa Ramasamy, Jackie Durfee, Maryia Cherneva, Ellen Carl, Jillian Carl, Channa Kolb, David Hojnacki, Robert Zivadinov

P2.399 Real-World Relapsing-

Remitting Multiple Sclerosis (RRMS) Patients in the Tysabri® Observational Program (TOP) Who Discontinued Natalizumab: Why They Stopped, Which Therapies They Switched To, and How Their Disease Activity Changed —Maria Trojano, Helmut Butzkueven, Ludwig Kappos, Timothy Spelman, Heinz Wiendl, Yi Chen, Pei-Ran Ho, Nolan Campbell

P2.400 Return of MS Disease Activity

P2.395 Brain atrophy and lesion

burden MRI trajectories after switch to natalizumab in multiple sclerosis patients —Tomas Uher, Manuela Vaneckova, Jan Krasensky, Michaela Andelova, Barbora Benova, Lucie Kadrnozkova, Lukas Sobisek, Zdenek Seidl, Eva Havrdova, Dana Horakova

P2.396 Stable Multiple Sclerosis

Patients on an Interferon Therapy Have Better Outcomes When Staying on

MEDICAL STUDENT ESSAY AWARD RECIPIENTS

P2.409 Recycling endosomes mediate local, Golgi-independent secretory trafficking in neuronal dendrites Recipient:

Aaron Bowen

P2.410 Utility of an Electronic

Customizable Sleep Behavioral Software Program “MySleepScript” in individuals with acquired brain injury Recipient:

Moon Jeong Lee

P2.411 Patients or Participants? The 1977 National Bioethics Commission and Multidisciplinary Oversight of “Innovative” Psychosurgery

Recipient:

Discontinuation in Patients with Multiple Sclerosis Over Age 60 —Le Hua, Huijun

Bob Sun

P2.412 Quantitative Comparison of

K-D Balance and Sway Balance™ System Mobile Device Applications Chelsea Zhang

Fan, Devon Conway, Tyler G. Kinzy, Nicholas Thompson

P2.402 Rebound of Multiple Sclerosis Disease Activity Following Fingolimod Cessation —Afagh Garjani, Esmaeil Nikfekr, Jithin George

P2.403 Reducing Rebound Disease

P2.404 WITHDRAWN P2.405 Real-World Treatment

Wray, Deren Huang, Qunming Dong, Daniel Jones, Crystal Watson, Mehul Jhaveri

Claudia Janoschka, Lisa Lohmann, Andreas Schulte-Mecklenbeck, Tilman SchneiderHohendorf, Nicholas Schwab, Catharina Grofl, Heinz Wiendl, Luisa Klotz

P2.401 Disease Modifying Therapy

Augusto Miravalle, Stanley Cohan, Kimberly Umans, Sami Fam

Lapierre, Mark Freedman, Francois GrandMaison, Liesly Lee, Katayoun Alikhani, Lorne Kastrukoff, Gregg MacLean, Paola Haddad, Robyn Schecter

Increased over One Year When MS Patients Switched from an Interferon Beta Therapy to Peginterferon Beta1a —Barry Hendin, Robert Naismith, Sibyl

treatment enhances the pathogenic signature of Th17 cells—potential implications for treatment cessation? —

Recipient:

P2.393 Tolerability and Retention

P2.394 Treatment Satisfaction

P2.408 Long-term natalizumab

after Daclizumab Discontinuation Did Not Exceed Baseline Levels in SELECT/ SELECTION Studies —Gavin Giovannoni,

Activity in Relapsing Multiple Sclerosis Patients Electively Transitioned from Natalizumab to Teriflunomide —Stanley

to Fingolimod in RRMS Patients who Switched from other Oral DMTs —Yves

Alfonso Narduc Capobianco, Marianna Lo Re, Maria Malentacchi, Francesca Sperli, Manuela Matta, Alessia Di Sapio, Simona Malucchi

MONDAY

mediated meningoencephalitis presenting with bilateral ear swelling and progressive mental deterioration. —

Therapy Than Patients Who Switch to Another Interferon —Chao Chen, Ning Wu,

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.

Cohan, Keith Edwards, Tiffany Gervasi, Chiayi Chen, Judy O’Connor, Kyle Smoot, Kiren KresaReahl

Persistence Among Multiple Sclerosis Patients on Injectable Disease Modifying Therapies —John Ko, Jacqueline Nicholas, Prakash Navaratnam, Howard Friedman, Frank Ernst, Vivian Herrera

P2.406 Effectiveness of Delayed-

release Dimethyl Fumarate on Clinical Measures and Patient-Reported Outcomes in Relapsing Multiple Sclerosis (RMS) Patients Switching After Suboptimal Response to Glatiramer Acetate, Including Patients with Early MS: Subgroup Analysis of RESPOND — Kiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, Macaulay Okwuokenye, Jason Mendoza

P2.407 High risk PML patients

switching from natalizumab to alemtuzumab —Antonio Bertolotto, Marco

Fast and easy registration · AAN.com/view/AM17 97


Poster Sessions

Poster Session III



MOVEMENT DISORDERS: TICS, TREMOR, AND ATAXIA I

P3.014 Improving Tremor Detection

P3.001 Postmortem changes in

Bruce Musicus, Catherine Medlock, Alan Oppenheim, Randall Davis, Diana Apetauerova, Julie Leegwater-Kim, E Palmer, Dana Penney, William Souillard-Mandar

the motor vs. non-motor cerebellum of essential tremor —William Tate, Geoffrey Kelly, Phyllis Faust, Elan Louis

P3.002 Antisense FMR1 splice

variant and loss of AGG interruptions are predictors of Fragile X-associated tremor/ataxia syndrome (FXTAS) —

and Quantification with Automated Measurements of Stroke Energy —

MOVEMENT DISORDERS: DYSTONIA AND NEUROTOXIN THERAPIES

Padmaja Vittal, Shrikant Pandya, Kevin Sharp, Elizabeth Berry-Kravis, Lili Zhou, Bichum Ouyang, Jonathan Jackson BS, Deborah Hall

P3.015 Associations between

P3.003 A Congenital Form of

Cook, Beverly Snively, Kathleen Sweadner, Ihtsham Haq, Mark Stacy, Laurie Ozelius, Allison Brashear

Spinocerebellar Ataxia 13 : Insights from Three Biological Models —Swati Khare, Jerelyn Nick, Pedro Fernandez-Funez, Jada Lewis, Harry Nick, Michael Waters

P3.004 SYNE1 mutations cause adult onset autosomal recessive ataxia with retained reflexes in Brazilian patients — Maria Thereza Drumond Gama, Jose Luiz Pedroso, Orlando Barsottini, Anne Noreau, Gabrielle Houle, Alexandre Dionne-Laporte, Patrick Dion, Guy Rouleau

P3.005 Analysis of the Repeat Size

Distribution of over 82,000 Alleles in the Spinocerebellar Ataxias —Zhenyuan

P3.016 Clinical Relevance of

Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study —Zoltan Mari, Khashayar Dashtipour, Joseph Jankovic, Charles Adler, Marc Schwartz, Mitchell Brin

P3.017 Prospective, Single-blind, pilot trial of AbobotulinumtoxinA (AboA) in oromandibular dystonia (OMD) —Stewart Factor, Michael Silver, John Hanfelt, Elaine Sperin, Laura Scorr, Alan Freeman, H. Jinnah

P3.018 Improvement of Dystonia

P3.006 Frequency of tolerance and

P3.019 Long-term changes in

Almeida, Bryan Klassen, Anhar Hassan

Martin Nevrly, Petr Hlustik, Pavel Otruba, Pavel Hok, Michaela Kaiserova, Zbynek Tudos, Petr Kanovsky

P3.007 Spinocerebellar Ataxia Type 3—Characterization of a Portuguese Cohort —Joana Ribeiro, Ana Margarida Novo, Mario Sousa, Luciano Vieira, LuÌs Negr„o, Cristina Januario

P3.008 The pharmacokinetics of

SAGE-217 in Phase 1 SAD and MAD studies —Ethan Hoffman, Jeffrey Wald,

TUESDAY

Shane Raines, George Nomikos, Helen Colquhoun, Stephen Kanes

P3.009 Next-generation neuroactive steroid SAGE-217 in a multipleascending dose study —George Nomikos,

Helen Colquhoun, Michael Quirk, Shane Raines, James Doherty, Ethan Hoffman, Abdul Sankoh, Steve Kanes

P3.010 A blinded assessment of balance in patients with orthostatic tremor —Danish Bhatti, Rebecca Thompson, Yiwen Xia, Amy Hellman, L Schmaderer, Cindy Penke, Regan Iske, John Bertoni, Diego Torres-Russotto

P3.011 Childhood Tremor:

Electophysiological Evaluation and Clinical Correlates —Pattamon Panyakaew, Bennett Lavenstein, Mark Hallett

P3.012 Psychiatric comorbidities are

common in patients with Orthostatic Tremor —Danish Bhatti, Rebecca Thompson, Kalyan Malgireddy, Mark Fleisher, Daniel Murman, Diego Torres-Russotto

P3.013 Dentate nucleus neuronal

density: a postmortem study of essential tremor vs. control brains —Geoffrey Kelly, William Tate, Phyllis Faust, Elan Louis

Poster Session III Neighborhoods

F

E

P3.145–222

P3.111–144

P3.101–110A

Poster Discussion

C

P3.081–100

P3.020 Increased insula-putamen

connectivity in X-linked dystoniaparkinsonism —Anne Blood, Jeffrey Waugh, Thomas Munte, Marcus Heldmann, Aloysius Domingo, Christine Klein, Hans Breiter, Lillian Lee, Raymond Rosales, Norbert Bruggemann

P3.021 A Phase 2, Open-label,

dose-escalating study to evaluate the safety and preliminary efficacy of Daxibotulinumtoxina for injection (RT002) in isolated cervical dystonia. — Cynthia Comella, Allison Brashear, Joseph Jankovic, Atul Patel, Daniel Truong, Marian Evatt, Caroline Chung, Roman Rubio

P3.022 Determinants of Quality of Life in Cranial Dystonia —Laura Scorr, Stewart Factor, H. Jinnah

P3.023 Neural oscillatory activities of the motor thalamus in dystonia —Nagako Murase, Masao Matsuhashi, Yuji Maeda, Hidehiro Hirabayashi

P3.024 Correllation Between Time

Course, Level of Impact of Illness, Functionality, and Postural Measures of Patients with Cervical Dystonia —Livia Oliveira, Francisco Germiniani, Helio Afonso Teive, Sibele Mattozo, Roberta Werle, Ana Guimar„es

P3.025 Autonomic Nervous System Dysfunction in X-linked Dystonia Parkinsonism (XDP): Does it exist? — Melanie Leigh Supnet, Raymond Rosales

98 2017 AAN Annual Meeting Scientific Program

H

B

P3.251–328

P3.031–070 ePosters

P3.071–080

I

P3.329–412

Management by Specific Training of General Neurologist and Family Doctors —Maja Relja

sensorimotor cortical modulation in response to BoNT therapy in cervical dystonia. The functional MRI study. —

G

P3.223–250

D

brain structure and motor-related manifestations of rapid-onset dystoniaparkinsonism —Christopher Whitlow, Jared

Wang, Marc Meservey, Rebecca Moore, Julie Snyder, Nicholas Tiebout, Tara McNamara, Craig Hebert, Diem Doan, Michelle Alvayero, Sat Dev Batish, Michelle York, Joseph Higgins

ataxia following VIM thalamic deep brain stimulation in 113 essential tremor patients —Kamilia Nozile-Firth, Leonardo

Tuesday, April 25  8:30 a.m.—7:00 p.m.

A

P3.001–030 A: Movement Disorders B: Practice, Policy, and Ethics; Sleep; Cerebrovascular Disease and Interventional Neurology ePosters C: Aging and Dementia D: Cerebrovascular Disease and Interventional Neurology Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Neuro-oncology; Neurocritical Care; Child Neurology G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease; Global Health I: MS and CNS Inflammatory Disease

P3.026 MYSTICOL: A multisite,

double-blind, randomized, placebocontrolled trial of rimabotulinumtoxinB for the treatment of sialorrhea in Parkinson’s disease (PD) and other neurological conditions —Stuart Isaacson,

Carlayne Jackson, Eric Molho, Richard Trosch, William Ondo, Thomas Clinch

P3.027 Safety and Efficacy of

High-Dose OnabotulinumtoxinA for PostStroke Upper Limb Spasticity: Results of a Double-Blind, Placebo-Controlled Trial —Atul Patel, Carolyn Geis, Katharine Alter, Grace Pan, Adele Thorpe, Lynn James, Rozalina Dimitrova

P3.028 Two Cases of Acute Allergic

Reaction Following Injection of Generic, Government-provided Botulinum Toxin a (GGP-BTA) for Hemifacial Spasm and Blepharospasm. —Laura Parolin, Francisco

Germiniani, Helio Afonso Teive, Rosana Scola, Conrado Borges

P3.029 IncobotulinumtoxinA in

Restless Legs Syndrome (RLS)—a Randomized Double Blind Cross Over Study —Duarte Machado, Diana Richardson, Bahman Jabbari

P3.030 Combined effects of rTMS and botulinum toxin therapy in benign essential blepharospasm —Wei Hu, Wissam Deeb, Joseph Legacy, Aparna Wagle-Shukla


PRACTICE, POLICY, AND ETHICS III

P3.031 Selective use of medication in Washington patients with amyotrophic lateral sclerosis seeking physicianassisted suicide —Leo Wang, Michael Elliott, Michael Weiss

P3.032 The preparations of patients

with amyotrophic lateral sclerosis for natural disaster after the Great East Japan earthquake; comparison between immediately after the earthquake and 5 years later —Yuji Tanaka

P3.033 Priorities of surrogate

decision makers when making decisions for intracerebral hemorrhage patients with poor prognosis: a latent class analysis of the US population —David Hwang, Andrea Knies, Robert Holloway, Douglas White, Kevin Sheth, Liana Fraenkel

P3.040 Percutaneous Endoscopic Gastrostomy in Patients with Acute Neurologic Injury —Kim Yen Thi Vu,

Andreea Xavier, Jade Woellner, Huimahn Choi

P3.041 Analysis of clinical practice

guidelines in Multiple Sclerosis using the Agree tool —Brian J. Villafuerte Trisolini,

Kevin R. Duque, Fiorella S. Adrianzen Alvarez, Darwin Vizcarra, Rodrigo Zamudio, Cesar Caparo, Ana Cruz, Marco Huertas, Jorge Martin Gavidia Chucan, Oscar Gonzales Gamarra, Maria Meza-Vega, Victor Montalvan Ayala, Nicanor Mori, Alda Rivara Castro, Edgar Rojas Huerto, Sheila Suarez

P3.042 Improvement in residents’

lumbar puncture skills by implementing the Kyoto Kagaku Lumbar puncture Stimulator II model in neurology residents’ training. —Mary-Ann Fares, Scott Silliman, Natalya Shneyder

P3.034 Teleneurology beyond stroke:

P3.043 Impact of Patients’ Income on

a component of value-based specialty care —Adam Cohen, Juan Estrada, Anand

Cost and Charge of Intracranial Hemorrhage and Cerebral Infarction Hospitalization —

Viswanathan, Lee Schwamm

Ross-Jordon Elliott, Golshan Fahimi, Ali Seifi

P3.035 Stroke Code De-escalation:

P3.044 Early Improvement in NIH

Safety and Outcomes —Jessica Jarnot, Christopher Streib, Angela Heyer, Amy Reichert, David Anderson, Rwoof Reshi, Kamakshi Lakshminarayan, Mustapha Ezzeddine

P3.036 Exercise for Brain Health.

The Science of Participation in Exercise: Conceptual Framework and Practical Application —Sarah Ingersoll, Jason Chen

P3.037 Social work implementation

Stoke Scale during Inter-hospital Transfer is Common and is Associated with Lower In-hospital Mortality —

Sadiqa Mahmood, Syed Ali, Khawja Siddiqui, Abigail Cohen, Lee Schwamm

P3.045 Pre-diagnosis journey—

perspectives of informal ALS caregivers: a thematic analysis —Miriam Galvin, Rebecca Gaffney, Bernie Corr, Iain Mays, Orla Hardiman

into an outpatient neurology clinic: utilization and patient outcomes —Scott

P3.046 Financial Relationships

P3.038 Onsite Consultation by

Narayanaswami

Vota, Melissa Byrne, Christopher Adcock

Neurologist vs. Tele-Neurology, Referring Physician Satisfaction. —Abraham Alhatou, Mohammad Alhatou

P3.039 Investigation and standardization of a neurology department’s protocols for the ability to recognize, triage and treat chemical nerve agent attacks. —Paul Wright, Saeyoan

P3.047 SPICE: Safe Practices

with Immunomodulators and Chemotherapeutics through Education —

Neuromonitoring in the Military —Matthew Holtkamp, Adam Juersivich, Jonathan Smith

P3.050 Qualitative Analysis of

Clinicians’ Readiness for Proposed Physician Reimbursement for Cognitive Diagnosis and Care Planning by Centers of Medicare and Medicaid Services — Anitha Rao, Marguerite Manteau-Rao

P3.051 The Need for the Extended Office Visit in Neurologic Care —Jane Knobler, Robert Knobler

P3.052 AAAS Capitol Hill Briefing

on Physical Activity and Brain Health — Sarah Ingersoll

P3.053 Tracking Quality of Multiple

Sclerosis Care: Experience of a Large Multiple Sclerosis Center —Mary Willis, Deborah Miller

P3.054 Pilot Interventions to Increase

Professional Medical Interpreter Services Use at an Academic Outpatient Neurology Clinic —Jessica Tran, Nicte Mejia

P3.055 Assessment of Economic

Aspects of Stroke in Different Clinical Management Settings: Academic vs. Non-academic —Golshan Fahimi, RossJordon Elliott, Ali Seifi

Wan-Yu Huang, Hung-Ming Wu

P3.060 Sleep duration and feeling rested are differentially associated with having children among men and women —Kelly Sullivan

P3.061 Making Time for Sleep in a Primary Care Clinic —Marija Vasiljevic,

Sharon Dlhosh, Charlene Gamaldo, Alyssa Gamaldo, Peter Dziedzic, Rachel Marie Salas

SLEEP AND NEUROLOGICAL DISORDERS

P3.062 Refining the frequency and

duration of RL Symptoms: Impact on the prevalence of Restless Leg Syndrome — Maurice Ohayon

P3.063 Online Medical Education

Improves Knowledge and Competence in the Management of Clinically Challenging Cases of Narcolepsy among Neurologists —Stacey Hughes, Thomas Finnegan, Stacey Ullman, Michael Thorpy

P3.064 The relationship between

mood disorder and insomnia depends on race in US veterans with epilepsy —Ima

SLEEP DISRUPTION AND MEDICAL COMORBIDITIES

P3.065 A Case Series of REM Sleep

P3.056 Restless Legs Syndrome /

Srikanth Muppidi, Safwan Jaradeh

Willis Ekbom Disease in Bariatric Surgery Patients —Melissa Lipford, Julie Williams, Paul

Lorentz, Maria Collazo-Clavell, John Park, Eric Olson, Erik St. Louis, Michael Silber, Todd Kellogg

P3.057 Comorbidity of Chronic

Gastro-Esophageal Reflux (GERD) with Sleep and Medical Disorders in a Longitudinal Survey of he American General Population —Maurice Ohayon, Cristina Milesi, Marc Van Dijk

P3.048 Telemedicine consultations

frequency of sleep medication use and brain morphology —Angeliki Tsapanou,

Stephen Samples

disturbance with Circulating Inflammatory Factors in Healthy Middle-aged Women —

Ebong, Maria Lopez, Andres Kanner, Douglas Wallace

Khalil Husari, Kyle Blackburn, Peter Sguigna, Worthy Warnack

for Inpatient services —Kuruvilla John,

P3.059 Associations of Sleep

P3.058 Association between

Yian Gu, Lamia Haider, Yaakov Stern, Nikolaos Scarmeas

Behavior Disorder in Pure Autonomic Failure —Mitchell Miglis, Emmanuel During,

P3.066 Clinical Trial Design for

Assessment of the Orexin Receptor Antagonist Suvorexant in the Treatment of Insomnia in Patients with Alzheimer’s Disease —William Herring, Ellen Snyder, Donald Biwise, Sonia Ancoli-Israel, Kerry Budd, Jill Hutzelmann, Tien Dam, David Michelson

P3.067 Heterotopic gray matter and

idiopathic Rapid Eye Movement Sleep Behavior Disorder —Ahmad El Kouzi, Najib Murr

P3.068 NA P3.069 NA P3.070 NA

Cerebrovascular Disease and Interventional Neurology ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P3.071 Moyamoya Syndrome

P3.074 Cerebral Microbleeds in

Doungporn Ruthirago, Yazan Alderazi

Filho, Fernando Cendes, Ana Coan, Li Li Min, Wagner Avelar

P3.072 Man-in-the-barrel’ syndrome

P3.075 Clinical Characteristics and

Secondary to Vasculopathy in Down Syndrome: A Case Report and Literature Review —Mohamed Shehab-Eldin,

with Delayed Diffusion-weighted MRI Findings —Rakesh Magun, Marilou Ching, Robert Sawyer, Ashkan Mowla

P3.073 Cowden Syndrome: A Dural Arterial Venous Malformation —Parth Upadhyaya, Anthony Torres, Rajneesh Agarwal MD

patients with asymptomatic carotid stenosis. —Alessandro Sousa, Sinval Carrijo

Healthcare Utilization of Hmong Patients Presenting with Stroke —Bhavani Kashyap, Carol Droegemueller, Lauren Erickson, Leah Hanson, Haitham Hussein

P3.076 Rituximab in primary angiitis of the CNS —Peter Berlit, Jana Becker, Markus Kraemer

P3.077 Safety Outcome of Carotid

Artery Stenting in Long Carotid Lesion with Proximal versus Distal Embolic Protection Devices —Vasu Saini, Kunakorn Atchaneeyasakul, Avirag Goswami, Sudheer Ambekar, Kevin Ramdas, Luis Guada, Dileep Yavagal

P3.078 Prolonged microcatheter-

based local thrombolytic infusion as a salvage treatment for failed endovascular treatment for cerebral venous thrombosis: A multicenter registry —Emrah Aytac, Adnan Qureshi,

Mikayel Grigoryan, Gaurav Guliani, Muhammad Saleem, Gustavo Rodriquez, Muhammad Suri

P3.079 Cryptogenic stroke and patent foramen ovale: The role of Valsalva maneuver and prolonged immobility —Ali Daneshmand, Ioannis Koulouridis, David Thaler

P3.080 Does Body Mass Index Impact the Outcome of Stroke Patients Who Received Intravenous Thrombolysis —

Maria Zambrano, Caila Vaughn, Annemarie Crumlish, Christopher Deline, Marilou Ching, Robert Sawyer, Ashkan Mowla

Fast and easy registration · AAN.com/view/AM17 99

TUESDAY

Thirunavuukarasu, Stephen Rush, Christine Molmenti, Edward Coffield

between Neurologists and Industry: An Analysis of the 2015 Open Payments Database —Aditi Ahlawat, Pushpa

P3.049 Current State of Intraoperative

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session III



AGING AND DEMENTIA: THERAPEUTIC APPROACHES I

SIB-based Composite Scale —Alireza Atri,

P3.081 Early treatment with CSF

P3.086 Response Across Multiple

diversion reduces mortality in normal pressure hydrocephalus —Kerstin Andrén, Carsten Wikkelso, Per Hellstrom, Mats Tullberg, Daniel Jaraj

P3.082 Memantine Added to

Background Cholinesterase-Inhibitors Reduces Agitation and Neuropsychiatric Symptoms in Alzheimer’s Disease — Alireza Atri, George Grossberg, Suzanne Hendrix, Noel Ellison, Merrilee Johnstone, John Edwards

P3.083 Novel Insights into

Therapeutic Potential of Multitargeted Benzylpiperidine Derivatives in the Management of Alzheimer’s Disease Associated Pathogenesis —Poonam Meena, Tiwari Manisha

P3.084 Effects of Aerobic Training on

Cognition and Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment —Fabio Porto, Artur Coutinho, Fabio Duran, Ana Pinto, Bruno Gualano, Carlos Buchpiguel, Ricardo Nitrini, Sonia Brucki

P3.085 Improved Detection of

Treatment Effects in Severe Alzheimer’s Disease: A Quantitatively-derived

Suzanne Hendrix, Noel Ellison, Mary Clare Kane, John Edwards, George Grossberg

Outcome Measures in a Randomized Trial of Extended-release Memantine (28 mg, once daily) in Patients with Moderate to Severe Alzheimer’s Disease Receiving Donepezil —George Grossberg, Gustavo Alva, Suzanne Hendrix, Noel Ellison, Merrilee Johnstone, John Edwards

Tuesday, April 25  8:30 a.m.—7:00 p.m. P3.090 Ketone beta-hydroxybutyrate up-regulates BDNF expression through NF-κB as an adaptive response against ROS, which may improve neuronal bioenergetics and enhance neuroprotection —Sang Woo Kim, Krisztina Marosi, Mark Mattson

P3.091 Exercise may increase

cerebral blood flow in amnestic mild cognitive impairment —Yinan Zhang,

prevalence in Greece —Paraskevi Sakka,

Mary Kosmidis, Mary Yannakoulia, Efthimios Dardiotis, Georgios Hadjigeorgiou, Nikolaos Scarmeas

P3.096 Public awareness, knowledge

and attitude toward Alzheimer’s disease in Aseer region, Saudi Arabia— community based cross sectional study —Ali Alqahtani, Mohammed Alqahtani,

Changyang Xing, Takashi Tarumi, Rong Zhang

Abdulmajeed Zarbah, Tariq ALAhmari, Adel Alhazzani

AGING AND DEMENTIA: EPIDEMIOLOGIC STUDIES

P3.097 Measuring subjective memory

P3.092 The temporal relationship

between pain intensity and interference and incident dementia: a communitybased prospective study. —Ali Ezzati,

P3.087 Efficacy of Memantine ER

on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-tosevere Alzheimer’s Disease —Gustavo

P3.095 HELIAD study: Dementia

complaint in a population-based study: comparison of two methods. —Rosanna

Dependence in Dementia Using A Conversion Algorithm of ADCS-ADL to Dependence Scale From a Double Blind Placebo Controlled Trial of Intepirdine (RVT-101) —Ebenezer Asare, Ilise Lombardo,

Cuiling Wang, Andrea Zammit, Mindy Katz, Molly Zimmerman, Carol Derby, Richard Lipton

Tortelli, Maria Barulli, Marco Piccininni, Rosa Capozzo, Marianna Tursi, Alessandra Grasso, Rodolfo Sardone, Francesco Coppola, Caterina Bonfiglio, Chiara Zecca, Gaetano Gagliardi, Madia Lozupone, Francesco Panza, Giancarlo Logroscino

P3.093 A Longitudinal Study

P3.098 Identifying New States with

P3.089 Transcranial direct current

Dueck, Dona Locke, Blake Langlais, Charlene Hoffman-Snyder, Bryan Woodruff

Marguerite Manteau-Rao LCSW MBA

P3.094 Alcohol consumption and

among Newly Diagnosed AD Patients —

Alva, George Grossberg, Suzanne Hendrix, Noel Ellison, Kristen Andersen, John Edwards

P3.088 An Assessment of

Carolyn Zhu, Yaakov Stern, Lawrence Friedhoff

stimulation (tDCS) improves picture naming in Alzheimer Disease and Frontotemporal dementia. —Howard

Chertkow, Carlos Roncero, Heike Kneifel, Alexander Thiel, Stephan Probst, Melanie Malus, Shelley Solomon

Capturing the Transition in Personality (NEO-PI-R) from Preclinical AD to Incident MCI —Richard Caselli, Amylou

dementia risk: a dose-response metaanalysis of prospective studies —Wei Xu, Jin-Tai Yu, Lan Tan

High Dementia Prevalence Among DualEligible Populations for Managed Care Demonstration Projects —Anitha Rao,

P3.099 Rates of Institutionalization

Christopher Black, Howard Fillit, Lin Xie, Rezaul Khandker, Furaha Kariburyo, Onur Baser, Huseyin Yuce, Baishali Ambegaonkar

P3.100 NA

Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Eleven abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 a.m. P3.101 Pulse Pressure in Ischemic Stroke Is an Independent Predictor for Long-Term Stroke Outcomes —Ning Su,

Fei-Fei Zhai, Jun Ni, Lixin Zhou, Ming Yao, Bin Peng, Yi-Cheng Zhu, Liying Cui

TUESDAY

Data Blitz:  11:50 a.m.–11:55 a.m. P3.102 Race and Sex Differences in tPA Utilization among Older Ischemic Stroke Patients —Michael Lyerly, Farhaan Vahidy, John Donnelly, Katrina Booth, Karen Albright

Data Blitz:  11:55 a.m.–12:00 p.m. P3.103 IV tPA Utilization and Outcomes in Asian Americans —Antonio

Mehndiratta, Chip Decker, Rob Lawrence, Dempsey Whitt, Dan Fellows, Tamara Broadnax, Vladimir Lavrentyev, Moshe Feldman, Jeneane Henry, Jason Wong, Andres Ruiz, Kevon Hekmatodoost, Kenichiro Ono, Muhammad Bhatti, Basit Rahim, Qaiser Toqeer, Jamie Ricks, Theandra Madu, Baaba Blankson, Jamie Heath, Pamela Brown, Poanna Bennam, Juan Lu, Warren Felton, Joseph Ornato, Sherita Chapman

Data Blitz:  12:05 p.m.–12:10 p.m. P3.105 Time from Consult Page to Tissue Plasminogen Activator Over Telemedicine Decreases with Experience —Amanda Jagolino, Shima

Moya, Ji Chong

Bozorgui, Arvind Bambhroliya, Christy Ankrom, Tiffany Cossey, Alyssa Trevino, Sean Savitz, Tzu-Ching Wu, Farhaan Vahidy

Data Blitz:  12:00 p.m.–12:05 p.m. P3.104 Clinical Simulation-based Usability Testing of a Mobile Telestroke System —Kaitlynne Heath, Prachi

Data Blitz:  12:10 p.m.–12:15 p.m. P3.106 Post Stroke Fatigue and Depression Predict Lower Health Related Quality of Life in Stroke Patients —

100 2017 AAN Annual Meeting Scientific Program

Gregory Toy, Jonathan Singer, Clotilde Balucani, Dimitre Stefanov, Alisen Huang, Douglas Halket, Jack Mlabasati, Alam Ahmed, Nadege Gilles, Steven Levine

prevents secondary brain atrophy and reduces astrocytic scar formation after transient middle cerebral artery occlusion in mice —Ya-chao Wang, Eduardo

Data Blitz:  12:15 p.m.–12:20 p.m. P3.107 Disability and mortality after permanent feeding tube placement in patients with acute stroke —Raed

Sanchez-Mendoza, Tayana Silva De Carvalho, Britta Kaltwasser, Patricia Machado, Thorsten R Doeppner, Claudio Bassetti, Dirk Hermann

Data Blitz:  12:20 p.m.–12:25 p.m. P3.108 Association between Atrial Fibrillation and Spinal Cord Infarction —

Liao, Nai-Chen Chao, Yi-Chung Lee

Joundi, Gustavo Saposnik, Rosemary Martino, Jimming Fang, Vasily Giannakeas, Joan Porter, Moira Kapral

Saad Mir, Sammy Pishanidar, Alexander Merkler, Babak Navi, Hooman Kamel

Data Blitz:  12:25 p.m.–12:30 p.m. P3.109 Post-acute delivery of GABAA receptor alpha5-antagonist S44819 promotes motor-coordination recovery,

Data Blitz:  12:30 p.m.–12:35 p.m. P3.110 Heterozygous HTRA1 mutation in Taiwanese patients with cerebral small vessel disease —Yi-Chu Data Blitz:  12:35 p.m.–12:40 p.m.

P3.110A   Stroke Call in the United

States: Challenges and Opportunities in Vascular Neurology —Edgar Kenton,

Yi-Chu Liao, Antonio Culebras, Nai-Chen Chao, Yi-Chung Lee, Pierre Fayad, Larry Goldstein, Enrique Leira, Helmi Lutsep, Lawrence Wechsler, Jose Biller, James Stevens, David Wang, Nellie Adams


MYOPATHIES AND MYASTHENIA GRAVIS III

P3.111 Clinical and epidemiological

features of myasthenia gravis in Chilean population —Jose Cea Munoz, David

Martinez, Rodrigo Salinas, Lorena Hoffmeister, Carolina Vidal, Andres Stuardo

P3.112 Evaluation of Respiratory

Testing for Patients with Myasthenia Gravis in the Neuromuscular Clinic —Vera Bril, Carolina Barnett Tapia

P3.113 Correlation between MRI

cerebral white matter changes, muscle structure and/or muscle function in myotonic dystrophy type 1 (DM1) — Cheryl Smith, Peggy Nopoulos, Richard Shields, Dan Thedens, Laurie Gutmann

P3.114 Treatment Related Effects

of anti-GAA Antibodies in Late Onset Pompe Disease —Marie Wencel, Claudia

Shaumbugh, Namita Goyal, Virginia Kimonis, Tahseen Mozaffar

P3.115 Cold-Induced Decrement

and Electrical Myotonia in a Family with DNM2 Mutation without Clinical Myotonia —Amro Stino, Stanley Iyadurai

P3.116 Reduced intramuscular

blood flow correlates with more severe pathology in boys with Duchenne/Becker muscular dystrophy —Alexander Dietz, Anne Connolly, Paul Golumbek, Craig Zaidman

P3.117 Awareness regarding

respiratory care of DMD patients among child neurology providers: an international survey —Poonam Bhatia, Rajeev Bhatia

P3.118 Borderline CNBP CCTG

Expansions in Myotonic Dystrophy Type 2 in over 16,000 Specimens Analyzed in a Clinical Laboratory —Elise Nedzweckas,

P3.124 Validation of a neuroimaging

Cynthia Lary, Lisa Ranzinger, Allison NewellSturdivant, Nicol Brandon, Nicole Lucas, Tiffany Williamson

Bede, Orla Hardiman

P3.133 CSF delivery of AAV9-

based diagnostic protocol for Amyotrophic Lateral Sclerosis —Peter

P3.125 TBK1 is misregulated in

sporadic ALS spinal cord and peripheral blood —Cindy Ly, Ted Hyman, Karoline Baker, Matthew Harms, Timothy Miller

P3.126 A Quality of Life

Measurement for Spinal and Bulbar Muscular Atrophy —Robert Guber,

Angela Kokkinis, Alice Schindler, Roxanna Bendixen, Chad Heatwole, Kenneth Fischbeck, Christopher Grunseich

P3.127 Adaptive Design Single

Center Phosphodiesterase Type 4 ( PDE4 ) Inhibitor - Ibudilast ( MN-166ALS-1201 ) Phase 1b / 2a Clinical Trial Double - Blind ( DB ) with Open Label Extension (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis ( ALS ) Patients [ 1 ] Not Requiring Non-Invasive Ventilation ( no NIV ) up to 5 years ( Early Cohort - EC ) and [ 2 ] Requiring NonInvasive Ventilation ( NIV ) up to 10 years ( Advanced NIV Cohort - ANC ) from Disease Onset - Report of Clinical Trial DB, OLE and Post-Treatment Cessation Epochs - Per-Protocol (PP) Treatment Completion Associated with Improved Survival and Post Treatment Cessation Loss of Muscle Strength —Benjamin

Brooks, Elena Bravver, Mohammed Sanjak, Velma Langford, Linda Moore, Nicole Smith, Nicole Lucas, Mindy Nichols, Cynthia Lary, Allison Newell-Sturdivant, Joanne Nemeth, Priscilla Russo, Nicol Brandon, Lisa Ranzinger, Maryanne Burdette, Kathryn Wright, Amber Ward, Scott Holsten, Michael Fischer, Rachel Hillberry, William Bockenek, Scott C Lindblom, Benjamin Bringardner, David Sachar, Joanna Dojillo, Kazuko Matsuda, Yuichi Iwaki

P3.128 Trials of L-serine in ALS —

P3.119 Telephonic Single Breath

P3.129 Bowel, Bladder, and

Syeda Alqadri, Raghav Govindarajan

Verena Samara, Summer Gibson, Mark Bromberg

P3.120 A Rare Case of Vacuolar

P3.130 Edaravone (MCI-186) for

Count Test Administered by Nurses in Diagnosing Myasthenia Exacerbation —

Myopathy. —Robert Murphy, Mazen

Dimachkie, Melanie Glenn, Omar Jawdat, Jeffrey Statland, Richard Barohn, Laura Herbelin, Mamatha Pasnoor

P3.121 Impact of Medications on

Myasthenia Gravis Patient Population at University Hospital —Rohit Gummi, Natalie Kukulka, Raghav Govindarajan

P3.122 Micro-RNAs and Muscle

Imaging in LGMD 1F as tools for following disease progression —Valentina Pegoraro, Corrado Angelini

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG): MOTOR NEURON DISEASE I

P3.123 CSF Neurofilament

proteins levels in Amyotrophic Lateral Sclerosis —Paolo Volanti, Daniela Rossi, Liliana Brambilla, Tiziana Colletti, Rossella Spataro, Vincenzo La Bella

Walter Bradley, Dan Moore, Robert Miller, David Saperstein, Dallas Forshew

Sudomotor Symptoms in ALS patients —

the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) by Domain and Individual Items —Joseph Palumbo, Koji Takei, Kikumi Tsuda, Shawn Liu

P3.131 The oculomotor restricted

protein synaptotagmin 13 protects motor neurons from degeneration in ALS and SMA —Monica Nizzardo, Federica Rizzo, Michela Taiana, Ilary Allodi, Julio Aguila Benitez, Jik Nijssen, Gianna Ulzi, Valentina Melzi, Roberto Del Bo, Nereo Bresolin, Giacomo Comi, Eva Hedlund, Stefania Corti

P3.132 Quantitative Labial,

Tongue Speech and Swallowing Rate Measurements at Diagnosis Correlate with ALS Functional Rating Scale— Revised (ALSFRS-R) Bulbar Subscore and Bulbar Subscore Item Scores - Effect of Nuedexta on Speech and Swallowing — Kathryn Wright, Benjamin Brooks, Velma Langford, Elena Bravver, William Bockenek,

Laura Ferraiuolo, Sukumar Nagendran, James L’Italien, Douglas M. Sproule, Minna Du, Jessica Cardenas, Arthur Burghes, Kevin D. Foust, Allan A. Kaspar, Shibi Likhite, Jerry Mendell, Brian Kaspar

P3.134 Assessment of Bulbar

Function in ALS —Richard Smith, Erik Pioro, Gary Pattee, Kimberly Goslin, Gregg Meekins, Jordan Green, Eric Macklin

P3.135 ALS Reversals:

Demographics, Disease Characteristics, Treatments and Co-Morbidities —Daniel Harrison, Richard Bedlack

P3.136 Essential Fatty Acid

Deficiency Related to the “Amino Acid Diet” in Patients with Spinal Muscular Atrophy —Julie Parsons, Laura Watne MS RD

P3.137 A Phase 1 Study Assessing the Infusion of Expanded Autologous Regulatory T Lymphocytes in Subjects with Amyotrophic Lateral Sclerosis —

Jason Thonhoff, David Beers, Weihua Zhao, Luis Lay, Della Brown, James Berry, Merit Cudkowicz, Elizabeth Shpall, Katy Rezvani, Stanley Appel

P3.138 A novel, muscle strength-

based endpoint for sensitively tracking disease progression in amyotrophic lateral sclerosis. —Toby Ferguson, Dawei Liu, Steve Han, Donald Johns

P3.139 Integrated [11C]-PBR28

MR-PET imaging in Amyotrophic Lateral Sclerosis —Mohamad J. Alshikho, Nicole

R. Zürcher, Marco Loggia, Paul Cernasov, Daniel Chonde, David Izquierdo Garcia, Ciprian Catana, James Chan, Suma Babu, Sabrina Paganoni, Eva-Maria Ratai, Jacob Hooker, Nazem Atassi

P3.140 Yield of an ALS Genetic

Testing Algorithm in a Tertiary Care ALS Clinic —Jennifer Roggenbuck, Adam Quick, Stephen Kolb

P3.141 Quantitative ultrasound of the tongue: gray scale level and quantitative backscatter analysis approaches for detection of disease-related changes in ALS —Courtney McIlduff, Sung Yim, Adam Pacheck, Aleksandar Mijailovic, Kristin Qi, Seward Rutkove

P3.142 ALS-related FUS Protein

is Mislocalized to Cytoplasm and is Recruited into Stress Granules in Fibroblasts of Asymptomatic FUS P525L Mutation Carriers. —Vincenzo La Bella, Margherita Lo Bello, Francesca Di Fini, Antonietta Notaro, Brigida Pistone, Tiziana Colletti, Francesca Conforti, Rossella Spataro

P3.143 NA P3.144 NA

P3.145 Identifying drug therapies for plexiform neurofibromas in Neurofibromatosis Type 1 through chemo-genomic analysis —Jaishri

Blakeley, Sara Gosline, Marigo Stathis, Rajarshi Guha, Xiaohu Zhang, Craig Thomas, Sharad Verma, Justin Guinney, Margaret Wallace, Marc Ferrer

P3.146 Efficacy and safety of

adjunctive everolimus for treatmentresistant focal onset seizures in tuberous sclerosis according to age: insights from EXIST-3 —Colin Roberts, Rachel Kuperman,

Mary Kay Koenig, Joyce Wu, Michael Kohrman, Paolo Curatolo, Rima Nabbout, Noah Berkowitz, Fabian Herbst, Antonia Ridolfi, David Franz

P3.147 Neurocognitive

Profiles of Adults with Cerebellar Medulloblastoma —Rebecca Harrison,

Jason M. Johnson, Catherine M. Sullaway, Shelli R. Kesler, Jeffrey S Wefel

P3.148 Risk factors for hypersomnia/ narcolepsy and response to therapy in survivors of childhood brain tumors —

Raja Khan, Thomas Merchant, Zsila Sadighi, Valerie Crabtree, Mercedes Bello, April Sykes, Zhaohua Lu, Jennifer Zabrowski, Andrea Simmons, Belinda Mandrell

P3.149 Genotype Does Not Correlate with Internal Whole Body Tumor Burden in Neurofibromatosis I (NF1) —Justin

Jordan, Marlon Seijo, James Walker, Serkin Erdin, Vanessa Merker, Wenli Cai, Gordon Harris, Miriam Bredella, James Gusella, Scott Plotkin

P3.150 Dabrafenib in Erdheim-

Chester Disease of the cerebellum induces remission. —Ahmad El Kouzi, Ali

Choucair, Paula Rauschkolb, James Gilchrist

P3.151 Dosimetric Analysis of

Radiation Therapy for Pediatric Neuroblastoma: Should the spine be included in the treatment field? —Narine Wandrey, Tiffany Chen, Tony Eng

P3.152 Doxycycline potentiates

antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in malignant peripheral nerve sheath tumor —Ming-Jen Lee, Shih-Hsuan

Hung, Mu-Ching Huang, Tsuimin Tsai, Chin-Tin Chen

P3.153 Meningeal

hemangiopericytomas: Imaging features helpful in distinguishing these tumors from meningiomas —Zehra Hooda, John Arrington, Nam Tran, Solmaz Sahebjam

P3.154 A case of abducens nerve

palsy in the context of Ecchordosis physaliphora —Chike Ilorah, Brandon Bond, Jorge Kattah, Bahareh Hassanzadeh

P3.155 A Rare Case of Primary

Angiitis of the Central Nervous System (PACNS) Associated with Metastatic Prostate Cancer —Tasneem F. Hasan, Stefania Maraka, Monica Loghin

P3.156 Neurolymphomatosis in a patient with prior meningeal spread in remission. —Michael Ackerl, Birgit Surboeck, Irmgard Brandl, Anna Grisold,

Fast and easy registration · AAN.com/view/AM17 101

TUESDAY

Rebecca Moore, Marc Meservey, Tara McNamara, Nicholas Tiebout, Zhenyuan Wang, Sat Dev Batish, Joseph Higgins

mediated gene therapy for SMA, a lethal neuromuscular disease in children: a dose-response study in mice and nonhuman primates —Kathrin Meyer,

NEURO-ONCOLOGY: PEDIATRIC AND OTHER RARE CNS TUMORS

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session III



Barbara Horvath, Elisabeth Lindeck-Pozza, Klaus Lindner, Stefan Meng, Rainer Poehnl, Wolfgang Grisold

Anderson, Andrea Knies, Belinda Nhundu, Cynthia Bautista, Kelly Poskus, Kevin Sheth, David Hwang

P3.157 A case of Pontine

P3.169 A Common Data Language for

sparing CLIPPERS Variant with both supratentorial and cervical spinal cord involvement —Aparna Vaddiparti, Alexandra Flowers, Phyllis Grable-Esposito, Paul Schwartz

P3.158 Recurrent Meningeal RosaiDorfman Disease with Spontaneous Regression —Brett Theeler, Jonathan Gilhooly, Patrick Malafronte, Keith Ryan

P3.159 Myeloid Sarcoma Involving

the Central Nervous System: A Rare Entity Mimicking Meningioma —J. Clay Goodman, Noel Agudo MD

P3.160 Quality of life as a therapeutic

endpoint in neurofibromatosis type 2—A prospective study —Aishwarya Shukla,

Clinical Research Studies: The National Institute of Neurological Disorders and Stroke and National Library of Medicine Cerebral Aneurysms and Subarachnoid Hemorrhage Common Data Elements Version 1.0 Recommendations —Muniza Sheikh, Sherita Alai, Joy Esterlitz, Liz Amos, Christophe Ludet, Joanne Odenkirchen, Jose Suarez

P3.170 Ensuring adequate nutrition delivery in the neurointensive care unit —David Do, Joshua VanDerWerf,

and Mortality in Multiple Sclerosis —

Kristen Steenerson, Katalin Kelemen, Shimon Kusne, Robert Orenstein, Marie Grill

P3.163 When the Imaging is No

Help—A Rare Presentation of Primary CNS Lymphoma —Justin Low, Akanksha

Sharma, Yi-Han Lin, Meghan Romba, Maciej Mrugala

P3.164 An Unusual Case of

Multiple Cranial Nerves’ Palsies and Concomitant Lumbar Radiculopathy as the First Presentation of CNS-infiltrating Lymphoma. —Mariana Canever, Francisco

TUESDAY

Germiniani, Helio Afonso Teive, Walter Arruda, Sergio Almeida, Ana Paula Azambuja, Débora Bertholdo, Gustavo Almeida

P3.165 primary CNS

lymphoma(PCNSL) mimicking HSV encephalitis: A false case of positive HSV PCR —Ifrah Zawar, Sung Cho NEUROCRITICAL CARE: NICU ISSUES

P3.166 Preventing Early Bouncebacks to the Neurointensive Care Unit —David Coughlin, Monisha Kumar, Neha Patel, Rebecca Hoffman, Scott Kasner

P3.167 Efficacy of two surface cooling devices for temperature management in a neurocritical care unit —Premkumar Nattanmai

Chandrasekaran, Christopher Newey, Sharmila Suri Mohanram, Keerthivaas Premkumar, Gurpreet Singh Aujla

P3.168 Primary care physician

involvement in shared decision making for neurocritically ill patients and family satisfaction with care —Kevin Huang, Urs Weber, Jennifer Johnson, Nathanial

with Intubation in Critical Illness Polyneuropathy (CIP), a New York Statewide Planning and Research Cooperation System (SPARCS) Database Report from 1998 to 2014. —Francisco Gomez, Jesyree Veitia, Abu Nasar, Jeffrey Kornitzer, Nizar Souayah

P3.173 Exploring Factors Associated with Intubation and Mechanical Ventilation in Critical Illness Myopathy (CIM), an Analysis of New York Statewide Planning and Research Cooperation System (SPARCS) Data 1998-2014. —Francisco Gomez, Kambiz Nazir, Abu Nasar, Jeffrey Kornitzer, Nizar Souayah

P3.174 Factors associated with

Intubation in HIV positive patients presenting with Critical Illness Myopathy (CIM) or Polyneuropathy (CIP), A New York Statewide Planning and Research Cooperation System Database Report. —Jesyree Veitia, Francisco Gomez, Abu Nasar, Jeffrey Kornitzer, Nizar Souayah

P3.175 Factors Influencing 30-day

Readmission Following Traumatic Spinal Cord Injury —Jimmy Nguyen, Paul Arnold

P3.176 Sympathetic System activity

in Acute Phase of Severe Traumatic Brain Injury: Neuroanatomical Factors significance. —Evgenia Alexandrova, Kseniia K. Kriukova, Aram S. Tonoyan, Natalia E. Zakharova, Alexander A. Sychev, Alexander A. Potapov

P3.177 Fibrinogen Extravasation is Associated with Microglial Activation and Neuronal Loss in Traumatic Brain Injury —Damian Jenkins

P3.193 Brain lesion load and

CHILD NEUROLOGY I transcriptomic changes in fetuses with myelomeningocele —Tomo Tarui, Aimee

P3.183 Maturation of the motor

cortex excitability in children with focal epilepsy, as measured by navigated transcranial magnetic stimulation — Roman Gersner, Harper Kaye, Lindsay Oberman, Ah Yeon Chung, Maria Sanchez, Nicolas Chiriboga, Aaron Boes, Alvaro Pascual-Leone, Alexander Rotenberg

P3.184 Nusinersen in Symptomatic Children with Later-onset Spinal Muscular Atrophy (SMA): Design of the Phase 3 CHERISH Study —Eugene

Schneider, Laurence Mignon, John Su, Ron Baldwin, Kathie Bishop, Zhenshao John Zhong, Wildon Farwell, Frank Bennett, On Behalf Of The CHERISH Study Group

P3.185 Time to retreatment after

abobotulinumtoxinA (Dysport) injections in children with dynamic equinus foot deformity —Nigar Dursun, Jorge Carranza, Ann Tilton, Resa Aydin, Ece Unlu, Belgin Erhan, Maria Luisa Rodriguez, Philippe Picaut, Anne-Sophie Grandoulier, Mauricio Delgado

P3.186 Retrospective Analysis of

Healthcare Resource Utilization (HRU) in Patients with Spinal Muscular Atrophy (SMA) in MarketScan® —Megan Teynor, Jia Zhou, Qiang Hou, Wendy Wells, Eric Hall, Francisco Javier Avendano

P3.187 Conventional imaging can still predict neurodevelopmental outcome in asphyxiated newborns treated with hypothermia —Fatema Al Amrani, Jaclyn Marcovitz, Christine Saint-Martin, Michael Shevell, Pia Wintermark

P3.188 Long-term Follow-up of

Children Treated with the Modified Atkins Diet —Wendy Chen

P3.189 Risks of psychiatric disorders

Darine Kassar, Mohtashim A Qureshi, Paisith Piriyawat, Alberto Maud, Gustavo Rodriguez, Salvador Cruz-Flores

P3.190 Molecular Mechanisms

after craniotomy: A meta-narrative review —Jonathan Rasouli, Molly Ratner, Alexander Chartrain, Stephan Mayer, Errol Gordon, Neha Dangayach

102 2017 AAN Annual Meeting Scientific Program

P3.192 Effect of Lamotrigine Therapy

Ramineni, Neha Dangayach, Stephen Griffiths, Maggie Keogh, Danielle Wheelwright, Vansh Sharma, Umesh Gidwani, Javaad Ahmad, Joshua Bederson, Jay Mocco, Stephan Mayer

Implications for the Neuro-ICU —Anil

P3.178 Black tar heroin skin popping

P3.179 Post-operative pain control

Marcin Bonikowski, Mark Gormley, AnneSophie Grandoulier, Philippe Picaut, Mauricio Delgado

on Consequences of Acute Hypoxia in the Developing Brain —Elie Abdelnour,

in children and young adults with demyelinating diseases of the central nervous system: a national recordlinkage study —Julia Pakpoor, Raph

as a cause of botulism —Ihtesham Qureshi,

deformity previously treated with botulinum toxins —Edward Dabrowski,

P3.181 “I believe in miracles”:

Kim, Lauren McClain, Inbar Fried, Donna Slonim, Alan Flake

P3.172 Factors Associated

nervous system posttransplant lymphoproliferative disorder after solid organ transplantation: report of four cases with distinct clinical characteristics —Cristina Valencia Sanchez,

Stephen Griffiths, Charles Francoeur, Errol Gordon, Neha Dangayach, Danielle Wheelwright, Anil Ramineni, Javaad Ahmad, Stephan Mayer

P3.171 Intensive Care Unit Admission

P3.161 A large cervical spinal

P3.162 Primary central

Surface Cooling System For Acute Fever Control In Neurocritical Care Patients —

P3.182 Amniotic fluid

Jose Diaz Perez, Ignacio Fuentes Fernandez, Rocio Hernandez Clares, Ester Carreon Guarnizo, Jose Meca Lallana

Rebecca Gillani, Eric Klawiter, Justin Jordan

P3.180 Performance of the EMCOOLs

Jennifer McKenna, Bethany Young, Kai Holder, John Chandler

Roy Strowd, Bronwyn Slobogean, Shannon Langmead, Yao Lu, Jaishri Blakeley

cord lesion in a patient with neurofibromatosis type 1: Multiple sclerosis plaque or hamartoma. —

Tuesday, April 25  8:30 a.m.—7:00 p.m.

Goldacre, Klaus Schmierer, Gavin Giovannoni, Emmanuelle Waubant, Michael Goldacre

that Contribute to Autism Spectrum Disorder —Gurleen Chadha, Daniel Campbell, Nicole Grepo

P3.191 Efficacy and safety of

abobotulinumtoxinA (Dysport®) in children with dynamic equinus foot

Michele Zeinieh, Rana Kurdi, Jimmy El-Hokayem, Rita Daderian, Eric Arehart, Marwan Sabban, Mohamad Mikati

anatomic distribution in patients with juvenile clinically isolated syndrome predicts rapid conversion to multiple sclerosis —Shay Menascu, Carolina Legrada, Shmuel Miron, Anat Achiron

P3.194 Altered amygdala functional connectivity subserves maladaptive social behavior in prematurely born young adults —Christina Johns, Dustin

Scheinost, Cheryl Lacadie, Betty Vohr, Laura Ment

P3.195 Oral deoxynucleoside for

the treatment of thymidine kinase 2 deficiency —Carlos Lopez Gomez, Rebecca

Levy, Maria J Sanchez-Quintero, Marti Juanola-Falgarona, Emanuele Barca, Beatriz Garcia-Diaz, Saba Tadesse, Caterina Garone, Michio Hirano

P3.196 Dual diagnosis can explain the phenotype in clinically heterogeneous neurological disorders —Davut Pehlivan,

Ender Karaca, Tamar Harel, Zeynep Coban Akdemir, Shalini Jhangiani, Yavuz Bayram, Donna Muzny, Eric Boerwinkle, Richard Gibbs, James Lupski

P3.197 Risk of long-term

neuropsychiatric impairment in pediatric anti-NMDA receptor encephalitis —Chloe Nunneley, Timothy Lotze, Eyal Muscal

P3.198 Characteristics of Status

Epilepticus in Alternating Hemiplegia of Childhood —Julie Uchitel, Lyndsey Prange,

Melissa McLean, Jeffrey Wuchich, Mohamad Mikati

P3.199 Estimates of Spinal Muscular Atrophy (SMA): Results from the TREAT NMD Research Program —Hanns Lochmuller, Agata Robertson, Ingrid E.C. Verhaart, Cynthia C. Jones, Suzanne F. Cook

P3.200 Structural Connectivity

Abnormalities Underlying Cognitive Impairment in Pediatric Multiple Sclerosis —Ermelinda De Meo, Elisabetta

Pagani, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Maria Amato, Laura Vacchi, Agnese Fiorino, Lorena Pippolo, Maria Carmela Pera, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

P3.201 The role of genetics in

ethanol-induced cell death in the forebrain and brainstem —Aria Shokoohi, Emilie Theberge, Kainuo Wu, Kristina Balce, Kristen Hamre, Daniel Goldowitz

P3.202 The Utility of Whole Exome

Sequencing in Pediatric Neuromuscular Disease at Texas Children’s Hospital — Michael Lopez, Danah Marafie, Isabella Herman, Farida Abid, Timothy Lotze

P3.203 A sensitive period for the

development of motor function in rats: a microgravity study —Neeraj Singh


P3.204 Syncope in Children: Etiology, Positive and Negative Predictors, and Utilization and Utility of Diagnostic Testing —Mary Elizabeth Reed Shenk, Arayamparambil Anilkumar

P3.205 Language competence and

brain structural integrity in children with perinatal stroke —Doris Trauner, Long Vu, Timothy Brown

P3.206 Examining Hospital

Utilization and Costs Following Rufinamide Treatment in Children with Intractable Seizures and Developmental Disorders —Xuan Li, Omar Olhaye, Russell Knoth

P3.207 Dysport®

(abobotulinumtoxinA) injection in muscles in pediatric patients with lower limb spasticity —Mauricio Delgado, Ann Tilton, Mark Gormley, Philippe Picaut, Daniel Snyder

P3.208 An infant born to a mother

Takahashi, Nkolika Odenigbo, Devorah Segal, Xue Ming

Fulton Velez, Kathryn Anastassopoulos, T. Christopher Bond, Xuezhe Wang, Hailong Cheng, David Blum, Joyce Cramer

P3.216 Identifying Anxiety and

P3.230 Trends in Hospital Inpatient

perampanel oral suspension and tablet formulations in healthy subjects: a Phase I, open-label, crossover study —Antonio

Sandipan Pati

P3.241 Categorical Analysis of

Depression in Youth with Epilepsy — Michelle Lally, Mary Kral, Andrea Boan

P3.217 Adverse early life events are not associated with pediatric multiple sclerosis (MS) —Cassandra Freitas, Julia

O’Mahony, Laura Zahavich, Colleen Guimond, E. Ann Yeh, Douglas Arnold, Amit Bar-Or, Dessa Sadovnick, Ruth-Ann Marrie, Brenda Banwell

P3.218 Quantifying Motor Deficits

in 15q11.2-q13.1 Duplications (Dup15q syndrome) —Rujuta Bhatt, Scott Huberty, Shafali Jeste

P3.219 Medical Resource Utilization

in Patients with Infantile Spasms After Receipt of Repository Corticotropin Injection (H.P. Acthar Gel): Results of a Physician Survey —Tara Nazareth, Michael

with anti-N-Methyl-D-Aspartate receptor (NMDAR) encephalitis —Nitish

Philbin, Jack Gallagher, Kylee Heap, Susan Carroll, Elaine Böing

P3.209 Characterizing Sleep Spindles

hemiparesis and a novel ATP1A2 mutation —Coral Stredny, Kellen Winden,

Chourasia, Michael Watkins, Jeremy Lankford, Ankur Kamdar

in Children with Autism Spectum Disorder (ASD), Developmental Delay and Neurotypical Development. —

P3.220 Recurrent transient

Amy Danehy, Richard Robertson, Cameron Trenor, Michael Rivkin, Laura Lehman, Miya Bernson-Leung

Priyanka Chilakamarri, Audrey Thurm, Cristan Farmer PhD, Susan Swedo, Scott A. Burroughs, Gregory Holmes, Ashura W. Buckley MD

P3.221 NA P3.222 NA

P3.210 MoveDMD Results: Effects

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: OUTCOMES AND PSYCHOSOCIAL

of Edasalonexent, an NF-kB Inhibitor, in 4 to 7 Year Old Patients with Duchenne Muscular Dystrophy —Joanne Donovan,

P3.223 Epilepsy Sub-types Related

Krista H. Elvire Vandenborne, L. Sweeney, Gihan Tennekoon, Erika Finanger, Sabrina Yum, Perry Shieh, Maria Mancini, Pradeep Bista, Andrew Nichols, Richard Finkel

Hospital Readmissions: Nationwide Analysis of Causes and Related Costs —

P3.211 Molecular diagnosis for

of stay, and mortality associated with super-refractory status epilepticus in Germany —Vijayveer Bonthapally, Sonja

neurodevelopmental disorders-an overview of multi-gene panels and whole exome sequencing —Jing Wang,

P3.212 Added value of interleukin-1

blockade to hypothermia in neonatal encephalopathy due to inflammatorysensitized hypoxia-ischemia: a preclinical study. —Mathilde Chevin, Clemence Guiraut, Guillaume Sebire

P3.213 Disorganized sulcal pattern in fetal brains with agenesis of corpus callosum —Tomo Tarui, Neel Madan,

Nabgha Farhat, Rie Kitano, Asye Tanritanir, George Graham, Borjan Gagoski, Alexa Craig, Caitlin Rollins, Cynthia Ortinau, Vidya Iyer, Ellen Grant

P3.214 Language patterns in

specific language impairment and high functioning autism —Megan Craig, Doris Trauner

P3.215 Use of CT Head in the

Pediatric Emergency Room in the Evaluation of Children with First Afebrile

Tapan Mehta, Smit Patel, Erica Schuyler

P3.224 Evaluation of the costs, length

Ansorge, Jana Hapfelmeier, M. Haim Erder, Felix Rosenow, Adam Strzelczyk

P3.225 How many are we missing?

Identification of potential surgical candidates in a non-specialist center —

Patrick Moloney, Eimer Maloney, Nora Ellard, Ian Callanan, Ronan Kilbride, Christopher McGuigan

P3.226 The Impact of Disparities

in Epilepsy Knowledge on Treatment Compliance and Seizure Control —

Shawna Benard, Carlos Millan, Andres Kanner

P3.227 Epilepsy-associated levels of perceived stigma: A study in Ecuador — Marcelo Cruz, Jaime Luna, Mandy Nizard, Alejandro Cruz, Antonio Cruz, Pierre-Marie Preux

P3.228 Antiepileptic drug class-

related healthcare costs among pediatric patients initiating monotherapy treatment for partial-onset seizures — Xiaoyun Pan, Fulton Velez, Chris Kozma, Joyce Cramer

P3.229 Relationship between Seizure

Frequency Reduction and Health-Related Quality of Life in Conversion-toMonotherapy and Adjunctive Therapy Trials of Eslicarbazepine Acetate —

Costs of Psychogenic Nonepileptic Seizures —Harshad Ladha, Sahil Gupta,

P3.231 Effectiveness of short-term

Video-Electroencephalography (STVEEG) in diagnosing Psychogenic Non Epileptic Seizures (PNES), their clinical profile and outcome in Western Indian population —

Paresh Zanzmera, Arvind Sharma, Mehul Luhar

P3.232 Diagnostic yield and

implications of concurrent EEG monitoring during neuropsychological evaluation of patients with epilepsy —

Ioannis Karakis, Casey Lynam, Olha Taraschenko, Ekaterina Staikova, David Loring, Daniel Drane

P3.233 Epilepsy: social media

and the Internet. To search or not to search? —Alejandro Thomson, Jose Molina

Melendres, Blas Couto, Guido Vazquez, Diego Nadile, Agustina Tamargo, Francisco Muñoz Giacomelli, Maria Elena Fontela, Alfredo Thomson

P3.234 Physician Expert Opinion

about Health Disparities and Access to Epilepsy Surgery —Cody Nathan, Petra Brayo, Sarah Zubkov, Mercedes Jacobson, Camilo Gutierrez

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: THERAPEUTICS I

P3.235 Simulation of changes in

steady-state plasma concentrations of perampanel following discontinuation of the enzyme-inducing antiepileptic drug (EIAED) carbamazepine —Edgar Schuck, Jim Ferry, Bhaskar Rege, Barry Gidal, Ziad Hussein

P3.236 Effect of adjunctive

perampanel on myoclonic and absence seizures: post-hoc analysis of data from the Extension Phase of a Phase III study in patients with idiopathic generalized epilepsy (IGE) —Christian Brandt, Robert

Wechsler, Terence O’Brien, Antonio Laurenza, Anna Patten, Francesco Bibbiani, Betsy Williams

P3.237 Predictions of the

pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling —Edgar Schuck, Bhaskar Rege,

Antonio Laurenza, Betsy Williams, Jim Ferry, Ziad Hussein

P3.238 Assessment of the long-

term efficacy and safety of adjunctive perampanel: pooled analyses of four open-label extension studies —Ivan

Rektor, Gregory Krauss, Yushi Inoue, Takahisa Hanada, Betsy Williams, Anna Patten, Francesco Bibbiani, Antonio Laurenza, Robert Wechsler

P3.239 Perampanel monotherapy in epilepsy: prospective open-label extension (OLE) and retrospective uncontrolled studies —Patrick Kwan,

Antonio Gil-Nagel, Antonio Laurenza, Anna Patten, Karen Cartwright

Laurenza, Nancy Hall, Oneeb Majid, Bhaskar Rege

Change in Seizure Frequency Following Conversion to Eslicarbazepine Acetate Monotherapy —Mohamad Koubeissi, David Vossler, Hailong Cheng, Todd Grinnell, David Blum

P3.242 Long-Term Safety

and Efficacy Outcomes following Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy in Patients with Partial-Onset Seizures (POS): A PostHoc Subgroup Analysis of Patients Who Continued to Receive ESL as Monotherapy for up to 12 Months — Steve Chung, Saurabh Sinha, Aashit Shah, John Stern, Hailong Cheng, Todd Grinnell, David Blum

P3.243 Relationship between

Adjunctive Eslicarbazepine Acetate (ESL) Use and Incidence of Psychiatric Adverse Events in Patients Taking Psychotropic Drugs in Three Phase III ESL Trials — Cynthia Harden, Mar Carreno, Helena Gama, Patricio Soares-da-Silva, JungAh Jung, Todd Grinnell, David Blum

P3.244 Physiologically-Based

and Population Pharmacokinetic Modeling and Simulation to Support Dose Selection and Study Design for Eslicarbazepine Acetate (ESL) Adjunctive Therapy in Infants with Partial Onset Seizures (POS) —Soujanya Sunkaraneni, Elizabeth Ludwig, Sebastien Bihorel, Denise Morris, Seth Hopkins, Gerald Galluppi, Jill Fiedler-Kelly, David Blum

P3.245 Analysis of Indices of Thyroid

Function with Short- and Long-term Use of Eslicarbazepine Acetate as Adjunctive and Monotherapy —Andreas Alexopoulos, Barry Gidal, Elinor Ben-Menachem, Arnaud Biraben, Helena Gama, Joana Moreira, Francisco Rocha, Hailong Cheng, Todd Grinnell, David Blum

P3.246 Modeling and Simulation

Strategy to Support Eslicarbazepine Acetate (ESL) Pediatric Dose Selection in the Treatment of Partial Onset Seizures Based on Matching Adult Exposures — Soujanya Sunkaraneni, Sebastien Bihorel, Seth Hopkins, Jill Fiedler-Kelly, Elizabeth Ludwig, Gerald Galluppi, David Blum

P3.247 Changes in Body Weight

During Eslicarbazepine Acetate Phase III Clinical Trials —Amit Verma, David Anschel, Cormac O’Donovan, Philippe Ryvlin, Joana GraÁa, Joana Moreira, Francisco Rocha, Todd Grinnell, David Blum, Hailong Cheng

P3.248 Efficacy and Safety of

USL255, Qudexy® XR (Topiramate) Extended-Release Capsules, and Second-Generation AEDs —Steve Chung, Robert Hogan, Ilan Blatt, Balduin Lawson, Mark Halvorsen

P3.249 Licarbazepine (LCBZ)

Pharmacokinetics with Once-Daily Oxtellar XR® (Extended-release Oxcarbazepine) —Shannon Mendes,

Elizabeth Hur, Welton O’Neal, Raman Sankar

Fast and easy registration · AAN.com/view/AM17 103

TUESDAY

Zoe Powis, Amal Yussuf, Jade Tinker, Heather Newman, Tiffiney Carter, Erica Smith, Rhonda Lassiter, Shoji Ichikawa, Negar Ghahramani, Sherry Dadgar, Brigette Tippin Davis, Amanda Bergner

P3.240 Bioequivalence evaluation of

Seizure —Aravindhan Veerapandiyan, James

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session III



Tuesday, April 25  8:30 a.m.—7:00 p.m.

P3.250 Pharmacokinetics of

P3.264 Characteristics of In-Flight

P3.279 Acute Ischemic Stroke

P3.295 Intrapartum thrombolysis

Tolbert, William Ravis, Aziz Karim

Yoon, Eung-Seok Lee, Dan A Oh, Hae In Park, Sang Won Lee, Joung-Ho Rha

Ramamoorthy, Jitesh Kar

Shashank Shekhar, Varun Sreenivasan, Rebecca Sugg

P3.280 Cerebral Vasculitis in

P3.296 An Unusual Complication of

Vaddiparti, Yan Zhang

Cole, Carolyn Cronin, Jay Shah, Steven Kittner, Dheeraj Gandhi

P3.281 Recurrent Cerebral Venous

P3.297 Persistence of Transverse

Solubilizing Agent Captisol® in Patients Receiving IV Carbamazepine —Dwain CEREBROVASCULAR DISEASE EPIDEMIOLOGY

P3.251 Stroke in women: Results

from the Mashhad Stroke Incidence Study (MSIS), a population based study in the Middle-East —Amin Amiri, Mahmoud Reza Azarpazhooh, Hamidreza Saber, Ashkan Shoamanesh, Reza Behrouz

P3.252 Circadian variation in patients with cryptogenic stroke and patent foramen ovale —Ali Daneshmand, David Thaler

P3.253 The frequency of Headache in Patients with First-ever Ischemic Stroke —Drini Dobi, Entela Basha, Eris RANXHA, Olsi TAKA, Ermir ROCI, Mira Rakacolli, Kapisyzi

P3.254 Elevated Serum Creatinine Predicts Higher Mortality in Stroke Patients —Bashair Ibrahim, Lama Rayyis, Mohammed Almekhlafi

P3.255 Outcome and Prognosis

Stroke in Korea —Hee-Kwon Park, Cindy

P3.265 Characteristics of Code

Stroke Cases in a Level 1 Trauma U.S. Military Treatment Facility: Comparison with a Civilian Stroke Center —Tyler Koehn, Jon Williams, Wendy Chao, Anthony Frattalone

P3.266 Clinical and Radiological

Features of Antiphospholipid Antibody Syndrome Associated with Stroke —Alaa Khayat, Hussien Alkully, Haneen Milyani, Mohammed Almekhlafi, Mahmoud Alshanqiti

CEREBROVASCULAR DISEASE CASE REPORTS II

P3.267 Sturge Weber syndrome’s

angioma electively occuring during pregnancy : case report and —Fatai Radji, Jean Sebastien LIEGEY, Elena Leca Radu

P3.268 Acute paraparesis and

sensory loss following intravenous corticosteroid administration in a case of spinal dural arteriovenous fistula —

Michael DiSano, Russell Cerejo, Mary Mays

of Middle Cerebral Artery Occlusive Disease in a Sample of Egyptian Patients. —Nada Elsaid, Ashraf El-Mitwalli,

P3.269 Limb-Shaking TIA as

P3.256 Prevalence of Ischemic Stroke

P3.270 Myocardial Wall Rupture

Mohammad Farrag, Osama Abdel Salam

the Presenting Symptom of ICA Dissection —Shannon LaBoy, Robert Mannel, Scott Silliman

as a Presenting Feature of Multiple Myeloma —Sebastian Chung, Rohini

a patient with Crohn’s disease on Adalimumab —Subhendu Rath, Aparna

Thrombosis in the Setting of Ulcerative Colitis —Pascal Atanga, Cynthia Hingtgen, Timothy Thoits, John Visser

P3.282 A case of Drug-induced

metabolic encephalopathy presenting to the stroke unit —Chinedy Maduakor, Saipriya Vasan, Usman Khan

P3.283 Pituitary apoplexy causing

in acute stroke patient —Disha Kohli,

Pipeline Stenting —Christopher Stack, John

Sinus Stenosis After Lumbar Puncture in Idiopathic Intracranial Hypertension (IIH) —Kannan Narayana, Amit Saindane,

Beau Bruce, Nancy Newman, Valerie Biousse

P3.298 Postpartum Cardiomyopathy with Cardioembolic Stroke —Pradeep

Kumbham, Bhavana Sharma, Achint Patel, Neil Masangkay

bilateral anterior cerebral infarction —

P3.299 Endovascular management of

P3.284 Isolated pseudoabducens

Eugene Scharf, Tia Chakraborty, Alejandro Rabinstein, Amrendra Miranpuri

Alejandro Vargas, Fernando Testai

palsy in acute thalamic stroke —Mehdi Ghasemi, Nazish Riaz, Anna Bjornsdottir, David Paydarfar

P3.285 Contrast induced

encephalopathy mimicking reperfusion injury —Ekaterina Bakradze, David Pasquale, Kathryn Kirchoff

P3.286 Spinal Cord Infarct Presenting as Brown-Sequard Syndrome —Kaitlyn Lillemoe, Michael Fara, Danielle Stember, Sara Rostanski

cerebral septic embolism: Three recent cases and review of the literature. —

P3.300 Endovascular Therapy for

Acute Ischemic Stroke with Distal Middle Cerebral Artery Occlusion; A Case Series —Sajid Suriya, Syed Quadri, Muhammad Taqi

ZIKA, CHIKUNGUNYA, WEST NILE VIRUS, AND OTHER VIRAL INFECTIONS II

P3.301 Next Generation Sequencing

After Protamine Reversal Of Heparin —

to Diagnose West Nile Encephalitis in an Immunocompromised Patient —Viren

Mansour Almarhoon, Omar Danoun, Kumar Rajamani

Patel, Amanda Piquet, Robert Schlaberg, John Greenlee, Safdar Ansari, Stacey Clardy

P3.288 Isolated Pontine Posterior

P3.302 Herpes Simplex positive

P3.258 Evaluation Of Cocaine As

young female: a novel presentation of anti-GAD autoimmunity —Xiumin Shermyn

Krishna Pokala, Mariam Mouti, Kent Ellington, Steven Warach

Miguel, Mauricio Farez, Alejandro Kohler, Eugenia Arias, Andrea Claudia Mora, Angel Cammarota, Marcelo Del Castillo

Jinjun Lou

P3.273 Moyamoya Vasculopathy in a

Sturge-Weber Syndrome. —Angelica Lee,

Ahmad, Rizwan Tahir, Panayiotis Mitsias

P3.290 Brain Embolism in the

in Cohort of Ulcerative Colitis Patients — Erika Horta, Hussain Tore, Kendall Nichols, Mustapha Ezzeddine, Christopher Streib, Rwoof Reshi

P3.257 To describe symptomatology and etiological factors of posterior fossa strokes involving only the basilar artery. —Leila Parand, Dinesh Jillella, Atif Zafar

A Risk Factor For Cerebrovascular Diseases —Xiaohong Si, Lianbin Xiang,

P3.259 Understanding race-ethnic

TUESDAY

disparities in hospital arrival after stroke symptom onset —Mellanie Springer

P3.260 Clinical features of acute

stroke in young adults—a qualitative study of patient experiences —Dylan

Jones, Haley Huggins, David Thaler, Paul Han, Lester Leung

P3.261 Age, Gender and Racial

Disparities in Acute Stroke Therapy in a Large Non-Academic Health System —

Reid Taylor, Robin Jones, Jackie Gosnell, Sean Snyder, Alexander Schneider

P3.262 Findings from the University of Minnesota Posterior Circulation Stroke Database —Caitlin Bell, David

Anderson, Kamakshi Lakshminarayan, Bharathi Jagadeesan, Rwoof Reshi, Benjamin Miller, Mustapha Ezzeddine, Christopher Streib

P3.263 Hypertension is the most

Risk Factor Stroke in Indonesia Stroke Registry —Fenny Yudiarto, Mochammad Machfoed, Darwin Amir, Anam Ong, Muhammad Kurniawan, Siswanto, Muhammad Karyana

Following tPA Administration: A Case Report and Review of the Literature —

Matthew Neu, Karen Albright, Michael Lyerly

P3.271 Hemorrhagic stroke following consumption of energy drink —Anand

Venkatraman, Ayaz Khawaja, Angela Hays Shapshak

P3.287 Successful Thrombolysis

P3.272 Acute ischemic stroke in a

Reversible Encephalopathy Syndrome (PRES) Presenting with Transient Right Hemiparesis —Myriam Abdennadher,

Neo, Kim En Lee, Rebekah Lee

P3.289 Atypical presentation of

Patient with Scleroderma: A Case Report and Review of the Literature —Ayesha

Mohammad El-Ghanem, Sarita Said Said, Ning Wu, Ibrahimi Muhammad

P3.274 A Case of Sudden Onset

Moyamoya Syndrome —Julie Grimes,

Beltagy, Khalid Stanazai, Muhammad Alvi

P3.291 Successful Treatment with

Anterograde Amnesia from Bilateral Hippocampal Strokes. —Abdelrahman

P3.275 Chronic Blood-Brain Barrier

Disruption: a case report —Syeda Imama Naqvi, Emi Hitomi, Richard Leigh

P3.276 Postpartum Thrombosis

of Developmental Venous Anomaly Complicated by Venous Infarct and Subarachnoid Hemorrhage —Maushmi

Savjani, Simona Treidler, Susan Law, Adrian Marchidann

P3.277 Aphemia: A rare presentation of an acute infarct —Jessica Stachyra, Alfredo Davalos-Balderas, Jennifer Lee, Joseph Kass

P3.278 Vertebrobasilar compression syndromes caused by aberrant intracranial vasculature—a report of two cases —Ayaz Khawaja, Anand Venkatraman, Maira Mirza

104 2017 AAN Annual Meeting Scientific Program

Samuel Snider, Henrikas Vaitkevicius, Viken Babikian, Nirav Patel

t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab —Tiffany Cossey, Sujan Teegala Reddy, Sean Savitz, James Grotta

P3.292 The Vertebral Body Infarct

Sign: A Case of Thoracic Spinal Cord Ischemic Stroke —Diane Chan, Amy Chan, Pue Farooque, Richard Nowak

P3.293 Tacrolimus-Associated

Posterior Reversible Encephalopathy Syndrome —Kavit Shah, Kayla Martin, Asad Yousuf, Arun Chandok

P3.294 Cor Triatriatum and Stroke: A

Case Report and Review of Literature — Jose Danilo Diestro, Adrian Espiritu, Maria Kristina Dorotan, Justin Regalado, Jose Leonard Pascual

PCR in Cerebrospinal Fluid: physiopathological role in adult patients —Lucas Alessandro, Wilken

P3.303 Chronic Progressive

Meningoencephalitis after West Nile Infection: Diagnostic Challenges in Prolonged Immunosuppression from Rituximab —Doungporn Ruthirago, Parunyou Julayanont, Yazan Alderazi

P3.304 A Fatal Case of West Nile

Virus Encephalitis Passively Transplanted to a post bone marrow transplant Pediatric Patient with AML —Day Breen, Sarah Risen, Jennifer Lee

P3.305 Encephalomyelitis by

hepatitis A virus infection —Sungyang Jo, Joon Hyun Baek, Ji-ye Jeon, Sang-Ahm Lee

P3.306 A Hiker’s Tale:

Cytomegalovirus associated extensive transverse myelitis —Luke O’Donnell, Parameswaran Iyer, Zara Togher, Dina Nduwke, Niall Tubridy, Eoin Feeney, Aoife Cotter, Anna O’Rourke, Justin Kinsella

P3.307 West Nile Virus Acute Flaccid Paralyis in Patient with Prior PML — Alexander Dietz, Asher Albertson, John Younce, Arun Varadhachary

P3.308 Acute Peripheral Neuropathy and Chikungunya Infection —Luiz Felipe

Dantas Pagliarini, Pamela Passos Dos Santos,


Arielle Kirmse, Ana Carolina Ferreira, Karina Pires, Caroline Amaral, Camila Pupe, Eduardo Davidovich, Osvaldo Nascimento

GLOBAL HEALTH

P3.322 Post-Stroke Disability at a

National Referral Hospital in Tanzania — FUNGAL AND PARASITIC DISEASE OF THE NERVOUS SYSTEM

Leah Wibecan, Theoflo Mmbando, Sara Grundy, Joshua Klein, Farrah Mateen, Kigocha Okengo

P3.309 Atypical Manifestations

P3.323 Neurologic Medical

of Central Nervous System Coccidioidomycosis —Chia-Chun Chiang, Erin Okazaki, Kara Asbury, Janis Blair, Holenarasipur Vikram, Marie Grill

P3.310 Presentation, diagnostic

hurdles, and therapeutic measures in a case of isolated coccodioidomycosis meningitis in an immunocompetent individual —Rohini Samudralwar, Joseph Kass, Steven Bellows, Corey Goldsmith

P3.311 Rapidly Progressive Dementia due to a Single Intraventricular Neurocysticercosis Cyst —Veeresh Kumar Nanjangud Shivamurthy, Abdul Rahman Alchaki, Nidhiben Anadani, Machteld Hillen

P3.312 A case of Creutzfeld-

Jakob Disease mimicking Progressive Encephalomyelitis with Rigidity and Myoclonus —Aidan Daly, Conor Fearon,

Campaigns in Peru: A Successful, Low-Cost Program for Huntington’s Disease and other Chronic Neurologic Diseases —Mario Cornejo Olivas, Anastasia

Vishnevetsky, Maryenela IIlanes-Manrique, Victoria Marca, Miguel Inca-Martinez, Karina Milla-Neyra, Olimpio Ortega-Davila, Elison Sarapura Castro, Erick Figueroa-Ildefonso, Ana Mascaro, Carmen Vicente, Pilar Mazzetti Soler

P3.324 Shortage of Neurological

Therapeutics: an Escalating Threat to Patient Care —Jacklyn Omorodion, Rami

Algahtani, Mark Zocchi, Jesse Pines, Henry Kaminski

P3.325 Going Global in Neurology:

An Innovative Neurology Curriculum for Trainees in Resource-limited Settings —

Orna O’Toole, Brian McNamara, Michael Farrell, Laura Williams, Noel Fanning

Eun Kyung Kim, Navid Valizadeh, Yunis Mayasi, Evdokia Eleftheriou, Firas Kaddouh, Anas Hannoun, Jatinder Patti, Muhammad Azeem, Tafline Kao, Anna Hohler, Melissa Fischer, Soaham Desai, Anindita Deb

P3.313 2 Cases of Creutzfeldt-

P3.326 Global Neurology Initiative:

Jakob disease presenting as focal hand dystonia —Diana Apetauerova, Pavel Houska

P3.314 A Rare Case of Chagas

Meningoencephalitis —Shailee Shah, David Harris, Stephen Silberstein

P3.315 Human Monocytic Ehrlichiosis presenting as Guillain-Barre syndrome — He Zhu MD, Venkat Arukala MD, Sadaf Sheikh MD, Ajay Uprety MD, David McCrary, Todd Silverman, Hope Cranston MD

Piloting an Innovative Global Health Curriculum for Neurology Residents at the University of Massachusetts in collaboration with Charutar Arogya Mandal in Gujarat, India —Ellen Kim, Navid Valizadeh, Yunis Mayasi, Malveeka Sharma, Anna Hohler, Melissa Fischer, Soaham Desai, Anindita Deb

P3.327 NA P3.328 NA

P3.316 Toxoplasma gondii infection

as a cause of demyelination and refractory status epilepticus in an immunocompetent host —Ewa Way, Syndi

QUALITY OF LIFE, SYMPTOMS AND SYMPTOMATIC THERAPY, COMORBIDITY, AND PATIENT REPORTED OUTCOMES IN MULTIPLE SCLEROSIS

P3.317 Disseminated Cerebral

P3.329 Comparing Quality of Life

Seinfeld

P3.318 Neurotoxocariasis, a treatable infectious etiology of Stroke —Juan

Garcia Monco, Itxaso Azkune Calle, Aintzine Ruisanchez Nieva, David Anguizola Tamayo, Lara Pardina Vilella, Jone Bocos Portillo, Marian Gomez-Beldarrain

P3.319 National utilization of IVIG,

Plasmapharesis or the combination in patients with Guillian-Barre Syndrome — Darine Kassar, Mohammad-Rauf Afzal, Mohtashim Qureshi, Gustavo Rodriguez, Salvador Cruz-Flores

P3.320 Benedikt Syndrome due to

Isolated Midbrain Neurocysticercosis — Zehra Husain, Jonathan Cheponis

P3.321 The difficulties in associating

neurophysiological and histopathological findings in leprosy neuropaythy —Izabela Pitta, Raquel Silveira, Ligia Andrade, Louise Giesel, Robson Vital, Sergio Antunes, Euzenir Sarno, Marcia Jardim

Stuchiner, Lindsay Lucas, Elizabeth Baraban, Chiayi Chen, Alden Smith, Lobat Hashemi, Stanley Cohan

P3.330 Quality of Life in Multiple

Sclerosis Patients in Saudi Arabia and some Arab Countries —Ahmad Abulaban,

Abdulrahman Altowairqi, Haitham Altowairqi, Abdulmajeed Almutairi, Saif Altalhi, Fahad Alotaibi, Inad Alabbadi, Suleiman Kojan, Mohammed Al-Jumah

P3.331 Chronic comorbidity in

multiple sclerosis is associated with dissolved intimate relationships —Anja

Thormann, Per Solberg Sorensen, Nils KochHenriksen, Lau Thygesen, Bjarne Laursen, Melinda Magyari

P3.332 Stigma in multiple sclerosis: association with work productivity loss, health-related quality of life and caregivers’ burden —Celestin Hategeka,

Anthony Traboulsee, Katrina McMullen, Larry D. Lynd

experiences with access to diseasemodifying therapies: A qualitative analysis on the patient impact of medication access barriers —Kristina Simacek, John Ko, Stefan Varga, Nicole Buechler, Debbie Moreton, Bozena Katic

P3.334 Impact of Multiple Sclerosis

on Patients’ Daily Activities, Emotional Well-Being and Relationships: Results of the Global vsMS™ Survey —Ann Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Maurer, Matthew Mandel, Kersten Sharrock, Barry Singer

P3.335 Comparison of Baseline

Characteristics of Natalizumab versus Healthy Controls in Multiple Sclerosis Patients on Brain Volume, Cognition and Neuro-QOL outcomes: Preliminary Analysis of a Longitudinal Observational Study —Enrique Alvarez, Kavita Nair, Brian

Hoyt, Stefan Sillau, Brittany Wedeman, Eric Engebretson, Augusto Miravalle, John Corboy, Timothy Vollmer, Justin Honce

P3.336 Association Between Sleep

Quality, Fatigue Severity and Salivatory Cortisol Levels in Multiple Sclerosis — Sibel Kabay, Mustafa Cetiner, Beyza Alkış

P3.337 Does Patients’ Experience

of Care Differ by Level of Adherence in Multiple Sclerosis? —Jennifer Smrtka,

Lori Mayer, Shaloo Gupta, John Chandy, Amy Phillips

P3.338 The impact of the Syrian war on Multiple Sclerosis (MS) patients — Eyad Almallouhi, Molham Almallouhi

P3.339 Understanding MS Fatigue:

Initial Subtype Discovery from the MS Mosaic Project —Katherine Heller, Fletcher Hartsell

P3.340 Comparing Neuro-QOL

Outcomes in a 2 year longitudinal assessment of new users of natalizumab and fingolimod with MS —Kavita Nair,

P3.345 Development of a Brief

Clinician-Reported Outcome Measure of Multiple Sclerosis Symptoms —Glenn Phillips, Louis Matza, Katie Stewart, Philip Delio, Robert Naismith

P3.346 Chronic comorbidity in

multiple sclerosis is associated with lower incomes —Anja Thormann, Per

Solberg Sorensen, Nils Koch-Henriksen, Lau Thygesen, Bjarne Laursen, Melinda Magyari

P3.347 Fatigue and depression

predict quality of life in patients with early multiple sclerosis: a longitudinal study —Bardia Nourbakhsh, Laura Julian, Emmanuelle Waubant

P3.348 Patient-Reported Outcomes

With Teriflunomide in Patients With No Prior Disease-Modifying Therapy Use Within 2 Years: Results From the Phase 4 Teri-PRO Study —Ralf Gold, Bhupendra

Khatri, Keith Edwards, Steven Cavalier, Pascal Rufi, Sandrine Brette, Prashant Kulkarni, Patricia Coyle

P3.349 Morphometric variation of

brain structures in relation to Fatigue Severity Scale in Multiple Sclerosis —

Kalyan Yarraguntla, Fen Bao, Rishi Sood, Wafaa Sweidan, Samuel Lichtman-Mikol, Sara Razmjou, Christina Caon, Navid SerajiBozorgzad, Evanthia Bernitsas, Omar Khan

P3.350 Abnormal functional

connectivity of thalamic sub-regions contributes to fatigue in MS —Milagros

Hidalgo De La Cruz, Maria Rocca, Alessandro D’Ambrosio, Paola Valsasina, Elisabetta Pagani, Bruno Colombo, Mariaemma Rodegher, Andrea Falini, Giancarlo Comi, Massimo Filippi

P3.351 A randomized controlled

trial of two group programs in multiple sclerosis: Long-term (12-month) followup effects on fatigue and self-efficacy —

Cinda Hugos, Zunqiu Chen, Yiyi Chen, Michelle Cameron, Dennis Bourdette

Stefan Sillau, Diane Fairclough, Deborah Miller, John Foley, Valdez Brooke, Lindsay Hosford, Tamara Hoyt, Laura Seawright, John Corboy, Enrique Alvarez, Terrie Livingston

P3.352 Study design for a pragmatic

P3.341 Effects of Methylphenidate

P3.353 Incidence and Prevalence

on Mobility, Cognition and Fatigue in Multiple Sclerosis: A Pilot Randomized Controlled Trial —Michelle Cameron

P3.342 THC:CBD (Nabiximols) has a beneficial effect on Multiple Sclerosis (MS) related spasticity and delays or negates the need for Intrathecal Baclofen pump implantation —Stefania

clinical trial of fatigue medications in multiple sclerosis —Bardia Nourbakhsh, Nisha Revirajan, Emmanuelle Waubant

of Uveitis in a Large Multiple Sclerosis Cohort from Fingolimod Trials —Lyndell

Lim, Helmut Butzkueven, Shannon Ritter, Marlies Van Hoef, Diego Silva, Anthony Hall

P3.354 Effects of a group spasticity

management program versus usual care in people with multiple sclerosis: A randomized controlled pilot trial —Cinda

De Trane, Katrina Buchanan, Liz Keenan, Claire Valentine, Michelle Liddicut, Val Stevenson, Rachel Farrell

Hugos, Michelle Cameron, Yiyi Chen, Zunqiu Chen, Dennis Bourdette

P3.343 Baseline affect predicts

MS and contributions to disability and MRI changes. —Jacob Sloane, Ursela

improved fatigue with telerehabilitation using remotely-supervised transcranial direct current stimulation (RS-tDCS) in adults with multiple sclerosis (MS) — William Chan, Bryan Dobbs, Michael Shaw, Margaret Kasschau, Kathleen Sherman, Lauren Krupp, Leigh Charvet

P3.344 Feasibility Study to Evaluate the Utility and Usage Frequency of a Digital Health Coach for Multiple Sclerosis (MS) Patients —Steven Pugh,

P3.355 Obstructive sleep apnea in Siddiqui

P3.356 Use of Medical Marijuana

for the Relief of Multiple Sclerosis (MS) Symptoms in a Community Cohort: Survey from the Pacific Northwest MS Registry —Tamela Stuchiner, Elizabeth Baraban, Lindsay Lucas, Stanley Cohan

Yashma Patel, Thomas Morrow

Fast and easy registration · AAN.com/view/AM17 105

TUESDAY

Toxoplasmosis in a Patient with Chronic Lymphocytic Leukemia: Case Report and Review of the Literature —Kuruvilla John

Between People Who Use Injectable Disease-Modifying Therapies and Those Who Switch to Oral Therapies: A Study From the Pacific Northwest Multiple Sclerosis (PNWMS) Registry —Tamela

P3.333 Multiple sclerosis patient

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session III



P3.357 The rate of occurrence of

migraine in multiple sclerosis patients — Samar Ahmed, Jasem Al-Hashel, Nasser A Abdelall, Farah Z Al-Kilani, Azza A Rady, Raed Alroughani

P3.358 Headache is a Common and

Disabling Comorbidity in People with Clinically Isolated Syndrome —Wei-Qiao

Liu, Luanne Metz, Dina Lavorato, Jamie Greenfield, Farnaz Amoozegar, Anthony Traboulsee, Pierre Duquette, Michael Yeung, Marcelo Kremenchutzky, Galina Vorobeychik, Virender Bhan, Mark Freedman, Gregg Blevins, James Marriott, Francois Grand-Maison, Liesly Lee, Manon Thibault, Minocycline In CIS Trial Investigators

P3.359 The varieties of psychosis in

Multiple Sclerosis: a systematic review of cases —Carlos Camara-Lemarroy, Beatriz

Ibarra-Yruegas, Rene Rodriguez, Idanis Berrios Morales, Carolina Ionete, Peter Riskind

P3.360 Prevalence of Epilepsy

and the Demographics, Clinical and Paraclinical Features in Patients with Multiple Sclerosis —Moogeh Baharnoori, James Stankiewicz, Tanuja Chitnis

P3.361 Impulsivity Traits in Patients with Multiple Sclerosis in Bogotá, Colombia. —Jaime Toro, Alejandra Duque,

David Cuellar Giraldo, Sa˙l Reyes, Luisa Blanco, Luis Orozco-Cabal

P3.362 Prospective evaluation of

movement disorders in early multiple sclerosis and other CNS demyelinating diseases —Hesham Abboud, Xin Xin Yu, Hubert Fernandez, Jeffrey Cohen

P3.363 Patient-Reported Outcomes

(PROs) in Patients Switching to Teriflunomide From a Prior DiseaseModifying Therapy (DMT): Results From the Phase 4 Teri-PRO Study —Patricia Coyle, Bhupendra Khatri, Keith Edwards, Steven Cavalier, Pascal Rufi, Sandrine Brette, Prashant Kulkarni, Ralf Gold

P3.364 Patient-Reported Outcome

TUESDAY

Measurement in Manual Ability for Multiple Sclerosis: Addressing the Targeting Issues of the ABILHAND —

Sharon Chen, Farrah Pompilus, Sara Strzok, Sophie Cleanthous, Stefan Cano, Patrick Marquis, Stanley Cohan, Myla Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, Michelle Mellion

P3.365 Exploratory Factor Analysis of a Patient-Reported Outcome Measure in a Multiple Sclerosis Population Cohort at a Large Academic Center —Luis Medina, Valdez Brooke, Enrique Alvarez, Kavita Nair

P3.366 Efficacy of Peripheral

Lidocaine Application (Neural Therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients —Yusuf Tamam, Hasan Huseyin Ozdemir, Abdullah Gedik, Cuneyt Tamam, Huseyin Nazlikul

P3.367 Restless Leg Syndrome (RLS)

in Multiple Sclerosis: Occurrence and frequent manifestation with neuropathic pain and phasic spasticity —Walter Poellmann, Wolfgang Walter Feneberg, Jurgen Koehler

P3.368 Assessing Preferences

for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study —Xiaolan Ye, Daniel Kantor, Luigi Barbato, Craig Wakeford, Min Yang, Macaulay Dendy, Thomas Marshall

P3.369 Towards a telemedicine-

derived disability scale in multiple sclerosis —Riley Bove, Priya Garcha, Carolyn Bevan, Elizabeth Crabtree-Hartman, Mitchell Wallin, Ari Green, Jeffrey Gelfand

P3.370 Anti-cholinergic medications

for bladder dysfunction worsen cognition in persons with Multiple Sclerosis — Sarah Morrow, Heather Rosehart, Alp Sener, Blayne Welk

P3.371 Maximizing brain health in

multiple sclerosis: a quality improvement framework —Gisela Kobelt, Jeremy Hobart,

Tuesday, April 25  8:30 a.m.—7:00 p.m. P3.379 HLA genotype as a marker of Multiple Sclerosis prognosis —Andreas

Lysandropoulos, Thibo Billiet, Kaoutar El Hafsi, Anke Maertens, Wim Van Hecke, Annemie Ribbens

P3.380 Incidence of Multiple

Sclerosis in the Republic of Ireland: an observational population-based study — Karen O’Connell, Niall Tubridy, Michael Hutchinson, Christopher McGuigan

P3.381 The influence of

HLA-DRB1*15 on motor cortical neurodegeneration in multiple sclerosis —Richard Yates, Margaret Esiri, Qizhu Li, Piotr Orlowski, Rafael Perera, Gabriele De Luca

P3.382 CpG Island methylation

patterns in Relapsing-Remitting Multiple Sclerosis —Maria Sokratous, Efthimios

Maggie Alexander, Amy Bowen, Helmut Butzkueven, Gavin Giovannoni, Tom Kenny, Tjalf Ziemssen

Dardiotis, Eleni Bellou, Zisis Tsouris, Amalia Michalopoulou, Maria Dardioti, Vasileios Siokas, Dimitrios Rikos, Georgios Tsivgoulis, Dimitrios Bogdanos, Georgios Hadjigeorgiou

P3.372 Effects of systolic blood

P3.383 The differences of microRNA

pressure on brain integrity in MS patients: a cross-sectional study —

Fernando Ventrice, Daiana Dossi, Hernán Chaves, Jorge Correale, Mauricio Farez

P3.373 The impact of the BBC

Panorama television programme on public awareness of autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis —Azza Ismail, Simon Hickman, David Paling, Julie Phelan, Jane Havercroft, Simon Webster, Helena Jidborg Alexander, John Snowden, Basil Sharrack

P3.374 The Evaluation of Small Fibers in Multiple Sclerosis —Javid Jahanroshan, Can Ebru Bekircan-kurt, Asli Tuncer, Sevim Erdem-Ozdamar, Ersin Tan

P3.375 Afferent trigeminal pathway involvement in early multiple sclerosis: clinical, MRI and neurophysiological study —Magdalena Krbot Skoric, Ivan Adamec, Luka Crnosija, Mario Habek

P3.376 Total Hip and Knee

Arthroplasty in Multiple Sclerosis Patients: The NYU Experience —Josef Gutman, Ran Schwarzkopf, Ilya Kister

MULTIPLE SCLEROSIS EPIDEMIOLOGY AND GENETICS

P3.377 Multi-omics profiling in

multiplex Italian families with Multiple Sclerosis: the ITALIANO study —

expressions profiles in peripheral blood cells in familial and sporadic multiple sclerosis patients —Zekiye Altun, Egemen Idiman, Pinar Ozcelik, Derya Kaya, Betul Tercan, Omercan Hasankoyoglu

P3.384 Comparative

Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial —Yang Mao-Draayer, Qi Wu, Qin Wang, Guangmei Mao, Catherine Dowling, Steven Lundy, Katy Demery, David Fox

P3.385 A genetic variant associated

with multiple sclerosis inversely affects the expression of microRNA-548ac and CD58 from a single transcript—an eQTL paradox —Michael Hecker, Nicolle Illner, Brit Fitzner, Dirk Koczan, Ina Schroder, HansJurgen Thiesen, Uwe Zettl

P3.386 Lower Age-At-Onset

(AAO) in Multiple Sclerosis (MS) is Associated with the HLA-DQA1*05/ HLA-DQB1*06:02 Cis- or TransHeterodimer —Paola Bronson, Chao Tian,

K.D. Nguyen, Karol Estrada, Sally John, Aaron Day-Williams

P3.387 Integrated Genomic and

Proteomic Analyses of Multiple Sclerosis —Elif Everest, Ugur Uygunoglu, Melih Tutuncu, Sabahattin Saip, Osman Sezerman, Aksel Siva, Eda Turanli

DIET AND ENVIROMENTAL RISK FACTORS FOR MULTIPLE SCLEROSIS

Elisabetta Mascia, Clara Guaschino, Andrea Zauli, Melissa Sorosina, Federica Esposito, Ana Osiceanu, Silvia Bonfiglio, Dejan Lazarevic, Alessandra Protti, Lucia Moiola, Vittorio Martinelli, Giovanni Meola, Giancarlo Comi, Sandra D’Alfonso, Filippo Martinelli Boneschi

P3.388 The Effect of the orally

P3.378 Multiple Sclerosis Prevalence

Duscha Alexander, Stefanie Joerg, Johannes Berg, Ralf Linker, Ralf Gold, Aiden Haghikia

Guarnizo, Rocio Hernandez Clares, Maria Cerdan Sanchez, Estefania Garcia Molina, Jose Diaz Perez, Jose Javier Martin Fernandez, Jose Meca Lallana

P3.389 Effects of olive oil on

in Southeastern Spain. —Ester Carreon

106 2017 AAN Annual Meeting Scientific Program

applied short chain fatty acid propionate on the immune regulation in MS: results of a human proof-of-concept study —

oxidative stress in an experimental model of multiple sclerosis —Eduardo

Aguera Morales, Cristina Conde-Gavilan, Evelio Luque-Carabot, Manuel LaTorre, Ana Giraldo-Polo, Montserrat Feijoo, Felix Gascon-

Luna, Rafael Lillo, Alberto Galvan-Jurado, Roberto Valverde-Moyano, Begona M. Escribano, Isaac Tunez

P3.390 Effects of intermittent calorie restriction on weight, fat mass, lean mass, visceral adipose tissue: Results from a pilot controlled-feeding study in multiple sclerosis patients —Kathryn

Fitzgerald, Diane Vizthum, Bobbie HenryBarron, Sandra Cassard, Patrick Sullivan, David Baer, Ellen Mowry

P3.391 Salt-sensitive alterations in

gut microbiota impact Th17 cells and neuroinflammation —Ralf Linker, Stefanie

Joerg, Nicola Wilck, Mariana Matus, Sean Kearney, Scott Olesen, Markus Kleinewietfeld, Eric Alm, Dominik Muller

P3.392 Vitamin D increases

glucocorticosteroid efficacy via mTORinhibition in Multiple Sclerosis —Robert

Hoepner, Anke Salmen, Maximilian Pistor, Lisa Schrewe, Louise Laverick, Melissa Gresle, Helmut Butzkueven, Holger Reichardt, Fred Luhder, Ralf Gold, Andrew Chan

P3.393 Serum Vitamin A levels and

Associated Retinoic Acid Markers are NOT associated with EDSS or Lesion Volume in Multiple Sclerosis Patients with Normal or Normalized Serum Vitamin D Levels —Priya Puttagunta, Jason

Lesdesma, Kristen Berube, Shayan Torabi Moghaddam, Jessica Serna, Diamond Garcia, Bijal Mehta

P3.394 Longitudinal and Cross

Sectional Study of Adipocytokine and Vitamin D in Multiple Sclerosis Patients Treated with Dimethyl Fumarate (DMF) —Moogeh Baharnoori, Cindy

T Gonzalez, Shrishti Saxena, Kiandokht Keyhanian, Pia Kivisakk, Brian Healy, Howard Weiner, Tanuja Chitnis

P3.395 Vitamin D-binding protein polymorphisms, 25-hydroxyvitamin D, sun exposure and risk of multiple sclerosis in blacks, Hispanics and whites —Annette Langer-Gould, Robyn

Lucas, Anny Xiang, Lie Chen, Jun Wu, Edlin Gonzales, Samantha Haraszti, Jessica Smith, Hong Quach, Lisa Barcellos

P3.396 Environmental exposures

and the risk of multiple sclerosis (MS) in Saudi Arabia (KSA), Case Control Study —Osama Al Wutayd, Ashry Gad

Mohamed, Jameela Saeedi, Hessa Alotaibi, Mohammed Al Jumah

P3.397 Exposure to Particulate

Matter Air Pollution and Risk of Multiple Sclerosis in Two Large Cohorts of US Nurses —Natalia Palacios, Kathryn Fitzgerald, Kassandra Munger, Jaime Hart, Marc Weisskopf, Tanuja Chitnis, Alberto Ascherio, Francine Laden

P3.398 Alteration of Microbiome in Relapsing Multiple Sclerosis —Simona

Nedelcu, Lauren Hall, Carolyn Griffin, Ana Luisa Maldonado-Contreras, Beth McCormick, Doyle Ward, Raffi Aroian, Carolina Ionete

ECONOMIC IMPLICATIONS OF MULTIPLE SCLEROSIS

P3.399 Do multiple sclerosis

cost-effectiveness studies follow best practice guidelines? A review of 5 case


Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m. studies —Jason Shafrin, Daniel Kantor,

Michelle Brauer, John Ko, Vivian Herrera, Dana Goldman

P3.400 Industry payments to

neurologists who commonly prescribe repository corticotropin gel (H.P. Acthar) —Dennis Bourdette, Shelby Van

Leuvin, Kirbee Johnston, Michelle Lei, Daniel Hartung

P3.401 Real-World Monitoring Costs

Associated with Initiation of DiseaseModifying Therapy Among Patients with Multiple Sclerosis —Maureen Lage, Ying Wu

P3.402 The Economic Burden of

Moderate-to-Severe Multiple Sclerosis Relapse in the United States: Findings from a Systematic Literature Review — Tara Nazareth, Molly Purser, Rikal Bhaila, Michael Philbin, Deirdre Mladsi

P3.403 Does opening access to oral

disease modifying therapy increase rates of initiation and reduce disease-related medical costs in a national population of patients with multiple sclerosis? —John Ko, Daniel Kantor, Richard DeClue, Dana Drzayich Antol, Adrianne Waldman Casebeer, Yong Liu, Stephen Stemkowski, Stefan Varga, Julie Cave, Vivian Herrera

P3.404 Understanding National

Trends of Unplanned Thirty Day Readmission in Multiple Sclerosis — Tapan Mehta, Smit Patel, Ninad Desai, Matthew Tremblay

P3.405 Healthcare Resource

Utilization and Costs of Multiple Sclerosis in Canada by Disability —

Luanne Metz, Jamie Greenfield, Ruth-Ann Marrie, Nathalie Jette, Oksana Suchowersky, Larry Svenson, Katayoun Alikhani, Maheer Khan, Shervin Gholizadeh, Cloris Xue

P3.406 Therapeutic inertia in

Multiple Sclerosis: Applying concepts of behavioral economics to understand how neurologists make decisions —Gustavo Saposnik, Angel Sempere, Daniel Prefasi, Daniel Selchen, Christian Ruff, Jorge Maurino, Philippe Tobler

TUESDAY

P3.407 Economic Burden of

Multiple sclerosis on Kuwait Health care system —Maryam Alowayesh, Raed

Alroughani, Samar Ahmed, Jasem Al-Hashel

P3.408 Employment status

change over 12-years is more strongly associated with early MRI than clinical measures. —Lucie Kadrnozkova, Manuela

Vaneckova, Jan Krasensky, Lukas Sobisek, Barbora Benova, Karolina Kucerova, Jiri Motyl, Michaela Andelova, Klara Novotna, Jana Lizrova Preiningerova, Eva Havrdova, Dana Horakova, Tomas Uher

Fast and easy registration · AAN.com/view/AM17 107


Poster Sessions

Poster Session IV



PARKINSON’S DISEASE: THERAPEUTICS AND TELEHEALTH II

P4.001 Reliability of Continuous

Parkinson’s Assessment Using Wearables —Dustin Heldman, Enrique

Urrea Mendoza, Nicola Mennucci, Carol Zimmerman, Joseph Giuffrida, Zoltan Mari, Michelle Burack, Fredy Revilla

P4.002 Exploring the use of wearable sensors to monitor drug response of patients with Parkinson’s disease in the home setting —Jean-Francois Daneault, Christoph Kanzler, Sunghoon Lee, Fatemeh Golabchi, Gloria Vergara-Diaz, Gabriela Ferreira Carvalho, Eric Fabara, Stefano Sapienza, Lewis Sudarsky, John Growdon, Paolo Bonato

P4.003 Telemedicine vs Office visits

in a Movement Disorder Specialty Clinic: Comparative Satisfaction of physicians and patients. —Ryan Hanson, Christopher Goetz, Marisa Truesdell, Glenn Stebbins, Allison Weathers

P4.004 Telehealth Management of

Parkinson’s Disease Using Wearable Sensors: An Exploratory Study —Dustin

Heldman, Denzil Harris, Timothy Felong, Kelly Andrzejewski, E. Ray Dorsey, Joseph Giuffrida, Barry Goldberg, Michelle Burack

P4.005 Virtual research visits in

individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis —Christopher

Potential Barriers and Prospective Strategies —Pinky Agarwal, Sudeshna Ray, Daniel Burdick, Alida Griffith, Arina Madan

ATYPICAL PARKINSONISM

P4.011 Predictors of survival in

progressive supranuclear palsy and multiple system atrophy—a systematic review and meta-analysis —Stella

dopaminergic dysfunction and clinical features in cerebellar type of multiple system atrophy —Chaewon Lee, Ho-Sung

Ryu, Minyoung Oh, Jungsu S Oh, Hyojeong Moon, Kye Won Park, Sooyeoun You, Mi-Jung Kim, Young Jin Kim, Juyeon Kim, Kiju Kim, Jae Seung Kim, Sun J. Chung

P4.013 Instrumented Gait and

Balance Analyses in Progressive Supranuclear Palsy and Mild Cognitive Impairment compared with Parkinson Disease —Trung Nguyen, L. Steven Brown,

Dewey, Pravin Khemani

P4.016 Whole-brain atrophy rates

Katya Bulatova

P4.017 The identification of

P4.018 Patient Quality of Life and

Mensikova, Radek Vodicka, Radek Vrtel, Kristina Kolarikova, Tereza Bartonikova, Michaela Kaiserova, Martin Prochazka, Petr Kanovsky

WEDNESDAY

Caregiver Burden in a multidisciplinary MSA clinic —Pravin Khemani, Elizabeth Kent, PARKINSON’S DISEASE: FUNCTIONAL AND STRUCTURAL IMAGING

P4.009 Human factors testing of

P4.019 Subcortical Volumes

Racial and Ethnic minority population in Clinical Trials in Parkinson’s Disease:

P4.251–328

ePosters

I

P4.329–412

A

P4.001–030 A: Movement Disorders B: Neuro-rehabilitation; General Neurology; Child Neurology and Epilepsy/Clinical Neurophysiology (EMG) ePosters C: Aging and Dementia D: Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Child Neurology; Behavioral and Cognitive Neurology; Neuro-rehabilitation G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Neuroepidemiology I: MS and CNS Inflammatory Disease

Larry Brown, Steven Vernino

Ramon Gil, Elizabeth Lindemulder, Robert Rubens, Suneel Gupta

P4.010 Optimizing Recruitment of

H

B

P4.015 Correlation of Clinical and

P4.008 Improvements in activities of

Hubert Fernandez, Alberto Espay, Rajkumar Conjeevaram, Ji Zhou, Matthew Kuntz, Edward Halpern, Janet Benesh

C

P4.081–100

Dale, Deniz Erten-Lyons, Frank Bittner, HoYann Jong, Dennis Bourdette, Randall Woltjer

Web-Enabled Parkinson’s Disease Study —Lama Chahine, Chelsea Caspell-

the levodopa-carbidopa intestinal gel delivery system in advanced Parkinson’s disease patients and healthcare providers —Ramon Rodriguez,

Poster Discussion

P4.071–080

molecular-genetic background of familial atypical parkinsonism in “Hornacko”, a specific region of the south-eastern Moravia, Czech Republic. —Katerina

daily living and quality of life measures in Hoehn & Yahr subgroups of advanced Parkinson’s disease patients following treatment with IPX066, extendedrelease carbidopa-levodopa —Rohit Dhall,

D

P4.014 Inflammatory pathology and

rapidly progressive dementia contribute to the classic PSP phenotype —Marian

G

P4.223–250

P4.101–110

P4.031–070

P4.006 ND0701: A novel safe

Garcia, Lauren McLaughlin, Connie Marras, David Standaert, Bernard Ravina, Christopher Kenney, Sohini Chowdhury, Todd Sherer, Catherine Kopil

F

P4.145–222

Rebecca Logan, Padraig O’Suilleabhain, Richard Dewey, Mary Quiceno, Pravin Khemani

add a retrospective application to improve the diagnostic accuracy of multiple system atrophy and progressive supranuclear palsy vs idiopathic Parkinson’s disease —Carlos Guevara Oliva,

P4.007 Fox Insight: a Large-Scale

E

P4.111–144

P4.012 Pre- and post-synaptic

Neuroimaging Features in Progressive Supranuclear Palsy —David French, Richard

Shaltiel-Karyo, Yonit Tsarfati, Eduardo Zawoznik, Irena Weinstock, Mara Nemas, Anna Rubinski, Yael S Schiffenbauer, Abraham Nyska, Oron Yacobi-Zeevi

Poster Session IV Neighborhoods

Glasmacher, Nigel Leigh, Romi Saha

Tarolli, Kelly Andrzejewski, Michael Bull, Steven Goldenthal, Michael O’Brien, Tanya Simuni, Grace Zimmerman, Kevin Biglan, E. Ray Dorsey

concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump —Ronit

Wednesday, April 26  8:30 a.m.—7:00 p.m.

differences among LRRK2, GBA and idiopathic Parkinson’s disease patients and non-manifesting first-degree relatives —Avner Thaler, Tamara Shiner, Anat Mirelman, Tanya Gurevich, Avi OrrUrtreger, Nir Giladi

P4.020 Comparative Analyses

in Brain’s MRI (Nigrosome and Neuromelanin) Versus 00mmTcTRODAT-1 Spect in Movement Disorders —Alex Baeta, Marcelo Schmid,

108 2017 AAN Annual Meeting Scientific Program

Julyne Sandes, Hennan Teixeira, Leticia Rigo, Marcio Escorcio-Bezerra, Victor Hugo Marussi, Anderson Belezia

Michal Gostkowski, Ilia Itin, Joseph Rudolph, Shnehal Patel, Kristin Appleby, Hubert Fernandez

P4.021 White matter tract alterations

P4.023 Cortical tissue deterioration

Agosta, Vladana Pica, Elisa Canu, Milica Jecmenica, Alexandra Tomic, Vladimir Kostic, Massimo Filippi

Tripathi, Kalyan Yarraguntla, Rajkumar Govindan, Fen Bao, Samuel Lichtman-Mikol, Navid Seraji-Bozorgzad, Omar Khan, Edwin George

P4.022 Evolution in Dopamine

P4.024 A Retrospective Chart

Schwann, Alexandra Mangel, Anwar Ahmed,

Katherine Amodeo, Ruth Schneider, Irene Richard

in Parkinson’s disease patients with punding —Francesca Imperiale, Federica

Transporter (DaT) Scan Utilization Patterns and its Effect on Treatment Decisions: Results of the Next 200 Scans —Xin Xin Yu, Dean Liou, Kiersten

in PD: a longitudinal DTI study —Richa

Review of Patients with Parkinsonism who underwent DaTSPECT Imaging to Distinguish Drug Induced Parkinsonism from Idiopathic Parkinson’s Disease —


P4.025 Patient-Based Quantitative

Analysis of DaT-SPECT uptake: Application in Patients with Parkinson and Asymptomatic Carriers of the G2019S LRRK2 Mutation Running title: Quantitative DaT in Parkinson’s disease —Avner Thaler, Moran Artzi, Einat

Even-Sapir, Hedva Lerman, Noa Bregman, Keren Regev, Avi Orr-Urtreger, Talma Hendler, Nir Giladi, Dafna Ben Bashat, Anat Mirelman

P4.026 Autonomic Testing

Profiles in Scans Without Evidence of Dopaminergic Deficit (SWEDD) —Derek Stitt, Elizabeth Coon, Rodolfo Savica

P4.027 Dopaminergic neuronal

oxidative stress is increased with disease progression in patients with Parkinson’s disease: A study with PET and SPECT —Masamichi Ikawa, Hidehiko

Okazawa, Hiroyuki Neishi, Yuki Kitazaki, Tetsuya Tsujikawa, Kenichiro Kikuta, Yasunari Nakamoto, Makoto Yoneda

P4.028 White matter microstructural

damage as predictor of cognitive decline in Parkinson’s disease —Sebastiano Galantucci, Federica Agosta, Tanya Stojkovic, Igor Petrovic, Elisa Canu, Elka Stefanova, Massimiliano Copetti, Vladimir Kostic, Massimo Filippi

P4.029 Diffusion tensor imaging

changes in the corpus callosum and cognitive impairment in Parkinson’s disease —Ian Bledsoe, Douglas Merkitch, Glenn Stebbins, Bryan Bernard, Jennifer Goldman

P4.030 NA NEURO-REHABILITATION: MOTOR RECOVERY AND SPASTICITY TREATMENT

P4.031 High-intensity interval

ergometer training improves aerobic capacity and fatigue in patients with Multiple Sclerosis —Stephan Schmidt, Marc Wonneberger

P4.032 Effect of early use of

AbobotulinumtoxinA (Dysport®) after stroke on spasticity progression: first results of a pilot study —Raymond Rosales, Khean Jin Goh, Witsanu Kumthornthip, Mazlina Mazlan, Lydia Abdul Latif, Mary Mildred De Los Santos, Chayaporn Chotiyarnwong, Phakamas Tanvijit, Jovita Balcaitiene, Pascal Maisonobe, Keng-He Kong

Electrostimulation (NMES) used for increasing quadriceps strength may also provide mild analgesia —William Mays, Jeffrey Metter, Tulio Bertorini, Pan Izaguirre Mei-Hsiu, Laura Talbot

P4.034 The Adult Spasticity

International Registry (ASPIRE) Study: 1-Year Results —Gerard Francisco, Daniel

P4.045 Bilateral sural neuropathy

P4.035 Efficacy of

P4.046 Quantitative and qualitative

Simpson, Jorg Wissel, Djamel Bensmail, Astrid Scheschonka, Birgit Flatau-Baque, Olivier Simon

Seze, Brigitte Samama, Catherine Mutter, Ludivine Chamard, Marc Debouverie, Nelly Boehm, Nicolas Collongues

IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults —David

during pregnancy: A case report —Derek Yuan, Marco Palmieri

normative dataset for intraepidermal nerve fibers at distal leg —Jerome De

P4.036 Duration of Treatment Effect

P4.047 Hypothyroidism Presenting

Elie Elovic, Michael Munin, Michael Althaus, Angelika Hanschmann, Irena Pulte, Christina Marciniak

Parker, Ammar Alobaidy, Nadeem Tajuddin, Ekta Kakkar, Son Viet Nguyen, Vitor Pacheco, Liang Lu

of IncobotulinumtoxinA in Upper Limb Spasticity —Bruce Rubin, Petr Kanovsky,

with Dysarthria and Intermittent Weakness of the Extremities —Alicia

P4.037 Efficacy of

P4.048 Clinico-radiological spectrum

Wissel, Djamel Bensmail, Astrid Scheschonka, Birgit Flatau-Baque, Olivier Simon, Dirk Dressler

Constantine Farmakidis, Kathleen Mullin, Matthew Robbins

IncobotulinumtoxinA In The Treatment Of Shoulder Spasticity —David Simpson, Jorg

P4.038 Duration of Effect of

Abobotulinumtoxina (Dysport®) In Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury —Jean-Michel Gracies, Allison

Brashear, Christina Marciniak, Robert Jech, Marta Banach, Phillippe Marque, Anne-Sophie Grandoulier, Claire Vilain, Philippe Picaut

P4.039 Effect of Rhythmic Auditory

Stimulation On Gait In Patients With Stroke —Mohamed Ahmed Ibrahim, Gehan Mousa Ahmed, Ebtesam Mohamed Fahmy

P4.040 The Effect of SSRIs in the

Outcomes of ICARE Trial —Samir Belagaje, Sarah Blanton, Li Ding, Christianne Lane, Monica Nelsen, Alexander Dromerick, Carolee Winstein, Steven Wolf

GENERAL NEUROLOGY: MYELOPATHIES, ALS AND PERIPHERAL NERVE

P4.041 Diffusion-Tensor-Imaging

MR-Neurography for the detection of polyneuropathy in Type 1 diabetes —

of intranasal heroin myelopathy: a case series —Alina Masters-Israilov, Olivia Tong,

P4.049 Imaging of Acute

Quadriparesis from Spinal Epidural Induced Pneumorrhachis —David Carter, Mahmoud Abu-Ata, Mohammad Alhatou

P4.050 Prevalence and treatment options for diabetic neuropathic pain in Kuwait. —Samar Ahmed, Maryam E

GENERAL NEUROLOGY: VASCULAR NEUROLOGY

P4.058 Albumin neuroprotection

in focal cerebral ischemia in humans: Another look at ALIAS trial subgroup —

Rakesh Khatri, Mohammad-Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Alberto Maud, Salvador Cruz-Flores, Gustavo Rodriguez, Adnan Qureshi

P4.059 Developmental Venous

Anomalies in Neurological Disease: A Report of Six Cases —Ahmed Obeidat, Bakkiam Subbiah, Thomas Tomsick, Pooja Khatri

P4.060 Intravascular T cell

Lymphoma: A Rare, Poorly Characterized Entity with Cytotoxic Phenotype — Tara Sharma, Gabrielle Yeaney, Payam Soltanzadeh, Yuebing Li, Claudiu Cotta

P4.061 Primary Angiitis of the Central Nervous System —Bader Alenzi, Hao Zhang, Joseph Kass

P4.062 Achieving better detection of vascular risk factors for stroke prevention —Man Mohan Mehndiratta, Swati Wadhai

Alkandri, Jasem Al-Hashel, Dalai Alhajerie, Raed Alroughani

P4.063 Intraventricular bleed or

P4.051 Hypertrophic Cranial

P4.064 Ischemic stroke in a patient

Bhagyadhan Patel

Ebiana, Sandeep Singh, Shaweta Khosa, Negar Moheb, Bhavesh Trikamji, Neal Rao, Shrikant Mishra

Polyneuropathies and Pituitary Lesions —Ninad Desai, Satish Khadilkar,

P4.052 Eslicarbazepine Acetate

in Neuralgic Pain —Pino Lopez Mendez, Arminda Maria Ruano Hernandez

P4.053 Recurrent postpartum bilateral bell’s palsy —Tanaporn

Rasameesoraj, Michael Devereaux

P4.054 Bilateral Bell’s Palsy

Associated with Vogt-Koyanagi-Harada Disease : A Case Report —George Lai, DeWitt Pyburn

foreign body? —Nilofar Dudha

with Parry-Romberg syndrome —Victoria

P4.065 Rapidly Progressive atypical

Posterior Reversible Encephalopathy Syndrome (PRES) associated with B-cell lymphoma —Yuri Bronstein, Mitchell Danesh, Marko Petrovic, Nazely Ashikian, Robert Arbuckle, Hannah Homafar

P4.066 Case Report: Posterior

reversible encephalopathy syndrome (PRES) associated with aseptic meningitis —Qiang Zhang, George Richerson, Nandakumar Narayanan

Michael Vaeggemose, Mirko Pham, Steffen Ringgaard, Hatice Tankisi, Niels Ejskjaer, Sabine Heiland, Per L. Poulsen, Henning Andersen

P4.055 Data-driven modelling of

P4.042 Diffusion Tensor Imaging of

Gabel, Mara Cercignani, Daniel Alexander, Alexandra L. Young, Ammar Al-Chalabi, Peter Leigh

Vaeth, Mirko Pham, Steffen Ringgaard, Uffe Birk Jensen, Hatice Tankisi, Niels Ejskjaer, Sabine Heiland, Henning Andersen

P4.056 Takotsubo syndrome

P4.043 A case of peripheral

Hiroyuki Nodera, Kazuto Nishinaka, Fukashi Udaka, Yoshihiko Nishida, Shigeo Murayama, Ryuji Kaji

P4.069 VCAM_1 as a endothelial

P4.057 Tissue-engineered skin model

Ebrahimi, Ahmad Sobhani

Peripheral Nerves in Patients with CMT Type 1A —Michael Vaeggemose, Signe

neuropathy due to pyridoxine toxicity in association with NOS energy drink consumption —Kaitlyn Blackburn, Katie Warren

P4.044 Incomplete spinal cord

lesions: probably the commonest cause of radicular syndromes but difficult to diagnose —Paul Teychenne

diffusion MRI changes in ALS indicates evolution of distal prior to proximal corticospinal tract pathology —Matt C.

complicated with amyotrophic lateral sclerosis —Yuishin Izumi, Ai Miyashiro,

derived from neurofibromatosis type 1 (NF1) patients to study tumor genesis and to predict response to therapy —

P4.067 Hyperthermia induced

posterior reversible encephalopathy syndrome: a rare presentation. —Rafael Rodriguez, Ahmed Yassin, Xiang Fang

P4.068 A Proposed Mechanism for Hypobaric-induced Neuronal Injury: A Swine Model —Philippine Dana Peralta,

John Sladky, Paul Sherman, Stephen McGuire

factor for diagnosis of dementia in Parkinson’s disease —Ali Ebrahimi, Homa

P4.070 NA

Vincent Roy, Lydia Touzel-Deschênes, Edouard Marques, Peter Kannu, Helene Khuong, Nicolas Dupre, Francois Gros-Louis

Fast and easy registration · AAN.com/view/AM17 109

WEDNESDAY

P4.033 Neuromuscular

Bandari, Ganesh Bavikatte, Wolfgang Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session IV



Wednesday, April 26  8:30 a.m.—7:00 p.m.

Child Neurology and Epilepsy/Clinical Neurophysiology (EEG) ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P4.071 Automated Seizure Detection

on the Median Power Spectrogram Using Computer Vision and Machine Learning Methods —Peter Yan, Zachary Grinspan

P4.072 PRES related reversible

epileptic Anton’s syndrome —Junaid

Siddiqui, Namir Khandker, Samden Lhatoo

P4.073 Morphometric Analysis

on T1-Weighted MRI Complements Visual MRI Review in Focal Cortical Dysplasia —Alexandra Santana Almansa,

Benjamin Brinkmann, Diego Tovar Quiroga, Daniel Kenney-Jung, Robert Witte, Jeffrey Britton, Lily Wong-Kisiel

P4.074 Postictal Clinical Features

of Focal Dyscognitive Seizures —David Harris, Catherine Schevon, Lisa Bateman

P4.075 Early epileptiform discharges as predictor of seizures in the pediatric intensive care unit —Ryan Hodgeman, Arnold Sansevere

P4.076 EEG findings in a Case of

P4.077 Efficacy of Cannabidiol in

Children with Intractable Epilepsy — Gurcharanjeet Kaur, Mary Andriola, Louis Manganas

P4.078 Further Delineation of

P4.079 SCALP/Schimmelpenning

Syndrome (SNS) Presenting with Aneurysms and Neonatal Status Epilepticus —Elizabeth Ng, Mary Andriola, Rebecca Spiegel, Louis Manganas

Clinical Phenotype of Cerebellar Ataxia, Mental Retardation, and Disequilibrium Syndrome type 4 (CAMRQ4); Report of 5 New Patients and Review of Previously Reported Cases. —Saud Alsahli, Majid

P4.080 A novel pediatric presentation

P4.092 Common and differential

Blood Flow vs. Glucose Metabolism —

Montembeault, Simona Brambati, Cecile Gallea, Bruno Dubois, Agnes Michon, Foudil Lamari, Dalila Samri, Didier Dormont, MarieOdile Habert, Aurelie Kas, Raffaella Migliaccio

P4.098 Brain Atrophy in Early

Alfadhel

of epilepsy, nonanesthetic malignant hyperthermia, and congenital developmental delay associated with likely pathologic RYR1 variant. —Anisha Schwarz, Sarah Bauer Huang

Congenital Zika Virus Syndrome — Gurcharanjeet Kaur, Louis Manganas

AGING AND DEMENTIA: COGNITIVE AND NEUROPSYCHIATRIC STUDIES

P4.087 Measuring an Individual’s

P4.081 Validity of DSM V Major

Howard Chertkow, Stephan Probst, Erwin Nikelski, Alexander Thiel

Neurocognitive disorder criteria for population research in India —Aashrai Gudlavalleti, AT Jotheeswaran

P4.082 Is Mini Mental State

Examination the best test for lower educated individuals? —Mariane De

Moraes Monteiro, Luis Felipe Scarabelot, Viviane Zetola

P4.083 Neuropsychiatric Symptoms Related to Neuropathologic vs. Clinical Diagnosis of Dementia —Letizia Borges,

Alfred Rademaker, Eileen Bigio, M. Mesulam, Sandra Weintraub

P4.084 Neuropsychiatric symptoms in Latino patients with Alzheimer’s disease: an analysis of the NACC database — Katya Rascovsky, Merilee A. Teylan, Corey McMillan, Lilah Besser, Walter Kukull, Murray Grossman

P4.085 Digital Self-Administered

Gerocognitive Examination (eSAGE): Correlations with Neuropsychological Evaluations —Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, Nicole Vrettos

P4.086 Mining Data from Verbal

Fluency Word Lists for Prediction of Amyloid Status —David Clark, JOHN Del

WEDNESDAY

Gaizo, Naira Goukasian, Kristy Hwang, Liana Apostolova

Degree of Semantic Impairment due to Temporal Pole Damage —Carlos Roncero,

P4.088 Dementia & Amyloid

Detection in Lewy Body Disorders Using The Philadelphia Brief Assessment of Cognition (PBAC) —Amy Halpin, Corey McMillan, Katya Rascovsky, Jacqueline Rick, Daniel Weintraub, Murray Grossman

P4.089 Clinical utility of memory

measures in the differential diagnosis of mild cognitive impairment and major depressive disorder —Bonnie Scott, Kami Winship, Andrew Schmitt

P4.090 A new treatment Paradigm

for Neurodegeneration: Peroxidationresistant polyunsaturated fatty acids (D-PUFA) lower brain amyloid beta and oxidation markers, and reverse cognition impairment in vivo —Mikhail Shchepinov, Mark Mattson, Brian Bennett

patterns of brain atrophy in Alzheimer’s disease-related and non-related variants of posterior cortical atrophy —Maxime

P4.093 Advanced 1H-MRS detects

decreased glutamate levels in amnestic MCI —Burcu Zeydan, Dinesh Deelchand, Nirubol Tosakulwong, Timothy Lesnick, Mary Machulda, David Knopman, Clifford Jack, Ronald Petersen, Gulin Oz, Kejal Kantarci

P4.094 ApoE-dependent differences in functional connectivity support memory performance in early-stage Alzheimer’s disease —Matteo De Marco, Annalena Venneri

P4.095 Gait parameters as useful

proxies in the early stage of Alzheimer’s disease: a Voxel Based Morphometry study —Micaela Mitolo, Camilla Della Piet‡,

AGING AND DEMENTIA: NEUROIMAGING

Elena Cosentino, Francesca Meneghello, Giorgio Levedianos, Vincenzo Iaia, Annalena Venneri

P4.091 Structural and functional

P4.096 An efficient approach to

Massimo Filippi, Silvia Basaia, Elisa Canu, Sebastiano Galantucci, Alessandro Meani, Francesca Caso, Giuseppe Magnani, Roberto Santangelo, Monica Falautano, Andrea Falini, Giancarlo Comi, Federica Agosta

Jinyi Qi, Bradford Dickerson, Ciprian Catana

brain connectome architecture in Alzheimer’s disease and amnesic mild cognitive impairment patients —

110 2017 AAN Annual Meeting Scientific Program

obtain optimized metabolic PET and morphological MR data in dementia patients —Kevin T. Chen, Stephanie Salcedo,

P4.097 Comparative Value of

ASL-MRI and FDG-PET Imaging in Neurodegenerative Diseases: Cerebral

Gustavo Roman, Steve Fung, Maria Alejandra Daza, Alirexa Faridar, Mario Dulay, Belen Pascual, Bryan Spann, Ronald Fisher

and Late Onset Alzheimer’s Disease and Suspected Non-Alzheimer’s Pathophysiology —Eddie Stage, Meredith

Phillips, Tugce Duran, Victor Canela, Gil Rabinovici, Bradford Dickerson, Maria Carrillo, Susan De Santi, Naira Goukasian, Shannon Risacher, Liana Apostolova

P4.099 Differences in brain

metabolism in Early and Late Onset Alzheimer’s Disease and Suspected Non-Alzheimer’s Pathophysiology —

Victor Hugo Canela, Eddie Stage, Meredith Phillips, Tugce Duran, Gil Rabinovici, Bradford Dickerson, Maria Carrillo, Susan De Santi, Shannon Risacher, Liana Apostolova

P4.100 The synergistic interaction

between amyloid and tau PET in the brain’s default mode network determines the clinical status in early Alzheimer’s disease. —Tharick Pascoal, Sulantha Mathotaarachchi, Kok Pin Ng, Serge Gauthier, Pedro Rosa Neto


Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 a.m. P4.101 The Association of Uncontrolled Seizures with HealthRelated Quality of Life by Age Group among Patients with Epilepsy —Fulton Velez, Lulu Lee

Data Blitz:  11:50 a.m.–11:55 a.m. P4.102 Temporal and spectral characteristics of dynamic functional connectivity between resting-state networks in temporal lobe epilepsy —

Sharon Chiang, Emilian Vankov, Hsiang Yeh, Michele Guindani, Marina Vannucci, Zulfi Haneef, John Stern

Data Blitz:  11:55 a.m.–12:00 p.m. P4.103 Healthcare Resource Utilization Among Patients With Lennox-Gastaut Syndrome Treated With Clobazam —Jesus Pina-Garza, Georgia Montouris, Francis Vekeman, Wendy Cheng, Ed Tuttle, Yuanyuan Shen, Mei-Sheng Duh, Jouko Isojarvi, Steven Kymes, Timothy Saurer

Data Blitz:  12:00 p.m.–12:05 p.m. P4.104 Healthcare Resource Utilization and Projected Long-Term Cost Savings Following Clobazam Initiation in Patients With LennoxGastaut Syndrome —John Stern, Augustina Ogbonnaya, Tasneem Lokhandwala, Pamela Landsman-Blumberg, Amy Duhig, Aroonrut J. Hantrakul, Steven Kymes, Clement Francois

Data Blitz:  12:05 p.m.–12:10 p.m. P4.105 Analysis of Changes in Plasma Sodium Levels and Related Treatment-Emergent Adverse Events During Short- and Long-Term Use of Eslicarbazepine Acetate as Adjunctive and Monotherapy —Robert Wechsler,

Rodney Radtke, Kenneth Laxer, Eugen Trinka, Mariana Vieira, Joana Moreira, Francisco Rocha, Hailong Cheng, Todd Grinnell, David Blum

P4.118 Generational Variance in

P4.111 Mutational analysis of CCNF

Nicholas Blondin

Pei-chien Tsai, Yi-Chu Liao

P4.112 Role of MicroRNA in

Amyotrophic Lateral Sclerosis:evidence for gender and age of onset difference — Valentina Pegoraro, Corrado Angelini

P4.113 Motor unit number estimation recording from the tongue: a pilot study —Courtney McIlduff, Aimee Boegle, Kristin Qi, Seward Rutkove

P4.114 An approach for optimizing muscle assessment with surface electrode array configurations used in electrical impedance myography —

Benjamin Sanchez, Hyeuknam Kwon, Adam Pacheck, Jin Seo, Seward Rutkove

for the Diagnosis of Amyotrophic Lateral Sclerosis —Scott Lewis, Gregg Meekins, Laura Foster, Chelley Chorn, Apostolos Georgopoulos

P4.116 Edaravone (MCI-186) for

the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment of the 40-Item ALS Assessment Questionnaire (ALSAQ-40) by Domain — Koji Takei, Joseph Palumbo, Kikumi Tsuda, Shawn Liu

P4.117 Electrical Impedance

Myography as a Surrogate Measure of Myofiber Size —Jia Li, Rebecca Taylor,

Adam Pacheck, Carmen Shin, Marie Mortreux, Benjamin Sanchez, Janice Nagy, Seward Rutkove

Data Blitz:  12:15 p.m.–12:20 p.m. P4.107 Long-term Postoperative Outcomes in Patients with Focal Cortical Dysplasia: Predictive Factors and AED Withdrawal —Pue Farooque, Emily Stanford, Alma Rechnitzer, Katie Bandt, Jennifer Bonito, Dennis Spencer, Lawrence Hirsch

Data Blitz:  12:20 p.m.–12:25 p.m. P4.108 A dose ranging safety and pharmacokinetic study of cannabidol (CBD) in children with Dravet syndrome (GWPCARE1) —Anup Patel, Orrin

Data Blitz:  12:25 p.m.–12:30 p.m. P4.109 A review of the drug—drug interactions of the new antiepileptic drug brivaracetam —Brian Moseley, Sophie Kervyn, Jean-Marie Nicolas, Armel Stockis

Data Blitz:  12:30 p.m.–12:35 p.m. P4.110 Randomized double-blind non-inferiority trial of lacosamide versus controlled-release carbamazepine monotherapy—subgroup analysis of unclassified patients with initial generalized tonic-clonic seizures only —

Konrad Werhahn, Felix Rosenow, Manuel Toledo, Michel Baulac, Kiyohito Terada, Ting Li, Melissa Brock, Marc De Backer

Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 Mutation —Evan Jameyfield,

P4.119 Use of Big Data Analytics for

Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS) —Tara Grawbowsky, Oodaye Shukla, Manjula Kasoji, Charlotte Merrill, Wendy Agnese, Nazem Atassi

P4.120 Counting the uncounted costs of Spinal muscular atrophy —Michelle Farrar, Kate Carey, Sarah-Grace Paguinto, Georgina Chamber, Nadine Kasparian

P4.121 Evaluation of Cognitive

Reserve in Amyotrophic lateral Sclerosis —Marcelo Francisco Rugiero,

Mariela Bettini, Juan Ignacio Rojas, Angel Golimstok, Edgardo Cristiano, Pamela Seilicovich

P4.122 Novel mutation in MYH7 gene causing scapuloperoneal syndrome —

Ricardo Varela, Ana Brás, Olinda Rebelo, Anabela Matos, Argemiro Geraldo, Ricardo Varela, Luis Negrao

P4.123 Axonal RNA Profiling of

Human Motor Neurons as a Novel Approach to Study Axonopathies —Mario Saporta, Renata De Moraes Maciel, Adriana Rebelo, Dana Bis, Cima Saghira, Stephan Zuchner

P4.124 EEG Measures of Altered

Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Amyotrophic Lateral Sclerosis —Bahman

Nasseroleslami, Michael Broderick, Kieran Mohr, Christina Schuster, Brighid Gavin, Russel McLaughlin, Mark Heverin, Alice Vajda, Parameswaran Iyer, Niall Pender, Peter Bede, Edmund Lalor, Orla Hardiman

P4.125 Subjective perception of

health in ALS: A moving target? —Nimish Thakore, Erik Pioro

P4.133 Immune Mediators as

Biomarker Candidates in Familial Amyotrophic Lateral Sclerosis —Anupama

P4.126 Differentiating Flail Limb

Kumar, Gabriel Pinilla Monsalve, Mary Kay Floeter, Carlos Pardo-Villamizar, Jeffrey Rothstein, Hristelina Ilieva

Nizar Souayah

P4.134 Ultra-High Field Proton MR

Syndrome from Amyotrophic Lateral Sclerosis —Jeffrey Kornitzer, Erin Feinstein,

P4.127 Clinicosocial Factors that

Influence Diagnostic Delay in ALS —Drew Young, Syeda Alqadri, Raghav Govindarajan

P4.128 Correlations of a novel

strength-based endpoint for tracking disease progression in amyotrophic lateral sclerosis with quality of life and functioning outcomes —Jennifer Petrillo,

Dawei Liu, Toby Ferguson, Steve Han, Donald Johns

P4.129 Assessment of olfactory

dysfunction as a potential biomarker in Amyotrophic Lateral Sclerosis —Cristina

Viguera, Elizabeth Mosmiller, Aiana Rodriguez, Nicholas Maragakis

P4.130 Predictors of Mortality in

Spectroscopy in Amyotrophic Lateral Sclerosis —Ian Cheong, Gulin Oz, Lynn

Eberly, Malgorzata Marjanska, David Walk

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG): PERIPHERAL NEUROPATHY I

P4.135 Haemodialysis Alters

Peripheral Nerve Morphology in Endstage Kidney Disease —Adeniyi Borire, Arun Krishnan

P4.136 Prominent Distal

demyelination is a feature of ZikaAssociated Guillain Barre Syndrome —

Natalia Betances, Carlos Luciano, Jose Carlo, Brenda Deliz-Roldan, Gishlaine Alfonso

Patients with Amyotrophic Lateral Sclerosis —Akanksha Sharma, Haley

P4.137 Identification of a Novel

P4.131 Effectiveness of automatic

Saperstein, Alan Pestronk, Jack Kent

Anderson, Leo Wang

intratracheal suctioning system for amyotrophic lateral sclerosis patients with tracheostomy-invasive ventilation —Kiyonobu Komai, Atsuro

Tagami, Chiho Ishida, Kazuya Takahashi, Yuko Motozaki, Akio Akagi, Taro Ozaki, Ai Shimizu

P4.132 Radiological “Snake Eyes”

Sign Due to Anterior Epidural Spinal Cyst Mimicking Hirayama Disease —Abdallah Hamdallah, Yuebing Li MD, Paul Twydell

Immune Mediated Cause for Small Fiber Neuropathy —Todd Levine, David

P4.138 Diffusion Tensor Imagine of

the Brachial Plexus and Cervical Spinal Nerve Roots: Case Controls Study in CIDP Patients and Controls —Eve Chanson, Matthieu Barriol, Frederic Taithe, Abderrahim Zerroug, Agnes Lhoste, Bruno Pereira, Louis Boyer, Betty Jean, Pierre Clavelou

P4.139 Long-term course of

idiopathic small fiber neuropathy —

Walter Haupt, Pia Flossdorf, Anna Brunn, Gereon Fink, Gilbert Wunderlich

Fast and easy registration · AAN.com/view/AM17 111

WEDNESDAY

P4.115 Development of Biomarkers

Fortin, Madelyn Barton, Genevieve Lupien, Marie-Pierre Lamothe, Dominic Chartrand, Anne Lortie, Philippe Major, Paola Diadori, Ala Birca, Lionel Carmant

Richard Appleton, Cynthia Harden, Kenneth Sommerville, Sam Greenwood, Gilmour Morrison

Devinsky, Elizabeth Thiele, Matthew Wong,

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG): MOTOR NEURON DISEASE II in ALS patients in Taiwan —Yi-Chung Lee,

Data Blitz:  12:10 p.m.–12:15 p.m. P4.106 Etiologies and developmental outcomes in infants with new onset epilepsy: report of 40 consecutive patients —Sandra Reiter-Campeau, Olivier

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session IV



P4.140 The evaluation of small

mediated autoimmune encephalitis in pediatrics —Daniel Reiff, Aashrayata Aryal

P4.182 Levodopa responsive chorea

P4.168 Novel mutations in RMND1

Kenneth Habetz

P4.155 Neuropsychological Profiles in

Maria J Sanchez-Quintero, Carlos Lopez Gomez, Uta Lichter-konecki, Laura Rosa Pisani, James Riviello, Michio Hirano, Catarina Quinzii Hirano

3 in a 44 year old woman: A Case report & review of literature. —Jessica Lowe,

Webb, Joon-Shik Moon

Mealy, Lisa Ferenc, Matthew Ryan, Michael Levy, Ana Arenivas

P4.169 A Case of GLUT1 Deficiency

P4.142 Alternate resistance and

P4.156 Association Between

BEHAVIORAL AND COGNITIVE NEUROLOGY: NEURODEGENERATIVE DISORDERS

Mikati

P4.184 Impaired Recognition of

fiber neuropathy: a survey of American Academy of Neurology members —Sujata Thawani, Nellie Adams, Thomas Brannagan, Brian Callaghan

P4.141 Effects of Plasmapheresis in

Neuropathic Pain, Local Inflammatory Cytokines, and Skin-Wrinkling-Response in Patients with Painful Peripheral Neuropathies. —Eduardo De Sousa, Tyler

endurance training improves muscle strength and aerobic capacity in patients with chronic inflammatory demyelinating polyneuropathy —Lars Markvardsen,

Kristian Overgaard, Karen Heje, Soren Sindrup, Ingelise Christiansen, John Vissing, Henning Andersen

P4.143 NA P4.144 NA CHILD NEUROLOGY II

P4.145 Case Report: A transverse

spinal cord infarct in a 15 year old male following lumbar epidural catheter placement —Daniel Savitt, Davut Pehlivan, Sarah Risen

P4.146 Readmissions within Pediatric Neurology: A Quality Improvement Initiative Involving Discharge Optimization —Jaime Heath, Oluwafemi

Ojo, Stephanie Garcia, Rebecca Leimkuhler

P4.147 Defining Hand Stereotypies in Rett Syndrome: A Movement Disorders Perspective —Marisela Dy, Jeffrey Waugh, Nutan Sharma, Heather O’Leary, Kush Kapur, Alissa D’ Gama, Mustafa Sahin, David Urion, Walter Kaufmann

P4.148 The Muscular Dystrophy

Association (MDA) U.S. Neuromuscular Disease (NMD) Registry: Initial Data on Patients with Spinal Muscular Atrophy (SMA) —Cynthia Jones, Susan Eaton, Li Li,

Nasha Wang, Valerie Cwik, Suzanne F. Cook, Sarah Gheuens, Anne Dilley

P4.149 Pediatric Thrombectomy:

Case Presentation and Standardizing the INR process. —Ittai Bushlin, Jenny Wilson

P4.150 Fetal central nervous system

WEDNESDAY

malformations: a ten year review of prenatal consultations at a tertiary care center —Sonika Agarwal, Jake Keller, Gary Clark, Lisa Emrick

P4.151 A ten year profile of

P4.154 Prophylactic therapy

Wednesday, April 26  8:30 a.m.—7:00 p.m.

of cyclic vomiting syndrome in children: comparison of amitriptyline, cyproheptadine, and topiramate —

Shervin Badihian, Negin Badihian, Zahra Bagherian, Hossein Saneian, Omid Yaghini

Pediatric Neuromyelitis Optica Spectrum Disorder —Eliza Gordon-Lipkin, Maureen

Affective Symptoms and School Bullying Experiences in Adults with Autism Spectrum Disorders —Bryan Woodruff, M’hamed Temkit, James Adams, Kathleen Yost

P4.157 D-DEMO, A Novel and

Distinct Phenotype Caused by ATP1A3 Mutations —Lyndsey Prange, Vandana

Shashi, Kristin Herman, Raphael Schiffmann, Elie Abdelnour, Joan Jasien, Sujay Kansagra, Melissa McLean, Nicole Walley, Adriana Azar, Erin Heinzen, Mohamad Mikati

P4.158 Healthcare Resource Use

in Patients with Diagnosis of Spinal Muscular Atrophy (SMA) in Optum™ U.S. Claims Database —Megan Teynor,

Qiang Hou, Jia Zhou, Eric Hall, Wendy Wells, Francisco Javier Avendano

P4.159 Truven Health MarketScan

commercial claims database for Juvenile Myasthenia Gravis (JMG) —Saahith Pochiraju, Likang Xu, Sumit Verma

P4.160 Autism Spectrum Disorder

in Cerebrotendinous Xanthomatosis. — Bianca Stelten, Aad Verrips, Olivier Bonnot, Hidde H Huidekoper, Leo AJ Kluijtmans, Ron Wevers

P4.161 Hypoperfusion, vascular pruning, and transient hemiparesis mimicking stroke in transient erythroblastopenia of childhood —

Christopher Calahan, Laura Lehman, Michael Rivkin, Jonathan Lipton, Amy Danehy, Richard Robertson, Nmazuo Ozuah, Cameron Trenor, Miya Bernson-Leung

P4.162 Malformations of cortical

development: a case series of prenatal neurologic consultations and outcomes —Jake Keller, Lisa Emrick, Gary Clark, Sonika Agarwal

P4.163 A Pilot Study to Assess

the Feasibility and Impact of a Home Exercise Program on Heart Rate and Heart Rate Variability in Children with Muscular Dystrophy —Aaron Zelikovich,

Pandit, Paul Larsen, Geetanjali Rathore

presenting with dystonia and seizures —

Associated Episodic Ataxia Without Epilepsy —Dmitry Tchapyjnikov, Mohamad

P4.170 Severe auto-immune

sensory-autonomic neuropathy in an adolescent —Zeyad Aljuhni, Doris Trauner

P4.171 Outcome Of Revascularization In Patients With ACTA2 Cerebral Vasculopathy —Trishna Kantamneni, Lileth Joy Mondok, Neil Friedman

P4.172 Rasmussen’s Encephalitis Treated with Responsive Neurostimulation System —Maite La

Vega-Talbott, Saadi Ghatan, Fedor Panov, Cynthia Harden

P4.173 Dysmorphology in the

Human Medial Superior Olive after Environmental Exposure to Pollution — Kaitlyn Blackburn, Randy Kulesza, Lisa Stevens, Lilian Calderón-Garciduenas

P4.174 Novel mutation of DARS2

gene leads to a rare and aggressive presentation of leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) —Geetanjali Rathore, Lois Star, Paul Larsen, William Rizzo

P4.176 Rapid-Onset Dystonia

Parkinsonism with a rare mutation. — Rachit Patil, Wei Chen, Kurt Hecox

P4.177 Co-occurrence of pathogenic

mutations in mutiple genes in 2 siblings with Brown-Vialetto-Van Laere Syndrome Type 2 phenotype. —Kallol Set,

LeBlanc, April Levin, Heather O’Leary, Lauren Baczewski, Charles Nelson

Caused by a Novel SLC6A1 Mutation with Marked Responsiveness to Zonisamide —Ashley Helseth, Mikati

P4.165 Disruptive Behavior Problems

Mohamad

Boan

neonatal diagnosis of Cornelia de Lange Syndrome: a case study —Michael

in Levetiracetam-Treated Youth with Epilepsy —Michelle Lally, Mary Kral, Andrea

P4.180 Challenges in prenatal and

P4.166 Acute Flaccid Myelitis (AFM):

Stanley, Alexa Craig, Tomo Tarui

Pizoli

dysmyelination in Jacobsen Syndrome —

P4.167 Decorticate posturing

with unresponsiveness- expanding the spectrum of Anti-VGKC antibody

112 2017 AAN Annual Meeting Scientific Program

Tippett, Rhonda Friedman, Argye Hillis

P4.186 Intonation as a disease

marker in behavioral variant Frontotemporal Degeneration —Naomi Nevler, Sharon Ash, Charles Jester, David Irwin, Mark Liberman, Murray Grossman

P4.187 Clinical characteristics of

32 patients with rapidly progressive dementia with Lewy bodies —Claudia

Chou, Jonathan Graff-Radford, Rodolfo Savica

P4.188 Sociodemographic Factors,

Clinical features and Course in Frontotemporal Dementia : A large cohort study from South India —Ratnavalli Ellajosyula, Jwala Narayanan

Tau Oligomers through Intravenous Immunoglobulin (IVIG) Antibodies for the Treatment of Alzheimer’s Disease —

P4.190 A case of sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia presenting as fronto-temporal dementia —Ye Hu, Ima Ebong, Gerald Feliz Reis, Kottil Rammohan, Xiaoyan Sun

P4.191 A Brief Dementia Screening

P4.192 Utility of Recognition

in a patient with neonatal onset nonketotic hyperglycinemia and hyperammonemia —Jeffrey Kornitzer,

Young, Sylvia Ounpuu

4 cases in 4 weeks —Rahul Sinha, Carolyn

Progressive Aphasia and Prediction of Naming Decline by Multi-Modality MRI —Andreia Faria, Aaron Meyer, Donna

P4.178 Homozygous AMT mutation

P4.152 Detection rate of

Spectral Power in Girls with Rett Syndrome —Katherine Roche, Jocelyn

P4.185 Characterization of Primary

Test in South Africa: Results from the Health and Aging Longitudinal Study of an INDEPTH community (HAALSI) —

Ahm Huq

P4.179 New Clinical Phenotype

P4.153 Electroencephalographic

Phillips, Harry Sutherland-Foggio, Amy Wright, Chiadi Onyike, Argye Hillis

Tasneem F. Hasan, Urmi Sengupta, Rakez Kayed

P4.164 Diagnostic Challenges in

Vanzo, Erin Harward, Karen Ho, E Robert Wassman

Sadness in Face or Voice Correlates with Spouses’ Perception of Empathy in Frontotemporal Dementia —Lauren

Dorn, Ashish Kulhari, Krishna Kandregula, Alireza Bozorgi, Mohammad Alrajeh, Sunil Manjila, Ciro Ramos-Estebanez

Aravindhan Veerapandiyan, Laurel Jakubowski, Caroline Hayes-Rosen, Xue Ming

chromosomal microarray genetic testing in patients with cerebral palsy —Rena

Chantal Bhan, Vivek Rai

P4.189 Targeting Neurotoxic

Stroke Management: a window for opportunity? —Jonathan Pace, Elizabeth

Theresa Oswald, Nancy Kuntz

Pediatric Onset Hereditary Spastic Paraparesis (HSP) —Gyula Acsadi, Richard

P4.183 Sturge-Weber Syndrome Type

P4.175 Acute Pediatric Ischemic

plasmapheresis use in pediatric neurologic disorders at a tertiary care center —Jake Keller, Eyal Muscal, Srivaths

Poyyapakkam, Timothy Lotze, Sonika Agarwal

with TITF1 mutation in brain-lung-thyroid disease —Vijeta Shukla, Debopam Samanta,

P4.181 Delayed versus

Henry Osso-Rivera, Mary Kay Koenig

Farrah Mateen, Elyse Jennings, Livia Montana, Ryan Wagner, Kathleen Kahn, Stephen Tollman, Lisa Berkman

Discriminability Index to Predict Conversion From Mild Cognitive Impairment to Alzheimer’s Disease in the Alzheimer’s Disease Neuroimaging Initiative —Maria Julieta Russo, Jorge Campos, Gabriela Cohen, Gustavo Sevlever, Ricardo Allegri

P4.193 Reading difficulties in a

cohort of Spanish-speaking patients with Primary Progressive Aphasia. —Jordi A. Matias-Guiu, Fernando Cuetos, Maria Nieves Cabrera-Martin, Maria Valles-Salgado, Teresa Moreno-Ramos, Jose Carreras, Jorge MatiasGuiu


P4.194 MCI subtypes are

heterogeneous and preceded by different risk factors: A study on aMCI and naMCI incidence —Andrea Zammit, Richard Lipton, Mindy Katz, Carol Derby, Charles Hall

P4.195 Rivastigmine and citalopram

treatment for Alzheimer’s disease in every day clinical praxis. —Krishna Prasad

Pathak, Arjun Pandit, Bashu Dev Ghimire, Tara Gaire

P4.196 Localization of primary

progressive apraxia of speech using functional MRI—a case study —Danielle Spengler, Dannaly Reyes-Baerga, Pradip Pattany, Joyce Gomes-Osman, David Adams, Corneliu Luca

P4.197 The neural basis of indirect

speech act comprehension: Evidence from behavioral variant frontotemporal degeneration —Meghan Healey, Nicola Spotorno, Caitlin Serva, Murray Grossman

P4.198 Late-Onset Wilson’s disease, Dementia, Ekbom syndrome and whitte matter hyperintensities —Paula Marques, Beltrami Larissa, Francisco Germiniani, Helio Afonso Teive, Francis Zorzetto

P4.199 FDG-PET, Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment —Janina

Krell-Roesch, Val Lowe, Anna Pink, Gorazd Stokin, Rosebud Roberts, Michelle Mielke, David Knopman, Teresa Christianson, Mary Machulda, Clifford Jack, Ronald Petersen, Yonas Geda

P4.200 Influence of dopaminergic

system on manipulospatial function in persons with mild dementia and mild cognitive impairment —Yutaka Tanaka,

Martin Albert, Dalia Cahana-Amitay, Midori Tanaka

P4.201 Implications for Management

of PET Amyloid Classification Technology (IMPACT) —Norman Foster, Rorie DuPrey M.S., Richard King, John Hoffman, Jeffery T. Yap, Satoshi Minoshima, Kevin Horn, Yue Zhang

P4.202 Novel microRNA related to

learning and memory in mouse brain —I Fang Wang

P4.206 Transcranial Direct Current

Stimulation in Post-Stroke Aphasia: The Impact of Baseline Severity and Task Specificity —Catherine Norise, Daniela Sacchetti, Roy Hamilton

Dina Di Giacomo, Domenico Passafiume

Alyssa Conigliaro, Elizabeth Spina, Susan Law, Steven Levine

P4.208 Meg Localization of Cortical

Activity During Language Processing Utilizing MR-Focus and Coherence Source Imaging —Andrew Michael Biondo, Susan Bowyer

P4.209 Impaired Gesture-Language

Integration in Adolescents with Autism Spectrum Disorder —Tracey Knaus, Jodi Kamps, Anne Foundas

P4.210 Areas Critical for Accessing

Semantics from Spoken Words —Hinna

Shahid, Julius Fridriksson, Chris Rorden, Rajani Sebastian, Amy Wright, Donna Tippett, Argye Hillis

P4.211 Overrepresentation of

isolated verbal repetition deficits in aphasic males with stroke: A systematic literature review and meta-analysis — Lucia Pertierra, Maria Jose Torres Prioris, Maria Guadalupe Davila, Ricardo Allegri, Marcelo Berthier Torres

P4.212 Neural Bases of Dysgraphia after Acute Stroke —Aishwarya Shukla, Hinna Shahid, Argye Hillis

P4.213 Detecting language

processing in traumatic disorders of consciousness: A stimulus-based EEG study —Camille Chatelle, Eric Rosenthal, Camille Spencer-Salmon, Brian Edlow

NEURO-REHABILITATION: MECHANISM OF RECOVERY

P4.214 Clinical and molecular effects of functional electrical stimulation / lower extremity training in Myotonic Dystrophy —Paola Cudia, Alfonc Baba, Valentina Pegoraro, Corrado Angelini

P4.215 Correlations between

Cerebral Vascular Reactivity Deficits and Brain Parenchymal Volumes after Chronic Moderate/Severe TBI —Kelley

P4.216 Effects of Intra-Arterial

connectivity between left dorsal frontal lobe and perisylvian language network —Borna Bonakdarpour, Hernando Fereira, Allan Wang, David Schnyer, Maya Henry

P4.205 Network Graph Theory

Analysis of Semantic Fluency in Russian—English Bilinguals —Supriya Mahajan, Frances Lissemore, Alan Lerner, Wojbor Woyczynski

Delivery of Mesenchymal Stem Cells on Infarct Size and Neurological Outcome in Rat Middle Cerebral Artery Occlusion Model: A Systematic Review and Metaanalysis —Kunakorn Atchaneeyasakul, Mitsuyoshi Watanabe, Tony Zhang, Steven Lord, Luis Guada, Pallab Bhattacharya, Kevin Ramdas, Ami Raval, Chuanhui Dong, Tatjana Rundek, Dileep Yavagal

P4.217 Revised Constraint-Induced

Aphasia Therapy (CIAT II): Neuroscience Foundations Traced from Basic Laboratory Research to Increased Spontaneous Real-World Speech and Cerebral Cortical Structure —Victor Mark, Edward Taub

Systematic Review —Jonathan Singer,

P4.220 What is the Molecular

Mechanism of WldS-Mediated Axon Protection? —Jack Wang, Jason Hinman

P4.221 NA P4.222 NA

scale validation in Argentina. —Blas

P4.234 Are depression and anxiety

disorders in epilepsy associated with atrophy of mesial temporal structures? —Carlos Millan, Ramses Ribot, Travis Stoub, Andres Kanner

P4.235 Drug-Resistant Focal Epilepsy and Chronic Traumatic Encephalopathy: clinical evaluation and pathological findings —Amy Jones, Jeffrey Britton,

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY (EEG): STATUS EPILEPTICUS

P4.223 Inadequacy of Benzodiazepine dosing in Status Epilepticus patients admitted to Neurointensive Care Unit —

Melissa Blessing, Joseph Parisi, Gregory Cascino

P4.236 Vitamin D and bone mineral density in epilepsy patients —James

Bathe, Deepti Zutshi, Rohit Marawar, Maysaa Basha, Aashit Shah

Wazim Mohamed, Advait Mahulikar, Shishir Rao, Kayla Martin, Aashit Shah, Mohammad Ibrahim

P4.237 Do neurology residents

P4.224 Treatment of Patients in

Status Epilepticus: A Retrospective Chart Review —Trenton Tollefson, Fahed Saada, Clifford Meyers, Lynn Liu

Barbara Dworetzky, Anita Yun, Gaston Baslet, W. LaFrance, Sigita Plioplys, Benjamin Tolchen, Jerzy Szaflarski, Victoria Wong, Tracey Milligan, Rochelle Caplan

P4.225 Quality Improvement for the

P4.238 Is a history of psychiatric

Management of Pediatric Patients with Status Epilepticus —Dmitry Tchapyjnikov, William Gallentine

P4.226 Clinical predictors and

need a curriculum for learning about psychogenic nonepileptic seizures? —

illness in patients with epilepsy a risk factor for developing psychiatric adverse events on antiepileptic medications? —Ai Sumida, Luis Torres, Andres Kanner

outcomes of refractory status epilepticus in a large urban hospital. —Bhrugav Raval,

P4.239 Cognitive Testing and

P4.227 Prolonged super-refractory

Laura Brennan, Carla LoPinto-Khoury

Nidhiben Anadani, David Marks

status epilepticus with excellent seizure and functional outcome. —Angelica Lee, Vinita Acharya, Jayant Acharya

P4.228 Levetiracetam in Non-

Depression scores in Patients with Epilepsy in relationship to Vitamin D levels —Matthew Heard, Kathryn Lester, EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CLINICAL EPILEPSY III

Convulsive Status Epilepticus —Guido

P4.240 Development and Validation

P4.229 Are we following the

David Cantu, Kathryn Davis, Heather Gatens, George Lai, Patricia McGoldrick, Bethany Thomas, Steven Wolf

Vazquez, Blas Couto, Alejandro Thomson, Jose Molina Melendres, Agustina Tamargo, Analia Calle, Maria Elena Fontela, Santiago Claverie, Alfredo Thomson

status epilepticus guidelines and does it matter? —Preena Uppal, Michael Cardamone, Nancy Briggs, John Lawson

P4.230 Convulsive status epilepticus due to all the evoluative stages of neurocysticercosis: Clinical profile and outcomes —Jagarlapudi Murthy, Devdutt Deshmukh

of the Refractory Epilepsy Screening Tool for Lennox-Gastaut Syndrome (REST-LGS): Improving Detection of LGS —Danielle Boyce, Jesus Pina-Garza,

P4.241 Motor phenotype

differentiates adult patients with Dravet Syndrome from Lennox-Gastaut Syndrome —Danah Aljaafari, Alfonso Fasano, Fabio Nascimento, Anthony Lang, Danielle Andrade

P4.231 Is serum albumin level

P4.242 The controversy surrounding

Maria Pacha, Fatima Pantiu, Lucas Orellana, Pablo Bonardo, Marcela Uribe Roca, Lucrecia Bandeo, Anibal Chertcoff, Ricardo Reisin, Oscar Martinez

Sweeney, Scott McNally, Anne Tebo, Thomas Haven, Perla Thulin, Stacey Clardy

associated with mortality? Correlation between proteins levels with status epilepticus mortality scoring systems. —

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CO-MORBIDITIES

P4.232 The Effects of Depression on

Length of Stay and Discharge Disposition among Patients with Epilepsy —Rabia

voltage-gated potassium channel (VGKC)-complex antibodies: Case and Discussion —Jonathan Galli, Michael

P4.243 Assessing the Role of the

Hippocampus in Visual Naming Using Hippocampal Morphometry in Left Temporal Lobe Epilepsy —Patrick Bauer,

Sara Swanson, David Sabsevitz, William Gross, Colin Humphries, Megan Rozman, Lisa Conant, Manoj Raghavan, Wade Mueller, Jeffrey Binder

Jamy, Sahil Gupta, Sandipan Pati

Fast and easy registration · AAN.com/view/AM17 113

WEDNESDAY

P4.203 Gesture Comprehension and

P4.204 Asymmetric intrahemispheric

Kuo, Yun-An Tsai, Yu-Chen Lu, I-Hui Lee

Couto, Jose Molina Melendres, Guido Vazquez, Maria Elena Fontela, Agustina Tamargo, Diego Nadile, Francisco Muñoz Giacomelli, Alejandro Thomson, Alfredo Thomson

P4.219 Central Post Stroke Pain: A

in Multiple Sclerosis —Nicoletta Caputi,

Flesher, Margalit Haber, Franck Amyot, Erika Silverman, Carol Moore, Kimbra Kenney, Ramon Diaz-Arrastia

Kamps, Anne Foundas

P4.233 Suicidality in epilepsy: NDDI-E

concurrent dual transcranial direct current stimulation over the motor cortex in subacute stroke —Chih-Wei Tang, I-Ju

P4.207 Naming of objects and actions

BEHAVIORAL AND COGNITIVE NEUROLOGY: LANGUAGE Language in Young Children with Autism Spectrum Disorder —Tracey Knaus, Jodi

P4.218 Neuromodulation by task-

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session IV



P4.244 Patient Experiences with

P4.257 Clinical and imaging

Lapalme-Remis, Andrea Leep Hunderfund, Khara Sauro, Nathalie Jette

Lester Leung, Haley Huggins

Epilepsy Treatments: Thematic Review of the Qualitative Literature —Samuel

P4.245 Clinical Center for the Lafora Epilepsy Cure Initiative (LECI): Clinical Trial Readiness for a Global Curative Drug Trial —Viet-Huong Nguyen, Reyna

Duron, Roberto Michelucci, Pierre Genton, Sanjib Sinha, Ahmad Beydoun, Maher Arabi, Miljana Kecmanovic, William Whitehouse, Inna Keselman, Iris Martinez-Juarez, Laura Guilhoto, Javier Salas-Puig, Julia Bailey, Elinor Ben-Menachem, Matthew Gentry, Berge Minassian, Jose Serratosa, Antonio DelgadoEscueta

P4.246 Patterns of Drug Resistant

characteristics of silent brain infarction and symptomatic stroke —Khaled Albazli,

P4.258 Early cognitive decline in

symptomatic carotid stenosis is related to plaque inflammation and concomitant intracranial stenosis —Chi Hsien Tan, Chandra Bharatendu, Prakash Paliwal, Hock Luen Teoh, Bernard Chan, Yanhong Dong, Arvind Sinha, Vijay Sharma

P4.259 Vasa Vasorum Enhancement on Computerized Tomographic Angiography Correlates with Symptomatic Patients with 50% to 70% Carotid Artery Stenosis —Raffaella Umeton, Javier Romero

Epilepsy in A Cohort of Adult Epilepsy Patients —Taha A-Hakam, Hassab Al Rasoul

P4.260 Association between

P4.247 Seizure intractibility in

Fa-Ming Ding, Fei Han, Xing-Lin Yang, Li-Xin Zhou, Jun Ni, Ming Yao, Ming-Li Li, Zheng-Yu Jin, Liying Cui, Shu-Yang Zhang, Yi-Cheng Zhu

Ali

geriatric and non-geriatric adult patients —Rohit Marawar, James Bathe,

Maysaa Basha, Deepti Zutshi, Aashit Shah

P4.248 Self-reported antiepileptic

medication adherence of adult patients with epilepsy —Fong Kit Tam, Phoebe Wing Lam Chan, Chang Richard Shek-kwan, Gao Yuau

P4.249 Quantitative EEG Detects

REM Sleep to Enhance Epileptogenic Zone Localization —Marcus Ng

P4.250 NA ACUTE AND DIAGNOSTIC IMAGING IN ISCHEMIC STROKE AND TIA

P4.251 Ultrasound Criteria for

Assessment of Vertebral Artery Origins —Cory Rice, Tamara Strohm, Larry

Raber, Irene Katzan, Ken Uchino, Muhammad Hussain

P4.252 Retinal and Ophthalmic

Artery Studies in Ischemic Stroke Patients Using Fundus Photography and Transcranial Doppler Methods —Kiran Patil, Sunil Narayan, Ramesh Babu K

P4.253 Cerebral blood flow and

auto-regulation in acute TIA patients from a general hospital in Qatar —Adham

WEDNESDAY

Mushtak, Darine Dimassi, Naveed Akhtar, Saadat Kamran, Saleha Abbasi, Ahmed Khattab, Ahmed El Sotouhy, Naim Haddad, Leopold Streletz

P4.254 Sigmoid Sinus Characteristics Correlate with Early Clinical and Imaging Surrogates in Anterior Circulation Ischemic Stroke —Johann Sellner, Jozef Magdic, David Liebeskind, Arthur Karamyan, Nele Bubel, Mark McCoy, Slavin Pikija

P4.255 Infarct location predicts

outcome in distal MCA occlusions —

Muhib Khan, Grayson Baird, Richard Goddeau, Brian Silver, Nils Henninger

P4.256 Factors Affecting Distal

Hyperintense Vessel Sign, a Postulated Marker for Intracranial Collateral Circulation —Tarun Girotra, Muhammad Affan, Horia Marin, Lonni Schultz, Daniel Miller

Increased Brachial-ankle Pulse Wave Velocity and Cerebral Perivascular Space —Fei-Fei Zhai, Yi-Cong Ye, Si-Yu Chen,

P4.261 Quick-brain MRI as first

imaging modality to diagnose pediatric stroke —Alison Christy, Jenny Wilson

Wednesday, April 26  8:30 a.m.—7:00 p.m. P4.268 Patient is Taking Antiplatelet

P4.278 Time Trend Analysis of

Mehla, Navdeep Lail, Harshit Shah, Caila Vaughn, Annemarie Crumlish, Christopher Deline, Marilou Ching, Robert Sawyer, Ashkan Mowla

Sandhya Mehla, Harshit Shah, Navdeep Lail, Caila Vaughn, Saurabh Joshi, Christopher Deline, Robert Sawyer, Marilou Ching, Ashkan Mowla

at home- Does This Increase the Risk of Post Intravenous Thrombolysis Intracranial Hemorrhage? —Sandhya

P4.269 Impact of Vascular Risk

factors on Hemorrhagic Transformation Following rt-PA Administration for Acute Ischemic Stroke —Amir Shaban, Nudrat Tasneem, Sudeepta Dandapat, Uzair Ahmed, Bruno Policeni, Heena Olalde, Edgar Samaniego, Hyungsub Shim, Connie Pieper, Enrique Leira, Santiago Ortega-Gutierrez, Harold Adams, Nandakumar Nagaraja

P4.270 Collaborative Interventions

Reduce Time-to-Thrombolysis for Acute Ischemic Stroke in an Urban, Public Hospital —Zachary Threlkeld, Benjamin Kozak, Sara Cole, Christine Martin, Vineeta Singh

P4.271 Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage —Nobl Barazangi, Sigrid

THROMBOLYSIS AND ACUTE EVALUATION IN ISCHEMIC STROKE

Sorensen, Charlene Chen, Christine Wong, Alan Yee, Michael Ke, Jack Rose, David Grosvenor, Ann Bedenk, Julia Fernandes, David Tong

P4.262 Early Clinical Improvement

P4.272 Trends in Alteplase Utilization

in Central Retinal Artery Occlusion is Associated with Central Retinal Artery Recanalization —Mohammed Alkuwaiti,

Shailesh Male, Stephen Hendriksen, Kevin Engel, Rwoof Reshi, Mustapha Ezzeddine, Tenbit Emiru, Christopher Logue, Christopher Streib

P4.263 Safety Of IV Thrombolysis

For Acute Ischemic Stroke Patients With Thrombocytopenia —Haris Kamal,

Noureldin Abdelhamid, James Grotta, Liang Zhu, Sean Savitz, Amrou Sarraj

P4.264 Intravenous Thrombolysis for

Acute Ischemic Stroke in Patients with Thrombocytopenia —Ashkan Mowla, Haris Kamal, Navdeep Lail, Caila Vaughn, Sandhya Mehla, Christopher Deline, Marilou Ching, Annemarie Crumlish, Robert Sawyer

P4.265 Minor Strokes with proximal

large vessel occlusion in anterior circulation; is intravenous thrombolysis enough —Haris Kamal, Muhammad Ahmed, Kunal Vakharia, Robert Sawyer, Ashkan Mowla

P4.266 Imaging predictors of

hemorrhagic transformation following intravenous rt-PA treatment for acute ischemic stroke. —Nudrat Tasneem,

Amir Shaban, Sudeepta Dandapat, Uzair Ahmed, Bruno Policeni, Heena Olalde, Edgar Samaniego, Hyung Shim, Connie Pieper, Enrique Leira, Santiago Ortega-Gutierrez, Harold Adams, Nandakumar Nagaraja

P4.267 Symptomatic Intracranial

Hemorrhage after IV tPA for Acute Ischemic Stroke Patients with Relative Contraindications to Treatment —Kyle Smith, Mohammed Alkuwaiti, Caitlin Bell, Donna Lindsay, Angela Heyer, Rwoof Reshi, Mustapha Ezzeddine, Christopher Streib

114 2017 AAN Annual Meeting Scientific Program

in Louisiana’s Level III Hospitals —

Digvijaya Navalkele, Paige Hargrove, Oleg Chernyshev, Joseph Acosta, Leopoldo DeAlvare, Gonzalo Hidalgo, Ramy El Khoury, Sheryl Martin-Schild

P4.273 Delays in Door-to-Needle

Time for Acute Ischemic Stroke in the Emergency Department: A Comprehensive Stroke Center Experience —Ashkan Mowla, Jordan Doyle, Navdeep Lail, Christopher Deline, Marilou Ching, Annemarie Crumlish, Robert Sawyer

P4.274 Characteristics of patients

presenting within the first 6 hours compared to historical controls —Abeer

Khoja, Dareen AlShaer, Hussien Alkully, Rayan Alshehri, Mohammed Almekhlafi, Omar Ayoub

P4.275 Intravenous Thrombolytic

Treatment of Acute Ischemic Stroke in Patients Older and Younger than 80 Years: Experience From One Hospital — Hernan Bayona, Camilo Diaz-Cruz, Camila Valencia-Mendoza, Andres Diaz

P4.276 Risk of Symptomatic

Intracranial Hemorrhage and Clinical Outcome after Intravenous Thrombolysis in Posterior Circulation Stroke: Results from the SITS-EAST Registry —Roman Herzig, Jan Waishaupt, Silvie Belaskova, Eva Vitkova, Katerina Blejcharova, Petr Geier, Ales Tomek, Michal Bar, Daniel Vaclavik, Robert Mikulik, Martin Valis

P4.277 Intravenous Tissue

Plasminogen Activator for Patients with Mild or Rapidly Improving Ischemic Strokes and Large Vessel Occlusions: Examining In-hospital Outcomes —Jeffrey Wagner, Constance McGraw, Kathryn McCarthy, Russell Bartt, Judd Jensen, Alessandro Orlando, David Bar-Or

Intravenous Thrombolytic Delivery across the Academic Year: an Academic Tertiary Medical Center Experience —

P4.279 Hispanic patients have longer door-to-needle times independent of age, gender and stroke severity —

Jonathan Cauchi, John Liang, Irene Boniece, Mandip Dhamoon

P4.280 Target Stroke

Implementation: Best Practice Strategies Cut Thrombolysis Time to  —Erika

Marulanda-Londono, Nirav Bhatt, Kunakorn Atchaneeyasakul, Negar Asdaghi, Amer Malik, Nida Akram, Tony Zhang, Daniel D’Amour, Kathy Hesse, Ralph Sacco, Jose Romano

P4.281 Increasing utilization of tissue plasminogen activator in acute ischemic stroke with staff changes —Mohammed Majeed, Christopher Cummings, Ramin Zand, Angela Groody, Neil Holland

P4.282 Analysis of Diagnostic

Accuracy, Workflow and Time to Treatment during In-house ‘Stroke Codes’ —Jody Manners, Ashutosh Jadhav

P4.283 Rapidly improving

neurological deficit of stroke; case series in Academic institute, KAUH, Jeddah — Abeer Khoja, Dareen AlShaer, Abdulellah Alturkustani, Mohammed Al-Mekhalfi

P4.284 Barriers to thrombolysis in a

tertiary care institute in eastern India — Apratim Chatterjee

P4.285 Resident door to needle

Analysis: A retrospective Chart rEview (RACE) —Neil Patel, Sonal Mehta

P4.286 High values of baseline and

24-hour Mean Arterial Pressure are associated with lower chance of early neurological improvement in acute stroke patients treated with thrombolysis — Svetlana Lorenzano, Maria Chiara Caselli, Alessia Zingaro, Federica Orlando, Danilo Toni

P4.287 Can admission Brain

Natriuretic Peptide level predict outcome after intravenous thrombolysis in acute ischemic stroke? —Gupta Harsh, Christopher Finlay, Sajish Jacob, Sunil Raina, Ricky Lee, Archana Hinduja

IN-HOSPITAL STROKE CARE

P4.288 Herniation despite

Decompression Hemicraniectomy in Large Hemispherical Strokes —Archana Hinduja, Yousef Hannawi, Rohan Samant

P4.289 Outcome of large hemispheric infarction in very elderly patients treated with medical management only —Sudhir Datar, Patrick Reynolds

P4.290 Early Decompressive

Hemicraniectomy for Malignant Middle Cerebral Artery Infarction: A single centre retrospective study —Chandra

Bharatendu, Yao Feng Victor Chong, Prakash Paliwal, Hock Luen Teoh, Leonard Yeo, Raymond Seet, Bernard Chan, Tseng Tsai Yeo, Sein Lwin, Chou Ning, Vijay Sharma


P4.291 Hemorrhagic transformation

Beneficiaries, 1999-2013 —Karen Albright,

Koon Ho Chan, Raymand Lee

Lei Huang, Justin Blackburn, George Howard, Michael Mullen, Vera Bittner, Paul Muntner, Virginia Howard

P4.292 Seizure Incidence in Ischemic

P4.304 Sex Differences in

Vaidyanathan, Angela Hawkins, Harold Morris

Alison Ayres, Katherine Crawford, Christina Kourkoulis, Edip Gurol, Anand Viswanathan, Alessandro Biffi, Jonathan Rosand, Christopher Anderson

of ischemic strokes: risk factors and prognostic implications —Ryan Cheung,

Stroke Patients Treated with and without tPA: A Single Center Study —Vaishnavi

P4.293 Pulmonary Embolism in Acute Ischaemic Stroke —Prasanna Venkatesan Eswaradass, Sadanand Dey, Dilip Singh, Michael Hill

P4.294 Early Carotid

Revascularization Reduces Readmission for Recurrent Ischemic Stroke in Acute Ischemic Stroke Patients: Analysis of United States Nationwide Readmissions Database —Saqib Chaudhry, Tariq Gheith, Shitong Gu, Mohammad-Rauf Afzal, Haseeb Rahman, Ahmed Riaz, Gautam Sachdeva, Ahsan Sattar, Anmar Razak, Adnan Qureshi

P4.295 Is Transesophageal

Echocardiogram Associated with Neurological Worsening after Ischemic Stroke? —Kevin Attenhofer, Dominique

Monlezun, Jr, Laurie Schluter, Alyana Samai, Digvijaya Navalkele, Sheryl Martin-Schild

P4.296 Recent Nationwide Trends in Transcranial Doppler Utilization During Acute Ischemic Stroke Hospitalizations —Yumei Liu, Abhishek

Lunagariya, Urvish Patel, Achint Patel, Wayne Feng, Bruce Ovbiagele

P4.297 Association of splenic

contraction and development of SIRS after acute ischemic stroke. —Alicia Zha,

Intracerebral hemorrhage Severity and Mortality —Sandro Marini, Andrea Morotti,

P4.305 Intermediate-term rates of

stroke following cardiac procedures: the Nationwide Readmissions Database —

Laura Stein, Alison Thaler, John Liang, Stanley Tuhrim, Amit Dhamoon, Mandip Dhamoon

P4.306 Self-perceived psychological stress and risk of all-cause mortality after stroke: the Mashhad Stroke Incidence Study (MSIS) —Hamidreza

Saber, Mohammad Sobhan Sheikh Andalibi, Naghmeh Mokhber, Amin Amiri, Mohammad Taghi Farzadfard, Ashkan Shoamanesh, Reza Behrouz, Mahmoud Reza Azarpazhooh

P4.307 Race/ethnic Disparities in

the Time from Stroke Symptom Onset to Hospital Arrival among Stroke Patients Arriving by EMS in the Florida-Puerto Rico Stroke Registry —Hannah Gardener,

Kefeng Wang, Chuanhui Dong, Maria Ciliberti, Carolina Gutierrez, Antonio Gandia, Peter Antevy, Wayne Hodges, Charles Sand, Angel Brotons, Jose Romano, Tatjana Rundek, Ralph Sacco

NEUROEPIDEMIOLOGY: CEREBROVASCULAR DISEASE II

Bhargav Tippinayani, Jaskaren Randhawa, Farhaan Vahidy, Sean Savitz

P4.308 Recurrence rate of Ischemic

P4.298 Analysis of current clinical

Goldanne Buenaflor

practice on initiation of anticoagulation in patients with acute ischemic stroke. — Edgar Olivas, Zahra Ajani, Janis Yao, Navdeep Sangha

stroke: A single center experience —Fasl

P4.309 No association of moon phase with stroke occurrence —Jori Ruuskanen, Jussi Sipila, Paivi Rautava, Ville Kyto

P4.299 Stroke versus non-stroke

P4.310 Delayed Cerebral

Alfredo Thomson, Jos Molina Melendres, Diego Nadile, Mara Gonzalez Toledo, Carlos Santiago Claverie, Alejandro Thomson, Margarita Peradejordi, Blas Couto, Liliana Ethel Favaloro, Roberto Favaloro, Alejandro Bertolotti, Francisco Klein

Krishna Amuluru, Rolla Nuoman, Mohammad El-Ghanem, Chirag Gandhi

neurological complications after cardiac transplant —Guido Vazquez,

P4.300 Dysautonomia and symptoms

Ischemia Secondary to Arteriovenous Malformation Rupture —Fawaz Al-Mufti,

P4.311 Obstructive Sleep Apnea

is Associated with Improved NonTraumatic Subarachnoid Hemorrhage Outcomes —Dominique Low, Mitchell Elkind

P4.312 Obstructive Sleep Apnea

P4.301 Stroke Associated

Mitchell Elkind

Kyong Jin Shin, Sam Yoel Ha

Pneumonia: The University HospitalsCleveland Medical Center experience — Hatim Attar, Colin Beilman, Cathy Sila

NEUROEPIDEMIOLOGY: CEREBROVASCULAR DISEASE I

P4.302 Probable rapid eye movement

sleep behavior disorder and risk of stroke: a prospective study —Chaoran Ma, Milena Pavlova, Yesong Liu, Ying Liu, Chunmei Huangfu, Shouling Wu, Xiang Gao

P4.303 Blacks Have Higher Risk

of 1-Year Recurrent Ischemic Stroke and Lower 30-day Case Mortality: An Analysis of White and Black Medicare

is Associated with Improved Ischemic Stroke Outcomes —Dominique Low,

P4.313 Prevalence of spasticity in

patients suffering from ischemic stroke in the internal carotid artery territory— the results of interim analysis of the national registry SONAR —Petr Kanovsky,

Tomas Dornak, Justanova Maria, Robert Jech, Martin Bares, Ladislav Dubek, Jan MuuÌk, Martina Hoskovcova, Romana Konvalinkova, Martin Srp, Michal Riha, Daniela Navratilova, Pavel Otruba

P4.314 Extrapyramidal involvement

in ALS: a prospective population-based study —Adriano Chio, Andrea Calvo, Stefania

Cammarosano, Francesca Dematteis, Carlo Alberto Artusi, Marco Pagani, Flavio Nobili, Angelina Cistaro, Michele Balma, Elisa Montanaro, Barbara Iazzolino, Maura Brunetti, Antonio Canosa, Leonardo Lopiano, Mario Rizzone

P4.315 A Survival Model for US

Patients Enrolled in the National ALS Registry Web Portal —Theodore Larson, Paul Mehta, D. Kevin Horton

P4.316 From Snow to Hill to ALS: An

odyssey in epidemiology —Carmel Armon

P4.317 Validation and continuing

development of a patient-reported survey of small-fiber polyneuropathy symptoms —Gary Zirpoli, Roi Treister, Mette

NEUROEPIDEMIOLOGY

P4.325 Gender Specific Outcomes

and Predictors of Concussion Recovery: A Single Site 15-year Ivy League Experience —Cecilia Davis-Hayes, James

Gossett, William Levine, Tanzid Shams, Jumpei Harada, Jeremy Mitnick, James Noble

P4.326 U.S. Burden of Hospital

Admissions and Utilization of Hospice Care for Patients with Malignant Brain Tumor —Benjamin George, Kylie George, Andrea Wasilewski, Nimish Mohile

P4.327 Prevalence of primary

headache disorders in Kuwait: A national study. —Jasem Al-Hashel, Samar Ahmed, Raed Alroughani

P4.328 Risk factors for developing

epilepsy in a U.S. commercially insured pediatric population —Ahyuda Oh, David Thurman, Hyunmi Kim

Lodahl, Magdalena Lang, Shlomo Sawilowsky, Eric Campbell, Shelley S. Tworoger, Anne Louise Oaklander

COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS: CLINICAL AND MRI CORRELATES

P4.318 A stratified approach for

P4.329 The Bayesian Risk Estimate at

mutational analysis delineates molecular epidemiology of early-onset SCD in the Japanese population —Yuka Hama, Masahiro Kanai, Shoko Watanabe, Hiroyuki Ishiura, Jun Mitsui, Jun Yoshimura, Koichiro Doi, Shinichi Morishita, Shoji Tsuji, Miho Murata, Yuji Takahashi

P4.319 Hearding: a new phenomenon affecting medical decision-making in Multiple Sclerosis care? —Gustavo

Saposnik, Jorge Maurino, Angel Sempere, Christian Ruff, Philippe Tobler

NEUROEPIDEMIOLOGY: MOVEMENT DISORDERS AND DEMENTIA

P4.320 Air Pollution and Risk

of Parkinson’s Disease in a Large Prospective Study of Men. —Natalia

Palacios, Kathryn Fitzgerald, Jaime Hart, Marc Weisskopf, Michael Schwarzschild, Alberto Ascherio, Francine Laden

P4.321 Well-water and risk of

Parkinson Disease: a case-control study of US Medicare beneficiaries —Maya Silver, Susan Searles Nielsen, Umber Dube, Brad Racette

P4.322 Mild Traumatic Brain Injury

Is Associated with Increased Risk of Parkinson Disease in Military Veterans: A Chronic Effects of Neurotrauma Consortium Study —Raquel Gardner, Amy Byers, Deborah Barnes, Yixia Li, John Boscardin, Kristine Yaffe

P4.323 Huntington Disease in Russia: an Epidemiological Challenge? —Yury

disease onset predicting early cognitive and physical disability in CIS and MS patients —Marianne Said, Nabil El Ayoubi, Bassem Yamout, Ribal Haddad, Leslie Saba, Youmna Jalkh, Samia Khoury

P4.330 Speeded Saccadic Eye

Movement Predicts Symbol Digit Modalities Test Performance in Multiple Sclerosis —Natali Baner, Colleen Schwarz, Michael Shaw, Rachel Nolan, Lauren Krupp, Laura Balcer, Leigh Charvet

P4.331 Improved processing speed in multiple sclerosis during fingolimod therapy: oral Symbol Digit Modalities Test response in PREFERMS —Ralph

Benedict, Douglas Arnold, Bruce Cree, Xiangyi Meng, Lesley Schofield, Fernanda Boulos, Nadia Tenenbaum

P4.332 Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS) predicts performance on instrumental activities of daily living —

Michael Shaw, Shannon Haas, Lauren Krupp, Ashley Clayton, Dawn Langdon, Leigh Charvet

P4.333 The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and Orientation Tests —Francesco Sacca, Teresa Costabile,

Antonio Carotenuto, Roberta Lanzillo, Marcello Moccia, Chiara Pane, Cinzia Valeria Russo, Anna Maria Barbarulo, Sara Casertano, Fabiana Rossi, Elisabetta Signoriello, Giacomo Lus, Vincenzo Brescia Morra

P4.334 TVA—a new technique to

detect early cognitive dysfunctions —

Seliverstov, Margarita Dranitsyna, Andrei Ivashynka, Michael Kravchenko, Sergey Klyushnikov, Sergei Illarioshkin

Wolfgang Koehler, Juergen Faiss, Martin Fischer, Frank Hoffmann, Annett Kunkel, Michael Sailer, Matthias Schwab, Erhard Stadler, Uwe Zettl, Peter Bublack

P4.324 High Prevalence of Mild

P4.335 Telerehabilitation using

Cognitive Impairment and Dementia in a social vulnerable population in Argentina: A starting point for dementia prevention. —Maria Julieta Russo, Leonardo Bartoloni, Ricardo Allegri

Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) Enhances the Benefit of At-Home Cognitive Training in Multiple Sclerosis —Bryan Dobbs, Michael Shaw, Margaret Kasschau, Ariana Frontario, Lauren Krupp, Leigh Charvet

Fast and easy registration · AAN.com/view/AM17 115

WEDNESDAY

aggravation in acute lacunar stroke —

NEUROEPIDEMIOLOGY: NEUROMUSCULAR AND MULTIPLE SCLEROSIS

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session IV



P4.336 Are cognitive deficits

P4.346 Unique Within-Network

Bublack, Juergen Faiss, Frank Hoffmann, Annett Kunkel, Michael Sailer, Matthias Schwab, Erhard Stadler, Uwe Zettl, Martin Fischer

Leavitt, James Sumowski, Christian Habeck

in MS related to cortical or whole brain atrophy—a chicken-and-egg problem? —Wolfgang Koehler, Peter

P4.337 Multiple Sclerosis: Brain

Functional Connections Characterize Memory and Information Processing Speed in Multiple Sclerosis —Victoria

P4.347 Pittsburgh compound-B PET

and MRI biomarkers of cognition in aging MS patients —Burcu Zeydan, Val Lowe,

Wednesday, April 26  8:30 a.m.—7:00 p.m. P4.358 Association of Quantitative MRI to Radiological Reporting for the Evaluation of Lesion Burden Status in Multiple Sclerosis: A Multi-Center Study —Annemie Ribbens, Thibo Billiet,

Heidi Beadnall, Manuela Vaneckova, Bianca Weinstock-Guttman, Linda Ly, Chenyu Wang, Deepa Ramasamy, Ruben Houbrechts, Niels Bergsland, Zdenek Seidl, Tomas Uher, Wim Van Hecke, Dana Horakova, Robert Zivadinov, Michael Barnett

Greif, Karl Wissemann, Lori Fafard, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Mark Gudesblatt

Scott Przybelski, Christopher Schwarz, Nirubol Tosakulwong, Samantha Zuk, Matthew Senjem, Jeffery Gunter, Rosebud Roberts, Michelle Mielke, Eduardo Benarroch, Moses Rodriguez, Mary Machulda, Timothy Lesnick, David Knopman, Ronald Petersen, Clifford Jack, Kejal Kantarci, Orhun Kantarci

P4.338 Cognitive performance in

P4.348 Extending the Concept of

Battaglini, Emilie Poirion, Mattia Veronese, Elisabeth Maillart, Federico Turkheimer, Nicola De Stefano, Bruno Stankoff

Sumowski, Maria Rocca, Victoria Leavitt, Alessandro Meani, Paolo Preziosa, Giancarlo Comi, Massimo Filippi

P4.360 Inhomogeneous

Atrophy and Computerized Cognitive Testing—A Longitudinal Investigation of Changes in Disease Impact —Eric

radiologically isolated syndrome —Anat Achiron, Maya Stern, Roi Aloni, David Magalshvili, Shay Menascu

P4.339 Thalamic functional

connectivity in Multiple Sclerosis: the role of temporal thalamic sub-region in maladaptation —Alessandro D’Ambrosio,

Reserve from Cognitive to Physical Disability in Multiple Sclerosis —James

P4.349 Multiple Sclerosis: Brain

Atrophy and Computerized Cognitive Testing—A Cross-Sectional Pilot Investigation —Eric Greif, Karl Wissemann,

Milagros Hidalgo De La Cruz, Paola Valsasina, Elisabetta Pagani, Bruno Colombo, Mariaemma Rodegher, Andrea Falini, Giancarlo Comi, Massimo Filippi, Maria Rocca

Lori Fafard, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Mark Gudesblatt

P4.340 Longitudinal Assessment of

P4.350 Cerebral regions involved

Large-Scale Brain Functional Networks in Patients with MS: Relationship with Clinical Disability and Cognitive Impairment —Fiammetta Pirro, Paola Valsasina, Annalisa Colombi, Elisabetta Pagani, Ermelinda De Meo, Bruno Colombo, Paolo Preziosa, Vittorio Martinelli, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

P4.341 Functional connectivity and

cognitive decline in MS patients- a crosssectional study —Lael Stone, Katherine Koenig, Jian Lin, Robert Bermel, Stephen Rao, Mark Lowe, Michael Phillips

P4.342 Maladaptive personality

in multiple sclerosis and its relation to cognitive status —Shumita Roy, Allison

Drake, Barbara Eizaguirre, Robert Zivadinov, Bianca Weinstock-Guttman, Ben Chapman, Ralph Benedict

P4.343 High conscientiousness

is related to less thalamic and other subcortical gray matter atrophy in multiple sclerosis —Tom Fuchs, Michael Dwyer, Niels Bergsland, Robert Zivadinov, Ralph Benedict

WEDNESDAY

P4.344 Attention and Processing

Speed Performance in Multiple Sclerosis is Mostly Related to Thalamic Volume — Alvino Bisecco, Svetlana Stamenova, Giuseppina Caiazzo, Alessandro D’Ambrosio, Rosaria Sacco, Renato Docimo, Sabrina Esposito, Mario Ciriillo, Fabrizio Esposito, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo

P4.345 Structural and Functional MRI

Predictors of Disability and Cognitive Impairment Accrual in Patients with Multiple Sclerosis —Fiammetta Pirro, Maria Rocca, Paola Valsasina, Elisabetta Pagani, Alessandro Meani, Massimiliano Copetti, Filippo Martinelli Boneschi, Vittorio Martinelli, Giancarlo Comi, Andrea Falini, Massimo Filippi

in executive dysfunctions in Multiple Sclerosis —Panagiotis Bachoumas, Pierre Branger, Caroline Harand, Gilles Defer, Nathalie Derache

P4.351 Looking into cognitive

impairment in primary-progressive MS —Maria Petracca, James Sumowski,

Michelle Fabian, Aaron Miller, Fred Lublin, Matilde Inglese

P4.352 Intra Individual Variability in

Reaction Time Is Sensitive Across the Lifespan in Multiple Sclerosis —William Pau, Michael Shaw, Rhea Patel, Margaret Kasschau, Ge Song, Lauren Krupp, Leigh Charvet

P4.353 Frontal structural connectivity is related to complex processing speed performance in relapsing-remitting multiple sclerosis. —Riccardo Manca, Micaela Mitolo, Basil Sharrack, Annalena Venneri

NEUROIMAGING I: LESIONS AND MYELIN IMAGING IN MULTIPLE SCLEROSIS

P4.354 MS lesions demonstrating a

QSM hyperintense-rim have more myelin loss compared to those without a QSM hyperintense-rim —Yihao Yao, Thanh Nguyen, Sneha Pandya, Sandra Hurtado Rua, Amy Kuceyeski, Yi Wang, Susan Gauthier

P4.355 Performance Evaluation for

Automated Lesion Segmentation Tool: Lesionquant —Weidong Luo, Kelly Leyden, Aziz Ulug, Sebastian Magda, Julia Albright, Robert Haxton, Chris Airriess

P4.356 Assessing T2 Lesion Stability Over Time in Multiple Sclerosis —Devon

Conway, Daniel Ontaneda

P4.357 Natural history of multiple sclerosis inflammatory brain lesions: a FLAIR and T1w post contrast MRI volumetric analysis —Pietro Maggi, Francesco Zellini, Alessandro Barilaro, Alessandro Passeri, Luca Massacesi

116 2017 AAN Annual Meeting Scientific Program

P4.359 Individual profiles of cortical myelin repair predict neurological disability in multiple sclerosis: a combined PET-MT approach —Marco

Magnetization Transfer (ihMT) in normal-appearing tissue correlates with disability of multiple sclerosis patients. —Elise Van Obberghen, Arnaud

Le Troter, Valentin Prevost, Samira Mchinda, Elisabeth Soulier, Patrick Viout, Gopal Varma, Maxime Guye, Jean Philippe Ranjeva, David Alsop, Olivier Girard, Guillaume Duhamel, Jean Pelletier

Sloane, Shahamat Tauhid, Fawad Yousuf, Sara Dupont, Eric Klawiter, Rohit Bakshi, Julien Cohen-Adad, Caterina Mainero

P4.366 A comprehensive assessment of cervical cord lesions in patients with multiple sclerosis on T1-MPRAGE at 3T: relationship with cord atrophy and disability —Loredana Storelli, Paola

Valsasina, Paolo Preziosa, Mohammad Aboulwafa, Mark Horsfield, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

P4.367 Structural connectivity in

multiple sclerosis and simulation of disconnection —Paolo Preziosa, Elisabetta Pagani, Ermelinda De Meo, Bruno Colombo, Vittorio Martinelli, Giancarlo Comi, Andrea Falini, Massimo Filippi, Maria Rocca

P4.368 Baseline hippocampal

subfield volumes differ in CIS patients converting to clinically defined MS: a 1 year follow-up study —Laura Cacciaguerra, Maria Rocca, Elisabetta Pagani, Sarlota Mesaros, Jelena Dackovic, Tatjana StosicOpincal, Jelena Drulovic, Massimo Filippi

P4.369 Dynamic changes of

hippocampal subfields in CIS patients: a 2-year MRI longitudinal study —Laura

P4.361 Quantitative Magnetization

Cacciaguerra, Elisabetta Pagani, Sarlota Mesaros, Jelena Dackovic, Tatjana StosicOpincal, Jelena Drulovic, Massimo Filippi, Maria Rocca

Francesca Bagnato, Simon Hametner, Subramaniam Sriram, Siddharama Pawate, Hans Lassmann, John Gore, Seth Smith, Richard Dortch

P4.370 MRI Evidence of Acute

Transfer Imaging of the Brain at 7.0 Tesla: Post Mortem Validation and in Vivo Application in Multiple Sclerosis —

NEUROIMAGING II: IMAGING BRAIN GRAY MATTER AND SPINAL CORD IN MULTIPLE SCLEROSIS

P4.362 The combined use of 3D T1-

and T2-weighted sequences improves cervical cord lesion detection in patients with multiple sclerosis: a multicenter study at 3T —Loredana Storelli, Maria Rocca, Mohammad Aboulwafa, Paola Valsasina, Paolo Preziosa, Massimiliano Copetti, Alex Rovira, Xavier Montalban, Hugh Kearney, Olga Ciccarelli, Lucy Matthews, Jacqueline Palace, Antonio Gallo, Alvino Bisecco, Carsten Lukas, Barbara Bellenberg, Giancarlo Comi, Massimo Filippi

P4.363 Repeated administrations of macrocyclic gadolinium based contrast agents in multiple sclerosis patients do not cause increased signal intensity in dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images —Arianna Sartori,

Antonio Giulio Gennari, Irene Zorzenon, Alessio Bratina, Maja Ukmar, Antonio Bosco, Maria Assunta Cova, Paolo Manganotti

P4.364 Subcortical gray matter

atrophy is predicted by white matter lesions in directly connected tracts in multiple sclerosis —Tom Fuchs, Keith

Carolus, Ralph Benedict, Niels Bergsland, Deepa Ramasamy, Robert Zivadinov, Michael Dwyer

P4.365 In vivo characterization

of grey and white matter spinal cord pathology in multiple sclerosis using ultra high field MRI —Russell Ouellette,

Tobias Granberg, Constantina Andrada Treaba, Elena Herranz, Benjamin De Leener, Jacob

Inflammation in Cortical Gray Matter of Early Multiple Sclerosis Patients —

Josefina Maranzano, David Rudko, Kunio Nakamura, Stuart Cook, Diego Cadavid, Leo Wolansky, Douglas Arnold, Sridar Narayanan

P4.371 Neuroinflammatory

component of gray matter pathology in multiple sclerosis: a combined 7T and 11C-PBR28 MR-PET imaging study —Elena Herranz, Costanza GiannÏ,

Celine Louapre, Constantina Treaba, Sindhuja Govindarajan, Russell Ouellette, Marco Loggia, Jacob Sloane, Nancy Madigan, David Izquierdo-Garcia, Noreen Ward, Gabriel Mangeat, Tobias Granberg, Eric Klawiter, Ciprian Catana, Jacob Hooker, Norma Taylor, Carolina Ionete, Revere Kinkel, Caterina Mainero

P4.372 Fingolimod-induced functional neuroplasticity in Multiple Sclerosis —

Nikolaos Petsas, Vicente González-Quintanilla, Manuela Giuliani, Floriana De Angelis, Francesca Tona, Maurizio Carmellini, Carlo Pozzilli, Patrizia Pantano

NEUROIMAGING III: MRI BRAIN ATROPHY MEASUREMENT TECHNIQUES AND ANALYSIS IN MULTIPLE SCLEROSIS

P4.373 Assessment of Brain Atrophy in Multiple Sclerosis Patients in Clinical Routine: A Multi-Center Comparison Study of Radiological and Quantitative Reports —Annemie Ribbens, Thibo Billiet,

Heidi Beadnall, Manuela Vaneckova, Bianca Weinstock-Guttman, Linda Ly, Chenyu Wang, Ellen Carl, Lene Claes, Michael Dwyer, Jan Krasensky, Tomas Uher, Dana Horakova, Wim Van Hecke, Michael Barnett, Robert Zivadinov

P4.374 Longitudinal brain atrophy measurement techniques in clinical multiple sclerosis practice using


magnetic resonance imaging —Heidi

Beadnall, Chenyu Wang, Wim Van Hecke, Annemie Ribbens, Michael Barnett

Donna Masterman, Corrado Bernasconi, Wei Wei, Hideki Garren, Peter Chin, Shibeshih Belachew, Douglas Arnold

P4.375 Detecting cerebral atrophy

P4.385 Prognostic value of early MRI

over 5 years in multiple sclerosis: application of a variety of 3T MRI automated segmentation pipelines — Renxin Chu, Gloria Kim, Shahamat Tauhid, Fariha Khalid, Brian Healy, Rohit Bakshi

follow-up for no evidence of disease activity (NEDA) after an initial diagnosis of acute disseminated encephalomyelitis (ADEM). —Diederik Koelman, Joshua Klein, David Benkeser, Farrah Mateen

P4.376 Comparison of Brain

P4.386 Multimodal EPs predict no

Nakamura, Stephen Jones, Wim Van Hecke, Douglas Arnold, Carl De Moor, Carrie Wager, Dominique Jennings, Nancy Richert, Richard Rudick, Jeffrey Cohen, Elizabeth Fisher

Mariangela Bianco, Simone Guerrieri, Giovanni Di Maggio, Marzia Romeo, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi

Atrophy Measurement Techniques in a Longitudinal Study of Multiple Sclerosis Patients with Frequent MRIs —Kunio

P4.377 The Impact of Automated

Brain Volumetric Analysis on Predicting Brain Atrophy in Patients with Multiple Sclerosis —Jia Lin, Charles Rawson, Kavita Nair, Stefan Sillau, Enrique Alvarez, Justin Honce

P4.378 Segmentation of the cerebral

deep gray matter nuclei using 3T and 7T MRI in patients with multiple sclerosis — Fawad Yousuf, Shahamat Tauhid, Shelley Hurwitz, Constantina A. Treaba, Russell Ouellette, Elena H. Muelas, Jonathan Willmer, Caterina Mainero, Rohit Bakshi

P4.379 Comparison of whole brain

atrophy assessed by proportional vs. registration-based automated pipelines from 3T MRI in multiple sclerosis —

Christopher Hemond, Renxin Chu, Subhash Tummala, Shahamat Tauhid, Brian Healy, Rohit Bakshi

P4.380 Normative Reference

Database for Lateral Ventricular Volume Change in Multiple Sclerosis Patients —

Emmanuele Ghione, Michael Dwyer, Niels Bergsland, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Deepa Ramasamy, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

P4.381 Staging of single MS patients with crossectional aquisition of global, regional and subregional brain atrophy in quantitative MRI —Alaleh Raji, Lothar Spies, Roland Opfer, Gerhard Winkler

P4.382 NeuroQuant® in clinical

practice: longitudinal observations and platform reliability and performance — Allen Nielsen, Lindsay Rosen

ventricular volume measurement on clinical routine FLAIR scans is clinically relevant even across complete scanner changes —Michael Dwyer, Niels Bergsland, Jesper Hagemeier, Dejan Jakimovski, Ivo Paunkoski, Emanuele Ghione, Rahil Ahmed, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman, Robert Zivadinov

NO EVIDENCE OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS

P4.384 Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial —Jerry Wolinsky, Xavier Montalban,

P4.387 Absolute and Relative Change in Neda After Treatment with Oral Disease Modifying Treatments in Ms Patients —Dimos Dimitrios Mitsikostas, Christina Deligianni

P4.388 Assessing no evidence of

disease activity status in patients with relapsing–remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world study —Bianca Weinstock-Guttman, Jennie Medin, Nasreen Khan, Jonathan Korn, Jennifer Price, Diego Silva, Ellen Lathi, Jason Silversteen, Keith Edwards, Robert Zivadinov

P4.389 “No evidence of disease

activity - cognition” in relapsingremitting multiple sclerosis: recommendation for an extensive assessment of disease activity —Serkan Ozakbas, Bilge Piri Cinar, Pinar Yigit, Gorkem Kosehasanogullari

P4.390 Early switch to fingolimod

for achieving no evidence of multiple sclerosis disease activity: 7-year analysis of data from the TRANSFORMS study —Jeffrey Cohen, Hans-Peter Hartung, Bhupendra Khatri, Diego Silva, Daniela Piani Meier, Shannon Ritter, Davorka Tomic, Frederik Barkhof, Ludwig Kappos, Xavier Montalban

P4.404 Revealing underlying

Pedrini, Alexandra Seewann, Wai Yan Yau, Arno Van De Bovenkamp, Ian James, Jason Burton, William Carroll, Allan Kermode

Ihtesham U Rehman, Basil Sharrack, Nicola Woodroofe

of benign multiple sclerosis in Western Australian cohort —Marzena J Fabis-

P4.395 Molecular-Based Diagnosis

of Multiple Sclerosis and Its Progressive Stages —Bibiana Bielekova, Peter Kosa,

Christopher Barbour, Mika Komori, Makoto Tanigawa, Tianxia Wu, Kory Johnson, Ronald Herbst, Yue Wang, Keith Tan, Mark Grenwood

P4.405 Gadolinium-enhanced

3D-FLAIR MRI: spectrum of pial pathology and imaging pitfalls —David Titelbaum, Renate Engisch, Eric Schwartz, Salvatore Napoli

P4.396 3D Shape and Surface

Features Contrast Multiple Sclerosis from Non-Specific White Matter Disease —Braeden Newton, Katy Wright,

Mandy Winkler, Francesca Bovis, Masaya Takahashi, Ivan Dimitrov, Maria Pia Sormani, Marco C. Pinho, Darin Okuda

P4.397 Number of OCBs in CSF at

diagnosis timepoint,—predictor of long term radiological outcome in MS? —Bjorn Evertsson, Virginija Karrenbauer, Leszek Stawiarz, Lars-Olof Wahlund, Jan Hillert, Eric Westman, Daniel Ferreira

P4.398 Differentiation of relapsing

remitting and progressive courses of multiple sclerosis on MR Spectroscopy using Machine Learning —Ziya Eksi, Muhammed Ozcan, Murat Cakiroglu, Emre Dandil, Ayse Aralasmak, Hasan Huseyin Karadeli

P4.399 Disability in the first 10 years of Relapse-onset MS is principally a product of relapses with incomplete recovery —Wisam Elmalik, Thomas Scott, Edward Gettings, Chris Hackett, Carol Schramke

P4.400 MRI characterization

of the “central vein sign” in brain white matter lesions of patients with multiple sclerosis but possible “better explanation of the diagnosis” —Matteo

Grammatico, Anna Repice, Giovanna Carlucci, Luisa Vuolo, Claudia Mechi, Alessandro Barilaro, Enrico Fainardi, Luca Massacesi

P4.391 No Evidence of Disease

P4.401 Exploring predictors for the

Hauser, William Honeycutt, Ludwig Kappos, Krzysztof Selmaj, Jerry Wolinsky, Shibeshih Belachew, Corrado Bernasconi, Regine Buffels, Hideki Garren, Wei Wei, Anthony Traboulsee

Bischof, Nico Papinutto, Carolyn Bevan, Gina Kirkish, William Stern, Alyssa Zhu, Jeffrey Gelfand, Douglas Goodin, Elizabeth Crabtree-Hartman, Jennifer Graves, Ari Green, Emmanuelle Waubant, Scott Zamvil, Bruce Cree, Stephen Hauser, Roland Henry

Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies —Eva Havrdova, Stephen

differences of NAWM from primary and secondary progressive MS —Ines Ramos,

transition from Relapsing to Secondary Progressive Multiple Sclerosis —Antje

P4.402 Assessment of clinical MULTIPLE SCLEROSIS DIAGNOSIS AND PHENOTYPE

definitions of conversion of relapsingremitting multiple sclerosis to secondary progressive multiple sclerosis —Camilo

of MS: First Empirical Test of the Recapitulation Hypothesis —Benjamin

Diaz-Cruz, Brian Healy, Alicia Chua, Shamik Bhattacharyya, Dorlan Kimbrough, Christopher Severson, James Stankiewicz, Neda Sattarnezhad, Bonnie Glanz, Howard Weiner, Tanuja Chitnis

P4.393 3T FLAIR* MRI improve

P4.403 Axonal degeneration is

P4.392 The Topographical Model

Laitman, Karin Cook, Madhuri Fletcher, Colleen Farrell, Stephen Krieger

the differentiation between multiple sclerosis and CNS vasculitis white matter lesions —Pietro Maggi, Nathan

Torcida, Niloufar Sadeghi, Julie Absil, Thierry Metens, Gaetano Perrotta, Andreas Lysandropoulos

present in benign multiple sclerosis. —

Adil Maarouf, Soraya Gherib, Fanelly Pariollaud, Maxime GUYE, Audrey Rico Lamy, Bertrand Audoin, Jean Philippe Ranjeva, Wafaa Zaaraoui, Jean Pelletier

Ludwig Kappos, Stephen Hauser, Gavin Giovannoni, Jerome De Seze, Amit Bar-Or,

Fast and easy registration · AAN.com/view/AM17 117

WEDNESDAY

P4.383 Longitudinal lateral

evidence of disease activity at two years of first line multiple sclerosis treatment —Letizia Leocani, Marco Pisa,

P4.394 A 20-year follow-up study

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session V



PARKINSON’S DISEASE: NON-MOTOR MANIFESTATIONS

P5.013 Accuracy of Placement of

P5.001 Comprehensive Identification

Deeb, Leonardo Almeida, Kelly Foote, Michael Okun

of Delusions and Olfactory, Tactile, Gustatory, and Minor Hallucinations in Parkinson’s Disease Psychosis — Catherine Kulick, Kathryn Montgomery, Melissa Nirenberg

P5.002 Gender differences in motor

and non-motor features in Parkinson’s Disease —Therese Dunne, Glenn Stebbins, Christopher Goetz, Jennifer Goldman

P5.003 Fatigue in Parkinson’s

Disease —Bhavana Patel, Rajesh Pahwa, Kelly Lyons

Deep Brain Stimulation Leads May be Better with a Staged Approach —Wissam

following Subthalamic and Pallidal deep brain stimulation for patients with Parkinson’s disease —Ahmed Abdou

of variable deep brain stimulation frequencies on static postural control in Parkinson Disease (PD) patients with Bilateral STN or GPi stimulators by employing force plate. —Aman Deep,

P5.016 INTREPID Trial: A Prospective,

Rossi, Glenn Stebbins, Brandon Barton

P5.006 Depression in newly

diagnosed Parkinson’s disease patients : a study of voxel based morphometry — Seong-il Oh, Kyong Jin Shin

P5.007 Development of dementia in a population based incidence cohort of Parkinson’s disease in Olmsted County, MN: 1991-2005 —Farwa Ali, Michelle Mielke, James Bower, Jonathan GraffRadford, J. Ahlskog, Rodolfo Savica

P5.008 Access to Emergency Care

and Outpatient Clinic Resources in Parkinson Disease with Orthostatic Hypotension. Are we missing something? —Zoe Berndt, Ricardo LopezCastellanos, Ritika Suri, Jennifer Vaughan, Aristide Merola, Alberto Espay

P5.009 Causes and outcomes of

hospitalization in dementia with Lewy bodies. —Amir Besharat, Daniel MartinezRamirez, Melissa Armstrong

P5.010 Demoralization in Parkinson Disease —Brian Koo, Christopher Chow,

Divya Shah, Farhan Khan, Danielle Derlein, Brittani Steinberg, Amar Patel, Elan Louis, John De Figueiredo

MOVEMENT DISORDERS: DEEP AND NON-INVASIVE BRAIN STIMULATION

P5.011 Deep Brain Stimulation in

Early Stage Parkinson’s Disease: LongTerm Quality of Life Outcome —Lauren

THURSDAY

Heusinkveld, Mallory Hacker, Maxim Turchan, Amanda Currie, Sarah Millan, Anna Molinari, Chandler Gill, Peter Konrad, Thomas Davis, Fenna Phibbs, Peter Hedera, David Charles

P5.012 Subthalamic Nucleus

Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis — Mallory Hacker, Maxim Turchan, Amanda Currie, Lauren Heusinkveld, Sarah Millan, Thomas Davis, Fenna Phibbs, Peter Hedera, Peter Konrad, P. Charles

F

Double blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple-Source, Constant-Current Rechargeable System in Parkinson’s Disease —Jerrold Vitek, Roshini Jain, Philip Starr

P5.017 The effect of low frequency

stimulation, with and without maintenance of the total electric energy delivered, on freezing of gait and other motor symptoms in PD patients who have freezing of gait at high frequency STN stimulation —Tao Xie, Mahesh

G

P5.145–222

P5.223–250

D

P5.015 Measurement of effect

Suzanne Moore, Max Hirshkowitz

in Parkinson’s Disease: Prevalence and Clinical Features in the Rush University Movement Disorders Clinic —Michael

E

P5.111–144

Negida, Doaa Attia

Abraham Lieberman, Rohit Dhall, Savdeep Singh

P5.005 Impulse Control Disorders

Poster Session V Neighborhoods

P5.014 Meta-analysis of mortality

P5.004 Leg Discomfort and Insomnia in Parkinson’s Disease —Aliya Sarwar,

Thursday, April 27  8:30 a.m.—7:00 p.m.

P5.101–110

Poster Discussion

C

P5.081–100

H

B

P5.251–328

P5.031–070 ePosters

P5.071–080

I

P5.329–412

Padmanaban

A

P5.018 Remotely supervised

transcranial Direct Current Stimulation in Parkinson’s disease patients —Shashank

P5.001–030

Agarwal, Natalie Pawlak, Leigh Charvet, Milton Biagioni

P5.019 DTI tractographic correlates of weight gain in Parkinson’s disease patients after STN DBS —Omar Ahmad MOVEMENT DISORDERS: OTHER II

P5.020 Movement disorders in

demyelinating diseases: a retrospective review from a tertiary academic center —Gerson Suarez-Cedeno, Raja Mehanna

P5.021 Preclinical Characterization

of SAGE-217 in a Rodent Model of Oral Dyskinesia —Gabriel Belfort, Alison Althaus, Rebecca Hammond, Michael Quirk, Michael Ackley, Michael Lewis, Albert Robichaud, James Doherty

P5.022 “Faciobrachial Dystonic

Seizures. Questioning the name paradigm” —Sahyli Perez Parra, Michael Lane, Aleksey Tadevosyan, Lara Ronan Kunschner, Mary Feldman

P5.023 Neuropathology of Spastic paraplegia-15 (SPG15) mimics that of Parkinson’s Disease —Hisatomo Kowa, Tohko Miyawaki, Maki Mitani, Naonobu Futamura, Itaru Funakawa, Kenji Jinnai

P5.024 Stiff person syndrome

masquerading as more common movement disorders —David Stone, Lesley Kaye, Meredith Wicklund, Irene Malaty

118 2017 AAN Annual Meeting Scientific Program

A: Movement Disorders B: Neurocritical Care; Neuromuscular and Clinical Neurophysiology (EMG) ePosters C: Aging and Dementia D: Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Neuro-rehabilitation; Neuro-oncology; Neuro-ophthalmology/ Neuro-otology; Neuro Trauma and Sports Neurology G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Autonomic Disorders I: MS and CNS Inflammatory Disease

P5.025 Vitamin B12 Measurements

P5.028 Hereditary Spastic

Nijee Luthra, Ariane Marcus, Nancy Hills, Chadwick Christine

Pereira, Cristina Januario

Across Neurodegenerative Disorders —

Paraplegias—experience of a tertiary center in Portugal —Joana Ribeiro, Miguel

P5.026 Genetic Testing for

P5.029 TECPR2 mutations and HSP

Machado

Adrian Turjanski, Sergio Nemirovsky, Juan Bustamante, Cesarini Martin, Alberto Espay

P5.027 FMR1, BDNF, and COMT

P5.030 NA

Beta-propeller Protein-Associated Neurodegeneration (BPAN) —Duarte

in Functional Movement Disorder Women —Emily Tharp, Maura Walsh, Bryan Bernard, Bichum Ouyang, Elizabeth BerryKravis, Deborah Hall

combined phenotype —Emilia Gatto,


NEUROCRITICAL CARE: COMA/MENTAL STATUS

P5.031 Prediction of Sedation Score using Wireless Accelerometers — Nicholas Peterson

P5.032 Probing Consciousness in

Unresponsive Wakefulness Syndrome Patients with a Vibrotactile P300-Based Brain-computer Interface —Rossella Spataro, Alexander Heilinger, Woosang Cho, Santino Marchese, Domenico De Cicco, Cesare Gregoretti, Paolo Volanti, Christoph Guger, Vincenzo La Bella

P5.033 Wakeup Call: A Retrospective Study of “Miraculous” Coma Recoveries —Eliezer Sternberg, Emad Nourollah-Zadeh, David Greer

P5.034 Temporal Shifts of the

Cerebral Autoregulation Curve in Comatose Patients with Acute Neurological Injury —Julian Sanchez-

Bautista, Wendy Ziai, Romergryko Geocadin, Charles Hogue, Marek Mirski, Lucia RiveraLara

P5.035 Comparison of hospital

utilization, hospital mortality and length of stay for patients in persistent vegetative state across different racial groups —Darine Kassar, Mohammad-Rauf

Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Alberto Maud, Rakesh Khatri, Gustavo Rodriguez, Salvador Cruz-Flores

P5.036 Resilience, Cognitive Reserve and Brain Reserve in Neurocritical Care: A Prospective Cohort Study —Neha

Dangayach, Stephen Griffiths, Rui Feng, Maggie Keogh, Vansh Sharma, Danielle Wheelwright, Deborah Marin, James Sumowski, Anthony Costa, Stanislaw Sobotka, Joshua Bederson, Jay Mocco, Errol Gordon, Stephan Mayer

P5.037 Novel quantitative imaging markers for understanding cognitive reserve in subdural hematoma (SDH) patients —Neha Dangayach, Kelly Nicol,

Stanislaw Sobotka, Stephen Griffiths, Anthony Costa, James Lee, Stephan Mayer, Jennifer Frontera, Errol Gordon, Joshua Bederson

RamÌrez, Hector Martinez, Juan Gongora Rivera, Rogelio Maya-Quintá, Joan Stephanie Celis Jasso

P5.042 EEG Can Be a Useful Tool in

Predicting Outcome in Patients with Post Cardiac Arrest Clinical Myoclonus — Omar Danoun, Maysaa Basha, Wazim Mohamed

P5.043 Isolated bilateral globus

pallidus infarcts in a patient with aortic dissection and Nitroprusside-induced hypotension: A case report —Megan Esch, Frank Diaz, Jeremy Rudnick

P5.044 National trends in utilization of Intravenous thrombolysis and endovascular treatment in acute ischemic stroke —Rakesh Khatri,

Mohammad-Rauf Afzal, Mohtashim A Qureshi, Ihtesham A Qureshi, Alberto Maud, Gustavo Rodriguez, Salvador Cruz-Flores

P5.045 Feasibility of Near Infra-

Red Spectroscopy in Blood Pressure Management Following Thrombectomy for Acute Large Vessel Occlusion Ischemic Stroke —Vasu Saini, Ashutosh Mahapatra, Kristine O’Phelan, Mohan Kottapally

P5.046 A Case of Spice use with

Subsequent Withdrawal and Posterior Reversible Encephalopathy Syndrome (PRES) —Christopher Stack

P5.047 Evaluation of a Novel

Noninvasive Cerebral Perfusion Monitor (C-Flow) After Cardiac Arrest —Charles

Francoeur, Stephen Griffiths, Danielle Wheelwright, Daniel Singer, Neha Dangayach, Errol Gordon, Anil Ramineni, Javaad Ahmad, Umesh Gidwani, Stephan Mayer

P5.048 Comparative analysis

of in-hospital outcomes between spontaneous vertebral and carotid arterial dissection at National level —

Ihtesham Qureshi, Mohammad-Rauf Afzal, Mohtashim Qureshi, Rakesh Khatri, Paisith Piriyawat, Gustavo Rodriguez, Salvador CruzFlores, Alberto Maud

NEUROCRITICAL CARE: ISCHEMIC INJURY

NEUROCRITICAL CARE: INTRACEREBRAL HEMORRHAGE

P5.038 Improving Neurologist

P5.049 International Normalized

Responsiveness For Telestroke Consultations: We Do Better! —Jeffrey

Wagner, Kristin Salottolo, Christopher Fanale, Judd Jensen, David Bar-Or

P5.039 Influence of Neurologic

Findings on the Early Transition to Less Aggressive Goals of Care after Cardiac Arrest —Glenn Schubert, David Tirschwell, Michele Olsufka, Francis Kim

unconsciousness with basilar artery (BA) occlusion —Hiroki Takano, Yohei Tanaka, Kenneth Cohen

P5.041 Acute Kidney Injury in Acute Stroke. A preliminary study in Hispanic population —Leticia Alejandra OlguÌn-

Mukarram, Norma Castillo, Andre Culpepper, Padmini Sekar, Matthew Flaherty, Andrew Ringer, Jennifer Osborne, Charles Moomaw, Carl Langefeld, Kevin Sheth, Daniel Woo

P5.050 : Herpes simplex virus (HSV)

encephalitis presenting as spontaneous intracerebral hemorrhage (ICH) —Chitra Sivasankar, Maranatha Ayodele

P5.051 Differences between the

modified rankin scale and barthel index in measuring intracerebral hemorrhage recovery at 12 months. —Anirudh Sreekrishnan, Audrey Leasure, Sonya Zhou, David Greer, Kevin Sheth

P5.061 Hemorrhagic Stroke Patients

Bentho, Neel Chari, Ashish Kulhari, Wei Xiong

Nick Thompson

Unit Non-Admission Criteria (ICHNIAC) for Patients with Intracerebral Hemorrhage —Ayham Alkhachroum, Oladi

P5.053 Treatment Patterns and

Outcomes of Patients Receiving Direct Oral Anticoagulants or Low Molecular Weight Heparin who Experienced Lifethreatening Intracranial Hemorrhage — Truman J. Milling, Charles Feronti, Carol L. Clark, Gregory J. Fermann, Shlee Song, Sam S. Torbati, Jeffrey Weiss, Dony Patel, Richey Neuman

P5.054 Reversal of Anticoagulation

Effects of Rivaroxaban and Associated Bleeding in a Rabbit Acute Hemorrhage Model by Andexanet Alfa vs. Coagulation Replacement Factors —

Genmin Lu, Polly Pine, Francis DeGuzman, Deogracias Canivel, John Malinowski, Pratikhya Pratikhya, Joyce Lin, Janet M. Leeds, John T. Curnutte, Pamela B. Conley

P5.055 Weight-based activated

prothrombin complex concentrate (FEIBA) is better than FFP alone for hematoma expansion in patients with warfarin-induced intracranial hemorrhage —Zakhar Serkin, Elizabeth

Messana, Wazim Mohamed, Suprat Wilson, Dennis Parker Jr., Mohammad Ibrahim

P5.056 Insular DWI Hyperintensities in Subdural Hematoma: A case series and pathophysiologic review —Daniel

Sacchetti, Sandra Yan, Bradford Thompson, Corey Fehnel

P5.057 Association between

Leucocyte Count and Perihematomal Edema Growth After Primary Intracerebral Hemorrhage —Aaron

Gusdon, Gino Gialdini, Hediyeh Baradaran, Alexander Merkler, Costantino Iadecola, Babak Navi, Ajay Gupta, Hooman Kamel, Santosh Murthy

P5.058 The Influence of Changes in

Barometric Pressure on the Occurrence of Primary Spontaneous Intracerebral Hemorrhage —Vishal Pandya, Sayona

Who Underwent EVD: Contemporary Mortality Trends in the National Inpatient Sample (NIS) —Gwendolyn Lynch,

P5.062 Circadian Rhythm Disruption and Severity of Impaired Arousal after Intracranial Hemorrhage —Matthew

Maas, Sabra Abbott, Eric Liotta, Bryan Lizza, Andrew Naidech, Kathy Reid, Phyllis Zee

P5.063 Prompt transition from

intravenous nicardipine to oral antihypertensives reduces resource utilization for patients with hypertensive intracerebral hemorrhage. —Omer Khayali, Cyrus Dastur, Yama Akbari, Leonid Groysman, Steven Atallah, Wengui Yu

NEUROCRITICAL CARE: SUBARACHNOID HEMORRHAGE

P5.064 SNO-Hb Levels Are

Reduced in Patients with Subarachnoid Hemorrhage —Ayham Alkhachroum, Mohammadreza Nazemian Yazdi, Amer Aldamouk, Alfred Hausladen, Jonathan Stamler, James Reynolds

P5.065 Volume of intracranial blood

is associated with occurrence of stress induced hyperglycemia after aneurysmal subarachnoid hemorrhage —Stephen Ross, David Thompson, Faranak Aghaei, Benjamin Cornwell, Dee Wu, Bin Zheng, Bappaditya Ray

P5.066 Efficacy of cilostazol in

prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized clinical trials —Hamidreza Saber, Zakhar Serkin, Mohammad Ibrahim, Wazim Mohamed, Kushak Suchdev, Maha Khan, Mahmoud Reza Azarpazhooh, Navid Seraji-Bozorgzad

P5.067 Selective Frontal Lobe

Metabolic Dysfunction after Subarachnoid Hemorrhage—Evidence for Flow-Metabolism uncoupling? —

John, George Lopez, Thomas Bleck, Max Berkelhammer, Rajeev Garg

Halinder Mangat, Jana Ivanidze, Xiangling Mao, Dikoma Shungu, Malik Fakhar, Ajay Gupta, Philip Stieg

P5.059 Andexanet Alfa for the

P5.068 Elevated ventricular CSF

Management of Acute Major Bleeding Associated with FXa Inhibitors —Stuart

Connolly, Truman J. Milling, John W. Eikelboom, C. Michael Gibson, John T. Curnutte, Alex Gold, Genmin Lu, Pamela B. Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T. Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Shelly Goodman, Janet M. Leeds, Deborah M. Siegal, Elena Zotova, Juliet Nakamya, W. Ting Lim, Mark Crowther

P5.060 Pre-existing renal failure

increases In-hospital mortality in Patients with Intracerebral hemorrhage —Mohammad-Rauf Afzal,

Rakesh Khatri, Mohtashim Qureshi, Alberto Maud, Dou Huanyu, Gustavo Rodriguez, Paisith Piriyawat, Salvador Cruz-Flores

lactate within the first week after aneurysmal subarachnoid hemorrhage is associated with poor outcome —Jackie Renfrow, Taylor Wilson, Madison Arnel, Stacey Wolfe, Sudhir Datar

P5.069 Does Intra-ICU Initiation

of Guided Mindfulness Meditation Decrease Anxiety and Depression in SAH?: A Unique Methodology for the Neurocritical Care Setting —Danielle

S. Wheelwright, Neha Dangayach, Stephen Griffiths, Errol Gordon, Joshua Bederson, Christopher Kellner, Kristine O’Phelan, Stephan Mayer

P5.070 To be or not to be: Delirium

screening for aneurysmal subarachnoid hemorrhage patients —Nicholas Panos, Micaela Ferreyra, Erum Kolsy, Sayona John

Fast and easy registration · AAN.com/view/AM17 119

THURSDAY

P5.040 Characteristics of acute

Ratio (INR) Reversal in Oral Anticoagulant-Associated Intracerebral Hemorrhage —Fernando Testai, Faisal

P5.052 Neuroscience Intensive Care

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session V



Thursday, April 27  8:30 a.m.—7:00 p.m.

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P5.071 Understanding the use of

noninvasive ventilation in the treatment of amyotrophic lateral sclerosis in the US and Europe: results of an international physician survey —Terry Heiman-Patterson, Merit Cudkowicz, Marcio De Carvalho, Angela Genge, Orla Hardiman, Caitlin Jackson, Noah Lechtzin, Hiroshi Mitsumoto, Vincenzo Silani, Stacy Rudnicki, Sarah Kulke, Jinsy Andrews, Leonard Van Den Berg

P5.072 Serial nerve ultrasound in

paediatric Guillian-Barre Syndrome —Ian Woodcock, Eppie Yiu, Monique Ryan

P5.073 Myasthenia gravis after

P5.076 Assessment of corticospinal

P5.078 Ultrasound Diagnosis of

Bob Bucelli, Arun Varadhachary

Remanan, Viktor Sukhotskiy, Mona Shahbazi, Edward Furlani, Dale Lange

Hajime Tokuno, Huned Patwa

hematopoietic stem cell transplantation: A comprehensive review —David Avila,

P5.074 Unraveling disease burden in familial ALS due to SOD1 mutation through the combination of brain and cervical cord MRI —Edoardo Spinelli,

Federica Agosta, Ivan Marjanovic, Zorica Stevic, Elisabetta Pagani, Paola Valsasina, Dragana Lavrnic, Vladimir Kostic, Massimo Filippi

tract dysfunction and disease severity in amyotrophic lateral sclerosis. —Rahul

P5.077 Mitochondrial Skeletal

and Cardiac Myopathy Responsive to Aggressive Immunosuppression in Rapidly Progressing Systemic Sclerosis —Crystal Yeo, Vivian Bunin,

Popovich Jovan, Matthew Cykowski, Robert Smith

P5.075 CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA) —Rocio Garcia

P5.081 Alzheimer’s Care Via

Telemedicine for Oregon (ACT-ON), Phase II: A Pilot Study of to-the-Home Dementia Care Via Telemedicine —Deniz

Erten-Lyons, Allison Lindauer, Katherine Mincks, Lisa Silbert, Bayard Lyons, Hiroko Dodge, Eran Klein, Ho-Yann Jong, Jeffrey Kaye

P5.082 Diagnostic flowchart of

adult-onset neuronal intranuclear inclusion disease —Jun Sone, Keiko Mori,

Haruki Koike, Tomohiko Nakamura, Michihito Masuda, Mari Yoshida, Yasushi Iwasaki, Fumiaki Tanaka, Masahisa Katsuno, Gen Sobue

P5.083 Rapidly Progressive Dementia in the Outpatient Clinic: More than Prions —Gregory Day, Erik Musiek, Gregory Alcazaren, John Morris

P5.084 A Clinical Registry of Rapidly

P5.079 A treatment classifier for

long-term follow-up of intravenous immunoglobulin therapy response. — Rahul Remanan, Pantelis Pavlakis, Mona Shahbazi, Dale Lange

P5.080 Quantification of

intramuscular blood flow with power Doppler ultrasonography in patients with small fiber neuropathy —Wei Ping Kay Ng, Alexander Dietz, Craig Zaidman

Santibanez, Alan Pestronk, Bob Bucelli

AGING AND DEMENTIA: OTHER

a Median Nerve Penetration by a Peripherally Inserted Central Catheter (PICC) Line —Arjumond Khan, Arben Brahaj,

Venugopalan Vishnu, Darakhshan Naheed, Awadh Pandit, Wilson Vinny, Manish Modi, Manoj Goyal, Vivek Lal

P5.090 Rodent models of delirium

P5.095 Tau in the nonfluent variant of

P5.086 Aerosol Exposure to

Eyal Kimchi, Brian Coughlin, Sydney Cash

Fregonara, Quentin Funk, Elijah Rockers, Neha Pal, Meixiang Yu, Bryan Spann, Paul Schulz, First Last, Joseph Masdeu

Cyanobacteria as a Potential Risk Factor for Neurological Disease —Patricia

Henegan, Angeline Andrew, Thomas Kuczmarski, Nara Michaelson, Jackson Storm, Aaron Atkinson, Brenda Waters, Jessica Crothers, Torrey Gallagher, Gregory Tsongalis, Walter Bradley, Elijah Stommel

AGING AND DEMENTIA: MODEL SYSTEMS

P5.087 Synthetic Metalloporphyrins and Resveratrol act synergistically as enhancers of cognitive performance through reduction of deposited amyloid beta and improvement of mitochondrial function in Alzheimer’s mice. —Natasa Dragicevic, Peter Zhang, Patrick Bradshaw

P5.088 Mechanisms linking amyloid

and encephalopathy: Behavioral and neurophysiological studies in aging —

P5.091 Electrical impedance

myography identifies age-associated changes in mouse gastrocnemius msucle —Rebecca Taylor, Jia Li, Carmen Shin, Marie Mortreux, Benjamin Sanchez, Janice Nagy, Seward Rutkove

primary progressive aphasia: Network involvement —Belen Pascual, Paolo Zanotti

P5.096 Anatomical Network

Degeneration in Primary Progressive Aphasia —John Medaglia, Christopher Olm, Corey McMillan, Murray Grossman

P5.092 Role of Microbiota Derived

P5.097 Comparison of

Pasinetti, Lap Ho, Kenjiro Ono, Tritia Yamasaki

Adamczuk, Michael Stepanovic, Sara Makaretz, Michael Brickhouse, Christina Caso, Megan Quimby, Rik Vandenberghe, Bradford Dickerson

Short Chain Fatty Acids in α-Synuclein Aggregation and Seeding —Giulio

P5.093 The synergy between brain

amyloidosis and hypometabolism on cognitive decline in humans and transgenic amyloid rats —Tharick Pascoal, Sulantha Mathotaarachchi, Serge Gauthier, Pedro Rosa Neto

hypometabolism and cortical atrophy in Primary Progressive Aphasia —Katarzyna

P5.098 Change in functional

organization of the speech and language network in non-fluent/agrammatic variant PPA —Maria Luisa Mandelli, Christa

ß and tau pathologies in neurons —Xiang Bai, Mel Feany

AGING AND DEMENTIA: PRIMARY PROGRESSIVE APHASIA

Watson, Jesse Brown, H Isabel Hubbard, Zachary Miller, Ariane E Welch, Bruce Miller, William Seeley, Maria Gorno Tempini

Gustavo Da Prat De Magahlaes, Virginia Laura Parisi, Gabriel Persi, Maria Bullrich, Victoria Aldinio, Emilia Gatto

P5.089 The anti-aging factor GDF11

P5.094 Alzheimer’s disease CSF

P5.099 Greater frequency of APOE E4

P5.085 Rapidly Progressive

Krolewski, Sean Buchanan, Lee Rubin

Progressive Dementia in Argentina: Towards a More Accurate Diagnosis of Autoimmune Dementias —Galeno Rojas,

Dementia: A retrospective cohort study from a tertiary care hospital —Anuja Patil,

has both direct and indirect effects on mouse neural stem cells —Richard

THURSDAY 120 2017 AAN Annual Meeting Scientific Program

profile in semantic variant of primary progressive aphasia and brain perfusion pattern —Raffaella Migliaccio, Geraldine Bera, Thibaut Michelin, Foudil Lamari, Marc Teichmann, Aurelie Kas

in logopenic variant primary progressive aphasia —Jessica Deleon, Zachary Miller,

Jennifer Yokoyama, Anna Karydas, Gil Rabinovici, Bruce Miller, Maria Gorno Tempini

P5.100 NA


Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 a.m. P5.101 Clinical and economical comparison of plasmapheresis and intravenous immunoglobulin in treating myasthenia gravis crisis: An analysis of 3808 cases from the Nationwide Inpatient Sample —Leila Darki, Said Beydoun, Nerses Sanossian, Ling Zheng, Steven Cen

Data Blitz:  11:50 a.m.–11:55 a.m. P5.102 A dedicated electrical impedance myography device in the assessment of Duchenne muscular dystrophy. —Craig Zaidman, Seward Rutkove, Julaine Florence, Anne Connolly, Brenda Wong, Michele Yang, Basil Darras, Kush Kapur, Jose Bohorquez

Data Blitz:  11:55 a.m.–12:00 p.m. P5.103 Sonomorphology in relation to functional changes in treatment-naive chronic inflammatory demyelinating

polyneuropathy: is it a continuum or spectrum of pathology? —Stephan

Goedee, Ludo Van Der Pol, Hessel Franssen, Jan-Thies Van Asseldonk, Leendert Visser, Leonard Van Den Berg

Data Blitz:  12:00 p.m.–12:05 p.m. P5.104 Electrical Impedance Myography (EIM) studies in subjects with C9ORF72 gene mutation —Michelle

OffitM.S., Tianxia Wu, Mary Kay Floeter, Tanya Lehky

Data Blitz:  12:05 p.m.–12:10 p.m. P5.105 Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) —F Schnell, C Donoghue, J Dworzak, JS Charleston, DE Frank, S Wilton, Sarah Lewis, JR Mendell, Louise RodinoKlapac, Zarife Sahenk

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG): PERIPHERAL NEUROPATHY II

P5.118 Prediabetes does not

P5.111 Ganglioside composite

P5.119 Guillain-Barré Syndrome

testing identifies immune responsive motor-onset MADSAM and MMN —

Jennifer Martinez-Thompson, Melissa Snyder, Michael Ettore, Jayawant Mandrekar, Andrew McKeon, Sean Pittock, Anthony Windebank, Christopher Klein

P5.112 Chemical Neuro Stimulation

by FLX-787, a co-activator of TRPA1/ TRPV1, for the Potential Treatment of Cramps, Spasms and Spasticity —Glenn

Short, Brooke Hegarty, Jennifer Szegda, Laura Rosen, Jennifer Cermak, Christoph Westphal, Thomas Wessel

P5.113 Molecular mechanisms of

age-dependent painful polyneuropathy in metabolic syndrome —Joe Ward, Can Zhang, Rudolph Tanzi, Hsinlin Cheng

P5.114 Predictors of motor recovery

cause small fiber neuropathy —Pariwat Thaisetthawatkul, J. Americo Fernandes, David Herrmann

Related to Zika Virus Infection in Brazil — Amilton Barreira, Wilson Marques, Alexandre Marreco, Camila De Aquino Cruz, Vanessa Marques, Danilo Lucas Alves Sposito, Taline Monteiro Klein, Bart Jacobs, Benedito Antonio Lop Fonseca, IGOS-ZIKA Study Group

P5.120 Recombinant cell-based

indirect immunofluorescence assay for the detection of IgM paraproteins in polyneuropathy —Rittika Chunder,

Christopher Linington, Francesc Graus, Lidia Sabater, Winfried Stoecker, Lars Komorowski, Christian Probst

P5.121 The Clinical Electrophysiologic and Pathologic Phenotype of Chemotherapy Induced Peripheral Neuropathy —Summer Karafiath, Noah Kolb, J. Singleton, A. Gordon Smith

P5.122 Mitochondrial ND5 mutation:

P5.115 Cranial Neuropathy in

Maria Thereza Drumond Gama, Juliana Harumi Arita, Felipe Gustavo Ravagnani, Mario Barros, Livia Rentas Sanches, FabÌola Rosa Picosse, Tania Oliveira Lopes, Patricia Aguiar, Marcos Chiaratti, Carolina Habermann Macabelli, Marcelo Rodrigues, Orlando Barsottini, Catarina Quinzii Hirano, Michio Hirano, Claudia Ferreiro-Barros

Choi, Sumit Verma, Katie Pelzek

patients with Peripheral Nerve Disorders. —Edrich Rodrigues, P. James B. Dyck, Justin Kao

P5.116 Early onset Charcot-MarieTooth disease: Clinical and genetic spectrum in a Tunisian series —Imen

Kacem, Amina Gargouri, Youssef Sidhom, Amira Nasri, Mouna Ben Djebara, Eric Leguern, Riadh Gouider

P5.117 A population-based approach to chemotherapy-induced peripheral neuropathy reveals the disease burden of early and late effects —Arya Shah, E. Hoffman, Christopher Klein, Nathan Staff

neurological improvement after CoQ10 supplementation —Jose Luiz Pedroso,

P5.123 Nerve conduction study of

sensory and motor lower limb nerves in children with type 1 diabetes mellitus attending Sudan Childhood Diabetes Center —Hana Ahmed, Nimat Abuelwafaa, Ilham Omer, Mohamed Abdullah, Ammar Ahmed, Afraa Musa

Joshua Winegar, J. Singleton, Peter Hauer, Adrienne Aperghis, A. Gordon Smith

Data Blitz:  12:15 p.m.–12:20 p.m. P5.107 Increased EEG theta spectral power in polysomnography of myotonic dystrophy type 1 compared to matched controls. —Chad Ruoff, Joe Cheung, Jennifer Perez, Sarada Sakamuri, Emmanuel Mignot, John Day, Jacinda Sampson

Data Blitz:  12:20 p.m.–12:25 p.m. P5.108 Selective network degeneration in ALS: a connectivitybased analysis of frontostriatal and cortico-basal circuitry —Peter Bede, Orla

Data Blitz:  12:25 p.m.–12:30 p.m. P5.109 Laser microdissection and proteomic analysis in the tubular aggregates myopathy. A preliminary study. —Andre Maues De Paula, Martin Krahn, Zuzana Krupova, Claudia Bevilacqua, Shahram Attarian, Marc Bartoli

Data Blitz:  12:30 p.m.–12:35 p.m. P5.110 Cumulative Distribution of Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (ALSFRS-R) Scores in a Phase 3 Study of Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment —Koji Takei, Joseph Palumbo, Kikumi Tsuda, Shawn Liu

Hardiman

P5.124 Diagnostic Challenges due

to Atypical presentations of CMT in Charcot Marie Tooth Disease type 4C associated with SH3TC2 mutations —

Nivedita Jerath, Christopher Grunseich, Hasna Baloui, Chioma Nnamdi-Emeratom, Alice Schindler, Roman Chrast, Michael Shy, Ami Mankodi

P5.125 Case Control Analysis of

Glycine Receptor Autoimmunity —Alfonso Lopez, Shannon Hinson, James Bower, Joseph Matsumoto, Anhar Hassan, Eati Basal, Vanda Lennon, Sean Pittock, Andrew McKeon

P5.126 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER): Study design and progress update —Jeffrey Allen, Mamatha Pasnoor,

Ted Burns, Senda Ajroud-Driss, Albert Cook, Thomas Brannagan, Victoria Lawson, John Ney, John Kissel, Kenneth Gorson, Richard Lewis, Timothy Walton

P5.131 Abnormal voltage-gated Na+ ion-channel function in regenerated motor fibers of aged mice —Christian

Krarup, Susana Herrero, Dragos Muraru, Mihai Moldovan

P5.132 Inflammatory diabetic

neuropathy: helpful diagnostic parameters —Pariwat Thaisetthawatkul, J.

Americo Fernandes, Ezequiel Piccione, Laetitia Truong, P. James B. Dyck

P5.133 Clinical and Laboratory

Profiles of Small Fiber Neuropathy In Children: Case Series —Ali Al Balushi, Minsoo Kim, Erik Krause, Jafar Kafaie

P5.134 Charcot-Marie-Tooth Disease in Turkey: Clinical and Genetic Findings from a Single-centre Experience —Halil

Ibrahim Akcay, Hacer Durmus, Feza Deymeer, Piraye Serdaroglu, Merve Sivaci, Ayse Candayan, Esra Battaloglu, Yesim Parman

P5.135 Assessment of

Atypical Unique Features —Monica

Neurologists Practice Patterns for Chronic Inflammatory Demyelinating Polyneuropathy: Perspectives on Diagnosis and Management —Thomas

Lavian, Namita Goyal, Tahseen Mozaffar

Finnegan, Gena Dolson

P5.128 Electrodiagnostic findings

P5.136 Coenzyme Q deficiency

Darras, Michal Vytopil

Di Meo, Giulio Kleiner, Xing-Huang Gao, Emanuele Barca, Maria J Sancez-Quintero, Saba Tadesse, Hongfeng Jiang, Changhong Qiao, Richard Rodenburg, Emmanuel Scalais, Markus Schuelke, Belinda Willard, Maria Hatzoglou, Valeria Tiranti, Catarina Quinzii Hirano

P5.127 Acquired Neuromyotonia:

in pediatric patients with winged scapula —Rajesh Gupta, Partha Ghosh, Basil

P5.129 Clinical and electrodiagnostic correlations of paraproteinemic neuropathies —Annie Daniel, Agnes JaniAcsadi

P5.130 Structural and Functional Tests of Neuropathy in Diabetes —

Christopher Gibbons, Jenniffer Garcia, Marcel Casasola, Roy Freeman

causes impairment of the sulfide oxidation pathway —Marcello Ziosi, Ivano

P5.137 Guillain-Barré Syndrome Trend of Hospital Length of Stay, Complication Rate and Mortality

Fast and easy registration · AAN.com/view/AM17 121

THURSDAY

in pediatric Acute Inflammatory Demyelinating Polyneuropathy —Jennifer

Data Blitz:  12:10 p.m.–12:15 p.m. P5.106 The Effect of Bariatric Surgery on Peripheral Nerve Regeneration —

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session V



Thursday, April 27  8:30 a.m.—7:00 p.m.

Depending from Method of the Treatment: IVIg vs. PLEX —Alexander

Ischemic Stroke Patients Receiving Thrombolytic Treatment —Muhammad

P5.162 The story of bithalamic

P5.174 Response of melanoma

P5.138 Identification of the

P5.151 Transcranial Direct Current

L Anne Hayman

P5.163 Primary and secondary

Raymond Huang, Christine Liang, Ryan Sullivan, Elizabeth Buchbinder, Elizabeth Claus, Priscilla Brastianos, Nancy Bailey, Ayal Aizer, Rifaquat Rahman, Hilary Donahue, Meredith Davis, Nageatte Ibrahim, Eudocia Lee

Mark Gilbert, Deric Park

P5.175 Are lateral cervical punctures

P5.164 A Clinical, Radiologic, and

Katherine Panageas, Adrienne Boire

Gevorgyan, Nerses Sanossian, Said Beydoun

CNTN1/CASPR complex as the target of autoantibodies in a patient with chronic inflammatory demyelinating polyneuropathy —Stephanie Kade, Christine Strippel, Bianca Teegen, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christian Probst, Christiane Radzimski, Winfried Stoecker, Nico Melzer, Lars Komorowski

P5.139 A Rare Cause of Rapidly Progressive Acute Motor Axonal Polyradiculoneuropathy —Bhavana

Sharma, Pradeep Kumbham, Kinshuk Sahaya, Appalnaidu Sasapu, Betul Gundogdu

P5.140 Contact Heat Evoked

Potential in normal subjects: is there any disparity among different Centers? —

Saleem, Adnan Qureshi

Stimulation in Post-Stroke Aphasia Rehabilitation: Bilateral vs Unilateral Online Stimulation —Angelo Torrente,

Giuseppe Giglia, Vincenzo Di Stefano, Massimo Gangitano, Tommaso Piccoli, Vanessa Costa, Brigida Fierro, Alexander T. Sack, Filippo Brighina

P5.152 Prevalence of insomnia

among stroke survivors in United States: Analysis of National Health and Nutrition Examination Surveys 2005 to 2008. —

Pathologic Review of Astroblastoma: The MD Anderson Experience —Joo Yeon Nam, Rebecca Harrison, Gregory Fuller, Jason Johnson, Barbara O’Brien

P5.165 Advanced head models

P5.153 A pilot study to examine

Markus Gramer, Steven De Vleeschouwer, Wim Van Paesschen

the effects of a multimodal sensory stimulation protocol for unilateral spatial neglect rehab in subacute MCA stroke —Janet Ebid, Tamer Emara, Ahmed

Zaki, Abdelrahman Mohammed

P5.141 Neurolymphomatosis: A

P5.154 Lower urinary tract symptoms

Vivar

gliosarcomas: clinical profile and outcomes at the National Cancer Institute —Surabhi Ranjan, Nicole Colwell,

Sher Afgan, Muhammad Saleem, Adnan Qureshi

Fernanda Herculano, Camila Pupe, Pamela Passos, Eduardo Davidovich, Bruno Pessoa, Osvaldo Nascimento

review of 82 cases —David Avila, Carolina

gliomas: A special emphasis on mass intermedia —Bhanu Gogia, Vinodh A Kumar,

and sexual dysfunction in patients with multiple sclerosis —Katarina Ivana Tudor,

to improve TMS-based motor cortex localization —Laura Seynaeve, Tom Haeck,

P5.166 Negative navigated

transcranial magnetic stimulation mapping in a patient with preoperative lower extremity weakness: A case report —Bhanu Gogia, Sujit Prabhu, Sudhakar Tummala

P5.142 Peripheral neuropathies after

Marija Bosnjak-Pasic, Hanna Pasic, Filip Mustac, Martina Doz

P5.167 Bevacizumab: is the lower

Jasem Al-Hashel, Hanaa Rashad, Doaa Youssry, Ayman Kilany, Walaa Elsayed, Adnan Khuraibet, Rossen Rousseff

P5.155 Is erectile dysfunction more

Veronique Bourg, Lydiane Mondot, Denys Fontaine, Fanny Vandenbos, Christine Lebrun Frenay

bariatric surgery: Kuwait experience —

P5.143 NA P5.144 NA CLINICAL NEURO-REHABILITATION

P5.145 Sex Disparities in Discharge

Ambulation Status after Acute Ischemic Stroke: The Florida-Puerto Rico Collaboration to Reduce Stroke Disparities (FL-PR CReSD) —Sofia Oluwole, Kefeng Wang, Chuanhui Dong, Maria CilibertiVargas, Carolina Gutierrez, Enid Garcia, Juan Carlos Zevallos, Salina Waddy, Dianne Foster, Jose Romano, Ralph Sacco, Tatjana Rundek

P5.146 Promoting network recovery after traumatic brain injury: exploring the targeted application of transcranial direct current stimulation —Lucia M Li, Ines Violante, Karl Zimmerman, Ewan Ross, Robert Leech, Adam Hampshire, David Carmichael, David Sharp

P5.147 Increased Prevalence of Early Post Stroke Depression Among Single Women after Ischemic Stroke. —Phillip

Kucab, Dana Sugar, Ramesh Madhavan, Pratik Bhattacharya

P5.148 National Estimates of

frequent among men with history of stroke: Analysis of National Health and Nutrition Examination Surveys 2001 to 2004 —Sher Afgan, Muhammad Saleem, Adnan Qureshi

P5.156 Evaluation of possible role

of repetitive transcranial magnetic stimulation for dysphagic patients with brain stem infarction. —Elsayed Tageldin, Mohamed Khalil, Wafik Bahnasy, Basem Fouda

P5.157 Harmonizing Together:

Speech and Music Therapy and Support for Patients and Partners with PPA — Megan Quimby, Joyce Shaprio-Gordon, Katherine Brandt, Caitlin Hyatt, Madeline Grimm, Lee Richardson, Kathleen Howland, Bradford Dickerson

P5.158 Posterior Reversible

Encephalopathy Syndrome Triggered by Autonomic Dysreflexia in a Spinal Cord Injury Patient —Salman Farooq, Kristin Garlanger, William Waring

P5.159 Cerebral FDG-PET Findings

in Patients with Traumatic Disorders of Consciousness: Preliminary Results of a Pilot Study —Lisandro Olmos, Maria Julieta Russo, Silvia Vazquez, Lucas Bonamico

NEURO-ONCOLOGY: GLIOMAS II

THURSDAY

Recurrent Intracranial Hemorrhage among Patients with Ruptured Intracranial Aneurysms: Effect of Treatment Modality —Adnan Qureshi,

P5.160 Cerebellar Diffuse Midline

P5.149 Characterization of pain and

Patrick Malafronte, Jeptha Johnson, Brett Theeler

Mohammad-Rauf Afzal, Saqib Chaudhry

fatigue following deployment-related mild traumatic brain injury —Jeffrey Lewis, Kristine Knutson, Eric Wassermann

P5.150 Ultra-early Institution of

Statin Treatment is Associated with Improved Outcomes Among Acute

Glioma, H3 K27M-Mutant in an Adult Patient: Case Report —Zachary Craig,

P5.161 Concurrent diagnosis of

glioblastoma (GBM), neuromyelitis optica (NMO) spectrum disorder and Progressive Multifocal Leukoencephalopathy (PML): imaging, pathology, and clinical course. —Laura

Donovan, George Zanazzi, Claire Riley, Peter Canoll, Marcus Pereira, Yazmin Odia

122 2017 AAN Annual Meeting Scientific Program

the better for glioblastoma patients in progression? —Lila Sirven-Villaros,

P5.168 Creation of a multicenter

glioblastoma ontology database: A therapy-guided analysis of genotype to phenotype relationships —Evan Noch, Yupu Liang, Mayu Frank, Cameron Coffran, Barry Coller, Robert Darnell

P5.169 Tumor Treating Fields

Distribution in Glioblastoma Volume Depends on Conductivity Parameters — Edwin Lok, Pyay San, Eric Wong

brain metastases to ipilimumab: a retrospective review. —Nancy Wang,

under-utilized? —Yoshie Umemura,

P5.176 Vismodegib Treatment

of Intracranial Invasion of Basal Cell Carcinoma —Evan Jameyfield, Nicholas Blondin

P5.177 Clinical Profile and Factors Affecting Survival in Leptomeningeal Carcinomatosis —Aashrai Gudlavalleti, Siddharth Shah, Amish Shah, Nibal Saad, Sheila Lemke

P5.178 CNS Recurrence of AML

Presenting as Cerebellitis —Edward Boyer, Thomas Rogers, Andrew Solomon

P5.179 Leptomeningeal

Myelomatosis as a rare Neurologic complication of Multiple Myeloma. —

Mina Lobbous, Sahil Gupta, Manmeet Kaur, Louis Nabors

P5.180 Seeing double: Trigeminal neurotropic melanoma as primary recurrence site, presenting as diplopia. —Neil Datta, Bhaskar Roy, Ekaterina Bakradze, David Waitzman

P5.181 Pancreatic Cancer with

Leptomeningeal Carcinomatosis: Case Presentation and Literature Review —

Adriana Perilla, Edward Melian, Michael Schneck

P5.182 Isolated Facial Nerve

Palsy Secondary to Temporal Bone Metastasis —Sangeetha Poongunam Isaac, Jason Yongsheng Chan, Yoon Sim Yap

NEURO-ONCOLOGY: BRAIN AND CNS METASTASES

P5.170 Cerebrospinal Fluid

Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors —Xuling Lin, Martin Fleisher, Marc Rosenblum, Oscar Lin, Samuel Briggs, Adrienne Boire, Yevgeniya Bensman, Brenda Hurtado, Lisa DeAngelis, Katherine Panageas, Larisa Shagabayeva, Antonio Omuro, Elena Pentsova

P5.183 A Rare Neurological

Complication of Waldenstrom’s Macroglobulinemia —Gabriel Torrealba

Acosta, Rajan Gadhia, Thabele Leslie-Mazwi

NEURO-OPHTHALMOLOGY/NEURO-OTOLOGY I

P5.184 Unilateral Optic Neuritis

And Retinal Vasculitis Due To Ocular Syphilis —Dulanji Kuruppu, Murtaza Khan, Tanav Popli, Devin Mackay

P5.171 Breast Cancer Brain

P5.185 Unilateral papilledema in

Swanson, Eric Wong

Pejman, A. Sundaram

Metastases Alter Chemokine and Cytokine Profiles in the Cerebrospinal Fluid —Johnson Fong, Edwin Lok, Kenneth

P5.172 DCE-MRI perfusion

predicts pseudoprogression in metastatic melanoma treated with immunotherapy —Yoshie Umemura, Diane

Wang, Kyung Peck, Weiji Shi, Zhigang Zhang, Robin Fatovic, Erik Anderson, Kathryn Beal, Thomas Kaley

P5.173 Recurrent breast cancer

presenting with indolent peripheral nerve metastases mimicking chronic inflammatory neuropathies: two cases. —Aditya Vuppala, Amrita Amanda Lakraj, Paul Barkhaus, M. Collins

idiopathic intracranial hypertension: a report of two cases and literature review —Emily Swinkin, Jabehdar Maralani

P5.186 Oculomotor nerve palsy by

non-aneurysm vascular compression —

Sungyang Jo, Young-Min Lim, Kwang-Kuk Kim, Hyun Jin Kim

P5.187 Isolated Inferior Rectus

Palsy as the Solitary Manifestation of Thiamine Deficiency in Patient with Diplopia —Mary-Ann Fares

P5.188 Optic Neuritis During

Pregnancy Following Tdpa Vaccination: Report of Two Cases. —Jose Maria

Cabrera Maqueda, Baidez Guerrero Ana Ester,


Rocio Hernandez Clares, Fuentes Rumi Luna, Ana Morales Ortiz, Jose Meca Lallana, Jose Javier MartÌn

P5.202 Dalfampridine Treatment in

Chang, Alan Finkel, Karen Schwab, Lisa Brenner, Scott Klimp, Henry McMillan, Ann Scher

P5.189 Castleman disease with

Robert Sergott, Benjamin Leiby

P5.215 Between Trial Reliability

Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) —Mark Moster,

follicular dendritic cell sarcoma presenting with pseudotumor cerebri and myasthenia gravis —Alexander Fein,

P5.203 Papilledema from

Alexander Hartmann, Amit Saindane, Beau Bruce, Nancy Newman, Valerie Biousse

Breedlove, Jessie Oldham, Anthony Kontos, Melissa DiFabio, Thomas Kaminski, James Clugston, Julianne Schmidt, Sara Chrisman, Ryan DeWolf, Justus Ortega, Thomas Buckley

P5.190 Ophthalmic findings in a

P5.204 Close encounter on

P5.216 Preliminary Analysis of Head

Humberto Trejo Bittar, Manisha Shende, Ernest Scalzetti, Melissa Ko

Hunter Syndrome patient on enzyme replacement therapy —Allison Jarstad, Austin Meeker, Melissa Ko

P5.191 Hemodynamic neuro-

ophthalmic complications from hemodialysis —Nailyn Rasool, Phillip

Meyers, Dean Cestari, Sara Rostanski, Roman Nowygrod, Golnaz Moazami, Jeffery Odel, Avni Patel, Benjamin Gallagher

Compression of Intracranial Venous Sinuses by Dural Meningiomas —

Thomas Buckley

P5.205 Identifying correlations

P5.217 Discordance between

Van Stavern

Cota, Ramon Diaz-Arrastia, Lawrence Latour, L. Turtzo

Felix Rosenow, Manuel Toledo, Kiyohito Terada, Ting Li, Marc De Backer, Melissa Brock, Konrad Werhahn

P5.218 Building the Four Corners

P5.229 Tolerability and efficacy of

Meeryo Choe, Philip Rosenbaum, Briana Meyer, Constance Johnson, Kristy Arbogast, Samuel Browd, Gerard Gioia, Kevin Guskiewicz, Ronni Kessler, Joseph Maldjian, Christina Master, Christopher Miles, David Popoli, Johna Register-Mihalik, Fred Rivara, Maegan Sady, Joel Stitzel, Christopher Whitlow, Christopher Giza

Robert Newton, Svetlana Dimova, Ying Zhang, Daya Chellun, Marc De Backer, Teresa Gasalla

between fluoroscopy-guided lumbar puncture and subsequent low-pressure syndrome in pseudotumor cerebri patients —Patricia Lu, Manu Goyal, Gregory

P5.206 Longitudinal Recovery of

Mohammad Humayun, Sharjeel Panjwani, Hongyan Li

P5.194 Vision Loss with Symmetric

Putaminal Lesions in Leber’s Hereditary Optic Neuropathy —Matthew Mercuri, Halina White, Cristiano Oliveira

P5.195 Swallow-Induced Eyelid

Myokymia: A Novel Synkinesis Syndrome —Amrita Amanda Lakraj, Gregory Griepentrog, Ryan Walsh

P5.196 CSF Protein in Patients with

Idiopathic Intracranial Hypertension (IIH) —Damian Berezovsky, Caroline Fajoles Vasseneix, Beau Bruce, Nancy Newman, Valerie Biousse

P5.197 Diffusion-weighted

MRI finding associated with retinal deficits. —Omar Alsinaidi, Aasef Shaikh

P5.198 Uhthoff Phenomenon and

Associated Factors in a Series of Optical Neuritis —Estefania Garcia Molina, Jose Diaz Perez, Rocio Hernandez Clares, Ester Carreon Guarnizo, Jose Maria Cabrera Maqueda, Luna Fuentes Rumi, Jose Meca Lallana

P5.199 High dose intravenous

steroids as first line treatment for severe idiopathic sudden sensorineural hearing loss —Sue Faye Siow, John Parratt, Hans Satyan, Phil Cremer

P5.200 Comparison Study of

Donny Suh, Geetanjali Rathore

P5.201 Optical Coherence

Tomography, full-field Visual Evoked Potentials and multifocal Visual Evoked Potentials to monitor and predict Optic Nerve damage and Clinical Outcome after Acute Optic Neuritis in Clinical Practice. —Simone Guerrieri, Giovanni Di

Maggio, Marco Pisa, Francesco Vitali, Roberto Santangelo, Stefania Medaglini, Lucia Moiola, Ubaldo Del Carro, Vittorio Martinelli, Giancarlo Comi, Letizia Leocani

Cerebrovascular Impairment Following Sports Related Concussion Utilizing Transcranial Doppler —Corey M. Thibeault, Seth Wilk, Shankar Radhakrishnan, Artin Sarraf, James LeVangie, Samuel Thorpe, Fabien Scalzo, Leo Petrossian, Robert Hamilton

P5.207 Magnetic Resonance

Spectroscopic Imaging at 7T (7T MRSI) abnormalities in Veterans with PTSD and mild TBI (mTBI) —Anne Van Cott, Monique Kelly, Jodi Roberts, Megan Miller, Anthony Kontos, Hoby Hetherington

P5.208 Association Between

Concussion and Lower Extremity Injuries in Collegiate Athletes —Thomas Buckley, Frances Gilbert, Barry Joyner, Trey Burdette, Tracy Llewellyn

P5.209 The relationship between

transcranial Doppler ultrasound measured pulsatility index and P2 ratio of the middle cerebral artery after sports related concussion —Samuel Thorpe, Corey Thibeault, Michael J. O’Brien, Ilyas Patanam, Nic Canac, Mina Ranjbaran, Seth Wilk, Shankar Radhakrishnan, James LeVangie, Leo Petrossian, Robert Hamilton

P5.210 History of Concussion does

not Adversely Affect Static Postural Control in Youth Ice Hockey Athletes — Jessie Oldham, Thomas Kaminski, Thomas Buckley

P5.211 Concussion Awareness

Program in High School Football Players and Coaches —Anthony Martino, Ashley

Documented Criteria for TBI and Written Emergency Department Diagnosis of TBI —Neekita Jikaria, Anita Moses, Martin

Youth Consortium (4CYC) for Brain Health in Youth Sports and Recreation —

P5.219 Utility of high-sensitivty

C Reactive Protein as Biomarker for Concussion —Shetty Teena, Aashka Dalal, Taylor Cogsil, Kelianne Cummings, Hannah Ferderber, Kristin Halvorsen, Davena Zhang, Joseph Nguyen

P5.220 Year to Year Reliability of the

King Devick Test in Collegiate StudentAthletes: An NCAA/DoD Grand Alliance Report. —Thomas Buckley, Katherine Breedlove, Jessie Oldham, Anthony Kontos, Melissa DiFabio, Thomas Kaminski, James Clugston, Julianne Schmidt, Sara Chrisman, Ryan DeWolf, Justus Ortega

P5.221 Cis p-tau directly links

traumatic brain injury with chronic traumatic encephalopathy and Alzheimer’s disease, but can be blocked by antibody —Alexander Houck, Asami Kondo, Kun Ping Lu

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CLINICAL EPILEPSY IV

P5.223 Extreme delta brush

in electroencephalogram may be nonspecific to the anti-NMDAR encephalitis. —Kanako Namekawa, Hitoshi

Marass, Mary Wilstrup

Mori, Hiromitsu Tabata, Hiroyuki Miyahara, Misako Minote, Akira Nishida, Katsuro Shindo

P5.212 Effects of Exercise on

P5.224 Ictal heart rate in focal

SCAT-3 Performance in Amateur Female Athletes —Andrew Gardner, Jean-Paul Chung Pin Yong, David Howell, Jinho Lee, Grant Iverson

epilepsy: implicancies for the heart-brain association. —Jose Molina Melendres, Blas Couto, Elena Fontela, Agustina Tamargo, Analia Calle, Alfredo Thomson

P5.213 Persistent dizziness after

P5.225 Bone health screening in

Guillermo Videla, Jorge Norscini, Liliana Patrucco, Edgardo Cristiano

Marawar, Deepti Zutshi, Aashit Shah, Maysaa Basha

mild traumatic brain injury —Ana Bisonni,

P5.214 Sensorimotor Vision

Screening in a Random Sample of Recently Deployed Soldiers With and Without a History of Mild TBI —Amy

the Epilepsy Clinic —James Bathe, Rohit

P5.226 Tolerability of Lacosamide

and Zonisamide in the treatment of elderly patients with epilepsy —Johny Nicolas, Jong Lee, Rani Sarkis

lacosamide monotherapy in patients with newly diagnosed epilepsy: A prospective randomized double-blind non-inferiority trial versus controlledrelease carbamazepine —Michel Baulac,

lacosamide monotherapy in patients with newly-diagnosed epilepsy and psychiatric comorbidities: Post hoc analysis of a prospective, randomized, double-blind trial —Bettina Schmitz, Mark

P5.230 Effectiveness of lacosamide monotherapy in clinical practice: a retrospective chart review in patients with focal seizures —Vicente Villanueva,

Beatriz Giráldez, Manuel Toledo, Gerrit-Jan De Haan, Eduardo Cumbo, Antonio Gambardella, Marc De Backer, Lars Joeres, Marcus Brunnert, Peter Dedeken, Jose Serratosa

P5.231 Outcomes following exposure to the antiepileptic drug lacosamide during pregnancy—results from a global safety database —Amanda Golembesky,

Maureen Cooney, John Craig, Christine Taeter, Azita Tofighy, Peter Dedeken

P5.232 Efficacy and tolerability of

lacosamide monotherapy in elderly patients with newly diagnosed epilepsy: subgroup analysis of a non-inferiority trial versus controlled-release carbamazepine —Felix Rosenow, Manuel Toledo, Michel Baulac, Kiyohito Terada, Ting Li, Melissa Brock, Simon Borghs, Marc De Backer, Konrad Werhahn

P5.233 Long-term safety and efficacy outcomes of adjunctive perampanel: an open-label extension (OLEx) of a Phase III study in patients with drug-resistant primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) —Robert Wechsler, Jacqueline French, Eugen Trinka, Christian Brandt, Terence O’Brien, Francesco Bibbiani, Anna Patten, Antonio Laurenza

P5.234 Perampanel (Fycompa) Use in

the Treatment of Pediatric Epilepsy —Jon Cokley, Prakash Kotagal, Jessica Hoover

P5.235 Continuity of Care With

IV Carbamazepine: A Case Report for Maintaining Treatment —Martin Brodie,

Pavel Klein, Raman Sankar, Barry Gidal, Dwain Tolbert

P5.236 A multicenter, open-label trial of ganaxolone in children with PCDH19 epilepsy —Jaakko Lappalainen, Michael Chez, Joseph Sullivan, Jozef Gecz, Nicola Specchio, Albena Patroneva

Fast and easy registration · AAN.com/view/AM17 123

THURSDAY

Ocular Fundus Examination of Pediatric Patients Using the D-EYE device and Conventional Indirect Ophthalmoscopy —Samiksha Fouzdar Jain,

P5.228 Efficacy and tolerability of

Impact Kinematics in Youth Ice Hockey —

Shabbir, Olivia Tong

dysfunction as initial manifestation of Waldenstrom Macroglobulinemia —

Baulac, Felix Rosenow, Kiyohito Terada, Ting Li, Marc De Backer, Melissa Brock, Konrad Werhahn

Braverman, Tamar Ben-Yosef

NEURO TRAUMA AND SPORTS NEUROLOGY I

P5.193 Vestibulocochlear nerve

monotherapy in patients with newly diagnosed epilepsy stratified by baseline disease severity: sub-analysis of data from a prospective non-inferiority trial versus controlled-release carbamazepine —Manuel Toledo, Michel

chromosome 14 —Sergiu Blumen, Itzhak

P5.192 Convergence spasm in

Wernicke’s encephalopathy —Syed

of the King Devick Test —Katherine

P5.227 Efficacy of lacosamide

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session V



P5.237 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Focal-Onset Seizures —Jaakko

Leopold Streletz, Hassan Al-hail, Dirk Deleu, Boulenouar Mesraoua, Gonzalo Alarcon, Ayman Al Jurdi, Ziyad Mahfoud

P5.250 NA

Lappalainen, Julia Tsai, William Amerine, Albena Patroneva

ACUTE CEREBROVASCULAR INTERVENTIONAL THERAPIES

P5.238 Bioequivalence and

P5.251 Thrombectomy Outcomes

Safety Profiles of a Novel, ExtendedRelease, High-Dosage Formulation of Levetiracetam in Healthy Adult Subjects —Yashoraj Zala, Nitin Dharmadhikari, Rama Rao

P5.239 Majority of Epileptic

Marijuana Users Perceive Decreased Seizure Frequency —Ruby Upadhyay, Bichum Ouyang, Maggie McNulty

P5.240 Burden Of Recreational And

Prescription Drugs Substance Abuse In Epilepsy And Seizure Hospitalizations. — Urvish Patel, Vishal Jani, Ram Mohan Sankaraneni, Kanishk Makhija, Abhishek Lunagariya, Jean Francois, Sanjay Singh

P5.241 Modified ketogenic diets

are likely the best option for the most refractory epilepsy patients—those who have failed epilepsy surgery —Jessica Walter, Kelly Roehl, Antoaneta Balabanov

P5.242 Do certain groups respond

better to modified ketogenic diet treatments? Evaluation of adults based on imaging abnormalities, seizure type, and diet type —Jessica Walter, Kelly Roehl, Antoaneta Balabanov

P5.243 Intravenous Immunoglobulin as a treatment for intractable epilepsy secondary to focal cortical dysplasia —

Fatema Al Amrani, Luis Bello-Espinosa, Bernard Rosenblatt, Myriam Srour, Guillaume Sebire

P5.244 Interpreting and Managing

Subjective Cognitive Dysfunction in Adult Epilepsy Clinic Patients —Lauren Gotterer, Jocelyn Bautista

P5.245 Patterns of Uses of

Antiepileptic Drugs (AEDs) in A Tertiary Neurology Clinic in Khartoum City, Sudan —Taha A-Hakam, Hassab Al Rasoul Ali

P5.246 Medical Education Improves

Knowledge Involved in Clinical Decisions Following Inadequate Response to Antiepileptic Drug Therapy —Stacey Hughes, Thomas Finnegan, Gena Dolson

P5.247 Antiepileptic drug

management in hospitalized epilepsy patients who cannot take their usual oral medications —Anna Bank, Jong Lee, Patricia Krause, Aaron Berkowitz

THURSDAY

P5.248 The incidence of movement disorders after hemispherectomy in drug resistant epilepsy in children: one center’s experience. —Sirorat

Suwannachote, Chima Oluigbo, Suresh Magge, William Gaillard, Dewi DepositarioCabacar

P5.249 Correlates of Epilepsy

Prognosis in Qatar: An Epidemiological Perspective —Fatima Al-Maadid, Naim

in Acute Ischemic Stroke due to Middle Cerebral Artery M2 Occlusion with Stent-Retriever, Aspiration, and MERCI: Multi-Center Experience —Kunakorn

Atchaneeyasakul, Amer Malik, Dileep Yavagal, Mehdi Bouslama, Diogo Haussen, Cynthia Kenmuir, Ashutosh Jadhav, Tudor Jovin, Raul Nogueira

P5.252 The Effect of Endovascular

Treatment on Outcome in Patients with Acute Ischemic Stroke Related to Isolated M2 Segment Middle Cerebral Artery Occlusion —Muhammad Saleem, Emrah Aytac, Asad Ahrar, Qureshi Adnan

P5.253 Is Endovascular Treatment

Beneficial in Acute Ischemic Stroke Patients with M2 Segment Middle Cerebral Artery Occlusion? —Emrah Aytac, Muhammad Saleem, Qureshi Adnan

P5.254 Outcomes after Endovascular Therapy in a Population with Mild Acute Ischemic Stroke and Large Vessel Occlusion: Does Treatment Help? —

Christopher Fanale, Alessandro Orlando, Donald Frei, Richard Bellon, Jeffrey Wagner, Judd Jensen, Russell Bartt, Rebecca Van Vliet, Kathryn McCarthy, David Bar-Or

P5.255 Outcomes after Endovascular

Therapy in a Population with Mild Acute Ischemic Stroke: A 6.5 Year Observational Cohort Study at a HighVolume Comprehensive Stroke Center —

Christopher Fanale, Alessandro Orlando, Donald Frei, Richard Bellon, Jeffrey Wagner, Judd Jensen, Russell Bartt, Rebecca Van Vliet, Kathryn McCarthy, David Bar-Or

P5.256 Outcomes for Endovascular

Therapy for Large Vessel Occlusion in Patients 80 years and Older —Nathaniel Wilson, James Conners, Sarah Song, Laurel Cherian

P5.257 Impact of Age on

Revascularization and Early Outcomes Post Mechanical Thrombectomy in Acute Ischemic Strokes with Large Vessel Occlusion; A single center real world data analysis —Muhammad Niazi, Mohammad El-Ghanem, Kevin Cockroft, Raymond Reichwein, David Ermak

Thursday, April 27  8:30 a.m.—7:00 p.m. P5.260 Effect size of acute

thrombectomy stroke trials: comparison of completed vs terminated early — Paisith Piriyawat, Mohammad-Rauf Afzal, Mohtashim Qureshi, Ihtesham Qureshi, Alberto Maud, Gustavo Rodriguez, Salvador Cruz-Flores

P5.261 Uncertainties of Endovascular Therapy Outside the AHA guidelines —

Amrou Sarraj, Ronald Budzik, Enrol Veznedaroglu, Joey English, Blaise Baxter, Bruno Bartolini, David Liebeskind, Antonin Krajina, Ryan Shields, Nancy Jin, Raul Nogueira, Rishi Gupta, Christine Farrell, Sean Savitz, Louise McCullough

124 2017 AAN Annual Meeting Scientific Program

Sanjeeva Onteddu, Thabele Leslie-Mazwi, Lee Schwamm

P5.273 Role of Pial Collateral Flow

in Acute Ischemic Stroke Outcomes —

Sumul Modi, Horia Marin, Panayiotis Varelas, Panayiotis Mitsias

P5.274 Validation of Safer and

Kulhari, Siddhart Mehta, Audrey Arango, Laura Suhan, Spozhmy Panezai, Jawad Kirmani

P5.263 Institution of Code

P5.275 Should Wake Up and

Laura Suhan, Audrey Arango, Siddhart Mehta, Jawad Kirmani

Ketevan Berekashvili, Amrou Sarraj, Sean Savitz, Chunyan Cai, James Grotta

Neurointervention Improves treatment times. —Ashish Kulhari, Spozhmy Panezai,

P5.264 Reducing Resource Utilization and Improving Efficiency Using A Separate Activation for Emergent Large Vessel Occlusion Ischemic Strokes — Merrick Tan, Sandhya Patel, Eduard Shaykhinurov, Mary Cres Rodrigazo, Barbara Neiswander, Shahram Majidi, Kathleen Burger, Christopher Leon-Guerrero

P5.265 Does RAPID reduce groin ®

puncture times in Acute ischemic stroke? —Haris Kamal, Noureldin Abdelhamid, Liang Zhu, Amrou Sarraj

P5.266 Transfer Patients and Patients

Presenting Directly to Endovascular Capable Centers Achieve Similar Good Outcome Rates with Endovascular Therapy —Amrou Sarraj, Enrol Veznedaroglu, Ronald Budzik, Joey English, Blaise Baxter, Bruno Bartolini, David Liebeskind, Antonin Krajina, Ryan Shields, Bin Xiang, Raul Nogueira, Spiros Blackburn, Christine Farrell, Sean Savitz, Louise McCullough, Rishi Gupta

P5.267 Circadian timing of

Unknown Time Onset Stroke Patients Be Lumped Together in Clinical Trials? —

SUBACUTE INTERVENTIONAL THERAPIES IN CEREBROVASCULAR DISEASE

P5.276 Utilization of Carotid

Revascularization for Ischemic Stroke/ TIA: A Canadian Perspective —Mohamed

Najm, Patty Lindsay, Michael Hill, Andrew Demchuk, Bijoy Menon

P5.277 Pattern of Utilization of

Carotid Endarterectomy in Acute Ischemic Stroke Patients Undergoing Early Carotid Endarterectomy According to Severity of Neurological Deficits and Infarct Size —Asad Ahrar, Qureshi Adnan, Muhammad Saleem

P5.278 Two-year Neurocognitive

Outcomes in ≥70% Asymptomatic Carotid Stenosis by Intervention or Aggressive Medical Therapy: A Multimodal Approach —Chun-Jen Lin,

Chung-Jung Lin, Feng-Chi Chang, Yu-Chen Lu, Pei-Ning Wang, I-Hui Lee

emergent large vessel occlusion and its association with efficacy of mechanical thrombectomy and patient outcomes. —

P5.279 Neurointerventional

Bakhtier Nurmukhamedov, Sameer Sharma, Hesham Masoud

Piske, Marcelo Schmid, Benedito Pereira, Renato Tosello, Ulyssses Batista, Julyne Sandes, Hennan Teixeira, Alex Baeta

P5.268 Factors correlating with

P5.280 Acute Extracranial-

Pamela Zelnick, Amrou Sarraj

Muhammad Hussain, Ken Uchino

reperfusion injury after endovascular therapy and tissue plasminogen activator for acute ischemic stroke —Jazba Soomro,

Al-Turkistani, Abeer Khoja, Mohammed Almekhlafi, Omar Ayoub

Haddad, Gayane Melikyan, Basim Uthman,

Rates of Endovascular Treatment for Patients Presenting with Acute Ischemic Stroke —Natasha Hameed, Syed Ali,

Asaithambi, Amy Castle, Lana Stein, Sandra Hanson

Kunakorn Atchaneeyasakul, Erika MarulandaLondono, Keith DeSousa, Varun Chaubal, Diego Condes, Luis Guada, Kevin Ramdas, Seemant Chaturvedi, Dileep Yavagal, Amer Malik

Thrombectomy with and without thrombolysis for acute large artery ischaemic stroke at a Tertiary Stroke Centre —Chee Keong Wee, Graeme Hankey

P5.272 Temporal Trends in the

Faster CT Imaging Technique to Assess Clot Size and Vessel Diameter in Acute Ischemic Stroke Interventions —Ashish

P5.269 Local Experience with a new

P5.259 Outcomes of Endovascular

Asad Ahrar, Saqib Chaudhry, Qureshi Adnan

Thrombectomy in Acute Ischemic Stroke: A Single-Center Experience —Ganesh

P5.262 Primary Aspiration

P5.258 Mechanical Thrombectomy in

Large Vessel Occlusion Stroke Patients with Low CT ASPECT score —Nirav Bhatt,

ischemic stroke patients. Is Bigger Better? —Ameer Hassan, Christina Sanchez,

retrievable stent (ERIC) in academic Center —Dareen AlShaer, Abduellah

P5.270 Statewide trends in

utilization of endovascular treatment and outcomes: Analysis of Minnesota Hospital Association data (2014 and 2015) —Haitham Hussein, Muhammad Saleem, Qureshi Adnan

P5.271 Comparison of 6 mm diameter and 3-4 mm diameter stent retrievers for mechanical thrombectomy in acute

management in web vessels —Ronie

Intracranial Bypass in Acutely Symptomatic Atherosclerotic Occlusion —Cory Rice, Sung Cho,

P5.281 Implications of invasive

vs non-invasive blood pressure measurements in neurointerventional procedures —Sean Pauzauskie, Ihtesham Qureshi, Mohtashim Qureshi, MohammadRauf Afzal, Alaaedin Alhomosh, Salvador Cruz-Flores, Gustavo Rodriguez

P5.282 MCA sphenoidal segment

(M1): Incidence of bifurcation within horizontal segment and relevance in mechanical thrombectomy —Mohtashim

Qureshi, Ihtesham Qureshi, Mohammad-Rauf Afzal, Salvador Cruz-Flores, Alberto Maud, Rakesh Khatri, Gustavo Rodriguez


P5.283 Correlation of Carotid

P5.295 Feasibility of Integrating

Guhan Ramamurthy, Christianne Sandhya Ravi Chandar, Lakshmi Ranganathan, Arun Shivaraman M M, Anto Nazarene, Pratheep Kumar S

Taboada, Isabelle Taboada, Amre Nouh

Arterial Bruit with Carotid Vascular Disease in Symptomatic Patients —

P5.284 High Rate of Stenosis

Progression Identified with Routine Carotid Doppler Surveillance —Angelia Kirkpatrick, Julie Stoner, Alfonso Tafur, Adrienne Elias, Calin Prodan

Post Stroke Rehabilitation and Recovery Assessments in Stroke Clinic —Susan

P5.296 Does Prior Use of Beta Blockers Affect Functional Outcomes Post Ischemic Stroke Endovascular Intervention? —Rawan Albadareen, Gary Gronseth, Manoj Mittal, Matthew Sharrock, Sanjeev Keshary, Michael Abraham

P5.309 Sympathetic skin response

and heart rate variability as a surrogate of early small fiber involvement during routine peripheral neuropathy evaluation —Rodolfo Callejas-Rojas

P5.310 HIV-associated autonomic

neuropathy: Relationship between vagal dysfunction and small intestinal bacterial overgrowth —Elizabeth Pedowitz, Alexandra Nmashie, Mary Catherine George, Sandeep Sharma, Gina Sam, Jessica Robinson Papp

P5.321 Analysis of Droxidopa for the

Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease —Lawrence Hewitt, Adam Ziemann, Italo Biaggioni, Yekaterina Dribinsky, Steven Vernino

P5.322 Sensory Neuropathic

Symptoms in Postural Tachycardia Syndrome: Insights from a CrossSectional Community-Based Survey —

P5.285 More to Atherosclerosis than

resting-state functional connectivity and structural connectivity in ischemic stroke —

P5.311 Seropositive and

Lauren Stiles, Brett H Shaw, Elizabeth A Green, Cyndya Shibao, Luis Okamoto, Emily Garland, Alfredo Gamboa, Amanda Peltier, Andre Diedrich, Italo Biaggioni, David Robertson, Satish Raj

Rai, David Thaler, Lester Leung, Neel Madan, Payam Salehi

P5.298 Association of Depression

Zhou, Naila Makhani

P5.323 Neurogenic Versus Non-

AUTONOMIC MANIFESTATIONS OF NEUROLOGIC AND SYSTEMIC DISEASE

Ah Kim, Phillip Low, David Sletten, Mariana Suarez, Paola Sandroni, Robert Fealey, Elizabeth Coon, Wolfgang Singer

Stenosis: Symptomatic Carotid Artery with Intraplaque Hemorrhage —Samhitha

P5.286 A Systematic Literature

Review of Patients with Carotid Web and Acute Ischemic Stroke. —Parth Dhruv, Jae Kim, Jonathan Koffel, David Anderson, Christopher Streib

STROKE RECOVERY AND REHABILITATION

P5.287 Race/Ethnic Disparities for

In-Hospital Mortality and Disability at Discharge after Acute Ischemic Stroke: Florida Puerto Rico Collaboration to Reduce Stroke Disparities —Marialaura

Simonetto, Hannah Gardener, Kefeng Wang, Carolina Gutierrez, Maria Ciliberti, Chuanhui Dong, Dianne Foster, Salina Waddy, Jose Romano, Tatjana Rundek, Ralph Sacco

P5.288 Acute stroke, effect on mood,

P5.297 Predicting brain atrophy from Ali Jannati, Aaron Boes, Andreas Horn, Alvaro Pascual-Leone, Amy Kuceyeski, Michael Fox

with Neuroimaging Markers of Brain Volumes and Vascular Disease: The Atherosclerosis Risk in Communities Study —Elizabeth Fracica, Myriam Fornage,

Clifford Jack, David Knopman, Thomas Mosley, Andrea Schneider, Rebecca Gottesman

P5.299 Integrity of Normal Appearing

White Matter and Functional Outcomes After Acute Ischemic Stroke —Mark Etherton, Ona Wu, Pedro Cougo, Anne-Katrin Giese, Lisa Cloonan, Kaitlin Fitzpatrick, Allison Kanakis, Gregoire Boulouis, Hasan Huseyin Karadeli, Arne Lauer, Jonathan Rosand, Karen Furie, Natalia Rost

seronegative presumed pediatric autoimmune dysautonomia: clinical features and immunotherapy —Melissa

P5.312 Idiopathic intracranial

neurogenic Orthostatic Hypotension— Practical Predictors for the Office —Hyun

hypertension and autonomic neuropathy as the heralding manifestations of neuroBehcet’s —Glen Cook, Nathan Tagg

P5.324 Development of a new

P5.313 Effects of Fingolimod on

Baker, Juan Racosta, Kurt Kimpinski

cardiovascular autonomic modulation after two years of therapy —Max J. Hilz, Ruihao

instrument to discriminate orthostatic from non-orthostatic symptoms: The Orthostatic Discriminant and Severity Scale —Jacquie

P5.325 Autonomic denervation of

Wang, Sankanika Roy, Carmen De Rojas Leal, Mao Liu, Francesca Canavese, Katharina Hosl, Klemens Winder, De-Hyung Lee, Ralf Linker

brain vessels in patients with NOH —

multi-modal feedback in chronic stroke patients —Christoph Guger, William Coon,

P5.314 A Case of Lateral Medullary

P5.326 The effect of food intake on

P5.301 The sequential and

Tridu Huynh, Barbara Decker, Ajay Tunguturi

P5.300 A motor rehabilitation BCI with James Swift, Brendan Allison, Gunter Edlinger

Infarction with Cardiovascular Autonomic Dysfunction: An Unusual Presentation —

Juan Racosta, Justin Paturel, Jacquie Baker, Kurt Kimpinski

hemodynamic response to orthostasis in patients with postural orthostatic tachycardia syndrome —Luka Crnosija,

and music therapy: a non-pharmacological intervention —Jessica Lee, Arpan Shrivastava,

P5.315 Autonomic dysfunction

Magdalena Krbot Skoric, Ivan Adamec, Mario Habek

Donglin Yan, Jessica Rushing

grammatically hierarchical recovery of receptive prosody after a right hemisphere stroke —Justin Chandler, Bogachan Sahin

P5.289 Post Stroke Fatigue in

P5.302 Acute infarct volume

Grill, Kate Grimsrud, Brent Goodman

AUTONOMIC TESTING

P5.316 Postural orthostatic

P5.327 Altered Skin Preparation

Crnosija, Tereza Gabelic, Barbara Barun, Ivan Adamec, Mario Habek

Wolfgang Singer, Paola Sandroni, Robert Fealey, Elizabeth Coon, Eduardo Benarroch, Sarah Berini, Michelle Mauermann, David Sletten, Phillip Low

P5.317 Symptoms of Autonomic

P5.328 Utility of

Mubashir Pervez, Ghazaleh Ranjbar, Gin Yau, Sherouk Sharaf, Huimahn Choi

Muppidi, Babak Razavi, Mitchell Miglis, Safwan Jaradeh

African/Caribbean Americans: Role of Stroke Severity, Depression, and Quality of Life —Alam Ahmed, Jonathan Singer, Dimitre Stefanov, Clotilde Balucani, Gregory Toy, Alisen Huang, Susan Law, Steven Levine

P5.290 Gender Differences in Post

Stroke Fatigue —Clotilde Balucani, Nadege Gilles, Jonathan Singer, Dimitre Stefanov, Douglas Halket, Jack Mlastabi, Alisen Huang, Sarah Weingast, Steven Levine

P5.291 Purpose in Life and Daytime Sleepiness in Post-Stroke Fatigue —

accounts for a small fraction of explained variance in quality of life measures at 3 months —Chen Lin, Carlos Corado, Neil Chatterjee, Timothy Carroll, Andrew Naidech, Shyam Prabhakaran

AUTONOMIC NEUROPATHIES

P5.303 Acute autonomic and sensory

neuropathy: a case series —Joel Gutierrez, Jose-Alberto Palma, Carlos MendozaSantiesteban, Horacio Kaufmann

Alisen Huang, Jonathan Singer, Clotilde Balucani, Dimitre Stefanov, Douglas Halket, Jack Mlabasati, Gregory Toy, Alam Ahmed, Nadege Gilles, Susan Law, Steven Levine

P5.304 NMDA-receptor

P5.292 Excessive Daytime Sleepiness

Dumitrascu, Andrew McKeon, Leslie Zuniga, Marie Grill, Brent Goodman

and Depression in Stroke Survivors —

Quynh Pham, Anjail Sharrief, Sean Savitz, Amrou Sarraj, Lauren Fournier, Farhaan Vahidy

P5.293 Dysphagia after stroke: State Nicole Langton-Frost, Mona Bahouth

P5.294 Enteral tube feeding in

acute ischemic stroke patients as a strong predictor of in-hospital stroke mortality —Maria Sheila Rocha, Lais

Medeiros, Maira Honorato, Luiz Fernando Oliveira, Patricia Nunes, Pablo Nascimento Oliveira, Julian Leticia Freitas, Luiz Dalfior

Dysregulation after Traumatic Brain Injury —Sophie Samuel, Monica Lee,

P5.318 Predictors of response to

P5.329 WITHDRAWN  P5.330 ASCEND Phase 3 Trial

droxidopa in patients with neurogenic orthostatic hypotension —Jose-Alberto

Palma, Carlos Mendoza-Santiesteban, Lucy Norcliffe-Kaufmann, Horacio Kaufmann

P5.319 Prospective Study of Real-

P5.306 Non Amyloidogenic Mutation of Transthyretin Associated with Autonomic Neuropathy —Todd Levine, Ruth Bland

P5.307 Spectrum of Autonomic

Dysfunction in Sjögren Syndrome —Brent Goodman, Priya Dhawan, Amy Crepeau, Julie Khoury

P5.308 A Case of Postganglionic Lourdes Bello

Electroencephalography (EEG) during Tilt Table Evaluation for Syncope —Srikanth

DISEASE MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: EFFICACY AND CLINICAL TRIAL OUTCOMES II

Palma, Jose Martinez, Miguel Perez, Horacio Kaufmann

disease with hidden tears —Jose-Alberto

Eliminates Spuriously Absent Sudomotor Axon Reflex Responses —Jeannie Corfits,

AUTONOMIC DISORDERS: ORTHOSTATIC HYPOTENSION AND POSTURAL TACHYCARDIA SYNDROME

P5.305 Familial dysautonomia: A

Cholinergic Dysautonomia Improving with Bethanechol —Bhumika Balgobin,

tachycardia predicts early conversion to multiple sclerosis after clinically isolated syndrome —Magdalena Krbot Skoric, Luka

World Outcomes in the Treatment of Neurogenic Orthostatic Hypotension With Droxidopa —Steven Kymes, Clement

Francois, Kim McLeod, Amy Duhig, Augustina Ogbonnaya, Apryl Quillen, Joan Cannon, Cyndya Shibao, Binglin Yue, Italo Biaggioni

P5.320 Norepinephrine levels

predicts the improvement in orthostatic symptoms after atomoxetine in patients with neurogenic orthostatic hypotension —Cyndya Shibao, Jose Martinez, Jose-Alberto Palma, Horacio Kaufmann, Italo Biaggioni

Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) —Hans-Peter

Hartung, Douglas Arnold, Mark Freedman, Eva Havrdova, Douglas Jeffery, Raju Kapoor, Aaron Miller, Finn Sellebjerg, Haihong Li, Nisha Lucas, Diego Cadavid, Nolan Campbell, Pei-Ran Ho, Deborah Steiner

P5.331 Cerebrospinal Fluid (CSF)

Cellular Analysis of Patients with Multiple Sclerosis (MS) Treated with Anti B-cell Therapy - Correlated with Treatment Response —Allison Liang,

Antara Finney-Stable, Jerry Lin, Saud Sadiq

Fast and easy registration · AAN.com/view/AM17 125

THURSDAY

of the science and environmental survey of a comprehensive stroke center —

Autoimmunity and OpsoclonusMyoclonus Syndrome Occurring with Rituximab Treatment of Autoimmune Autonomic Neuropathy —Oana

secondary to Whipple’s disease: a rare complication of a rare disorder —Marie

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session V



P5.332 Alemtuzumab Improves

Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNβ-1a: CARE-MS II Extension Study 4-Year Follow-up —Alexey Boyko,

Michael Barnett, David Brassat, Dominique Dive, Raymond Hupperts, Jan Lycke, Xavier Montalban, Basil Sharrack, Sibyl Wray, David Margolin, Karthinathan Thangavelu, Madalina Chirieac, Heinz Wiendl, On Behalf Of The CAR Investigators

P5.333 Neuroprotective/

neuroreparative activity of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis —Rebecca Girvan, Vicky Pearson, Masoud Hassanpour, Gill Webster

P5.334 MIS416, a myeloid targeted

immune modulator for the treatment of secondary progressive multiple sclerosis acts directly within the CNS to induce Type I IFN and suppress neuroinflammation —Reza Khorooshi, Vian Wais, Gill Webster, Trevor Owens

P5.335 Myelin water imaging

provides evidence of long-term remyelination and neuroprotection in Alemtuzumab treated multiple sclerosis patients —Irene Vavasour, Cornelia Laule, Shannon Kolind, Roger Tam, David Li, Alex McKay, Anthony Traboulsee

P5.336 Clinical and Radiologic

Benefits of Alemtuzumab Over 5 Years in Patients of African Descent With Active RRMS —Annette Okai, Keith Edwards, Brian Steingo, David Margolin, Sourav Santra, Mitzi Williams, On Behalf Of The CAR And CAMMS03409 Investigators

P5.337 Additional Efficacy Analyses from the Phase 2b SYNERGY Study Investigating the Anti-LINGO-1 Monoclonal Antibody Opicinumab for Treatment of Disabling Multiple Sclerosis —Michelle Mellion, Keith

Edwards, Raymond Hupperts, Jelena Drulovic, Xavier Montalban, Hans-Peter Hartung, Bruno Brochet, Peter Calabresi, Richard Rudick, Adama Ibrahim, Yiwei Zhang, Diego Cadavid, Lei Xu, On Behalf Of The SYNERGY Investigators

P5.338 Efficacy and Safety of

Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study —Krzysztof Selmaj, Mario Habek, Ann Bass, David Brassat, Vesna Brinar, Alasdair Coles, Anton Vladic, Sibyl Wray, David Margolin, Karthinathan Thangavelu, Madalina Chirieac, Linda Kasten, Edward Fox, On Behalf Of The CAM Investigators

THURSDAY

P5.339 Alemtuzumab Suppresses

MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active RelapsingRemitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II —Sven Schippling, Anthony

Traboulsee, Michael Barnett, Giancarlo Comi, Jerome De Seze, Gavin Giovannoni, Daniel Pelletier, Alex Rovira, David Margolin, Karthinathan Thangavelu, Douglas Arnold, On Behalf Of The CAR Investigators

P5.340 Fingolimod has diverse

effects on gene expression by differentiating human neuronal progenitors —Micheline McCarthy, Biju Issac, Alicia De Las Pozas, Rebeca Geffin

P5.341 Persistent B lymphocytes in

multiple sclerosis plaques after rituximab treatment —Siamac Esfandi, Sasan Salimian, John Corboy, Enrique Alvarez

P5.342 Improvements in Quality

of Life Over 6 Years in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab: Results From the CARE-MS II Extension Study — Rafael Arroyo Gonzalez, David Margolin, Xiaobi Huang, Hongwei Wang, Wei Zhang, Jennifer Guo, David Cella, On Behalf Of The CAR Investigators

P5.343 MRI Outcomes in Patients

Treated with Daclizumab in the EXTEND Open-Label Extension Study: Interim Report at Week 48 —Stanley Cohan,

Douglas Arnold, Ludwig Kappos, Oksana Mokliatchouk, Steven J. Greenberg, Sami Fam

P5.344 Recombinant human growth

hormone for remyelination in MS: Results of a pilot trial in patients with chronically delayed VEP —Muriel Stoppe,

Barbara Ettrich, Eva Thomae, Donald Lobsien, Juergen Kratzsch, Dirk Hasenclever, Florian Then Bergh

P5.345 Using Diffusion Tensor

Imaging to Quantify Effects of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis Patients —Jenny Feng, Jian Lin, Ken Sakaie, Sarah Planchon, Mark Lowe, Jeffrey Cohen, Daniel Ontaneda

P5.346 Tecfidera modulates short

term metabolomic signatures in people with multiple sclerosis —Constantinos

Savva, Arie Gafson, Charlie Mckechnie, Paul Matthews

P5.347 Efficacy and safety of

alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France —Xavier Ayrignac,

Nicolas Collongues, Jerome De Seze, Patrick Vermersch, Damien Biotti, David Brassat, Sandra Vukusic, Francoise Durand Dubief, Gilles Edan, Emmanuelle Lepage, Veronique Deburghgraeve, Elisabeth Maillart, Caroline Papeix, Philippe Alla, Eric Berger, Bertrand Bourre, Olivier Casez, Sophie Pittion, Marc Debouverie, Marie Theaudin, Nathalie Derache, Gilles Defer, Olivier Gout, Romain Deschamps, Ayman Tourbah, Fabien Zagnoli, Aurelie Ruet, Jean Ouallet, Bruno Brochet, Eric Manchon, Thibault Moreau, Agnes Fromont, Pierre Clavelou, Anne Marie Guennoc, JeanPhillippe Camdessanche, Antoine Carpentier, Irene Antoanela Coman, Bertrand Audoin, Jean Pelletier, Laurent Magy, Jonathan Ciron, Sandrine Wiertlevski, David Laplaud, Thomas De Broucker, Christine Lebrun Frenay, Mikael Cohen, Pierre Labauge

P5.348 Relationship between MRI

Lesion Count and B Cell Count Reduction under Ofatumumab Treatment —Marina Savelieva, Joseph Kahn, Katy Demery, David Leppert

P5.349 Durable Efficacy of

Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity

126 2017 AAN Annual Meeting Scientific Program

Thursday, April 27  8:30 a.m.—7:00 p.m. (Relapse) Between Courses 1 and 2 —

Barry Singer, Heinz Wiendl, Simon Broadley, Mark Freedman, Guillermo Izquierdo, Jan Lycke, Carlo Pozzilli, Brian Steingo, David Margolin, Sourav Santra, Karthinathan Thangavelu, Aaron Boster, On Behalf Of The CAR Investigators

P5.350 Impact of fingolimod on MRI

brain volume measures in routine clinical practice: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients —Robert Zivadinov, Nasreen Khan, Jennie Medin, Jonathan Korn, Niels Bergsland, Michael Dwyer, Jennifer Price, Diego Silva, Tanuja Chitnis, Robert Naismith, Enrique Alvarez, Peter Kinkel, Bianca Weinstock-Guttman

P5.351 Effect of the natalizumab

treatment on cererospinal fluid measures in multiple sclerosis: a longitudinal study. —Barbora Benova, Michaela

ASCEND —Gavin Giovannoni, Deborah

Steiner, Finn Sellebjerg, Stanley Cohan, Douglas Jeffery, David Rog, Yi Chen, Qunming Dong, Pei-Ran Ho, Nolan Campbell, Diego Cadavid, Diogo Amarante

P5.360 Durable Improvement in

Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNβ-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up —Celia Oreja-Guevara, Raed Alroughani, David Brassat, Alexey Boyko, Pamela McCombe, Brian Steingo, Bart Van Wijmeersch, David Margolin, Kathinathan Thangavelu, Claudio E Rodriguez, Patrick Vermersch, On Behalf Of The CAR Investigators

P5.361 Real World Effectiveness of First-Line Use of Gilenya: A Two-Site Retrospective Study —Sarah Planchon,

Andelova, Lucie Kadrnozkova, Eva Havrdova, Dana Horakova, Tomas Uher

Brandi Vollmer, Uriel Kim, Stefan Sillau, Hong Li, Radhika Rastogi, Sudarshana M Dattanand, Maria Cecilia Vieira, Kavita Nair, Daniel Ontaneda, Enrique Alvarez

P5.352 Effect of dimethyl fumarate

P5.362 Evaluation of neurological

Bergsland, Bianca Weinstock-Guttman, Deepa Ramasamy, Jackie Durfee, Maryia Cherneva, Ellen Carl, Jillian Carl, Robert Zivadinov

P5.363 Safety and Efficacy of

on gray and white matter pathology in subjects with relapsing multiple sclerosis over 24 months —Jesper Hagemeier, Niels

P5.353 Predictive biomarkers

for optimal therapeutic response to fingolimod treatment in MS patients —

Bibiana Quirant-Sanchez, Aina Teniente-Serra, Jose Vicente Hervas, Silvia Presas, M José Mansilla, Juan Navarro, Cristina Ramo, Eva Martinez-Caceres

improvements in secondary progressive multiple sclerosis patients treated with myeloid targeted immune modulator MIS416 —Gill Webster, Nancy Mayo Delayed-release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from Asia-Pacific and Other Countries: Interim Analysis of the APEX Extension Study —Takahiko Saida,

Takashi Yamamura, Takayuki Kondo, Jang Yun, Jie Li, Beverley Forsythe, Sarah Sheikh, Bing Zhu

P5.354 A two-year study using

P5.364 Cellular composition of

Yousuf, Shahamat Tauhid, Renxin Chu, Gloria Kim, Subhash Tummala, Tanuja Chitnis, Brian Healy, Rohit Bakshi

Heininger, Sandra Pleiser, Sabine Seibert, Norman Putzki, Bernd Kieseier, Orhan Aktas, Clemens Warnke, Hans-Peter Hartung

cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis —Sheena Dupuy, Fawad

P5.355 Comparing 5 year clinical-MRI relationships in two comprehensive care multiple sclerosis centers in the SUMMIT study —Rohit Bakshi, Sheena

Dupuy, Monica Bucci, Anisha Keshavan, Fariha Khalid, Gina Kirkish, Valentina Panara, Shahamat Tauhid, Fawad Yousuf, Alyssa Zhu, Howard Weiner, Stephen Hauser, Roland Henry

P5.356 Effects of Alemtuzumab

peripheral blood mononuclear cells during 4 years long-term treatment with fingolimod —Thomas Dehmel, Maximilian

P5.365 5 years safety of fingolimod in real world: First results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice —Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen

on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS) —Regina Berkovich

P5.366 Alemtuzumab; The Walton

P5.357 Progression of Whole

P5.367 Alemtuzumab Improves

Brain and Gray Matter Atrophy in Relapsing MS Despite Treatment with Natalizumab —Adil Javed, Nancy Arndt, Anthony Reder

P5.358 A potential role for

continuation of natalizumab therapy in patients with secondary progressive multiple sclerosis. —Siew Mei Yap, Nuala McNicholas, Niall Tubridy, Michael Hutchinson, Christopher McGuigan

P5.359 Sustained Disability

Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from

Centre Experience —Mona Ghadiri-Sani, Joshua Fulton, Martin Wilson

Patient-Reported Quality of Life Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients With Highly Active Disease: Results From the CARE-MS II Extension Study —Rafael Arroyo Gonzalez,

Jennifer Guo, Hongwei Wang, Wei Zhang, Denise Bury, Maria Melanson, David Cella, On Behalf Of The CAR Investigators


DISEASE MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: RISK ASSESSMENT AND SAFETY

P5.368 Reduction in JCV antibody

titers in multiple sclerosis patients treated with rituximab —Ursela Siddiqui,

Jacob Sloane, Emily Egnor, Pamela Johnson, Chamariela Mojica

P5.369 Safety and Tolerability of

Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial —Peter McCroskery, Krzysztof Selmaj, Oscar Fernandez, Luigi Maria Grimaldi, Eli Silber, Gabriel Pardo, S Freedman, Yiwei Zhang, Lei Xu, Diego Cadavid, Michelle Mellion

P5.370 Natalizumab therapy is

associated with greater variability in JC Virus Antibody levels —John Peters, Eric Williamson

P5.371 Retrospective review on

the prevalence of lymphopenia in patients aged 55 years and over taking oral disease-modifying therapies for multiple sclerosis —Clover Youn, Mary

Picone, Frederick Foley, Jeffrey Portnoy, Laura Schiraldi, Karen Blitz-Shabbir

P5.372 Dimethyl fumarate can cause

a severe reduction in CD8+ cells without causing significant total lymphopenia — Casey Spinelli, Bridget Bagert

P5.373 Dimethyl Fumarate

in Relapsing Remitting Multiple Sclerosis: Effects of Dose Reduction on Lymphopenia —Ka-Ho Wong, Erica Marini, Stacey Clardy, L DeWitt, Julia Klein, M. Paz Soldan, John Rose

P5.374 Exploratory PML risk

assessment on Extended Interval Natalizumab Dosing. —Lana Zhovtis

Ryerson, John Foley, Ilya Kister, Teresa Frohman, Krupa Pandey, Xiaochun Lu, Judith Goldberg, Guadalupe Zuniga - Estrada, Tamara Hoyt, April Jacob, Tamar Bacon, Eugene Major, Elliot Frohman

P5.375 Safety, Tolerability, and

Pharmacodynamics of Intravenous and Subcutaneous Doses of the Anti-CD52 Antibody GLD52 in Patients With Progressive MS: A Randomized, Controlled, Single Ascending Dose Trial —David Margolin, Nastaran Karimi-

Anderesi, Madalina Chirieac, Christiana Frosio, Xiaodong Luo, Andreas Hueser, Fredrik Albach, Frank-Dietrich Wagner

P5.376 Characterization of Baseline

Buckle, Daniel Bandari, Jeffrey Greenstein, Mark Gudesblatt, Bhupendra Khatri, Mariko Kita, Pavle Repovic, Emily Riser, Bianca Weinstock-Guttman, Katherine Riester, Nicholas Everage, Christian Von Hehn, Monica Mann

P5.377 Predictive Factors of

Intolerability to Dimethyl Fumarate —

Adnan Subei, Carrie Hersh, Ian Rossman, Samuel Cohn, Daniel Ontaneda, Jeffrey Cohen

Demonstrates Safety and Efficacy of Intrathecal Autologous Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs) for the Treatment of Progressive Multiple Sclerosis —Violaine Harris, James Stark, Gloria Joo, Tamara Vyshkina, Saud Sadiq

P5.379 Absolute lymphocyte count

recovery in patients with relapsingremitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension — Per Soelberg-Sorensen, Fernando Dangond, Christine Hicking, Gavin Giovannoni

P5.380 Interim Results of an

Open-Label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients with Relapsing-remitting Multiple Sclerosis — Christian Von Hehn, Devangi Mehta, Claudia Prada, Lili Yang, Shifang Liu, Soma Ray, Sarah Sheikh

P5.381 Prospective and Open label

study to compare the cardiac safety profile during first-dose monitoring period of two Fingolimod products: (Gilenya vs Generic version) in RRMS patients —Maria Curbelo, Judith Steinberg, Carlos Vrech, Domingo Garcea, Ricardo Alonso, Maria Romero, Alejandra Martinez, ALBERTO ZINNERMAN, Sergio Lindembaum

P5.389 Possible cerebral

P5.400 Symptomatic

De Mercanti, Carlo Alberto Artusi, Pierangelo Barbero, Marco Iudicello, Luca Durelli

Michelle Apperson

toxoplasmosis in a fingolimod- treated MS patient —Marinella Clerico, Stefania

P5.390 HSV Encephalitis associated

with off-label Rituximab use in a case of relapsing multiple sclerosis. —Aparna

Vaddiparti, Bharti Manwani, Catherine Hosley, Matthew Tremblay

P5.391 Absolute Lymphocyte

Count in Patients with RelapsingRemitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management —Robert Fox, Andrew Chan,

Ralf Gold, J. Theodore Phillips, Lili Yang, Shifang Liu, Claudia Prada, Soma Ray, Devangi Mehta, Catherine Miller, Monica Fay

P5.392 Dimethyl fumarate-induced

lymphopenia: effects on T-cell activation and function —Erin Longbrake, Claudia

Thrombocytopenia After One Dose of Alemtuzumab With Successful Rechallenge —Andrea Derlet, Mark Agius,

P5.401 Safety monitoring of

alemtuzumab therapy in active relapsing multiple sclerosis: necessary, manageable but resource-intensive. —

Siew Mei Yap, Luke O’Donnell, Zara Togher, Mary Dillon, Nuala McNicholas, Niall Tubridy, Michael Hutchinson, Christopher McGuigan

P5.402 Infectious diseases safety

protocol in multiple sclerosis patients treated with alemtuzumab. Real-world implementation and outcomes. —Jose Meca Lallana, Elisa Garcia Vazquez, Rocio Hernandez Clares, Ester Carreon Guarnizo, Maria Cerdan Sanchez, Estefania Garcia Molina, Jose Diaz Perez, Antonio Moreno Docon, Judith Jimenez Veiga, Jose Javier Martin Fernandez

Cantoni, Francesca Cignarella, Anne Cross, Laura Piccio

P5.403 Case report: Leukocytoclastic

P5.393 Glatiramer Acetate Induced Serum Sickness —Paul Ferguson

Keith Edwards, Cecilia Lezcano, Joel Spiro, Jessica Siuta, Samantha Belcher

P5.394 Cladribine tablets in the

P5.404 Prediction of long-term

treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program —Stuart Cook, Thomas Leist,

vasculitis in an MS patient following alemtuzumab treatment —Lore Garten,

persistency of Natalizumab anti-drug antibodies —Florian Deisenhammer, Marlies

P5.382 Title Effect of DMT’s on

Giancarlo Comi, Xavier Montalban, Elke Sylvester, Christine Hicking, Fernando Dangond

Jank, Anna Lauren, Anders Sjodin, Malin Ryner, Anna Fogdell-Hahn, Claudia Sievers, Raija Lindberg, Poul Erik Jensen, Louis Christodoulou, Mary Birchler, Michael Auer, Marc Pallardy

Napoli, Sarah Cardoso

P5.395 An examination of

P5.405 Different infusion reaktions

lymphocytes and infections —Salvatore

P5.383 Safety of Delayed-release

Dimethyl Fumarate in RelapsingRemitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results —Carlo Pozzilli, J. Theodore Phillips,

Robert Fox, Claudia Prada, Lili Yang, Catherine Miller, Monica Fay

P5.384 Clinical and Safety

Outcomes From Patients Treated With Teriflunomide in the Phase 4 Teri-PRO Study —Ralf Gold, Bhupendra Khatri, Keith

Edwards, Jose Meca Lallana, Steven Cavalier, Pascal Rufi, Myriam Benamor, Sandrine Brette, Somankumar Chowdhury, Patricia Coyle

P5.385 Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis —David Bargiela, Matt

Bianchi, M. Westover, Brian Healy, Philip De Jager, Zongqi Xia

P5.386 A Risk Aversion Calculator

lymphocyte subpopulations in MS patients on dimethyl fumarate before and after therapy coupled with analysis of JCV testing —Christopher Perrone, Eric Williamson

P5.396 Tolerability and safety

of Fingolimod in Spanish Clinical practice. Pooled Analysis data: Study Fingoview —Guillermo Izquierdo, Jose Meca

Lallana, Jose Ramon Ara, Celia Oreja-Guevara, Lucia Forero Diaz, Lucia, Javier Jose Mallada Frechin, Teresa Ayuso, Angel Sempere, Nicolás Herrera, Yessica Contreras, Izaskun Salutregui, Francisco Javier Ricart, Eli Garcia

P5.397 Effect of Extended Interval

Dose Natalizumab therapy on CD19+ and CD34+ cell mobilization from bone marrow and JC Viremia. —Lana Zhovtis Ryerson, Maria Chiara Monaco, Ilya Kister, Guadalupe Zuniga - Estrada, April Jacob, Tamar Bacon, Peter Jensen, Eugene Major

for Multiple Sclerosis Immunomodulator Selection: a Patient-Centered Approach —Fletcher Hartsell, Katherine

P5.398 A four year immunological

P5.387 EEG findings and clinico-

Luca Durelli, Simona Rolla, Stefania De Mercanti, Valentina Bardina, Angele Cucci, Daniela Taverna, Eleonora Cocco, Anton Vladic, Silva Soldo-Butkovic, Mario Habek, Ivan Adamec, Pietro Osvaldo Luigi Annovazzi, Dana Horakova, Franco Novelli, Marinella Clerico

Heller

radiographic correlation in nataluzimabassociated progressive multifocal leukoencephalopathy —Zehra Husain,

Roumen Balabanov, Miral Jhaveri, Fabian Sierra Morales, Igor Koralnik, Adriana Bermeo Ovalle

P5.388 Shared decision making

in Multiple Sclerosis: Revisiting the psychometric properties of the SDM-Q-9 questionnaire —Javier Ballesteros, Ester Moral Torres, Luis Brieva, Elena Ruiz-Beato, Daniel Prefasi, Jorge Alejandro Maurino

of two treatment schedules with alemtuzumab in patients with multiple sclerosis —Peter Von Wussow, Martin Schreiber

P5.406 Pneumonitis as an early

complication of alemtuzumab treatment —Daniel Kantor, Brian Steingo

P5.407 Safety of Ocrelizumab in

Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis —Ludwig

Kappos, Stephen Hauser, Xavier Montalban, Regine Buffels, Peter Chin, Carrie Li, Deborah Mortensen, Julie Napieralski, Johan Van Beek, David Wormser, Jerry Wolinsky

P5.408 The safety and efficacy of

Rituximab Use in Secondary-Progressive Multiple Sclerosis (SPMS) at UMMHC: five years follow up data —Idanis Berrios

Morales, Evdokia Eleftheriou, Louise Maranda, Letterio Politi, Carolina Ionete

study of responsive and non responsive MS patients after alemtuzumab to search for indications of retreatment —

P5.399 Development of an

Automated Blood Monitoring Algorithm for Alemtuzumab-Treated Patients —

Krista Barclay, Victoria Hunter, Candace Moore, Henry Deane, Stephan Mueller, Michael Gottlieb, Anthony Traboulsee, Robert Carruthers

Fast and easy registration · AAN.com/view/AM17 127

THURSDAY

Lymphocytes and Their Influence on Subsequent ALC and Lymphocyte Subset Decline in Patients with Relapsing Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate in a Retrospective, Multicenter, Observational Study (REALIZE) —Guy

P5.378 Phase I Clinical Trial

Poster Sessions

Presenters Stand by Posters 5:30 p.m.–7:00 p.m.


Poster Sessions

Poster Session VI



PARKINSON’S DISEASE: PHENOMENOLOGY, EPIDEMIOLOGY AND OBSERVATIONAL STUDIES

P6.001 ‘Advanced’ Parkinson’s

disease characteristics in clinical practice: results from the OBSERVE-PD study, a cross-sectional observational study of 2615 patients —Alfonso Fasano,

Leonardo Lopiano, Bulent Elibol, Irina G. Smolentseva, Klaus Seppi, AnnaMaria Takats, Koray Onuk, Juan Carlos Parra, Lars Bergmann, Ashley Yegin, Zvezdan Pirtosek

P6.002 Socioeconomic factors are associated with different medication side effect profiles in Parkinson’s Disease patients —Daniella Sisniega,

Divya Madhusudhan, Elham Rahmani, Robert McInnis, Janice Weinberg, Anna Hohler

P6.003 Gait Parameters Across

Parkinson’s Disease Patients Treated With Psychotropics —Daniel Martinez-

Ramirez, Janine Wolf, Leonardo Almeida, Juan Giugni, Michael Okun, Chris Hass

P6.004 Racial Disparities in

Parkinsons Disease at a Tertiary Movement Disorders Center —Chantale

Branson, Luke Quehl, Janice Weinberg, Anna Hohler, Marie-Helene Saint-Hilaire

P6.005 Patient’s Perspective of

Physicians Counseling on Exercise in Parkinson’s Disease (PD) —Jung Yeon Park, Susan Bressman, Erin Deegan, Rivka Sachdev, Rachel Saunders-Pullman, William Severt, Sarah Buckingham, Jeffrey Ratliff, Jonathan Squires, Vicki Shanker

P6.006 Through new eyes: gaze

analysis of Parkinson disease patients performing the Symbol Digit Modalities Test —Yassar Alamri, Maddie Pascoe, John Dalrymple-Alford, Tim Anderson, Michael MacAskill

P6.007 Impact of Off time on

Quality of Life and Caregiver Burden in Parkinson’s Disease —Phaedra Dowell, Kelly Lyons, Peter Schmidt, Rajesh Pahwa

P6.008 Professional exposure to

pesticides and heavy metals hastens Parkinson Disease onset —Pierre-Luc

Gamache, Noemie Roux-Dubois, Pierre Provencher, Jacques Lebouthiller, Ziv Gan-Or, Nicolas Dupre

P6.013 Clinico-neuropathological classification of Parkinson’s disease subtypes —Daniela Petrova, Michael

Hurley, Inga Prokopenko, David Dexter, Lefkos Middleton

P6.014 Comparison of Clinical

Features Among Parkinson Disease Subtypes —Takuya Konno, Maryam Ossi,

Michael Heckman, Emily Vargas, Audrey Strongosky, Owen Ross, Zbigniew Wszolek

Lauren Walter, Mary-Kate Hedrick, Connie Marras

MOVEMENT DISORDERS: TICS, TREMOR AND ATAXIA II

F

P6.145–222

Study of Antipsychotic Safety in Children with Tourette Syndrome —Tamara Pringsheim, Josephine Ho, Justyna Sarna, Tracy Hammer, Scott Patten

P6.017 Next-generation neuroactive steroid SAGE-217 in a single-ascending dose study —George Nomikos, Helen

Colquhoun, Mike Quirk, Shane Raines, James Doherty, Ethan Hoffman, Abdul Sankoh, Steve Kanes

D

Poster Discussion

C

P6.081–100

H

B

P6.251–328

P6.031–070 ePosters

P6.071–080

3 and 10 - Relation between the onset or worsening of the Ataxia with the gestational period and postpartum. —

Patricia Bonilha, Giulia Vilela, Salmo Raskin, Tetsuo Ashizawa, Helio Afonso Teive

P6.019 What are the phenotypes

of Brazilian patients with autossomal recessive spastic ataxia of CharlevoixSaguenay (ARSACS)?: Neurological, ophthalmological and neuroimaging features of seven genetically confirmed cases. —Flavio Rezende Filho, Jose Luiz

Pedroso, Fernando Kok, Marcondes Franca, Jr., Juliana Maria Sallum, Ingrid De Vasconcellos, Paola Giunti, Orlando Barsottini

P6.020 Apathy in adolescents with Tourette syndrome (TS), more than a teenager attitude —Wissam Deeb,

Matthew Hensley, Angelina Bernier, Irene Malaty

mutation in Adult-onset cerebellar ataxia —Kalyan Malgireddy, Rebecca

P6.022 Abnormal Findings in

Polisomnographic Records of Patients with Spinocerebellar Ataxia Type 2 (SCA2) —Livia Oliveira, Alessandra Zanatta,

A

P6.001–030 A: Movement Disorders B: Neuro-ophthalmology/Neuro-otology; Neurocritical Care; Aging, Dementia, Behavioral, and Cognitive Neurology ePosters C: Aging and Dementia D: Aging and Dementia Poster Discussion E: Neuromuscular and Clinical Neurophysiology (EMG) F: Neuro Trauma and Sports Neurology; Neuro-oncology; General Neurology; Behavioral and Cognitive Neurology G: Epilepsy/Clinical Neurophysiology (EEG) H: Cerebrovascular Disease and Interventional Neurology; Behavioral and Cognitive Neurology I: MS and CNS Inflammatory Disease

P6.024 A Novel Deep Brain

P6.027 An Uptick in Tics: Acute

Anhar Hassan, James Bower, Elizabeth Coon

Stimulation Programming Paradigm for Essential Tremor —Jessica Karl, Leonard

Francisco Germiniani, Anna Crippa, Helio Afonso Teive

Verhagen Metman

Schmidt

P6.011 Which Parkinson disease

P6.023 Association of Tic Disorders

Functional Capacity and Balance in Patients with Spinocerebellar Ataxias (SCAs): comparison between types 3 and 10. —Paula Marques, Katia Konno, Marise

Lynn Chouhfeh, Erik Barr, Ann Gruber-Baldini, F. Rainer Von Coelln, Lisa Shulman

P6.012 Contrast Sensitivity and

FRIDAY

Executive Dysfunction in Parkinson Disease and Healthy Older Adults —

Raima Memon, Aparajita Chakrabarty, Adeel Memon, Allen Joop, Jennifer Pilkington, Kimberly Wood, Amy Amara

I

P6.329–412

P6.018 Spinocerebellar Ataxias types

Thompson, Diego Torres-Russotto

patients are most and least active? —

G

P6.223–250

P6.101–110

P6.016 A Prospective Longitudinal

Gabi Zeilig, Meir Plotnik, Amihai Gotlieb, Rachael Kizony, Sevasti BostantjopoulouKambouroglou

Affect the Progression of Parkinson’s Disease —Amie Hiller, Joseph Quinn, Peter

E

P6.111–144

OFF periods in Parkinson’s disease: A linguistic patient-physician dialogue analysis —David Squillacote, Anna Levit,

P6.021 A novel CABC1/ADCK3

P6.010 Does Psychological Stress

Poster Session VI Neighborhoods

P6.015 Communication gaps on

P6.009 Parkinson’s disease impact

on computer use. A patients’ and caregivers’ perspective —Zoe Katsarou,

Friday, April 28  8:30 a.m.—5:30 p.m.

with Poor Academic Performance. A longitudinal, mainstream-population based study —Esther Cubo Delgado, Cristina Gonzalez-Deza, Vanesa Ausin-Villaverde, Vanesa Delgado-Benito, Sara Saez, Sara Calvo, Xose Garcia, Jose Cordero, Aikaterini Kompoliti, Elan Louis, Raquel De La Fuente

128 2017 AAN Annual Meeting Scientific Program

P6.025 Severity Assessment,

Zonta, Ana Guimaraes, Helio Afonso Teive, Francisco Germiniani

P6.026 Lateralization of fine motor

actions in Tourette syndrome persisting through adulthood —David Martino, Cecile Delorme, Elisa Pelosin, Andreas Hartmann, Julia Worbe, Laura Avanzino

Worsening of Tourette’s Syndrome on Varenicline —Shivam Mittal, Bryan Klassen,

P6.028 Treatment of Holmes Tremor

by Deep Brain Stimulation of the Prelemniscal Radiations. —Thomas Foutz, Vicente Martinez, Shu-Ching Hu, Andrew Ko

P6.029 What factors predict Fitbit

adherence in Stroke and Parkinson disease? —Katrina Schrader, Helena Mentis, Michael Phipps, Erik Barr, Ann Gruber-Baldini, Karen Yarbrough, F. Rainer Von Coelln, Lisa Shulman

P6.030 NA


NEURO-OPTHALMOLOGY/NEURO-OTOLOGY II

P6.031 pRNFL as a predictor of

medium/long term disability in MS patients —Christian Cordano, Vincent

Damotte, Michael Devereux, Nicholas Baker, Riley Bove, Carolyn Bevan, Elizabeth Crabtree-Hartman, Bruce Cree, Douglas Goodin, Jennifer Graves, Jill Hollenbach, Stephen Hauser, Roland Henry, Pierre-Antoine Gourraud, Jeffrey Gelfand, Ari Green

P6.032 Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults —Michael Ward, Nicholas Baker,

Brianne Bettcher, Jeffrey Gelfand, Yagiao Li, Robert Chen, Shubir Dutt, Bruce Miller, Joel Kramer, Ari Green

P6.033 Use of ganglion cell layer

measurements on spectral-domain optical coherence tomography as an adjunct for determining the chronicity of occipital lobe lesions —Bryan Pham, Marc Dinkin

P6.034 Bedside Optical Coherence

Tomography for Terson’s Syndrome screening in Acute Subarachnoid Hemorrhage: A pilot study —Maryo Kohen, Alireza Bozorgi, Jonathan Pace, Krishna Kandregula, Sunil Manjila, Stephanie Chen, David Malkin, Gagandeep Singh, Faruk Orge, Ciro Ramos-Estebanez

P6.035 Opposing Effects of

Huntington’s Disease on the Retina: What goes up, must come down —

Sheridan Reed, Samuel Lichtman-Mikol, Carla Santiago Martinez, Sara Razmjou, Navid Seraji-Bozorgzad, Edwin George, Omar Khan

P6.036 Mobile Universal Lexicon

Evaluation System (MULES): Pre-Season Baseline Concussion Testing for a New Measure of Rapid Picture Naming —Lucy Cobbs, Lisena Hasanaj, Nikki Webb, Julia Brandt, Prin Amorapanth, John-Ross Rizzo, Rachel Nolan, Liliana Serrano, Jenelle Raynowska, Janet Rucker, Barry Jordan, Arlene Silverio, Steven Galetta, Laura Balcer

P6.037 Gaze-Position Dependent Opsoclonus in Post-Concussive Syndrome —Alexandra J. Lloyd-Smith

Sequeira, WeiWei Dai, John-Ross Rizzo, Todd Hudson, Ivan Selesnick, David Zee, Steven Galetta, Laura Balcer, Janet Rucker

P6.038 The Validity of an Eye Tracker with Low Temporal Resolution to Assess Eye Movements during a Rapid Number Naming Task: Performance of the EyeTribe versus the EyeLink in Controls —Jenelle Raynowska, John-Ross

Rizzo, Janet Rucker, Weiwei Dai, Joel Birkemeier, Julian Hershowitz, Ivan Selesnick, Laura Balcer, Steven Galetta, Todd Hudson

P6.039 Eye Movement Underpinnings of the Mobile Universal Lexicon Evaluation System (MULES): Computerized Analysis of Rapid Picture Naming Using EyeLink —Lisena Hasanaj,

Todd Hudson, John-Ross Rizzo, Wei-Wei Dai, Janet Rucker, Steven Galetta, Laura Balcer

P6.040 Saccade Sequences and

Rapid Number Naming in Chronic Concussion —Doria Gold, Weiwei Dai,

John-Ross Rizzo, Todd Hudson, Ivan Selesnick, Lisena Hasanaj, Laura Balcer, Steven Galetta, Janet Rucker

P6.041 Characterizing Ocular Motor

Abnormalities in Patients with Vestibular Migraines and Their Response to Migraine Preventive Therapy —Stacy Smith, Shamin Masrour, Deborah Friedman, Shin Beh

P6.051 Video head impulse test

P6.062 Monitoring Intracranial

Toker, Jorge Kattah

Verma, Raj Kamal

for follow up of cranial nerve 3, 4, or 6 paresis —Ali Saber Tehrani, David NewmanNEUROCRITICAL CARE: BRAIN DEATH/ORGAN DONATION

P6.052 Role Of Sulfonylureas In

Perihematomal Edema In Spontaneous Intracerebral Hemorrhage —Shailesh

Male, Jetter Robertson, Mohammed Alkuwaiti, Caitlin Bell, Donna Lindsay, Rwoof Reshi, Mustapha Ezzeddine, Christopher Streib

P6.053 Brain Death

Determination—a dataset analysis in Parana State Between 2013-2015 — Marlon Caeira, Francisco Germiniani, José Rodrigues, Carlos Silvado

pressure (ICP) in Severe Traumatic brain Injury decreases Mortality —Himanshu

P6.063 Sinking Skin Flap Syndrome

Presenting with Cranial Neuropathies —

Vanessa Tiongson, Nina Kim, Scott Grossman, Sujata Thawani

P6.064 Dynamic interaction between EEG and ICP: a pilot study based on wavelet coherence —Claudia Perez,

Fenghua Tian, DaiWai Olson, Venkatesh Aiyagari, Sonja Stutzman, Jennifer Griffin, Junaid Kalia, Rong Zhang, Kan Ding

P6.065 Ventricular Catheter Tract Hemorrhage as a Risk Factor for Ventriculostomy Related Infection —

P6.042 A Retrospective Case

P6.054 From diagnosis of brain death

Juhyun Kim, Rui Feng, Alexander Chartrain, Stanislaw Sobotka, Neha Dangayach, Stephan Mayer, Errol Gordon

Londono, Ali Tehrani, Jorge Kattah

Caeira, Francisco Germiniani, José Rodrigues, Carlos Silvado

NEUROCRITICAL CARE: EPILEPSY AND SEIZURES

P6.043 Gentamicin vestibulotoxicity

P6.055 Reliability of Brain flow SPECT

P6.066 Predictors of Outcome

Smyth, Stuart Mossman, Mark Weatherall, Evan Jolliffe, Jennifer Taylor, Purwa Joshi, Katie Thorne, Eloise Watson, Ruth Leadbetter, Benjamin Mossman, Tawhai Moss, Erich Schneider, Nick Todd

Ramdani, Elena Schmidt, Julius Latorre

Basha, Deepti Zutshi, Navid Seraji-Bozorgzad, Mohammad Ibrahim

Study Characterizing the Oculomotor Abnormalities in Patient with Immunemediated Cerebellar Ataxias —Diana

is uncommon with modern dosing regimens: a prospective study using video head impulse testing —Duncan

P6.044 Increased uncertainty about the direction of gravity in bilateral vestibulopathy correlates with residual utricular function —Alexander Tarnutzer, Christopher Bockisch, Aline Buergin

P6.045 Central positional vertigo — Duilio De Schutter, Jorge Kattah

P6.046 Maintenance home-based

neuromodulation therapy with tDCS after induction treatment with rTMS for mal de debarquement syndrome —YoonHee Cha, Diamond Urbano, Nicole Pariseau

P6.047 Role of pulse wave velocity

for the diagnosis of dizziness or vertigo due to stroke —Bang-Hoon Cho, Sung-Sik Kim, Seung-Han Lee, Man Seok Park

P6.048 Theta burst stimulation for

mal de debarquement syndrome —YoonHee Cha, Diamond Urbano, Guofa Shou, Han Yuan, Lei Ding

P6.049 What’s behind cerebellar dizziness? —Katharina Feil, Alexander

Schindler, Siegbert Krafczyk, Florian Schoeberl, Andreas Zwergal, Michael Strupp

P6.050 Central positional nystagmus due to cerebellar PICA infarctions — Wolfgang Heide, Johannes Pollak

to organ procurement - Analysis of data on Parana - Brazil - 2013 to 2015 —Marlon

scan in excluding Brainstem perfusion: A case of false positive Brain SPECT in a diagnosis of brain Death. —Wyssem

P6.056 The attitude of healthcare

providers toward brain death and organ donation —Dareen AlShaer, Emad Fadel,

Abdulaziz Almakfour, Ali Sonbaa, Omar Ayoub

P6.057 Consent rate for organ

donation after Brain Death: a single center experience over 11 years. —

Mohammed Kananeh, Lisa Louchart, Paul Brady, Chandan Mehta, Mohammed Rehman, Ariane Lewis, David Greer, Panayiotis Varelas

P6.058 Buproprion Overdose

in patients with Status Epilepticus admitted to Neurointensive Care Unit —Advait Mahulikar, Shishir Rao, Maysaa

P6.067 Hypocapnea with mechanical ventilation and poor outcome of refractory status epilepticus —Bong-Su Kang, Jung-Hwan Oh, Young-Soo Kim

P6.068 Preclinical Pharmacology and

Pharmacodynamic Interactions of SAGE547: Relevance to Super Refractory Status Epilepticus (SRSE). —Rebecca Hammond, Michael Ackley, Mike Quirk, Gabriel Belfort, James Doherty

Mimicking Brain Death: A Case Report —

P6.069 Predictors of Non convulsive

P6.059 Single or dual brain death

Shishir Rao, Advait Mahulikar, Maysaa Basha, Aashit Shah, Mohammad Ibrahim

Alan Wang, Neveen Malik, Syed Omar Shah

exams: tertiary hospital experience over 11 years. —Mohammed Kananeh,

Lisa Louchart, Paul Brady, Chandan Mehta, Mohammed Rehman, Ariane Lewis, David Greer, Panayiotis Varelas

P6.060 A Case of Guillain Barre

Syndrome Mimicking Brain Death and Review of the Literature —Sandhya

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.

Status Epilepticus —Wazim Mohamed,

P6.070 Comparative Efficacy of

Antiepileptic Drugs in patients with Status Epilepticus admitted to the Neurocritical Care Unit —Shishir Rao,

Advait Mahulikar, Kushak Suchdev, Deepti Zutshi, Aashit Shah, Navid Seraji-Bozorgzad, Wazim Mohamed

Ravikumar, Poysophon Poysophon, Roy Poblete, May Kim-Tenser

NEUROCRITICAL CARE: INTRACRANIAL PRESSURE

P6.061 Sagittal sinus stenosis

as a cause of increased intracranial pressure —Hunan Chaudhry, Reena Ghode, Lakshmi Warrior

FRIDAY

Fast and easy registration · AAN.com/view/AM17 129


Poster Sessions

Poster Session VI



Friday, April 28  8:30 a.m.—5:30 p.m.

Aging, Dementia, Behavioral and Cognitive Neurology ePoster Session Ten e-posters have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch-screen displays. P6.071 Finger-to-nose test findings

in Alzheimer’s disease —David Bergeron,

Antoine Vermette, Justine De La SablonniËre, Anne-Marie Cayer, Robert Laforce, Remi Bouchard

P6.072 The “Worried Well”:

Characteristics of Cognitively Normal Patients Presenting to a Rural and Remote Memory Clinic —Ryan Verity,

Andrew Kirk, Chandima Karunanayake, Debra Morgan

P6.073 Association between LongTerm Slow-Wave Sleep Enhancement and Cognitive Performance —Alice La,

Christine Walsh, Thomas Neylan, Bruce Miller, Elissaios Karageorgiou

AGING AND DEMENTIA: THERAPEUTIC APPROACHES II

P6.081 Brain Exercises for Synaptic

Plasticity (BEST Study): A randomized, placebo-controlled cognitive intervention trial for brain health in older adults —Tyler Hammond, Sylvia Cerel-Suhl, Hardin Stevens, Brooke Beech, Yang Jiang, Allison Caban-Holt, Erin Abner, Gregory Jicha

P6.082 A simulation study of

the clinical and economic impact of discontinuation rules for a hypothetical disease modifying therapy (DMT) for patients with Alzheimer’s Disease (AD) —Anuraag Kansal, Oscar HerreraRestrepo, Yogesh Kulkarni, Ali Tafazzoli

P6.083 Long-Term Safety And

Tolerability Of Escalating Doses Of Crenezumab In Patients With Mild-ToModerate Alzheimer’s Disease —Veronica Asnaghi, Helen Lin, Michael Rabbia, Susanne Ostrowitzki, Jillian Smith, William Cho

P6.084 Achieving the optimal profile

for Alzheimer’s immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers —Steven Plotkin, Ebrima Gibbs, Xubiao Peng, Judith Silverman, Neil Cashman

P6.074 Multimodal structural

MRI differentiates in vivo the three clinical variants of primary progressive aphasia —Federica Agosta, Francesca

Imperiale, Elisa Canu, Francesca Caso, Massimiliano Copetti, Giuseppe Magnani, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.075 Cross-sectional associations

between clinical and serological evidence of periodontal disease and cognitive impairment in a multi-ethnic elderly population. —James Noble, Sandra Burkett, Bin Cheng, Yizhen Chen, Jaffer Shariff, Romi Celenti, Caitlin Watson, Panos Papapanou

P6.085 A Clinical Precision Medicine Approach Reduces Alzheimer’s, Dementia and Vascular Risk and Improves Cognition: A Prospective Cohort Study —Richard Isaacson, Emily

Caesar, Katherine Hackett, Chiashin Shih, Hollie Hristov, Josefina Meléndez-Cabrero, Octavio Rodriguez, Jessica Shum, Lisa Mosconi, Randy Cohen, Mary Montgomery, Matthew Schelke, Roberta Marongiu, Robert Kachko, Robert Krikorian, Alon Seifan

P6.086 Gender and age are

associated with changes in blood biomarkers and cognition after multimodal Alzheimer’s prevention precision medicine intervention —Richard Isaacson,

P6.076 The Independent Effect of

Cerebral Microbleeds on Cognition — Xu Cong Ruan, Anne Cristine Guevarra, Nagaendran Kandiah

P6.077 Tau PET Imaging Predicts

Cognition in Atypical Variants of Alzheimer’s Disease —Jeffrey Phillips,

Sandhitsu Das, Corey McMillan, David Irwin, Ilya Nasrallah, David Wolk, Murray Grossman

Connectivity of brain lesions causing immoral behavior —Richard Darby, Michael Fox

P6.080 Mixed Transcortical Aphasia

Hallucinations —Warren Wen, Shankar

P6.094 Mental imagery strategy and

age from hierarchical brain volumes using a random forest regression can provide a personalized lifetime metric

Ramaswamy, Kunal Kishnani, Geetha Ramaswamy, Lawrence Friedhoff

P6.089 Repurposing of a Novel

Prostate Cancer Chemotherapeutics as a Brain Bioavailable Nurr1 Transactivator for Treatment of α-Synuclein-related Dementia in Parkinson’s Disease —Giulio Pasinetti

P6.090 Effect of donepezil on

transcranial magnetic stimulation parameters in Alzheimer’s disease —Yun

Tae Hwang, Paul Hammond, Lorenzo Rocchi, Vishal Rawji, Chris Hardy, Jason Warren, Basil Ridha, John Rothwell, Martin Rossor

P6.087 A comparative study of

Ridha, Sebastian Crutch, Martin Rossor, Jason Warren

perceptual learning in Alzheimer’s disease —Chris Hardy, Yun Tae Hwang, Basil

COGNITIVE AND MOTOR STUDIES OF AGING

Oroszlan-Szovik, Viviane Anquez, Karlheinz Baumann, Eric Kusznir, Francoise Gerber, Jürg Messer, Sylwia Huber, Jens Niewoehner, Wolfgang Richter, Georg Tiefenthaler

P6.092 Neural substrates of falls in

P6.088 A Phase 2 Study of

P6.093 Increased gait variability

FRIDAY 130 2017 AAN Annual Meeting Scientific Program

P6.079 Making a murderer:

in Association with Neurodegenerative Disease —Usama Tariq, Alicia Parker, Leila

P6.091 Donepezil modulates

Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual

Andrew Plassard, Katherine Elizabeth Aboud, Laurie Cutting, Landman Bennett

P6.078 Prediction of chronological

Emily Caesar, Katherine Hackett, Hollie Hristov, Chiashin Shih, Jessica Shum, Lisa Mosconi, Robert Krikorian

binding properties of gantenerumab and aducanumab analog to aggregated amyloid-beta —Bernd Bohrmann, Krisztina

of aging. —Camilo Bermudez, Yuankai Huo,

aging: a compensatory mechanism. —

Allali Gilles, Joe Verghese, Olivier Beauchet

while dual tasking predicts cognitive decline in older adults: a prospective longitudinal cohort pilot study —Olivier Beauchet, Gilles Allali

Saadatpour, Fareed Khan, Hoss Mardani, Doty Leilani, Kenneth Heilman

body position effects on imagining gait in healthy young and old adults: results from a cross-sectional study —Harmehr Sekhon, Gilles Allali, Olivier Beauchet

P6.095 Evolution of objective

measures of gait and balance with age —Tuhin Virmani, Jesal Shah, Harsh Gupta

P6.096 Resting-state functional

network connectivity differs between healthy aged individuals with and without reports of subjective cognitive change —Lauren Zajac, BangBon Koo, Ronald Killiany

P6.097 Serum Uric Acid and Cognitive Function in Middle-Aged and Elderly Men: Within Study Cross-Sectional and Prospective Analysis Comparison —Vy Nguyen, David Sparrow, Marc Weisskopf

P6.098 Measures of hippocampal

structure and functional connectivity differentiate healthy aged subjects with and without reports of subjective cognitive change —Lauren Zajac, BangBon Koo, Ronald Killiany

P6.099 NA P6.100 NA


Aging and Dementia Poster Discussion Session: Novel Approaches in Neurodegenerative Diseases: Genetics, Biomarkers, and Therapies Ten abstracts have been selected for presentation during a poster discussion session. In addition to the traditional display and author standby times, the poster discussion session authors will each present a five-minute blitz presentation on the poster discussion stage. The blitz schedule is listed below. Data Blitz:  11:45 a.m.–11:50 a.m. P6.101 Clinicopathological contribution of rare deleterious ABCA7 mutations to early-onset Alzheimer disease —Tobi Van Den Bossche, Arne De

Roeck, Raquel Sanchez Del Valle Diaz, Albert Llado, Caroline Graff, Hakan Thonberg, Pau Pastor, Sara Ortega-Cubero, Maria Pastor, Luisa Benussi, Roberta Ghidoni, Giuliano Binetti, Jordi Clarimon, Alberto Lleo, Juan Fortea, Alexandre De MendonÁa, Madalena Martins, Ellen Gelpi, Oriol Grau, Estrella Gomez-Tortosa, Benedetta Nacmias, Sandro Sorbi, Barbara Borroni, Alessandro Padovani, Maria Rosario Almeida, Isabel Santana, Janine Diehl-Schmid, Panagiotis Alexopoulos, Maria Koutroumani, Magda Tsolaki, Patrick Cras, Julie Van Der Zee, Kristel Sleegers, Christine Van Broeckhoven

Data Blitz:  11:50 a.m.–11:55 a.m. P6.102 Clinical and genetic characterisation of adult onset leukoencephalopathy —David Lynch,

Lakshmanan, Indran Davagnanam, Nick Fox, Elaine Murphy, Fernando Kok, Jeremy Chataway, Henry Houlden

Data Blitz:  11:55 a.m.–12:00 p.m. P6.103 In vivo quantification of regional tau and β-amyloid deposition in progressive posterior cortical dysfunction due to Alzheimer disease —

Gregory Day, Brian A Gordon, Kelley Jackson, Jon Christensen, Maria R Ponisio, Yi Su, Beau Ances, Tammie Benzinger, John Morris

Data Blitz:  12:00 p.m.–12:05 p.m. P6.104 CSF biomarkers suggest a strong role of glial inflammation in the pathogenesis of frontotemporal dementia —Julio Rojas -Martinez, Marc

Suarez Calvet, Anna Karydas, Gernot Kleinberger, Joel Kramer, Howard Rosen, Gil Rabinovici, Bruce Miller, Anne Fagan, Christian Haass, Adam Boxer

Anderson Paiva, Wei Jia Zhang, Rahul

NEUROMUSCULAR AND CLINICAL NEUROPHYSIOLOGY (EMG): PERIPHERAL NEUROPATHY III

P6.111 Small Fibre Neuropathy:

Classification and Search for Autoimmunity Against Peripheral Nerve Components —Amanda Chan, Nobuhiro Yuki, Jerome Devaux, Einar Wilder Smith

P6.112 Guillain-Barre Syndrome: Tertiary Center Experience in Saudi Arabia —Ahmad Abulaban, Abdullah

Alzahrani, Muhannad Alsharidah, Roula AlHadyan, Budoor Alsalman, Zeyad Abualiat, Ali Mohammed Alshehri

P6.113 HTLV-1 presenting as a motor neuropathy —Nina Kim, Vanessa Tiongson, Perrin Pleninger

P6.114 Comparison of pre and post

procedural pain and anxiety related to electromyography/nerve conduction study (EMG/NCS) in patients provided detailed information vs standard of care —Karthika Veerapaneni, Robert Murphy,

Anai Hamasaki, Daniel Kimple, Laura Herbelin, Omar Jawdat, Melanie Glenn, Jeffrey Statland, Mazen Dimachkie, Richard Barohn, Mamatha Pasnoor

P6.115 Clinical, Radiological and

Electrodiagnostic (EMG/NCS) profile in Acute Flaccid Myelitis(AFM) —Rifali Patel,

P6.116 A case of posterior

interosseous nerve entrapment inside lipoma and compressed by collateral

P6.117 Anderman-like syndrome

Data Blitz:  12:20 p.m.–12:25 p.m. P6.108 Patient and caregiver assessment of perceived benefits from clinical use of amyloid PET imaging —

Data Blitz:  12:10 p.m.–12:15 p.m. P6.106 Cortical Amyloid-beta and Slow Gait in Older Adults without Dementia: Influence of Cognition and APOE Genotype —Neelesh Nadkarni, K.

Data Blitz:  12:25 p.m.–12:30 p.m. P6.109 Data-driven cluster analysis of neuropsychological data identifies several cognitive subtypes in early onset cognitive impairment —Liana Apostolova,

Data Blitz:  12:15 p.m.–12:20 p.m. P6.107 Cognitive Changes after Working Memory Training in Healthy Older Adults: Evidence From a Multi-Site, Randomized Controlled Trial —Sharon

Data Blitz:  12:30 p.m.–12:35 p.m. P6.110 Tau accumulation in normal and impaired older individuals assessed with serial PET —Danielle Cosio, J. Alex

Simon, Erich Tusch, Kerstin Hakansson, Abdul Mohammed, Kirk Daffner

Becker, Aaron Schultz, Chris Lee, Nick Andrea, Bernard Hanseeuw, Reisa Sperling, Keith Johnson

P6.122 Isolated Bilateral Radial

P6.129 A case of Anti Ganglioside

Langenhove, Olivier Piguet, James Burrell, Cristian Leyton, David Foxe, Melissa Abela, Lauren Bartley, Kim Woojin, Eve Jary, Yue Huang, Carol Dobson-Stone, John Kwok, Glenda Halliday, John Hodges

Perera, Beth Snitz, Jeff Williamson, Steven DeKosky, Chester Mathis, Oscar Lopez, William Klunk

Nerve Palsies in a Newborn —Rocio Vazquez Do Campo, Keith Starnes, Erick Viorritto

presenting with a dHMN —Yonglu Huang,

P6.123 Pathological Findings of

P6.118 Clinical, electrophysiological

Namita Goyal

Jeffrey Cohen, Victoria Lawson

and histopathological features of IVIGresponsive pure motor neuropathies: Beyond anti-GM1 antibodies and motor conduction block. —Pantelis Pavlakis, Arthur Hays, Steven Chin, Ehud Lavi, Dale Lange

P6.119 Poems Syndrome Without

“M” – Could it be Possible? A Case Report —Paulo Carrilho, Brenda Camila Reck

Subhendu Rath, Lawrence Bluth, Annie Daniel

P6.124 Gluteal Compartment

Nandhagopal Ramachandiran, Patrick Scott, Douja Meftah

Syndrome with Neurologic Impairment: Report of Two Cases and Review of the Literature —Gregory Kuhlman, Kelly Gwathmey

P6.125 The sensitivity of worldwide

P6.120 Terminal latency index

P6.126 Weak above the knees:

Lumbar Root Non-Hodgkin Lymphoma invasion —Neil Datta, Bhaskar Roy, Lucas Meira Benchaya, Carl Boland

Schultz, Kavita Grover, Ximena Arcila-Londono, Naganand Sripathi, Bashiruddin Ahmad

P6.127 Ficolin 3, a potential

P6.121 Sequential EDX testing

Kornitzer, Nizar Souayah

Nguyen, Armelle Magot, Guillemette Fayet, Laurence Leclair, Jean-Michel Nguyen, Yann Pereon

antibody negative Bickerstaff’s Brainstem Encephalitis- Miller Fisher overlap syndrome —Bharti Manwani,

P6.130 A Novel Mutation in the

De Oliveira, Emanuelle Bianchi Da Silva, Taline Alison Artemi Lazzarin Silva, Leticia Da Silva Schran, Christina Covolo De Carvalho, Rosana Scola

identifies differential susceptibility of the median nerve to prolonged wrist extension in normal subjects —Anne-Lise

Kathleen Lane, Gil Rabinovici, Bradford Dickerson, Maria Carrillo, Susan De Santi, Sujuan Gao

Epineurial Microvasculitis in Neuralgic Amyotrophy —Tahseen Mozaffar, Tim Lai,

normative reference values for intraepidermal nerve fiber density for diagnosis of small fiber neuropathy is lower in Chinese-American patients compared to non-Chinese American patients —Peter Jin, Lan Zhou

(TLI) and sensory electrophysiology in paraproteinemic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). —Anza Memon, Sarah Madani, Lonni

Rafid Mustafa, Gil Rabinovici, Bradford Dickerson, Maria Carrillo, Bradley Glazier, Sujuan Gao, Martha Tierney, Keith Fargo, Jared Brosch, Mary Guerriero Austrom, Susan De Santi, David Clark, Liana Apostolova

biomarker for demyelination in diabetic neuropathy —Hongxin Chen, Jeffrey

P6.128 Novel Compound

Heterozygous Mutation of SH3TC2 in Patients with Charcot-Marie-Tooth Disease —Carla Zingariello, Kathryn Lalor, Ryan Castoro, Jun Li, Megan Simmons

SIGMAR1 Gene Underlies Recessive Distal Motor Neuropathy in Oman —

P6.131 Multifocal Motor Neuropathy masquerading as a primary peripheral nerve tumor —Lucas Meira Benchaya, Joel Bauman, Qian Wu, Agnes Jani-Acsadi

P6.132 Diagnostic Accuracy of

Electromyography Referrals, with a Focus on Carpal Tunnel Syndrome — Shivkumar Bhadola, Kate Daniello

P6.133 Failed Back Surgery

Syndrome: is there a small fiber involvement? A contact heat evoked potentials (CHEPs) study —Luiz Felipe

Dantas Pagliarini, Arielle Kirmse, Bruno Coutinho, Carlos Bruno Nogueira, Felipe Vianna, Ricardo Dornas, Eduardo Davidovich, Bruno Pessoa, Osvaldo Nascimento

P6.134 Normal parameters of the blink reflex test among Sudanese population —Amani Musa, Afraa Musa, Musadak Karrar, Ammar Ahmed

P6.135 A Quality Improvement

Strategy: Ulnar Nerve Conduction Study of the First Dorsal Interosseous Muscle —Charenya Anandan, William Litchy, Ruple Laughlin, Andrea Leep Hunderfund, Elie Naddaf

Fast and easy registration · AAN.com/view/AM17 131

FRIDAY

Parul Goyal, Sumit Verma

arteries in a patient with radial artery excision for coronary artery bypass grafting —Alireza Bozorgi, David Preston

Data Blitz:  12:05 p.m.–12:10 p.m. P6.105 Predicting development of amyotrophic lateral sclerosis in frontotemporal dementia —Tim Van

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session VI



P6.136 The role of Ultrasound e

MR 3D neurography in the diagnostic work-up of peripheral neuropathies. —

Alessandro Salvalaggio, Mario Cacciavillani, Marta Campagnolo, Marta Ruiz, Roberto Gasparotti, Chiara Briani

P6.137 Late-onset unilateral

peripheral neuropathy in a patient with chromosome 15q11.2 deletion —Sumanjit Kaur, Rafael Rodriguez, Chilvana Patel, Jianli Dong, Xiang Fang

P6.138 Facial Diplegia and

Autoimmune Hepatitis After Pembrolizumab Therapy —Micah Yost, Teerin Liewluck

P6.139 Autonomic dysfunction following coronary artery bypass surgery —Meenakshi Sundaram

Salvadeeswaran, Sridhar Venugopal, Vivek Bose, Subburamakrishnan Palanikumar, Krishnan Srinivasan, Bharathi Sundar

P6.140 Motor neuronopathy and

myelopathy in Leber’s hereditary optic neuropathy —Russell Sawyer, Ashby Turner, Hani Kushlaf

P6.141 Evaluation of median nerve T2 signal changes in patients with surgically treated carpal tunnel syndrome —Yavuz

Iverson, Noah Silverberg, Paul Gerrard, Joseph E. Atkins, Ross Zafonte, Paul Berkner, Tad Seifert

P6.151 Utility of Anatomic MRI and

Specific Neurological Assessments in mTBI —Shetty Teena, Taylor Cogsil, Aashka Dalal, Luca Marinelli, Apostolos Tsiouris, Sumit Niogi, Joseph Nguyen

P6.152 Minimum Detectable Change of Tandem Gait Following Concussion — Jessie Oldham, Melissa DiFabio, Ryan DeWolf, Thomas Kaminski, Thomas Buckley

P6.153 Preseason symptom scores

and abnormal exam findings in youth and high school football players. —Anthony Savino, Matthew McCarthy, Erik Beltran, Natalie Pizzimenti, Sean Rose

P6.154 The Role of Cytosolic

PSD-95 Interactor (Cypin) in Traumatic Brain Injury —Nicholas Cuccolo, Peter Swiatkowski, Emily Sewell, Dave Meaney, Bonnie Firestein

P6.155 Prognosis for consciousness and motor functions recovery in posttraumatic Diffuse Axonal Injury —

Evgenia Alexandrova, Natalia Zakharova, Anna Kormilitsina, Aram Tonoyan, Alexander Potapov

Friday, April 28  8:30 a.m.—5:30 p.m. of a 17-year-old Female Rugby Player —

Maryam Mian, Michael Alosco, Jesse Mez, Patrick Kiernan, Daniel Daneshvar, Christopher Nowinski, Neil Kowall, Robert Stern, Douglas Katz, Robert Cantu, Ann McKee

P6.165 Chronic Traumatic

Encephalopathy in a 24-year-old former soccer player —Joseph Phalen, Michael Alosco, Patrick Kiernan, Philip Montenigro, Todd Solomon, Robert Stern, Douglas Katz, Ann McKee, Jesse Mez

P6.166 Longitudinal MRI and

cognitive change in Professional Fighters —Charles Bernick, Guogen Shan, Virendra Mishra, Sarah Banks

P6.167 Barriers to Recovery in

Concussion —Kristin Halvorsen, Jaskaran

Bains, Joseph Nguyen, Taylor Cogsil, Kelianne Cummings, Aashka Dalal, Davena Zhang, Shetty Teena

P6.168 Adolescent Sleep-Wake

Disturbance Following Concussion —

Briana Meyer, Sonal Singh, David McArthur, Christopher Giza

P6.169 Factors Contributing to

Subjective Cognitive Symptoms in mTBI — Nancy Madigan, Alexandra Stillman, Karen Torres, Natasha Swan, Michael Alexander

Samanci, Yesim Karagoz, Mehmet Yaman, Ibrahim Burak Atci, UFUK EMRE, Nuri Ozgur Kilickesmez, Suat Erol Celik

P6.156 Effects of Exercise on SCAT-3

P6.170 Preseason computerized

P6.142 Increased sNCAM levels in

David Howell, Grant Iverson

McCarthy, Anthony Savino, Erik Beltran, Natalie Pizzimenti, Sean Rose

acute peripheral demyelination —Adam

Andrzey Niezgoda, Slawomir Michalak, Jacek Losy, Wojciech Kozubski

P6.143 NA P6.144 NA NEURO TRAUMA AND SPORTS NEUROLOGY II

P6.145 Effects of the New York State Lystedt Law on Concussion-Related Emergency Healthcare Visits among Adolescents, 2005-2014 —David Baker, Erin Kulick, Amelia Boehme, James Noble

P6.146 Dual-task gait abnormalities

after sport-related concussion and their association with prolonged symptom duration —William Meehan III, David Howell

P6.147 Novel Method of Weighting Cumulative Helmet Impacts Improves Correlation with Brain White Matter Changes After One Football Season of Sub-Concussive Head Blows —Kian Merchant-Borna, Patrick Asselin

P6.148 Normative Tandem Gait in

Collegiate Student-Athletes: Implications for Clinical Concussion Assessment — Jessie Oldham, Melissa DiFabio, Ryan DeWolf, Thomas Kaminski, Thomas Buckley

P6.149 Reduced information

processing speed and event-related EEG synchronization in traumatic brain injury —Sophie Dautricourt, Inês Violante,

FRIDAY

Emma-Jane Mallas, Richard Daws, Ewan Ross, Amy Jolly, Romy Lorenz, David Sharp, Nikos Gorgoraptis

P6.150 Migraine History and

Associated Comorbidities in High School Athletes —Magdalena Wojtowicz, Grant

Performance in Professional Male Athletes —Andrew Gardner, Jinho Lee,

P6.157 Dual-task gait deficits

and acute injury in the year after concussion —David Howell, William Meehan III

P6.158 Improved prediction of

subconcussive neurophysiological changes by kinematic impulse —Katherine

Breedlove, Evan Breedlove, Trey Shenk, Kausar Abbas, Thomas Bowman, Larry Leverenz, Eric Nauman, Thomas Talavage

P6.159 Rates and significance of new or worse headaches following pediatric mild TBI —Dana Coleman, Nori Minich, H. Taylor, Keith Yeates

P6.160 Traumatic Brain Injury

in Domestic Violence Victims: A Retrospective Study at the Barrow Neurological Institute —Glynnis Zieman, Ashley Bridwell, Javier Cardenas

P6.161 A Common Data Language

for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke, National Institutes of Health and Department of Defense Traumatic Brain Injury Sports Concussion Common Data Elements Version 1.0 Recommendations —Kristen Joseph,

neurocognitive testing in youth and high school football players —Matthew

NEUROLOGIC COMPLICATIONS OF CANCER

P6.171 Retrospective Analysis of

Neil Nedley, Francisco Eduardo Ramirez

P6.164 The Clinical and

Neuropathological Correlates of Second-Impact Syndrome: Case Report

132 2017 AAN Annual Meeting Scientific Program

after radiation therapy (SMART) syndrome a case series of three patients. —Yasmeen Rauf, Daniel Boulter, Jaime Imitola

P6.180 Atypical Brain Lesion in

Patients with Non-metastatic Cancer: The Critical Role of Histopathology in Diagnosing Cancer-associated Necrotizing CNS Vasculitis —Joshua

Sheehan, Jessica Tate, Rachel Wolfe, Ryan Mott, Carol Geer, Amy Guzik, Roy Strowd

P6.181 Stroke Like Syndrome and

Simple Partial Seizures Secondary to Intrathecal Methotrexate Use for the Treatment of Acute Lymphocytic Leukemia —Mary-Ann Fares, Scott Silliman

P6.182 A Rare Case of AMPA-R

Antibody Positive Paraneoplastic Limbic Encephalitis —Callie Takahashi, Stephen

Holmes, Melvin Wong

P6.183 Sleep patten in breast cancer patients receiving adjuvant treatment (chemotherapy and/or radiotherapy) —

Elsayed Tageldin, Samar Galal Younis, Lamiss Mohamed Abd El Aziz, Amr Tageldin, Sherif Tarek Erfan

P6.184 Steroid responsive migratory

brain lesions causing intractable epilepsy in multiple myeloma. —Maria Prieto Eibl, Pierre Giglio, Vinaykumar Puduvalli

P6.185 Seronegative progressive

in vinorelbine treatment for breast cancer —Anna Grisold, Michael Ackerl, Birgit

Neuropathy with Docetaxel versus Paclitaxel in Women Treated for Breast Cancer —Summer Karafiath, Noah Kolb, J. Singleton, A. Gordon Smith

P6.173 Glutamate metabolism in

peripheral blood mononuclear cells and neurological complications in lung cancer patients —Michal Szulc, Joanna Rybacka - Mossakowska, Wojtck Ambrosius, Joanna Gazdulska, Iwona Golda-Gocka, Wojciech Kozubski, Rodryg Ramlau

P6.174 The Spectrum of Neurological

Adverse Events from Immune Checkpoint Blockade: A Comprehensive Review of Literature —Ahmad Daher, Sudhakar Tummala

P6.175 Myasthenic syndrome with pembrolizumab use —Upendra Hegde,

occurring in solid tumor cohort treated with PD-1 inhibitors —Justin Kao, Bing Liao,

the Head on Depression and Anxiety —

P6.179 Stroke like migraine attacks

P6.172 Incidence of Peripheral

Sandipan Pati, Paula Warren, Louis Nabors

P6.162 Cervical neurapraxia in

P6.163 Effect of a Significant Hit to

Karam, Tobias Walbert, Ian Lee

encephalomyelitis with rigidity and myoclonus (PERM) —Ehtesham Khalid,

Ayushi Chauhan, Ninad Desai

McCarthy, Sean Rose, Jeffrey Kutcher

associated with radiation and laser ablation for brain tumors —Stefania Maraka, Asmaro

Outcomes in Hospitalized Malignant Brain Neoplasm Patients with Status Epilepticus —Mina Lobbous, Sahil Gupta,

Joanne Odenkirchen, Sherita Alai, Joy Esterlitz, Sarah Tanveer, Patrick Bellgowan

college football players with cervical spinal canal narrowing —Matthew

P6.178 Malignant cerebral edema

P6.176 Neuromuscular complications

Svetomir N. Markovic, Elie Naddaf, Nathan Staff, Christopher Klein, Julie Hammack, Paola Sandroni, Heidi Finnes, Michelle Mauermann

P6.177 Gamma irradiated microglia

produce exosomes that cause molecular and functional changes in neurons: a human model system. —Gabriel Arismendi, Parnela Rameshwar, Nizar Souayah, Oleta Sandiford

Dagoberto Estevez-Ordonez, Patrick Lavin

P6.186 Multifocal neuropathy

Surboeck, Bruno Giometto, Wolfgang Grisold

P6.187 A case of neuronal gigantism

and cortical thickening: A rare complication of therapeutic radiation —Nawal Shaikh, Priya Kumthekar, Jeffrey Raizer, Karan Dixit

P6.188 Neurologic manifestations of

geriatric patients with cancer —Bernardo Cacho Diaz, Nydia Lorenzana-Mendoza, Gervith Reyes, Angel Herrera Gomez

P6.189 Paraneoplastic cerebellar

degeneration (PCD) with a normal serum paraneoplastic panel and high anti-Yo titers in the cerebrospinal fluid (CSF): case report and literature review — Somayyeh Sabet, Sunhee Kim, Melvin Wichter, Martin Nicholas

GENERAL NEUROLOGY: INFLAMMATION, INFECTIONS, AND AUTOIMMUNITY

P6.190 GRIN1 polymorphisms do

not affect susceptibility or phenotype in NMDA receptor encephalitis —Gregory Day, Harald Pruss, Susanne Benseler, Tara Paton, Andrew Paterson, Danielle Andrade

P6.191 It’s never lupus…until it is;

Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis


treated with intravenous immunoglobulin and rituximab; a case study. —Emily

BEHAVIORAL AND COGNITIVE NEUROLOGY: EMOTION/BEHAVIOR

BEHAVIORAL AND COGNITIVE NEUROLOGY: INTERVENTIONS

P6.192 Adult onset EBV-associated

P6.204 Maladaptive Behaviors in

P6.216 Recognizing Cognitive

Anjali Sadhwani, Jennifer Willen, Miganush Stepanians, Nicole LaVallee, Rene BarbieriWelge, Lucia Horowitz, Lisa Noll, Rachel Hundley, Lynn Bird, Wen-Hann Tan

Davis, Angela Wang, Melissa S. Briley, Kevin M. Duff, Jian Ying, Yao He, Reid Holbrook

Watson, Samantha Minehan, Richard White

hemophagocytic lymphohistiocyotosis initially presenting as progressive myelopathy —Young Hee Jung, Jin-Myoung Seok, Misong Choi, Ju-Hong Min, Byung-Ok Choi, Jin-Sung Park, Byoung-Joon Kim

P6.193 Rabbit Holes of

Autoimmunity: Paraneoplastic and Autoimmune Neurological Disorders —

Ahnas Ahmed, Praveen Venkatachalam, Shireen Khan, Michael Kentris, Thomas Pitts, Larry Hall, Atif Hashmi, Suraj Rajan

P6.194 A Case Highlighting the

Phenotypic Variants Associated with Anti-GQ1B IgG Spectrum Disorders —

Niraja Suresh, Charles Schutt, Ambica Tumkur, Yazan Suradi

P6.195 A case of CJD with concomitant HHV -6 infection —Aiga Rakhesh, Sari Ann Yonaty, Vishal Shah, Julius Latorre

P6.196 Seek and you will find: an

unusual immune mediated encephalitis with multiple neuronal antibodies. —Luke O’Donnell, Parameswaran Iyer, Zara Togher, Dina Nduwke, Sulaiman Al Hatmi, Christopher McGuigan, Aidan McCormick, Andrew Westbrook, Eoin Feeney, Sarosh Irani, Justin Kinsella

P6.197 Fatal Case of Thyrotoxic

Periodic Paralysis, Presenting as Hyperacute Ascending Paralysis and Cardiac Arrhythmia —Abdul Rahman

Alchaki, Taha Nisar, Dan Guzman, Gregory Sugalski, Machteld Hillen

P6.198 Idiopathic Hypertrophic

Cranial Pachymeningitis misdiagnosed as venous sinus thrombosis. —Fatemah Alshawaf, Hayyan Homaidan, Osamah Albaker, Tariq Alfahad

P6.199 Chronic and subacute

meningitis: differentiating between neoplastic and non- neoplastic etiologies —Mariano Marrodan, Catalina

Individuals with Angelman Syndrome —

P6.205 Acute Psychosis as Main

P6.217 Improvement in Neurocognitive

Parasram, Harsh Patel, Chike Ilorah, Deepak Reddy, Hrachya Nersesyan

Orning, Ashkan Zarrieneh, Dilip Pandey, Sepideh Amin-Hanjani, Fernando Testai

Manifestation of Central Pontine Myelinolysis —Mangala Gopal, Melvin

P6.206 The Cerebellar Cognitive

Affective / Schmahmann Syndrome Scale —Franziska Hoche, Xavier Guell, Mark

Vangel, Janet Sherman, Jeremy Schmahmann

P6.207 Neuropsychiatric Associations

with Gender, Illness Duration and Work Disability Status in a U.S. Based Functional Neurological Disorders Clinic Population —

Nassim Matin, Sigrid Young, Benjamin Williams, W. LaFrance, Julie King, David Caplan, Zeina El-Chemali, Jeffrey Weilburg, Bradford Dickerson, David Perez

P6.208 Catatonia as a rare

manifestation of HIV associated psychosis in adolescents. —Yoshimi

Hisamoto, Genevieve Gabriel, Sonam Verma, Cemal Karakas, Geetha Chari

P6.209 Evaluation of Possible

“Impulsivity” Following Ventromedial Thalamic Nucleus Deactivation in the Rat Using a Fixed Consecutive Number Task —Akshay Goswami, Darryl Neill Ph.D

P6.210 Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use —Andrea Formella, David Alexander, Andrew Cutler, Stephen D’Amico, Flora Hammond, William Sauve, Richard Zorowitz, Joao Siffert

P6.211 Objective biomarkers of

Stress in Motor Functional Neurological (Conversion) Disorder —Selma Aybek, Kalliopi

Bensi, Alejandro Muggeri, Alejandro Kohler, Lucas Alessandro, Mauricio Farez

Apazoglou, Jennifer Wegzyrk, Viridiana Mazzola

P6.200 CNS Lyme Disease Leading

mechanisms and associated features —

to Acute Inflammatory Demyelinating Polyradiculoneuropathy —Clarence Li, Kate Hocquard, Eric Sorenson

P6.201 Isoniazid Induced Cerebellar Neurotoxicity in a 45-Year-Old-Woman with Sjogren’s Disease, Chronic Renal Insufficiency, and Extrapulmonary Tuberculosis: A Case Report —Hannah Park, Vanessa Tiongson, Sujata Thawani, Matthew Young

P6.202 Copper Deficiency in patient with prior diagnosis of AIDP —Parth

Upadhyaya, Farzan Ghodsianzadeh, Rebecca Romero, Ratna Bhavaraju-Sanka

P6.203 Psuedo-tumoral Form of

Arizmendi, Gabriela Raina, Veronica Tkachuk, Ariel Bustos, Juan Pablo Paviolo

P6.212 Apathy in Parkinson’s disease: Kinan Muhammed, Masud Husain

P6.213 A Randomized, Placebo-

Function in Moyamoya Patients with Surgical Bypass —Alejandro Vargas, Jennifer

P6.218 Transcranial direct current

stimulation effects in inhibitory control in individuals with attention deficit/ hyperactivity disorder —Camila Cosmo,

Abrahao Baptista, Arao Nogueira De Araujo, Raphael Do Rosario, Jose Garcia Vivas Miranda, Joan Camprodon, Pedro Montoya, Eduardo Ponde De Sena

P6.219 Related factors and predictors of cognitive dysfunction in Chronic Kidney Disease Patients on maintenance haemodialysis in Nigeria —Lukman

Owolabi, Aliyu Ibrahim, Desola Owolabi, Aisha Nalado, Bappa Adamu, Aminu Taura

P6.220 The Impact of Computer-

Based Mindfulness Training on Attention to Novelty in Healthy Older Adults — Nicole Feng, Eliza Ryan, Erich Tusch, Phillip Holcomb, Abdul Mohammed, Kirk Daffner

P6.221 NA P6.222 NA EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: CLINICAL EPILEPSY V

P6.223 Prognostication of

seizure remission in patients with pharmacoresistant epilepsy: accuracy of physician estimates of seizure freedom after epilepsy surgery —Priyanka Sabharwal, Steven Pacia, Daniel Friedman, Orrin Devinsky, Patricia Dugan

P6.224 Visual Hallucinations

as a Novel Complication Following Hemispherectomy —Monisha Sachdev, Jonas Vanags, Eric Arehart, Gerald Grant, Mohamad Mikati

P6.214 Stress-Mediated Alterations

unrecognized adverse effect of Levetiracetam —Rodica Di Lorenzo, Yuebing Li

P6.215 Brain Network for Emotional

Body Language Reading: Structural and Effective Connectivity —Arseny Sokolov,

Peter Zeidman, Michael Erb, Wolfgang Grodd, Frank Pollick, Richard Frackowiak, Karl Friston, Marina Pavlova

EPILEPSY AND CLINICAL NEUROPHYSIOLOGY: THERAPEUTICS II

P6.231 Laser Ablation of Mesial

Temporal Structures: A New Treatment for Epilepsy Surgery —Andres Kanner, Ramses Ribot, Enrique Serrano, Merredith Lowe, Leticia Tornes, Gustavo Rey, Jonathan Jagid, Naymee Velez-Ruiz

P6.232 Modulation of post-traumatic

epilepsy by MIS416, a novel innate immune modulator for the treatment of neuroinflammation —Min Chen, Vy Truong, Gill Webster, David Reutens

P6.233 Brivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers —Sjoerd J. Finnema,

Joel Mercier, Mika Naganawa, Nabeel Nabulsi, Sophie Kervyn, Shannan Henry, JeanMarie Nicolas, Yiyun Huang, Ming-Kai Chen, Jonas Hannestad, Henrik Klitgaard, Armel Stockis, Richard Carson

P6.234 Hemodynamic properties of SAGE-547 in patients with superrefractory status epilepticus: results from a phase 1/2 clinical trial —Helen

Colquhoun, Shane Raines, Stephen Kanes

Spray in Pediatric Subjects with Epilepsy —

P6.225 Understanding Variability in

David Beversdorf, Neetu Nair, John Hegarty, Katherine Lane, Brad Ferguson, Patrick Hecht, Michael Tilley, Jeffrey Johnson, Shawn Christ

Memon, Farkhanda Qaiser, Arunbabu Sankaranarayanan, Sandipan Pati

P6.235 Tolerability of Midazolam Nasal

Controlled, Blinded, Crossover, SingleCenter Study of the Effects of Nuedexta in the Treatment of Neurobehavioral Symptoms of Adults with Autism Spectrum Disorder —Michael Chez, Shawn Kile of Amygdalar Activation and Cortical Network Coherence Associated with Serotonin Transporter Polymorphisms —

referral to go under the knife? Process Mapping the epilepsy pre-surgical evaluation —Adeel Memon, Raima

Driving Recommendations for Patients with Seizures —Sidrah Mahmud, Derek Cheng, Scott Stevens, Sean Hwang

P6.226 Rhabdomyolysis—an

P6.227 Pregnancy outcomes in Women with Epilepsy in Urban Detroit —Yuvraj Heir

P6.228 Characterization of childhood epilepsy in a third level health care center. —Erika Paola Guartazaca Guerrero,

Jorge Llibre Guerra, Maria Martha Unaucho Pilalumbo, Nicolás Garófalo Gómez

P6.229 Wada memory performance

does not predict memory and seizure outcome after epileptic surgery —Sandy

Chan, Angeline Andrew, David Roberts, Krzysztof Bujarski, Vijay Thadani, Erik Kobylarz, Barbara Jobst, George Thomas

Lindy Bancke, Tze-Chiang Meng, Barbara Kapelan, Cindy Moe, Al Berg, Peter Van Ess

P6.236 Inhaled Alprazolam, a Potential Rescue Medication, Works Rapidly in Patients with Photosensitive Epilepsy —

Jacqueline French, Daniel Friedman, Robert Wechsler, Bree DiVentura, Michael Gelfand, John Pollard, Keith Huie, Blanca Vazquez, Lily Gong, James Cassella, Ed Kamemoto

P6.237 Congenital Malformations

in Children of Epileptic Mothers with Intrauterine Exposures to Antiepileptic Drugs and Comparison with a Control Group. Update from Pinar del Rio Epilepsy Pregnancy Multicenter Study, Experience 1996-2016. —Juan Miguel Riol Lozano

P6.238 Efficacy of adjunctive

brivaracetam in patients with secondarily generalized tonic-clonic seizures at baseline: pooled results from long-term follow-up studies —Brian Moseley, Anyzeila Diaz, Sami Elmoufti, John Whitesides

P6.239 Online CME Improved

Knowledge and Confidence among Neurologists Regarding the Use of Third Generation Antiepileptic Drugs —Piyali Chatterjee, Thomas Finnegan, Gena Dolson

P6.240 Adherence to Classic

Ketogenic Diet vs. Modified Atkins Diet in an Observational Cohort —Bonnie Wong, Courtney Glick, Pegah Jalali, Orrin Devinsky, Sanjeev Kothare, Daniel Friedman

P6.241 Pharmacokinetics of SAGE547 in patients with super refractory status epilepticus —Helen Colquhoun,

Ethan Hoffman, Shane Raines, Jeffrey Wald, Stephen Kanes

Fast and easy registration · AAN.com/view/AM17 133

FRIDAY

Wegener’s Disease as an Atypical Manifestation of Central Nervous System Involvement —Marianela Crespo

Impairment Is Not Enough: Improved Outcomes with Cognitive Specialty Team Care —Norman Foster, Nancy A. Allen, Kelly

P6.230 How long does it take from

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session VI



Friday, April 28  8:30 a.m.—5:30 p.m.

P6.242 Preliminary Results of Efficacy

P6.255 Intracranial and Extracranial

P6.267 Money is Brain: Financial

PREVENTION OF CEREBROVASCULAR DISEASE

Luo, Jing Ding, Xin Wang

Nasr, Vance Lehman, Giuseppe Lanzino, Harry Cloft, Waleed Brinjikji

King-Shier, Braden J Manns, Michael Hill, David JT Campbell

P6.279 Carotid Revascularization and

P6.243 Evaluation of abuse potential

P6.256 20 years of Modifying

P6.268 Efficency in Emergency

Moeller, Allistair Abraham, Zarir Khademian

Hargrove, Oleg Chernyshev, Joseph Acosta, Leopoldo DeAlvare, Gonzalo Hidalgo, Ramy El Khoury, Digvijaya Navalkele

and Cognitive affects of Cathodal Transcranial Direct Current Stimulation for the Treatment of Epilepsy —Wenyi

of brivaracetam in healthy recreational CNS depressant users —Kerri Schoedel, Armel Stockis, Edward Sellers

P6.244 Resective epilepsy surgery

following Vagal Nerve Stimulator placement —Keely Fitzgerald, Marcia Kerr, Jeremy Lankford, Michael Watkins, Michael Funke, Gretchen Von Allmen, Manish Shah

P6.245 Application of the Portable

Electromagnetic Navigation System in Epilepsy Surgery —Vsevolod Shurkhay, Dmitry Kopachev, Anastasia Shkatova

P6.246 Role of Vagus Nerve

Stimulation in the Management of Drug Resistant Refractory Epilepsy in Children with Major Cerebral Malformations —

Neurovascular Manifestations of Takayasu Arteritis —Kamila Bond, Deena

Stroke Risk in Sickle Cell Disease (SCD) Patients: a Single Center Experience of Bone Marrow Transplant (BMT) in SCD. —Jessica Carpenter, Raquel Farias-

P6.257 Vertebrobasilar

dolichoectasia relates to cerebral microbleeds in a population-based study —Fei-Fei Zhai, Quan Wang, Jun Ni,

Li-Xin Zhou, Ming Yao, Ming-Li Li, Zheng-Yu Jin, Liying Cui, Shuyang Zhang, Yi-Cheng Zhu

P6.258 Clinical and Neuroimaging Correlations in Cerebral Venous Thrombosis —Lakshmi Ranganathan,

Batool Kirmani, Mary Dang, Richard Castillo

Balaji Nagarajan, Guhan Ramamurthy, Arun Shivaraman M M, Priyadarshini Lakshminarasimhan, Kalaimani Elango, Chandramouleeswaran Venkatraman

P6.247 Plasmapharesis led to clinical

P6.259 Efficacy and Safety of

recovery in a case of Super Refractory Nonconvulsive Status Epilepticus caused by Hashimoto’s encephalopathy —Bharti Manwani, Sarah Meira Benchaya, Yan Zhang

P6.248 Retinal Structure and

Function During Adjunctive Vigabatrin Treatment: Case Reports of Potentially Significant Changes During a Phase IV Study —Kenneth Laxer, Eugene Ramsay,

Jeremy Slater, Ekrem Kutluay, Chris Johnson, Robert Sergott

P6.249 An Evaluation of QT/QTc in

Adult Patients With Epilepsy Receiving Short-Term IV Carbamazepine —Aziz Karim, Dwain Tolbert, David Wesche, Jouko Isojarvi

P6.250 Pharmacokinetics of IV and

Oral Carbamazepine by Renal Function Status —William Ravis, Dwain Tolbert, Aziz Karim, James Cloyd

NON-ATHEROSCLEROTIC ANGIOPATHIES AND CEREBRAL VENOUS THROMBOSIS

P6.251 Adult Moyamoya Syndrome Caused by Varicella Zoster Virus Infection: A Case Series —Khalil Husari, Peter Sguigna, Tiesong Shang

P6.252 Moyamoya and ethnic

diversity —Khadija Irshad, Lonni Schultz, Salman Zahoor, Shaneela Malik

P6.253 Cervicocephalic arterial

dissection in a Latin-American cohort: Are there any differences throughout the various stages of life? —Maria Pacha,

Lucrecia Bandeo, Anibal Chertcoff, Julieta Quiroga, Luciana Vanesa Leon Cejas, Marcela Uribe Roca, Pablo Bonardo, Oscar Martinez, Gabriel Napoli, Javier Halfon, Manuel Fernandez Pardal, Ricardo Reisin

P6.254 Comparative analysis

FRIDAY

between vertebral and carotid dissections from a statewide inpatient dataset. —Mohammad-Rauf Afzal, Rakesh Khatri, Mohtashim Qureshi, Alberto Maud, Dou Huanyu, Gustavo Rodriguez

Edaravone in Acute Cerebral Venous Thrombosis – A Retrospective Case Control Study in 90 Subjects —Bobby

Panikulam, Mustare Veerendra Kumar, Girish Kulkarni

P6.260 “BEAST” at the University Of Virginia: Demographic and Phenotypic Data of Patients Contributing to a Biorepository to Establish the Etiology Of Sinovenous Thrombosis —Nicole

Barriers and Consequences for Canadian Stroke Patients —Aravind Ganesh, Kathryn

Stroke Evaluation is Associated with Patient Volume in Louisiana’s Level III Hospitals —Sheryl Martin-Schild, Paige

CEREBROVASCULAR DISEASE: HEALTH SERVICES RESEARCH

P6.269 Getting to the Core of

Stroke Care: Real Time Chart Review Improves Hospital Compliance with Core Measures —Constance Katsafanas, Joseph Furbeyre, Vicki Coppen, Wayne Hodges, Loretta Schnepel, Diane Falk, Jose Alonso, Ahn Tran, Michael Northcut, Alison Toback, Scott Silliman

P6.270 Hospital Readmissions

following Stroke: a Retrospective Study —Simy Parikh, Paul George, Nadia Liyanage-Don, Anna Hohler, Rybin Denis, Janice Weinberg

P6.271 Modified Rankin Scale

Disability Status at Day 4 Poststroke is an Informative Predictor of Final Day 90 Outcome —Samuel Asanad, Sidney Starkman, Scott Hamilton, Robin Conwit, Nerses Sanossian, Jeffrey Saver

Chiota-McCollum, Matthew Ehrlich, Michelle Johansen, Shareena Rahman, Sherita Chapman, Bradford Worrall

P6.272 Can we Improve on Neuro-

CEREBROVASCULAR DISEASE: SYSTEMS OF CARE AND HEALTH POLICY

P6.273 The Impact of Post-acute

P6.261 Stroke system of care in

Diogo Haussen, Jeffrey Saver, Mayank Goyal, David Liebeskind, Dileep Yavagal, Tudor Jovin

Louisiana —Digvijaya Navalkele, Paige

Hargrove, Oleg Chernyshev, Joseph Acosta, Leopoldo DeAlvare, Gonzalo Hidalgo, Ramy El Khoury, Sheryl Martin-Schild

P6.262 Barriers and facilitators to

seeking medical care for young adults with acute stroke—a qualitative study —Dylan Jones, Haley Huggins, David Thaler, Paul Han, Lester Leung

P6.263 Utilization of Hospice Care

and Patient Characteristics Associated With Discharge to Hospice in Acute Ischemic Stroke Patients —Mai Vuong,

Syed Ali, Nabeel Chauhan, Sanjeeva Onteddu

P6.264 NA P6.265 Stroke Units with Dedicated Bedside Monitoring Improves Blood Pressure Control —Audrey Arango, Laura

Suhan, Yong-Bum Song, Briana DeCarvalho, Siddhart Mehta, Ashish Kulhari, Spozhmy Panezai, Jawad Kirmani

prognostication for Patients with Severe Ischemic Stroke? —Julia Bu, Colin Beilman, Cathy Sila

discharge disposition on outcomes in the SWIFT PRIME Trial —Samir Belagaje,

P6.274 WITHDRAWN P6.275 Extended length of stay in

cryptogenic stroke patients admitted over weekend —Jorge Pesquera, Digvijaya Navalkele, Sheryl Martin-Schild

P6.276 Five-year recurrence rate

following stroke in the Mashhad Stroke Incidence Study: A population-based study of stroke in the Middle East —

Amin Amiri, Maryam Salehi, Mahmoud Reza Azarpazhooh, Amanda G. Thrift, Moira Kapral, Luciano Sposato, Ali Shoeibi, Peyman Hashemi, Mohammad Taghi Farzadfard

P6.277 Association between

Demographic Characteristics and Hospital Admission in Patients Presenting to the Emergency Department for Transient Neurological Attack —Benjamin Kummer, Neal Parikh, Alexander Merkler, Hooman Kamel

P6.266 Transient Ischemic Attack

P6.278 Ischemic Stroke Outcomes

Hermanson, Nirali Vora, Wendy Brown, Sarah Jane DeVoe, Alicia Edwards, Nancy Isenberg

Arunodaya Gujjar, Nandhagopal Ramachandiran, Abdullah Al Alasmi, S. Ganguly, Rana Shoaib

(TIA) Rapid-Access Clinic: Improving outcomes and reducing costs —Sarah

in Oman: Experience of a University Hospital Based Stroke Registry —

Medical Management for Asymptomatic Carotid Stenosis: CREST-2 Update — Kevin Barrett, James Meschia, Brajesh Lal, George Howard, Gary Roubin, Robert Brown, Seemant Chaturvedi, Marc Chimowitz, Bart Demaerschalk, Virginia Howard, John Huston, Ronald Lazar, Wesley Moore, Claudia Moy, Tanya Turan, Jenifer Voeks, Thomas Brott

P6.280 Selection and Activation of

Sites in a Large Multi-center Randomized Clinical Trial —Bart Demaerschalk, Robert Brown, Virginia Howard, Meelee Tom, Mary Longbottom, Jenifer Voeks, Eldina Kadiric, James Meschia, Thomas Brott

P6.281 Evaluation of Antithrombotic

Bridging Methods in Acute Ischemic Stroke Patients with Atrial Fibrillation — Kara Swafford, Jessica Lee

P6.282 Risk Factors Among

Young Stroke Victims in Underserved Communities: Are These Strokes Preventable? —Matthew Wu, Neal Rao

P6.283 Predicting Pharmacokinetic

Versus Pharmacodynamic Aspirin Resistance in Patients —Erica Westphal, Michelle Rainka, Michelle Amsler, Traci Aladeen, Vernice Bates, Francis Gengo

P6.284 The Clinical Implications of

Assessing Platelet Responsiveness to Aspirin Using Whole Blood Platelet Aggregation versus Urinary 11-Dehydrothromboxane Testing —Erica

Westphal, Michelle Rainka, Patrick Galdun, Sarah Stanford, Vernice Bates, Francis Gengo

P6.285 Difference of Clinical

Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants —Taizen Nakase, Junta Moroi, Tatsuya Ishikawa

P6.286 Assessment of large vessel

posterior circulation thrombus with MRI and noncontrast CT. —Siddhart Mehta, Spozhmy Panezai, Ashish Kulhari, Audrey Arango, Briana DeCarvalho, Aashish Patel, Jawad Kirmani

P6.287 Is there a correlation between embolic strokes of undetermined source (ESUS) and patent foramen ovale (PFO)?—A contrasted Transcranial Doppler Ultrasound (cTCD) study. — Valéria Scavasine, Jamileh Chamma, Tatiana Bruch, Gabriel Braga, Rodrigo Bazan, Ayrton Massaro, Francisco Germiniani, Marcos Lange, Viviane Zetola

P6.288 Predictors for Early Atrial

Fibrillation Detection Among Cryptogenic Stroke Patients with Insertable Cardiac Monitors: A Single-Center Experience — Ganesh Asaithambi, Jane Monita, Sandra Hanson

P6.289 Risk factors of stroke

recurrence in a low income country: case of Senegal —Daniel Gams Massi, Japhari Nyassinde

P6.290 Diabetic microvascular

complications and stroke risk in the Asian population in Taiwan: A population based case-control study —Wei Chen, Sui-Foon Lo, Fung-Chang Sung

134 2017 AAN Annual Meeting Scientific Program


P6.291 Rates of Adverse Events

P6.304 Argentinian Validation of the

P6.316 Temporal Dot Sign of

Stanley, Caroline Knight, Robert Stein

Daniel Sanchez, Eugenia Lopez, Clara Pinasco, Teresa Torralva, Alfredo Thomson, Maria Roca, Bruno Diana

Niranjan Singh, Sushma Yerram

in the Very Old: A Community Anticoagulation Clinic Study —Michael

P6.292 Early cerebral ischemic

events in symptomatic carotid stenosis are related to plaque inflammation —Chi Hsien Tan, Prakash Paliwal, Arvind Sinha, Eric Ting, Hock Luen Teoh, Bernard Chan, Vijay Sharma

P6.293 Aspirin use is associated

with decreased initial stroke severity in patients with acute ischemic stroke: Pilot study —Judd Jensen, Jan Leonard, Raphael Bar-Or, Leonard Rael, Russell Bartt, Jeffrey Wagner, David Bar-Or

CARDIOVASCULAR ISSUES IN ISCHEMIC STROKE

Aggie Figures Learning Test (AFLT) —

P6.305 Application of

Neuropsychological Measures for Patients with Amyotrophic Lateral Sclerosis (ALS) —Megan Parmenter, Mona Shahbazi, Dale Lange

P6.306 Neural basis of the

Addenbrooke’s Cognitive Examination III: an 18F-fluorodeoxyglucose positron emission tomography study. —Jordi A

Matias-Guiu, Maria Nieves Cabrera-MartÌn, Alicia Perez-Perez, Maria Valles-Salgado, Teresa Rognoni, Ana Cortes-Martinez, Teresa Moreno-Ramos, Jose Carreras, Jorge MatiasGuiu

P6.307 Improving Cognitive

in patients with cryptogenic stroke —

Screening Accuracy and Efficiency II: Application for Parkinson’s disease —

P6.295 Acute Stroke Therapy in

P6.308 Improving Cognitive

Sung Cho, Lucy Zhang, Ken Uchino, Dolora Wisco

Davis, William Souillard-Mandar, Rhoda Au, Dana Penney

P6.294 Predictors of atrial fibrillation Swetha Renati, Leonardo Almeida, Sonisha Warren, Christina Wilson

Infective Endocarditis—Case Series and Systematic Review —Robert Marquardt,

Randall Davis, William Souillard-Mandar, Rhoda Au, Dana Penney

Screening Accuracy and Efficiency for Minimally Impaired Individuals —Randall

P6.296 Acute neurologic

P6.309 Is minimal effort effortless? A

Horn, Magdy Selim, Lester Leung

Bruno Lenne, Pascal Antoine

complications of cardiac catheterization: clinical syndromes and outcomes —Sarah

P6.297 Characterizing Ischemic

Stroke and Hemorrhagic Conversion in Infectious Endocarditis —Robert

Marquardt, Sung Cho, Lucy Zhang, Ken Uchino, Dolora Wisco

qualitative analysis of response bias on memory assessment —Rekha Barthelemy,

P6.310 Rapidly progressive dementia

as a manifestation of neurosyphilis: case report —Kelly Meza Capcha, Humberto Huapaya, Sheila Suarez, MarÌa Meza

Transient Global Amnesia—Case series and Literature review —Jagkirat Singh,

P6.317 Diagnostic Challenges

of Fahr’s Disease: A Case Report — Ellen Fitzmorris, Esther Bit-Ivan, Borna Bonakdarpour

P6.318 Congenital Extra-hepatic

porto-systemic shunt presenting with adult-onset fluctuating myelopathy and encephalopathy : a case report —Danielle Lux, Anna Naito, Neil Munro, Harikrishnan Sreedharan

P6.319 Retrospective Study

of Neurocognitive Outcomes in Autoimmune Encephalitis —Julien Hebert, Maria Gamoias Simoes, Claude Steriade, David Tang-Wai, Richard Wennberg

P6.320 Longitudinal Assessment

of Neuropsychological Performance in Patients with Idiopathic REM Sleep Behavior Disorder —Youngsin Jung,

Tanis Ferman, Mary Machulda, Julie Fields, Jonathan Graff-Radford, David Jones, Rodolfo Savica, David Knopman, Erik St. Louis, Michael Silber, Ronald Petersen, Bradley Boeve

P6.321 Does the cerebellum help

solve the “signal-to-noise” problem in sensory processing: evidence from vestibular activation in patients with cerebellar dysfunction —Raquel GalvanGarza, Yulia Valko, Kilian Dahlem, Ajitkumar Mulavara, Jeremy Schmahmann, Richard Lewis

P6.322 Cognitive Fatigue in Multiple Sclerosis: Objective Measures and Structural Correlates —Christos Bakirtzis,

P6.298 Altered Cerebral

BEHAVIORAL AND COGNITIVE NEUROLOGY: PHARMACOLOGICAL EFFECTS

Marina Boziki, Ioannis Nikolaidis, Panagiotis Ioannidis, Dimitris Karacostas, Nikolaos Grigoriadis

Alexandra Reynolds, Nicholas Morris, Joshua Willey

P6.311 Impact of Psychotropic drugs

P6.323 Cardiovascular risk factors

Hemodynamics Causing Neurologic Dysfunction in VA-ECMO —Lauren Dunn,

P6.299 Emergent MRI during a Stroke

on Seizure threshold —Muhammad Bhatti, Parshaw Dorriz

Alert. Single center experience. —Nidhi

P6.312 The Acute and Long Term

P6.300 Retrospective analysis of

Arsen Hunanyan, Adriana Azar, April Ratliff, Mohamad Mikati

Kapoor, Courtney Iser, David Thompson, Margaret Elaine Haxton, Evgeny Sidorov

Spinal Cord Infarction after Aortic Repair —Gino Gialdini, Alexander Merkler, Neal Parikh, Michael Lerario, Abhinaba Chatterjee, Hooman Kamel

P6.301 Association between stroke

subtype and left ventricular dysfunction evolution over time —Yi Li, Timothy Fitzgibbons, Nils Henninger

BEHAVIORAL AND COGNITIVE NEUROLOGY: DIAGNOSTIC TESTING

P6.302 Cognitive Neurology Toolkit:

An iPad App for Mental Status Testing — Daniel Press, Isabella Aslarus, Ellison Lim, Seth Amarasinghe, Chun Lim

P6.303 Validation of an ecological

Diana, Paula Carolina Torres, Vladimiro Sinay, Pagani Cassara Fatima, Maria Roca

P6.313 Persistence of Effect of

Dextromethorphan Hydrobromide/ Quinidine Sulfate (DM/Q) for Pseudobulbar Affect (PBA): Results from a 12-Week Open-Label Extension (OLE) Study —Benjamin Brooks, Erik Pioro, Paul

Maria-Beatriz Jurado, Michael Palacios, Daniel Moreno-Zambrano, Carlos Cevallos, Ibeth Regato Ugalde, Ximena Gamboa, MariaCarolina Duarte, Carlos Penaherrera, Leonardo Tamariz, Rocio Santibanez

P6.324 Lesion Mapping of Bilateral

Motor Threshold in Chronic Post-Stroke Hemiparesis —Aaron Boes, Douglas

Labar, Amy Kuceyeski, Alvaro Pascual-Leone, Michael Fox, Dylan Edwards

P6.325 Selective Deficits in Prosody

Shin, Ryan Law, Andrea Formella

after Right Hemisphere Stroke —Harry

BEHAVIORAL AND COGNITIVE NEUROLOGY: COGNITIVE DEFICITS IN NEUROLOGICAL DISORDERS

P6.326 Measurement of Social

Sutherland-Foggio, Amy Wright, Rajani Sebastian, Argye Hillis

Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study —

P6.314 Distinct Behavioural

Tom Burke, Marta Pinto Grau, Katie Lonergan, Marwa Elamin, Peter Bede, Emmet Costello, Orla Hardiman, Niall Pender

Elamin, Marta Pinto Grau, Katie Lonergan, Peter Bede, Mark Heverin, Alice Vajda, Russell McLaughlin, Niall Pender, Orla Hardiman

P6.327 What Makes Right

P6.315 Curious Case of Starvation

Sutherland-Foggio, Corey Demsky, Amy Wright, Sadhvi Saxena, Donna Tippett, Daniel Fogerty, Argye Hillis

Phenotypes in ALS: A Population Based Factor Analysis —Tom Burke, Marwa

Induced Wernicke’s Encephalopathy — Sharjeel Panjwani, Mohammad Humayun, Noor Pirzada

Hemisphere Stroke Patients Sound Emotionless? —Alexandra Basilakos, Harry

P6.328 Combined Mania and Visual-

Auditory Hallucinations in a Patient with Isolated Right Thalamic Hemorrhage: the

Parunyou Julayanont, Doungporn Ruthirago, Khondoker Alam, Yazan Alderazi

DISEASE MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: EFFICACY AND CLINICAL TRIAL OUTCOMES I

P6.329 Efficacy of Interferon β-1a

Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups: Post Hoc Analysis of PRISMS Data —Eric

Williamson, Hao Zhang, Julie Aldridge, Scott Baver, Regina Berkovich

P6.330 Safety and efficacy in

patients receiving natalizumab therapy in Hungary —Tunde Csepany, Gabor Lovas, Krisztina Bencsik, Csilla Rozsa, Krisztina Kovacs, Samuel Komoly, Peter Barsi, Zoltan Mor

P6.331 The Phase 2b SYNERGY

Trial: Analyses of Acute Brain Lesion Recovery —Karleyton Evans, Robert Brown,

Jie Li, Lei Xu, Douglas Arnold, Elizabeth Fisher, Robert Naismith, Alexey Boyko, Nikolaos Evangelou, Martin Valis, Nancy Richert, Diego Cadavid, Michelle Mellion

P6.332 Early Fingolimod Treatment

Improves Disease Outcomes at 2 and 4 years in Patients with RelapsingRemitting Multiple Sclerosis —Reinhard Hohlfeld, Ludwig Kappos, Davorka Tomic, Diego Silva, Kathrin Ringwald, Daniela Piani Meier, Krzysztof Selmaj

P6.333 Safety and Efficacy of

Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice: Interim Analysis of ESTEEM —Nicholas Everage, Claudia Prada, Shifang Liu, Konstantin Balashov, Richard Macdonell, Joerg Windsheimer, Kathryn Giles

P6.334 Evaluating the Effect of

Teriflunomide on Cortical Gray Matter Atrophy in the Phase 3 TOPIC Study —

Robert Zivadinov, Michael Dwyer, Ellen Carl, Kathinathan Thangavelu, Steven Cavalier, Niels Bergsland

P6.335 Long term efficacy and safety

of Dimethyl Fumarate: A 3 year follow-up in a single MS center —Peiqing Qian, Julia Joo, James Scanlan, James Bowen

P6.336 Clinical Trial Design protocol Tolervit-MS: TOLerance-induction with dendritic cells treated with VITamin-D3 and loaded with myelin peptides in Multiple Sclerosis patients. —Silvia

Presas, M José Mansilla, Juan Navarro, Aina Teniente-Serra, Bibiana Quirant-Sanchez, Ascension Lopez, Susana Inoges, Felipe Prosper, Eva Martinez-Caceres, Cristina Ramo

P6.337 Effects of Ocrelizumab on

Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design —Ann Herman, Bruno Musch,

Christopher Harp, Jian Han, Beverly Assman, Damian Fiore, Donna Masterman, Anne Cross, Amit Bar-Or

P6.338 Efficacy of Ocrelizumab on

Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies —

Fast and easy registration · AAN.com/view/AM17 135

FRIDAY

test of incidental learning useful at medical office —Agostina Galiani, Bruno

Toxicity of Dextromethorphan in the Developing Brain —Jordan Richardson,

contribute differentially to cognitive functioning in middle-aged adults —

Behavioral Disconnection Syndrome —

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Poster Sessions

Poster Session VI



Anthony Traboulsee, Stephen Hauser, Eva Havrdova, Ludwig Kappos, Michael Racke, Krzysztof Selmaj, Shibeshih Belachew, Corrado Bernasconi, Donatella Morandi, Hideki Garren, Wei Wei, Douglas Arnold

P6.339 Long-term Efficacy of

Teriflunomide in Patients Recently Diagnosed With Relapsing Forms of MS —Jiwon Oh, Mark Freedman, Aaron Miller, Kathinathan Thangavelu, Philippe Truffinet, Giancarlo Comi

P6.340 Treatment with interferon

reduces the appearance of lesions in clinically relevant white matter (WM) tracts in patients with clinically isolated syndrome (CIS) —Marco Battaglini,

Hugo Vrenken, R Tappa Brocci, G Gentile, L Luchetti, A Versteeg, Mark Freedman, Bernard Uitdehaag, Ludwig Kappos, Giancarlo Comi, Frederik Barkhof, Nicola De Stefano

P6.341 Benefit of Long-term

Treatment With Teriflunomide on Disability Outcomes: Results From TEMSO and TOWER —Fred Lublin, Mark

CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion —Amy

Lovett-Racke, Yue Liu, Michael Racke, Richard Shubin, Sibyl Wray, Wendy Su, James Eubanks, Edward Fox

P6.349 Cladribine tablets in

the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) —Giancarlo Comi, Thomas Leist,

Mark Freedman, Bruce Cree, Patricia Coyle, Hans-Peter Hartung, Patrick Vermersch, Doris Damian, Fernando Dangond

P6.350 In treatment-naive patients

with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real-world results from the TYSABRI® Observational Program (TOP) —Timothy Spelman, Helmut

Freedman, Giancarlo Comi, Aaron Miller, Kathinathan Thangavelu, Philippe Truffinet, Ludwig Kappos

Butzkueven, Ludwig Kappos, Maria Trojano, Heinz Wiendl, Yi Chen, Nolan Campbell, Stephanie Licata, Pei-Ran Ho

P6.342 Assessment of the effect

P6.351 Defining High Disease

of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis —

Subhash Tummala, Shahamat Tauhid, Shelley Hurwitz, Rohit Bakshi

P6.343 Clinical Efficacy of

Interferon β-1a Subcutaneously Three Times Weekly According to Baseline Radiological Characteristics: Post Hoc Analyses of PRISMS Data —Flavia Nelson, Gary Cutter, Kathleen Hawker, Julie Aldridge, Anthony Reder

P6.344 The RADIANCE and

SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics —

Bruce Cree, Krzysztof Selmaj, Jeff Kopicko, Tjalf Ziemssen, Nicola De Stefano, Amit BarOr, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalban, Eva Havrdova, Ludwig Kappos, Jeffrey Cohen

P6.345 5 years effectiveness of

fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany —

Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study —Gavin Giovannoni, Kottil Rammohan, Stuart Cook, Giancarlo Comi, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Fernando Dangond, Christine Hicking

P6.352 Efficacy of Delayed-release

Dimethyl Fumarate at Seven-Year Follow-up in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE —Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert Fox, James Xiao, Catherine Miller

P6.353 Durable efficacy of

cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies —Per Soelberg-Sorensen, Gavin

Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Patrick Vermersch, Christine Hicking, Abidemi Adeniji, Fernando Dangond

P6.354 Interferon BETA-1B Efficacy

Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen

in Real-life Clinical Setting: A Long-term Follow-up Study —Rocco Totaro, Caterina

P6.346 Effect of oral fingolimod

P6.355 Highly active relapsing

treatment on brain volume loss in patients with relapsing-remitting multiple sclerosis estimated using Bayesian methodology —Guosheng Yin, Xiangyi Meng, M. Zahur Islam

P6.347 Short and long-term

FRIDAY

predictors of relapses or disability worsening in patients with multiple sclerosis in the phase 3 TRANSFORMS study —Pavle Repovic, Aaron Boster, Xiangyi

Di Carmine, Samanta Sciamanna, Carmine Marini, Antonio Carolei

remitting multiple sclerosis following hematopoietic stem cell transplantation: a case report —Amanda Piquet, Laura Baldassari, M. Paz Soldan

P6.356 Real-life long-term

effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort —Chiara Zecca, Serge Roth,

Meng, Daniela Piani Meier, Fernanda Boulos, Till Sprenger, Frederik Barkhof

Oliver Findling, Guillaume Perriard, Valérie Bachmann, Misha Pless, Andreas Baumann, Christian Kamm, Patrice LaLive, Adam Czaplinski

P6.348 Preliminary results of Phase

P6.357 Predictors of Disability in

2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-

Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate

136 2017 AAN Annual Meeting Scientific Program

Friday, April 28  8:30 a.m.—5:30 p.m. Low-frequency Administration (GALA) Study —Jessica Alexander, Donald Daudt,

Mat Davis, Natalia Ashtamker, Scott Kolodny

P6.358 Effect of early versus delayed treatment (DT) with subcutaneous IFN β-1a (scIFNβ-1a) on radiological activity free (RAF) or clinical activity free (CAF) status in patients with clinically isolated syndrome (CIS): A post-hoc analysis of REFLEXION —Mark Freedman, Giancarlo Comi, Patricia Coyle, Liang Chen, Kurt Marhardt, Ludwig Kappos

P6.359 Multi-center, randomized,

double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) The TERIS study —Christine Lebrun Frenay, Aksel Siva, Orhun Kantarci, Christina Azevedo, Maria Pia Sormani, Daniel Pelletier, Darin Okuda

P6.360 Efficacy of Cladribine Tablets

3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study —Gavin Giovannoni, Kottil Rammohan,

Stuart Cook, Giancarlo Comi, Peter Rieckmann, Per Soelberg-Sorensen, Patrick Vermersch, Fernando Dangond, Christine Hicking

P6.361 Impact of Long-term

Teriflunomide Treatment on Severe Relapses: Analysis of TEMSO and TOWER Extensions —Mathias Maurer,

Aaron Miller, Giancarlo Comi, Ludwig Kappos, Jerry Wolinsky, Martin Stangel, Richard Macdonell, Philippe Truffinet, Kathinathan Thangavelu, Mark Freedman

P6.362 Teriflunomide Is Effective in

Reducing Brain Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA Data —Mark Freedman, Till Sprenger, Ernst-Wilhelm Radue, Jens Wuerfel, Aaron Miller, Kathinathan Thangavelu, Steven Cavalier,

P6.363 Effectiveness of Delayed-

release Dimethyl Fumarate on Clinical Measures and Patient-reported Outcomes in Newly Diagnosed and Other Early Relapsing-Remitting Multiple Sclerosis Patients: Subgroup Analysis of PROTEC —Thomas Berger, Bruno Brochet, Paolo Confalonieri, Paul Giacomini, Xavier Montalban, Antonio Salgado, Macaulay Okwuokenye, Monica Fay, Adrien Bretagne

P6.364 Prolonged-Release

Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial —

Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew Goodman, Rachel Farrell, Veronica Englishby, Manjit McNeill, Ih Chang, Lahar Mehta, Jacob Elkins

P6.365 Effectiveness of fingolimod

in patients with relapsing-remitting multiple sclerosis in daily clinical practice in Spain: results from the multivariate pooled analysis Fingoview. —Jose Meca Lallana, Guillermo Izquierdo, Jose Ramon Ara, Celia Oreja-Guevara, Lucia Forero Diaz, Lucia, Teresa Ayuso, Angel Sempere, Nicholas Herrera, Yessica Contreras, Irene SanchezVera, Maria Jose Moreno Jimenez, Francisco Javier Ricart, Eli Garcia

COMPARATIVE EFFICACY OF DISEASE MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

P6.366 Comparison of Adherence

and Persistence to Glatiramer Acetate 40 mg/mL Three-Times Weekly Subcutaneous Injections Versus Oral Therapies in Multiple Sclerosis —Helen

Trenz, Djibril Liassou, Ryan Wolbeck, Ravi Iyer, Ying Wu

P6.367 SC peginterferon beta-1a

every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 5 Phase 3 trials —Patricia Coyle, Shulian Shang, Carmen Castrillo-Viguera

P6.368 Peginterferon Beta-1a

Demonstrated Better Clinical Outcomes than Teriflunomide in Patients with Relapsing MS, Using a Matchingadjusted Comparison of Phase 3 Trials —

Scott Newsome, Maria Naylor, Shulian Shang, Carmen Castrillo-Viguera

P6.369 Comparison of treatment

retention and efficacy outcomes with fingolimod, interferons and glatiramer acetate in PREFERMS —Florian Thomas,

Douglas Arnold, Mark Cascione, Edward Fox, Cecilia Vieira Da Silva, John Ko, Xiangyi Meng, Lesley Schofield, Fernanda Boulos, Nadia Tenenbaum, Bruce Cree

P6.370 A Bayesian Random Effects Mixed Treatment Comparison of Daclizumab Versus Other Disease Modifying Treatments for RelapsingRemitting Multiple Sclerosis —Craig Wakeford, Richard Birnie, Robert Wolff, Elizabeth Kinter, Guido Sabatella, Giorgio Giannattasio, Xiaolan Ye, Ying Liu, Jos Kleijnen

P6.371 Advanced Myelin-related

MRI Measures in Relapsing Multiple Sclerosis Patients treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks —Shannon Kolind, Irene Vavasour, Lisa Tang, Roger Tam, Alexander Rauscher, David Clayton, Victoria Levesque, Robert Carruthers, Rick White, David Li, Anthony Traboulsee

P6.372 Comparative analysis of MS

outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide —Timothy

Spelman, Tomas Kalincik, Maria Trojana, Francois Grand-Maison, Guillermo Izquierdo, Eva Havrdova, Dana Horakova, Alessandra Lugaresi, Pierre Duquette, Pierre Grammond, Raymond Hupperts, Jeannette Lechner-Scott, Franco Granella, Thor Peterson, Murat Terzi, Eugenio Pucci, Patrizia Sola, Vincent Van Pesch, Gerardo Iuliano, Cavit Boz, Roberto Bergamaschi, Mark Slee, Helmut Butzkueven

P6.373 Comparable efficacy of

fingolimod and natalizumab in real life study —Roberta Lanzillo, Antonio Carotenuto, Marcello Moccia, Cinzia Valeria Russo, Chiara Criscuolo, Luigi Lavorgna, Marco Massarelli, Anna De Rosa, Francesco Sacca, Vincenzo Brescia Morra

P6.374 A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a


and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis —Thomas Scott, Shulian Shang, Carmen Castrillo-Viguera

P6.375 Comparative Effectiveness

of Delayed-release Dimethyl Fumarate Versus Fingolimod and Teriflunomide on Risk of Relapse —Jacqueline Nicholas, Aaron Boster, Ning Wu, Ming-Yi Huang, Katherine Riester, Mehul Jhaveri, Michael Edwards, Andrew Lee

P6.376 Fingolimod significantly

lowers neurofilament light chain blood levels in RRMS patients as compared to interferon beta-1a or placebo —Jens Kuhle, Christian Barro, Ludwig Kappos, Rolf Meinert, Frank Dahlke, Harald Kropshofer, Davorka Tomic, David Leppert

P6.377 Efficacy of Natalizumab

and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting: a 2-year follow-up —Rocco

Totaro, Gianfranco Costantino, Maura Danni, Paolo Bellantonio, Caterina Di Carmine, Roberta Fantozzi, Raffaella Cerqua, Aurora Fuiani, Ciro Mundi, Carmine Marini, Diego Centonze, Leandro Provinciali, Antonio Carolei

P6.378 Myelin repair and improved

axonal integrity over time in relapsing remitting multiple sclerosis; comparative analysis of Fingolimod, Natalizumab and Glatitramer acetate —Sara Razmjou, Fen Bao, Kalyan Yarraguntla, Samuel LichtmanMikol, Rishi Sood, Christina Caon, Carla Santiago Martinez, Navid Seraji-Bozorgzad, Evanthia Bernitsas, Omar Khan

P6.379 Effect of dimethyl

P6.384 Number Needed to Treat

Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab —Giancarlo Comi, Raed Alroughani, Regina Berkovich, Volker Limmroth, Richard Macdonell, Thibault Moreau, Heinz Wiendl, Bart Van Wijmeersch, Maria Melanson, Kathinathan Thangavelu, Mark Freedman, Aaron Boster

P6.394 Lipid profile in neuromyelitis optica spectrum disorder between clinical attack and remission state. —

Misong Choi, Jin-Myoung Seok, Hee-Young Shin, Kwang Lee, Byoung Joon Kim, Ju-Hong Min

P6.395 Diffusion Weighted Imaging in a Case of Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica —Lauren Gluck, Sarah Vollbracht

NEUROMYELITIS OPTICA SPECTRUM DISORDER, TRANSVERSE MYELITIS, AND OPTIC NEURITIS B

OPTICAL COHERENCE TOMOGRAPHY IN MULTIPLE SCLEROSIS

P6.385 Earlier Treatment of Acute

P6.396 Retinal Layer Thinning May

Relapses in Neuromyelitis Optica Spectrum Disorder Leads to Better Outcomes —Jessica Coleman, Jennifer Ng, Maureen Mealy, Michael Levy

P6.386 Defining Area Postrema

(AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) —Eslam

Shosha, Masoud Majed, Brian Weinshenker, Eoin Flanagan, Carey Huebert, Jessica Sagen, Michael Levy, Benjamin Greenberg, Sean Pittock

P6.387 Area postrema syndrome

more specific than extension of lesion on MRI for Neuromyelitis Optica Spectrum Disorder —Divyanshu Dubey, Sean Pittock, Karl Krecke, Eoin Flanagan

P6.388 Oral lipoic acid as a

treatment for acute optic neuritis: A blinded, placebo-controlled randomized trial —Vijayshree Yadav, Michele Mass,

Reflect Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: The Ethnicity Role —Samuel Lichtman-Mikol, Sheridan Reed, Sara Razmjou, Fen Bao, Kalyan Yarraguntla, Rishi Sood, Christina Caon, Carla Santiago Martinez, Evanthia Bernitsas, Navid Seraji-Bozorgzad, Omar Khan

interferon for treatment of relapsingremitting multiple Sclerosis —Neda

Sattarnezhad, Brian Healy, Moogeh Baharnoori, Camilo Diaz-Cruz, James Stankiewicz, Howard Weiner, Tanuja Chitnis

P6.382 PREFERMS study: post hoc

analyses of patient retention, key clinical outcomes and patient satisfaction in an African-American patient subgroup — Mark Cascione, Jeanette Wendt, Bruce Cree, Xiangyi Meng, Lesley Schofield, Nadia Tenenbaum

Alemtuzumab: efficacy and autoimmunity in multiple sclerosis induction treatment —Klaus Schmierer,

Samuel Herrod, Cesar Alvarez-Gonzalez, David Baker

in multiple sclerosis patients and healthy controls through angio-OCT and correlations to disease features. —

P6.391 Atypical myelitis of multiple

Ashwini Nandoskar, Jeremy Chataway, John Greenwood

P6.392 Color vision impairment

following optic neuritis and its association with retinal atrophy —Netta Levin, Michael Devereux, Nicholas Baker, Ari Green

P6.393 Detection of Anti Mog

Antibodies in Demyelinating Disorders of the Central Nervous System (CNS) — Antonio Bertolotto, Marco Alfonso Narduc Capobianco, Michela Spadaro, Arianna Sala

Architecture and Blood Flow in Multiple Sclerosis —Richard Nicholas, Adam Dubis,

P6.402 Optical Coherence

Tomography Segmentation Analysis in Relapsing Remitting versus Progressive Multiple Sclerosis —Raed Behbehani, Abdullah Abu Al-Hassan, Ali Al-Salahat, Devarajan Sriraman, Jonathan Oakley, Raed Alroughani

P6.403 Clinical and optical coherence tomography outcome in secondary progressive multiple sclerosis patients after autologous mesenchymal stem cells intrathecal transplantation. —

Mariola Matysiak, Malgorzata Siger, Joanna Wojtkiewicz, Monika Barczewska, Katarzyna Jezierska-Wozniak, Igor Selmaj, Wojciech Maksymowicz, Krzysztof Selmaj

Fast and easy registration · AAN.com/view/AM17 137

FRIDAY

P6.383 Cladribine versus

Croese, Simone Guerrieri, Giovanni Di Maggio, Stefania Medaglini, Lucia Moiola, Ubaldo Del Carro, Vittorio Martinelli, Roberto Furlan, Giancarlo Comi, Letizia Leocani

P6.401 Changes in Retinal Vessel

Clarisse Carra-Dalliere, Pierre Labauge, Xavier Ayrignac, Mikael Cohen, Christine Lebrun Frenay, Jerome De Seze, Nicolas Collongues

Pandey, Jillian Mohn, Shira Russell-Giller

relapsing multiple sclerosis is associated with visual and global disability and MRI and neurphysiological measures of CNS damage —Marco Pisa, Tommaso

Pedrini, Christine Bundell, Chee Keong Wee, Michaela Lucas, William Carroll, Allan Kermode

sclerosis: description of a French cohort —Carole Lambert, Laurent Kremer,

Function and Optical Coherence Tomography (OCT) Measures in Persons with Multiple Sclerosis (MS) —Krupa

P6.399 Retinal axonal loss in

Roberta Lanzillo, Chiara Criscuolo, Gilda Cennamo, Antonio Carotenuto, Nunzio Velotti, Federica Sparnelli, Alessandra Cianflone, Marcello Moccia, Vincenzo Brescia Morra

P6.381 Dimethyl fumarate versus

P6.406 Self-Reported Cognitive

Pisa, Simone Guerrieri, Giovanni DiMaggio, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Letizia Leocani

P6.390 Low Prevalence of anti

Justin Honce, Kavita Nair, Brian Hoyt, Stefan Sillau, Brittany Wedeman, Eric Engebretson, Maria Vieira, Nadia Tenenbaum, Lisa Siconolfi, John Corboy, Timothy Vollmer, Enrique Alvarez

Maria Petracca, Catarina Saiote, Enricomaria Mormina, Jonathan Howard, Paolo Gallo, Aaron Miller, Fred Lublin, Matilde Inglese

different subtipes of multiple sclerosis: an OCT, ffVEP and mfVEP study. —Marco

P6.400 Retinal vascular network

aquaporin 4 antibody in neuromyelitis optica spectrum disorder and multiple sclerosis in Western Australia —Marzena

based measure to explore the visual pathways in primary-progressive Multiple Sclerosis —Valentina Poretto,

P6.398 Visual pathway damage in

Joachim Bas, Michel Ticchioni, Maria Rosenthal, Romaric Lacroix, Corinne Brunet, Audrey Rico Lamy, Jean Pelletier, Bertrand Audoin, Christine Lebrun Frenay

changes in Brain Volume in Long Term Users of Glatiramer Acetate versus Fingolimod in Multiple Sclerosis: Preliminary analysis of a Two-Year Longitudinal Observational Study —

P6.405 A composite MRI and OCT

Razmjou, Sheridan Reed, Samuel LichtmanMikol, Christina Caon, Carla Santiago Martinez, Navid Seraji-Bozorgzad, Evanthia Bernitsas, Omar Khan

P6.380 Comparison of 12 month

B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study —Mikael Cohen, Gwendoline Romero,

Tabiri, Jared Srinivasan, Karl Wissemann, Damanjyot Anand, Lori Fafard, Barbara Bumstead, Marijean Buhse, Myassar Zarif, Mark Gudesblatt

benign & relapsing remitting multiple sclerosis; more evidence that benign multiple sclerosis is not benign. —Sara

Gail Marracci, Rohan Wanchu, Allison Fryman, William Hills, Julie Falardeau, Dennis Bourdette

P6.389 Monitoring CD27+ memory

into the Relationship between Visual Evoked Potential Latency (VEP-L) and Outcome Parameters from Optical Coherence Tomography (OCT) in Patients With Multiple Sclerosis (PwMS) —Kojo

P6.397 Similar retinal pathology in

fumarate and glatiramer acetate on the immunological profiles and gut microbiota in Multiple Sclerosis patients —Ilana Katz Sand, Yunjiao Zhu, Egle

Cekanaviciute, Bruce Cree, Sarkis Mazmanian, Hennesys Disla, Justine Debelius, Rob Knight, Corey Watson, Sneha Singh, Rachel Kanner, Sergio Baranzini, Patrizia Casaccia

P6.404 A Preliminary Investigation

Poster Sessions

Presenters Stand by Posters 4:00 p.m.–5:30 p.m.


Connect at Social Events There’s no better way to combine an evening of great fun and entertainment with unparalleled networking than to experience the Opening Party, Closing Party Happy Hour—or both. Whether you attend the Annual Meeting at the beginning or the end, these exciting social events are not-to-be-missed.

Opening Party

Sunday, April 23, 6:00 p.m.–10:00 p.m. Each registered meeting attendee will receive one free ticket to this event. Guest tickets are available through registration for $50.

Neurobowl®

6:00 p.m.–8:00 p.m. This popular event hosted by AAN former president Thomas R. Swift, MD, FAAN, is one of the Annual Meeting’s premier happenings. Neurobowl showcases the best and brightest in neurology competing for the coveted Neurobowl trophy in an entertaining game-show format.

NEW! Exhibit Hall Networking Reception

Monday, April 24, 4:30 p.m.–6:00 p.m. Sponsored by:

Open to all Annual Meeting attendees, this new event extends hall hours to give attendees an opportunity to mingle with exhibitors. Light snacks and beverages are served in the Exhibit Hall, Monday, April 24, 4:30 p.m.–6:00 p.m.

2017 AAN Run/Walk for Brain Research

Tuesday, April 25, 6:30 a.m.–8:30 a.m. Support research in neurology and join us for a 5k run or one-mile walk along the scenic Boston waterfront. Both occasional and seasoned runners, as well as walkers, will enjoy this beautiful event for a good cause. All proceeds will go to help support brain research. The race is open to all meeting attendees and their families. Refreshments will be available following the race. The registration fee is $50.

Trinity Irish Dance Company 8:30 p.m.–9:15 p.m.

Billed as “everything you expect but nothing you imagine,” Trinity Irish Dance Company quickly dispels whatever notions you may have about Irish dance. The company dazzles audiences with hard-driving percussive power, lightning-fast agility, aerial grace, and the awe-inspiring precision of its dancers that led them to win an unprecedented 17 World Championships for the US and appearances in feature films by Disney, DreamWorks, Touchstone, and Universal and on the Tonight Show.

Live DJ and Dancing: 9:15 p.m.–10:00 p.m.

Get down with friends and colleagues to some of the most memorable dance tunes spanning the past six decades.

NEW! Exhibit Hall Opening Lunch Sunday, April 23, 11:30 a.m.–1:30 p.m. Sponsored by:

Attend the opening lunch to mingle with fellow attendees and preview the latest products and services available in the neurologic industry. The exhibits will be open at this time.

138 2017 AAN Annual Meeting Science Program

Bus service to and from the race site will be provided. For registration and details, visit AAN.com/view/SocialEvents or contact Andrew Halverson at ahalverson@aan.com or (612) 928-6117.

Closing Party Happy Hour Friday, April 28, 5:30 p.m.–7:00 p.m.

Celebrate the end of a great meeting at a special early-evening happy hour event! Enjoy drinks, and socializing with colleagues, and swing out to your favorite jazz standards with a live performance by NEUROJAZZ, a four-piece ensemble led by AAN member Phillip Pearl, MD, FAAN. Each registered meeting attendee will receive one free ticket to this event. Guest tickets are available through registration for $50.

Reunion/In Conjunction With Meetings

Reconnect with your peers and program directors, and network with your fellow alumni at various department reunion meetings occurring throughout the Annual Meeting. These In Conjunction With (ICW) Meetings, formerly known as Affiliate Meetings, are designed for functions that include Annual Meeting attendees but are not planned by or sponsored by the AAN. If your department is interested in hosting its alumni meeting during the 2017 Annual Meeting, reserve your meeting today at AAN.com/view/ICW or by contacting Grace Henderson at ICW@aan.com or (612) 928-6103.


CLOSING PARTY! DON’T MISS THE

Friday, April 28

5:30 p.m.–7:00 p.m.

Celebrate the end of a great meeting at a special early-evening happy hour event! • Enjoy drinks and socializing with colleagues • Swing out to your favorite jazz standards with a live performance by NEURO JAZZ, a four-piece ensemble led by AAN member Phillip Pearl, MD, FAAN • Make plans to explore beautiful, historic Boston afterwards


Enhance your Annual Meeting experience with Annual Meeting On Demand. There is no better place than the AAN Annual Meeting for a high-quality educational experience in neurology. With the robust offering of concurrent courses available during the meeting, it is impossible to attend every one. Annual Meeting On Demand delivers captured content from the Annual Meeting to your doorstep so that you can experience all that the meeting has to offer. Annual Meeting On Demand is a CME accredited comprehensive digital library with more than 500 hours1 of presentations from the 2017 AAN Annual Meeting including syllabi for 200+ programs. Features of Annual Meeting On Demand include: • Online access to content within 24 hours of live presentations. • Integrated online CME testing. • An advanced search engine that delivers a direct link to the specific presentations and slides containing your search terms. • Downloadable PDFs of presentation slides and syllabi summaries. • Downloadable MP3 files provide the option of listening to any (or all) lectures while driving, traveling, or any occasion where audio is most convenient. • A complimentary portable hard drive2 for offline viewing when internet is not available. 1

2

Specific presentations within a session may not be available or may be audio only if the presenter has confidential patient information or otherwise declines to be recorded. Hard drive does not include all the functionality available online, such as Advanced Search, MP3/PDF Downloads, Bookmarks, Recently Viewed and CME testing.

.

140 2017 AAN Annual Meeting Science Program


Annual Meeting Attendee Pricing: Gold Registration Upgrade to gold registration and receive all sessions at the meeting* as well as access to Annual Meeting On Demand. With so many concurrent sessions, Gold Registration is the best value for attendees who want to experience the full value of the meeting. * Skills Workshops, Neurology MOC Prep Course, Improving Your Leadership Skills: A Practical Approach, Women in Leadership, Leadership Effectiveness for Clerkship and Program Directors Academy, Early Career Research Training Symposium, The Most Important Tool in Your Black Bag: Gallup StrengthsFinder™ Assessment Courses, and Mentoring…Growing the Next Generation of Neurologist are not included in the Annual Meeting registration price. These courses require pre-registration, may have a separate registration fee, and are subject to closure due to reaching maximum capacity.

Gold Registration BEFORE March 30, 2017

AFTER March 30, 2017

STUDENTS

$199

$199

SENIOR & HONORARY

$399

$399

JUNIOR

$444

$534

NON-NEUROLOGIST MEMBER

$619

$769

MEMBER

$1,119

$1,379

NONMEMBER

$1,819

$2,259

Select Gold Registration when you register for the meeting!

Syllabi USB Upgrade! All attendees will receive complimentary online access to all Annual Meeting syllabi for one year. Upgrade to a Syllabi On Demand USB drive for permanent use. Syllabi On Demand is a quick reference tool with summaries for 200+ programs from the 2017 Annual Meeting. Order Online: AAN.com/view/Register

Not attending the 2017 Annual Meeting? You can still pre-order On Demand products prior to the meeting and receive a special discount. Learn more by calling or visiting online. Order Online: AANonDemand.com/PreMeeting Order by Phone: (800) 501-2303 or (818) 844-3299 Pre-meeting discounts expire April 21, 2017.

Syllabi USB Pricing Syllabi On Demand (USB upgrade)

MEMBER, SENIOR, & HONORARY

$39

NONMEMBER

$59

JUNIOR AND NONNEUROLOGIST MEMBER

$29

Non-Attendee Pricing Annual Meeting On Demand

Syllabi On Demand

MEMBER, SENIOR, & HONORARY

$649

$199

NONMEMBER

$949

$299

JUNIOR AND NONNEUROLOGIST MEMBER

$199

$99

Fast and easy registration · AAN.com/view/AM17 141


2017 Award Recipients The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy, fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey.

Alliance Awards: Founders

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance

Recipient: Emer McGrath, MB, BCh Boston, MA S35: Aging and Dementia: Neuroimaging in Neurodegenerative Diseases Wednesday, April 26, 3:30 p.m.

S. Weir Mitchell

Sponsored by the American Academy of Neurology and endowed by the former American Academy of Neurology Alliance

Recipient: Richard Ryan Darby, MD Boston, MA S18: Behavioral and Cognitive Neurology Monday, April 24, 3:42 p.m.

American Academy of Neurology President’s Award

Recipient: Anthony G. Alessi, MD, FAAN Norwich, CT

American Brain Foundation Chair’s Award Sponsored by the American Brain Foundation

Recipient: Francis I. Kittredge, Jr., MD, FAAN Bangor, ME

Association of Indian Neurologists in America (AINA) Lifetime Achievement Award

Sponsored by the American Brain Foundation and endowed by the Association of Indian Neurologists in America (AINA)

Recipient: Kapil D. Sethi, MD, FRCP, FAAN Augusta, GA

Award for Creative Expression of Human Values in Neurology

Sponsored by the Ethics, Law, and Humanities Committee, a joint committee of the American Academy of Neurology, the American Neurological Association, and the Child Neurology Society

Recipient: Kathryn Rae Wagner, MD, PhD Baltimore, MD Taking Emmanuel Home

A.B. Baker Award for Lifetime Achievement in Neurologic Education

Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals

Recipient: Harold P. Adams, Jr., MD, FAAN Iowa City, IA C74: Annual A.B. Baker Program: Focus on Professionalism Monday, April 24, 7:00-9:00 am

Dreifuss-Penry Epilepsy Award

Sponsored by the AAN and endowed by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Neuroscience; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma

Recipient: William Stacey, MD, PhD Ann Arbor, MI S34: Epilepsy and Clinical Neurophysiology (EEG) II Wednesday, April 26, 3:30 p.m.

John Dystel Prize for Multiple Sclerosis Research

Sponsored by the AAN and National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society.

Recipient: Alan J. Thompson, MD, FRCP, FAAN London, United Kingdom S33: Progressive MS Therapeutics Wednesday, April 26, 3:30 p.m.

Sheila Essey Award: An Award for ALS Research

Presented by the AAN and the ALS Association and supported through the philanthropy of the Essey family and the ALS Association

Recipient: John M. Ravits, MD, FAAN La Jolla, CA S3: ALS: Disease Mechanism and Therapeutics Sunday, April 23, 1:00 p.m.

Norman Geschwind Prize in Behavioral Neurology

Sponsored by the American Academy of Neurology and endowed through Dr. Geschwind’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology

Recipient: Peter Turkeltaub, MD, PhD Washington, DC S18: Behavioral and Cognitive Neurology Monday, April 24, 3:30 p.m.

142 2017 AAN Annual Meeting Science Program


Wayne A. Hening Sleep Medicine Investigator Award

Sponsored by the AAN and endowed by UCB Inc. Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening

Recipient: Tiffany Braley, MD, MS Ann Arbor, MI S14: Highlights in Sleep Science Monday, April 24, 1:24 p.m.

International Scholarship Award Sponsored by the American Academy of Neurology

Recipients: Dr. Cyrus Escabillas Manila, Philippines Dr. Fabio Porto Sao Paulo, Brazil Dr. Alagoma Iyagba Port Harcourt, Nigeria Dr. Miguel Wilken Buenos Aires, Argentina Dr. Julia Pakpoor Oxford, United Kingdom Dr. Imen Kacem La Manouba, Tunis, Tunisia Dr. Tan Lin Qingdao, Shandong, China

Dr. Roosevelt Francois Mirebalais, Haiti Dr. Janet Ebid Cairo, Egypt Dr. JieQiong Li Qingdao, Shandong, China Dr. Kiran Patil Puducherry, India Dr. Seid Gugssa Addis Ababa, Ethiopia Dr. Makoto Hara Tokyo, Japan Dr. Fei Han Beijing, China Dr. FeiFei Zhai Beijing, China

Mitchell B. Max Award for Neuropathic Pain

Sponsored by the AAN and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max

Recipient: C Peter N Watson, MD Toronto, Ontario S38: Pain and Palliative Care Thursday, April 27, 1:00 p.m.

Lawrence C. McHenry Award: An Award for the History of Neurology Sponsored by the American Academy of Neurology

Recipient: Christopher J. Boes, MD, FAAN Rochester, MN S28: History of Neurology Wednesday, April 26, 1:00 p.m.

Medical Student Essay Awards: Extended Neuroscience Award

Sponsored by the American Academy of Neurology

Recipient: Aaron Bowen Denver, CO P2.409: Recycling endosomes mediate local, Golgiindependent secretory trafficking in neuronal dendrites Monday, April 24, 8:30 am

G. Milton Shy Award in Clinical Neurology Sponsored by the American Academy of Neurology

Recipient: Moon Jeong Lee Baltimore, MD P2.410: Utility of an Electronic Customizable Sleep Behavioral Software Program “MySleepScript” in individuals with acquired brain injury Monday, April 24, 8:30 am

Roland P. Mackay Award in Historical Aspects Sponsored by the American Academy of Neurology

Recipient: Bob Sun Cleveland, OH P2.411: Patients or Participants? The 1977 National Bioethics Commission and Multidisciplinary Oversight of “Innovative” Psychosurgery Monday, April 24, 8:30 am

Saul R. Korey Award in Experimental Neurology Sponsored by the American Academy of Neurology

Recipient: Chelsea Zhang Dallas, TX P2.412: Quantitative Comparison of K-D Balance and Sway Balance™ System Mobile Device Applications Monday, April 24, 8:30 am

Movement Disorders Research Award

Sponsored by the AAN, the Parkinson’s Disease Foundation, and the AAN Movement Disorders Section and endowed by the Parkinson’s Disease Foundation.

Recipient: Andrew Singleton, PhD Bethesda, MD S22: Parkinson’s Disease: Observational Studies Tuesday, April 25, 1:00 p.m.

Neuro-oncology Investigator Award

Sponsored by the American Academy of Neurology and supported by friends of Dr. Jerome Posner

Recipient: Michelle Monje, MD, PhD Stanford, CA S41: Neuro-oncology Thursday, April 27, 1:00 p.m.

Neuro-oncology Scientific Award

Sponsored by the American Academy of Neurology and supported by friends of Dr. WK Alfred Yung

Recipient: Mario Suva, MD, PhD Boston, MA S41: Neuro-oncology Thursday, April 27, 1:12 p.m.

Neuroendocrine Research Award

Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog

Recipient: Gustavo Roman, MD, DrHC Houston, TX Neuroendocrinology Section Meeting Fast and easy registration · AAN.com/view/AM17 143


2017 Award Recipients Neuroscience Research Prize

Sponsored by the American Academy of Neurology and the Child Neurology Society

Recipient: Pravin Ravishanker Sunnyvale, CA P1.408:  ALZCan: Predicting Future Onset of Alzheimer’s Using Polygenic Risk Scores, Cognitive Tests, CSF Biomarkers, and Multiple Neuroimaging Modalities Sunday, April 23, 8:30 a.m. Recipient: Tejas Athni Macon, GA P1.409:  Inhibiting the Proliferation of Patient-Derived Glioblastoma Multiforme (GBM) Cells and U-87 MG Cell Line Using Leaf Extract of Bacopa monnieri Sunday, April 23, 8:30 a.m. Recipient: Gokul Kannan Highland, MD P1.410:  Triggering the brain to heal itself after traumatic brain injury: where glia, anesthesia and nanomedicine meet Sunday, April 23, 8:30 a.m.

Child Neurology Neuroscience Research Prize

Sponsored by the American Academy of Neurology and the Child Neurology Society

Recipient: Lauren Singer Scarsdale, NY Child Neurology Society Meeting Transient Visually-Evoked Potentials as a Novel Biomarker for Autism and Phelan-McDermid Syndrome

Michael S. Pessin Stroke Leadership Prize Sponsored by the AAN and endowed by Dr. Pessin’s family, friends, and colleagues.

Recipient: James F. Burke, MD, MS Ann Arbor, MI S25: Cerebrovascular Disease and Interventional Neurology: Prehospital and Emergency Department Ischemic Stroke Care Tuesday, April 25, 3:30 p.m.

Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases

Sponsored by the AAN and the American Brain Foundation and funded through the philanthropy of the Potamkin family

Recipients: Claudia Kawas, MD Irvine, CA S7: Aging and Dementia: Clinical and Translational Studies in Neurodegenerative Diseases Sunday, April 23, 3:30 p.m. Kristine Yaffe, MD San Francisco, CA S7: Aging and Dementia: Clinical and Translational Studies in Neurodegenerative Diseases Sunday, April 23, 3:30 p.m.

144 2017 AAN Annual Meeting Science Program

Safety and Quality Award

Sponsored by the American Academy of Neurology

Recipients: David Do, MD Philadelphia, PA Ensuring Adequate Nutrition Delivery in the Neurointensive Care Unit Preston Douglas, MD Maywood, IL Simulation-based training in brain death determination incorporating family discussion Raghav Govindarajan, MD Columbia, MO Telephonic Single Breath Count Test Administered by Nurses in Diagnosing Myasthenia Exacerbation James E. Siegler III, MD Philadelphia, PA Inter-Provider Communication Using a Scheduled Provider Alert-Response Communication System (SPARCS) in 3 Inpatient Neurology Units

Irwin Schatz Award for Autonomic Disorders Sponsored by the American Academy of Neurology and endowed by Lundbeck, Inc.

Recipient: Phillip A. Low, MD, FAAN Rochester, MN S11: Autonomic Disorders: Synucleinopathies Monday, April 24, 1:00 p.m.

Bruce S. Schoenberg International Award in Neuroepidemiology Sponsored by the American Academy of Neurology and endowed by GlaxoSmithKline, Inc.

Recipient: Yogeshwar V. Kalkonde, MD Gadchiroli, Maharashtra, India S15: Neuroepidemiology Monday, April 24, 3:30 p.m.

Sleep Science Award

Sponsored by the American Academy of Neurology and the Sleep Section and endowed by Cephalon, Inc.

Recipients: Carlos H. Schenck, MD Minneapolis, MN S14: Highlights in Sleep Science Monday, April 24, 1:00 p.m. Mark W. Mahowald, MD Minneapolis, MN S14: Highlights in Sleep Science Monday, April 24, 1:00 p.m.


Jon Stolk Award in Movement Disorders for Young Investigators

Sponsored by the AAN and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and VelaPharma

Recipient: Marios Politis, MD, MSC, DIC, PhD, FEAN London, United Kingdom S22: Parkinson’s Disease: Observational Studies Tuesday, April 25, 1:00 p.m.

Harold Wolff-John Graham Award: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals.

Recipient: Simple Futarmal Kothari Aarhus, Denmark S52: Headache: Clinical Trials and Disease Burden Friday, April 28, 1:00 p.m.

H. Richard Tyler Award

Sponsored by the American Academy of Neurology and the AAN History Section

Recipient: Douglas Lanska, MD, FAAN Tomah, WI

Kenneth M. Viste Jr., MD Patient Advocate of the Year Award

Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends and patients

Recipient: Elaine C. Jones, MD, FAAN Bristol, RI

CESC: 17AM Family Friendly Activities Ad—Half Page Horizontal> AN Placed in AANnews 8.25 x 5.25 +0.125 bleed, 4C

We’re Making It Easier to Bring the Entire Family! We’re making it easier than ever to bring the entire family to the totally customizable Annual Meeting! You’ll have more opportunities to take in your favorite sessions, attend to the family, and still have time to explore beautiful, historic Boston. z Enjoy the enhanced mothers room with a quiet, comfortable family lounge and changing stations z Discover a variety of child care options available throughout Boston—check with your hotel concierge for details

z Explore beautiful, historic Boston and take in familyfriendly fun like the New England Aquarium, IMAX Theatres, Children’s Theater, Science Museum, Franklin Park Zoo, and more—visit familyfriendlyboston.com for more ideas

AAN.com/view/AM17


2017 Research Program Recipients Career Development Award

Funded by the American Academy of Neurology

Recipient: Lidia Maria Moura, MD, MPH Massachusetts General Hospital/Harvard Medical School

Neurology Research Training Scholarship Funded by the American Academy of Neurology

Recipient: Hsiao-Tuan Chao, MD PhD Baylor College of Medicine

Clinical Research Training Fellowship in ALS Research Funded by the ALS Association

Recipient: Nicholas Thompson Olney, MD UCSF

Clinical Research Training Fellowship in Epilepsy Funded by Lundbeck

Recipient: Shennan Weiss, MD, PhD Thomas Jefferson University

Clinical Research Training Fellowship in Muscular Dystrophy

Cosponsored by the American Academy of Neurology, the American Brain Foundation and the Muscular Dystrophy Association

Recipient: Johanna Hamel, MD University of Rochester

Clinical Research Training Fellowship in Parkinson’s Disease

Funded by the American Academy of Neurology, the American Brain Foundation and AbbVie

Recipient: Baijayanta Maiti, MD, PhD Washington University in St. Louis

Clinical Research Training Fellowship in Parkinson’s Disease Funded by Lundbeck

Recipient: Laurie Robak, MD, PhD Baylor College of Medicine

Clinical Research Training Fellowship in Parkinson’s Disease

Cosponsored by the American Academy of Neurology, the American Brain Foundation and the Parkinson’s Disease Foundation

Recipient: Michelle Fullard, MD University of Pennsylvania

Clinical Research Training Fellowship in Tourette Syndrome

Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the Tourette Association of America

Recipients: Flint Martin Espil, PhD Stanford University Joseph McGuire, PhD University of California Los Angeles

146 2017 AAN Annual Meeting Science Program

Clinical Research Training Scholarship (formerly Fellowship)

Funded by the American Academy of Neurology

Recipients: Melissa M. Cortez, DO University of Utah Isaac Marin-Valencia, MD The Rockefeller University Afsaneh Shirani, MD University of Texas Southwestern Medical Center, Dallas

Clinician-Scientist Development Award in Multiple Sclerosis

Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the National MS Society

Recipient: TBD

Clinician-Scientist Development Three-Year Award in ALS Research Funded by the ALS Association

Recipient: Sabrina Paganoni, MD, PhD Massachusetts General Hospital

Lawrence M. Brass, MD, Stroke Research Fellowship

Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the American Heart Association/American Stroke Association

Recipient: TBD

Practice Research Training Scholarship (formerly Fellowship)

Funded by the American Academy of Neurology

Recipients: Christopher Tarolli, MD University of Rochester

Research Training Fellowship in Ataxia

Cosponsored by the American Academy of Neurology, the American Brain Foundation and the National Ataxia Foundation

Recipient: Jill Sergesketter Butler, PhD University of Alabama at Birmingham

Robert Katzman Clinical Research Training Fellowship in Alzheimer’s Research

Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the Alzheimer’s Association

Recipient: Joel Salinas, MD, MBA, MSc Massachusetts General Hospital, Harvard Medical School

Susan S. Spencer Clinical Research Training Fellowship

Cosponsored by the American Academy of Neurology, the American Brain Foundation, the American Epilepsy Society, and the Epilepsy Foundation

Recipient: Alice Lam, MD, PhD Massachusetts General Hospital


Let’s Give Back to Our 2017 Annual Meeting Host City Help prepare young people from Boston Public Schools for health and science careers and contribute to the skilled science workforce of the future! The AAN is proud to partner with The Center for Community Health and Health Equity at Brigham and Women’s Hospital to help give back to the Boston community during the 2017 AAN Annual Meeting. Your support will help send Boston Public School 9th graders through the innovative Summer Science Academy program, exposing them to health care professions in a hospital setting, and providing hands-on science education that links to real-world professional—and personal—application. Donations will provide transportation, equipment, public health curriculum and student funding.

To learn more and donate today, visit AAN.com/view/AANGivesBack. Your Support Makes a Real Difference! A comprehensive evaluation showed that 100% of the 2016 Summer Science Academy students reported experiencing positive change in their academic motivation, and 94% reported a positive change in learning interest and academic perseverance.


General Information Accreditation/CME/Core Competencies Accreditation The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation The American Academy of Neurology Institute designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/Participation Records AANI has mechanisms in place to record, and when authorized by the participating physician, verify participation in the CME activity. To receive CME for the Annual Meeting live program, participants must: (1) have their badge printed on site and be verified as eligible for credit; (2) attend the program(s); and (3) submit the evaluation form for the program(s). CME is given only when all three steps are completed. AAN member CME and participation transcripts are available approximately four to six weeks following the close of the meeting via the AAN’s NeuroTracker™ at AAN.com/view/NeuroTracker. Nonmembers’ CME credits and participation transcripts will be sent automatically via email.

ABPN Statement The American Board of Psychiatry and Neurology has reviewed the AAN Annual Meeting and has approved this product as a part of a comprehensive lifelong learning program which is mandated by the ABMS as a necessary component of maintenance of certification.

Core Competencies The AANI develops its activities/educational interventions in the context of the desirable physician attributes; specifically, of the Accreditation Council for Graduate Medical Education (ACGME) Core Competencies which include: }} Patient Care }} Medical Knowledge }} Interpersonal and Communication Skills }} Practice-Based Learning and Improvement }} Professionalism }} Systems-Based Practice For more information on the definitions of the ACGME core competencies, please consult the following webpage: ACGME.org . Once again, the Annual Meeting CME offerings, at the program and lecture level, are identified according to these competencies. Through identifying individual programs by competencies, attendees can easily identify and attend programs that meet each core competency.

148 2017 AAN Annual Meeting Science Program

AMA CME Definition/Educational Content of Certified CME The AMA HOD and the Council on Medical Education have defined continuing medical education as follows: CME consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is the body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine and the provision of health care to the public. (HOD policy #300.988) Certified CME is defined as: 1. Nonpromotional learning activities certified for credit prior to the activity by an organization authorized by the credit system owner, or 2. Nonpromotional learning activities for which the credit system owner directly awards credit Accredited CME providers may certify nonclinical subjects (e.g., office management, patient-physician communications, faculty development) for AMA PRA Category 1 Credit™ as long as these are appropriate to a physician audience and benefit the profession, patient care, or public health. CME activities may describe or explain complementary and alternative health care practices. As with any CME activity, these need to include discussion of the existing level of scientific evidence that supports the practices. However, education that advocates specific alternative therapies or teaches how to perform associated procedures, without scientific evidence or general acceptance among the profession that supports their efficacy and safety, cannot be certified for AMA PRA Category 1 Credit™.

Content Validation The AANI, as an ACCME accredited provider, is responsible for validating the clinical content of CME activities that it provides. Specifically, 1. All the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. 2. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.


General Information Disclaimers/Disclosures Disclaimer The primary purpose of the Annual Meeting is to meet the educational needs of its members and address practice gaps by providing practice-oriented and scientifically based educational activities that will maintain and advance competence and performance in the field of neurology. A diversity of opinions exists in the medical field and the views of the Annual Meeting faculty do not represent those of the AAN/ AANI or constitute endorsement by the AAN/AANI. The AAN/AANI disclaims any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed at the Annual Meeting. The activities conducted and content distributed at the Annual Meeting are for educational purposes only and do not constitute standard of care or substitute for professional medical advice, diagnosis, or treatment. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the content provided is voluntary. The AAN/AANI provide this information on an “as is” basis and makes no warranty, expressed or implied, regarding the information. The AAN/AANI specifically disclaim any warranties of merchantability or fitness for a particular use or purpose. The AAN/ AANI assume no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. Attendee assumes any and all liability associated with attendance/participation at the Annual Meeting.

Relationship Disclosure and Conflict of Interest Resolution According to AANI and ACCME policies, everyone who is in a position to control the content of an education activity must disclose financial relationships with any commercial interest to the provider. An individual who refuses to disclose relevant financial relationships is disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. In addition, the AANI must implement a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The resolution of conflict is handled by the Education and Science Committees. Disclosures for everyone in the position to control Annual Meeting content can be found on the AAN Annual Meeting website. In addition, education and science faculty disclosures can also be found in the syllabi, slides, handouts, and/or are given verbally from the podium.

Unlabeled Use Disclosure The AANI requires all Annual Meeting presenters to disclose if a therapy/product is not labeled for the use being discussed or if the therapy/product is still investigational. Unlabeled use disclosures can be found in the program materials.

Continued Grants Some Annual Meeting education and scientific programs are supported in part by educational grants from commercial entities. Disclosure of the educational grant is done through acknowledgment statements on the program materials, signs outside of the room, and verbally from the podium. Although educational grants are received, all programs are developed and implemented solely by the Education Committee and Science Committee. The terms, conditions, and purposes of the commercial support are documented in a written agreement between the AANI and commercial supporter. The AAN uses grant funds to support and enhance existing, as well as new, education programs.

Services Luggage Check No luggage check is available at The Boston Convention and Exhibition Center (BCEC). Check with your concierge at your hotel to make your arrangements.

Transportation Due to the proximity of the hotels to The Boston Convention and Exhibition Center, the AAN will provide shuttle service for select hotels. The housing website indicates whether a hotel is walkable or in the shuttle zone. Please use this information when making your housing selection.

Wireless Connection Wireless Internet hotspots will be available at The Boston Convention and Exhibition Center.

First Aid Station A First Aid station is located on the lobby level of The Boston Convention and Exhibition Center. The station is staffed by licensed medical professionals and fully equipped with supplies, including automatic external defibrillators (AED). The station is operational throughout the duration of the Annual Meeting.

Prayer Room A prayer room will be available in the Convention Center for attendees looking for a quiet space for thought, reflection, and prayer.

Child Care Information A variety of child care options are available in Boston. Check with the concierge at your hotel on or before your arrival to make your arrangements.

Mothers’ Room A private room will be available for nursing mothers and others with sensitive personal health needs. Please note that this room will not be staffed.

Fast and easy registration · AAN.com/view/AM17 149


Guidelines Photography and Recording of Programs The AAN strictly prohibits all unauthorized photography (flash, digital, or otherwise), audio and/or video recording during the Annual Meeting. Equipment will be confiscated. Photography is allowed only in the Poster Sessions.

Consent to Use of Images All portions of the Annual Meeting may be photographed, videotaped, or recorded for future rebroadcast, distribution, promotion, or other commercial purpose. By attending the Annual Meeting you are consenting to being recorded, photographed, and videotaped without acknowledgment, payment or remuneration of any kind. Any recordings, photographs, or videos of any nature are the sole property of AAN and its successors and assignees.

Cell Phones The AAN requests that attendees turn cellular phones and pagers to vibrate mode upon entering all Annual Meeting programs.

Language The official language of the Annual Meeting is English. No simultaneous translation is available.

No Smoking The Boston Convention and Exhibition Center is a nonsmoking facility. For the health and comfort of everyone, smoking is prohibited at Annual Meeting functions, which include all education and scientific activities and social functions.

Press Room Only authorized media may use the Press Room at the Annual Meeting. Journalists must check in at the Press Room and provide proper credentials. For more information, contact Renee Tessman at rtessman@aan.com or (612) 928-6137.

Volunteer Opportunities Education and Scientific Program Monitors Monitors are needed for all education program offerings and scientific platform sessions to assist directors, faculty, session co-chairs, and staff as required. The AAN will give discounts to registration fees as well as grant CME credit for the monitored program. Space is available on a first-come, first-served basis for current Junior and Student AAN members. For an application form or more information, contact Laurie Dixon at ldixon@aan.com or (612) 928-6154.

Skills Workshop Volunteers Volunteers are needed to participate in the Clinical Uses of Botulinum Toxin for Dystonia Workshop on Sunday, April 23, the Neurophysiologic Intraoperative Monitoring Skills Workshop on

150 2017 AAN Annual Meeting Science Program

Monday, April 24, the Neuromuscular Ultrasound Skills Workshop on Tuesday, April 25, the EMG Skills Workshop: Basic on Wednesday, April 26, and the Clinical Uses of Botulinum Toxin for Spasticity Workshop on Thursday, April 27. Skills workshop subjects will receive a waived meeting registration and workshop fee as well as payment of $40 per noninvasive session and $60 per invasive session. Space is available on a first-come, first-served basis for current Junior and Student AAN members. For more information, contact Laurie Dixon at ldixon@aan.com or (612) 928-6154.

Weather/Attire April brings spring-like temperatures to Boston. Temperatures usually range from 37 degrees to 54 degrees Fahrenheit. The AAN promotes business casual attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary.


Thank You 2O17 Annual Meeting Supporters* The American Academy of Neurology (AAN) thanks the following companies, foundations, and organizations for their demonstrated vision, commitment, and strong support of programs which find answers and improve lives through neurologic education and research. AbbVie, Inc. ¡ ¡ ¡ ¡

Exhibit Guide Door Drop Exhibit Hall Passport Industry Therapeutic Update

ACADIA Pharmaceuticals ¡ ¡ ¡ ¡ ¡ ¡

AANextra Door Drop Exhibit Guide Exhibit Hall Passport Industry Therapeutic Update C140 Nonmotor Manifestations of Parkinson’s Disease II

The Allergan Foundation

¡ Enhanced Residents Leadership Program ¡ Medical Student Diversity Program

Allergan Inc.

Brain Health Fair Platinum Sponsor Women in Leadership Diversity Leadership Program Palatucci Advocacy Leadership Forum ¡ Transforming Leaders Program ¡ Women Leading in Neurology ¡ ¡ ¡ ¡

¡ ¡ ¡ ¡ ¡ ¡ ¡

Exhibit Hall Digital Billboard Exhibit Hall Opening Reception Exhibit Hall Passport Exhibit Hall Pillar Marketing Industry Therapeutic Updates Presentation Stage Tabletop Graphics

Cox Health

¡ Faculty and Trainee Night

¡ 5k Run/1K Walk for Brain Research ¡ Exhibit Hall Passport ¡ Exhibit Guide

Geisinger Health System

¡ ¡ ¡ ¡

5k Run/1k Walk for Brain Research Cell Phone Charging Station Exhibit Guide Science Program

Bayer ¡ ¡ ¡ ¡

AANextra Exhibit Guide Exhibit Hall Passport Tabletop Graphics

Biogen ¡ ¡ ¡ ¡ ¡

5k Run/1k Walk for Brain Research AANextra Cell Charging Hub Cell Charging Skyway Lounge Door Drop Insert

¡ Exhibit Hall Passport ¡ Office of the Future Gold Sponsorship

Sage Therapeutics

¡ 5k Run/1k Walk for Brain Research ¡ Door Drop Insert

¡ Faculty and Trainee Night

Genentech

AANextra Cell Charging Hub Door Drop Insert Exhibit Hall Footprints Exhibit Hall Pillar Marketing Industry Therapeutic Update Tabletop Graphics

Grifols

¡ C12 Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular and MuSK Myasthenia

Sanofi Genzyme ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡

5k Run/1k Walk for Brain Research AANextra Door Drop Exhibit Hall Pillar Marketing Exhibit Guide Industry Therapeutic Update Presentation Stage Resident Scholarship Fund Transforming Leaders Program

Sunovion Pharmaceuticals Inc.

Lundbeck

¡ Enhanced Residents Leadership Program ¡ Transforming Leaders Program

Merz Neurosciences

¡ C97 The Dystonias: Diagnosis, Treatment, and Update on Causes

MT Pharma America ¡ ¡ ¡ ¡ ¡ ¡ ¡

AANextra Door Drop Insert Exhibit Hall Park Benches Exhibit Guide Industry Therapeutic Update Mobile App

Outcome Health

EMD Serono

Arbor Pharmaceuticals, LLC

AveXis, Inc.

¡ ¡ ¡ ¡ ¡ ¡

Electrical Geodesics Inc. (EGI) ¡ Exhibit Guide

AANextra Door Drop Insert Exhibit Hall Footprints Exhibit Hall Passport Industry Therapeutic Update

Novartis Pharmaceuticals Corporation

¡ Exhibit Hall Passport ¡ Exhibit Guide

¡ Cell Charging Hub ¡ Hotel Key Cards & Sleeves ¡ Industry Therapeutic Update ¡ Exhibit Hall Footprints ¡ Exhibit Hall Passport ¡ Industry Therapeutic Update

¡ ¡ ¡ ¡ ¡

Eisai Inc.

¡ ¡ ¡ ¡ ¡ ¡ ¡

Amgen, Inc.

Neurocrine Biosciences

AANextra Cell Charging Hub Door Drop Insert Exhibit Hall Passport Exhibit Hall Pillar Marketing Exhibit Guide Industry Therapeutic Update

nts mitme * Com

¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡

5k Run/1k Walk for Brain Research AANextra Cell Phone Charging Station Cell Charging Area Cell Charging Skyway Lounge Door Drop Insert Exhibit Hall Footprints Exhibit Hall Networking Reception Exhibit Hall Passport Exhibit Hall Pillar Marketing Industry Therapeutic Update Office of Future Silver Sponsorship Presentation Stage Tabletop Graphics Wifi Access on Shuttle Buses

017 y 20, 2 r a u n of Ja ed as receiv

Supernus Pharmacueticals Inc.

¡ C131 Hot Topics in Headaches and Related Disorders I: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances ¡ 5k Run/1k Walk for Brain Research ¡ Brain Health Fair Gold Sponsorship ¡ Cell Charging Area ¡ Diversity Leadership Program ¡ Door Drop Insert ¡ Exhibit Hall Coffee Break ¡ Exhibit Guide ¡ Resident Scholarship Fund ¡ Transforming Leaders Forum ¡ Medical Student Diversity Program

Teva CNS ¡ ¡ ¡ ¡

Door Drop Exhibit Hall Pillar Marketing Exhibit Guide Palatucci Advocacy Leadership Forum

UCB, Inc. ¡ ¡ ¡ ¡

Door Drop Bag Sponsorship Exhibit Hall Passport Exhibit Guide Graphics at Exhibit Hall Entrance

Upsher-Smith Laboratories, Inc. ¡ Door Drop Insert ¡ Exhibit Hall Passport ¡ Exhibit Guide

Validus Pharmaceuticals LLC ¡ Exhibit Hall Passport

Wolters Kluwer Health– Publisher of AAN Publications 5k Run/1k Walk for Brain Research Bookbags Brain Health Fair Bookbags Cell Phone Charging Locker Exhibit Hall Passport Graphics at Faculty and Trainee Night Entrance ¡ Wifi Access ¡ Water Bottle ¡ ¡ ¡ ¡ ¡ ¡


Hotels and Amenities Hotel Name / Address

Lowest Rates* (SGL / DBL)

Distance to Convention Center

High Speed Shuttle Internet Access Service** Per Day

2

Aloft Boston Seaport Hotel 401-403 D Street

$283.00 / $283.00

1 Block

No

No Charge

0

3

Boston Courtyard Downtown 275 Tremont Street

$289.00 / $289.00

1.4 Miles

Yes

No Charge

1

4

Boston Park Plaza Hotel 50 Park Plaza at Arlington Street

$295.00 / $295.00

1.6 Miles

Yes

$11.99

5

5

Boston Marriott Long Wharf 296 State Street

$369.00 / $369.00

1.3 Miles

Yes

$16.95

1

6

Colonnade Hotel 120 Huntington Avenue

$329.00 / $329.00

2.3 Miles

Yes

No Charge

1

7

DoubleTree by Hilton - Boston Downtown 821 Washington Street

$289.00 / $289.00

1.4 Miles

Yes

$9.95

1

8

Element Boston Seaport 391-395 D Street

$293.00 / $293.00

2 Blocks

No

No Charge

0

9

Embassy Suites Boston at Logan Airport 207 Porter Street

$234.00 / $234.00

3.4 Miles

Yes

No Charge

1

10

Fairmont Copley Plaza 138 St. James Avenue

$337.00 / $337.00

2 Miles

Yes

$11.00

1

11

Four Seasons Hotel Boston 200 Boylston Street

$405.00 / $405.00

1.4 Miles

Yes

No Charge

1

12

Hilton Boston Back Bay 40 Dalton Street

$285.00 / $285.00

2.6 Miles

Yes

$14.95

1

13

Hilton Boston Downtown / Faneuil Hall 89 Broad Street

$315.00 / $315.00

1.1 Miles

Yes

$15.99

1

14

Hilton Boston Logan Airport 1 Hotel Drive

$289.00 / $289.00

3.5 Miles

Yes

$6.95

2

15

Hotel Commonwealth 500 Commonwealth Avenue

$329.00 / $329.00

3 Miles

Yes

No Charge

2

16

Hyatt Regency Boston One Avenue de Lafayette

$290.00 / $290.00

1.1 Miles

Yes

No Charge

1

17

InterContinental Boston 510 Atlantic Avenue

$344.00 / $344.00

8 Blocks

Yes

$12.95

2

18

Langham Hotel 250 Franklin Street

$343.00 / $343.00

1 Mile

Yes

No Charge

2

19

Lenox Hotel 61 Exeter Street at Boylston

$299.00 / $299.00

2 Miles

Yes

No Charge

2

20

Liberty Hotel Boston 215 Charles Street

$369.00 / $369.00

2.1 Miles

Yes

No Charge

2

21

Marriott Copley Place 110 Huntington Avenue

$292.00 / $292.00

2.1 Miles

Yes

$12.95

1

22

Midtown Hotel 220 Huntington Avenue

$179.00 / $179.00

2.5 Miles

Yes

No Charge

0

Number of Restaurants

*Lowest available rate shown. Availability in that room category may be limited; other room categories may be available at a higher rate. **Hotels without shuttle service are walkable.

152 2017 AAN Annual Meeting Science Program


Ch els ea St

Meridian St

Ha no ve rS t

BS t

27

By pa ss Br oa dw ay

W

1s tS t

Headquarter Hotel Convention Center

St

E Broadway

e Av

St

y lon Co Old

7t h

Massport Haul Rd

Hotel

E 1st St

W

Farragut Rd

2

D

A

W

William J Day Blvd

St

Rd

8

S

No rth ern

M as Su sp m or t H a m er St Drydock Ave

1

Marginal Rd

24 St

ul

A

Co ng res s

Bo st on

Travel er St

25

L Street

Unio Mald n Park St en S t St y n ba Al

Se ap or tB lvd

W ay

Av e

Co ng re ss St

St ree t

Kne elan dS t

Dorchester Ave

Ha rr is on

St

Linc oln St

Su mm er St

St re et

Av e Co lu m bu s

Ave de Lafa yett e

Pa pp as

Tr em on tS t

Tre mo nt S t

Av e

Hu nt in gt on

t eS e as v rch ic A Pu lant At

Essex St

Harr ison Ave

Sorr ow D r

2 Mi les O ut

g way S t

Boston Convention and Exhibition Center 415 Summer St, Boston, MA 02210

13 17

16

St

Hem en

Park Dr

Bro ad S t

St lin nk Fra

W4 th S t

St

d or nc Co

Pa rke rS t

18

Sch ool

1 Mile O ut

e Av

St

am th al W

E

n to ew N

St

St

St State

Hera ld St

St

n to ng hi as W

e Av ut m aw h S

E

t tS on em Tr

Cou rt St

5

Jo hn F

rt

e Rd urfac rald S zge Fit

t yS kele Ber

am dh De

Av e

23

3 7

Cr os sS t

St arl Pe

z Park Pl

EB erk ele y

W

M as sa ch us et ts

ut Waln

St rles Cha Boylston St

St on rd

St ress Cong

Joy St

Charles St

t nS ngto Arli

Westla nd Ave

St don ren Cla

Belvid ere St

4

11

ha

No

St con Bea

28

St uth tmo Dar

Ru gg les

21

22

St yth Fors

way Fen

St don ren Cla

n St lsto Boy

6

on Dalt

12

t ter S Exe

Charlesgate

26

on St Mt Vern t St stnu Che

t nS lsto Boy ve es A am St J t rt S a Stu

10

19

Pinckney St

Bowdoin St

Cambridge St

t yS kele Ber

Ave etts hus sac Mas

15

C New

h

Longfellow Bridge

Dr row Sor St on c a Be St gh u o r rlbo Ma Ave alth nwe mo Com t yS bur New

Merr ima c St

29

Atlantic Ave

ay W ey

m

St

Blo ss o

20

To ma ha wk Dr

Ha rb or

St St ay ew us a C

Lom asn

Se rvi ce Rd

ua

Com me rcia lS t

W

Nash

St re et

Rd

9

Hotel Name / Address

Lowest Rates* (SGL / DBL)

Distance to Convention Center

23

Omni Parker House 60 School Street

$259.00 / $259.00

1.2 Miles

Yes

No Charge

1

24

Renaissance Boston Waterfront Hotel 606 Congress Street

$303.00 / $303.00

4 Blocks

No

$16.95

1

25

Seaport Boston Hotel One Seaport Lane

$316.00 / $316.00

3 Blocks

No

No Charge

1

26

Sheraton Boston Hotel 39 Dalton Street

$280.00 / $280.00

2.5 Miles

Yes

$9.95

1

27

Westin Boston Waterfront 425 Summer Street

$325.00 / $325.00

Less Than 1 Block

No

$12.95

1

28

Westin Copley Place Boston Hotel 10 Huntington Avenue

$303.00 / $303.00

2.1 Miles

Yes

$14.95

1

29

Wyndham Boston Beacon Hill 5 Blossom Street

$299.00 / $299.00

2 Miles

Yes

No Charge

1

tel Driv e Ho

Ri ve rD am

St ton ing ash NW

Ch ar les

Po rte rS t

High Speed Shuttle Internet Access Service** Per Day

Number of Restaurants

Fast and easy registration · AAN.com/view/AM17 153

14


Hotel and Reservations Why Book a Hotel Room Through the AAN? Booking your room through the official AAN housing company assures you are getting a room at the hotel that best fits your needs. You are also helping the AAN maintain consistent and competitive registration fees. The reason is simple. When a city is selected as the site for the AAN Annual Meeting, contracts are signed with several hotels reserving a specific number of rooms to be available for meeting attendees. If these rooms are not sold, the AAN is liable financially. Penalties incurred affect the overall costs of the Annual Meeting and what the AAN charges for registration, exhibit space, and other services. Discounted hotel rates are available until March 8, 2017, or until the block is filled. After this date, reservations are subject to availability. Hotel fees will be posted and charged in American dollars.

Save on Hotel Reservations Take advantage of the AAN’s special hotel rates to make your trip more affordable. Annual Meeting hotel reservations are processed by Convention Management Resources (CMR).

AAN Online Hotel Reservations

Telephone Reservations

AAN.com/view/BookHotel The AAN makes it easy and convenient to book your hotel rooms for the 69th Annual Meeting. Booking online allows you to: }} Take advantage of the AAN’s special hotel rates }} View room descriptions, photos, and availability }} Access maps of hotel proximity to Annual Meeting locations

All correspondence, questions, and inquiries should be directed to CMR at: Phone: Hours: US/Canada (800) 676-4226 Credit card reservations only International (415) 979-2283 Monday–Friday 6:00 a.m.–6:00 p.m. PT

Deposits

Group Accommodations Deadline: March 8, 2017

}} All hotels require a credit card guarantee of $300 (US dollars) per room and $500 (US dollars) per suite. Deposits will be credited towards your first night’s room and tax. }} No hotel reservation will be processed without a credit card guarantee. }} Deposits are refundable up to seven days prior to arrival, after which there will be no refunds. }} Credit cards will be charged for one night’s room and tax if you fail to arrive on the confirmed date of arrival or if you fail to cancel your reservation at least seven days prior to arrival.

Confirmations, Changes, and Cancellations }} You will receive your hotel confirmation from CMR. This is the only confirmation you will receive. }} Please check your arrival and departure dates on the confirmation carefully. }} After March 8, 2017, contact CMR to book a room. After this date, however, rooms are subject to availability. Note: Some hotels may charge a penalty for changes made to your departure date after you have checked in.

154 2017 AAN Annual Meeting Science Program

Blocks of 10 or more sleeping rooms are considered a group. Email your written request to aanam.cmrushelp.com and you will be contacted by an AAN Housing Consultant.

Additional Tax/Assessments }} Rates do not include the 15% hotel tax. }} An $8 per night assessment fee is included to offset the expense of the meeting.

It has come to our attention that a number of parties not associated with the AAN are unjustly offering to arrange travel, housing, and registration for the Annual Meeting. We strongly advise you to book your arrangements through CMR, the only official registration vendor for the AAN. No other hotel management company or travel agency is authorized to place reservations on behalf of AAN, and rates and policies cannot be guaranteed through other companies.


Travel Information Save with Annual Meeting Travel Reservation Through Travel Agency

Direct Through Airlines

The official travel agency for the Annual Meeting is ATC Travel Management. For 2%–10% discounted airline tickets to the Annual Meeting, contact them at: Phone: (800) 458-9383 Email: reservations@atcmeetings.com Hours: Monday–Friday, 8:30 a.m.–7:00 p.m. ET Closed weekends and holidays

You may also contact your preferred airline directly. You must reference the AAN Annual Meeting and provide the appropriate airline discount codes listed below.

A $33 service fee will be assessed per ticket for reservations made via phone.

Travel Website

Airline Delta United

Discount Code Phone Number Website NMPBD (800) 328-1111 Delta.com ZVM8 820754 (800) 521-4041 United.com

For travel forms and information updates, visit the AAN Annual Meeting website at AAN.com/view/AM17.

Travel Tips Travel Documents/Passports and Entry Requirements

Luggage

N